{"text_format":"1","workbook":"xlsx","n_sheets":2,"sheets":["Overview","Detail"],"not_rendered":{"charts":0,"images":0,"macros":1,"external_links":1,"defined_names":3,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Overview","index":0,"n_rows":4034,"n_cols":12,"rows_kept":4034,"cut":false,"hidden":false,"merged":[]}
["Overview - AOP ",null,null,{"$f":"(HYPERLINK(\"https://aopwiki.org/aops/57\",\"aop57\"))","v":"aop57"}]
["AhR activation leading to hepatic steatosis"]
["MeSH Chemical Name (hyperlinked)","ChemName","chemuid","1_MIE","2_KE","3_KE","5_KE","7_KE","9_KE","11_KE","12_KE","13_AO"]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C4,B4)","v":"Ethanol"},"Ethanol","D000431",5,47,0,7,0,72,14,47,1187]
["Cholesterol","Cholesterol","D002784",2,863,0,4,221,3643,2,88,887]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251",2,10,0,6,1,12,9,5,558]
["Fructose","Fructose","D005632",0,38,0,4,9,28,0,16,541]
["Glucose","Glucose","D005947",22,55,1,173,45,126,3,22,394]
["Choline","Choline","D002794",0,7,0,0,0,11,0,1,359]
["Blood Glucose","Blood Glucose","D001786",0,50,1,58,6,151,3,10,311]
["Metformin","Metformin","D008687",2,10,0,8,6,36,2,3,248]
["Vitamin E","Vitamin E","D014810",1,78,0,0,16,469,5,23,239]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791",0,173,0,1,8,372,1,41,227]
["Orotic Acid","Orotic Acid","D009963",0,8,0,0,0,4,0,2,221]
["pioglitazone","pioglitazone","C060836",0,3,0,5,9,32,0,7,170]
["Carnitine","Carnitine","D002331",0,12,7,1,0,17,0,72,150]
["rosiglitazone","rosiglitazone","C089730",0,9,0,11,20,40,0,5,149]
["Uric Acid","Uric Acid","D014527",1,8,0,1,1,37,1,5,148]
["Tamoxifen","Tamoxifen","D013629",5,9,0,0,4,20,7,1,140]
["Ursodeoxycholic Acid","Ursodeoxycholic Acid","D014580",0,0,0,0,1,20,0,2,132]
["Tetracycline","Tetracycline","D013752",0,2,0,0,1,2,0,1,117]
["Betaine","Betaine","D001622",0,2,0,0,0,4,0,3,115]
["Palmitic Acid","Palmitic Acid","D019308",0,4,0,3,28,19,0,37,111]
["Vitamin D","Vitamin D","D014807",0,2,0,0,1,18,2,1,99]
["resveratrol","resveratrol","C059514",62,1,0,2,1,49,41,4,98]
["Silymarin","Silymarin","D012838",0,2,0,0,0,6,5,0,91]
["Valproic Acid","Valproic Acid","D014635",0,0,3,0,2,4,2,14,91]
["Ezetimibe","Ezetimibe","D000069438",0,10,0,0,7,61,0,4,90]
["Biotin","Biotin","D001710",0,1,0,5,1,8,2,0,89]
["Oleic Acid","Oleic Acid","D019301",0,23,0,5,21,46,1,138,87]
["Vitamin B 12","Vitamin B 12","D014805",0,0,0,0,0,5,0,3,85]
["Folic Acid","Folic Acid","D005492",2,1,0,0,0,18,1,3,81]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059",0,42,0,0,14,222,0,3,80]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118",0,31,0,0,7,57,2,115,80]
["Pentoxifylline","Pentoxifylline","D010431",0,0,0,0,0,1,1,2,74]
["Coffee","Coffee","D003069",7,4,0,0,0,16,7,0,71]
["Curcumin","Curcumin","D003474",17,0,0,0,12,47,19,12,71]
["Liver Glycogen","Liver Glycogen","D008112",1,0,0,20,0,0,1,1,70]
["Bilirubin","Bilirubin","D001663",10,1,0,0,1,18,8,0,68]
["Fenofibrate","Fenofibrate","D011345",0,37,0,2,8,71,2,12,67]
["Catechin","Catechin","D002392",17,1,0,1,2,69,17,2,63]
["Sucrose","Sucrose","D013395",0,23,0,2,0,23,1,10,61]
["Thioctic Acid","Thioctic Acid","D008063",1,2,0,0,0,21,0,2,61]
["Inositol","Inositol","D007294",0,6,0,0,0,7,0,0,59]
["Methotrexate","Methotrexate","D008727",1,1,0,0,0,5,1,0,58]
["Vitamin A","Vitamin A","D014801",3,18,0,4,5,35,16,8,58]
["Taurine","Taurine","D013654",0,3,0,0,0,25,1,1,56]
["Chenodeoxycholic Acid","Chenodeoxycholic Acid","D002635",0,6,0,0,1,18,0,0,54]
["Ammonia","Ammonia","D000641",0,0,0,13,0,2,0,0,50]
["Dexamethasone","Dexamethasone","D003907",12,15,0,56,2,21,22,22,49]
["Quercetin","Quercetin","D011794",13,2,0,0,6,50,27,0,49]
["Tea","Tea","D013662",13,1,0,0,1,59,17,2,49]
["Acetaminophen","Acetaminophen","D000082",2,0,0,0,0,7,11,0,46]
["Hyaluronic Acid","Hyaluronic Acid","D006820",0,1,0,0,3,12,0,0,46]
["Nitric Oxide","Nitric Oxide","D009569",5,7,0,9,10,198,12,9,45]
["Sitagliptin Phosphate","Sitagliptin Phosphate","D000068900",0,0,0,0,1,1,0,0,45]
["Phenobarbital","Phenobarbital","D010634",10,7,0,9,0,7,50,2,44]
["Gadolinium DTPA","Gadolinium DTPA","D019786",0,0,0,0,0,2,0,0,43]
["Berberine","Berberine","D001599",9,1,0,3,6,45,8,1,42]
["Dietary Fiber","Dietary Fiber","D004043",0,28,0,0,0,58,1,2,42]
["Caffeine","Caffeine","D002110",6,1,0,0,3,8,17,1,41]
["Pyridoxine","Pyridoxine","D011736",0,1,0,0,0,5,1,2,41]
["silybin","silybin","C440975",0,0,0,0,0,0,1,0,41]
["Simvastatin","Simvastatin","D019821",0,22,0,0,3,221,0,9,40]
["Sulfobromophthalein","Sulfobromophthalein","D013448",0,0,0,0,0,0,0,0,40]
["Tolbutamide","Tolbutamide","D014044",0,3,0,4,0,0,1,0,40]
["Urea","Urea","D014508",0,2,0,4,4,8,1,1,40]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C68,B68)","v":"troglitazone"},"troglitazone","C057693",0,6,0,0,5,34,2,11,38]
["Amiodarone","Amiodarone","D000638",0,0,0,1,0,10,5,1,37]
["gadolinium ethoxybenzyl DTPA","gadolinium ethoxybenzyl DTPA","C073590",0,0,0,0,0,0,0,0,37]
["Indocyanine Green","Indocyanine Green","D007208",0,0,0,0,0,6,0,0,37]
["Niacin","Niacin","D009525",0,21,0,1,7,44,0,0,37]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450",0,0,0,0,0,4,1,0,35]
["epigallocatechin gallate","epigallocatechin gallate","C045651",13,1,0,1,1,20,10,2,34]
["Galactose","Galactose","D005690",0,1,0,3,1,7,0,0,34]
["Fluorodeoxyglucose F18","Fluorodeoxyglucose F18","D019788",0,0,0,0,0,3,0,0,33]
["Halothane","Halothane","D006221",0,1,0,0,0,0,0,1,33]
["obeticholic acid","obeticholic acid","C464660",0,0,0,0,0,0,0,0,33]
["Adenine","Adenine","D000225",0,3,0,0,0,6,0,14,32]
["Glycogen","Glycogen","D006003",0,1,0,28,3,1,0,1,32]
["Linoleic Acid","Linoleic Acid","D019787",0,15,0,0,6,47,2,211,30]
["Losartan","Losartan","D019808",0,0,0,1,4,18,0,0,30]
["rimonabant","rimonabant","C089032",0,1,0,0,0,3,0,1,30]
["Bezafibrate","Bezafibrate","D001629",0,35,1,0,1,59,1,11,29]
["Chlortetracycline","Chlortetracycline","D002751",0,0,0,0,0,0,0,0,29]
["Sirolimus","Sirolimus","D020123",0,2,0,0,2,17,0,4,29]
["Thioacetamide","Thioacetamide","D013853",0,3,0,0,0,2,0,0,29]
["Ascorbic Acid","Ascorbic Acid","D001205",3,10,0,1,0,136,16,8,28]
["Glycerol","Glycerol","D005990",0,19,0,31,1,10,2,3,28]
["Ubiquinone","Ubiquinone","D014451",0,9,0,0,3,70,3,8,28]
["Calcifediol","Calcifediol","D002112",0,0,0,0,0,0,0,0,27]
["Genistein","Genistein","D019833",10,0,0,1,0,29,8,1,27]
["osthol","osthol","C046627",0,0,0,0,0,2,0,0,27]
["Fluorouracil","Fluorouracil","D005472",0,0,0,0,0,3,3,2,26]
["Isoniazid","Isoniazid","D007538",0,0,0,0,0,0,0,0,26]
["Olive Oil","Olive Oil","D000069463",1,10,0,0,1,72,1,16,26]
["Prednisolone","Prednisolone","D011239",0,1,0,2,0,4,0,0,26]
["Aspirin","Aspirin","D001241",6,1,3,1,5,42,3,0,25]
["bisphenol A","bisphenol A","C006780",6,0,0,0,1,0,6,0,25]
["lycopene","lycopene","C015329",0,3,0,0,2,45,2,7,25]
["Particulate Matter","Particulate Matter","D052638",36,0,0,0,3,13,44,0,25]
["Riboflavin","Riboflavin","D012256",1,0,0,0,0,1,0,23,25]
["Linseed Oil","Linseed Oil","D008043",0,3,0,0,0,10,1,23,24]
["telmisartan","telmisartan","C084178",0,0,0,0,2,15,0,0,24]
["Aminopyrine","Aminopyrine","D000632",0,0,0,0,0,0,0,0,23]
["Clofibrate","Clofibrate","D002994",0,82,0,2,0,105,2,42,23]
["Norepinephrine","Norepinephrine","D009638",0,3,0,3,1,10,1,0,23]
["oxaliplatin","oxaliplatin","C030110",0,0,0,0,0,0,0,0,23]
["Thiamine","Thiamine","D013831",0,0,0,0,1,1,1,0,23]
["Tretinoin","Tretinoin","D014212",16,2,0,14,4,12,15,10,23]
["Acetaldehyde","Acetaldehyde","D000079",0,5,0,3,2,23,1,3,22]
["Rifampin","Rifampin","D012293",3,1,0,0,0,3,6,1,22]
["Rosuvastatin Calcium","Rosuvastatin Calcium","D000068718",0,12,0,0,0,72,0,0,22]
["TO-901317","TO-901317","C423915",0,2,0,0,2,7,0,4,22]
["alpha-Linolenic Acid","alpha-Linolenic Acid","D017962",0,2,1,0,1,12,1,181,21]
["Glycyrrhizic Acid","Glycyrrhizic Acid","D019695",0,0,0,1,0,0,2,0,21]
["Niacinamide","Niacinamide","D009536",1,1,0,0,0,4,1,3,21]
["orlistat","orlistat","C055122",0,0,0,0,0,3,0,0,21]
["1-Propanol","1-Propanol","D000433",0,2,0,0,0,3,0,0,20]
["Ethionamide","Ethionamide","D005000",0,0,0,0,0,0,0,0,20]
["Nicotine","Nicotine","D009538",0,2,0,0,1,11,18,0,20]
["perfluorooctane sulfonic acid","perfluorooctane sulfonic acid","C076994",1,0,0,0,0,2,3,2,20]
["schizandrin B","schizandrin B","C015499",0,0,0,0,0,1,0,0,20]
["Serotonin","Serotonin","D012701",1,4,0,1,3,27,1,0,20]
["alpha-Tocopherol","alpha-Tocopherol","D024502",2,20,0,0,16,83,3,1,19]
["Probucol","Probucol","D011341",0,22,0,0,5,164,0,2,19]
["Sulfur Hexafluoride","Sulfur Hexafluoride","D013459",0,0,0,0,0,0,0,0,18]
["Water","Water","D014867",3,0,0,0,0,14,3,1,18]
["acylcarnitine","acylcarnitine","C116917",0,0,6,0,0,0,0,10,17]
["Camptothecin","Camptothecin","D002166",3,0,0,0,0,0,0,0,17]
["DDT","DDT","D003634",7,1,0,2,0,2,11,2,17]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C132,B132)","v":"essential 303 forte"},"essential 303 forte","C011246",0,0,0,0,0,1,0,0,17]
["ferumoxides","ferumoxides","C065507",0,0,0,0,2,1,0,0,17]
["Heparin","Heparin","D006493",0,68,0,0,3,189,0,0,17]
["Histamine","Histamine","D006632",1,0,0,0,0,7,3,0,17]
["ipragliflozin","ipragliflozin","C572941",0,0,0,0,0,2,0,0,17]
["irinotecan","irinotecan","C051890",0,0,0,0,0,0,0,0,17]
["Prednisone","Prednisone","D011241",0,2,0,0,0,8,0,0,17]
["Chloroform","Chloroform","D002725",0,0,0,0,0,0,2,3,16]
["Cholecalciferol","Cholecalciferol","D002762",1,1,0,0,3,6,2,0,16]
["Galactosamine","Galactosamine","D005688",0,3,0,1,0,2,0,0,16]
["olmesartan","olmesartan","C437965",0,0,0,0,0,2,0,1,16]
["trans-10,cis-12-conjugated linoleic acid","trans-10,cis-12-conjugated linoleic acid","C496197",0,0,0,0,4,2,0,10,16]
["Antipyrine","Antipyrine","D000983",0,0,0,0,0,4,1,0,15]
["Cholic Acid","Cholic Acid","D019826",0,4,0,0,0,8,0,4,15]
["Gallic Acid","Gallic Acid","D005707",0,0,0,0,1,4,1,0,15]
["oltipraz","oltipraz","C026209",9,0,0,0,0,0,10,0,15]
["Tobacco Smoke Pollution","Tobacco Smoke Pollution","D014028",18,1,0,0,0,12,37,5,15]
["Vinyl Chloride","Vinyl Chloride","D014752",0,0,0,0,0,0,0,0,15]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035",95,1,1,1,1,1,76,3,14]
["Aflatoxin B1","Aflatoxin B1","D016604",7,1,0,0,0,4,36,0,14]
["Allopurinol","Allopurinol","D000493",0,0,0,0,1,6,0,0,14]
["Carbamazepine","Carbamazepine","D002220",0,0,0,0,0,2,6,0,14]
["Chlorogenic Acid","Chlorogenic Acid","D002726",0,0,0,0,0,4,0,0,14]
["Clofibric Acid","Clofibric Acid","D002995",1,11,0,0,1,36,4,27,14]
["contrast agent BR1","contrast agent BR1","C420843",0,0,0,0,0,0,0,0,14]
["Cycloheximide","Cycloheximide","D003513",6,3,0,5,0,3,4,0,14]
["Isoproterenol","Isoproterenol","D007545",0,0,0,5,0,5,0,5,14]
["Meglumine","Meglumine","D008536",0,0,0,0,0,0,0,0,14]
["Methylprednisolone","Methylprednisolone","D008775",0,2,0,1,0,4,0,0,14]
["oleuropein","oleuropein","C002769",0,0,0,0,0,1,1,0,14]
["Petroleum","Petroleum","D010578",13,0,0,0,0,1,86,0,14]
["phosphatidylethanolamine","phosphatidylethanolamine","C483858",0,1,0,0,2,0,0,1,14]
["qushi huayu","qushi huayu","C533465",0,0,0,0,0,0,0,0,14]
["Spironolactone","Spironolactone","D013148",0,1,0,0,0,5,0,0,14]
["tributyltin","tributyltin","C011559",7,0,0,0,0,0,9,0,14]
["ursolic acid","ursolic acid","C005466",0,0,0,0,3,5,0,0,14]
["Arachidonic Acid","Arachidonic Acid","D016718",1,6,0,1,6,41,14,168,13]
["bicyclol","bicyclol","C477843",0,0,0,0,0,1,0,0,13]
["Celecoxib","Celecoxib","D000068579",0,0,0,0,2,2,0,0,13]
["Cholestyramine Resin","Cholestyramine Resin","D002792",0,24,0,1,0,76,0,0,13]
["Cottonseed Oil","Cottonseed Oil","D003369",0,1,0,1,0,1,0,6,13]
["Diethylnitrosamine","Diethylnitrosamine","D004052",7,0,0,1,0,0,6,0,13]
["Disulfiram","Disulfiram","D004221",0,0,0,0,0,0,0,0,13]
["Iron, Dietary","Iron, Dietary","D019266",0,0,0,0,0,3,0,2,13]
["lard","lard","C029310",0,5,0,0,0,20,1,2,13]
["Neopterin","Neopterin","D019798",0,1,0,0,2,11,0,0,13]
["palmitoleic acid","palmitoleic acid","C008757",0,2,0,0,0,1,0,33,13]
["Sphingosine","Sphingosine","D013110",2,3,0,0,2,25,0,7,13]
["Vitamin K","Vitamin K","D014812",4,1,0,0,0,1,3,0,13]
["Chlorpromazine","Chlorpromazine","D002746",0,0,0,0,0,2,2,0,12]
["Dinoprostone","Dinoprostone","D015232",8,3,0,2,3,17,3,13,12]
["Emodin","Emodin","D004642",0,0,0,0,1,1,1,0,12]
["gadobenic acid","gadobenic acid","C064572",0,0,0,0,0,0,0,0,12]
["IGL-1 solution","IGL-1 solution","C504757",0,0,0,0,0,0,0,0,12]
["Lactic Acid","Lactic Acid","D019344",0,1,0,13,0,9,2,3,12]
["naringenin","naringenin","C005273",6,3,0,1,0,7,3,0,12]
["Sodium Chloride","Sodium Chloride","D012965",0,2,0,1,0,4,0,17,12]
["Trichloroethylene","Trichloroethylene","D014241",0,0,0,0,0,0,3,0,12]
["4-pentenoic acid","4-pentenoic acid","C009785",0,0,0,0,0,0,0,6,11]
["anandamide","anandamide","C078814",0,0,0,0,2,1,0,4,11]
["Butter","Butter","D002079",0,0,0,0,0,7,0,0,11]
["Chloramphenicol","Chloramphenicol","D002701",0,0,0,0,0,0,0,0,11]
["Colchicine","Colchicine","D003078",0,5,0,0,0,1,0,3,11]
["Corn Oil","Corn Oil","D003314",1,3,0,0,1,13,0,6,11]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C196,B196)","v":"Cysteamine"},"Cysteamine","D003543",0,1,0,0,0,0,0,0,11]
["Glucosamine","Glucosamine","D005944",0,1,0,1,0,12,0,0,11]
["Masoprocol","Masoprocol","D009637",0,3,0,0,0,0,0,0,11]
["octanoic acid","octanoic acid","C031492",0,3,0,3,2,1,0,4,11]
["oligofructose","oligofructose","C120489",0,0,0,0,0,0,0,0,11]
["Oxytetracycline","Oxytetracycline","D010118",0,0,0,0,0,2,1,0,11]
["Phenytoin","Phenytoin","D010672",0,1,0,0,0,1,2,0,11]
["polyene phosphatidylcholine","polyene phosphatidylcholine","C029449",0,0,0,0,0,0,0,0,11]
["Remaxol","Remaxol","C555877",0,0,0,0,0,0,0,0,11]
["sorafenib","sorafenib","C471405",0,0,0,0,0,0,0,0,11]
["Sunflower Oil","Sunflower Oil","D000074242",0,5,0,0,0,9,1,24,11]
["1,2-diacylglycerol","1,2-diacylglycerol","C011439",0,0,0,0,0,0,0,0,10]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024",24,6,0,0,0,6,33,2,10]
["Acetone","Acetone","D000096",0,1,0,1,0,1,3,0,10]
["Adamantane","Adamantane","D000218",0,1,0,0,0,8,0,0,10]
["baicalin","baicalin","C038044",3,0,0,0,0,2,2,0,10]
["beta Carotene","beta Carotene","D019207",1,9,0,0,2,77,7,8,10]
["Calcitriol","Calcitriol","D002117",1,1,0,0,0,11,0,0,10]
["Canola Oil","Canola Oil","D000074262",0,4,0,0,0,8,0,6,10]
["Capsaicin","Capsaicin","D002211",1,0,0,0,1,4,2,3,10]
["cyanidin 3-O-glucoside","cyanidin 3-O-glucoside","C114438",2,0,0,0,0,3,1,0,10]
["Dehydrocholic Acid","Dehydrocholic Acid","D003685",0,0,0,0,0,0,0,0,10]
["Deoxycholic Acid","Deoxycholic Acid","D003840",0,1,0,0,0,13,0,1,10]
["Dichlorodiphenyl Dichloroethylene","Dichlorodiphenyl Dichloroethylene","D003633",3,0,0,0,0,0,8,0,10]
["Diethylstilbestrol","Diethylstilbestrol","D004054",2,8,0,0,0,3,3,0,10]
["Epinephrine","Epinephrine","D004837",0,3,0,4,0,13,1,18,10]
["geniposide","geniposide","C007835",0,0,0,0,0,1,2,0,10]
["glyceryl 2-arachidonate","glyceryl 2-arachidonate","C094503",0,0,0,0,1,2,0,0,10]
["Glycyrrhetinic Acid","Glycyrrhetinic Acid","D006034",0,0,0,0,0,0,1,1,10]
["Guanine","Guanine","D006147",3,0,0,0,0,1,4,0,10]
["Malondialdehyde","Malondialdehyde","D008315",1,3,0,0,0,153,1,4,10]
["Palm Oil","Palm Oil","D000073878",0,3,0,0,0,6,0,8,10]
["Phytic Acid","Phytic Acid","D010833",0,0,0,0,0,0,0,0,10]
["pirinixic acid","pirinixic acid","C006253",0,0,0,0,1,1,0,13,10]
["pitavastatin","pitavastatin","C108475",0,4,0,0,1,26,0,0,10]
["Propranolol","Propranolol","D011433",1,16,0,1,0,19,4,0,10]
["Raloxifene Hydrochloride","Raloxifene Hydrochloride","D020849",3,1,0,0,0,6,0,0,10]
["Risperidone","Risperidone","D018967",0,3,0,0,0,1,0,2,10]
["sodium arsenite","sodium arsenite","C017947",4,0,0,2,0,1,7,0,10]
["Tacrolimus","Tacrolimus","D016559",0,2,0,1,3,20,0,0,10]
["Tenofovir","Tenofovir","D000068698",0,0,0,0,0,1,0,0,10]
["WAY-362450","WAY-362450","C540004",0,0,0,0,0,2,0,0,10]
["xuezhikang","xuezhikang","C496822",0,0,0,0,0,2,0,0,10]
["2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","C585906",0,0,0,0,0,0,0,0,9]
["Carbon Dioxide","Carbon Dioxide","D002245",0,0,0,31,0,1,0,4,9]
["Chitosan","Chitosan","D048271",1,2,0,0,1,15,0,0,9]
["coenzyme Q10","coenzyme Q10","C024989",0,8,0,0,2,41,2,2,9]
["Ellagic Acid","Ellagic Acid","D004610",0,0,0,0,0,7,4,0,9]
["eplerenone","eplerenone","C414690",0,1,0,0,0,3,0,0,9]
["irbesartan","irbesartan","C081309",0,0,0,0,1,4,0,0,9]
["Lactulose","Lactulose","D007792",0,0,0,0,0,0,0,0,9]
["mepanipyrim","mepanipyrim","C104083",0,2,0,0,0,0,0,0,9]
["Mercaptoethanol","Mercaptoethanol","D008623",0,0,0,0,0,2,0,0,9]
["Naltrexone","Naltrexone","D009271",0,0,0,0,0,1,0,0,9]
["Oleanolic Acid","Oleanolic Acid","D009828",1,0,0,0,2,9,3,0,9]
["Propofol","Propofol","D015742",0,3,1,0,1,3,2,0,9]
["puerarin","puerarin","C033607",0,0,0,0,1,8,0,0,9]
["Pyruvic Acid","Pyruvic Acid","D019289",0,0,0,10,0,1,0,3,9]
["rhein","rhein","C020491",0,0,0,0,0,0,0,0,9]
["Rutin","Rutin","D012431",1,1,0,0,0,12,2,0,9]
["Sorbitol","Sorbitol","D013012",0,2,0,0,0,0,0,0,9]
["Technetium Tc 99m Pentetate","Technetium Tc 99m Pentetate","D016284",0,0,0,0,0,0,0,0,9]
["Toluene","Toluene","D014050",6,0,0,0,0,2,9,0,9]
["xanthohumol","xanthohumol","C104536",0,0,0,0,0,2,3,0,9]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C260,B260)","v":"Xylitol"},"Xylitol","D014993",0,0,0,1,0,0,0,0,9]
["18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","C521270",0,0,0,0,0,0,0,0,8]
["2,4-Dinitrophenol","2,4-Dinitrophenol","D019297",0,0,0,0,0,0,0,0,8]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155",0,2,1,1,0,2,0,0,8]
["Acarbose","Acarbose","D020909",0,6,0,0,0,7,0,0,8]
["Bortezomib","Bortezomib","D000069286",0,0,0,0,0,2,1,0,8]
["Butyric Acid","Butyric Acid","D020148",0,0,0,0,3,3,1,2,8]
["Calcium, Dietary","Calcium, Dietary","D002136",0,0,0,0,0,4,0,1,8]
["Carbon Disulfide","Carbon Disulfide","D002246",0,1,0,0,0,3,0,0,8]
["Citric Acid","Citric Acid","D019343",0,0,0,0,0,2,0,0,8]
["daidzein","daidzein","C004742",1,1,0,1,0,12,5,1,8]
["dan-shen root extract","dan-shen root extract","C028972",0,0,0,0,0,0,0,0,8]
["Diethylhexyl Phthalate","Diethylhexyl Phthalate","D004051",7,1,0,4,0,2,4,12,8]
["Edetic Acid","Edetic Acid","D004492",0,1,0,0,0,6,0,1,8]
["entecavir","entecavir","C413685",0,0,0,0,0,0,0,0,8]
["hydrazine","hydrazine","C029424",0,0,0,6,0,0,1,2,8]
["jiangzhi","jiangzhi","C000597921",0,0,0,0,0,0,0,0,8]
["Lidocaine","Lidocaine","D008012",0,0,0,0,0,0,1,0,8]
["Luteolin","Luteolin","D047311",5,0,0,0,0,10,0,0,8]
["maraviroc","maraviroc","C502411",0,0,0,0,0,0,0,0,8]
["Menhaden oil","Menhaden oil","C033266",0,2,0,0,0,2,0,4,8]
["Nitrofurantoin","Nitrofurantoin","D009582",0,0,0,0,0,0,3,0,8]
["Promethazine","Promethazine","D011398",0,0,0,0,0,0,0,0,8]
["salicylsalicylic acid","salicylsalicylic acid","C014182",0,0,0,0,0,0,0,0,8]
["sophocarpine","sophocarpine","C035933",0,0,0,0,0,0,0,0,8]
["Soybean Oil","Soybean Oil","D013024",0,7,0,0,0,9,1,18,8]
["technetium Tc 99m tin colloid","technetium Tc 99m tin colloid","C033493",0,0,0,0,0,0,0,0,8]
["Tetrachloroethylene","Tetrachloroethylene","D013750",0,0,0,0,0,0,0,0,8]
["Thiamine Pyrophosphate","Thiamine Pyrophosphate","D013835",0,0,0,0,0,0,0,0,8]
["Thromboxane A2","Thromboxane A2","D013928",0,3,0,0,1,19,0,0,8]
["Ticlopidine","Ticlopidine","D013988",0,1,0,0,0,6,0,0,8]
["Toremifene","Toremifene","D017312",0,0,0,0,0,1,1,0,8]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946",0,1,0,3,2,3,0,3,7]
["Ammonium Chloride","Ammonium Chloride","D000643",0,0,0,2,0,5,0,1,7]
["Cellulose","Cellulose","D002482",1,8,0,0,1,25,2,0,7]
["Creatinine","Creatinine","D003404",0,1,0,0,0,2,0,0,7]
["Dimethyl Sulfoxide","Dimethyl Sulfoxide","D004121",0,0,0,0,0,3,6,0,7]
["Doxorubicin","Doxorubicin","D004317",1,3,0,0,1,24,3,2,7]
["fructooligosaccharide","fructooligosaccharide","C116580",0,1,0,0,0,0,0,0,7]
["Grape Seed Extract","Grape Seed Extract","D056604",0,3,0,0,1,4,0,0,7]
["Guaiacol","Guaiacol","D006139",1,0,0,0,0,2,0,0,7]
["GW 4064","GW 4064","C412815",0,0,0,0,1,0,0,0,7]
["gypenoside","gypenoside","C474918",0,0,0,0,0,0,0,0,7]
["honokiol","honokiol","C005499",0,0,0,0,0,1,0,1,7]
["Hydrochlorothiazide","Hydrochlorothiazide","D006852",0,3,0,0,0,13,1,0,7]
["Inulin","Inulin","D007444",0,0,0,0,0,1,0,0,7]
["Lactose","Lactose","D007785",0,0,0,0,0,3,0,1,7]
["methacetin","methacetin","C035495",0,0,0,0,0,0,0,0,7]
["Nifedipine","Nifedipine","D009543",0,1,0,0,1,22,2,3,7]
["piperine","piperine","C008922",0,0,0,0,0,5,1,0,7]
["Pravastatin","Pravastatin","D017035",0,22,0,0,0,116,0,0,7]
["pyrazolanthrone","pyrazolanthrone","C432165",7,0,0,0,0,1,3,0,7]
["Taurochenodeoxycholic Acid","Taurochenodeoxycholic Acid","D013655",0,0,0,0,1,2,0,0,7]
["tauroursodeoxycholic acid","tauroursodeoxycholic acid","C031655",0,0,0,0,1,2,0,0,7]
["Theophylline","Theophylline","D013806",0,4,0,2,0,4,16,0,7]
["Trimetazidine","Trimetazidine","D014292",0,0,1,0,0,4,0,0,7]
["Uracil","Uracil","D014498",0,0,0,0,0,1,0,0,7]
["vildagliptin","vildagliptin","C502012",0,0,0,0,0,1,0,0,7]
["1,1,1-trichloroethane","1,1,1-trichloroethane","C024566",0,0,0,0,0,0,0,0,6]
["1,3-butylene glycol","1,3-butylene glycol","C028491",0,0,0,0,0,0,0,0,6]
["25-hydroxycholesterol 3-sulfate","25-hydroxycholesterol 3-sulfate","C534977",0,0,0,0,0,0,0,0,6]
["3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine","3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine","C579035",0,0,0,0,0,0,0,0,6]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975",0,0,0,0,0,9,0,3,6]
["4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","C082137",0,0,0,0,1,1,0,0,6]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C324,B324)","v":"4-hydroxy-2-nonenal"},"4-hydroxy-2-nonenal","C027576",0,1,0,0,5,37,0,0,6]
["acetaminophen glucuronide","acetaminophen glucuronide","C037386",0,0,0,0,0,0,0,0,6]
["allyl sulfide","allyl sulfide","C038491",0,0,0,0,0,2,6,0,6]
["Aminoimidazole Carboxamide","Aminoimidazole Carboxamide","D000620",3,0,0,2,6,3,2,0,6]
["anastrozole","anastrozole","C090450",0,0,0,0,0,0,0,0,6]
["barbituric acid","barbituric acid","C032232",0,0,0,0,0,0,0,0,6]
["Bentonite","Bentonite","D001546",0,0,0,0,1,0,0,0,6]
["Biopterin","Biopterin","D001708",0,0,0,0,0,10,0,2,6]
["BMS201038","BMS201038","C473731",0,0,0,0,0,5,0,0,6]
["Butylated Hydroxytoluene","Butylated Hydroxytoluene","D002084",0,2,0,0,0,2,4,0,6]
["CA-19-9 Antigen","CA-19-9 Antigen","D018395",0,1,0,0,0,1,0,0,6]
["Cocaine","Cocaine","D003042",0,0,0,0,0,1,0,0,6]
["Cyclophosphamide","Cyclophosphamide","D003520",3,8,0,0,0,2,5,0,6]
["diethyl phthalate","diethyl phthalate","C007379",1,0,0,0,0,0,0,0,6]
["dihydroguaiaretic acid","dihydroguaiaretic acid","C015816",0,0,0,0,0,0,0,0,6]
["Dihydroxyacetone","Dihydroxyacetone","D004098",0,0,0,0,0,0,0,0,6]
["diisopropyl 1,3-dithiol-2-ylidenemalonate","diisopropyl 1,3-dithiol-2-ylidenemalonate","C024808",0,0,0,0,0,1,0,1,6]
["Dimethoate","Dimethoate","D004117",0,0,0,0,0,0,0,0,6]
["emeriamine","emeriamine","C045761",0,1,0,0,0,0,0,2,6]
["fumonisin B1","fumonisin B1","C056933",1,1,0,0,0,0,3,3,6]
["GC 1 compound","GC 1 compound","C413355",0,0,0,0,1,2,0,0,6]
["Hexestrol","Hexestrol","D006589",0,0,0,0,0,0,0,0,6]
["hexestrol bis(diethylaminoethyl ether)","hexestrol bis(diethylaminoethyl ether)","C100116",0,0,0,0,0,0,0,0,6]
["Hydrogen Peroxide","Hydrogen Peroxide","D006861",4,1,0,2,4,44,4,6,6]
["Hydroxocobalamin","Hydroxocobalamin","D006879",0,0,0,0,0,0,0,0,6]
["Isotretinoin","Isotretinoin","D015474",0,3,0,0,0,5,2,2,6]
["lathosterol","lathosterol","C001521",0,5,0,0,1,16,0,0,6]
["Levamisole","Levamisole","D007978",1,0,0,0,0,2,0,0,6]
["Lindane","Lindane","D001556",0,1,0,0,0,0,5,0,6]
["lysophosphatidic acid","lysophosphatidic acid","C032881",1,0,0,1,3,11,0,0,6]
["lysophosphatidylethanolamine","lysophosphatidylethanolamine","C008301",0,0,0,0,0,0,0,1,6]
["matrine","matrine","C034244",0,0,0,0,0,0,0,0,6]
["Methylene Chloride","Methylene Chloride","D008752",0,0,0,0,0,0,1,0,6]
["Methylnitrosourea","Methylnitrosourea","D008770",3,0,0,0,0,0,0,0,6]
["Mirex","Mirex","D008917",0,0,0,0,0,0,0,0,6]
["Morphine","Morphine","D009020",0,0,0,1,0,1,2,2,6]
["N,N-dimethyl-3-hydroxy-5-cholenamide","N,N-dimethyl-3-hydroxy-5-cholenamide","C413890",0,0,0,0,0,0,0,0,6]
["O(2)-vinyl-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate","O(2)-vinyl-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate","C107010",0,0,0,0,0,0,0,0,6]
["oil red O","oil red O","C011049",0,0,0,0,0,0,0,0,6]
["omegaven","omegaven","C568345",0,0,0,0,0,0,0,0,6]
["oxymatrine","oxymatrine","C037573",0,0,0,0,0,0,0,0,6]
["Paraoxon","Paraoxon","D010261",0,0,0,0,0,1,0,0,6]
["p-Dimethylaminoazobenzene","p-Dimethylaminoazobenzene","D004124",2,1,0,2,0,3,0,0,6]
["Pentetic Acid","Pentetic Acid","D004369",0,0,0,0,0,2,1,0,6]
["peoniflorin","peoniflorin","C015423",0,0,0,0,0,1,0,0,6]
["perfluorooctanoic acid","perfluorooctanoic acid","C023036",1,1,0,0,1,0,4,8,6]
["Phenformin","Phenformin","D010629",0,3,0,0,0,3,0,0,6]
["Phenylethyl Alcohol","Phenylethyl Alcohol","D010626",1,0,0,0,0,15,2,5,6]
["platycodin D","platycodin D","C108953",0,0,0,0,0,1,0,0,6]
["polydatin","polydatin","C058229",0,0,0,0,0,2,0,1,6]
["pycnogenols","pycnogenols","C024070",0,0,0,0,0,2,0,0,6]
["Pyridoxal Phosphate","Pyridoxal Phosphate","D011732",0,0,0,1,0,5,0,4,6]
["red yeast rice","red yeast rice","C117343",0,0,0,0,0,4,0,0,6]
["Reserpine","Reserpine","D012110",0,0,0,0,0,6,0,0,6]
["Rubber","Rubber","D012408",0,0,0,0,0,0,2,0,6]
["Sodium, Dietary","Sodium, Dietary","D012982",0,0,0,0,0,2,0,0,6]
["stearic acid","stearic acid","C031183",0,2,0,0,0,2,0,28,6]
["Streptozocin","Streptozocin","D013311",0,2,0,3,0,5,0,2,6]
["sulforafan","sulforafan","C016766",0,0,0,0,0,2,1,0,6]
["Technetium Tc 99m Sulfur Colloid","Technetium Tc 99m Sulfur Colloid","D013671",0,0,0,0,0,0,0,0,6]
["teucrium extract","teucrium extract","C040618",0,0,0,0,0,0,0,0,6]
["Thalidomide","Thalidomide","D013792",0,0,0,0,0,2,4,0,6]
["ubiquinone 9","ubiquinone 9","C030571",0,1,0,0,0,1,0,0,6]
["Urethane","Urethane","D014520",0,0,0,0,0,2,3,0,6]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C388,B388)","v":"vagotonin"},"vagotonin","C009641",0,0,0,0,0,0,0,0,6]
["1-(carboxyethylthio)tetradecane","1-(carboxyethylthio)tetradecane","C062077",0,0,0,0,0,0,0,0,5]
["10-(6'-ubiquinonyl)decyltriphenylphosphonium bromide","10-(6'-ubiquinonyl)decyltriphenylphosphonium bromide","C476756",0,0,0,0,0,0,0,0,5]
["10,12-octadecadienoic acid","10,12-octadecadienoic acid","C094849",0,0,0,0,0,1,0,3,5]
["2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid","2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid","C559288",0,1,0,0,0,0,0,0,5]
["5-(4-(1-(4-(difluoromethoxy)benzoyl)piperidin-4-yloxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione","5-(4-(1-(4-(difluoromethoxy)benzoyl)piperidin-4-yloxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione","C577950",0,0,0,0,0,0,0,0,5]
["Acetic Acid","Acetic Acid","D019342",0,0,0,0,0,1,1,0,5]
["Acetylcarnitine","Acetylcarnitine","D000108",0,0,0,0,0,0,0,2,5]
["allyl isothiocyanate","allyl isothiocyanate","C004471",0,0,0,0,0,0,2,0,5]
["alpha-ketoglutaric acid","alpha-ketoglutaric acid","C029743",0,0,0,3,0,0,0,0,5]
["Amlodipine","Amlodipine","D017311",0,0,0,0,0,18,0,0,5]
["Amylopectin","Amylopectin","D000687",0,0,0,0,0,1,0,0,5]
["apo-10'-lycopenoic acid","apo-10'-lycopenoic acid","C523199",0,0,0,0,0,0,0,1,5]
["arachidonyl-2-chloroethylamide","arachidonyl-2-chloroethylamide","C119325",0,0,0,0,0,0,0,0,5]
["aroclor 1260","aroclor 1260","C026987",1,0,0,0,0,0,2,0,5]
["arsenic trioxide","arsenic trioxide","C006632",0,0,0,0,1,0,1,0,5]
["Aurothioglucose","Aurothioglucose","D006051",0,0,0,0,0,0,0,0,5]
["baicalein","baicalein","C006680",4,0,0,0,0,2,3,0,5]
["Benzene","Benzene","D001554",11,0,0,0,0,1,9,0,5]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564",207,4,0,0,0,8,338,0,5]
["beta-glucan, (1-3)(1-4)-","beta-glucan, (1-3)(1-4)-","C067858",0,0,0,0,0,0,0,0,5]
["butyramide","butyramide","C006866",0,0,0,0,0,0,0,0,5]
["caffeic acid","caffeic acid","C040048",0,0,0,0,0,15,1,0,5]
["campesterol","campesterol","C021273",0,5,0,0,1,7,0,2,5]
["candesartan","candesartan","C081643",0,0,0,0,0,5,0,0,5]
["Carbenoxolone","Carbenoxolone","D002229",0,1,0,0,0,1,0,0,5]
["CD3 Complex","CD3 Complex","D017252",0,0,0,0,1,6,0,2,5]
["Cetirizine","Cetirizine","D017332",0,1,0,0,1,1,0,0,5]
["Chlorobutanol","Chlorobutanol","D002724",0,0,0,0,0,0,0,0,5]
["Chlorpropamide","Chlorpropamide","D002747",0,2,0,0,0,0,0,0,5]
["cilostazol","cilostazol","C045645",0,0,0,0,3,4,0,1,5]
["Clomiphene","Clomiphene","D002996",0,0,0,0,0,2,0,0,5]
["Clozapine","Clozapine","D003024",0,0,0,0,0,2,2,0,5]
["coumarin","coumarin","C030123",0,0,0,0,0,1,2,0,5]
["deferasirox","deferasirox","C415250",0,0,0,0,0,0,0,0,5]
["Dopamine","Dopamine","D004298",1,0,0,1,1,2,1,0,5]
["eicosapentaenoic acid ethyl ester","eicosapentaenoic acid ethyl ester","C035276",0,3,0,0,0,7,0,1,5]
["Epoprostenol","Epoprostenol","D011464",0,7,0,0,1,64,1,0,5]
["ethyl eicosapentaenoic acid","ethyl eicosapentaenoic acid","C495711",0,4,0,0,0,0,0,0,5]
["ethyl pyruvate","ethyl pyruvate","C046522",0,0,0,0,0,2,0,0,5]
["fisetin","fisetin","C017875",0,0,0,1,1,4,0,0,5]
["fosfestrol","fosfestrol","C004955",0,0,0,0,0,0,0,0,5]
["FP 736-04","FP 736-04","C106557",0,0,0,0,0,0,0,0,5]
["Furosemide","Furosemide","D005665",0,1,0,1,0,2,0,0,5]
["gamma-Linolenic Acid","gamma-Linolenic Acid","D017965",0,0,0,0,1,3,0,101,5]
["genipin","genipin","C007834",0,0,0,0,1,0,1,0,5]
["gingerol","gingerol","C007845",1,0,0,0,0,0,1,0,5]
["Guanidine","Guanidine","D019791",0,0,0,0,0,0,0,0,5]
["GW 3965","GW 3965","C473027",0,0,0,0,0,3,0,0,5]
["GW 501516","GW 501516","C425931",0,1,0,0,2,4,0,0,5]
["Hexobarbital","Hexobarbital","D006591",0,0,0,0,0,1,0,4,5]
["Ibuprofen","Ibuprofen","D007052",0,0,0,0,0,2,1,0,5]
["Iodized Oil","Iodized Oil","D007459",0,0,0,0,0,0,0,0,5]
["keishibukuryogan","keishibukuryogan","C054593",0,0,0,0,0,0,0,0,5]
["Ketoprofen","Ketoprofen","D007660",0,0,0,0,0,0,0,0,5]
["Linagliptin","Linagliptin","D000069476",0,0,0,0,0,1,0,0,5]
["lycium barbarum polysaccharide","lycium barbarum polysaccharide","C500223",0,0,0,0,0,0,0,0,5]
["magnolol","magnolol","C005498",0,0,0,0,0,1,2,0,5]
["Margarine","Margarine","D008383",0,1,0,0,0,8,0,3,5]
["marimastat","marimastat","C100342",0,0,0,0,0,0,0,0,5]
["Methoxyflurane","Methoxyflurane","D008733",0,0,0,0,0,0,0,7,5]
["Methylene Blue","Methylene Blue","D008751",0,0,0,0,0,0,0,2,5]
["Myristic Acid","Myristic Acid","D019814",0,0,0,3,6,4,0,25,5]
["norclozapine","norclozapine","C058272",0,0,0,0,0,0,1,0,5]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C452,B452)","v":"nuciferine"},"nuciferine","C008692",0,0,0,0,0,0,0,0,5]
["palonosetron","palonosetron","C083418",0,0,0,0,0,0,0,0,5]
["policosanol","policosanol","C080710",0,2,0,0,0,13,0,0,5]
["Polyvinyl Chloride","Polyvinyl Chloride","D011143",0,0,0,0,0,0,0,0,5]
["Promazine","Promazine","D011395",0,0,0,0,0,0,1,0,5]
["proxigermanium","proxigermanium","C066750",0,0,0,0,0,2,0,0,5]
["puag-haad","puag-haad","C034912",0,0,0,0,0,0,0,0,5]
["qianggan","qianggan","C527657",0,0,0,0,0,0,0,0,5]
["Raltegravir Potassium","Raltegravir Potassium","D000068898",0,0,0,0,1,2,0,0,5]
["raspberry ketone","raspberry ketone","C035522",0,0,0,0,0,0,0,0,5]
["resolvin D1","resolvin D1","C518399",1,0,0,0,0,0,1,1,5]
["Roxarsone","Roxarsone","D012406",0,0,0,0,0,0,0,0,5]
["safingol","safingol","C005682",0,0,0,0,0,1,0,2,5]
["salvin","salvin","C018381",0,0,0,0,0,2,0,1,5]
["shen ling bai zhu","shen ling bai zhu","C532982",0,0,0,0,0,0,0,0,5]
["sibutramine","sibutramine","C058254",0,0,0,0,0,1,0,0,5]
["sodium arsenate","sodium arsenate","C009277",0,0,0,0,0,0,1,0,5]
["sphingosine 1-phosphate","sphingosine 1-phosphate","C060506",0,3,0,0,2,20,0,0,5]
["Starch","Starch","D013213",0,6,0,2,0,11,0,3,5]
["tetramethylpyrazine","tetramethylpyrazine","C017953",0,0,0,0,0,4,0,0,5]
["tributyrin","tributyrin","C005830",0,0,0,0,0,2,0,0,5]
["triheptanoin","triheptanoin","C531010",0,0,1,1,1,0,0,0,5]
["tropisetron","tropisetron","C045504",0,0,0,0,0,0,0,0,5]
["valproic acid glucuronide","valproic acid glucuronide","C041285",0,0,0,0,0,0,0,0,5]
["Vincristine","Vincristine","D014750",0,0,0,0,0,1,0,0,5]
["vinyl acetate","vinyl acetate","C011566",0,0,0,0,0,0,0,0,5]
["(1-6)-alpha-glucomannan","(1-6)-alpha-glucomannan","C022901",0,2,0,0,0,2,0,0,4]
["1,2-dilauroylphosphatidylcholine","1,2-dilauroylphosphatidylcholine","C015153",0,0,0,0,0,0,0,0,4]
["2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","C093026",1,0,0,0,0,3,0,0,4]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996",0,1,0,0,2,10,0,0,4]
["4-phenylbutyric acid","4-phenylbutyric acid","C075773",0,0,0,0,0,3,0,0,4]
["7,3'-dihydroxy-4'-methoxyisoflavone","7,3'-dihydroxy-4'-methoxyisoflavone","C121707",0,0,0,0,0,0,0,0,4]
["7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester","7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester","C041398",0,0,0,0,0,0,1,0,4]
["8,11,14-Eicosatrienoic Acid","8,11,14-Eicosatrienoic Acid","D015126",0,1,0,0,0,7,2,59,4]
["8-epi-prostaglandin F2alpha","8-epi-prostaglandin F2alpha","C075750",0,3,0,0,0,22,0,0,4]
["9,11-linoleic acid","9,11-linoleic acid","C046938",0,1,0,0,1,4,0,18,4]
["Acetylglucosamine","Acetylglucosamine","D000117",0,0,0,0,2,0,0,0,4]
["Alloxan","Alloxan","D000496",0,0,0,0,0,0,0,0,4]
["alpha-galactosylceramide","alpha-galactosylceramide","C493154",0,0,0,0,0,0,0,0,4]
["ankaflavin","ankaflavin","C499916",0,0,0,0,0,0,0,0,4]
["AO 128","AO 128","C054577",0,0,0,0,0,0,0,0,4]
["APD668","APD668","C000617192",0,0,0,0,0,0,0,0,4]
["Apigenin","Apigenin","D047310",2,0,0,0,0,6,3,0,4]
["benzoylecgonine","benzoylecgonine","C005618",0,0,0,0,0,1,0,0,4]
["betulinic acid","betulinic acid","C002070",0,0,0,0,0,0,0,2,4]
["butylurea","butylurea","C006865",0,0,0,0,0,0,0,0,4]
["Candicidin","Candicidin","D002174",0,0,0,0,0,0,0,0,4]
["Cefoperazone","Cefoperazone","D002438",0,0,0,0,0,0,0,0,4]
["Chitin","Chitin","D002686",0,2,0,0,0,3,0,0,4]
["Coconut Oil","Coconut Oil","D000074263",0,3,0,0,0,14,0,4,4]
["conophylline","conophylline","C099167",0,0,0,0,0,0,0,0,4]
["dihydromyricetin","dihydromyricetin","C472036",0,0,0,0,0,2,0,0,4]
["diisopropylamine dichloroacetate","diisopropylamine dichloroacetate","C001002",0,0,0,0,0,0,0,0,4]
["Dinoprost","Dinoprost","D015237",0,3,0,1,0,43,0,0,4]
["Dolichol","Dolichol","D004286",0,3,0,0,0,5,0,0,4]
["Ephedrine","Ephedrine","D004809",0,0,0,1,0,0,0,0,4]
["Eugenol","Eugenol","D005054",5,1,0,0,0,4,5,0,4]
["Ezetimibe, Simvastatin Drug Combination","Ezetimibe, Simvastatin Drug Combination","D000069499",0,0,0,0,0,8,0,0,4]
["Fenretinide","Fenretinide","D017313",0,0,0,0,0,0,0,2,4]
["Ferrosoferric Oxide","Ferrosoferric Oxide","D052203",0,0,0,0,0,0,0,0,4]
["Fluoxetine","Fluoxetine","D005473",0,0,0,0,0,0,2,0,4]
["Formaldehyde","Formaldehyde","D005557",0,1,0,0,0,7,1,0,4]
["fucoidan","fucoidan","C007789",0,0,0,0,1,4,0,0,4]
["ginsenoside M1","ginsenoside M1","C112772",0,0,0,0,0,0,0,0,4]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C516,B516)","v":"Glyceraldehyde"},"Glyceraldehyde","D005985",0,0,0,0,0,0,0,0,4]
["glycolaldehyde","glycolaldehyde","C010972",0,0,0,0,2,4,0,0,4]
["Gold Colloid","Gold Colloid","D017979",0,0,0,0,0,5,0,0,4]
["Haloperidol","Haloperidol","D006220",0,1,0,0,0,3,2,2,4]
["HhAntag691","HhAntag691","C538724",0,0,0,0,0,0,0,0,4]
["Hydrogen Sulfide","Hydrogen Sulfide","D006862",0,0,0,0,1,15,1,2,4]
["Hydroxyethylrutoside","Hydroxyethylrutoside","D006896",0,0,0,0,0,1,0,0,4]
["inchinko-to","inchinko-to","C078038",0,0,0,0,0,0,0,0,4]
["Iopamidol","Iopamidol","D007479",0,0,0,0,0,0,0,0,4]
["isosilybin","isosilybin","C075820",0,0,0,0,0,0,0,0,4]
["juzentaihoto","juzentaihoto","C063587",0,0,0,0,0,0,0,0,4]
["Keratan Sulfate","Keratan Sulfate","D007632",0,0,0,0,0,0,0,0,4]
["LC15-0444","LC15-0444","C534891",0,0,0,0,0,0,0,0,4]
["lipostabil","lipostabil","C005152",0,0,0,0,0,3,0,0,4]
["Lithocholic Acid","Lithocholic Acid","D008095",0,0,0,0,1,1,0,0,4]
["Lutein","Lutein","D014975",0,1,0,0,3,8,0,2,4]
["mangiferin","mangiferin","C013592",0,0,0,0,3,1,0,0,4]
["mangostin","mangostin","C021053",0,0,0,0,0,4,0,0,4]
["Methamphetamine","Methamphetamine","D008694",0,0,0,0,0,0,0,0,4]
["methyl tert-butyl ether","methyl tert-butyl ether","C043243",0,0,0,0,0,1,2,0,4]
["Methyltestosterone","Methyltestosterone","D008777",1,1,0,0,0,2,2,0,4]
["Methylthiouracil","Methylthiouracil","D008779",0,0,0,0,0,0,0,0,4]
["Metronidazole","Metronidazole","D008795",0,0,0,0,0,0,1,2,4]
["Mevalonic Acid","Mevalonic Acid","D008798",0,4,0,0,0,22,0,2,4]
["muricholic acid","muricholic acid","C004821",0,0,0,0,0,1,0,0,4]
["N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid","N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid","C060076",0,0,0,0,0,0,0,0,4]
["N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine","N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine","C510788",0,0,0,0,0,0,0,0,4]
["Neomycin","Neomycin","D009355",0,4,0,0,0,4,0,2,4]
["oleoylethanolamide","oleoylethanolamide","C488250",0,0,0,0,4,1,0,1,4]
["Penicillin G","Penicillin G","D010400",0,0,0,0,0,0,0,0,4]
["perfluorododecanoic acid","perfluorododecanoic acid","C522391",0,0,0,0,0,0,0,0,4]
["Phenoxybenzamine","Phenoxybenzamine","D010643",0,0,0,0,0,0,0,0,4]
["piperonal","piperonal","C005454",0,0,0,0,0,0,0,0,4]
["psicose","psicose","C003243",0,0,0,0,1,1,0,0,4]
["purine","purine","C030985",0,0,0,0,0,0,0,0,4]
["Pyrazinamide","Pyrazinamide","D011718",0,0,0,0,0,0,0,0,4]
["retinol palmitate","retinol palmitate","C014794",0,8,0,0,1,10,1,1,4]
["rhapontin","rhapontin","C023538",0,0,0,0,0,1,0,0,4]
["rifaximin","rifaximin","C042734",0,0,0,0,0,0,0,1,4]
["salvianolic acid B","salvianolic acid B","C076944",0,0,0,0,2,6,0,0,4]
["Sesame Oil","Sesame Oil","D012715",0,0,0,0,0,4,0,0,4]
["shosaiko-to","shosaiko-to","C461320",1,0,0,0,0,0,1,0,4]
["SHU 508","SHU 508","C059891",0,0,0,0,0,0,0,0,4]
["silydianin","silydianin","C015505",0,0,0,0,0,0,0,0,4]
["Squalene","Squalene","D013185",1,6,0,0,1,8,1,0,4]
["thermozymocidin","thermozymocidin","C001996",0,1,0,0,0,1,0,0,4]
["thiobarbituric acid","thiobarbituric acid","C029684",0,2,0,0,0,2,0,0,4]
["thymoquinone","thymoquinone","C003466",0,0,0,0,0,3,1,0,4]
["trigonelline","trigonelline","C009560",0,0,0,0,0,0,0,0,4]
["yin-chen-hao-tang","yin-chen-hao-tang","C542425",0,0,0,0,0,0,0,0,4]
["zoledronic acid","zoledronic acid","C088658",0,0,0,0,0,2,0,0,4]
["(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine","(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine","C516138",0,0,0,0,0,0,0,0,3]
["1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide","1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide","C554616",0,0,0,0,0,0,0,0,3]
["1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide","1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide","C481758",0,0,0,0,0,0,0,0,3]
["1,1,1,2-tetrafluoro-2-chloroethane","1,1,1,2-tetrafluoro-2-chloroethane","C072959",0,0,0,0,0,0,0,0,3]
["1,2,3,4,7,8-hexachlorodibenzodioxin","1,2,3,4,7,8-hexachlorodibenzodioxin","C078219",4,0,0,3,0,0,2,0,3]
["1,3-butadiene","1,3-butadiene","C031763",0,0,0,0,0,0,0,0,3]
["1,3-dithia-2-thioxocyclopent-4-ene","1,3-dithia-2-thioxocyclopent-4-ene","C111193",0,0,0,0,0,0,0,0,3]
["1,4-bis(2-(3,5-dichloropyridyloxy))benzene","1,4-bis(2-(3,5-dichloropyridyloxy))benzene","C028474",8,1,0,0,0,1,0,0,3]
["10-carboxymethyl-9-acridanone","10-carboxymethyl-9-acridanone","C026430",0,0,0,0,0,0,0,0,3]
["17-iodoheptadecanoic acid","17-iodoheptadecanoic acid","C027252",0,0,0,0,0,0,0,0,3]
["18alpha-glycyrrhetinic acid","18alpha-glycyrrhetinic acid","C119129",0,0,0,0,0,0,0,1,3]
["1-Deoxynojirimycin","1-Deoxynojirimycin","D017485",0,0,0,0,1,3,0,0,3]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295",5,0,0,0,0,0,7,0,3]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C580,B580)","v":"2,2-dichloro-1,1,1-trifluoroethane"},"2,2-dichloro-1,1,1-trifluoroethane","C067411",0,0,0,0,0,0,0,0,3]
["2,2-difluoro-4-pentenoic acid","2,2-difluoro-4-pentenoic acid","C096093",0,0,0,0,0,0,0,0,3]
["2,2'-methylenebis(4-methyl-6-tert-butylphenol)","2,2'-methylenebis(4-methyl-6-tert-butylphenol)","C008437",0,0,0,0,0,0,0,0,3]
["2,2'-methylenebis(ethyl-6-tert-butylphenol)","2,2'-methylenebis(ethyl-6-tert-butylphenol)","C030577",0,0,0,0,0,0,0,0,3]
["24-norursodeoxycholic acid","24-norursodeoxycholic acid","C081331",0,0,0,0,0,0,0,0,3]
["2-fluoro-2-propyl-4-pentenoic acid","2-fluoro-2-propyl-4-pentenoic acid","C096095",0,0,0,0,0,0,0,0,3]
["2-heptylformononetin","2-heptylformononetin","C584672",0,0,0,0,0,0,0,0,3]
["2-methyl-3-(2-((4-nitrooxybutyloxy)carbonyl)vinyl)phenyl ursodeoxycholic acid ester","2-methyl-3-(2-((4-nitrooxybutyloxy)carbonyl)vinyl)phenyl ursodeoxycholic acid ester","C433771",0,0,0,0,0,0,0,0,3]
["2-propyl-4-pentenoic acid","2-propyl-4-pentenoic acid","C045022",0,0,0,0,0,0,0,0,3]
["3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid","3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid","C526273",0,0,0,0,0,0,0,0,3]
["3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","C090937",0,0,0,0,0,2,0,0,3]
["3,3'-Dichlorobenzidine","3,3'-Dichlorobenzidine","D015101",0,0,0,0,0,0,0,0,3]
["3,4-di-O-caffeoylquinic acid","3,4-di-O-caffeoylquinic acid","C478100",0,0,0,0,0,0,0,0,3]
["3,5-diethoxycarbonyl-1,4-dihydrocollidine","3,5-diethoxycarbonyl-1,4-dihydrocollidine","C530773",0,0,0,0,0,0,0,0,3]
["4-(4-fluorophenyl)-1,3-dithia-2-thioxocyclopent-4-ene","4-(4-fluorophenyl)-1,3-dithia-2-thioxocyclopent-4-ene","C111195",0,0,0,0,0,0,0,0,3]
["4,4-difluoro-4-bora-3a,4a-diaza-s-indacene","4,4-difluoro-4-bora-3a,4a-diaza-s-indacene","C095489",0,0,0,0,0,1,0,0,3]
["4,4'-methylenebis(2,6-di-tert-butylphenol)","4,4'-methylenebis(2,6-di-tert-butylphenol)","C030593",0,0,0,0,0,0,0,0,3]
["4-aminopyrazolo(3,4-d)pyrimidine","4-aminopyrazolo(3,4-d)pyrimidine","C004420",0,1,0,0,0,4,0,0,3]
["4-Butyrolactone","4-Butyrolactone","D015107",1,0,0,0,0,2,1,0,3]
["4-methylene-2-octyl-5-oxofuran-3-carboxylic acid","4-methylene-2-octyl-5-oxofuran-3-carboxylic acid","C406734",0,0,0,0,0,0,0,0,3]
["4-phenyl-1,3-dithia-2-thioxocyclopent-4-ene","4-phenyl-1,3-dithia-2-thioxocyclopent-4-ene","C111194",0,0,0,0,0,0,0,0,3]
["5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid","5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid","C499823",0,0,0,0,0,1,0,0,3]
["7-ketocholesterol","7-ketocholesterol","C003001",2,2,0,0,3,30,1,0,3]
["ABO Blood-Group System","ABO Blood-Group System","D000017",0,1,0,0,2,1,1,0,3]
["aceclofenac","aceclofenac","C056498",0,0,0,0,0,0,0,0,3]
["acetaminophen sulfate ester","acetaminophen sulfate ester","C045667",0,0,0,0,0,0,1,0,3]
["acetovanillone","acetovanillone","C056165",0,0,0,0,0,4,0,0,3]
["acetylhydrazine","acetylhydrazine","C014949",0,0,0,0,0,0,0,0,3]
["Acrylamide","Acrylamide","D020106",0,0,0,0,0,2,5,0,3]
["Acrylonitrile","Acrylonitrile","D000181",3,0,0,0,0,0,2,0,3]
["actein","actein","C096064",0,0,0,0,0,0,0,0,3]
["aflatoxin G1","aflatoxin G1","C027955",0,0,0,0,0,0,0,0,3]
["ajoene","ajoene","C048980",0,0,0,0,0,0,0,0,3]
["aliskiren","aliskiren","C446481",0,0,0,0,1,1,2,0,3]
["Allantoin","Allantoin","D000481",0,0,0,0,0,2,0,0,3]
["Allylamine","Allylamine","D000499",0,1,0,0,0,4,0,0,3]
["alpha-terpineol","alpha-terpineol","C016775",0,0,0,0,0,0,1,0,3]
["Alprostadil","Alprostadil","D000527",0,0,0,0,0,21,0,3,3]
["ALS-L1023","ALS-L1023","C000608553",0,0,0,0,0,0,0,0,3]
["AM 251","AM 251","C103505",0,0,0,0,0,0,0,0,3]
["Amantadine","Amantadine","D000547",0,0,0,0,0,0,1,0,3]
["Amitriptyline","Amitriptyline","D000639",0,0,0,0,0,0,0,0,3]
["Amitrole","Amitrole","D000640",0,0,0,0,0,0,0,0,3]
["amlexanox","amlexanox","C045742",0,0,0,0,0,0,0,0,3]
["amlodipine, atorvastatin drug combination","amlodipine, atorvastatin drug combination","C487936",0,0,0,0,0,2,0,0,3]
["Amoxicillin","Amoxicillin","D000658",0,0,0,0,0,0,0,0,3]
["Amphotericin B","Amphotericin B","D000666",0,2,0,0,0,20,0,0,3]
["Ampicillin","Ampicillin","D000667",0,0,0,0,0,0,0,0,3]
["Apomorphine","Apomorphine","D001058",0,0,0,0,0,0,0,0,3]
["aramchol","aramchol","C455117",0,0,0,0,0,1,0,1,3]
["arprinocid","arprinocid","C016245",0,0,0,0,0,0,0,0,3]
["artesunate","artesunate","C039726",0,0,0,0,0,1,0,0,3]
["asoxime chloride","asoxime chloride","C022870",0,0,0,0,0,0,0,0,3]
["aurapten","aurapten","C105832",0,0,0,0,0,0,0,0,3]
["AZ 876","AZ 876","C559287",0,0,0,0,0,0,0,0,3]
["beeswax","beeswax","C038228",0,0,0,0,0,0,0,0,3]
["beraprost","beraprost","C048081",0,0,0,0,0,0,0,0,3]
["berlition","berlition","C532845",0,0,0,0,0,0,0,0,3]
["beta-Aminoethyl Isothiourea","beta-Aminoethyl Isothiourea","D000338",0,0,0,0,0,0,0,0,3]
["beta-hydroxyphosphocarnitine","beta-hydroxyphosphocarnitine","C000598410",0,0,0,0,0,0,0,0,3]
["blackcurrant seed oil","blackcurrant seed oil","C077230",0,0,0,0,0,0,0,0,3]
["borage oil","borage oil","C079363",0,0,0,0,0,1,0,6,3]
["Bromocriptine","Bromocriptine","D001971",0,0,0,0,0,2,1,0,3]
["Bupropion","Bupropion","D016642",0,0,0,0,0,0,0,0,3]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C644,B644)","v":"butane"},"butane","C046888",0,0,0,0,0,0,0,0,3]
["Butylhydroxybutylnitrosamine","Butylhydroxybutylnitrosamine","D002085",1,0,0,0,0,0,1,0,3]
["calebin-A","calebin-A","C448819",0,0,0,0,0,0,0,0,3]
["Cannabidiol","Cannabidiol","D002185",1,0,0,0,0,2,5,0,3]
["Carbimazole","Carbimazole","D002231",0,1,0,0,0,1,0,0,3]
["Carbon Monoxide","Carbon Monoxide","D002248",1,1,0,0,0,6,2,0,3]
["carvedilol","carvedilol","C043211",0,0,0,0,0,15,1,2,3]
["Ceroid","Ceroid","D002566",0,0,0,0,0,8,0,0,3]
["Chlordecone","Chlordecone","D007631",0,1,0,0,0,2,1,0,3]
["Chlormadinone Acetate","Chlormadinone Acetate","D002715",0,2,0,0,0,2,0,0,3]
["Chloroquine","Chloroquine","D002738",0,3,0,1,0,17,1,0,3]
["Chlorothiazide","Chlorothiazide","D002740",0,0,0,0,0,0,0,0,3]
["cholest-5-en-3 beta,7 alpha-diol","cholest-5-en-3 beta,7 alpha-diol","C011724",0,0,0,0,1,10,0,0,3]
["choline, dehydrocholic acid, magnesium orotate, orotic acid, Vitamin B12 drug combination","choline, dehydrocholic acid, magnesium orotate, orotic acid, Vitamin B12 drug combination","C015916",0,0,0,0,0,0,0,0,3]
["chrysin","chrysin","C043561",7,0,0,0,0,1,10,0,3]
["chuangxiong extract","chuangxiong extract","C101574",0,0,0,0,0,0,0,0,3]
["Cimetidine","Cimetidine","D002927",0,0,0,0,0,0,5,0,3]
["cinnamic acid","cinnamic acid","C029010",0,0,0,0,0,0,0,0,3]
["ciprofibrate","ciprofibrate","C019304",0,3,0,0,1,14,2,3,3]
["Clioquinol","Clioquinol","D007464",0,0,0,0,0,0,0,0,3]
["clozapine N-oxide","clozapine N-oxide","C079149",0,0,0,0,0,0,1,0,3]
["cobaltiprotoporphyrin","cobaltiprotoporphyrin","C007095",0,0,0,0,0,0,0,0,3]
["Colesevelam Hydrochloride","Colesevelam Hydrochloride","D000069472",0,1,0,0,0,4,0,0,3]
["crataegus extract","crataegus extract","C007145",0,1,0,0,0,1,0,0,3]
["crocin","crocin","C029036",0,0,0,0,0,3,0,0,3]
["cucurbitacin B","cucurbitacin B","C041246",0,0,0,0,0,0,0,0,3]
["Cyanamide","Cyanamide","D003484",0,0,0,0,0,0,0,0,3]
["cyanidin","cyanidin","C017154",0,0,0,0,0,1,0,0,3]
["cyclopropanecarboxylic acid","cyclopropanecarboxylic acid","C015766",0,0,0,0,0,0,0,0,3]
["cyproconazole","cyproconazole","C093628",0,0,0,0,0,0,0,0,3]
["Cytochalasin B","Cytochalasin B","D003571",0,0,0,0,0,1,0,0,3]
["Cytosine","Cytosine","D003596",0,0,0,1,0,2,0,0,3]
["D 002","D 002","C104511",0,0,0,0,0,0,0,0,3]
["Dabigatran","Dabigatran","D000069604",0,0,0,0,0,0,0,0,3]
["Dacarbazine","Dacarbazine","D003606",0,0,0,0,0,0,3,0,3]
["Daunorubicin","Daunorubicin","D003630",0,0,0,0,1,14,0,0,3]
["Desmosterol","Desmosterol","D003897",0,0,0,0,0,2,0,0,3]
["Desoximetasone","Desoximetasone","D003899",0,0,0,0,0,0,0,0,3]
["Dextropropoxyphene","Dextropropoxyphene","D011431",0,0,0,0,0,0,0,0,3]
["diallyl trisulfide","diallyl trisulfide","C042577",0,0,0,0,0,2,1,0,3]
["diarachidonyl diglyceride","diarachidonyl diglyceride","C035561",0,0,0,0,0,0,0,0,3]
["dibenz(b,f)(1,4)oxazepine","dibenz(b,f)(1,4)oxazepine","C036433",0,0,0,0,0,0,0,0,3]
["dibutyldichlorotin","dibutyldichlorotin","C020735",0,0,0,0,0,0,0,0,3]
["Diclofenac","Diclofenac","D004008",1,0,0,0,0,2,5,0,3]
["Dienestrol","Dienestrol","D004028",0,0,0,0,0,0,0,0,3]
["difebarbamate, febarbamate, phenobarbital drug combination","difebarbamate, febarbamate, phenobarbital drug combination","C006648",0,0,0,0,0,0,0,0,3]
["dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate","dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate","C510843",0,0,0,0,0,0,0,0,3]
["di-n-butyltin","di-n-butyltin","C056189",0,0,0,0,0,0,0,0,3]
["disalicylaldehyde ethylenediamine","disalicylaldehyde ethylenediamine","C011452",0,0,0,0,0,0,0,0,3]
["Doxylamine","Doxylamine","D004319",0,0,0,0,0,0,0,0,3]
["elaidic acid","elaidic acid","C011459",0,1,0,0,1,3,0,8,3]
["eleostearic acid","eleostearic acid","C004934",0,0,0,0,0,0,0,2,3]
["empagliflozin","empagliflozin","C570240",0,0,0,0,0,0,0,0,3]
["Enflurane","Enflurane","D004737",0,0,0,0,0,0,0,3,3]
["epicatechin gallate","epicatechin gallate","C062669",0,0,0,0,0,2,1,0,3]
["erucic acid","erucic acid","C049811",0,0,0,0,0,0,0,8,3]
["Escin","Escin","D004928",0,0,0,0,0,0,0,0,3]
["esculetin","esculetin","C007628",0,0,0,0,0,1,0,0,3]
["ethylene dichloride","ethylene dichloride","C024565",0,0,0,0,0,0,0,0,3]
["ethylmethylhydroxypyridine succinate","ethylmethylhydroxypyridine succinate","C517040",0,0,0,0,0,0,0,0,3]
["EUK-134","EUK-134","C433928",0,0,0,0,0,0,0,0,3]
["Famotidine","Famotidine","D015738",0,0,0,0,0,0,1,0,3]
["fenarimol","fenarimol","C033789",0,0,0,0,0,0,2,0,3]
["Fenitrothion","Fenitrothion","D005278",0,0,0,0,0,0,2,0,3]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C708,B708)","v":"fenugreek seed meal"},"fenugreek seed meal","C056164",0,0,0,0,0,1,0,0,3]
["fexofenadine","fexofenadine","C093230",0,0,0,0,1,0,0,0,3]
["Finasteride","Finasteride","D018120",0,0,0,0,0,0,0,0,3]
["Fingolimod Hydrochloride","Fingolimod Hydrochloride","D000068876",1,0,0,0,0,3,0,0,3]
["fipronil","fipronil","C082360",0,0,0,0,0,0,0,0,3]
["flavan-3-ol","flavan-3-ol","C404987",0,0,0,0,0,0,0,0,3]
["flavangenol","flavangenol","C504746",0,0,0,0,0,0,0,0,3]
["formononetin","formononetin","C007768",1,0,0,0,0,0,1,0,3]
["fosamprenavir","fosamprenavir","C426859",0,0,0,0,0,0,0,0,3]
["fructose 2,6-diphosphate","fructose 2,6-diphosphate","C027652",0,0,0,2,0,0,0,0,3]
["Fucose","Fucose","D005643",0,1,0,0,0,2,0,0,3]
["fucoxanthin","fucoxanthin","C025164",0,0,0,0,0,0,0,3,3]
["fuzheng huayu","fuzheng huayu","C532829",0,0,0,0,0,0,0,0,3]
["Galantamine","Galantamine","D005702",0,0,0,0,0,0,0,0,3]
["gamma-oryzanol","gamma-oryzanol","C013172",0,0,0,1,0,1,0,0,3]
["gamma-Tocopherol","gamma-Tocopherol","D024504",1,3,0,0,2,4,1,0,3]
["gardenoside","gardenoside","C056587",0,0,0,0,0,0,0,0,3]
["Gasoline","Gasoline","D005742",2,0,0,0,0,2,13,0,3]
["GGEx18","GGEx18","C573356",0,0,0,0,0,0,0,0,3]
["ginsenoside Rg3","ginsenoside Rg3","C097367",0,0,0,0,0,1,0,0,3]
["Gliclazide","Gliclazide","D005907",0,0,0,0,1,12,0,0,3]
["Glucaric Acid","Glucaric Acid","D005937",0,0,0,0,0,0,0,0,3]
["gosha-jinki-gan","gosha-jinki-gan","C119642",0,0,0,0,0,0,0,0,3]
["guar gum","guar gum","C007894",0,1,0,0,0,7,0,0,3]
["Halofenate","Halofenate","D006218",0,4,0,0,0,3,0,0,3]
["Herpes Zoster Vaccine","Herpes Zoster Vaccine","D053061",0,0,0,0,0,0,0,0,3]
["Hesperidin","Hesperidin","D006569",2,2,0,0,0,6,3,1,3]
["hexachloro-4-xylene","hexachloro-4-xylene","C000294",0,0,0,0,0,0,0,0,3]
["Hexachlorophene","Hexachlorophene","D006582",0,0,0,0,0,0,0,0,3]
["hexadecafluoro-nonanoic acid","hexadecafluoro-nonanoic acid","C018959",0,0,0,0,0,0,0,0,3]
["hydroxycitric acid","hydroxycitric acid","C007999",0,0,0,3,1,5,0,0,3]
["Hydroxyurea","Hydroxyurea","D006918",0,0,0,1,4,0,0,0,3]
["imidazolone","imidazolone","C117197",0,0,0,0,0,0,0,0,3]
["Industrial Waste","Industrial Waste","D007220",10,0,0,0,0,0,52,0,3]
["isopentane","isopentane","C067038",0,0,0,0,0,0,0,0,3]
["isoprothiolane","isoprothiolane","C023889",0,0,0,0,0,0,0,0,3]
["ivacaftor","ivacaftor","C545203",0,0,0,0,0,0,0,0,3]
["JD5037","JD5037","C577200",0,0,0,0,0,0,0,0,3]
["Kainic Acid","Kainic Acid","D007608",2,0,0,0,0,0,2,0,3]
["kartolin 2","kartolin 2","C068790",0,0,0,0,0,0,0,0,3]
["Kerosene","Kerosene","D007648",0,0,0,0,0,0,0,0,3]
["Ketoconazole","Ketoconazole","D007654",9,0,0,0,0,9,15,0,3]
["kutkin","kutkin","C057463",0,0,0,0,0,4,0,0,3]
["lauryl gallate","lauryl gallate","C008259",0,0,0,0,0,0,0,0,3]
["LDN 193189","LDN 193189","C554430",0,0,0,0,0,2,0,0,3]
["lei gong teng","lei gong teng","C041579",0,0,0,0,0,0,0,0,3]
["limonene","limonene","C008281",0,0,0,0,0,1,0,0,3]
["Lipofuscin","Lipofuscin","D008062",0,0,0,0,0,6,0,0,3]
["LY2409021","LY2409021","C000601762",0,0,0,0,0,0,0,0,3]
["lysophosphatidylinositol","lysophosphatidylinositol","C025449",0,0,0,0,0,0,0,0,3]
["Malathion","Malathion","D008294",0,0,0,1,0,1,2,0,3]
["Maprotiline","Maprotiline","D008376",0,0,0,0,0,0,0,0,3]
["Medroxyprogesterone Acetate","Medroxyprogesterone Acetate","D017258",0,3,0,0,0,9,0,1,3]
["Mefloquine","Mefloquine","D015767",0,0,0,0,0,0,0,0,3]
["Methanol","Methanol","D000432",1,0,0,0,0,3,1,0,3]
["Methenolone","Methenolone","D008710",0,0,0,0,0,0,0,0,3]
["Methotrimeprazine","Methotrimeprazine","D008728",0,0,0,0,0,0,0,0,3]
["Methoxamine","Methoxamine","D008729",0,0,0,0,0,0,0,0,3]
["methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate","methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate","C445068",0,0,0,0,0,0,0,0,3]
["methyl iodide","methyl iodide","C014055",0,0,0,0,0,0,0,0,3]
["methyl linoleate hydroperoxide","methyl linoleate hydroperoxide","C008464",0,0,0,0,0,0,0,0,3]
["Methylcholanthrene","Methylcholanthrene","D008748",97,0,0,0,0,0,82,2,3]
["Metoclopramide","Metoclopramide","D008787",0,0,0,0,0,0,0,0,3]
["Metyrapone","Metyrapone","D008797",0,0,0,0,0,0,5,0,3]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C772,B772)","v":"Mianserin"},"Mianserin","D008803",0,0,0,0,0,1,0,0,3]
["milacemide","milacemide","C039332",0,0,0,0,0,0,1,0,3]
["mirtazapine","mirtazapine","C035133",0,0,0,0,0,1,0,0,3]
["MK0626","MK0626","C570834",0,0,0,0,0,0,0,0,3]
["MK615 extract","MK615 extract","C517469",0,0,0,0,0,0,0,0,3]
["ML 7","ML 7","C070571",0,0,0,0,0,0,0,0,3]
["monascin","monascin","C517880",0,0,0,0,0,0,0,0,3]
["Monocrotaline","Monocrotaline","D016686",0,0,0,0,0,2,0,0,3]
["morphine-3-glucuronide","morphine-3-glucuronide","C018108",0,0,0,0,0,0,0,0,3]
["mustard oil","mustard oil","C027793",0,1,0,0,0,0,0,0,3]
["N-((2-hydroxy-3-N,N-dimethylhexadecylammonium)propyl)chitosan chloride","N-((2-hydroxy-3-N,N-dimethylhexadecylammonium)propyl)chitosan chloride","C569571",0,0,0,0,0,1,0,0,3]
["N-(2-hydroxy-2-phenylethyl)-6-(4-(2-methylbenzoyl)piperidin-1-yl)pyridazine-3-carboxamide","N-(2-hydroxy-2-phenylethyl)-6-(4-(2-methylbenzoyl)piperidin-1-yl)pyridazine-3-carboxamide","C582665",0,0,0,0,0,0,0,1,3]
["N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide","N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide","C492919",0,0,0,0,0,0,0,0,3]
["N,N'-bis(salicylideneamino)ethane-manganese(II)","N,N'-bis(salicylideneamino)ethane-manganese(II)","C090577",0,0,0,0,0,0,0,0,3]
["N,N'-diphenyl-4-phenylenediamine","N,N'-diphenyl-4-phenylenediamine","C004845",0,0,0,0,0,1,0,0,3]
["Nalidixic Acid","Nalidixic Acid","D009268",0,0,0,0,0,0,2,0,3]
["Nelfinavir","Nelfinavir","D019888",0,0,0,0,0,0,0,0,3]
["nile red","nile red","C044808",0,0,0,0,0,4,0,0,3]
["Niridazole","Niridazole","D009560",0,0,0,0,0,0,0,0,3]
["nitroaspirin","nitroaspirin","C102148",0,0,0,0,0,3,0,0,3]
["Nitrosomethylurethane","Nitrosomethylurethane","D009605",0,0,0,0,0,0,0,0,3]
["Non-Ovlon","Non-Ovlon","C010260",0,0,0,0,0,0,0,0,3]
["Norethandrolone","Norethandrolone","D009639",0,0,0,0,0,0,0,0,3]
["NP-1 compound","NP-1 compound","C572148",0,0,0,0,0,0,0,0,3]
["O2-vinyl 1-(2-(carboxylato)pyrrolidin-1-yl)diazen-1-ium-1,2-diolate","O2-vinyl 1-(2-(carboxylato)pyrrolidin-1-yl)diazen-1-ium-1,2-diolate","C560906",0,0,0,0,0,0,1,0,3]
["Obidoxime Chloride","Obidoxime Chloride","D009768",0,0,0,0,0,0,0,0,3]
["O-carboxymethylchitosan","O-carboxymethylchitosan","C504164",0,0,0,0,0,1,0,0,3]
["olanzapine","olanzapine","C076029",1,3,0,0,1,4,2,3,3]
["Omacor","Omacor","C405603",0,4,0,0,0,2,0,0,3]
["Opium","Opium","D009892",0,0,0,0,0,0,0,0,3]
["paclobutrazol","paclobutrazol","C053370",1,0,0,0,0,0,1,0,3]
["panadiplon","panadiplon","C069443",0,0,0,0,0,0,0,0,3]
["Paraquat","Paraquat","D010269",0,0,0,1,0,1,3,3,3]
["Parathion","Parathion","D010278",0,0,0,0,0,1,3,0,3]
["pazopanib","pazopanib","C516667",0,0,0,0,0,0,0,0,3]
["pentabromodiphenyl ether","pentabromodiphenyl ether","C086401",5,0,0,1,0,0,10,0,3]
["perfluorobutane","perfluorobutane","C108042",0,0,0,0,0,0,0,0,3]
["Perindopril","Perindopril","D020913",0,1,0,0,0,0,0,0,3]
["Peroxynitrous Acid","Peroxynitrous Acid","D030421",0,0,0,0,1,31,0,0,3]
["Pertussis Vaccine","Pertussis Vaccine","D010567",0,0,0,0,0,0,0,0,3]
["phenacyl bromide","phenacyl bromide","C013190",0,0,0,0,0,0,0,0,3]
["phenyl-N-tert-butylnitrone","phenyl-N-tert-butylnitrone","C029217",0,2,0,0,0,2,0,0,3]
["Phloretin","Phloretin","D010693",0,0,0,0,0,0,0,0,3]
["photomirex","photomirex","C016665",0,0,0,0,0,0,0,0,3]
["pifithrin","pifithrin","C121565",6,0,0,0,0,2,3,0,3]
["Pikasol","Pikasol","C077446",0,0,0,0,0,0,0,3,3]
["Pirenzepine","Pirenzepine","D010890",0,0,0,0,0,0,0,0,3]
["PNU-282987","PNU-282987","C498513",0,0,0,0,0,0,0,0,3]
["PolyGlycoplex","PolyGlycoplex","C540519",0,0,0,0,0,0,0,0,3]
["polyol","polyol","C024617",0,0,0,0,0,0,0,0,3]
["polysorbate 40","polysorbate 40","C068430",0,0,0,0,0,0,0,0,3]
["Polytetrafluoroethylene","Polytetrafluoroethylene","D011138",0,0,0,0,0,1,0,0,3]
["Proadifen","Proadifen","D011335",0,0,0,0,0,1,1,0,3]
["procyanidin B1","procyanidin B1","C479579",0,0,0,0,0,0,0,0,3]
["pyrazole","pyrazole","C031280",0,0,0,0,0,0,2,0,3]
["qinggan huoxue","qinggan huoxue","C527179",0,0,0,0,0,0,0,0,3]
["qingzhi","qingzhi","C539708",0,0,0,0,0,0,0,0,3]
["quinomethionate","quinomethionate","C005266",0,0,0,0,0,0,0,0,3]
["ragaglitazar","ragaglitazar","C432703",0,0,0,0,0,0,0,0,3]
["raltitrexed","raltitrexed","C068874",0,0,0,0,0,0,0,0,3]
["resazurin","resazurin","C005843",0,0,0,0,0,0,0,0,3]
["retinol oleate","retinol oleate","C042067",0,1,0,0,0,0,0,0,3]
["rilmenidine","rilmenidine","C032302",0,0,0,0,0,0,0,0,3]
["Rolitetracycline","Rolitetracycline","D012382",0,0,0,0,0,0,0,0,3]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C836,B836)","v":"RS 102895"},"RS 102895","C573791",0,0,0,0,0,0,0,0,3]
["rubratoxins","rubratoxins","C100297",0,0,0,1,0,0,0,0,3]
["S 17092-1","S 17092-1","C118986",0,0,0,0,0,0,0,0,3]
["S 4048","S 4048","C403582",0,1,0,0,0,0,0,0,3]
["Safflower Oil","Safflower Oil","D012450",0,4,0,0,0,14,0,17,3]
["Santowhite powder","Santowhite powder","C030594",0,0,0,0,0,0,0,0,3]
["sanumgerman","sanumgerman","C050437",0,0,0,0,0,0,0,0,3]
["Selenic Acid","Selenic Acid","D064586",3,0,0,2,0,0,1,0,3]
["Shao-Fu-Zhu-Yu","Shao-Fu-Zhu-Yu","C529850",0,0,0,0,0,0,0,0,3]
["Simazine","Simazine","D012839",3,0,0,0,0,0,1,0,3]
["simvastatin hydroxyacid","simvastatin hydroxyacid","C532833",0,0,0,0,0,0,0,0,3]
["sinigrin","sinigrin","C010330",0,0,0,0,0,1,0,0,3]
["Sodium Cholate","Sodium Cholate","D020358",0,1,0,0,0,2,0,1,3]
["Sodium Fluoride","Sodium Fluoride","D012969",0,0,0,0,0,0,1,0,3]
["sodium nitrate","sodium nitrate","C031618",0,0,0,0,0,0,0,0,3]
["Soman","Soman","D012999",0,0,0,0,0,0,0,0,3]
["Spermine","Spermine","D013096",0,0,0,0,0,3,0,0,3]
["SRT1720","SRT1720","C525422",0,0,0,0,0,0,0,0,3]
["stearidonic acid","stearidonic acid","C062895",0,0,0,0,0,1,0,20,3]
["Steel","Steel","D013232",0,0,0,0,0,0,0,0,3]
["Styrene","Styrene","D020058",2,0,0,1,0,0,3,0,3]
["Sulfamethoxazole","Sulfamethoxazole","D013420",0,1,0,0,0,0,2,0,3]
["Sulfur Dioxide","Sulfur Dioxide","D013458",0,0,0,0,0,0,3,0,3]
["taeeumjowuitang","taeeumjowuitang","C000620173",0,0,0,0,0,0,0,0,3]
["Taheebo","Taheebo","C543691",0,0,0,0,0,0,1,0,3]
["taizhi'an","taizhi'an","C513940",0,0,0,0,0,0,0,0,3]
["TAK-652","TAK-652","C506967",0,0,0,0,0,0,0,0,3]
["temozolomide","temozolomide","C047246",0,0,0,0,0,0,0,0,3]
["Terfenadine","Terfenadine","D016593",0,0,0,0,1,0,0,0,3]
["tetraarsenic tetrasulfide","tetraarsenic tetrasulfide","C534735",0,0,0,0,0,0,0,0,3]
["theaflavin","theaflavin","C056068",3,0,0,0,0,2,3,0,3]
["Thioacetazone","Thioacetazone","D013828",0,0,0,0,0,0,0,0,3]
["Thioridazine","Thioridazine","D013881",0,0,0,0,0,0,1,0,3]
["Thiouracil","Thiouracil","D013889",0,0,0,0,0,0,0,0,3]
["Thiourea","Thiourea","D013890",0,0,0,0,0,1,1,0,3]
["Thromboxane B2","Thromboxane B2","D013929",0,1,0,0,0,6,0,0,3]
["tianeptine","tianeptine","C050504",0,0,0,0,0,0,0,0,3]
["tocotrienol, delta","tocotrienol, delta","C082097",0,1,0,0,0,1,0,0,3]
["Tolmetin","Tolmetin","D014046",0,0,0,0,0,0,0,0,3]
["tranilast","tranilast","C012293",4,0,0,0,0,1,1,0,3]
["tricarbonyldichlororuthenium (II) dimer","tricarbonyldichlororuthenium (II) dimer","C447082",0,0,0,0,0,2,0,0,3]
["Trichlorfon","Trichlorfon","D014236",0,0,0,0,0,0,0,0,3]
["trichlorobenzene","trichlorobenzene","C036720",0,0,0,0,0,0,0,0,3]
["Trifluoperazine","Trifluoperazine","D014268",0,0,0,0,0,5,0,0,3]
["Trinitrotoluene","Trinitrotoluene","D014303",0,0,0,0,0,0,3,0,3]
["Triolein","Triolein","D014304",0,6,0,0,0,6,0,4,3]
["triptolide","triptolide","C001899",0,0,0,0,0,0,0,0,3]
["troxerutin","troxerutin","C005865",0,0,0,0,0,0,0,0,3]
["U 0126","U 0126","C113580",4,0,0,0,0,0,2,0,3]
["ursodeoxycholyl lysophosphatidylethanolamide","ursodeoxycholyl lysophosphatidylethanolamide","C000598975",0,0,0,0,0,0,0,0,3]
["urushiol","urushiol","C003747",0,0,0,0,0,0,0,0,3]
["Vanillic Acid","Vanillic Acid","D014641",0,0,0,0,0,4,0,0,3]
["Y 27632","Y 27632","C108830",0,0,0,0,0,1,0,0,3]
["Zinc Oxide","Zinc Oxide","D015034",1,0,0,0,0,1,1,0,3]
["zinc protoporphyrin","zinc protoporphyrin","C017803",0,0,0,0,0,0,0,0,3]
["zopolrestat","zopolrestat","C067172",0,0,0,0,0,0,0,0,3]
["(2-(2',3'-dihydrobenzo(1,4)dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethylethyl)nonanoic acid amide","(2-(2',3'-dihydrobenzo(1,4)dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethylethyl)nonanoic acid amide","C520404",0,0,0,0,0,0,0,0,2]
["(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid","(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid","C487689",0,0,0,0,0,0,0,0,2]
["(Z)-N-(2-hydroxyethyl) docos-13-enamide","(Z)-N-(2-hydroxyethyl) docos-13-enamide","C583814",0,0,0,0,0,0,0,0,2]
["1,25-dihydroxyvitamin D","1,25-dihydroxyvitamin D","C097949",0,0,0,0,1,1,0,1,2]
["1,3-dichloro-2-propanol","1,3-dichloro-2-propanol","C033489",0,0,0,0,0,0,0,0,2]
["13-oxo-9,11-octadecadienoic acid","13-oxo-9,11-octadecadienoic acid","C064441",0,0,0,0,0,0,0,0,2]
["1-aminobenzotriazole","1-aminobenzotriazole","C033020",0,0,0,0,0,0,6,0,2]
["1-hexacosanol","1-hexacosanol","C051942",0,0,0,0,0,0,0,0,2]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C900,B900)","v":"2-((2,4-dihydroxyphenyl)sulfonyl)isoindoline-4,6-diol"},"2-((2,4-dihydroxyphenyl)sulfonyl)isoindoline-4,6-diol","C588035",0,0,0,0,0,0,0,0,2]
["2,4-dinitrophenol methyl ether","2,4-dinitrophenol methyl ether","C000590645",0,0,0,0,0,0,0,0,2]
["2,5-bis(2-fluoro-6-(trifluoromethyl)benzylidene)cyclopentanone","2,5-bis(2-fluoro-6-(trifluoromethyl)benzylidene)cyclopentanone","C000615599",0,0,0,0,0,0,0,0,2]
["25-Hydroxyvitamin D 2","25-Hydroxyvitamin D 2","D015652",0,0,0,0,0,0,0,0,2]
["2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide","2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide","C492908",0,0,0,0,0,0,0,0,2]
["2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione","2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione","C581182",0,0,0,0,0,0,0,0,2]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621",6,0,0,0,0,1,2,0,2]
["3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid","3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid","C487112",0,0,0,0,0,0,0,0,2]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392",14,0,0,0,0,0,13,0,2]
["3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid","3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid","C049113",0,0,0,0,0,0,0,0,2]
["3-methylquercetin","3-methylquercetin","C047368",0,1,0,0,0,3,0,0,2]
["4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one","4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one","C557982",0,0,0,0,0,0,0,0,2]
["4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone","4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone","C016583",1,0,0,0,0,0,1,0,2]
["4-Aminobenzoic Acid","4-Aminobenzoic Acid","D010129",0,0,0,0,0,0,0,0,2]
["4-O-methylhonokiol","4-O-methylhonokiol","C542058",0,0,0,0,0,0,0,0,2]
["5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","C581247",0,0,0,0,0,3,0,0,2]
["5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline","5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline","C517687",0,0,0,0,0,0,0,0,2]
["5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one","5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one","C080669",0,0,0,0,0,0,0,0,2]
["6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid","6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid","C000595150",0,0,0,0,0,0,0,0,2]
["6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)","6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)","C011923",0,0,0,0,0,0,0,0,2]
["6,6'-methylenebis(2,2-dimethyl-4-methanesulfonic acid-1,2-dihydroquinoline)","6,6'-methylenebis(2,2-dimethyl-4-methanesulfonic acid-1,2-dihydroquinoline)","C044964",0,0,0,0,0,1,0,0,2]
["6-Aminonicotinamide","6-Aminonicotinamide","D015120",0,0,0,0,0,0,0,0,2]
["6-methyluracil","6-methyluracil","C008378",0,0,0,0,0,0,0,0,2]
["6-N-methylnaltrexamine","6-N-methylnaltrexamine","C000619250",0,0,0,0,0,0,0,0,2]
["7 alpha-hydroxy-4-cholesten-3-one","7 alpha-hydroxy-4-cholesten-3-one","C002656",0,0,0,0,0,1,0,0,2]
["7-(4,6-di-tert-butylpyrimidin-2-yl)-3-(4-trifluoromethoxyphenyl)-5,6,7,8-tetrahydro(1,2,4)triazolo(4,3-a)pyrazine","7-(4,6-di-tert-butylpyrimidin-2-yl)-3-(4-trifluoromethoxyphenyl)-5,6,7,8-tetrahydro(1,2,4)triazolo(4,3-a)pyrazine","C000606936",0,0,0,0,0,0,0,0,2]
["Acetazolamide","Acetazolamide","D000086",0,0,0,0,0,0,0,0,2]
["Acetylcholine","Acetylcholine","D000109",0,0,0,0,0,4,0,2,2]
["acrylic acid","acrylic acid","C036658",0,0,0,0,0,0,0,2,2]
["Agar","Agar","D000362",0,0,0,0,0,5,0,0,2]
["Alendronate","Alendronate","D019386",0,0,0,0,0,0,0,0,2]
["Allylisopropylacetamide","Allylisopropylacetamide","D000502",0,0,0,0,0,0,1,0,2]
["alpha-Chlorohydrin","alpha-Chlorohydrin","D000517",0,0,0,0,0,0,0,0,2]
["alpha-glycerophosphoric acid","alpha-glycerophosphoric acid","C029620",0,1,0,3,0,0,0,1,2]
["alpha-ketoisocaproic acid","alpha-ketoisocaproic acid","C013082",0,0,0,0,0,0,0,0,2]
["alpha-naphthoflavone","alpha-naphthoflavone","C011512",27,0,0,0,0,0,20,1,2]
["ambrisentan","ambrisentan","C467894",0,0,0,0,0,0,0,0,2]
["aminosterol 1436","aminosterol 1436","C117498",0,0,0,0,0,0,0,0,2]
["ammonium acetate","ammonium acetate","C018824",0,0,0,0,0,0,0,0,2]
["Amylose","Amylose","D000688",0,0,0,0,0,0,0,0,2]
["anhydroecgonine methyl ester","anhydroecgonine methyl ester","C068464",0,0,0,0,0,0,0,0,2]
["antioxidant biofactor AOB","antioxidant biofactor AOB","C501911",0,0,0,0,0,0,0,0,2]
["argatroban","argatroban","C031942",0,0,0,0,0,1,0,0,2]
["arogya-wardhani","arogya-wardhani","C020973",0,0,0,0,0,0,0,0,2]
["arsenite","arsenite","C015001",8,0,0,1,1,0,9,0,2]
["AS602868","AS602868","C519899",0,0,0,0,0,0,0,0,2]
["ascorbic acid 2-sulfate","ascorbic acid 2-sulfate","C001956",0,0,0,0,0,0,0,0,2]
["asiatic acid","asiatic acid","C017032",0,0,0,0,0,0,0,0,2]
["B-22956-1","B-22956-1","C440468",0,0,0,0,0,0,0,0,2]
["barium chloride","barium chloride","C024986",0,0,0,0,0,0,0,0,2]
["bendiocarb","bendiocarb","C007725",0,0,0,0,0,0,0,0,2]
["benzohexonium","benzohexonium","C021628",0,0,0,0,0,0,0,0,2]
["betaine citrate","betaine citrate","C018229",0,0,0,0,0,0,0,0,2]
["betaine glucuronate","betaine glucuronate","C416677",0,0,0,0,0,0,0,0,2]
["bicalutamide","bicalutamide","C053541",0,0,0,0,0,0,0,0,2]
["bifendate","bifendate","C465548",0,0,0,0,0,0,0,0,2]
["biochanin A","biochanin A","C004541",3,0,0,0,0,1,2,0,2]
["bis(4-hydroxycinnamoyl)methane","bis(4-hydroxycinnamoyl)methane","C034786",0,0,0,0,1,4,0,0,2]
["bixin","bixin","C004588",0,0,0,0,0,1,0,0,2]
["Buformin","Buformin","D002026",0,1,0,0,0,1,0,0,2]
["Calcium Gluconate","Calcium Gluconate","D002125",0,0,0,0,0,0,0,0,2]
["Calcium Hydroxide","Calcium Hydroxide","D002126",0,0,0,0,0,0,0,0,2]
["camphene","camphene","C019286",0,0,0,0,0,0,0,0,2]
["capsiate","capsiate","C470213",0,0,0,0,0,0,0,0,2]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C964,B964)","v":"carcinolipin"},"carcinolipin","C005463",0,0,0,0,0,0,0,0,2]
["CD68 antigen, human","CD68 antigen, human","C067980",0,0,0,0,2,14,0,0,2]
["cernilton","cernilton","C010070",0,0,0,0,0,1,0,0,2]
["Cerulenin","Cerulenin","D002569",0,0,0,0,1,0,0,2,2]
["Chalcone","Chalcone","D002599",0,0,0,0,1,5,4,0,2]
["chicoric acid","chicoric acid","C100435",0,0,0,0,0,2,0,0,2]
["Chlordiazepoxide","Chlordiazepoxide","D002707",0,0,0,0,0,0,0,0,2]
["Chlorisondamine","Chlorisondamine","D002714",0,0,0,0,0,0,0,0,2]
["cholagogum","cholagogum","C038265",0,0,0,0,0,0,0,0,2]
["cholebine","cholebine","C106574",0,1,0,0,0,3,0,0,2]
["Cholestanol","Cholestanol","D004083",0,0,0,0,0,5,0,0,2]
["chromic acid","chromic acid","C034944",0,0,0,0,0,0,0,0,2]
["chunggan","chunggan","C000589484",0,0,0,0,0,0,0,0,2]
["cinnamamide","cinnamamide","C411088",0,0,0,0,0,0,0,0,2]
["Ciprofloxacin","Ciprofloxacin","D002939",0,0,0,0,0,0,2,0,2]
["cis-9, trans-11-conjugated linoleic acid","cis-9, trans-11-conjugated linoleic acid","C503589",0,0,0,0,1,2,0,11,2]
["Cisapride","Cisapride","D020117",0,0,0,0,0,0,0,0,2]
["clematichinenoside","clematichinenoside","C581539",0,0,0,0,0,0,0,0,2]
["Clodronic Acid","Clodronic Acid","D004002",0,0,0,0,0,0,0,0,2]
["Clove Oil","Clove Oil","D045783",0,0,0,0,0,0,0,0,2]
["CNB 001","CNB 001","C529348",0,0,0,0,0,0,0,0,2]
["cocaethylene","cocaethylene","C066444",0,0,0,0,0,1,0,0,2]
["Codeine","Codeine","D003061",0,0,0,0,0,0,0,0,2]
["Coke","Coke","D003077",3,0,0,0,0,0,10,0,2]
["colestimide","colestimide","C417427",0,0,0,0,0,2,0,0,2]
["corosolic acid","corosolic acid","C113861",0,0,0,0,0,0,0,0,2]
["cumene hydroperoxide","cumene hydroperoxide","C007164",0,0,0,0,0,0,0,0,2]
["cyclopentanone","cyclopentanone","C007201",0,0,0,0,0,0,0,0,2]
["Cyproheptadine","Cyproheptadine","D003533",0,0,0,0,0,1,1,0,2]
["Cystamine","Cystamine","D003538",0,0,0,0,0,0,0,0,2]
["daisaikoto","daisaikoto","C051121",0,0,0,0,0,1,0,0,2]
["daumone, C elegans","daumone, C elegans","C496586",0,0,0,0,0,0,0,0,2]
["Dexamethasone Isonicotinate","Dexamethasone Isonicotinate","D003908",0,0,0,0,0,0,0,0,2]
["Dextran Sulfate","Dextran Sulfate","D016264",2,4,0,0,1,39,1,0,2]
["Dextroamphetamine","Dextroamphetamine","D003913",0,0,0,0,0,0,0,0,2]
["Diatrizoate","Diatrizoate","D003973",0,0,0,0,0,0,0,0,2]
["Diazoxide","Diazoxide","D003981",0,0,0,0,0,0,0,0,2]
["Dichlorodiphenyldichloroethane","Dichlorodiphenyldichloroethane","D003632",0,0,0,0,0,0,2,0,2]
["dicholine succinate","dicholine succinate","C000612721",0,0,0,0,0,0,0,0,2]
["diisononyl phthalate","diisononyl phthalate","C012125",0,0,0,0,0,0,2,0,2]
["Dimethylnitrosamine","Dimethylnitrosamine","D004128",0,0,0,0,0,0,2,0,2]
["dronedarone","dronedarone","C118667",0,0,0,0,0,0,0,0,2]
["DT56a","DT56a","C478341",0,0,0,0,0,0,0,0,2]
["ecgonine methyl ester","ecgonine methyl ester","C034524",0,0,0,0,0,1,0,0,2]
["efavirenz","efavirenz","C098320",0,0,0,0,0,2,0,0,2]
["eliglustat","eliglustat","C522917",0,0,0,0,0,0,0,0,2]
["Emetine","Emetine","D004640",0,0,0,0,0,0,0,0,2]
["Engerix-B","Engerix-B","C075654",0,0,0,0,0,0,0,0,2]
["Eosine Yellowish-(YS)","Eosine Yellowish-(YS)","D004801",0,0,0,0,0,0,0,0,2]
["Epichlorohydrin","Epichlorohydrin","D004811",0,0,0,0,0,2,0,0,2]
["epiplakin","epiplakin","C426678",0,0,0,0,0,0,0,0,2]
["eriocitrin","eriocitrin","C114706",0,0,0,0,0,0,0,0,2]
["Ethambutol","Ethambutol","D004977",0,0,0,0,0,0,0,0,2]
["Ethanolamine","Ethanolamine","D019856",0,3,0,0,0,0,0,5,2]
["Ether","Ether","D004986",0,0,0,0,0,1,0,0,2]
["ethyl 2-(4-(bis(1-ethyl-1H-indol-3-yl)methyl)phenoxy)propanoate","ethyl 2-(4-(bis(1-ethyl-1H-indol-3-yl)methyl)phenoxy)propanoate","C573841",0,0,0,0,0,1,0,0,2]
["ethyl 4-(4-(bis(1-methyl-1H-indol-3-yl)methyl)phenoxy)butanoate","ethyl 4-(4-(bis(1-methyl-1H-indol-3-yl)methyl)phenoxy)butanoate","C573842",0,0,0,0,0,1,0,0,2]
["ethyl acetate","ethyl acetate","C007650",0,0,0,0,0,0,0,0,2]
["Ethylene Chlorohydrin","Ethylene Chlorohydrin","D005023",0,0,0,0,0,0,0,0,2]
["Ethylnitrosourea","Ethylnitrosourea","D005038",0,0,0,0,0,1,0,0,2]
["Etodolac","Etodolac","D017308",0,0,0,0,1,0,0,0,2]
["eucalyptol","eucalyptol","C010087",0,0,0,0,0,1,1,0,2]
["evodiamine","evodiamine","C049639",1,0,0,0,0,0,2,0,2]
["fatclean","fatclean","C544329",0,0,0,0,0,0,0,0,2]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1028,B1028)","v":"Febuxostat"},"Febuxostat","D000069465",0,0,0,0,0,2,0,0,2]
["Fenfluramine","Fenfluramine","D005277",0,1,0,1,0,2,0,2,2]
["fenofibric acid","fenofibric acid","C006012",0,4,0,0,0,11,0,0,2]
["ferric citrate","ferric citrate","C025314",0,0,0,0,0,0,0,0,2]
["ferric oxide","ferric oxide","C000499",0,0,0,0,0,1,3,0,2]
["ferrous sulfate","ferrous sulfate","C020748",0,0,0,0,0,2,0,0,2]
["ferulic acid","ferulic acid","C004999",0,0,0,1,0,12,1,0,2]
["ferumoxtran-10","ferumoxtran-10","C097921",0,0,0,0,2,0,0,0,2]
["Fluorescein","Fluorescein","D019793",0,0,0,0,0,1,0,0,2]
["G004 compound","G004 compound","C000600709",0,0,0,0,0,0,0,0,2]
["gamma-butyrobetaine","gamma-butyrobetaine","C002889",0,0,0,0,0,0,0,0,2]
["gastrodin","gastrodin","C045345",0,0,0,0,0,0,0,0,2]
["geraniol","geraniol","C007836",0,0,0,0,0,1,1,0,2]
["ginsenoside Rb1","ginsenoside Rb1","C442759",2,0,0,0,0,2,2,0,2]
["ginsenoside Re","ginsenoside Re","C049864",0,0,0,0,0,0,0,0,2]
["glimepiride","glimepiride","C057619",0,0,0,0,0,2,0,0,2]
["glucose-1-phosphate","glucose-1-phosphate","C031590",0,0,0,0,0,0,0,0,2]
["Glutaral","Glutaral","D005976",0,0,0,0,0,0,0,0,2]
["Glyburide","Glyburide","D005905",0,7,0,4,1,9,0,0,2]
["GW0742","GW0742","C479979",0,0,0,1,0,1,0,0,2]
["H128 compound","H128 compound","C555346",0,0,0,0,0,0,0,0,2]
["Hematoxylin","Hematoxylin","D006416",0,0,0,0,0,1,0,0,2]
["Heme","Heme","D006418",3,0,0,0,0,16,9,0,2]
["Heparin, Low-Molecular-Weight","Heparin, Low-Molecular-Weight","D006495",0,0,0,0,0,4,0,0,2]
["Hexamethonium","Hexamethonium","D018738",0,0,0,0,0,0,0,0,2]
["homoorientin","homoorientin","C057912",0,0,0,0,0,1,0,0,2]
["huanglian","huanglian","C494417",0,0,0,0,1,3,0,0,2]
["hugan qingzhi","hugan qingzhi","C000594496",0,0,0,0,0,0,0,0,2]
["Hydroxyindoleacetic Acid","Hydroxyindoleacetic Acid","D006897",0,0,0,0,0,0,0,0,2]
["hydroxyoctadecadienoic acid","hydroxyoctadecadienoic acid","C495366",0,0,0,0,0,0,0,0,2]
["hydroxypyruvic acid","hydroxypyruvic acid","C012375",0,0,0,0,0,0,0,0,2]
["ifetroban","ifetroban","C078904",0,0,0,0,0,0,0,0,2]
["imidazole","imidazole","C029899",1,0,0,0,0,1,1,0,2]
["Imipramine","Imipramine","D007099",0,0,0,0,0,1,0,0,2]
["indole-3-carbinol","indole-3-carbinol","C016517",41,0,0,0,0,0,41,0,2]
["Indomethacin","Indomethacin","D007213",0,0,0,1,2,4,0,0,2]
["indomonocarbocyanine","indomonocarbocyanine","C029920",0,0,0,0,0,0,0,0,2]
["iodofiltic acid","iodofiltic acid","C049338",0,0,0,0,14,0,0,0,2]
["Iohexol","Iohexol","D007472",0,0,0,0,0,0,0,0,2]
["iomeprol","iomeprol","C057937",0,0,0,0,0,0,0,0,2]
["iopromide","iopromide","C038192",0,0,0,0,0,0,0,0,2]
["Iothalamate Meglumine","Iothalamate Meglumine","D007482",0,0,0,0,0,0,0,0,2]
["Isoflurane","Isoflurane","D007530",0,0,0,0,0,1,0,0,2]
["isoliquiritigenin","isoliquiritigenin","C040920",1,0,0,0,1,0,1,0,2]
["isopentyl alcohol","isopentyl alcohol","C029683",0,0,0,0,0,0,0,2,2]
["isoquercitrin","isoquercitrin","C016527",1,0,0,0,0,1,3,0,2]
["isothiocyanic acid","isothiocyanic acid","C037152",0,0,0,0,0,0,0,0,2]
["Kangen-karyu","Kangen-karyu","C468270",0,0,0,0,0,0,0,0,2]
["Ketamine","Ketamine","D007649",0,0,1,0,0,0,2,0,2]
["KMUP 1","KMUP 1","C439304",0,0,0,0,0,2,0,0,2]
["lacto-N-fucopentaose III","lacto-N-fucopentaose III","C434666",0,0,0,0,0,0,0,0,2]
["Latex","Latex","D007840",0,0,0,0,0,0,0,0,2]
["leflunomide","leflunomide","C045463",9,0,0,0,0,0,2,0,2]
["Leukotriene B4","Leukotriene B4","D007975",1,0,0,0,0,9,0,2,2]
["levocetirizine","levocetirizine","C472067",0,1,0,0,0,1,0,0,2]
["Lewis X Antigen","Lewis X Antigen","D016256",0,0,0,0,0,1,0,0,2]
["liquiritigenin","liquiritigenin","C083152",0,0,0,0,0,0,0,0,2]
["Lithium Chloride","Lithium Chloride","D018021",0,0,0,2,0,0,1,2,2]
["Liv 52","Liv 52","C002614",0,0,0,0,0,0,0,0,2]
["Lomustine","Lomustine","D008130",0,0,0,0,0,0,0,0,2]
["Lovastatin","Lovastatin","D008148",1,52,0,0,6,237,0,6,2]
["maltitol","maltitol","C010745",0,0,0,0,0,0,0,0,2]
["Maltose","Maltose","D008320",0,0,0,0,0,1,0,0,2]
["mancozeb","mancozeb","C013099",0,0,0,0,0,0,0,0,2]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1092,B1092)","v":"Maneb"},"Maneb","D008344",0,0,0,0,0,0,0,0,2]
["manganese chloride","manganese chloride","C025340",0,2,0,0,0,1,0,0,2]
["Mannose","Mannose","D008358",0,1,0,1,0,1,0,0,2]
["Mechlorethamine","Mechlorethamine","D008466",1,0,0,0,0,2,0,0,2]
["Medroxyprogesterone","Medroxyprogesterone","D008525",0,5,0,0,0,8,0,0,2]
["Meglutol","Meglutol","D015093",0,0,0,0,0,1,0,0,2]
["meloxicam","meloxicam","C065757",0,0,0,0,0,0,0,0,2]
["Meprobamate","Meprobamate","D008620",0,0,0,0,0,0,0,0,2]
["Methadone","Methadone","D008691",1,0,0,1,0,0,1,0,2]
["Methandriol","Methandriol","D008695",0,0,0,0,0,0,0,0,2]
["methylone","methylone","C400939",0,0,0,0,0,0,0,0,2]
["Midazolam","Midazolam","D008874",0,0,0,0,0,0,1,0,2]
["Mineral Oil","Mineral Oil","D008899",0,0,0,0,0,0,1,0,2]
["monoethylglycinexylidide","monoethylglycinexylidide","C001173",0,0,0,0,0,0,0,0,2]
["morphazinamide","morphazinamide","C038993",0,0,0,0,0,0,0,0,2]
["morphine-6-glucuronide","morphine-6-glucuronide","C035349",0,0,0,0,0,0,0,0,2]
["Moxalactam","Moxalactam","D009070",0,0,0,0,0,0,0,0,2]
["N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide","N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide","C531525",0,0,0,0,0,0,0,0,2]
["N-(4-trifluoromethylphenyl) 3,4-dimethoxycinnamamide","N-(4-trifluoromethylphenyl) 3,4-dimethoxycinnamamide","C000604692",0,0,0,0,0,0,0,0,2]
["N',N''-diacetylspermine","N',N''-diacetylspermine","C029453",0,0,0,0,0,0,0,0,2]
["N-acetyl-4-benzoquinoneimine","N-acetyl-4-benzoquinoneimine","C028473",0,0,0,0,0,0,1,0,2]
["N-Acetylneuraminic Acid","N-Acetylneuraminic Acid","D019158",0,5,0,0,1,41,0,0,2]
["naringin","naringin","C005274",0,0,0,0,0,5,1,0,2]
["ND-630","ND-630","C000610197",0,0,0,0,0,0,0,0,2]
["nectandrin-B","nectandrin-B","C524653",0,0,0,0,0,0,0,0,2]
["neoprontosil","neoprontosil","C021144",0,0,0,0,0,0,0,0,2]
["Neostigmine","Neostigmine","D009388",0,0,0,1,0,0,0,0,2]
["Nialamide","Nialamide","D009526",0,0,0,0,0,0,0,0,2]
["Niclosamide","Niclosamide","D009534",0,0,0,0,0,0,1,0,2]
["Nicorandil","Nicorandil","D020108",0,0,0,0,0,2,0,0,2]
["nicotinamide-beta-riboside","nicotinamide-beta-riboside","C018613",0,0,0,0,0,0,0,0,2]
["N-methylaminoethanol","N-methylaminoethanol","C017500",0,4,0,0,0,1,0,0,2]
["nobiletin","nobiletin","C008661",0,2,0,0,2,7,0,1,2]
["nonylphenol","nonylphenol","C025256",6,0,0,0,0,0,14,0,2]
["norbixin","norbixin","C099823",0,0,0,0,0,0,0,0,2]
["oligonol","oligonol","C514283",0,0,0,0,0,0,0,0,2]
["Osmium Tetroxide","Osmium Tetroxide","D009993",0,0,0,0,0,0,0,0,2]
["Panax notoginseng extract","Panax notoginseng extract","C519374",0,0,0,0,0,0,0,0,2]
["Pantetheine","Pantetheine","D010204",0,2,0,0,0,4,0,0,2]
["pantethine","pantethine","C005425",0,2,0,0,0,4,0,0,2]
["pantoprazole","pantoprazole","C064276",0,0,0,0,0,1,5,0,2]
["parnaparin","parnaparin","C080945",0,0,0,0,0,0,0,0,2]
["Penicillin G Procaine","Penicillin G Procaine","D010402",0,0,0,0,0,0,0,0,2]
["Pentobarbital","Pentobarbital","D010424",1,0,0,0,0,0,0,0,2]
["perfluorononanoic acid","perfluorononanoic acid","C584865",0,0,0,0,0,0,0,0,2]
["perilla seed oil","perilla seed oil","C058216",0,0,1,0,0,2,0,0,2]
["Phenol","Phenol","D019800",1,0,0,0,0,4,0,0,2]
["Phenylbutazone","Phenylbutazone","D010653",0,0,0,0,0,0,0,0,2]
["Phenylpropanolamine","Phenylpropanolamine","D010665",0,0,0,0,0,0,0,0,2]
["Phlorhizin","Phlorhizin","D010695",0,0,0,2,0,0,0,0,2]
["phosphatidylcholine hydroperoxide","phosphatidylcholine hydroperoxide","C057590",0,0,0,0,0,2,0,0,2]
["phosphine","phosphine","C044646",0,0,0,0,0,0,0,0,2]
["Phosphogliv","Phosphogliv","C504418",0,0,0,0,0,0,0,0,2]
["physcione","physcione","C008905",0,0,0,0,0,0,0,0,2]
["Pindolol","Pindolol","D010869",0,1,0,0,0,3,0,0,2]
["ping-tang","ping-tang","C574218",0,0,0,0,0,0,0,0,2]
["piragliatin","piragliatin","C553963",0,0,0,0,0,0,0,0,2]
["pirfenidone","pirfenidone","C093844",0,0,0,0,0,0,0,0,2]
["plant extract, Houttuynia cordata","plant extract, Houttuynia cordata","C442781",1,0,0,0,0,1,0,0,2]
["plant extract, Puerariae Radix","plant extract, Puerariae Radix","C442842",0,0,0,0,0,0,0,0,2]
["Platelet Activating Factor","Platelet Activating Factor","D010972",0,5,0,1,1,50,1,0,2]
["platensimycin","platensimycin","C510909",0,0,0,0,0,0,0,0,2]
["Polyglycolic Acid","Polyglycolic Acid","D011100",0,0,0,0,0,4,1,0,2]
["polylactic acid-polyglycolic acid copolymer","polylactic acid-polyglycolic acid copolymer","C043435",0,0,0,0,0,3,1,0,2]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1156,B1156)","v":"Povidone"},"Povidone","D011205",0,0,0,0,0,5,0,0,2]
["PQQ Cofactor","PQQ Cofactor","D045542",0,0,0,0,0,0,0,0,2]
["Procaine","Procaine","D011343",0,0,0,0,0,0,0,0,2]
["Prochlorperazine","Prochlorperazine","D011346",0,0,0,0,0,0,0,0,2]
["propionic acid","propionic acid","C029658",0,0,0,1,0,0,0,0,2]
["propiverine","propiverine","C015586",0,0,0,0,0,0,0,0,2]
["Propylene Glycol","Propylene Glycol","D019946",0,0,0,0,0,0,1,0,2]
["Propylthiouracil","Propylthiouracil","D011441",0,1,0,0,1,0,0,2,2]
["protectin D1","protectin D1","C487679",0,0,0,0,0,0,0,0,2]
["protocatechuic acid","protocatechuic acid","C009091",0,0,0,0,0,10,1,0,2]
["protopanaxatriol","protopanaxatriol","C081552",0,0,0,0,0,0,0,0,2]
["punicalagin","punicalagin","C115642",0,0,0,0,0,2,1,0,2]
["Pyridoxal","Pyridoxal","D011730",0,0,0,0,0,1,0,0,2]
["pyrimidine","pyrimidine","C030986",0,0,0,0,0,0,0,0,2]
["Pyruvaldehyde","Pyruvaldehyde","D011765",0,0,0,0,1,10,0,0,2]
["Quinine","Quinine","D011803",0,0,0,0,0,0,1,0,2]
["rhapontigenin","rhapontigenin","C431126",0,0,0,0,0,0,2,0,2]
["Rice Bran Oil","Rice Bran Oil","D000073879",0,0,0,0,0,4,0,0,2]
["Ringer's lactate","Ringer's lactate","C029239",0,0,0,0,0,0,0,0,2]
["Ritonavir","Ritonavir","D019438",0,3,0,0,7,11,0,0,2]
["Roflumilast","Roflumilast","C424423",0,0,0,0,0,0,0,0,2]
["Rose Bengal","Rose Bengal","D012395",0,0,0,0,0,1,0,0,2]
["rosiglitazone-metformin combination","rosiglitazone-metformin combination","C471074",0,0,0,0,0,0,0,0,2]
["ruscogenin","ruscogenin","C012541",0,0,0,0,0,0,0,0,2]
["saikosaponin","saikosaponin","C025759",0,0,0,0,1,3,0,0,2]
["salecan","salecan","C577623",0,0,0,0,0,0,0,0,2]
["salvianolic acid","salvianolic acid","C568740",0,0,0,0,0,1,0,0,2]
["schizandrin C","schizandrin C","C031409",0,0,0,0,0,1,0,0,2]
["Scopoletin","Scopoletin","D012603",0,0,0,0,0,0,0,0,2]
["Selegiline","Selegiline","D012642",0,0,0,0,0,1,0,0,2]
["Selenious Acid","Selenious Acid","D020887",0,0,0,0,0,0,0,0,2]
["sesamin","sesamin","C054125",0,0,0,0,0,3,3,16,2]
["sesamol","sesamol","C025583",0,0,2,0,0,2,0,2,2]
["sevoflurane","sevoflurane","C009250",0,0,0,0,2,1,0,0,2]
["shugan jianpi","shugan jianpi","C534230",0,0,0,0,0,0,0,0,2]
["Silicon Dioxide","Silicon Dioxide","D012822",1,0,0,0,3,5,6,0,2]
["SK0506","SK0506","C558813",0,0,0,0,0,0,0,0,2]
["Smoke","Smoke","D012906",38,1,0,0,1,14,33,2,2]
["sodium bisulfide","sodium bisulfide","C025451",0,0,0,0,0,0,0,0,2]
["sodium borate","sodium borate","C010634",0,0,0,0,0,0,0,0,2]
["Sodium Chloride, Dietary","Sodium Chloride, Dietary","D017673",0,0,0,0,0,2,2,0,2]
["Sodium Nitrite","Sodium Nitrite","D012977",0,1,0,0,0,1,0,0,2]
["Sodium Pertechnetate Tc 99m","Sodium Pertechnetate Tc 99m","D013670",0,1,0,0,0,2,0,0,2]
["SR9238","SR9238","C000593811",0,0,0,0,0,0,0,0,2]
["stachyose","stachyose","C005695",0,0,0,0,0,0,0,0,2]
["Stanozolol","Stanozolol","D013197",0,3,0,0,0,6,0,0,2]
["Streptomycin","Streptomycin","D013307",0,0,0,0,0,1,0,0,2]
["Sugammadex","Sugammadex","C453980",0,0,0,0,0,0,0,0,2]
["swertiamarin","swertiamarin","C013270",0,0,0,0,0,1,0,0,2]
["syringic acid","syringic acid","C001945",0,0,0,0,0,0,0,0,2]
["systhane","systhane","C446685",0,0,0,0,0,0,0,0,2]
["taurine-ursodeoxycholate conjugate","taurine-ursodeoxycholate conjugate","C030141",0,0,0,0,0,0,0,0,2]
["Taurocholic Acid","Taurocholic Acid","D013656",0,3,0,1,0,2,0,0,2]
["Taurolithocholic Acid","Taurolithocholic Acid","D013658",0,0,0,0,0,0,0,0,2]
["technetium Tc 99m stannous phytate","technetium Tc 99m stannous phytate","C019099",0,0,0,0,0,0,0,0,2]
["tetrabromobisphenol A","tetrabromobisphenol A","C020806",1,0,0,0,0,0,3,0,2]
["thiacremonone","thiacremonone","C524083",0,0,0,0,0,0,0,0,2]
["Thymol","Thymol","D013943",0,0,0,0,0,2,0,0,2]
["Tolazoline","Tolazoline","D014043",0,0,0,0,0,0,0,0,2]
["Trehalose","Trehalose","D014199",0,0,0,2,0,2,0,1,2]
["trichloromethyl free radical","trichloromethyl free radical","C025280",0,0,0,0,0,0,0,0,2]
["tripterine","tripterine","C050414",1,0,0,0,0,3,1,1,2]
["TY 51469","TY 51469","C524344",0,0,0,0,0,0,0,0,2]
["tyrphostin AG 1478","tyrphostin AG 1478","C101044",0,0,0,0,0,0,0,0,2]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1220,B1220)","v":"ursocholic acid"},"ursocholic acid","C030712",0,0,0,0,0,0,0,0,2]
["vineatrol","vineatrol","C509818",0,0,0,0,0,0,0,0,2]
["Vitamin B 6","Vitamin B 6","D025101",0,0,0,0,0,0,0,0,2]
["Vitamin K 1","Vitamin K 1","D010837",0,1,0,0,1,4,0,0,2]
["Voriconazole","Voriconazole","D065819",0,0,0,0,0,0,0,0,2]
["wedelolactone","wedelolactone","C051122",0,0,0,0,0,1,0,0,2]
["withaferin A","withaferin A","C009684",0,0,0,0,0,0,0,0,2]
["Xanthopterin","Xanthopterin","D014976",0,0,0,0,0,0,0,0,2]
["Xue-Fu-Zhu-Yu decoction","Xue-Fu-Zhu-Yu decoction","C513826",0,0,0,0,0,0,0,0,2]
["Xylose","Xylose","D014994",0,0,0,0,0,0,0,0,2]
["Y 39041","Y 39041","C406663",0,0,0,0,0,0,0,0,2]
["YHK herbal compound","YHK herbal compound","C516652",0,0,0,0,0,0,0,0,2]
["yiki-huoxue","yiki-huoxue","C033946",0,0,0,0,0,0,0,0,2]
["Yiqi Sanju formula","Yiqi Sanju formula","C528001",0,0,0,0,0,0,0,0,2]
["zeaxanthin dipalmitate","zeaxanthin dipalmitate","C109854",0,0,0,0,0,0,0,0,2]
["zhenqing","zhenqing","C550196",0,0,0,0,0,0,0,0,2]
["Zineb","Zineb","D015038",0,0,0,0,0,0,0,0,2]
["1-(beta-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetra-hydroisoquinoline","1-(beta-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetra-hydroisoquinoline","C495109",0,0,0,0,0,0,0,0,1]
["1,3-bis(3,5-dichlorophenyl)urea","1,3-bis(3,5-dichlorophenyl)urea","C577482",0,0,0,0,0,0,0,0,1]
["1,4-butanediol","1,4-butanediol","C039681",0,0,0,0,0,0,0,0,1]
["11-octadecenoic acid","11-octadecenoic acid","C050413",0,1,0,0,0,2,0,22,1]
["14,15-epoxy-5,8,11-eicosatrienoic acid","14,15-epoxy-5,8,11-eicosatrienoic acid","C046782",0,1,0,0,0,3,0,0,1]
["14-deoxyandrographolide","14-deoxyandrographolide","C114791",0,0,0,0,0,0,0,0,1]
["17-(dimethylaminoethylamino)-17-demethoxygeldanamycin","17-(dimethylaminoethylamino)-17-demethoxygeldanamycin","C448659",0,0,0,0,0,0,0,0,1]
["17,18-epoxy-5,8,11,14-eicosatetraenoic acid","17,18-epoxy-5,8,11,14-eicosatetraenoic acid","C070378",0,0,0,0,0,0,0,0,1]
["2,2'-(hydroxynitrosohydrazono)bis-ethanamine","2,2'-(hydroxynitrosohydrazono)bis-ethanamine","C094210",0,0,0,0,0,0,0,0,1]
["2,4,6-trimethyl-N-((3'-(methylsulfonyl)-4-biphenylyl)methyl)-N-((5-(trifluoromethyl)-2-furanyl)methyl)benzenesulfonamide","2,4,6-trimethyl-N-((3'-(methylsulfonyl)-4-biphenylyl)methyl)-N-((5-(trifluoromethyl)-2-furanyl)methyl)benzenesulfonamide","C549350",0,0,0,0,0,0,0,0,1]
["22-hydroxycholesterol","22-hydroxycholesterol","C003585",0,0,0,0,1,1,0,0,1]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997",0,1,0,0,0,32,0,0,1]
["3-(1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl)propanoic acid","3-(1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl)propanoic acid","C000593222",0,0,0,0,0,0,0,0,1]
["4-(4-(2-(n-butoxy)ethoxy)-5-methylthiazol-2-yl)-2-fluorobenzoic acid","4-(4-(2-(n-butoxy)ethoxy)-5-methylthiazol-2-yl)-2-fluorobenzoic acid","C507711",0,0,0,0,0,0,0,0,1]
["4-(6-hydroxy-7-tricyclo(3.3.1.13,7)dec-1-yl-2-naphthalenyl)benzoic acid","4-(6-hydroxy-7-tricyclo(3.3.1.13,7)dec-1-yl-2-naphthalenyl)benzoic acid","C000591478",0,0,0,0,0,0,0,0,1]
["4-hydroxybutyric acid","4-hydroxybutyric acid","C111420",0,0,0,0,0,0,0,0,1]
["4-hydroxydebrisoquin","4-hydroxydebrisoquin","C012359",0,0,0,0,0,0,0,0,1]
["5,7-dimethoxyflavone","5,7-dimethoxyflavone","C060298",0,0,0,0,0,0,3,0,1]
["5-hydroxy-6,8,11,14,17-eicosapentaenoic acid","5-hydroxy-6,8,11,14,17-eicosapentaenoic acid","C058722",0,0,0,0,0,0,0,0,1]
["6-ethyl-24-norcholane-3,7,23-triol-23 sulfate","6-ethyl-24-norcholane-3,7,23-triol-23 sulfate","C000602622",0,0,0,0,0,0,0,0,1]
["7-hydroxycoumarin","7-hydroxycoumarin","C031477",0,0,0,0,0,0,0,0,1]
["7-monohydroxyethylrutoside","7-monohydroxyethylrutoside","C522803",0,0,0,0,0,1,0,0,1]
["9,10-anthraquinone","9,10-anthraquinone","C042834",0,0,0,0,0,0,0,0,1]
["acanthoic acid","acanthoic acid","C099958",0,0,0,0,0,0,0,0,1]
["acetylshikonin","acetylshikonin","C073944",0,0,0,0,0,0,0,0,1]
["adefovir","adefovir","C053001",0,0,0,0,0,0,0,0,1]
["adrenic acid","adrenic acid","C011395",0,0,0,0,0,0,0,2,1]
["akebia saponin D","akebia saponin D","C534004",0,0,0,0,0,0,0,0,1]
["alginic acid","alginic acid","C008970",0,0,0,0,0,0,1,0,1]
["alisol A 24-acetate","alisol A 24-acetate","C457233",0,0,0,0,0,1,0,0,1]
["alisol B 23-acetate","alisol B 23-acetate","C526957",0,0,0,0,0,0,0,0,1]
["allicin","allicin","C006452",0,0,0,0,0,3,0,0,1]
["alogliptin","alogliptin","C520853",0,0,0,0,0,1,0,0,1]
["alpha-carotene","alpha-carotene","C041635",0,1,0,0,1,4,0,0,1]
["alpha-methyldopamine","alpha-methyldopamine","C023492",0,0,0,0,0,0,0,0,1]
["altenusin","altenusin","C095643",0,0,0,0,0,0,0,0,1]
["aminoimidazole carboxamide phosphate","aminoimidazole carboxamide phosphate","C028212",0,0,0,0,0,0,0,0,1]
["andrographolide","andrographolide","C030419",2,0,0,0,3,3,6,0,1]
["aucubin","aucubin","C006650",0,0,0,0,0,0,0,0,1]
["avermectin","avermectin","C019264",0,0,0,0,0,0,0,0,1]
["BCG Vaccine","BCG Vaccine","D001500",0,0,0,0,0,1,0,0,1]
["Benzbromarone","Benzbromarone","D001553",0,0,0,0,0,0,0,0,1]
["beta-hydroxyisovaleric acid","beta-hydroxyisovaleric acid","C004961",0,0,0,0,0,0,0,0,1]
["beta-lapachone","beta-lapachone","C014638",0,0,0,0,0,0,0,0,1]
["beta-LGND2","beta-LGND2","C585485",0,0,0,0,0,0,0,0,1]
["betulin","betulin","C002503",0,0,0,0,0,0,0,0,1]
["bis(4-hydroxyphenyl)sulfone","bis(4-hydroxyphenyl)sulfone","C543008",1,0,0,0,0,0,1,0,1]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1284,B1284)","v":"bishofit"},"bishofit","C072517",0,0,0,0,0,0,0,0,1]
["bofu-tsusho-san","bofu-tsusho-san","C098310",0,0,0,0,0,2,0,0,1]
["boldine","boldine","C011686",0,0,0,0,0,2,1,0,1]
["boswellic acid","boswellic acid","C054625",0,0,0,0,0,0,0,0,1]
["cafestol","cafestol","C053400",0,4,0,0,0,10,1,0,1]
["caryophyllene","caryophyllene","C024714",0,0,0,0,0,0,0,0,1]
["Chlormethiazole","Chlormethiazole","D002719",0,0,0,0,0,0,1,0,1]
["cholesterol 7-hydroperoxide","cholesterol 7-hydroperoxide","C041011",0,0,0,0,0,7,0,0,1]
["Cotinine","Cotinine","D003367",0,0,0,0,0,3,4,0,1]
["cycloastragenol","cycloastragenol","C061014",0,0,0,0,0,0,0,0,1]
["Debrisoquin","Debrisoquin","D003647",0,0,0,0,0,0,1,0,1]
["Deferoxamine","Deferoxamine","D003676",1,0,0,0,0,5,0,0,1]
["demethyleneberberine","demethyleneberberine","C477155",0,0,0,0,0,3,0,0,1]
["Deoxyepinephrine","Deoxyepinephrine","D003846",0,0,0,0,0,0,0,0,1]
["dihydroartemisinin","dihydroartemisinin","C039060",0,0,0,0,0,0,0,0,1]
["dihydroceramide","dihydroceramide","C109343",0,0,0,0,0,0,0,8,1]
["dioscin","dioscin","C019357",1,0,0,0,0,1,1,0,1]
["Diosgenin","Diosgenin","D004144",1,0,0,0,0,1,1,0,1]
["epomediol","epomediol","C031365",0,0,0,0,0,0,0,0,1]
["Ethiodized Oil","Ethiodized Oil","D004998",0,0,0,0,0,0,0,0,1]
["evening primrose oil","evening primrose oil","C028498",0,0,0,0,0,1,0,23,1]
["fluvastatin","fluvastatin","C065180",0,6,0,0,2,72,0,0,1]
["galactoarabino-rhamnogalaturonan","galactoarabino-rhamnogalaturonan","C000613472",0,0,0,0,0,0,0,0,1]
["gambigyeongsinhwan","gambigyeongsinhwan","C000607504",0,0,0,0,0,0,0,0,1]
["gamma-sitosterol","gamma-sitosterol","C025473",0,0,0,0,0,5,0,0,1]
["gardenin A","gardenin A","C000589472",0,0,0,0,0,0,0,0,1]
["gehua jiejiu xiaozhi","gehua jiejiu xiaozhi","C528005",0,0,0,0,0,0,0,0,1]
["ginkgolide A","ginkgolide A","C477042",0,0,0,0,0,0,0,0,1]
["ginsenoside Rb2","ginsenoside Rb2","C048026",0,0,0,0,0,0,0,0,1]
["glucoraphanin","glucoraphanin","C119494",3,0,0,0,0,0,2,0,1]
["Glycerylphosphorylcholine","Glycerylphosphorylcholine","D005997",0,1,0,0,0,3,0,0,1]
["glycycoumarin","glycycoumarin","C515155",0,0,0,0,0,0,0,0,1]
["Ibogaine","Ibogaine","D007050",0,0,0,0,0,0,0,0,1]
["isofraxidin","isofraxidin","C008182",0,0,0,0,0,0,0,0,1]
["isomaltoheptaose","isomaltoheptaose","C035220",0,0,0,0,0,0,0,0,1]
["Ivermectin","Ivermectin","D007559",0,0,0,0,0,0,1,0,1]
["kahweol","kahweol","C053401",0,1,0,0,0,6,1,0,1]
["kukoamine A","kukoamine A","C096274",0,0,0,0,0,0,0,0,1]
["li-gan-shi-liu-ba-wei-san","li-gan-shi-liu-ba-wei-san","C000611221",0,0,0,0,0,0,0,0,1]
["Lisosan G","Lisosan G","C522933",0,0,0,0,0,1,0,0,1]
["lobeglitazone","lobeglitazone","C546215",0,0,0,0,0,0,0,0,1]
["Magnesium Chloride","Magnesium Chloride","D015636",0,0,0,0,0,0,0,0,1]
["MBX-2982","MBX-2982","C000608114",0,0,0,0,0,0,0,0,1]
["MCC-950","MCC-950","C000597426",0,0,0,0,0,0,0,0,1]
["ME3738","ME3738","C477463",0,0,0,0,0,0,0,0,1]
["Memantine","Memantine","D008559",0,0,0,0,0,0,1,0,1]
["Menthol","Menthol","D008610",0,0,0,0,0,0,0,0,1]
["mepirodipine","mepirodipine","C050699",0,0,0,0,0,0,0,0,1]
["Mifepristone","Mifepristone","D015735",0,0,0,0,0,4,0,2,1]
["miglitol","miglitol","C045621",0,0,0,0,0,0,0,0,1]
["Misoprostol","Misoprostol","D016595",0,0,0,0,0,0,0,0,1]
["morin","morin","C008548",0,0,0,0,1,7,0,0,1]
["mosapride","mosapride","C062720",0,0,0,0,0,0,0,0,1]
["MSDC-0602","MSDC-0602","C000619119",0,0,0,0,0,0,0,0,1]
["myricetin","myricetin","C040015",0,0,0,0,1,8,1,0,1]
["Naloxone","Naloxone","D009270",0,0,0,1,0,0,0,0,1]
["necrox-7","necrox-7","C556282",0,0,0,0,0,0,0,0,1]
["neomangiferin","neomangiferin","C442164",0,0,0,0,0,1,0,0,1]
["nimesulide","nimesulide","C012655",0,0,0,0,0,1,0,0,1]
["olaparib","olaparib","C531550",1,0,0,0,0,0,0,0,1]
["oligochitosan","oligochitosan","C493484",0,0,0,0,0,0,0,0,1]
["paeonol","paeonol","C013638",0,0,0,0,2,8,0,0,1]
["parthenolide","parthenolide","C002669",0,0,0,0,0,0,0,0,1]
["pentadecanoic acid","pentadecanoic acid","C117025",0,0,0,0,0,0,0,2,1]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1348,B1348)","v":"potassium tetraiodomercurate"},"potassium tetraiodomercurate","C009009",0,0,0,0,0,0,0,0,1]
["Probenecid","Probenecid","D011339",0,0,0,0,0,0,0,0,1]
["procyanidin","procyanidin","C017674",1,0,0,0,0,10,2,0,1]
["rhodioloside","rhodioloside","C009172",0,0,0,0,0,2,0,0,1]
["S 20098","S 20098","C084711",0,0,0,0,0,0,0,0,1]
["Salicylic Acid","Salicylic Acid","D020156",1,0,0,0,0,4,0,10,1]
["Scutellaria baicalensis extract","Scutellaria baicalensis extract","C499814",0,0,0,0,0,1,0,0,1]
["Sevelamer","Sevelamer","D000069603",0,0,0,0,0,1,0,0,1]
["sparstolonin B","sparstolonin B","C561322",0,0,0,0,0,0,0,0,1]
["Stigmasterol","Stigmasterol","D013265",0,0,0,0,0,1,0,0,1]
["Succinic Acid","Succinic Acid","D019802",0,0,0,3,0,0,0,0,1]
["Sulfamethazine","Sulfamethazine","D013418",0,0,0,0,0,0,0,0,1]
["Suramin","Suramin","D013498",0,0,0,0,0,3,0,0,1]
["SY-102","SY-102","C000597556",0,0,0,0,0,0,0,0,1]
["tauromuricholic acid","tauromuricholic acid","C037351",0,0,0,0,0,0,0,0,1]
["taxifolin","taxifolin","C003377",1,0,0,0,0,2,2,0,1]
["technetium phytate","technetium phytate","C026177",0,0,0,0,0,0,0,0,1]
["tectoridin","tectoridin","C120040",0,0,0,0,0,0,0,0,1]
["tert-Butylhydroperoxide","tert-Butylhydroperoxide","D020122",0,0,0,0,0,4,0,0,1]
["triacsin C","triacsin C","C034613",0,0,0,0,0,1,0,0,1]
["trimethyloxamine","trimethyloxamine","C005855",1,0,0,0,0,3,0,0,1]
["Vaccinium myrtillus extract","Vaccinium myrtillus extract","C073305",0,0,0,0,0,2,0,0,1]
["VB-201","VB-201","C552500",0,0,0,0,0,0,0,0,1]
["VB-703","VB-703","C000621292",0,0,0,0,0,0,0,0,1]
["wogonin","wogonin","C085514",1,0,0,0,0,1,0,0,1]
["xyloketal B","xyloketal B","C515343",0,0,0,0,0,2,0,0,1]
["zingerone","zingerone","C013738",0,0,0,0,0,1,0,0,1]
["(1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea)","(1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea)","C496792",0,0,0,0,2,1,0,0,0]
["(1-(chloromethyl)-1,2-dihydropyrrolo(3,2-e)indol-3(6H)-yl)(5-methoxy-1H-indol-2-yl)methanone","(1-(chloromethyl)-1,2-dihydropyrrolo(3,2-e)indol-3(6H)-yl)(5-methoxy-1H-indol-2-yl)methanone","C581919",0,0,0,0,0,0,1,0,0]
["(1-hydroxy-2-oxo-3-(N-methyl-3-aminopropyl)-3-methyl-3-aminopropyl)-3-methyl-1-triazene","(1-hydroxy-2-oxo-3-(N-methyl-3-aminopropyl)-3-methyl-3-aminopropyl)-3-methyl-1-triazene","C100973",0,0,0,0,0,2,0,0,0]
["(2,2-bis(docosyloxymethyl)propyl-5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium oxysulfonyl)glycero-alpha-galacto-2-nonulopyranosid)onate","(2,2-bis(docosyloxymethyl)propyl-5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium oxysulfonyl)glycero-alpha-galacto-2-nonulopyranosid)onate","C413863",0,0,0,0,0,1,0,0,0]
["(3,4-dihydroxyphenylamino)-2-imidazoline","(3,4-dihydroxyphenylamino)-2-imidazoline","C011775",0,0,0,0,0,2,0,0,0]
["(3,5,6-trimethylpyrazin-2-yl)methyl 2-(4-(2-methylpropyl)phenyl)propanoate","(3,5,6-trimethylpyrazin-2-yl)methyl 2-(4-(2-methylpropyl)phenyl)propanoate","C495410",3,0,0,0,0,0,1,0,0]
["(5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine","(5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine","C502305",0,0,0,0,0,1,0,0,0]
["(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid","(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid","C561635",0,0,0,0,0,0,0,2,0]
["(9Z, 11E)-tetradecadienyl acetate","(9Z, 11E)-tetradecadienyl acetate","C505894",0,0,0,0,0,0,0,2,0]
["(all-E) phytoene","(all-E) phytoene","C100185",0,0,0,0,0,2,0,0,0]
["(cyano-C)(diphenyl(aminomethyl)phosphonate-N)dihydroboron","(cyano-C)(diphenyl(aminomethyl)phosphonate-N)dihydroboron","C076461",0,0,0,0,0,1,0,0,0]
["(methylcarboxy-C)(triethylphosphonate-P)dihydroboron","(methylcarboxy-C)(triethylphosphonate-P)dihydroboron","C076462",0,0,0,0,0,1,0,0,0]
["(R)-3-hydroxybutyl (R)-3-hydroxybutyrate","(R)-3-hydroxybutyl (R)-3-hydroxybutyrate","C576699",0,0,0,0,0,2,0,0,0]
["1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid","1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid","C466644",0,0,0,0,0,3,0,0,0]
["1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine, monohydrochloride","1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine, monohydrochloride","C569631",0,0,0,0,0,1,0,0,0]
["1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea","1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea","C561574",0,0,0,0,0,0,1,0,0]
["1-(1,4-benzodioxan-6-ylcarbonyl)piperidine","1-(1,4-benzodioxan-6-ylcarbonyl)piperidine","C443080",0,0,0,0,0,1,0,0,0]
["1-(1H-indol-3-yl)-3-(3H-indol-3-ylidene)propan-2-one","1-(1H-indol-3-yl)-3-(3H-indol-3-ylidene)propan-2-one","C547593",3,0,0,0,0,0,0,0,0]
["1-(1H-indol-3-yl)-9H-pyrido(3,4-b)indole","1-(1H-indol-3-yl)-9H-pyrido(3,4-b)indole","C561449",3,0,0,1,0,0,1,0,0]
["1-(1-propynyl)pyrene","1-(1-propynyl)pyrene","C402363",3,0,0,0,0,0,1,0,0]
["1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole","1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole","C472829",0,0,0,0,1,0,0,0,0]
["1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one","1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one","C000603962",0,0,0,0,0,1,0,0,0]
["1-(3-trifluoromethylphenyl)-2-(N-(2-hydroxyethyl)amino)propane","1-(3-trifluoromethylphenyl)-2-(N-(2-hydroxyethyl)amino)propane","C073864",0,0,0,0,0,2,0,0,0]
["1-(4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)butyl)-4-aza-1-azoniabicyclo(2.2.2)octane","1-(4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)butyl)-4-aza-1-azoniabicyclo(2.2.2)octane","C466800",0,0,0,0,0,3,0,0,0]
["1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone","1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone","C517943",1,0,0,0,0,0,0,0,0]
["1-(4-chlorophenyl)-benzo-2,5-quinone","1-(4-chlorophenyl)-benzo-2,5-quinone","C000597136",1,0,0,0,0,0,1,0,0]
["1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine","1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine","D019307",0,0,0,0,1,1,0,0,0]
["1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione","1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione","C060229",0,0,0,0,0,0,0,1,0]
["1'-(6-(5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl)pyridazin-3-yl)-5-(trifluoromethyl)-3,4-dihydrospiro(chromene-2,4'-piperidine)","1'-(6-(5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl)pyridazin-3-yl)-5-(trifluoromethyl)-3,4-dihydrospiro(chromene-2,4'-piperidine)","C548720",0,0,0,0,0,0,0,1,0]
["1-(carboxymethylthio)tetradecane","1-(carboxymethylthio)tetradecane","C062078",0,2,0,0,0,5,0,3,0]
["1,1,2,2-tetrahydroheptadecafluorodecanol-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol","1,1,2,2-tetrahydroheptadecafluorodecanol-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol","C505284",0,0,0,0,0,0,0,1,0]
["1,1,3,3-tetramethylurea","1,1,3,3-tetramethylurea","C004168",0,1,0,0,0,0,0,0,0]
["1,10-bis(carboxymethylthiodecane)","1,10-bis(carboxymethylthiodecane)","C062079",0,1,0,0,0,0,0,2,0]
["1,10-phenanthroline","1,10-phenanthroline","C025205",3,0,0,0,0,0,1,0,0]
["1,12-benzoperylene","1,12-benzoperylene","C006718",4,0,0,0,0,0,1,0,0]
["1,1-bis(3'-indolyl)-1-(4-t-butylphenyl)methane","1,1-bis(3'-indolyl)-1-(4-t-butylphenyl)methane","C505816",2,0,0,0,0,0,0,0,0]
["1,1-bis(3'-indolyl)methane","1,1-bis(3'-indolyl)methane","C512018",1,0,0,0,0,0,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1412,B1412)","v":"1,1-dichloroethane"},"1,1-dichloroethane","C501196",0,0,0,0,0,0,1,0,0]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931",0,1,0,0,0,23,0,0,0]
["1,2,3,4,4a,7,8,8a-octahydro-4,4a-methano-7-methyl-8-(2-(2,4-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthyl 2-methylbutanoate","1,2,3,4,4a,7,8,8a-octahydro-4,4a-methano-7-methyl-8-(2-(2,4-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthyl 2-methylbutanoate","C120872",0,0,0,0,0,1,0,0,0]
["1,2,3,4,5,6-hexachloronaphthalene","1,2,3,4,5,6-hexachloronaphthalene","C049022",0,0,0,0,0,0,3,0,0]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839",2,0,0,5,0,0,7,0,0]
["1,2,3,4,6,7-hexachlorinated naphthalene","1,2,3,4,6,7-hexachlorinated naphthalene","C412791",0,0,0,0,0,0,1,0,0]
["1,2,3,4-tetrachlorodibenzodioxin","1,2,3,4-tetrachlorodibenzodioxin","C092155",2,0,0,0,0,0,1,0,0]
["1,2,3,5,6,7-hexachloronaphthalene","1,2,3,5,6,7-hexachloronaphthalene","C575652",0,0,0,0,0,0,1,0,0]
["1,2,3,6,7,8-hexachlorodibenzodioxin","1,2,3,6,7,8-hexachlorodibenzodioxin","C046838",0,0,0,1,0,0,2,0,0]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452",6,0,0,3,0,0,10,0,0]
["1,2,4,5-tetrabromobenzene","1,2,4,5-tetrabromobenzene","C110818",0,0,0,0,0,0,2,0,0]
["1,2,4,5-tetrachlorobenzene","1,2,4,5-tetrachlorobenzene","C018673",0,0,0,0,0,0,1,0,0]
["1,2,4-triazine","1,2,4-triazine","C093444",0,0,0,0,0,0,1,0,0]
["1,2,4-trichlorobenzene","1,2,4-trichlorobenzene","C009947",0,0,0,0,0,0,2,0,0]
["1,2,4-trichlorodibenzo-1,4-dioxin","1,2,4-trichlorodibenzo-1,4-dioxin","C090523",1,0,0,0,0,0,0,0,0]
["1,2,5,6-dibenzanthracene","1,2,5,6-dibenzanthracene","C026486",1,0,0,0,0,0,1,0,0]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379",12,0,0,0,0,0,4,0,0]
["1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester","1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester","C070379",0,0,0,0,0,1,0,0,0]
["1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid","1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid","C025603",0,0,0,0,0,1,0,0,0]
["1,2-cyclohexanedione","1,2-cyclohexanedione","C018031",0,2,0,0,0,4,0,0,0]
["1,2-dibromo-1,2-dichloroethane","1,2-dibromo-1,2-dichloroethane","C033164",0,0,0,0,0,0,0,3,0]
["1,2-dihydro-1,2-dihydroxy-5-methylchrysene","1,2-dihydro-1,2-dihydroxy-5-methylchrysene","C017229",0,0,0,0,0,0,1,0,0]
["1,2-dihydro-1,2-dihydroxy-6-nitrochrysene","1,2-dihydro-1,2-dihydroxy-6-nitrochrysene","C042316",1,0,0,0,0,0,0,0,0]
["1,2-Dimethylhydrazine","1,2-Dimethylhydrazine","D019813",0,0,0,0,0,0,3,0,0]
["1,2-dioctanoylglycerol","1,2-dioctanoylglycerol","C044295",0,0,0,1,0,0,0,0,0]
["1,2-Dipalmitoylphosphatidylcholine","1,2-Dipalmitoylphosphatidylcholine","D015060",0,0,0,0,0,3,0,0,0]
["1,2-diselenolane-3-pentanoic acid","1,2-diselenolane-3-pentanoic acid","C109588",0,0,0,0,0,1,0,0,0]
["1,2-distearoylphosphatidylethanolamine","1,2-distearoylphosphatidylethanolamine","C038089",0,0,0,0,0,0,0,1,0]
["1,2-dithiol-3-thione","1,2-dithiol-3-thione","C049325",1,0,0,0,0,0,0,0,0]
["1,2-linoleoylphosphatidylcholine","1,2-linoleoylphosphatidylcholine","C002448",0,0,0,0,0,2,0,0,0]
["1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril","1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril","C012385",0,0,0,0,0,1,0,0,0]
["1,3,6,8-tetrachlorodibenzofuran","1,3,6,8-tetrachlorodibenzofuran","C049040",2,0,0,0,0,0,1,0,0]
["1,3,7,8-tetrachlorodibenzo-4-dioxin","1,3,7,8-tetrachlorodibenzo-4-dioxin","C078329",1,0,0,0,0,0,0,0,0]
["1,3-benzodioxole","1,3-benzodioxole","C040539",0,0,0,0,0,0,1,0,0]
["1,3-di(1H-indol-3-yl)propan-2-one","1,3-di(1H-indol-3-yl)propan-2-one","C547592",3,0,0,0,0,0,0,0,0]
["1,3-diiopanoate glyceryl ether","1,3-diiopanoate glyceryl ether","C474281",0,0,0,0,0,1,0,0,0]
["1,3-dimethyluric acid","1,3-dimethyluric acid","C031274",0,0,0,0,0,0,1,0,0]
["1,3-dinitropyrene","1,3-dinitropyrene","C037413",0,0,0,0,0,0,1,0,0]
["1,3-dioleoyl-2-(4-pyrenylbutanoyl)glycerol","1,3-dioleoyl-2-(4-pyrenylbutanoyl)glycerol","C046906",0,1,0,0,0,0,0,0,0]
["1,4-dihydropyridine","1,4-dihydropyridine","C038806",0,0,0,0,0,2,0,0,0]
["1,4-dihydroxy-2-naphthoic acid","1,4-dihydroxy-2-naphthoic acid","C024023",3,0,0,0,0,0,1,0,0]
["1,4-phenylenebis(methylene)selenocyanate","1,4-phenylenebis(methylene)selenocyanate","C074153",0,0,0,0,0,0,2,0,0]
["1,5-anhydrofructose","1,5-anhydrofructose","C048927",0,0,0,0,0,2,0,0,0]
["1,5-I-AEDANS","1,5-I-AEDANS","C006421",0,0,0,3,0,0,0,0,0]
["1,6-dinitropyrene","1,6-dinitropyrene","C033309",0,0,0,0,0,0,1,0,0]
["1,6-di-O-galloyl-beta-D-glucose","1,6-di-O-galloyl-beta-D-glucose","C504375",0,0,0,0,0,1,0,0,0]
["1,7-phenanthroline","1,7-phenanthroline","C053486",3,0,0,0,0,0,2,0,0]
["1,8-dinitropyrene","1,8-dinitropyrene","C033310",0,0,0,0,0,0,1,0,0]
["1,9-benz-10-anthrone","1,9-benz-10-anthrone","C000609119",2,0,0,0,0,0,0,0,0]
["10,12-tetradecadienoic acid","10,12-tetradecadienoic acid","C447625",0,0,0,0,0,0,0,2,0]
["10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid","10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid","C000591716",0,0,0,0,0,1,0,0,0]
["10-azabenzo(a)pyrene","10-azabenzo(a)pyrene","C023961",0,0,0,0,0,0,2,0,0]
["10-chloro-7H-benzimidazo(2,1-a)benzo(de)Isoquinolin-7-one","10-chloro-7H-benzimidazo(2,1-a)benzo(de)Isoquinolin-7-one","C000593972",4,0,0,0,0,0,0,0,0]
["10-hydroxy-2-decenoic acid","10-hydroxy-2-decenoic acid","C055543",0,0,0,0,0,1,0,0,0]
["10-nitro-oleic acid","10-nitro-oleic acid","C521487",0,0,0,0,0,1,0,0,0]
["11,12-epoxy-5,8,14-eicosatrienoic acid","11,12-epoxy-5,8,14-eicosatrienoic acid","C046783",0,1,0,0,0,4,0,0,0]
["11-hexadecenal","11-hexadecenal","C061128",0,0,0,0,1,1,0,0,0]
["11-hydroxytetradecanoic acid","11-hydroxytetradecanoic acid","C101376",0,0,0,0,0,0,0,2,0]
["11-tetradecenoic acid","11-tetradecenoic acid","C432948",0,0,0,0,0,0,0,5,0]
["12-(1-pyrene)dodecanoylcerebroside sulfate","12-(1-pyrene)dodecanoylcerebroside sulfate","C058912",0,0,0,0,0,1,0,0,0]
["12-(3-methoxy-4-(methoxymethoxy) phenyl)-10-oxododec-8-enoic acid ethyl ester","12-(3-methoxy-4-(methoxymethoxy) phenyl)-10-oxododec-8-enoic acid ethyl ester","C579625",0,0,0,0,1,0,0,0,0]
["12-(4-hydroxy-3-methoxyphenyl)-10-oxododec-8-enoic acid ethyl ester","12-(4-hydroxy-3-methoxyphenyl)-10-oxododec-8-enoic acid ethyl ester","C579627",0,0,0,0,1,0,0,0,0]
["12-(9-anthroyloxy)stearic acid","12-(9-anthroyloxy)stearic acid","C026653",0,0,0,0,0,1,0,0,0]
["12,13-dihydroxyoctadecenoic acid","12,13-dihydroxyoctadecenoic acid","C425204",0,0,0,0,3,0,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1476,B1476)","v":"12,13-epoxy-9-octadecenoic acid"},"12,13-epoxy-9-octadecenoic acid","C119104",0,0,0,0,0,0,0,2,0]
["12-doxylstearate methyl ester","12-doxylstearate methyl ester","C024283",0,0,0,0,0,1,0,0,0]
["12-hydroxy-4-(2-propenyl)-5-cholest-24-en-3-ol","12-hydroxy-4-(2-propenyl)-5-cholest-24-en-3-ol","C400813",0,0,0,0,0,1,0,0,0]
["12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","D019377",4,0,0,0,0,1,2,0,0]
["12-hydroxyellipticine","12-hydroxyellipticine","C517214",0,0,0,0,0,0,1,0,0]
["12-hydroxytetradecanoic acid","12-hydroxytetradecanoic acid","C101377",0,0,0,0,0,0,0,2,0]
["13,14-dihydroprostaglandin E1","13,14-dihydroprostaglandin E1","C069881",0,0,0,0,0,3,0,0,0]
["13,17-bispropanoylaspartic acid-3-ethenyl-8-((N,N',N'', N'''-tetrakis(carboxylmethyl)diethylenetriaminoacetyloxy)methyl-2,7,12,18-tetramethylporphyrinato)manganese(III)","13,17-bispropanoylaspartic acid-3-ethenyl-8-((N,N',N'', N'''-tetrakis(carboxylmethyl)diethylenetriaminoacetyloxy)methyl-2,7,12,18-tetramethylporphyrinato)manganese(III)","C091730",0,0,0,0,0,1,0,0,0]
["13-hexadecen-11-ynoic acid","13-hexadecen-11-ynoic acid","C524873",0,0,0,0,0,0,0,2,0]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649",0,0,0,0,0,10,0,0,0]
["13-hydroperoxylinoleic acid","13-hydroperoxylinoleic acid","C032890",0,0,0,0,1,0,0,0,0]
["13-hydroxy-9,11-octadecadienoic acid","13-hydroxy-9,11-octadecadienoic acid","C024348",0,0,0,0,0,5,0,0,0]
["13-hydroxyellipticine","13-hydroxyellipticine","C517215",0,0,0,0,0,0,1,0,0]
["14'-apolycopen-14'-oic acid","14'-apolycopen-14'-oic acid","C557871",0,0,0,0,0,0,0,2,0]
["14-tigloylschinlignan D","14-tigloylschinlignan D","C000614641",0,0,0,0,0,1,0,0,0]
["15-deoxy-delta(12,14)-prostaglandin J2","15-deoxy-delta(12,14)-prostaglandin J2","C097240",0,0,0,0,2,2,0,0,0]
["15-deoxyprostaglandin J2","15-deoxyprostaglandin J2","C477819",0,0,0,0,4,3,0,0,0]
["15-hydroperoxy-5,8,11,13-eicosatetraenoic acid","15-hydroperoxy-5,8,11,13-eicosatetraenoic acid","C025086",0,0,0,0,0,2,0,0,0]
["15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid","15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid","D019796",0,0,0,0,0,2,0,0,0]
["15-hydroxy-5,8,11,13-eicosatetraenoic acid","15-hydroxy-5,8,11,13-eicosatetraenoic acid","C025984",0,0,0,0,1,0,0,0,0]
["15-keto-13,14-dihydroprostaglandin F2alpha","15-keto-13,14-dihydroprostaglandin F2alpha","C008228",0,0,0,0,0,1,0,0,0]
["17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid","17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid","C062894",0,0,0,0,0,0,0,2,0]
["17-methylandrost-2-en-17-ol","17-methylandrost-2-en-17-ol","C500374",0,0,0,0,0,1,0,0,0]
["1a alloantigen, human","1a alloantigen, human","C039231",0,0,0,0,2,0,0,0,0]
["1-acetyl-4-phenyl-1,2,4-triazolidine-3,5-dione","1-acetyl-4-phenyl-1,2,4-triazolidine-3,5-dione","C078499",0,0,0,0,0,3,0,0,0]
["1-acyl-2-acetyl-sn-glycero-3-phosphocholine","1-acyl-2-acetyl-sn-glycero-3-phosphocholine","C069030",0,0,0,0,0,1,0,0,0]
["1-alkyl-2-acyl-sn-glycero-3-phosphocholine","1-alkyl-2-acyl-sn-glycero-3-phosphocholine","C036761",0,0,0,0,0,1,0,0,0]
["1-amino-3,7,8-trichlorodibenzo-4-dioxin","1-amino-3,7,8-trichlorodibenzo-4-dioxin","C014981",1,0,0,0,0,0,0,0,0]
["1-benzylimidazole","1-benzylimidazole","C017062",1,0,0,0,0,0,1,0,0]
["1-Butanol","1-Butanol","D020001",0,0,0,0,0,0,0,2,0]
["1-chloropyrene","1-chloropyrene","C040345",1,0,0,0,0,0,0,0,0]
["1-cyano-2-hydroxy-3-butene","1-cyano-2-hydroxy-3-butene","C055903",1,0,0,0,0,0,0,0,0]
["1-cyano-3,4-epithiobutane","1-cyano-3,4-epithiobutane","C062529",0,0,0,0,0,0,1,0,0]
["1-ethynylpyrene","1-ethynylpyrene","C042881",3,0,0,0,0,0,3,0,0]
["1-furan-2-yl-3-pyridin-2-yl-propenone","1-furan-2-yl-3-pyridin-2-yl-propenone","C508534",1,0,0,0,0,0,1,0,0]
["1-hexadecyl-2-acetyl-glycero-3-phosphocholine","1-hexadecyl-2-acetyl-glycero-3-phosphocholine","C037145",0,0,0,0,1,0,0,0,0]
["1-hydroxyphenanthrene","1-hydroxyphenanthrene","C092102",0,0,0,0,0,0,1,0,0]
["1-hydroxypyrene","1-hydroxypyrene","C033146",4,0,0,0,0,0,23,0,0]
["1-hydroxypyrene-glucuronide","1-hydroxypyrene-glucuronide","C093851",1,0,0,0,0,0,1,0,0]
["1-isopropyl-3,5-bis((pyridine-3-yl)methylene)piperidine-4-one","1-isopropyl-3,5-bis((pyridine-3-yl)methylene)piperidine-4-one","C000622636",1,0,0,0,0,0,0,0,0]
["1-methyl-3,5-bis((4-pyridyl)methylidene)-4-piperidone","1-methyl-3,5-bis((4-pyridyl)methylidene)-4-piperidone","C579034",1,0,0,0,0,0,0,0,0]
["1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","D015632",0,0,1,0,1,1,4,0,0]
["1-methyl-4-phenyl-2,3-dihydropyridinium","1-methyl-4-phenyl-2,3-dihydropyridinium","C044755",0,0,0,0,0,0,1,0,0]
["1-Methyl-4-phenylpyridinium","1-Methyl-4-phenylpyridinium","D015655",0,0,0,0,0,1,1,0,0]
["1-methylphenanthrene","1-methylphenanthrene","C041507",0,0,0,0,0,0,1,0,0]
["1-N-5-iodovaleramido-3,7,8-trichlorodibenzo-4-dioxin","1-N-5-iodovaleramido-3,7,8-trichlorodibenzo-4-dioxin","C042433",1,0,0,0,0,0,0,0,0]
["1-naphthoic acid","1-naphthoic acid","C085312",2,0,0,0,0,0,1,0,0]
["1-Naphthylisothiocyanate","1-Naphthylisothiocyanate","D015058",4,0,0,0,0,1,1,0,0]
["1-nitronaphthalene","1-nitronaphthalene","C016614",0,0,0,0,0,0,1,0,0]
["1-nitropyrene","1-nitropyrene","C032668",4,0,0,0,0,0,5,1,0]
["1-octyl-3-methylimidazolium","1-octyl-3-methylimidazolium","C528768",1,0,0,0,0,0,1,0,0]
["1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine","1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine","C043051",0,0,0,0,0,2,0,0,0]
["1-palmitoyl-2-(1'-pyreneoctanoyl)glycero-3-phosphochine","1-palmitoyl-2-(1'-pyreneoctanoyl)glycero-3-phosphochine","C062484",0,0,0,0,0,1,0,0,0]
["1-palmitoyl-2-(5-oxovaleroyl)phosphatidylcholine","1-palmitoyl-2-(5-oxovaleroyl)phosphatidylcholine","C119546",0,0,0,0,0,2,0,0,0]
["1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","C400184",0,0,0,0,1,5,0,0,0]
["1-palmitoyl-2-(6-(N-(7-nitrobenz)-2-oxa-1,3-diazol-4-yl)aminocaproyl)phosphatidylcholine","1-palmitoyl-2-(6-(N-(7-nitrobenz)-2-oxa-1,3-diazol-4-yl)aminocaproyl)phosphatidylcholine","C044745",0,0,0,0,0,1,0,0,0]
["1-palmitoyl-2-(9-oxononanoyl)-sn-glycero-3-phosphocholine","1-palmitoyl-2-(9-oxononanoyl)-sn-glycero-3-phosphocholine","C097369",0,0,0,0,0,1,0,0,0]
["1-palmitoyl-2-arachidonyl-3-phosphorylcholine","1-palmitoyl-2-arachidonyl-3-phosphorylcholine","C468114",0,0,0,0,2,2,0,0,0]
["1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","C400185",0,0,0,0,0,4,0,0,0]
["1-palmitoyl-2-linoleoylphosphatidylcholine","1-palmitoyl-2-linoleoylphosphatidylcholine","C055402",0,0,0,0,0,2,0,0,0]
["1-palmitoyl-2-lysophosphatidylcholine","1-palmitoyl-2-lysophosphatidylcholine","C089215",0,0,0,0,0,1,0,0,0]
["1-palmitoyl-2-oleoylphosphatidylcholine","1-palmitoyl-2-oleoylphosphatidylcholine","C028694",0,1,0,0,0,3,0,0,0]
["1-palmitoyl-2-pyrenedecanoylphosphatidylcholine","1-palmitoyl-2-pyrenedecanoylphosphatidylcholine","C021248",0,0,0,0,0,1,0,0,0]
["1-phenylazo-2-naphthol","1-phenylazo-2-naphthol","C024336",0,0,0,0,0,0,4,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1540,B1540)","v":"1-phenylimidazole"},"1-phenylimidazole","C037738",2,0,0,0,0,0,2,0,0]
["1-phenylpropanol","1-phenylpropanol","C439395",0,0,0,0,0,1,0,0,0]
["1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine","1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine","C027891",0,0,0,0,0,1,0,0,0]
["2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester","2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester","C520611",1,0,0,0,0,0,1,0,0]
["2-(1-((2,3-dihydro-1H-imidazol-2-yl)methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo(d)imidazole","2-(1-((2,3-dihydro-1H-imidazol-2-yl)methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo(d)imidazole","C000622243",0,0,0,0,0,1,0,0,0]
["2-(10H-phenothiazin-2-yloxy)-N,N-dimethylethanamine","2-(10H-phenothiazin-2-yloxy)-N,N-dimethylethanamine","C073191",0,0,0,0,0,1,0,0,0]
["2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C584446",4,0,0,0,0,0,1,0,0]
["2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C548651",9,0,0,0,0,0,1,0,0]
["2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid","2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid","C483845",0,1,0,0,0,0,0,0,0]
["2-(2,2,3,3,3-pentafluoropropoxy)-3-(4-(2,2,2-trifluoroethoxy)phenyl)-5,7-dihydro-3H-pyrrolo(2,3-d)pyrimidine-4,6-dione","2-(2,2,3,3,3-pentafluoropropoxy)-3-(4-(2,2,2-trifluoroethoxy)phenyl)-5,7-dihydro-3H-pyrrolo(2,3-d)pyrimidine-4,6-dione","C000621111",0,0,0,0,0,0,0,2,0]
["2-(2',4'-dibromophenoxy)-3,5-dibromoanisole","2-(2',4'-dibromophenoxy)-3,5-dibromoanisole","C496823",1,0,0,0,0,0,0,0,0]
["2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","C093973",4,0,0,0,0,0,3,0,0]
["2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide","2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide","C096011",0,0,0,0,0,1,0,0,0]
["2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol","2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol","C529054",0,0,0,1,0,0,0,0,0]
["2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione","2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione","C074534",0,0,0,0,0,3,0,0,0]
["2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole","2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole","C507816",1,0,0,0,0,0,2,0,0]
["2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino)ethanol","2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino)ethanol","C532995",0,0,0,0,0,1,0,0,0]
["2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid","2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid","C079315",0,0,0,0,0,1,0,0,0]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784",9,0,0,0,0,0,13,0,0]
["2-(4-aminophenyl)benzothiazole","2-(4-aminophenyl)benzothiazole","C111133",3,0,0,0,0,0,3,0,0]
["2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol","2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol","C405041",0,0,0,0,0,1,0,0,0]
["2-(4-bromophenyl)-N-(4-fluorophenyl)-3-propyl-3H-imidazo(4,5-b)pyridin-5-amine","2-(4-bromophenyl)-N-(4-fluorophenyl)-3-propyl-3H-imidazo(4,5-b)pyridin-5-amine","C576502",0,0,0,0,0,1,0,0,0]
["2-(4-hydroxy-3-methoxyphenyl)benzothiazole","2-(4-hydroxy-3-methoxyphenyl)benzothiazole","C000602051",1,0,0,0,0,0,0,0,0]
["2-(4-hydroxyphenoxy)acetic acid-formaldehyde polymer","2-(4-hydroxyphenoxy)acetic acid-formaldehyde polymer","C090697",0,0,0,0,0,2,0,0,0]
["2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","C085911",1,0,0,1,0,0,1,0,0]
["2-(6-(4-(2-chloro-5-fluorophenoxy)piperidin-1-yl)pyridazin-3-yl)-5-methyl-1,3,4-oxadiazole","2-(6-(4-(2-chloro-5-fluorophenoxy)piperidin-1-yl)pyridazin-3-yl)-5-methyl-1,3,4-oxadiazole","C531040",0,0,0,0,0,0,0,1,0]
["2-(7-methoxy-4-methylquinazolin-2-yl)guanidine","2-(7-methoxy-4-methylquinazolin-2-yl)guanidine","C000622242",0,0,0,0,0,1,0,0,0]
["2-(indol-3-ylmethyl)-3,3'-diindolylmethane","2-(indol-3-ylmethyl)-3,3'-diindolylmethane","C120667",2,0,0,0,0,0,0,0,0]
["2-(N-ethylperfluorooctanesulfonamido)ethyl alcohol","2-(N-ethylperfluorooctanesulfonamido)ethyl alcohol","C435127",0,0,0,0,0,0,0,2,0]
["2-(omega-carboxyethyl)pyrrole","2-(omega-carboxyethyl)pyrrole","C000602461",0,0,0,0,1,1,0,0,0]
["2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene","2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene","C054919",0,2,0,0,0,1,0,0,0]
["2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid","2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid","C054917",0,2,0,0,0,1,0,0,0]
["2,2',3,4,4',5,5'-heptachloro-3'-hydroxybiphenyl","2,2',3,4,4',5,5'-heptachloro-3'-hydroxybiphenyl","C000602900",0,0,0,0,0,0,1,0,0]
["2,2',3,5',6-pentachlorobiphenyl","2,2',3,5',6-pentachlorobiphenyl","C032904",2,0,0,0,0,0,0,0,0]
["2,2',4,4',5-brominated diphenyl ether","2,2',4,4',5-brominated diphenyl ether","C477694",3,0,0,0,0,0,5,0,0]
["2,2',4,4',5-pentachlorodiphenyl ether","2,2',4,4',5-pentachlorodiphenyl ether","C058905",0,0,0,0,0,0,2,0,0]
["2,2',4,4',6,6'-hexabromobiphenyl","2,2',4,4',6,6'-hexabromobiphenyl","C508511",1,0,0,0,0,0,1,0,0]
["2,2',4,4'-tetrahydroxybenzophenone","2,2',4,4'-tetrahydroxybenzophenone","C035476",1,0,0,0,0,0,0,0,0]
["2,2',4,6,6'-pentachlorobiphenyl","2,2',4,6,6'-pentachlorobiphenyl","C417207",2,0,0,0,0,0,2,0,0]
["2,2',4,6'-tetramethoxystilbene","2,2',4,6'-tetramethoxystilbene","C541980",0,0,0,0,0,0,1,0,0]
["2,2,4-trimethylpentane","2,2,4-trimethylpentane","C045798",0,0,0,0,0,0,2,0,0]
["2,2',5-trichlorobiphenyl","2,2',5-trichlorobiphenyl","C078449",0,0,0,0,0,0,2,0,0]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728",0,0,0,0,0,13,0,0,0]
["2,2-dimethyl-5-tert-butyl-1,3-benzodioxole","2,2-dimethyl-5-tert-butyl-1,3-benzodioxole","C037778",2,0,0,0,0,0,1,0,0]
["2,2'-Dipyridyl","2,2'-Dipyridyl","D015082",0,0,0,0,0,0,2,0,0]
["2,3,3',4,4',5,5'-heptachlor-1'-methyl-1,2'-bipyrrole","2,3,3',4,4',5,5'-heptachlor-1'-methyl-1,2'-bipyrrole","C503289",1,0,0,0,0,0,1,0,0]
["2,3,3',4,4',5-hexabromobiphenyl","2,3,3',4,4',5-hexabromobiphenyl","C029186",1,0,0,0,0,0,0,0,0]
["2,3,3',4,4',5-hexachlorobiphenyl","2,3,3',4,4',5-hexachlorobiphenyl","C087667",1,0,0,0,0,0,2,0,0]
["2,3,3',4,4'5,6-heptabromobiphenyl","2,3,3',4,4'5,6-heptabromobiphenyl","C029187",1,0,0,0,0,0,0,0,0]
["2,3,3',4,4'-pentachlorobiphenyl","2,3,3',4,4'-pentachlorobiphenyl","C067940",0,0,0,0,0,0,4,0,0]
["2,3,3',4',5-pentachloro-4-hydroxybiphenyl","2,3,3',4',5-pentachloro-4-hydroxybiphenyl","C111120",0,0,0,0,0,0,1,0,0]
["2',3,3',4',5-pentachloro-4-hydroxybiphenyl","2',3,3',4',5-pentachloro-4-hydroxybiphenyl","C111118",0,0,0,0,0,0,1,0,0]
["2,3,4,2',3',4'-hexachlorobiphenyl","2,3,4,2',3',4'-hexachlorobiphenyl","C014218",1,0,0,0,0,0,2,0,0]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055",3,0,0,0,0,0,6,0,0]
["2',3',4',5'-tetrahydroxystilbene-2-O-beta-D-glucoside","2',3',4',5'-tetrahydroxystilbene-2-O-beta-D-glucoside","C489707",0,0,0,0,0,1,0,0,0]
["2,3,4,6-tetra-O-acetyl-1-thioglucopyranose","2,3,4,6-tetra-O-acetyl-1-thioglucopyranose","C508252",0,0,0,0,0,1,0,0,0]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890",12,0,0,0,0,0,11,0,0]
["2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate","2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate","C041942",0,0,0,0,0,0,0,1,0]
["2,3,6,2',3',6'-hexachlorobiphenyl","2,3,6,2',3',6'-hexachlorobiphenyl","C010498",0,0,0,0,0,0,1,0,0]
["2,3,6,7-tetrachlorobiphenylene","2,3,6,7-tetrachlorobiphenylene","C516412",3,0,0,0,0,0,1,0,0]
["2,3,6-trichlorobiphenylene","2,3,6-trichlorobiphenylene","C516411",3,0,0,0,0,0,1,0,0]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841",10,0,0,0,0,0,7,0,0]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211",21,0,0,0,0,0,22,0,0]
["2,3,7,8-tetrachlorophenothiazine","2,3,7,8-tetrachlorophenothiazine","C531157",0,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1604,B1604)","v":"2,3,7,8-tetrachlorothainthrene"},"2,3,7,8-tetrachlorothainthrene","C112084",0,0,0,0,0,0,1,0,0]
["2,3,7,8-tetrafluorodibenzodioxin","2,3,7,8-tetrafluorodibenzodioxin","C092566",1,0,0,0,0,0,2,0,0]
["2,3-bis(4-nitrophenyl)acrylonitrile","2,3-bis(4-nitrophenyl)acrylonitrile","C570603",3,0,0,0,0,0,1,0,0]
["2,3-diaminotoluene","2,3-diaminotoluene","C100420",2,0,0,0,0,0,0,0,0]
["2,3-dichlorobiphenylene","2,3-dichlorobiphenylene","C516410",3,0,0,0,0,0,1,0,0]
["2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","C106512",0,0,0,0,0,6,0,0,0]
["2,3-dihydroxybenzoic acid","2,3-dihydroxybenzoic acid","C009135",0,0,0,0,0,1,0,0,0]
["2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2(alpha)","2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2(alpha)","C411579",0,0,0,0,0,1,0,0,0]
["2,3-dinor-6-ketoprostaglandin F1alpha","2,3-dinor-6-ketoprostaglandin F1alpha","C028290",0,0,0,0,0,1,0,0,0]
["2,3-dinor-thromboxane B2","2,3-dinor-thromboxane B2","C028965",0,0,0,0,0,2,0,0,0]
["2,4,2',4'-tetrachlorobiphenyl","2,4,2',4'-tetrachlorobiphenyl","C035976",1,0,0,0,0,0,1,0,0]
["2,4,3',5'-tetramethoxystilbene","2,4,3',5'-tetramethoxystilbene","C440850",0,0,0,0,0,0,2,0,0]
["2,4,4'-trichlorobiphenyl","2,4,4'-trichlorobiphenyl","C081766",0,0,0,0,0,0,4,0,0]
["2,4,5,2',4',5'-hexabromobiphenyl","2,4,5,2',4',5'-hexabromobiphenyl","C018566",0,1,0,0,0,1,0,0,0]
["2,4,5,2',5'-pentachlorobiphenyl","2,4,5,2',5'-pentachlorobiphenyl","C009828",0,0,0,0,0,0,1,0,0]
["2,4,5,3',4'-pentabromobiphenyl","2,4,5,3',4'-pentabromobiphenyl","C035354",1,0,0,0,0,0,0,0,0]
["2,4,5-trichlorophenol","2,4,5-trichlorophenol","C009534",0,0,0,0,0,0,1,0,0]
["2,4,5-Trichlorophenoxyacetic Acid","2,4,5-Trichlorophenoxyacetic Acid","D015085",1,0,0,0,0,0,0,0,0]
["2,4,6,8-tetrachlorodibenzofuran","2,4,6,8-tetrachlorodibenzofuran","C049041",2,0,0,0,0,0,1,0,0]
["2,4,6-tribromoanisole","2,4,6-tribromoanisole","C484217",1,0,0,0,0,0,1,0,0]
["2,4,6-trichlorophenyl 4-nitrophenyl ether","2,4,6-trichlorophenyl 4-nitrophenyl ether","C010422",0,0,0,0,0,0,1,0,0]
["2,4,6-trichlorophenyl-4'-aminophenyl ether","2,4,6-trichlorophenyl-4'-aminophenyl ether","C067259",0,0,0,0,0,0,1,0,0]
["2,4,6-triphenyl-1,3-dioxane","2,4,6-triphenyl-1,3-dioxane","C054589",0,0,0,1,0,0,0,0,0]
["2,4,6-triphenyl-1-hexene","2,4,6-triphenyl-1-hexene","C533342",1,0,0,0,0,0,1,0,0]
["2,4,8-trichlorodibenzofuran","2,4,8-trichlorodibenzofuran","C063566",0,0,0,0,0,0,1,0,0]
["2,4,8-trihydroxybicyclo(3.2.1)octan-3-one","2,4,8-trihydroxybicyclo(3.2.1)octan-3-one","C571833",0,0,0,0,0,1,0,0,0]
["2,4-diaminotoluene","2,4-diaminotoluene","C010914",2,0,0,0,0,0,0,0,0]
["2,4-Dichlorophenoxyacetic Acid","2,4-Dichlorophenoxyacetic Acid","D015084",2,0,1,0,0,0,1,2,0]
["2',4'-dihydroxy-4-methoxydihydrochalcone","2',4'-dihydroxy-4-methoxydihydrochalcone","C514624",0,0,0,1,0,0,0,0,0]
["2,4-dinitrophenylhydrazone","2,4-dinitrophenylhydrazone","C001072",0,0,0,0,0,1,0,0,0]
["2,4-dinitrotoluene","2,4-dinitrotoluene","C016403",0,0,0,0,0,0,1,0,0]
["2,5,2',5'-tetrachlorobiphenyl","2,5,2',5'-tetrachlorobiphenyl","C009407",3,0,0,0,0,0,3,0,0]
["2,5-diaminotoluene","2,5-diaminotoluene","C007303",2,0,0,0,0,0,0,0,0]
["2,5-dihydroxybenzoic acid","2,5-dihydroxybenzoic acid","C010925",0,0,0,0,0,4,1,0,0]
["2,6-diaminotoluene","2,6-diaminotoluene","C025235",2,0,0,0,0,0,0,0,0]
["2,6-diisopropylphenyl ((4-(3-methoxyphenyl)-1-pyrimidin-2-ylpiperidin-4-yl)carbonyl)sulfamate","2,6-diisopropylphenyl ((4-(3-methoxyphenyl)-1-pyrimidin-2-ylpiperidin-4-yl)carbonyl)sulfamate","C549344",0,0,0,0,0,1,0,0,0]
["2',7'-dichlorofluorescein","2',7'-dichlorofluorescein","C037631",0,0,0,0,0,0,1,0,0]
["2,8-dichlorodibenzo-4-dioxin","2,8-dichlorodibenzo-4-dioxin","C068993",1,0,0,0,0,0,0,0,0]
["2016481B compound","2016481B compound","C550230",0,0,0,0,1,1,0,0,0]
["2038751B compound","2038751B compound","C550229",0,0,0,0,1,1,0,0,0]
["20-hydroxy-5,8,11,14-eicosatetraenoic acid","20-hydroxy-5,8,11,14-eicosatetraenoic acid","C055987",0,0,0,0,0,1,0,0,0]
["22-hydroxy-25-fluorocholesterol","22-hydroxy-25-fluorocholesterol","C039341",0,0,0,0,0,1,0,0,0]
["23-valent pneumococcal capsular polysaccharide vaccine","23-valent pneumococcal capsular polysaccharide vaccine","C414006",0,0,0,0,0,1,0,0,0]
["24,25-epoxycholesterol","24,25-epoxycholesterol","C028358",0,1,0,0,0,2,0,0,0]
["24-hydroxycholesterol","24-hydroxycholesterol","C044563",0,1,0,0,1,2,0,0,0]
["26-aminocholesterol","26-aminocholesterol","C058194",0,0,0,0,0,2,0,0,0]
["26-thiacholesterol","26-thiacholesterol","C058193",0,0,0,0,0,1,0,0,0]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073",4,0,0,0,0,0,10,0,0]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584",3,0,0,0,0,0,19,0,0]
["2-amino-3-(3,5-dibromo-4-(4-hydroxy-3-(6-oxo-1,6-dihydro-pyridazin-3-ylmethyl)-phenoxyl)-phenyl)-propionic acid","2-amino-3-(3,5-dibromo-4-(4-hydroxy-3-(6-oxo-1,6-dihydro-pyridazin-3-ylmethyl)-phenoxyl)-phenyl)-propionic acid","C113777",0,0,0,0,0,1,0,0,0]
["2-amino-3,4-dimethylimidazo(4,5-f)quinoline","2-amino-3,4-dimethylimidazo(4,5-f)quinoline","C036989",0,0,0,0,0,0,3,0,0]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990",3,0,0,0,0,0,7,0,0]
["2-amino-3-methyl-9H-pyrido(2,3-b)indole","2-amino-3-methyl-9H-pyrido(2,3-b)indole","C017821",0,0,0,0,0,0,1,0,0]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216",2,0,0,0,0,0,13,0,0]
["2-amino-9H-pyrido(2,3-b)indole","2-amino-9H-pyrido(2,3-b)indole","C017822",0,0,0,0,0,0,2,0,0]
["2-aminodiphenyl","2-aminodiphenyl","C014970",1,0,0,0,0,0,0,0,0]
["2-aminofluorene","2-aminofluorene","C012177",0,0,0,0,0,0,1,0,0]
["2-anthramine","2-anthramine","C006593",0,0,0,0,0,0,7,0,0]
["2-azido-3-iodo-7,8-dibromodibenzo-1,4-dioxin","2-azido-3-iodo-7,8-dibromodibenzo-1,4-dioxin","C054916",4,0,0,0,0,0,0,0,0]
["2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one","2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one","C587262",1,0,0,0,0,0,0,0,0]
["2-bromopalmitate","2-bromopalmitate","C022776",0,0,0,0,0,0,0,2,0]
["2-butenal","2-butenal","C012796",0,0,0,0,0,0,1,0,0]
["2-chloro-5-nitrobenzanilide","2-chloro-5-nitrobenzanilide","C457499",0,0,0,0,1,1,0,0,0]
["2-chloroethyl ethyl sulfide","2-chloroethyl ethyl sulfide","C031278",0,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1668,B1668)","v":"2-chlorosyringaldehyde"},"2-chlorosyringaldehyde","C103515",0,0,0,0,0,0,1,0,0]
["2-cresol","2-cresol","C034047",0,0,0,0,0,0,1,0,0]
["2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid","2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid","C116817",0,0,0,0,1,0,0,0,0]
["2-cyclopentyl-N-(2,4-dichloro-3-((isoquinolin-5-yloxy)methyl)phenyl)-N-methylacetamide","2-cyclopentyl-N-(2,4-dichloro-3-((isoquinolin-5-yloxy)methyl)phenyl)-N-methylacetamide","C555068",0,0,0,1,0,0,0,0,0]
["2-dichlorobenzene","2-dichlorobenzene","C004726",0,0,0,0,0,0,1,0,0]
["2-ethynylnaphthalene","2-ethynylnaphthalene","C065012",0,0,0,0,0,0,1,0,0]
["2-hexadecynoic acid","2-hexadecynoic acid","C031203",0,0,0,0,0,0,0,2,0]
["2'-hydroxy dihydroguaiaretic acid","2'-hydroxy dihydroguaiaretic acid","C497853",0,0,0,0,0,1,0,0,0]
["2-hydroxy-1,3,7,8-tetrachlorodibenzo-4-dioxin","2-hydroxy-1,3,7,8-tetrachlorodibenzo-4-dioxin","C049089",3,0,0,0,0,0,0,0,0]
["2'-hydroxy-4-methoxychalcone","2'-hydroxy-4-methoxychalcone","C031742",0,0,0,0,0,1,0,0,0]
["2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C060533",0,0,0,0,0,0,1,0,0]
["2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline","2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline","C032012",0,0,0,0,0,0,1,0,0]
["2-hydroxyatorvastatin","2-hydroxyatorvastatin","C518963",0,1,0,0,0,3,0,0,0]
["2'-hydroxychalcone","2'-hydroxychalcone","C013031",0,0,0,0,0,1,0,0,0]
["2-hydroxyethylhydrazine","2-hydroxyethylhydrazine","C037834",0,0,0,0,0,0,1,0,0]
["2-hydroxyoleic acid","2-hydroxyoleic acid","C483229",0,0,0,0,0,0,0,1,0]
["2-Hydroxypropyl-beta-cyclodextrin","2-Hydroxypropyl-beta-cyclodextrin","D000073738",0,1,0,0,0,2,0,0,0]
["2-hydroxyursolic acid","2-hydroxyursolic acid","C412810",0,0,0,0,0,1,0,0,0]
["2-iodo-3,7,8-trichlorodibenzo-4-dioxin","2-iodo-3,7,8-trichlorodibenzo-4-dioxin","C060352",4,0,0,0,0,0,0,0,0]
["2-iodo-7,8-dibromodibenzo-1,4-dioxin","2-iodo-7,8-dibromodibenzo-1,4-dioxin","C056902",4,0,0,0,0,0,0,0,0]
["2-mercaptoacetate","2-mercaptoacetate","C017487",0,1,1,0,0,2,0,6,0]
["2-mercaptobenzimidazole","2-mercaptobenzimidazole","C030698",0,0,0,0,0,0,1,0,0]
["2-methyl-1-(2,4,6-trihydroxy-3-(3-methyl2-butenyl)phenyl)-1-propanone","2-methyl-1-(2,4,6-trihydroxy-3-(3-methyl2-butenyl)phenyl)-1-propanone","C572891",0,0,0,0,0,1,0,0,0]
["2-methyl-1-(2,4,6-trihydroxy-3,5-di(3-methyl-2-butenyl)phenyl)-1-propanone","2-methyl-1-(2,4,6-trihydroxy-3,5-di(3-methyl-2-butenyl)phenyl)-1-propanone","C572889",0,0,0,0,0,1,0,0,0]
["2-methyl-1-(2,4,6-trihydroxyphenyl)-1-propanone","2-methyl-1-(2,4,6-trihydroxyphenyl)-1-propanone","C572890",0,0,0,0,0,1,0,0,0]
["2-methyl-5-tert-butyl-1,3-benzodioxole","2-methyl-5-tert-butyl-1,3-benzodioxole","C037777",0,0,0,0,0,0,1,0,0]
["2-methylisoborneol","2-methylisoborneol","C005536",0,0,0,0,0,0,1,0,0]
["2-morpholinomethyl-2',3',4'-trimethoxyacrylophenone","2-morpholinomethyl-2',3',4'-trimethoxyacrylophenone","C075405",0,0,0,0,0,2,0,0,0]
["2-naphthaldehyde","2-naphthaldehyde","C018686",0,0,0,0,0,0,1,0,0]
["2-naphthol","2-naphthol","C028405",0,0,0,0,0,0,3,0,0]
["2-naphthol orange","2-naphthol orange","C014722",0,0,0,0,0,0,1,0,0]
["2-Naphthylamine","2-Naphthylamine","D015081",1,1,0,0,0,4,0,0,0]
["2-nitro-6H-dibenzo(b,d)pyran-6-one","2-nitro-6H-dibenzo(b,d)pyran-6-one","C097142",0,0,0,0,0,0,1,0,0]
["2-nitrofluoranthene","2-nitrofluoranthene","C049030",0,0,0,0,0,0,1,0,0]
["2-nonenal","2-nonenal","C013166",0,0,0,0,0,2,0,0,0]
["2-O-(9-octadecenyl)glycerol","2-O-(9-octadecenyl)glycerol","C084967",0,0,0,0,0,0,0,2,0]
["2-octynoic acid","2-octynoic acid","C060855",0,0,0,0,0,0,0,2,0]
["2-oxohexyl isothiocyanate","2-oxohexyl isothiocyanate","C524315",1,0,0,0,0,0,3,0,0]
["2-parinarolyllecithin","2-parinarolyllecithin","C030048",0,0,0,0,0,1,0,0,0]
["2-pentenal","2-pentenal","C064599",0,0,0,0,0,2,0,0,0]
["2-phenyl-2-(1-piperidinyl)propane","2-phenyl-2-(1-piperidinyl)propane","C412835",0,0,0,0,0,0,2,0,0]
["2-phenylchromone","2-phenylchromone","C525486",3,0,0,0,0,0,1,0,0]
["2-phenylphenanthridinone","2-phenylphenanthridinone","C089169",1,0,0,0,0,0,1,0,0]
["2-propenyl-5,6-secocholestan-3-ol","2-propenyl-5,6-secocholestan-3-ol","C113842",0,0,0,0,0,1,0,0,0]
["2-pyrazinoylguanidine","2-pyrazinoylguanidine","C056104",0,0,0,0,0,1,0,0,0]
["2-tert-butylhydroquinone","2-tert-butylhydroquinone","C018855",10,0,0,0,0,0,2,0,0]
["2-tetradecylglycidic acid","2-tetradecylglycidic acid","C021756",0,1,0,0,0,0,0,0,0]
["2-toluidine","2-toluidine","C023622",0,0,0,0,0,0,1,0,0]
["3-((2,4-dimethylpyrrol-5-yl)methylidenyl)-2-indolinone","3-((2,4-dimethylpyrrol-5-yl)methylidenyl)-2-indolinone","C549241",3,0,0,0,0,0,1,0,0]
["3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate","3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate","C028213",0,0,0,0,0,1,0,0,0]
["3-((3-phenoxyphenyl)((3-(1,1,2,2-tetrafluoroethoxy)phenyl)methyl)amino)-1,1,1-trifluoro-2-propanol","3-((3-phenoxyphenyl)((3-(1,1,2,2-tetrafluoroethoxy)phenyl)methyl)amino)-1,1,1-trifluoro-2-propanol","C465459",0,1,0,0,0,1,0,0,0]
["3-(2-(2,4,6-trimethylphenyl)thioethyl)-4-methylsydnone","3-(2-(2,4,6-trimethylphenyl)thioethyl)-4-methylsydnone","C048192",0,0,0,0,0,0,1,0,0]
["3-(2,2,2-trimethylhydrazine)propionate","3-(2,2,2-trimethylhydrazine)propionate","C050147",0,0,1,0,0,1,0,0,0]
["3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H,2,4-triazol","3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H,2,4-triazol","C543497",0,0,0,0,0,0,1,0,0]
["3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole","3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole","C030266",0,0,0,0,0,0,2,0,0]
["3-(2-hydroxyethoxy)-4-methoxy-N-(5-(3-trifluoromethylbenzyl)thiazol-2-yl)benzamide","3-(2-hydroxyethoxy)-4-methoxy-N-(5-(3-trifluoromethylbenzyl)thiazol-2-yl)benzamide","C545364",0,0,0,0,0,0,0,2,0]
["3-(3,4,5-trimethoxyphenyl)-1-oxo-2-propene","3-(3,4,5-trimethoxyphenyl)-1-oxo-2-propene","C520655",1,0,0,0,0,0,1,0,0]
["3-(3,5-dichlorophenyl)-2,4-thiazolidinedione","3-(3,5-dichlorophenyl)-2,4-thiazolidinedione","C532666",0,0,0,0,0,0,1,0,0]
["3-(4-(2-carbazol-9-ylethoxy)phenyl)-2-ethoxypropionic acid","3-(4-(2-carbazol-9-ylethoxy)phenyl)-2-ethoxypropionic acid","C448626",0,0,0,0,0,1,0,0,0]
["3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide","3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide","C548780",0,0,0,0,0,1,0,0,0]
["3-(4-hydroxy-3-(3-oxo-but-1-enyl)-phenyl)-acrylic acid","3-(4-hydroxy-3-(3-oxo-but-1-enyl)-phenyl)-acrylic acid","C110594",0,0,0,0,0,1,0,0,0]
["3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid","3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid","C526155",0,0,0,0,1,1,0,0,0]
["3-(4-methylphenylsulfonyl)-2-propenenitrile","3-(4-methylphenylsulfonyl)-2-propenenitrile","C434003",0,0,0,0,0,0,0,2,0]
["3-(alpha,alpha-dimethylallyl)psoralen","3-(alpha,alpha-dimethylallyl)psoralen","C020740",0,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1732,B1732)","v":"3-(carboxymethyl)-5-(6-(2,4-dichlorophenyl)hexyl)-3-hydroxytetrahydrofuran-2-one"},"3-(carboxymethyl)-5-(6-(2,4-dichlorophenyl)hexyl)-3-hydroxytetrahydrofuran-2-one","C114594",0,1,0,0,0,0,0,0,0]
["3-(N-phenylamino)-1,2-propanediol 1,2-dioleoyl ester","3-(N-phenylamino)-1,2-propanediol 1,2-dioleoyl ester","C092835",0,0,0,0,0,1,0,0,0]
["3,3',4,4',5,5'-hexabromobiphenyl","3,3',4,4',5,5'-hexabromobiphenyl","C032790",2,0,0,0,0,0,3,0,0]
["3,3',4,4'-tetrabromobiphenyl","3,3',4,4'-tetrabromobiphenyl","C036685",1,0,0,0,0,0,2,0,0]
["3,3',4',5,6,7,8-heptamethoxyflavone","3,3',4',5,6,7,8-heptamethoxyflavone","C059294",0,0,0,0,0,2,0,0,0]
["3,3',4',5-tetrachloro-4-hydroxybiphenyl","3,3',4',5-tetrachloro-4-hydroxybiphenyl","C111117",0,0,0,0,0,0,1,0,0]
["3,3',4,5'-tetrahydroxystilbene","3,3',4,5'-tetrahydroxystilbene","C041525",1,0,0,0,1,1,2,0,0]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286",0,0,0,0,0,12,0,0,0]
["3,3'-iminodipropionitrile","3,3'-iminodipropionitrile","C008110",0,2,0,0,0,0,0,0,0]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451",41,0,0,0,0,2,50,0,0]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309",8,0,0,0,0,0,9,0,0]
["3,4-dichloroaniline","3,4-dichloroaniline","C014464",1,0,0,0,0,0,1,0,0]
["3',4'-dihydroxy-5,6,7,8-tetramethoxyflavone","3',4'-dihydroxy-5,6,7,8-tetramethoxyflavone","C547849",0,0,0,0,1,1,0,0,0]
["3,4-dihydroxyphenyllactic acid","3,4-dihydroxyphenyllactic acid","C035055",0,0,0,0,1,2,0,0,0]
["3',4'-dimethoxy-alpha-naphthoflavone","3',4'-dimethoxy-alpha-naphthoflavone","C557505",3,0,0,0,0,0,0,0,0]
["3',4'-dimethoxyflavone","3',4'-dimethoxyflavone","C509288",1,0,0,0,0,0,1,0,0]
["3,4-dixydroxyphenylethanol elenolic acid","3,4-dixydroxyphenylethanol elenolic acid","C121925",0,0,0,0,0,2,0,0,0]
["3,5 dimethylpyrazole-peroxy-vanadate","3,5 dimethylpyrazole-peroxy-vanadate","C000621804",0,0,0,0,1,0,0,0,0]
["3,5,3',4',5'-pentamethoxystilbene","3,5,3',4',5'-pentamethoxystilbene","C494914",0,0,0,0,0,0,1,0,0]
["3,5-dibromo-2-(2,4-dibromophenoxy)phenol","3,5-dibromo-2-(2,4-dibromophenoxy)phenol","C085794",3,0,0,0,0,0,0,0,0]
["3,5-dibromo-4-nitrosobenzenesulfonate","3,5-dibromo-4-nitrosobenzenesulfonate","C048757",0,0,0,0,0,2,0,0,0]
["3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine","3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine","C030826",0,0,0,0,0,0,1,0,0]
["3,5-dihydroxy-4'-methoxystilbene","3,5-dihydroxy-4'-methoxystilbene","C439024",0,0,0,0,0,0,1,0,0]
["3,5-dihydroxystilbene","3,5-dihydroxystilbene","C510000",0,0,0,0,0,0,2,0,0]
["3,5-dimethylpyrazole","3,5-dimethylpyrazole","C027635",0,0,0,0,0,1,0,0,0]
["3,5-di-O-galloyl-4-O-digalloylquinic acid","3,5-di-O-galloyl-4-O-digalloylquinic acid","C061725",0,0,0,0,0,2,0,0,0]
["3,6,24-trihydroxy-24,24-bis(trifluoromethyl)cholane","3,6,24-trihydroxy-24,24-bis(trifluoromethyl)cholane","C532886",0,1,0,0,0,2,0,0,0]
["3,6,9,12,15-octadecapentaenoic acid","3,6,9,12,15-octadecapentaenoic acid","C432384",0,0,0,0,0,0,0,2,0]
["3,6-dichlorocarbazole","3,6-dichlorocarbazole","C558653",0,0,0,0,0,0,2,0,0]
["3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one","3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one","C026423",0,0,0,0,0,1,1,0,0]
["3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","C019132",0,0,0,0,0,0,5,0,0]
["3-amino-1-methyl-5H-pyrido(4,3-b)indole","3-amino-1-methyl-5H-pyrido(4,3-b)indole","C019133",0,0,0,0,0,0,3,0,0]
["3-amino-2-oxazolidinone","3-amino-2-oxazolidinone","C000209",0,0,0,0,0,0,1,0,0]
["3-aminobenzamide","3-aminobenzamide","C025160",0,0,0,2,0,0,0,0,0]
["3-aminobenzanthrone","3-aminobenzanthrone","C475568",1,0,0,0,0,0,6,0,0]
["3-aminopicolinic acid","3-aminopicolinic acid","C018451",0,0,0,8,0,0,0,0,0]
["3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one","3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one","C553471",0,0,0,0,0,1,0,0,0]
["3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine","3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine","C511179",0,0,0,0,0,1,0,0,0]
["3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","C006261",0,0,0,0,0,5,0,0,0]
["3-carboxy-11-(2,4-dichlorophenyl)-3,5-dihydroxyundecanoic acid","3-carboxy-11-(2,4-dichlorophenyl)-3,5-dihydroxyundecanoic acid","C114593",0,1,0,0,0,0,0,0,0]
["3-chloro-2-methyl-N-(4-(2-(4-methyl-1-piperazinyl)-2-oxoethyl)-1,3-thiazol-2-yl)benzenesulfonamide","3-chloro-2-methyl-N-(4-(2-(4-methyl-1-piperazinyl)-2-oxoethyl)-1,3-thiazol-2-yl)benzenesulfonamide","C474501",0,0,0,1,0,0,0,0,0]
["3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone","3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone","C054121",0,0,0,0,0,0,1,0,0]
["3-chlorocarbazole","3-chlorocarbazole","C558654",0,0,0,0,0,0,2,0,0]
["3'-demethylnobiletin","3'-demethylnobiletin","C515880",0,0,0,0,1,0,0,0,0]
["3'-deoxy-4-O-methylepisappanol","3'-deoxy-4-O-methylepisappanol","C548568",0,0,0,0,0,1,0,0,0]
["3-deoxyglycero-galacto-nonulosonic acid","3-deoxyglycero-galacto-nonulosonic acid","C050008",0,0,0,0,0,1,0,0,0]
["3-hydroxy-2-(4-(trifluoromethyl)phenyl)(1,2,3)triazolo(1,5-a)quinolinium","3-hydroxy-2-(4-(trifluoromethyl)phenyl)(1,2,3)triazolo(1,5-a)quinolinium","C587352",3,0,0,0,0,0,0,0,0]
["3-hydroxy-3-methyl-1(3H)-isobenzofuranone","3-hydroxy-3-methyl-1(3H)-isobenzofuranone","C104226",0,2,0,0,0,3,0,0,0]
["3-hydroxy-3-methylbutene","3-hydroxy-3-methylbutene","C027250",0,0,0,0,0,0,0,1,0]
["3-hydroxy-5-cholestenoic acid","3-hydroxy-5-cholestenoic acid","C029435",0,1,0,0,0,1,0,0,0]
["3-Hydroxyanthranilic Acid","3-Hydroxyanthranilic Acid","D015095",0,0,0,3,0,3,0,0,0]
["3-hydroxybenzoic acid","3-hydroxybenzoic acid","C032948",0,0,0,0,0,1,0,0,0]
["3-hydroxydodecanoic acid","3-hydroxydodecanoic acid","C022145",0,0,3,0,0,0,0,0,0]
["3-hydroxyflavone","3-hydroxyflavone","C041477",1,0,0,0,0,0,0,0,0]
["3-hydroxyisovalerylcarnitine","3-hydroxyisovalerylcarnitine","C098116",0,0,1,0,0,0,0,0,0]
["3-hydroxylanost-7-en-15-one","3-hydroxylanost-7-en-15-one","C091763",0,0,0,0,0,1,0,0,0]
["3-hydroxylanost-7-en-15-one 15-oxime","3-hydroxylanost-7-en-15-one 15-oxime","C091764",0,0,0,0,0,1,0,0,0]
["3-hydroxypalmitic acid","3-hydroxypalmitic acid","C108229",0,0,4,0,0,0,0,0,0]
["3-hydroxypyridine","3-hydroxypyridine","C023500",1,0,0,0,0,1,3,0,0]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363",0,0,0,46,0,0,0,0,0]
["3-methoxy-4-aminoazobenzene","3-methoxy-4-aminoazobenzene","C044436",0,0,0,0,0,0,1,0,0]
["3-methoxy-4'-methylthiostilbene","3-methoxy-4'-methylthiostilbene","C000601815",0,0,0,0,0,0,1,0,0]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768",16,0,0,0,0,0,8,0,0]
["3-methyladenine","3-methyladenine","C025946",0,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1796,B1796)","v":"3-methylethergalangin"},"3-methylethergalangin","C480203",0,0,0,0,0,1,0,0,0]
["3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate","3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate","C441128",0,0,0,0,0,1,0,0,0]
["3-nitrobenzanthrone","3-nitrobenzanthrone","C117220",1,0,0,0,0,0,6,0,0]
["3-nitroperylene","3-nitroperylene","C035987",1,0,0,0,0,0,0,0,0]
["3-O-(1-hexadecyl)cholesterol","3-O-(1-hexadecyl)cholesterol","C035237",0,0,0,0,2,0,0,0,0]
["3'-O-methylepicatechin","3'-O-methylepicatechin","C424450",0,0,0,0,0,1,0,0,0]
["3-phenoxybenzoic acid","3-phenoxybenzoic acid","C017618",0,1,0,0,0,0,0,0,0]
["3-phenylpropyl isothiocyanate","3-phenylpropyl isothiocyanate","C093849",0,0,0,0,0,0,2,0,0]
["3-xylene","3-xylene","C031285",0,0,0,0,0,0,2,0,0]
["4-(((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)-2-(trifluoromethyl)-3-pyridinyl)methylamino)methyl)benzoic acid","4-(((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)-2-(trifluoromethyl)-3-pyridinyl)methylamino)methyl)benzoic acid","C000598201",0,0,0,0,0,1,0,0,0]
["4-(1-(4-tert-butylphenyl)-2-oxo-4-pyrrolidinyl)methoxybenzoic acid","4-(1-(4-tert-butylphenyl)-2-oxo-4-pyrrolidinyl)methoxybenzoic acid","C482648",0,3,0,0,0,0,0,0,0]
["4-(1,1'-biphenyl)-2-hydroxytetronic acid","4-(1,1'-biphenyl)-2-hydroxytetronic acid","C113935",0,0,0,0,0,1,0,0,0]
["4-(1-adamantyloxy)aniline","4-(1-adamantyloxy)aniline","C018807",0,0,0,0,0,1,0,0,0]
["4-(2-(2-(4-chlorophenyl)-5,6-difluorobenzoimidazol-1-yl)-2-cyclohexylacetylamino)-3-fluorobenzoic acid","4-(2-(2-(4-chlorophenyl)-5,6-difluorobenzoimidazol-1-yl)-2-cyclohexylacetylamino)-3-fluorobenzoic acid","C558287",0,0,0,0,0,1,0,0,0]
["4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid","4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid","C000598200",0,0,0,0,0,1,0,0,0]
["4-(2,4-dichlorophenoxy)butyric acid","4-(2,4-dichlorophenoxy)butyric acid","C004764",0,0,1,0,0,0,0,2,0]
["4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol","4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol","C556295",1,0,0,0,0,0,0,0,0]
["4-(2-propenyl)cholest-24-en-3-ol","4-(2-propenyl)cholest-24-en-3-ol","C121236",0,0,0,0,0,2,0,0,0]
["4-(2-succinimidyloxycarbonylethyl)phenyl-10-methylacridinium-9-carboxylate","4-(2-succinimidyloxycarbonylethyl)phenyl-10-methylacridinium-9-carboxylate","C053333",0,0,0,0,0,1,0,0,0]
["4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid","4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid","C520164",0,0,0,0,0,1,0,0,0]
["4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","C524106",0,0,0,0,1,3,1,0,0]
["4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol","4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol","C040692",0,0,0,0,0,0,1,0,0]
["4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol","4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol","C525025",0,0,0,0,0,1,0,0,0]
["4-(4,6-diphenyl-1,3-dioxan-2-yl)-N,N-dimethylaniline","4-(4,6-diphenyl-1,3-dioxan-2-yl)-N,N-dimethylaniline","C000592353",0,0,0,1,0,0,0,0,0]
["4-(4'-chloro-1,1'-biphenyl)-2-hydroxytetronic acid","4-(4'-chloro-1,1'-biphenyl)-2-hydroxytetronic acid","C113938",0,0,0,0,0,1,0,0,0]
["4-(4'-chlorobenzyloxy)benzyl nicotinate","4-(4'-chlorobenzyloxy)benzyl nicotinate","C042413",0,1,0,0,0,1,0,0,0]
["4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine","4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine","C101091",0,0,0,0,0,0,0,2,0]
["4-(4-chlorophenyl)-2-hydroxytetronic acid","4-(4-chlorophenyl)-2-hydroxytetronic acid","C060438",0,1,0,0,0,2,0,0,0]
["4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole","4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole","C090942",1,0,0,0,0,0,1,0,0]
["4-(5-thioxo-5H-1,2-dithiol-3-yl)-phenyl 2-acetoxybenzoate","4-(5-thioxo-5H-1,2-dithiol-3-yl)-phenyl 2-acetoxybenzoate","C571292",0,0,0,0,0,0,1,0,0]
["4-(benzylamino)-2-((2-(3-chloro-4-hydroxyphenyl)ethyl)amino)pyrimidine-5-carboxamide","4-(benzylamino)-2-((2-(3-chloro-4-hydroxyphenyl)ethyl)amino)pyrimidine-5-carboxamide","C544923",0,0,0,0,1,0,0,0,0]
["4,4'-diaminodiphenylmethane","4,4'-diaminodiphenylmethane","C009505",0,0,0,0,0,0,1,0,0]
["4,4'-diaponeurosporene","4,4'-diaponeurosporene","C091058",0,0,0,0,1,0,0,0,0]
["4,4'-dihydroxy-3,3'-dimethoxy-5,5'-biphenyl-1,1'-(diphthalazin-1-yl)methylhydrazone","4,4'-dihydroxy-3,3'-dimethoxy-5,5'-biphenyl-1,1'-(diphthalazin-1-yl)methylhydrazone","C530304",0,0,0,0,0,1,0,0,0]
["4,5-di-O-(E)-caffeoylquinic acid","4,5-di-O-(E)-caffeoylquinic acid","C500583",0,0,0,0,0,1,0,0,0]
["4,6-dibromo-2-(2',4'-dibromo)phenoxyanisole","4,6-dibromo-2-(2',4'-dibromo)phenoxyanisole","C471837",1,0,0,0,0,0,1,0,0]
["4,7,10-hexadecatrienoic acid","4,7,10-hexadecatrienoic acid","C094145",0,0,0,0,0,0,0,2,0]
["4',7-dihydroxy-3,4-dihydroisoflavone","4',7-dihydroxy-3,4-dihydroisoflavone","C007610",0,0,0,0,0,4,1,0,0]
["4,9,13,17,21-pentamethyldocosa-2,4,6,8,10,12,14,16,20-nonaenoic Acid","4,9,13,17,21-pentamethyldocosa-2,4,6,8,10,12,14,16,20-nonaenoic Acid","C557870",0,0,0,0,0,0,0,2,0]
["4-acetylaminofluorene","4-acetylaminofluorene","C028676",2,0,0,0,0,0,0,0,0]
["4-acetylaminostilbene","4-acetylaminostilbene","C028520",2,0,0,0,0,0,0,0,0]
["4-amino-alpha,alpha,2-trimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol","4-amino-alpha,alpha,2-trimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol","C095471",0,0,0,0,1,0,0,0,0]
["4-aminodiphenylamine","4-aminodiphenylamine","C031506",3,0,0,0,0,0,1,0,0]
["4-aminoquinoline","4-aminoquinoline","C001920",0,0,0,0,0,0,1,0,0]
["4-biphenylamine","4-biphenylamine","C006757",1,0,0,0,0,0,1,0,0]
["4-bromocrotonic acid","4-bromocrotonic acid","C034444",0,0,0,0,0,0,0,2,0]
["4'-bromoflavone","4'-bromoflavone","C117304",0,0,0,0,0,0,1,0,0]
["4-bromomethaqualone","4-bromomethaqualone","C102576",0,1,0,0,0,0,0,0,0]
["4-bromotiglic acid","4-bromotiglic acid","C115522",0,0,3,0,0,0,0,0,0]
["4-Chloro-7-nitrobenzofurazan","4-Chloro-7-nitrobenzofurazan","D009327",0,0,0,0,0,8,0,0,0]
["4-chlorobiphenyl","4-chlorobiphenyl","C006983",2,0,0,0,0,0,2,0,0]
["4'-chloroflavone","4'-chloroflavone","C083064",3,0,0,0,0,0,1,0,0]
["4'-demethylnobiletin","4'-demethylnobiletin","C515881",0,0,0,0,1,0,0,0,0]
["4-dichlorobenzene","4-dichlorobenzene","C018511",2,0,0,0,0,0,1,0,0]
["4-hydroperoxy-2-nonenal","4-hydroperoxy-2-nonenal","C547259",0,0,0,0,1,2,0,0,0]
["4-hydroxy-2-ethyl-5-methyl-3(2H)-furanone","4-hydroxy-2-ethyl-5-methyl-3(2H)-furanone","C112945",0,0,0,0,0,1,0,0,0]
["4-hydroxy-2-hexenal","4-hydroxy-2-hexenal","C045934",0,0,0,0,0,1,0,0,0]
["4-hydroxy-2-octenal","4-hydroxy-2-octenal","C046538",0,0,0,0,0,1,0,0,0]
["4-hydroxyatorvastatin","4-hydroxyatorvastatin","C518964",0,0,0,0,0,2,0,0,0]
["4-hydroxyhexenal","4-hydroxyhexenal","C063409",0,0,0,0,0,2,0,0,0]
["4-hydroxyphenylacetaldehyde","4-hydroxyphenylacetaldehyde","C097891",0,1,0,0,0,3,0,0,0]
["4-hydroxyphenylethanol","4-hydroxyphenylethanol","C011867",0,0,0,0,0,4,1,0,0]
["4-hydroxypropranolol","4-hydroxypropranolol","C001422",0,1,0,0,0,2,0,0,0]
["4-hydroxypyrazole","4-hydroxypyrazole","C014606",0,0,0,0,0,0,2,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1860,B1860)","v":"4'-iodoflavone"},"4'-iodoflavone","C099018",6,0,0,0,0,0,1,0,0]
["4-iodopyrazole","4-iodopyrazole","C010201",0,0,0,0,0,0,2,0,0]
["4-ipomeanol","4-ipomeanol","C001470",0,0,0,0,0,0,2,0,0]
["4'-MeSO(2)-2,2',4,5,5'-pentachlorobiphenyl","4'-MeSO(2)-2,2',4,5,5'-pentachlorobiphenyl","C472352",0,0,0,0,0,0,1,0,0]
["4'-MeSO(2)-2,2',4,5'-tetrachlorobiphenyl","4'-MeSO(2)-2,2',4,5'-tetrachlorobiphenyl","C472353",0,0,0,0,0,0,1,0,0]
["4'-methoxyflavone","4'-methoxyflavone","C487850",0,0,0,0,0,0,1,0,0]
["4-methyl-7-ethoxycoumarin","4-methyl-7-ethoxycoumarin","C115983",0,0,0,0,0,0,1,0,0]
["4-nitrophenol","4-nitrophenol","C024836",3,0,0,0,0,3,2,0,0]
["4-nitrophenyl butyrate","4-nitrophenyl butyrate","C033592",0,0,0,0,0,1,0,0,0]
["4-nitrophenylglucuronide","4-nitrophenylglucuronide","C002730",2,0,0,0,0,0,1,0,0]
["4-nonylphenol","4-nonylphenol","C041594",2,0,0,0,0,0,6,0,0]
["4-octylphenol","4-octylphenol","C080417",0,0,0,0,0,0,2,0,0]
["4-O-deacetyl vinorelbine","4-O-deacetyl vinorelbine","C520600",0,0,0,0,1,0,0,0,0]
["4-oxofenretinide","4-oxofenretinide","C494898",0,0,0,0,0,0,0,1,0]
["4-phenyl-3-butyn-2-one","4-phenyl-3-butyn-2-one","C454401",0,0,0,0,0,0,1,0,0]
["4-phenyl-5,5-dicarbethoxy-2-pyrrolidinone","4-phenyl-5,5-dicarbethoxy-2-pyrrolidinone","C041986",0,0,0,0,0,2,0,0,0]
["4-tert-octylphenol","4-tert-octylphenol","C105260",0,0,0,0,0,0,1,0,0]
["4'-trifluoromethyl-2,3,4,5-tetrachlorobiphenyl","4'-trifluoromethyl-2,3,4,5-tetrachlorobiphenyl","C091911",0,0,0,0,0,0,1,0,0]
["4-trifluoromethyl-7,8-pyranocoumarin","4-trifluoromethyl-7,8-pyranocoumarin","C000602647",2,0,0,0,0,0,0,0,0]
["4-vinyl-1-cyclohexene dioxide","4-vinyl-1-cyclohexene dioxide","C012606",1,0,0,0,0,0,0,0,0]
["4-vinylcyclohexene","4-vinylcyclohexene","C013733",1,0,0,0,0,0,0,0,0]
["4-vinylphenyl boronic acid","4-vinylphenyl boronic acid","C427523",0,0,0,0,0,1,0,0,0]
["4-xylene","4-xylene","C031286",0,0,0,0,0,0,1,0,0]
["5-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid","5-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid","C524722",0,0,0,0,0,0,1,0,0]
["5-((5-bromo-1H-indol-3-yl)methylene)-3-(4-chlorobenzyl)thiazolidine-2,4-dione","5-((5-bromo-1H-indol-3-yl)methylene)-3-(4-chlorobenzyl)thiazolidine-2,4-dione","C583084",0,0,0,0,0,1,0,0,0]
["5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol","5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol","C571829",3,0,0,0,0,0,0,0,0]
["5-(3,4-dihydroxyphenyl)-1-piperidin-1-yl-penta-2,4-dien-1-one","5-(3,4-dihydroxyphenyl)-1-piperidin-1-yl-penta-2,4-dien-1-one","C000607169",0,0,0,0,0,1,0,0,0]
["5-(3,5-di-tert-butyl-4-hydroxybenzylidene)thiazolidine-2,4-dione","5-(3,5-di-tert-butyl-4-hydroxybenzylidene)thiazolidine-2,4-dione","C507175",0,0,0,0,0,1,0,0,0]
["5-(3-methyl-1-triazeno)imidazole-4-carboxamide","5-(3-methyl-1-triazeno)imidazole-4-carboxamide","C010243",0,0,0,0,0,0,1,0,0]
["5-(4-dimethylaminobenzoyl)-aminovaleric acid hydroxamate","5-(4-dimethylaminobenzoyl)-aminovaleric acid hydroxamate","C521334",0,0,0,0,0,0,1,0,0]
["5-(4-hydroxy-2,5-dimethylphenoxy)-2,2-dimethyl pentanoic acid","5-(4-hydroxy-2,5-dimethylphenoxy)-2,2-dimethyl pentanoic acid","C407182",0,0,0,0,0,1,0,0,0]
["5-(5-bromo-2-methoxybenzylidene)-3-(4-methyl-benzyl)thiazolidine-2,4-dione","5-(5-bromo-2-methoxybenzylidene)-3-(4-methyl-benzyl)thiazolidine-2,4-dione","C576055",0,0,0,0,0,1,0,0,0]
["5,10,15,20-tetrakis(4-methoxyphenyl)porphyrin","5,10,15,20-tetrakis(4-methoxyphenyl)porphyrin","C445706",0,0,0,0,0,1,0,0,0]
["5,10,15,20-tetraphenyl-1-3-(4-(4-aminobutyl)-7-chloroquinoline)propioamidoporphine","5,10,15,20-tetraphenyl-1-3-(4-(4-aminobutyl)-7-chloroquinoline)propioamidoporphine","C064271",0,0,0,0,0,1,0,0,0]
["5,11-methenyltetrahydrohomofolate","5,11-methenyltetrahydrohomofolate","C032418",0,0,0,0,0,2,0,0,0]
["5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate","5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate","C434605",0,0,0,0,0,1,0,0,0]
["5,5'-bis-trifluoromethyl-2,2'-dichlorobiphenyl","5,5'-bis-trifluoromethyl-2,2'-dichlorobiphenyl","C107005",0,0,0,0,0,0,1,0,0]
["5,5'-dibutoxy-2,2'-bifuran","5,5'-dibutoxy-2,2'-bifuran","C530807",0,0,0,0,0,1,0,0,0]
["5,6,11,12,17,18-hexahydrocyclononatriindole","5,6,11,12,17,18-hexahydrocyclononatriindole","C074140",1,0,0,0,0,0,1,0,0]
["5,6-epoxycholesterol","5,6-epoxycholesterol","C119784",0,0,0,0,0,1,0,0,0]
["5,6-secosterol","5,6-secosterol","C479527",0,0,0,0,0,1,0,0,0]
["5,8,11,14-Eicosatetraynoic Acid","5,8,11,14-Eicosatetraynoic Acid","D015117",0,0,0,0,0,0,0,5,0]
["5,8-tetradecadienoic acid","5,8-tetradecadienoic acid","C108157",0,0,0,0,0,0,0,2,0]
["5,9,12-octadecatrienoic acid","5,9,12-octadecatrienoic acid","C034302",0,0,0,0,0,2,0,3,0]
["5,9-dimethyldibenzo(c,g)carbazole","5,9-dimethyldibenzo(c,g)carbazole","C039387",0,0,0,0,0,0,2,0,0]
["5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid","5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid","C553926",0,0,0,3,0,0,0,0,0]
["5-carboxamidotryptamine","5-carboxamidotryptamine","C047087",0,0,0,0,0,1,0,0,0]
["5-diphosphomevalonic acid","5-diphosphomevalonic acid","C046285",0,0,0,0,0,2,0,0,0]
["5-ethyl-5-phenyloxazolidinedione","5-ethyl-5-phenyloxazolidinedione","C080851",0,0,0,0,0,0,1,0,0]
["5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone","5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone","C521815",0,0,0,0,0,2,0,0,0]
["5-hydroxy-6-formyl-7-norcholesterol","5-hydroxy-6-formyl-7-norcholesterol","C479528",0,0,0,0,0,1,0,0,0]
["5-hydroxymethylfurfural","5-hydroxymethylfurfural","C008046",0,0,0,0,0,1,0,0,0]
["5-methoxypsoralen","5-methoxypsoralen","C022909",0,0,0,0,0,2,2,0,0]
["5-methoxysterigmatocystin","5-methoxysterigmatocystin","C578082",0,0,0,0,0,0,1,0,0]
["5-methylchrysene","5-methylchrysene","C008422",1,0,0,0,0,0,1,0,0]
["5-Methylcytosine","5-Methylcytosine","D044503",0,0,0,0,0,1,0,0,0]
["5-methyltetrahydrofolate","5-methyltetrahydrofolate","C005984",0,0,0,0,0,3,0,0,0]
["5-octadecenoic acid","5-octadecenoic acid","C114874",0,0,0,0,0,0,0,1,0]
["5-oxovaaleroyl cholesterol","5-oxovaaleroyl cholesterol","C120394",0,0,0,0,0,2,0,0,0]
["5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione","5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione","C505144",0,0,0,0,0,1,0,0,0]
["5-tert-butyl-1,3-benzodioxole","5-tert-butyl-1,3-benzodioxole","C037776",0,0,0,0,0,0,1,0,0]
["6-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid","6-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid","C000607197",0,0,0,0,0,1,0,0,0]
["6-(4-(2-methylbenzoyl)piperidin-1-yl)pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide","6-(4-(2-methylbenzoyl)piperidin-1-yl)pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide","C549137",0,0,0,0,0,0,0,1,0]
["6-(4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl)pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide","6-(4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl)pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide","C583719",0,0,0,0,0,0,0,1,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1924,B1924)","v":"6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione"},"6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione","C454039",1,0,0,0,0,0,1,0,0]
["6-(5-(4-amidinophenyl)furan-2-yl)nicotinamidine","6-(5-(4-amidinophenyl)furan-2-yl)nicotinamidine","C504229",0,0,0,0,0,0,1,0,0]
["6,12-diformylindolo(3,2-b)carbazole","6,12-diformylindolo(3,2-b)carbazole","C111854",2,0,0,0,0,0,1,0,0]
["6,2',4'-trimethoxyflavone","6,2',4'-trimethoxyflavone","C546607",3,0,0,0,0,0,0,0,0]
["6,9,12,15,18-heneicosapentaenoic acid","6,9,12,15,18-heneicosapentaenoic acid","C108158",0,0,0,0,0,0,0,3,0]
["6,9,12,15-octadecatetraenoic acid","6,9,12,15-octadecatetraenoic acid","C432383",0,0,0,0,0,0,0,2,0]
["6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine","6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine","C541593",0,0,0,0,0,2,0,0,0]
["6-amino-2-mercapto-5-methylpyrimidine-4-carboxylic acid","6-amino-2-mercapto-5-methylpyrimidine-4-carboxylic acid","C070934",0,0,0,0,0,1,0,0,0]
["6-amino-4-(N-(4-chlorophenyl)-N-(1H-imidazol-2ylmethyl)amino)-3-hydroxyl-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran","6-amino-4-(N-(4-chlorophenyl)-N-(1H-imidazol-2ylmethyl)amino)-3-hydroxyl-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran","C000595877",0,0,0,0,0,1,0,0,0]
["6-aminocholesterol","6-aminocholesterol","C095995",0,0,0,0,0,1,0,0,0]
["6-bromoflavone","6-bromoflavone","C099934",0,0,0,0,0,0,1,0,0]
["6-carboxyfluorescein","6-carboxyfluorescein","C024098",0,0,0,0,0,1,0,0,0]
["6-chloromercuricholesterol","6-chloromercuricholesterol","C049524",0,0,0,0,0,1,0,0,0]
["6-chrysenamine","6-chrysenamine","C100101",1,0,0,0,0,0,0,0,0]
["6-demethoxycapillarisin","6-demethoxycapillarisin","C514569",0,0,0,1,0,0,0,0,0]
["6-dimethylamino-2-naphthaldehyde","6-dimethylamino-2-naphthaldehyde","C506914",0,0,0,0,0,0,1,0,0]
["6-fluoromevalonolactone","6-fluoromevalonolactone","C045174",0,0,0,0,0,2,0,0,0]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855",47,0,0,0,0,0,12,0,0]
["6-hydroxy-2-((4-(bis(4--fluorophenyl)methyl)piperazin-1-yl)methyl)-1,4-benzodioxin","6-hydroxy-2-((4-(bis(4--fluorophenyl)methyl)piperazin-1-yl)methyl)-1,4-benzodioxin","C439957",0,1,0,0,0,1,0,0,0]
["6-hydroxy-2-((4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)oxo)-1,4-benzodioxin","6-hydroxy-2-((4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)oxo)-1,4-benzodioxin","C439956",0,1,0,0,0,1,0,0,0]
["6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid","6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid","C010643",0,0,0,0,0,9,1,0,0]
["6-hydroxychlorzoxazone","6-hydroxychlorzoxazone","C039289",0,0,0,0,0,0,1,0,0]
["6-hydroxydoxazosin","6-hydroxydoxazosin","C087263",0,0,0,0,0,2,0,0,0]
["6-ketoprostaglandin E1","6-ketoprostaglandin E1","C022950",0,0,0,0,0,1,0,0,0]
["6-Ketoprostaglandin F1 alpha","6-Ketoprostaglandin F1 alpha","D015121",0,2,0,0,0,8,0,0,0]
["6-methoxybenzoxazolinone","6-methoxybenzoxazolinone","C031896",0,0,0,0,0,1,0,0,0]
["6-methyl-1,3,8-trichlorodibenzofuran","6-methyl-1,3,8-trichlorodibenzofuran","C054923",17,0,0,0,0,0,6,0,0]
["6-methyl-8-iodo-1,3-dichlordibenzofuran","6-methyl-8-iodo-1,3-dichlordibenzofuran","C066925",1,0,0,0,0,0,1,0,0]
["6-methylchrysene","6-methylchrysene","C047249",1,0,0,0,0,0,0,0,0]
["6-nitro-1,3,8-trichlorodibenzofuran","6-nitro-1,3,8-trichlorodibenzofuran","C073785",0,0,0,0,0,0,1,0,0]
["6-nitrobenzo(a)pyrene","6-nitrobenzo(a)pyrene","C034699",1,0,0,0,0,0,0,0,0]
["6-nitrochrysene","6-nitrochrysene","C035986",1,0,0,0,0,0,3,0,0]
["6-OH-BDE-47","6-OH-BDE-47","C580599",1,0,0,0,0,0,0,0,0]
["6-phosphogluconic acid","6-phosphogluconic acid","C008884",0,0,0,3,0,0,0,0,0]
["6-prenylnaringenin","6-prenylnaringenin","C521871",0,0,0,0,0,0,1,0,0]
["7-(3'-hydroxymethyl-3'-methylallyloxy)coumarin","7-(3'-hydroxymethyl-3'-methylallyloxy)coumarin","C000608395",1,0,0,0,0,0,0,0,0]
["7,11-heptacosadiene","7,11-heptacosadiene","C096032",0,0,0,0,0,0,0,2,0]
["7,12-benz(a)anthraquinone","7,12-benz(a)anthraquinone","C077646",2,0,0,0,0,0,0,0,0]
["7,12-dihydroxymethylbenz(a)anthracene","7,12-dihydroxymethylbenz(a)anthracene","C046810",5,0,0,0,0,0,1,0,0]
["7,12-dimethylbenz(a)anthracene-dihydrodiol","7,12-dimethylbenz(a)anthracene-dihydrodiol","C013956",3,0,0,0,0,0,2,0,0]
["7,7-azocholestanol","7,7-azocholestanol","C472706",0,0,0,0,0,1,0,0,0]
["7,8-benzoquinoline","7,8-benzoquinoline","C117298",0,0,0,0,0,0,2,0,0]
["7,8-diacetoxy-4-methylcoumarin","7,8-diacetoxy-4-methylcoumarin","C114369",0,0,0,0,0,0,1,0,0]
["7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide","7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide","D015123",6,0,0,0,0,2,16,0,0]
["7,8-dihydromethysticin","7,8-dihydromethysticin","C107882",4,0,0,0,0,1,2,0,0]
["7,8-dihydroneopterin","7,8-dihydroneopterin","C000976",0,0,0,0,2,10,0,0,0]
["7,8-dihydroxy-3-methyl-isochromanone-4","7,8-dihydroxy-3-methyl-isochromanone-4","C542962",0,0,0,0,0,2,0,0,0]
["7,8-dihydroxy-4-methylcoumarin","7,8-dihydroxy-4-methylcoumarin","C114368",0,0,0,0,0,0,1,0,0]
["7,8-dimethylalloxazine","7,8-dimethylalloxazine","C001559",1,0,0,0,0,0,0,0,0]
["7-benzyloxy-4-trifluoromethylcoumarin","7-benzyloxy-4-trifluoromethylcoumarin","C419147",0,0,0,0,0,0,2,0,0]
["7-chlorobenz(a)anthracene","7-chlorobenz(a)anthracene","C046094",0,0,0,0,0,0,1,0,0]
["7-dehydrocholesterol","7-dehydrocholesterol","C016705",0,0,0,0,0,1,0,0,0]
["7-difluoromethyl-5,4'-dimethoxygenistein","7-difluoromethyl-5,4'-dimethoxygenistein","C541079",0,0,0,0,0,1,0,0,0]
["7-ethoxycoumarin","7-ethoxycoumarin","C017299",0,0,0,0,0,0,3,0,0]
["7-ethynylcoumarin","7-ethynylcoumarin","C409442",0,0,0,0,0,0,1,0,0]
["7H-dibenzo(c,g)carbazole","7H-dibenzo(c,g)carbazole","C013478",0,0,0,0,0,0,13,0,0]
["7-hydroxydoxazosin","7-hydroxydoxazosin","C087264",0,0,0,0,0,2,0,0,0]
["7-hydroxyellipticine","7-hydroxyellipticine","C055440",1,0,0,0,0,0,0,0,0]
["7-ketocholesteryl-9-carboxynonanoate","7-ketocholesteryl-9-carboxynonanoate","C510905",0,0,0,0,1,4,0,0,0]
["7-methoxyresorufin","7-methoxyresorufin","C076580",0,0,0,0,0,0,2,0,0]
["7-methyl-3-(3-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrocinnolin-5-ol","7-methyl-3-(3-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrocinnolin-5-ol","C000602443",1,0,0,0,0,0,1,0,0]
["7-nitrobenz-2-oxa-1,3-diazol-4-ylcholesterol","7-nitrobenz-2-oxa-1,3-diazol-4-ylcholesterol","C077527",0,0,0,0,0,1,0,0,0]
["8-(3-(4-hydroxy-3-methoxyphenyl) propanamido) octanoic acid ethyl ester","8-(3-(4-hydroxy-3-methoxyphenyl) propanamido) octanoic acid ethyl ester","C579626",0,0,0,0,1,0,0,0,0]
["8,12-iso-isoprostane F2alpha-VI","8,12-iso-isoprostane F2alpha-VI","C115626",0,0,0,0,0,4,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1988,B1988)","v":"8,9-epoxyeicosatrienoic acid"},"8,9-epoxyeicosatrienoic acid","C050715",0,1,0,0,0,1,0,0,0]
["8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid","8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid","C581236",0,0,0,0,0,1,0,0,0]
["8-isoprostaglandin E2","8-isoprostaglandin E2","C011987",0,0,0,0,0,2,0,0,0]
["8-methyl-1,3,8-trichlorodibenzofuran","8-methyl-1,3,8-trichlorodibenzofuran","C111836",3,0,0,0,0,0,1,0,0]
["8-oxo-7,8-dihydrodeoxyguanine","8-oxo-7,8-dihydrodeoxyguanine","C078307",0,0,0,0,0,1,2,0,0]
["8-prenylnaringenin","8-prenylnaringenin","C119737",0,0,0,0,0,1,1,0,0]
["8-tetradecenyl acetate","8-tetradecenyl acetate","C587602",0,0,0,0,0,0,0,5,0]
["9-(4-(2,5-dimethyl-4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1H-benzimidazol-1-yl)butyl)-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide","9-(4-(2,5-dimethyl-4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1H-benzimidazol-1-yl)butyl)-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide","C424429",0,0,0,0,0,1,0,0,0]
["9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole","9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole","C421010",0,0,0,0,0,0,2,0,0]
["9,10-dihydroxypalmitic acid","9,10-dihydroxypalmitic acid","C018519",0,0,0,0,0,0,0,2,0]
["9,10-Dimethyl-1,2-benzanthracene","9,10-Dimethyl-1,2-benzanthracene","D015127",31,0,0,0,0,0,33,3,0]
["9,11-tetradecadienoic acid","9,11-tetradecadienoic acid","C432949",0,0,0,0,0,0,0,3,0]
["9,12-hexadecadienoic acid","9,12-hexadecadienoic acid","C080021",0,0,0,0,0,1,0,2,0]
["9-deoxy-delta-9-prostaglandin D2","9-deoxy-delta-9-prostaglandin D2","C037112",0,0,0,0,0,1,0,0,0]
["9-hydroperoxy-11,12-octadecadienoic acid","9-hydroperoxy-11,12-octadecadienoic acid","C049606",0,0,0,0,0,1,0,0,0]
["9-hydroxy-10,12-octadecadienoic acid","9-hydroxy-10,12-octadecadienoic acid","C024347",0,0,0,0,1,15,0,2,0]
["9-hydroxybenzo(a)pyrene","9-hydroxybenzo(a)pyrene","C021337",0,0,0,0,0,0,2,0,0]
["9-hydroxyellipticine","9-hydroxyellipticine","C008009",2,0,0,0,0,0,0,0,0]
["9-methoxyellipticine","9-methoxyellipticine","C001729",0,0,0,0,0,1,0,0,0]
["9-O-acetyl-GD3 ganglioside","9-O-acetyl-GD3 ganglioside","C049132",0,1,0,0,0,0,0,0,0]
["9-oleyloxy-N(2)-methylellipticinium oleate","9-oleyloxy-N(2)-methylellipticinium oleate","C082586",0,0,0,0,0,2,0,0,0]
["9-oxononanoyl cholesterol","9-oxononanoyl cholesterol","C114702",0,0,0,0,0,4,0,0,0]
["A 769662","A 769662","C512408",0,0,0,2,0,0,0,0,0]
["A2-E (N-retinylidene-N-retinylethanolamine)","A2-E (N-retinylidene-N-retinylethanolamine)","C112040",0,0,0,0,0,1,0,0,0]
["A73025","A73025","C013786",0,0,0,0,0,1,0,0,0]
["abietic acid","abietic acid","C023710",0,0,0,0,3,0,3,0,0]
["abyssinone V","abyssinone V","C056679",0,0,0,0,0,1,0,0,0]
["acacetin","acacetin","C023717",0,0,0,0,0,0,1,0,0]
["acenaphthene","acenaphthene","C042552",1,0,0,0,0,0,1,0,0]
["acenaphthylene","acenaphthylene","C042553",2,0,0,0,0,0,3,0,0]
["acephate","acephate","C001969",0,1,0,0,0,0,0,0,0]
["acerogenin L","acerogenin L","C509355",0,0,0,0,0,1,0,0,0]
["acetoacetic acid","acetoacetic acid","C016635",0,3,0,2,0,2,0,0,0]
["acetylcellulose","acetylcellulose","C005062",0,0,0,0,0,0,1,0,0]
["Acetylene","Acetylene","D000114",0,0,0,0,0,0,3,0,0]
["Acetylgalactosamine","Acetylgalactosamine","D000116",0,0,0,0,0,7,0,0,0]
["acid blue 80","acid blue 80","C433873",0,0,0,0,0,0,1,0,0]
["acipimox","acipimox","C027696",0,4,0,0,0,16,0,0,0]
["Acitretin","Acitretin","D017255",0,1,0,0,0,3,1,0,0]
["aclacinomycins","aclacinomycins","C011157",0,0,0,0,0,3,0,0,0]
["Aclarubicin","Aclarubicin","D015250",0,0,0,0,0,4,0,0,0]
["Aconitine","Aconitine","D000157",0,0,0,0,0,0,1,0,0]
["Acrolein","Acrolein","D000171",1,1,0,1,2,6,2,0,0]
["acrylodan","acrylodan","C038518",0,0,0,0,0,1,0,0,0]
["acteoside","acteoside","C058956",0,0,0,0,0,2,0,0,0]
["Acyclovir","Acyclovir","D000212",0,0,0,0,0,0,1,0,0]
["adiachrome","adiachrome","C487618",0,1,0,0,0,1,0,0,0]
["adipic acid","adipic acid","C029900",0,0,0,0,0,0,0,6,0]
["AdipoRon","AdipoRon","C585113",0,0,0,0,0,1,0,1,0]
["AE0047","AE0047","C064970",0,0,0,0,0,2,0,0,0]
["afimoxifene","afimoxifene","C016601",1,0,0,0,0,2,0,0,0]
["aflatoxin B1-8,9-dihydrodiol-Tris buffer complex","aflatoxin B1-8,9-dihydrodiol-Tris buffer complex","C092991",0,0,0,0,0,0,1,0,0]
["AG 1879","AG 1879","C412373",1,0,0,0,1,0,1,0,0]
["Agent Orange","Agent Orange","D000075182",2,0,0,0,0,0,0,0,0]
["AGN 193109","AGN 193109","C096920",1,0,0,0,0,0,2,0,0]
["AL 0670","AL 0670","C088267",0,0,0,0,0,3,0,0,0]
["alachlor","alachlor","C000188",0,0,0,0,0,0,4,0,0]
["alantolactone","alantolactone","C004363",0,0,0,0,0,0,1,0,0]
["Albendazole","Albendazole","D015766",0,0,0,2,0,0,2,0,0]
["Albuterol","Albuterol","D000420",0,0,0,0,0,3,0,0,0]
["Aldrin","Aldrin","D000452",0,0,0,0,0,0,1,0,0]
["alitretinoin","alitretinoin","C103303",0,0,0,1,2,1,2,1,0]
["alizarin","alizarin","C010078",0,0,0,0,0,0,1,0,0]
["alkoxyl radical","alkoxyl radical","C059688",1,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2052,B2052)","v":"alkylbenzyl sulfonic acid"},"alkylbenzyl sulfonic acid","C030641",0,0,0,0,0,0,1,0,0]
["allocryptopine","allocryptopine","C109505",1,0,0,0,0,0,1,0,0]
["allyl formate","allyl formate","C034499",0,0,0,0,0,0,1,0,0]
["alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone","alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone","C043438",0,0,0,0,0,1,0,0,0]
["alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid","alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid","D018350",0,0,0,0,0,0,1,0,0]
["alpha-cyano-4-hydroxycinnamate","alpha-cyano-4-hydroxycinnamate","C007175",0,0,0,0,0,1,0,0,0]
["alpha-cyclodextrin","alpha-cyclodextrin","C032613",0,4,0,0,0,6,0,0,0]
["alpha-hederin","alpha-hederin","C010177",1,0,0,0,0,0,2,0,0]
["alpha-hydroxyglutarate","alpha-hydroxyglutarate","C019417",0,0,0,0,0,0,0,4,0]
["alpha-ionone","alpha-ionone","C011879",0,0,0,0,0,0,1,0,0]
["alpha-methylbenzylaminobenzotriazole","alpha-methylbenzylaminobenzotriazole","C059849",0,0,0,0,0,0,6,0,0]
["alpha-naphthyl thiourea","alpha-naphthyl thiourea","C005277",0,0,0,0,0,1,0,0,0]
["alpha-resorcylic acid","alpha-resorcylic acid","C076950",0,0,0,0,0,1,0,0,0]
["alpha-tocopherol phosphate","alpha-tocopherol phosphate","C012552",0,0,0,0,5,2,0,0,0]
["alpha-tocopherol quinol","alpha-tocopherol quinol","C024838",0,0,0,0,0,1,0,0,0]
["alpha-tricalcium phosphate","alpha-tricalcium phosphate","C485828",0,0,0,1,0,0,0,0,0]
["alpinetin","alpinetin","C436748",0,0,0,0,0,1,0,0,0]
["alpinumisoflavone","alpinumisoflavone","C000154",0,0,0,0,0,1,0,0,0]
["Alprenolol","Alprenolol","D000526",0,0,0,0,0,1,0,0,0]
["alternariol","alternariol","C005197",2,0,0,0,0,0,1,0,0]
["alternariol monomethyl ether","alternariol monomethyl ether","C018206",2,0,0,0,0,0,1,0,0]
["aluminum chloride","aluminum chloride","C010845",0,0,0,0,0,1,0,0,0]
["Aluminum Oxide","Aluminum Oxide","D000537",0,0,0,0,0,0,2,0,0]
["aluminum phthalocyanine disulfonate","aluminum phthalocyanine disulfonate","C064331",0,0,0,0,0,3,0,0,0]
["aluminum sulfate","aluminum sulfate","C041524",0,0,0,0,0,2,0,0,0]
["aluminum(III) phthalocyanine trisulfonic acid","aluminum(III) phthalocyanine trisulfonic acid","C063071",0,0,0,0,0,1,0,0,0]
["alvocidib","alvocidib","C077990",0,0,0,0,0,0,0,2,0]
["alyssin","alyssin","C524316",1,0,0,0,0,0,3,0,0]
["amarogentin","amarogentin","C102609",0,0,0,1,0,0,0,0,0]
["Amiloride","Amiloride","D000584",0,0,0,0,0,0,2,0,0]
["aminoflavone","aminoflavone","C413760",12,0,0,0,0,0,8,0,0]
["Aminoglutethimide","Aminoglutethimide","D000616",0,1,0,0,0,5,0,0,0]
["Aminooxyacetic Acid","Aminooxyacetic Acid","D000625",0,0,0,0,0,0,1,0,0]
["Aminosalicylic Acid","Aminosalicylic Acid","D010131",0,1,0,0,0,0,0,0,0]
["amitraz","amitraz","C014983",0,0,0,0,0,0,1,0,0]
["ammonium metavanadate","ammonium metavanadate","C101036",2,0,0,0,0,0,1,0,0]
["Amodiaquine","Amodiaquine","D000655",0,0,0,0,0,0,1,0,0]
["Amphetamine","Amphetamine","D000661",0,1,0,0,0,0,0,2,0]
["amphotericin B, deoxycholate drug combination","amphotericin B, deoxycholate drug combination","C059765",0,0,0,0,0,1,0,0,0]
["AMTP-3A","AMTP-3A","C421842",0,0,0,0,0,1,0,0,0]
["Amygdalin","Amygdalin","D000678",0,0,0,0,0,1,0,0,0]
["anacardic acid","anacardic acid","C088115",0,0,0,0,0,0,0,2,0]
["anacetrapib","anacetrapib","C530884",0,2,0,0,0,4,0,0,0]
["anagliptin","anagliptin","C583175",0,1,0,0,0,1,0,0,0]
["anatoxin a","anatoxin a","C509783",0,0,0,0,0,0,1,0,0]
["androstane","androstane","C033936",1,0,0,0,0,0,0,0,0]
["angelicae sinensis extract","angelicae sinensis extract","C044613",0,0,0,0,0,2,0,0,0]
["anipamil","anipamil","C045313",0,1,0,0,0,1,0,0,0]
["anisodamine","anisodamine","C003922",0,1,0,0,0,1,0,0,0]
["Anisomycin","Anisomycin","D000841",1,0,0,0,0,1,1,0,0]
["Anna Pavala Sindhooram","Anna Pavala Sindhooram","C035984",0,1,0,0,0,1,0,0,0]
["annamycin","annamycin","C080315",0,1,0,0,0,0,0,0,0]
["annomontine","annomontine","C508838",1,0,0,0,0,0,1,0,0]
["anthracene","anthracene","C034020",0,0,0,0,0,0,2,0,0]
["anthrax toxin","anthrax toxin","C030325",0,0,0,0,0,4,0,0,0]
["antigens, CD200","antigens, CD200","C042739",0,0,0,0,1,0,0,0,0]
["Antimony Sodium Gluconate","Antimony Sodium Gluconate","D000967",0,0,0,3,0,0,0,0,0]
["AP5055","AP5055","C576728",0,0,0,0,1,0,0,0,0]
["Apamin","Apamin","D001030",0,0,0,0,0,1,0,0,0]
["Aphidicolin","Aphidicolin","D016590",0,0,0,1,0,0,0,0,0]
["API 0134","API 0134","C099652",0,0,0,0,0,1,0,0,0]
["apigeninidin","apigeninidin","C104027",0,0,0,0,0,1,0,0,0]
["apocarotenal","apocarotenal","C004984",2,0,0,0,0,0,2,0,0]
["apomine","apomine","C407151",0,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2116,B2116)","v":"aprepitant"},"aprepitant","C114556",0,0,0,0,0,1,0,0,0]
["APS-1 polysaccharide","APS-1 polysaccharide","C507753",0,0,0,0,0,1,0,0,0]
["AQ4N","AQ4N","C094428",0,0,0,0,0,0,1,0,0]
["AR 12456","AR 12456","C046930",0,0,0,0,0,5,0,0,0]
["AR 12463","AR 12463","C053729",0,0,0,0,0,3,0,0,0]
["AR 12465","AR 12465","C059531",0,0,0,0,0,3,0,0,0]
["arabinoxylan","arabinoxylan","C085118",0,0,0,0,0,1,0,0,0]
["arachidonyltrifluoromethane","arachidonyltrifluoromethane","C081565",0,0,0,0,1,0,0,0,0]
["archazolid B","archazolid B","C519728",0,0,0,0,0,2,0,0,0]
["arctigenin","arctigenin","C071942",0,0,0,0,0,1,0,0,0]
["Arecoline","Arecoline","D001115",1,0,0,1,0,1,2,0,0]
["argan oil","argan oil","C555574",0,0,0,0,0,1,0,0,0]
["Aripiprazole","Aripiprazole","D000068180",0,0,0,0,0,1,0,0,0]
["aristolochic acid C","aristolochic acid C","C092652",0,0,0,0,0,0,1,0,0]
["aristolochic acid I","aristolochic acid I","C000228",2,0,0,0,0,0,21,0,0]
["arjunaphthanoloside","arjunaphthanoloside","C480719",0,0,0,0,0,1,0,0,0]
["Aroclor 1016","Aroclor 1016","C027386",0,0,0,0,0,0,2,0,0]
["aroclor 1221","aroclor 1221","C032739",0,0,0,0,0,0,1,0,0]
["aroclor 1242","aroclor 1242","C027423",1,0,0,0,0,0,4,0,0]
["aroclor 1248","aroclor 1248","C028617",0,0,0,0,0,0,2,0,0]
["Aroclor 1268","Aroclor 1268","C492961",2,0,0,0,0,0,0,0,0]
["artemisic acid","artemisic acid","C047721",0,0,0,0,1,0,0,0,0]
["arvanil","arvanil","C121153",0,0,0,0,1,0,0,0,0]
["arzanol","arzanol","C517830",0,0,0,0,0,1,0,0,0]
["asarone","asarone","C012195",0,0,0,0,0,1,0,0,0]
["Asbestos, Serpentine","Asbestos, Serpentine","D017632",0,0,0,0,0,0,1,0,0]
["ascochlorin","ascochlorin","C415745",0,0,0,0,0,1,0,0,0]
["ascorbate-2-phosphate","ascorbate-2-phosphate","C011669",0,0,0,0,0,1,0,0,0]
["ascorbigen","ascorbigen","C053152",0,0,0,0,0,0,2,0,0]
["asphalt","asphalt","C006647",0,0,0,0,0,0,8,0,0]
["Aspirin, Dipyridamole Drug Combination","Aspirin, Dipyridamole Drug Combination","D000068342",0,0,0,0,0,2,0,0,0]
["astaxanthine","astaxanthine","C005948",0,0,0,0,1,4,2,0,0]
["astragaloside A","astragaloside A","C052064",0,0,0,0,0,1,0,0,0]
["Atenolol","Atenolol","D001262",0,4,1,0,0,9,0,0,0]
["ATI-111 cpd","ATI-111 cpd","C559195",0,0,0,0,0,1,0,0,0]
["atractylenolide I","atractylenolide I","C424804",0,0,0,0,0,1,0,0,0]
["Atracurium","Atracurium","D001279",0,0,0,0,0,0,1,0,0]
["atranorin","atranorin","C026304",1,0,0,0,0,0,0,0,0]
["Atrazine","Atrazine","D001280",4,0,0,0,1,0,9,0,0]
["Atropine","Atropine","D001285",0,0,0,1,0,1,0,0,0]
["Aurintricarboxylic Acid","Aurintricarboxylic Acid","D001312",0,0,0,0,0,1,0,0,0]
["aurone","aurone","C486837",1,0,0,0,0,0,1,0,0]
["avarol","avarol","C023663",0,0,0,0,0,0,1,0,0]
["avarone","avarone","C046374",0,0,0,0,0,0,1,0,0]
["avasimibe","avasimibe","C423185",0,1,0,0,0,6,1,0,0]
["avenanthramide-2C","avenanthramide-2C","C514463",0,0,0,0,0,1,0,0,0]
["avicin D","avicin D","C478445",0,0,0,1,0,0,0,0,0]
["axitrome","axitrome","C104715",0,0,0,0,0,1,0,0,0]
["azalanstat","azalanstat","C082410",0,0,0,0,0,2,0,0,0]
["azaspiracid","azaspiracid","C406592",0,0,0,0,0,1,0,0,0]
["azelaic acid","azelaic acid","C010038",0,0,0,0,0,1,0,0,0]
["azimilide","azimilide","C086123",0,0,0,0,0,0,1,0,0]
["azobenzene","azobenzene","C009850",1,0,0,0,0,0,1,0,0]
["bafilomycin A1","bafilomycin A1","C040929",0,0,0,0,0,2,0,0,0]
["bafilomycin B1","bafilomycin B1","C052501",0,0,0,0,0,1,0,0,0]
["bathocuproine","bathocuproine","C002478",0,0,0,0,0,1,0,0,0]
["bathocuproine sulfonate","bathocuproine sulfonate","C028559",0,0,0,0,0,1,0,0,0]
["Bay Y3118","Bay Y3118","C079807",0,0,0,0,0,1,0,0,0]
["baysilon","baysilon","C013830",0,0,0,0,0,2,0,0,0]
["beclobrate","beclobrate","C020978",0,1,0,0,0,0,0,0,0]
["behenic acid","behenic acid","C007547",0,1,0,0,0,0,0,2,0]
["benazepril","benazepril","C044946",0,0,0,0,0,2,0,0,0]
["benfluorex","benfluorex","C001584",0,0,0,1,0,2,0,0,0]
["benidipine","benidipine","C061004",0,0,0,0,0,3,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2180,B2180)","v":"Benomyl"},"Benomyl","D001542",0,0,0,0,0,0,1,0,0]
["benoxaprofen","benoxaprofen","C011677",0,0,0,0,0,0,1,0,0]
["benz(a)anthracene","benz(a)anthracene","C030935",4,0,0,0,0,0,3,0,0]
["benzamide","benzamide","C037689",0,0,0,0,1,1,0,0,0]
["benzamidoxime","benzamidoxime","C053561",0,0,0,0,0,0,0,1,0]
["benzanthrone","benzanthrone","C012768",1,0,0,0,0,0,2,0,0]
["benzenesulfonic acid","benzenesulfonic acid","C032365",0,0,0,0,0,1,0,0,0]
["benzimidazole","benzimidazole","C031000",0,0,0,0,0,1,3,1,0]
["benzo(a)pyrene 7,8-dihydrodiol","benzo(a)pyrene 7,8-dihydrodiol","C017228",2,1,0,0,0,1,13,0,0]
["benzo(a)pyrene diolepoxide I","benzo(a)pyrene diolepoxide I","C072019",0,0,0,0,0,0,2,0,0]
["benzo(a)pyrene-7,8-dione","benzo(a)pyrene-7,8-dione","C076588",1,0,0,0,0,0,0,0,0]
["benzo(b)fluoranthene","benzo(b)fluoranthene","C006703",1,0,0,0,0,0,0,0,0]
["benzo(d)thiazol-2-amine","benzo(d)thiazol-2-amine","C560953",0,0,0,0,0,0,1,0,0]
["benzo(e)pyrene","benzo(e)pyrene","C026487",3,0,0,0,0,0,5,0,0]
["benzo(k)fluoranthene","benzo(k)fluoranthene","C022921",4,0,0,0,0,0,10,0,0]
["benzofuran","benzofuran","C105430",1,0,0,0,0,0,0,0,0]
["Benzoic Acid","Benzoic Acid","D019817",0,0,0,1,0,0,0,0,0]
["benzophenone","benzophenone","C047723",0,0,0,0,0,1,0,0,0]
["benzophenone O-(2,6-bis(4,6-dimethoxypyrimidin-2-yloxy)benzoyl)oxime","benzophenone O-(2,6-bis(4,6-dimethoxypyrimidin-2-yloxy)benzoyl)oxime","C454324",0,0,0,0,0,0,1,0,0]
["benzoporphyrin D","benzoporphyrin D","C504224",0,0,0,0,0,9,0,0,0]
["benzothiazole","benzothiazole","C005465",1,0,0,0,0,0,1,0,0]
["benzotriazole","benzotriazole","C012771",2,0,0,0,0,0,3,0,0]
["benzotript","benzotript","C013841",0,0,4,0,0,0,0,2,0]
["benzoxazolone","benzoxazolone","C017057",0,0,0,0,0,1,0,0,0]
["benzyl 3,3,5-trimethylcyclohexyl ether","benzyl 3,3,5-trimethylcyclohexyl ether","C089470",0,0,0,0,0,1,0,0,0]
["Benzyl Alcohol","Benzyl Alcohol","D019905",0,0,0,0,0,3,0,0,0]
["benzyl isothiocyanate","benzyl isothiocyanate","C031403",0,0,0,0,0,1,2,0,0]
["benzyl selenocyanate","benzyl selenocyanate","C054108",0,0,0,0,0,0,2,0,0]
["benzylaminopurine","benzylaminopurine","C480551",1,0,0,0,0,0,0,0,0]
["benzylideneacetone","benzylideneacetone","C025383",0,0,0,0,0,0,1,0,0]
["Bepridil","Bepridil","D015764",0,0,0,0,0,5,0,0,0]
["berberrubine","berberrubine","C115958",0,0,0,0,0,3,0,0,0]
["bergamottin","bergamottin","C068337",0,0,0,0,0,0,2,0,0]
["beta-1,3-glucan","beta-1,3-glucan","C033363",0,0,0,0,0,6,0,0,0]
["beta-apo-10'-carotenal","beta-apo-10'-carotenal","C427759",0,0,0,0,0,0,0,2,0]
["beta-benzalbutyramide","beta-benzalbutyramide","C033391",0,0,0,0,0,1,0,0,0]
["betadex","betadex","C031215",0,2,0,0,3,3,0,0,0]
["beta-glycerophosphoric acid","beta-glycerophosphoric acid","C031463",0,0,0,0,0,2,0,0,0]
["beta-hydroxyisovalerylshikonin","beta-hydroxyisovalerylshikonin","C118460",0,0,0,0,0,0,0,1,0]
["beta-hydroxymyristic acid","beta-hydroxymyristic acid","C009893",0,0,6,0,0,0,0,0,0]
["beta-ionone","beta-ionone","C008157",0,0,0,0,0,0,2,0,0]
["Betamethasone","Betamethasone","D001623",1,2,0,0,0,2,0,0,0]
["beta-myrcene","beta-myrcene","C008574",0,0,0,0,0,0,1,0,0]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324",102,0,0,1,0,0,131,0,0]
["beta-penta-O-galloyl-glucose","beta-penta-O-galloyl-glucose","C013185",0,0,0,0,0,1,0,0,0]
["Betaxolol","Betaxolol","D015784",0,0,0,0,0,1,0,0,0]
["bexarotene","bexarotene","C095105",1,1,0,0,0,1,0,0,0]
["BIBB 515","BIBB 515","C107350",0,0,0,0,0,2,0,0,0]
["bifenthrin","bifenthrin","C099952",0,0,0,0,0,1,1,0,0]
["Biliverdine","Biliverdine","D001664",4,0,0,0,0,0,0,0,0]
["bilobalide","bilobalide","C073710",0,0,0,0,0,0,1,0,0]
["bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine","bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine","C072758",0,0,0,0,0,1,0,0,0]
["bis(maltolato)oxovanadium(IV)","bis(maltolato)oxovanadium(IV)","C074212",0,0,0,1,0,0,0,0,0]
["bis(monoacylglyceryl)phosphate","bis(monoacylglyceryl)phosphate","C012786",0,0,0,0,0,3,0,0,0]
["bisabolol","bisabolol","C004497",0,0,0,0,0,0,1,0,0]
["bisamidine","bisamidine","C469777",0,0,0,0,1,0,0,0,0]
["bisvanillyl-hydralazone","bisvanillyl-hydralazone","C562068",0,0,0,0,0,1,0,0,0]
["bitucarpin A","bitucarpin A","C488768",0,0,0,0,0,1,0,0,0]
["blood dendritic cell antigen 3, human","blood dendritic cell antigen 3, human","C516094",0,0,0,0,1,0,0,0,0]
["BM 15.0639","BM 15.0639","C088480",0,0,0,0,0,2,0,0,0]
["BM 15766","BM 15766","C047457",0,0,0,0,0,2,0,2,0]
["BM 910228","BM 910228","C103832",0,0,0,0,0,1,0,0,0]
["BMS 181095","BMS 181095","C090412",0,0,0,0,0,1,0,0,0]
["BMS 200150","BMS 200150","C101970",0,1,0,0,0,0,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2244,B2244)","v":"BMS-764459"},"BMS-764459","C584056",0,0,0,0,0,0,1,0,0]
["borapetoside A","borapetoside A","C585193",0,0,0,1,0,0,0,0,0]
["bornaprolol","bornaprolol","C018417",0,1,0,0,0,1,0,0,0]
["botrocetin","botrocetin","C030961",0,0,0,0,1,0,0,0,0]
["Brefeldin A","Brefeldin A","D020126",0,3,0,0,0,6,0,0,0]
["brevetoxin","brevetoxin","C053342",1,0,0,0,0,0,1,0,0]
["brevetoxin T17","brevetoxin T17","C041017",0,1,0,0,0,1,0,0,0]
["Bromisovalum","Bromisovalum","D001968",0,0,0,0,0,0,1,0,0]
["Bromkal 70","Bromkal 70","C063747",0,0,0,0,0,0,3,0,0]
["bromoacetylalprenololmenthane","bromoacetylalprenololmenthane","C045331",0,0,0,0,0,1,0,0,0]
["bromobenzene","bromobenzene","C032036",0,0,0,0,0,0,1,0,0]
["bromodichloromethane","bromodichloromethane","C025191",0,0,0,0,0,0,1,0,0]
["Bromotrichloromethane","Bromotrichloromethane","D001975",0,0,0,0,0,0,0,3,0]
["bropirimine","bropirimine","C033560",0,0,0,0,0,1,0,0,0]
["brucine","brucine","C083806",0,0,0,0,0,0,1,0,0]
["bufuralol","bufuralol","C010831",0,0,0,0,0,0,1,0,0]
["bunazosin","bunazosin","C018176",0,0,0,0,0,3,0,0,0]
["Buprenorphine","Buprenorphine","D002047",1,0,0,0,0,0,0,0,0]
["butein","butein","C040918",0,0,0,0,0,1,0,0,0]
["butenylisothiocyanate","butenylisothiocyanate","C079114",0,0,0,0,0,0,1,0,0]
["butyl isocyanate","butyl isocyanate","C002509",0,0,0,0,0,0,1,0,0]
["Butylated Hydroxyanisole","Butylated Hydroxyanisole","D002083",0,0,0,0,0,0,1,0,0]
["butylbenzyl phthalate","butylbenzyl phthalate","C027561",3,0,0,0,0,0,2,0,0]
["butyrylcarnitine","butyrylcarnitine","C427065",0,0,0,0,0,0,0,2,0]
["buyang huanwu","buyang huanwu","C460102",0,0,0,0,0,1,0,0,0]
["C 525","C 525","C096706",0,0,0,0,0,1,0,0,0]
["Cacodylic Acid","Cacodylic Acid","D002101",1,0,0,0,0,0,0,0,0]
["Cadmium Chloride","Cadmium Chloride","D019256",6,0,0,0,0,0,9,0,0]
["caffeic acid phenethyl ester","caffeic acid phenethyl ester","C055494",1,0,0,0,0,2,1,2,0]
["caffeoylquinic acid","caffeoylquinic acid","C472707",0,0,0,0,0,1,0,0,0]
["Calcimycin","Calcimycin","D000001",0,0,0,1,0,3,0,0,0]
["Calcium Carbonate","Calcium Carbonate","D002119",0,0,0,0,0,1,0,0,0]
["Calcium Chloride","Calcium Chloride","D002122",0,1,0,0,0,6,0,0,0]
["Calcium Dobesilate","Calcium Dobesilate","D002123",0,0,0,0,0,2,0,0,0]
["calcium fructoborate","calcium fructoborate","C507177",0,0,0,0,0,1,0,0,0]
["Calcium Oxalate","Calcium Oxalate","D002129",0,0,0,0,0,1,0,0,0]
["calcium phosphate","calcium phosphate","C020243",0,0,0,1,0,1,0,0,0]
["calcium phosphate, dibasic, anhydrous","calcium phosphate, dibasic, anhydrous","C485829",0,0,0,1,0,0,0,0,0]
["calcium phosphate, monobasic, anhydrous","calcium phosphate, monobasic, anhydrous","C485838",0,0,0,1,0,0,0,0,0]
["Calcium Pyrophosphate","Calcium Pyrophosphate","D002131",0,1,0,0,0,3,0,0,0]
["calendic acid","calendic acid","C428441",0,0,0,0,0,0,0,2,0]
["calphostin C","calphostin C","C058819",1,0,0,1,0,0,0,0,0]
["calycosin-7-O-beta-D-glucoside","calycosin-7-O-beta-D-glucoside","C526426",2,0,0,0,0,0,0,0,0]
["campestanol","campestanol","C003535",0,0,0,0,0,1,0,0,0]
["Canagliflozin","Canagliflozin","D000068896",0,0,0,0,0,1,0,0,0]
["cannabidiol dimethyl ether","cannabidiol dimethyl ether","C065844",0,0,0,0,0,2,0,0,0]
["Canthaxanthin","Canthaxanthin","D016644",2,0,0,0,0,3,0,0,0]
["captax","captax","C005563",0,0,0,0,0,0,1,0,0]
["caraway oil","caraway oil","C104525",0,0,0,0,0,2,0,0,0]
["Carbachol","Carbachol","D002217",0,0,0,0,0,1,0,0,0]
["carbamic acid","carbamic acid","C070766",0,0,0,0,0,1,0,0,0]
["Carbaryl","Carbaryl","D012721",5,0,0,0,0,0,5,0,0]
["carbazole","carbazole","C041514",2,0,0,0,0,0,3,0,0]
["carbendazim","carbendazim","C006698",3,1,0,0,0,0,4,0,0]
["carbene","carbene","C030011",0,2,0,0,0,1,0,0,0]
["Carbidopa","Carbidopa","D002230",4,0,0,0,0,0,0,0,0]
["Carbofuran","Carbofuran","D002235",0,0,0,0,0,0,3,0,0]
["Carboplatin","Carboplatin","D016190",0,0,0,0,0,0,0,2,0]
["carbopol 940","carbopol 940","C006903",0,1,0,0,0,6,0,0,0]
["carboxyethyl-hydroxychroman","carboxyethyl-hydroxychroman","C483420",1,0,0,0,0,1,0,0,0]
["carboxyifosfamide","carboxyifosfamide","C064446",0,0,0,0,0,0,1,0,0]
["carboxymethyl-beta-1,3-glucan","carboxymethyl-beta-1,3-glucan","C029933",0,0,0,0,0,2,0,0,0]
["Carboxymethylcellulose Sodium","Carboxymethylcellulose Sodium","D002266",0,0,0,0,0,2,0,0,0]
["cardiosulfa","cardiosulfa","C545674",1,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2308,B2308)","v":"cariporide"},"cariporide","C093373",0,0,0,0,1,0,0,0,0]
["Carmine","Carmine","D002329",0,0,0,0,0,0,1,0,0]
["Carmustine","Carmustine","D002330",0,0,0,0,0,1,1,0,0]
["carnosol","carnosol","C068623",1,0,0,0,0,1,1,0,0]
["carprofen","carprofen","C007005",0,0,0,0,0,1,0,0,0]
["Carrageenan","Carrageenan","D002351",1,0,0,0,1,1,0,0,0]
["castanospermine","castanospermine","C037806",0,0,0,0,0,2,0,0,0]
["Castor Oil","Castor Oil","D002368",0,0,0,0,0,0,0,2,0]
["catechol","catechol","C034221",0,0,0,0,0,0,1,0,0]
["CD320 antigen, human","CD320 antigen, human","C538894",0,0,0,0,0,1,0,0,0]
["CD8 antigen, alpha chain","CD8 antigen, alpha chain","C409469",1,0,0,0,0,1,0,0,0]
["CD8alpha antigen","CD8alpha antigen","C431698",0,0,0,0,2,0,0,0,0]
["CDV-085","CDV-085","C574298",0,0,0,0,0,1,0,0,0]
["CDw17 antigen","CDw17 antigen","C009744",0,0,0,0,0,8,0,0,0]
["Celiprolol","Celiprolol","D017272",0,1,0,0,0,5,0,0,0]
["Cellobiose","Cellobiose","D002475",0,0,0,0,0,4,0,0,0]
["cellulose diacetate","cellulose diacetate","C026170",0,0,0,0,0,1,0,0,0]
["cellulose sulfate","cellulose sulfate","C020254",0,0,0,0,1,0,0,0,0]
["Cellulose, Oxidized","Cellulose, Oxidized","D002483",0,0,0,0,0,2,0,0,0]
["Centella asiatica extract","Centella asiatica extract","C526146",0,0,0,0,1,0,0,0,0]
["cerivastatin","cerivastatin","C086276",0,1,0,0,1,15,0,0,0]
["cetrimonium","cetrimonium","C004322",0,0,0,0,0,1,0,0,0]
["cetyl alcohol","cetyl alcohol","C005031",0,0,0,0,0,0,0,2,0]
["CGP 12177","CGP 12177","C033394",0,0,0,0,0,2,0,0,0]
["CGP 2881","CGP 2881","C121115",0,0,0,0,0,1,0,0,0]
["CGS 23425","CGS 23425","C108180",0,0,0,0,0,2,0,0,0]
["CGS 25159","CGS 25159","C106476",0,0,0,0,0,1,0,0,0]
["CGS 27023A","CGS 27023A","C097658",0,0,0,0,0,1,0,0,0]
["chelerythrine","chelerythrine","C016299",3,0,0,0,0,0,1,0,0]
["chetomin","chetomin","C001598",1,0,0,0,0,0,0,0,0]
["chimyl alcohol","chimyl alcohol","C004348",0,1,0,0,0,0,0,2,0]
["chloramine","chloramine","C030816",0,1,0,0,0,1,0,0,0]
["Chlordan","Chlordan","D002706",0,0,0,2,0,0,0,0,0]
["chloroaluminum phthalocyanine","chloroaluminum phthalocyanine","C044797",0,0,0,0,0,1,0,0,0]
["chlorobactene","chlorobactene","C006980",0,0,0,0,0,0,0,2,0]
["Chlorodiphenyl (54% Chlorine)","Chlorodiphenyl (54% Chlorine)","D020111",11,0,0,0,0,0,35,5,0]
["Chlorophyll","Chlorophyll","D002734",0,0,0,0,0,5,0,2,0]
["chlorophyllin","chlorophyllin","C007020",0,0,0,0,0,0,3,0,0]
["chloroquine diphosphate","chloroquine diphosphate","C023676",0,0,0,0,0,3,0,0,0]
["Chlorpheniramine","Chlorpheniramine","D002744",0,0,0,0,0,0,1,0,0]
["Chlorphentermine","Chlorphentermine","D002745",0,0,0,0,0,0,1,0,0]
["Chlorpyrifos","Chlorpyrifos","D004390",0,0,0,0,0,1,4,0,0]
["Chlorthalidone","Chlorthalidone","D002752",0,2,0,0,0,8,0,0,0]
["chlortoluron","chlortoluron","C007033",0,0,0,0,0,0,1,0,0]
["Chlorzoxazone","Chlorzoxazone","D002753",0,0,0,0,0,0,3,0,0]
["cholest-5-ene-3 beta,26-diol","cholest-5-ene-3 beta,26-diol","C007042",0,1,0,0,0,6,0,0,0]
["cholest-5-ene-3,4-diol","cholest-5-ene-3,4-diol","C099828",0,0,0,0,0,1,0,0,0]
["cholest-8(14)-en-3-ol-15-one","cholest-8(14)-en-3-ol-15-one","C015073",0,2,0,0,0,2,0,0,0]
["cholesta-5,7,9-trien-3 beta-ol","cholesta-5,7,9-trien-3 beta-ol","C025498",0,1,0,0,0,2,0,0,0]
["cholestane-3,5,6-triol","cholestane-3,5,6-triol","C000474",0,0,0,0,0,4,0,0,0]
["cholestatrienyl oleate","cholestatrienyl oleate","C029396",0,0,0,0,0,1,0,0,0]
["cholesterol alpha-oxide","cholesterol alpha-oxide","C002415",0,0,0,0,0,4,0,0,0]
["cholesterol hydroperoxide","cholesterol hydroperoxide","C002843",0,0,0,0,0,5,0,0,0]
["cholesteryl 1,12-dicarba-closo-dodecaboranel-carboxylate","cholesteryl 1,12-dicarba-closo-dodecaboranel-carboxylate","C496891",0,0,0,0,0,2,0,0,0]
["cholesteryl 4,4-difluoro-5,7-dimethyl-4-bora-3,4-diaza-3-indacenedodecanoate","cholesteryl 4,4-difluoro-5,7-dimethyl-4-bora-3,4-diaza-3-indacenedodecanoate","C084200",0,0,0,0,1,1,0,0,0]
["cholesteryl 5-carboxypentyl ether N-hydroxysuccinimide ester","cholesteryl 5-carboxypentyl ether N-hydroxysuccinimide ester","C055178",0,0,0,0,1,0,0,0,0]
["cholesteryl arachidonate","cholesteryl arachidonate","C029382",0,0,0,0,0,4,0,0,0]
["cholesteryl ester hydroperoxide","cholesteryl ester hydroperoxide","C081459",0,2,0,0,1,5,0,0,0]
["cholesteryl hexyl ether","cholesteryl hexyl ether","C048982",0,0,0,0,0,1,0,0,0]
["cholesteryl iopanoate","cholesteryl iopanoate","C039133",0,0,0,0,0,2,0,0,0]
["cholesteryl linoleate","cholesteryl linoleate","C021976",0,1,0,0,1,14,0,0,0]
["cholesteryl linoleyl ether","cholesteryl linoleyl ether","C027575",0,1,0,0,0,8,0,0,0]
["cholesteryl nitrolinoleate","cholesteryl nitrolinoleate","C487539",0,0,0,0,1,0,0,0,0]
["cholesteryl oleate","cholesteryl oleate","C014409",0,6,0,0,1,20,0,1,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2372,B2372)","v":"cholesteryl oleyl ether"},"cholesteryl oleyl ether","C023511",0,0,0,0,1,6,0,0,0]
["cholesteryl palmitate","cholesteryl palmitate","C026651",0,0,0,0,0,2,0,0,0]
["cholesteryl parinaratecholesteryl parinarate","cholesteryl parinaratecholesteryl parinarate","C029395",0,0,0,0,0,1,0,0,0]
["cholesteryl sulfate","cholesteryl sulfate","C007045",0,0,0,0,0,2,0,0,0]
["cholesteryl-12-(3-iodophenyl)dodecyl ether","cholesteryl-12-(3-iodophenyl)dodecyl ether","C072486",0,0,0,0,0,1,0,0,0]
["cholesteryl-3-iodobenzyl ether","cholesteryl-3-iodobenzyl ether","C072484",0,0,0,0,0,1,0,0,0]
["cholesteryl-6-pyrenylhexanoate","cholesteryl-6-pyrenylhexanoate","C045900",0,0,0,0,0,1,0,0,0]
["cholosas","cholosas","C037297",0,0,0,0,0,1,0,0,0]
["Chondroitin","Chondroitin","D002807",0,0,0,0,0,8,0,0,0]
["chondroitin sulfate D","chondroitin sulfate D","C065068",0,0,0,0,0,1,0,0,0]
["chondroitin sulfate glycosaminoglycan","chondroitin sulfate glycosaminoglycan","C038142",0,0,0,0,0,1,0,0,0]
["chromium trioxide","chromium trioxide","C028801",1,0,0,0,0,0,1,0,0]
["chrysanthemic acid","chrysanthemic acid","C007051",0,0,0,0,0,2,0,0,0]
["chrysene","chrysene","C031180",3,0,0,0,0,0,6,0,0]
["chrysoeriol","chrysoeriol","C007054",0,0,0,0,0,0,1,0,0]
["CI 924","CI 924","C038574",0,0,0,0,0,1,0,0,0]
["ciclopirox","ciclopirox","C011585",1,0,0,0,0,0,0,0,0]
["ciglitazone","ciglitazone","C039671",0,0,0,0,2,6,0,2,0]
["cinnabarinic acid","cinnabarinic acid","C000483",5,0,0,0,0,0,1,0,0]
["cinnamic aldehyde","cinnamic aldehyde","C012843",1,0,0,1,1,0,0,0,0]
["cinnamtannin A2","cinnamtannin A2","C425558",0,0,0,0,0,1,0,0,0]
["Cinnarizine","Cinnarizine","D002936",0,1,0,0,0,1,0,0,0]
["cirsiliol","cirsiliol","C039824",0,0,0,0,0,0,2,0,0]
["Cisplatin","Cisplatin","D002945",5,2,0,0,0,4,2,5,0]
["cis-vaccenic acid","cis-vaccenic acid","C065593",0,0,0,0,0,0,0,1,0]
["cis-vaccenyl acetate","cis-vaccenyl acetate","C505385",0,0,0,0,1,0,0,2,0]
["CJ-12950","CJ-12950","C111272",0,0,0,0,0,1,0,0,0]
["CJ-13357","CJ-13357","C111273",0,0,0,0,0,1,0,0,0]
["Clark 1","Clark 1","C098345",0,0,0,0,0,0,1,0,0]
["Clark 2","Clark 2","C098346",0,0,0,0,0,0,1,0,0]
["Clenbuterol","Clenbuterol","D002976",0,2,0,0,0,0,2,0,0]
["cleomiscosin A","cleomiscosin A","C041934",0,0,0,0,0,1,0,0,0]
["cleomiscosin C","cleomiscosin C","C438427",0,0,0,0,0,1,0,0,0]
["Clobetasol","Clobetasol","D002990",1,0,0,0,0,0,0,0,0]
["clofibrate, inositol nicotinate drug combination","clofibrate, inositol nicotinate drug combination","C008291",0,1,0,0,0,1,0,0,0]
["Clonidine","Clonidine","D003000",0,0,0,0,0,0,1,0,0]
["Clopamide","Clopamide","D003005",0,0,0,0,0,1,0,0,0]
["clophen A50","clophen A50","C025647",0,0,0,0,0,0,2,0,0]
["clopidogrel","clopidogrel","C055162",0,0,0,0,0,2,0,0,0]
["Clotrimazole","Clotrimazole","D003022",2,0,0,0,0,1,5,0,0]
["CM108","CM108","C516924",0,0,0,0,0,1,0,0,0]
["Coal","Coal","D003031",2,0,0,0,0,0,5,0,0]
["Coal Ash","Coal Ash","D060729",0,0,0,0,0,0,1,0,0]
["Coal Tar","Coal Tar","D003033",4,0,0,0,0,0,6,0,0]
["cobalt-ethylenediamine tetraacetic acid chelate","cobalt-ethylenediamine tetraacetic acid chelate","C028222",0,0,0,0,0,0,0,1,0]
["cocoa butter","cocoa butter","C052387",0,0,0,0,0,1,0,0,0]
["Cod Liver Oil","Cod Liver Oil","D003060",0,0,0,0,0,1,0,2,0]
["Colestipol","Colestipol","D003084",0,5,0,0,0,29,0,0,0]
["Colforsin","Colforsin","D005576",0,0,0,0,0,3,1,0,0]
["Collodion","Collodion","D003101",0,0,0,0,0,1,0,0,0]
["compound A (octyltriazole)","compound A (octyltriazole)","C524574",0,2,0,0,0,0,0,0,0]
["concanamycin A","concanamycin A","C036978",0,0,0,0,0,1,0,0,0]
["concanamycin B","concanamycin B","C036979",0,0,0,0,0,3,0,0,0]
["coniferonic acid","coniferonic acid","C432390",0,0,0,0,0,0,0,2,0]
["coniferyl 9-O-(beta-D-apiofuranosyl(1-6))-O-beta-D-glucopyranoside","coniferyl 9-O-(beta-D-apiofuranosyl(1-6))-O-beta-D-glucopyranoside","C497295",0,0,0,0,0,1,0,0,0]
["copper benzochlorin","copper benzochlorin","C081504",0,0,0,0,0,1,0,0,0]
["copper phthalocyanine","copper phthalocyanine","C015445",0,0,0,0,0,2,0,0,0]
["Copper Sulfate","Copper Sulfate","D019327",0,3,0,0,0,25,4,0,0]
["coprogen","coprogen","C010896",0,0,0,0,0,1,0,0,0]
["Coptidis rhizoma extract","Coptidis rhizoma extract","C107393",0,0,0,0,0,2,0,0,0]
["coptisine","coptisine","C034384",0,0,0,0,0,2,0,0,0]
["corexit 9500","corexit 9500","C470995",0,0,0,0,0,0,3,0,0]
["coriandrin","coriandrin","C063218",0,0,0,0,0,0,1,0,0]
["corilagin","corilagin","C049096",0,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2436,B2436)","v":"CP 060"},"CP 060","C115426",0,0,0,0,0,2,0,0,0]
["CP 105696","CP 105696","C089698",0,0,0,0,0,1,0,0,0]
["CP 92768-2","CP 92768-2","C092660",0,0,0,1,0,0,0,0,0]
["cremophor EL","cremophor EL","C000515",0,1,0,0,0,4,0,0,0]
["Creosote","Creosote","D003407",1,0,0,0,0,0,5,0,0]
["crepenynic acid","crepenynic acid","C047148",0,0,0,0,0,0,0,4,0]
["crezacin","crezacin","C047413",0,0,0,0,0,2,0,0,0]
["crocetin","crocetin","C010561",0,0,0,0,0,1,0,0,0]
["Cromolyn Sodium","Cromolyn Sodium","D004205",0,0,0,0,0,2,0,0,0]
["cryptotanshinone","cryptotanshinone","C037886",0,0,0,0,0,2,0,0,0]
["cucurbit(6)uril","cucurbit(6)uril","C454805",0,0,0,0,0,1,0,0,0]
["cuprammonium cellulose","cuprammonium cellulose","C009865",0,1,0,0,0,1,0,0,0]
["cutin","cutin","C000521",0,0,0,0,0,0,0,2,0]
["CVT-11,563","CVT-11,563","C541977",0,0,0,0,0,0,0,1,0]
["CY5.5 cyanine dye","CY5.5 cyanine dye","C098793",0,0,0,0,0,1,0,0,0]
["Cyanacure","Cyanacure","C061702",0,0,0,0,0,0,1,0,0]
["cyanidin 3-galactoside","cyanidin 3-galactoside","C546035",0,0,0,0,0,1,0,0,0]
["cyanidin-3-O-beta-glucopyranoside","cyanidin-3-O-beta-glucopyranoside","C462279",0,0,0,0,0,1,0,0,0]
["cyanophenphos","cyanophenphos","C002488",0,0,0,0,0,1,0,0,0]
["Cyclandelate","Cyclandelate","D003495",0,0,0,0,0,2,0,0,0]
["cyclopentaphenanthrene","cyclopentaphenanthrene","C013460",0,0,0,0,0,0,1,0,0]
["Cyclopenthiazide","Cyclopenthiazide","D003518",0,0,0,0,0,1,0,0,0]
["cyclopropane fatty acids","cyclopropane fatty acids","C028775",0,0,0,0,0,0,0,4,0]
["cynaropicrin","cynaropicrin","C075687",2,0,0,0,0,0,0,0,0]
["cypermethrin","cypermethrin","C017160",0,1,0,0,0,0,3,0,0]
["cyprodinil","cyprodinil","C108338",2,0,0,0,0,0,1,0,0]
["Cyproterone","Cyproterone","D003534",0,4,0,0,0,5,0,0,0]
["Cyproterone Acetate","Cyproterone Acetate","D017373",0,3,0,0,0,4,0,0,0]
["Cytochalasin D","Cytochalasin D","D015638",0,1,0,0,0,2,0,0,0]
["D-003 sugarcane wax acid mixture","D-003 sugarcane wax acid mixture","C418063",0,1,0,0,0,1,0,0,0]
["daidzein-7-O-beta-D-glucoside","daidzein-7-O-beta-D-glucoside","C544629",0,1,0,0,0,0,0,0,0]
["daidzin","daidzin","C013908",2,0,0,0,0,1,1,0,0]
["dalcetrapib","dalcetrapib","C411602",0,0,0,0,0,5,0,0,0]
["Dalteparin","Dalteparin","D017985",0,0,0,0,0,2,0,0,0]
["daltroban","daltroban","C051762",0,0,0,0,0,1,0,0,0]
["dalvastatin","dalvastatin","C071481",0,0,0,0,0,1,0,0,0]
["Danazol","Danazol","D003613",0,1,0,0,0,4,0,0,0]
["danhong","danhong","C540581",0,0,0,0,0,2,0,0,0]
["danshensu bingpian zhi","danshensu bingpian zhi","C571351",0,0,0,0,0,1,0,0,0]
["dansyl phosphatidylethanolamine","dansyl phosphatidylethanolamine","C024284",0,2,0,0,0,0,0,0,0]
["dansyl-heparin","dansyl-heparin","C032585",0,0,0,0,0,2,0,0,0]
["Dapsone","Dapsone","D003622",0,0,0,0,0,0,1,0,0]
["darapladib","darapladib","C529040",0,0,0,0,0,3,0,0,0]
["darglitazone","darglitazone","C089948",0,2,0,0,2,1,0,0,0]
["dauricine","dauricine","C035934",0,0,0,0,2,0,0,0,0]
["decabromobiphenyl ether","decabromobiphenyl ether","C010902",10,0,0,0,0,0,6,0,0]
["decabromodiphenyl ethane","decabromodiphenyl ethane","C491509",0,0,0,0,0,0,1,0,0]
["decamethrin","decamethrin","C017180",0,0,0,0,0,0,3,0,0]
["decamethylcyclopentasiloxane","decamethylcyclopentasiloxane","C114768",0,0,0,0,0,0,1,0,0]
["decan-4-olide","decan-4-olide","C109757",0,0,0,0,0,0,0,2,0]
["decanoic acid","decanoic acid","C031071",0,1,0,1,0,0,0,0,0]
["DEET","DEET","D003671",0,0,0,0,0,0,1,1,0]
["deferiprone","deferiprone","C044919",0,0,0,0,0,2,0,0,0]
["dehydroabietic acid","dehydroabietic acid","C013913",0,0,0,0,0,0,6,0,0]
["Dehydroascorbic Acid","Dehydroascorbic Acid","D003683",2,0,0,0,0,6,0,2,0]
["dehydroequol","dehydroequol","C433165",0,0,0,0,0,1,0,0,0]
["dehydroergosterol","dehydroergosterol","C010905",0,0,0,0,0,4,0,0,0]
["dehydroevodiamine","dehydroevodiamine","C028633",0,0,0,0,0,0,1,0,0]
["dehydrosilybin","dehydrosilybin","C515097",0,0,0,0,0,0,1,0,0]
["dehydroxymethylepoxyquinomicin","dehydroxymethylepoxyquinomicin","C464444",0,0,0,0,0,1,0,0,0]
["delphinidin","delphinidin","C017185",0,0,0,0,0,4,1,0,0]
["delphinidin 3-O-glucopyranoside","delphinidin 3-O-glucopyranoside","C494120",0,0,0,0,0,3,0,0,0]
["delta(3) valproic acid","delta(3) valproic acid","C113682",0,0,0,0,0,0,0,1,0]
["delta(6)-hexadecenoic acid","delta(6)-hexadecenoic acid","C090151",0,0,0,0,0,0,0,5,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2500,B2500)","v":"delta-tocopherol"},"delta-tocopherol","C479072",0,0,0,0,0,0,1,0,0]
["demethoxycurcumin","demethoxycurcumin","C050229",0,0,0,0,1,4,0,0,0]
["demethyldiisoeugenol","demethyldiisoeugenol","C095957",0,0,0,0,0,1,0,0,0]
["demethylfruticuline A","demethylfruticuline A","C539555",0,0,0,0,1,0,0,0,0]
["Denshici-to-Chiusei","Denshici-to-Chiusei","C551353",0,0,0,0,0,1,0,0,0]
["densipolic acid","densipolic acid","C105774",0,0,0,0,0,0,0,2,0]
["Deoxyglucose","Deoxyglucose","D003847",0,1,0,0,1,0,0,0,0]
["deoxynivalenol","deoxynivalenol","C007262",0,0,0,0,0,0,2,0,0]
["Deoxyribose","Deoxyribose","D003855",0,0,0,0,0,1,0,0,0]
["depsidone","depsidone","C000875",0,0,0,0,1,1,0,0,0]
["Dermatan Sulfate","Dermatan Sulfate","D003871",0,0,0,0,0,4,0,0,0]
["desethylamiodarone","desethylamiodarone","C036116",0,0,0,0,0,2,4,0,0]
["desferricoprogen","desferricoprogen","C047664",0,0,0,0,0,1,0,0,0]
["Desogestrel","Desogestrel","D017135",0,3,0,0,0,10,0,0,0]
["deuteroporphyrin-IX","deuteroporphyrin-IX","C028839",0,0,0,0,0,2,0,0,0]
["dexamethasone 21-palmitate","dexamethasone 21-palmitate","C035081",0,0,0,0,0,1,0,0,0]
["dexamethasone acetate","dexamethasone acetate","C018038",0,0,0,0,0,1,0,0,0]
["DH 990","DH 990","C012656",0,0,0,0,0,0,0,2,0]
["Diacetyl","Diacetyl","D003931",0,0,0,6,0,0,0,0,0]
["diacetyldichlorofluorescein","diacetyldichlorofluorescein","C029569",0,0,0,0,0,2,0,0,0]
["diacetylrhein","diacetylrhein","C025292",0,0,0,0,0,1,0,0,0]
["diacylglycerol pyrophosphate","diacylglycerol pyrophosphate","C408642",0,0,0,0,0,1,0,0,0]
["diallyl disulfide","diallyl disulfide","C028009",0,0,0,0,0,4,2,0,0]
["Diazepam","Diazepam","D003975",0,2,0,0,0,1,1,0,0]
["Diazinon","Diazinon","D003976",0,0,0,1,0,0,4,0,0]
["dibenzacridine","dibenzacridine","C022289",0,0,0,0,0,0,1,0,0]
["dibenzanthracenes","dibenzanthracenes","C016365",1,0,0,0,0,0,1,0,0]
["dibenzazepine","dibenzazepine","C527817",0,0,0,0,0,1,0,0,0]
["dibenzo(1,4)dioxin","dibenzo(1,4)dioxin","C020887",1,0,0,0,0,1,6,0,0]
["dibenzo(a,l)pyrene","dibenzo(a,l)pyrene","C041517",2,0,0,0,0,0,10,0,0]
["dibenzo(a,l)pyrene 11,12-dihydrodiol","dibenzo(a,l)pyrene 11,12-dihydrodiol","C071371",0,0,0,0,0,0,1,0,0]
["dibenzoanthracene-3,4-dihydrodiol","dibenzoanthracene-3,4-dihydrodiol","C018912",0,0,0,0,0,0,1,0,0]
["dibenzofuran","dibenzofuran","C023614",4,0,0,0,0,0,10,0,0]
["dibenzothiophene","dibenzothiophene","C016366",3,0,0,0,0,0,2,2,0]
["dibenzothiophene-5,5-dioxide","dibenzothiophene-5,5-dioxide","C090101",0,0,0,0,0,0,0,2,0]
["dibenzoylmethane","dibenzoylmethane","C061481",1,0,0,0,0,0,0,0,0]
["dibenzyl diselenide","dibenzyl diselenide","C073177",0,0,0,0,0,0,1,0,0]
["dibromoacetic acid","dibromoacetic acid","C088674",0,0,0,0,0,0,2,0,0]
["Dibutyl Phthalate","Dibutyl Phthalate","D003993",1,0,0,0,1,0,0,0,0]
["dibutyldi(4-chlorobenzohydroxamato)tin(IV)","dibutyldi(4-chlorobenzohydroxamato)tin(IV)","C542282",0,0,0,0,1,0,0,0,0]
["dibutylnitrosamine","dibutylnitrosamine","C012279",0,0,0,0,0,0,3,0,0]
["Dicarbethoxydihydrocollidine","Dicarbethoxydihydrocollidine","D003997",0,0,0,0,0,0,1,0,0]
["dicarbine","dicarbine","C100106",0,0,0,0,0,5,0,0,0]
["dichlobanil","dichlobanil","C055869",0,0,0,0,0,0,1,0,0]
["dichlorfop-methyl","dichlorfop-methyl","C012891",0,0,0,0,0,0,2,0,0]
["Dichloroacetic Acid","Dichloroacetic Acid","D003999",0,0,0,0,0,3,0,0,0]
["Dicumarol","Dicumarol","D001728",0,0,0,0,0,0,2,0,0]
["Dieldrin","Dieldrin","D004026",0,0,0,1,0,0,1,0,0]
["Diethyl Pyrocarbonate","Diethyl Pyrocarbonate","D004047",0,0,0,1,0,1,0,0,0]
["difenoconazole","difenoconazole","C115058",0,0,0,0,0,0,0,2,0]
["difloxacin","difloxacin","C047225",0,0,0,0,0,0,2,0,0]
["digalactosyldiacylglycerol","digalactosyldiacylglycerol","C007388",0,0,0,0,0,0,0,4,0]
["Digitoxin","Digitoxin","D004074",0,0,0,0,0,1,0,0,0]
["Digoxigenin","Digoxigenin","D004076",0,0,0,0,0,1,0,0,0]
["Digoxin","Digoxin","D004077",0,0,0,0,0,1,0,0,0]
["Dihematoporphyrin Ether","Dihematoporphyrin Ether","D017323",0,0,0,0,0,15,0,0,0]
["Dihydralazine","Dihydralazine","D004078",0,0,0,0,0,0,2,0,0]
["dihydroberberine","dihydroberberine","C039639",0,0,0,0,0,1,0,0,0]
["dihydrodaidzein","dihydrodaidzein","C433163",0,0,0,0,0,1,0,0,0]
["dihydroethidium","dihydroethidium","C067883",0,0,0,0,0,2,0,0,0]
["dihydrolipoic acid","dihydrolipoic acid","C015144",0,0,0,0,0,4,0,0,0]
["dihydronarciclasine","dihydronarciclasine","C064338",0,0,0,0,0,0,1,0,0]
["dihydronicotinamide","dihydronicotinamide","C015145",0,0,0,0,0,1,0,0,0]
["dihydroresveratrol","dihydroresveratrol","C544754",0,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2564,B2564)","v":"dihydrosafrole"},"dihydrosafrole","C035396",0,0,0,0,0,0,1,0,0]
["dihydrosanguinarine","dihydrosanguinarine","C501843",0,0,0,0,0,0,1,0,0]
["dihydrosphingosine 1-phosphate","dihydrosphingosine 1-phosphate","C060504",0,1,0,0,0,1,0,0,0]
["dihydrosterculic acid","dihydrosterculic acid","C029355",0,0,0,0,0,0,0,1,0]
["Dihydroxyacetone Phosphate","Dihydroxyacetone Phosphate","D004099",0,0,0,3,0,0,0,0,0]
["diisodecyl phthalate","diisodecyl phthalate","C042080",0,0,0,0,0,0,1,0,0]
["diisoeugenol","diisoeugenol","C087580",0,0,0,0,0,1,0,0,0]
["dilactitol tyramine","dilactitol tyramine","C049133",0,1,0,0,1,0,0,0,0]
["Diltiazem","Diltiazem","D004110",0,2,0,0,0,6,1,0,0]
["dimethoxyphenylvinyl thiophene","dimethoxyphenylvinyl thiophene","C490433",0,0,0,0,0,0,1,0,0]
["dimethyl pyrocarbonate","dimethyl pyrocarbonate","C061815",0,0,0,1,0,0,0,0,0]
["Dimethyl Suberimidate","Dimethyl Suberimidate","D004120",0,0,0,0,0,1,0,0,0]
["dimethyl sulfide","dimethyl sulfide","C004784",0,0,0,0,0,0,1,0,0]
["dimethylamine","dimethylamine","C034516",0,0,0,0,0,0,1,0,0]
["Dimyristoylphosphatidylcholine","Dimyristoylphosphatidylcholine","D004134",0,1,0,0,0,7,1,0,0]
["dimyristoylphosphatidylglycerol","dimyristoylphosphatidylglycerol","C002773",0,0,0,0,0,1,0,0,0]
["dinitrophenylhydrazine","dinitrophenylhydrazine","C446799",0,0,0,0,0,1,0,0,0]
["diosmetin","diosmetin","C039602",3,0,0,0,0,0,5,0,0]
["Diosmin","Diosmin","D004145",3,0,0,0,0,1,3,0,0]
["Diphenhydramine","Diphenhydramine","D004155",0,0,0,0,0,0,1,0,0]
["diphenyl sulfide","diphenyl sulfide","C444009",1,0,0,0,0,0,0,0,0]
["diphenyl-1-pyrenylphosphine","diphenyl-1-pyrenylphosphine","C066322",0,0,0,0,0,1,0,0,0]
["Diphenylamine","Diphenylamine","D004159",0,0,0,0,0,0,1,0,0]
["diphenylarsinic acid","diphenylarsinic acid","C493087",1,0,0,0,0,0,0,0,0]
["diphenyldiselenide","diphenyldiselenide","C061132",0,0,0,0,0,8,0,0,0]
["diphosphoric acid","diphosphoric acid","C107241",0,0,0,0,0,1,0,0,0]
["dipicolinic acid","dipicolinic acid","C004860",0,0,0,0,0,1,0,0,0]
["dipropyl sulfide","dipropyl sulfide","C087894",0,0,0,0,0,0,4,0,0]
["Dipyridamole","Dipyridamole","D004176",0,1,0,0,1,7,0,0,0]
["Diquat","Diquat","D004178",0,0,0,0,0,0,2,0,0]
["dithianone","dithianone","C018529",0,0,0,0,0,0,1,0,0]
["dithiobis(succinimidylpropionate)","dithiobis(succinimidylpropionate)","C011240",0,0,0,0,0,3,0,0,0]
["Dithionitrobenzoic Acid","Dithionitrobenzoic Acid","D004228",0,0,0,0,0,0,0,2,0]
["Dithiothreitol","Dithiothreitol","D004229",0,0,0,0,0,0,0,2,0]
["Ditiocarb","Ditiocarb","D004050",0,0,0,0,0,2,0,0,0]
["Diuron","Diuron","D004237",4,0,0,0,0,0,5,0,0]
["DMP-565","DMP-565","C110089",0,0,0,0,0,2,0,0,0]
["DMU-212","DMU-212","C521792",1,0,0,0,0,0,3,0,0]
["docetaxel","docetaxel","C067311",0,0,0,0,0,3,1,1,0]
["docosapentaenoic acid","docosapentaenoic acid","C026219",0,1,0,0,0,0,0,24,0]
["dodecanedioic acid","dodecanedioic acid","C036836",0,0,0,0,0,0,0,2,0]
["dodecylphosphocholine","dodecylphosphocholine","C028810",0,0,0,0,0,1,0,0,0]
["dodecylthioacetic acid","dodecylthioacetic acid","C064348",0,0,0,0,0,1,0,0,0]
["dolutegravir","dolutegravir","C562325",0,0,0,0,0,1,0,0,0]
["domoic acid","domoic acid","C012301",1,0,0,0,0,0,2,0,0]
["donepezil","donepezil","C076946",0,0,0,0,0,1,0,0,0]
["Doxazosin","Doxazosin","D017292",0,0,0,0,0,15,0,0,0]
["Doxycycline","Doxycycline","D004318",0,0,0,0,0,1,0,3,0]
["Drinking Water","Drinking Water","D060766",3,0,0,0,0,0,0,4,0]
["Dronabinol","Dronabinol","D013759",1,2,0,0,0,2,4,0,0]
["drospirenone","drospirenone","C035144",0,0,0,0,0,3,0,0,0]
["Durapatite","Durapatite","D017886",0,0,0,0,0,3,0,0,0]
["Dust","Dust","D004391",5,0,0,0,0,1,12,0,0]
["Dydrogesterone","Dydrogesterone","D004394",0,0,0,0,0,2,0,0,0]
["dyspropterin","dyspropterin","C045652",0,0,0,0,0,0,0,2,0]
["E 5324","E 5324","C090175",0,0,0,0,0,1,0,0,0]
["E 5531","E 5531","C092845",0,0,0,0,0,1,0,0,0]
["E5564","E5564","C404742",0,0,0,0,0,2,0,0,0]
["EAB 309","EAB 309","C087390",0,1,0,0,0,0,0,0,0]
["EBNA-3A antigen","EBNA-3A antigen","C508151",1,0,0,0,0,0,0,0,0]
["EBNA-3B antigen","EBNA-3B antigen","C422762",1,0,0,0,0,0,0,0,0]
["ebselen","ebselen","C042986",0,0,0,0,0,5,0,3,0]
["ecabapide","ecabapide","C058308",0,0,0,0,0,0,2,0,0]
["echinocystic acid","echinocystic acid","C022999",0,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2628,B2628)","v":"Echothiophate Iodide"},"Echothiophate Iodide","D004456",0,0,0,0,0,1,0,0,0]
["ecteinascidin 729","ecteinascidin 729","C100350",0,0,0,0,0,0,1,0,0]
["edelfosine","edelfosine","C026659",0,0,0,0,0,1,0,0,0]
["eflucimibe","eflucimibe","C418062",0,0,0,0,1,1,0,0,0]
["efonidipine","efonidipine","C066425",0,1,0,0,0,2,0,0,0]
["Egtazic Acid","Egtazic Acid","D004533",0,0,0,1,0,2,0,0,0]
["eiconol","eiconol","C089938",0,0,0,0,0,1,0,0,0]
["eicosa-5,11,14-trienoic acid","eicosa-5,11,14-trienoic acid","C045533",0,0,0,0,0,0,0,4,0]
["ellipticine","ellipticine","C034192",1,0,0,0,0,2,6,0,0]
["elliptinium","elliptinium","C027767",0,0,0,0,0,4,0,0,0]
["emamectin benzoate","emamectin benzoate","C108024",0,0,0,0,0,0,1,0,0]
["emoxypine succinate","emoxypine succinate","C070020",0,0,0,0,0,3,0,0,0]
["Endosulfan","Endosulfan","D004726",1,0,0,0,0,0,6,0,0]
["endothelium-dependent hyperpolarization factor","endothelium-dependent hyperpolarization factor","C067410",0,0,0,0,0,1,1,0,0]
["endotoxin, Escherichia coli","endotoxin, Escherichia coli","C044101",0,0,0,0,0,3,1,0,0]
["Endrin","Endrin","D004732",1,0,0,1,0,0,0,0,0]
["enfenamic acid","enfenamic acid","C019126",0,0,0,1,0,0,0,0,0]
["enilconazole","enilconazole","C017435",2,0,0,0,0,0,1,0,0]
["Enoxacin","Enoxacin","D015365",0,0,0,0,0,0,2,0,0]
["enrofloxacin","enrofloxacin","C052904",0,0,0,0,0,0,6,0,0]
["enterotoxin F, Staphylococcal","enterotoxin F, Staphylococcal","C030107",0,0,0,0,0,1,0,0,0]
["enterotoxin, Clostridium","enterotoxin, Clostridium","C035598",0,0,0,0,0,1,0,1,0]
["entinostat","entinostat","C118739",0,0,0,0,0,0,0,1,0]
["EP2302","EP2302","C500325",0,0,0,0,0,3,0,0,0]
["EP2306","EP2306","C500324",0,0,0,0,0,3,0,0,0]
["epiberberine","epiberberine","C061432",0,0,0,0,0,1,0,0,0]
["epicatechin-3'-O-glucuronide","epicatechin-3'-O-glucuronide","C480662",0,0,0,0,0,1,0,0,0]
["epitiostanol","epitiostanol","C002976",0,1,0,0,0,0,0,0,0]
["eprosartan","eprosartan","C068373",0,0,0,0,0,2,0,0,0]
["Equol","Equol","D060754",0,0,0,0,1,4,1,0,0]
["Ergonovine","Ergonovine","D004874",0,0,0,0,0,1,0,0,0]
["Ergosterol","Ergosterol","D004875",0,0,0,0,0,4,0,8,0]
["eriodictyol","eriodictyol","C007619",0,0,0,0,0,1,0,0,0]
["eritadenine","eritadenine","C100029",0,1,0,0,0,0,0,12,0]
["Erlotinib Hydrochloride","Erlotinib Hydrochloride","D000069347",0,0,0,0,0,0,1,0,0]
["erucin","erucin","C073539",2,0,0,0,0,0,4,0,0]
["erucylcarnitine","erucylcarnitine","C002232",0,1,0,0,0,0,0,0,0]
["erybraedin C","erybraedin C","C488769",0,0,0,0,0,1,0,0,0]
["erysolin","erysolin","C073538",0,0,0,0,0,0,2,0,0]
["erythritol anhydride","erythritol anhydride","C007366",0,0,0,0,0,0,1,0,0]
["Erythromycin","Erythromycin","D004917",0,0,0,0,0,2,3,0,0]
["Esomeprazole","Esomeprazole","D064098",0,0,0,0,0,0,1,0,0]
["Etanidazole","Etanidazole","D017341",0,0,0,0,0,1,0,0,0]
["Ethacrynic Acid","Ethacrynic Acid","D004976",0,0,0,1,0,0,0,0,0]
["Ethacure 300","Ethacure 300","C061701",0,0,0,0,0,0,1,0,0]
["Ethamoxytriphetol","Ethamoxytriphetol","D004978",0,0,0,0,0,3,0,0,0]
["Ethidium","Ethidium","D004996",0,0,0,0,0,3,0,0,0]
["ethofenprox","ethofenprox","C076840",0,0,0,0,0,0,1,0,0]
["ethoxidine","ethoxidine","C404513",0,0,0,0,0,0,1,0,0]
["Ethoxyquin","Ethoxyquin","D005015",1,0,0,0,0,0,0,0,0]
["ethoxyresorufin","ethoxyresorufin","C007649",0,0,0,0,0,0,10,0,0]
["ethyl 2-((5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl)oxy)-2-methylpropanoate","ethyl 2-((5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl)oxy)-2-methylpropanoate","C053573",0,0,0,0,0,1,0,0,0]
["ethyl 4-(4-hydoxyphenyl)methylidene-2-methyl-5-oxoimidazoleacetate","ethyl 4-(4-hydoxyphenyl)methylidene-2-methyl-5-oxoimidazoleacetate","C409202",0,0,0,0,0,0,0,2,0]
["Ethyl Chloride","Ethyl Chloride","D005018",0,0,0,0,0,0,1,0,0]
["ethyl linoleate","ethyl linoleate","C007678",0,0,0,0,0,1,0,0,0]
["Ethyl Methanesulfonate","Ethyl Methanesulfonate","D005020",0,0,0,0,0,0,0,2,0]
["ethyl oleate","ethyl oleate","C033180",0,0,0,0,0,3,0,0,0]
["ethyl palmitate","ethyl palmitate","C007680",0,0,0,0,0,3,0,0,0]
["ethylbenzene","ethylbenzene","C004912",0,0,0,0,0,0,4,0,0]
["ethylene","ethylene","C036216",0,0,0,0,0,0,0,2,0]
["ethylisopropylamiloride","ethylisopropylamiloride","C039614",0,0,0,0,0,0,1,0,0]
["Ethylmaleimide","Ethylmaleimide","D005033",0,0,0,0,0,1,0,3,0]
["ethylmalonic acid","ethylmalonic acid","C038080",0,0,0,0,0,0,0,14,0]
["Ethylmorphine","Ethylmorphine","D005036",0,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2692,B2692)","v":"ethyl-p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoic acid"},"ethyl-p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoic acid","C034814",0,0,0,0,0,1,0,0,0]
["ethylphenylhydantoin","ethylphenylhydantoin","C014544",0,0,0,0,0,0,1,0,0]
["Ethynodiol Diacetate","Ethynodiol Diacetate","D005040",0,0,0,0,0,1,0,0,0]
["Etidronic Acid","Etidronic Acid","D012968",0,0,0,0,0,1,0,0,0]
["etiracetam","etiracetam","C026098",0,0,0,0,0,2,1,0,0]
["etofibrate","etofibrate","C009746",0,2,0,0,0,8,0,0,0]
["etonogestrel","etonogestrel","C044815",0,0,0,0,0,1,0,0,0]
["Etoposide","Etoposide","D005047",0,0,0,0,0,4,0,4,0]
["Etretinate","Etretinate","D005050",0,0,0,0,0,3,0,0,0]
["eupalinilide E","eupalinilide E","C585894",1,0,0,0,0,0,0,0,0]
["eupatilin","eupatilin","C045325",0,0,0,1,0,0,0,0,0]
["eupatorin","eupatorin","C103110",0,0,0,0,0,0,1,0,0]
["eupatorin-5-methyl ether","eupatorin-5-methyl ether","C000593130",0,0,0,0,0,0,2,0,0]
["europium(III) tetracycline","europium(III) tetracycline","C488317",0,0,0,0,0,1,0,0,0]
["euscaphic acid","euscaphic acid","C007695",0,0,0,0,0,2,0,0,0]
["evacetrapib","evacetrapib","C568301",0,0,0,0,0,2,0,0,0]
["Evans Blue","Evans Blue","D005070",0,0,0,0,0,1,0,0,0]
["exemestane","exemestane","C056516",0,0,0,0,0,0,1,0,0]
["F 1394","F 1394","C094918",0,1,0,0,0,1,0,0,0]
["Fadrozole","Fadrozole","D017316",0,1,0,0,0,1,0,0,0]
["Farnesol","Farnesol","D005204",0,0,0,0,0,1,0,0,0]
["farnesylthiosalicylic acid","farnesylthiosalicylic acid","C093323",0,0,0,0,0,1,0,0,0]
["fasudil","fasudil","C049347",0,0,0,0,1,1,0,0,0]
["fatty aldehyde","fatty aldehyde","C001634",0,0,0,0,1,1,0,0,0]
["Felodipine","Felodipine","D015736",0,0,0,0,0,2,0,0,0]
["Fenbendazole","Fenbendazole","D005273",0,0,0,0,0,0,1,0,0]
["fenbutol","fenbutol","C085805",0,0,0,0,0,2,0,0,0]
["Fendiline","Fendiline","D005275",0,0,0,0,0,1,0,0,0]
["fenpropathrin","fenpropathrin","C044267",0,0,0,0,0,0,1,0,0]
["fenpyroximate","fenpyroximate","C415144",0,0,0,0,0,0,1,0,0]
["fenvalerate","fenvalerate","C017690",0,0,0,0,0,0,1,0,0]
["ferric carboxymaltose","ferric carboxymaltose","C522335",0,0,0,0,0,1,0,0,0]
["ferric gluconate","ferric gluconate","C035552",0,0,0,0,0,2,0,0,0]
["ferric nitrilotriacetate","ferric nitrilotriacetate","C020326",0,0,0,0,0,0,1,0,0]
["ferric oxide, saccharated","ferric oxide, saccharated","C008169",0,0,0,0,0,2,0,0,0]
["ferric sulfate","ferric sulfate","C024823",0,0,0,0,0,2,0,0,0]
["ferulic acid beta-glucuronide","ferulic acid beta-glucuronide","C109839",0,0,0,0,0,1,0,0,0]
["Filipin","Filipin","D005372",0,0,0,0,1,6,0,0,0]
["Firefly Luciferin","Firefly Luciferin","D049454",1,0,0,0,0,0,0,0,0]
["Firemaster 550","Firemaster 550","C000591741",3,0,0,0,0,0,1,0,0]
["Firemaster BP-6","Firemaster BP-6","C015885",1,0,0,0,0,0,0,0,0]
["Flamin","Flamin","C015886",0,0,0,0,0,1,0,0,0]
["flavanone","flavanone","C028610",0,0,0,0,0,0,2,0,0]
["flavipin","flavipin","C000621062",3,0,0,0,0,0,0,0,0]
["flavone","flavone","C043562",2,0,0,0,0,1,5,0,0]
["floranol","floranol","C488030",0,0,0,0,0,1,0,0,0]
["flubendazole","flubendazole","C018945",0,0,0,0,0,0,3,0,0]
["Fluconazole","Fluconazole","D015725",2,0,0,0,0,0,1,0,0]
["Flufenamic Acid","Flufenamic Acid","D005439",0,0,0,0,0,1,0,0,0]
["flumecinol","flumecinol","C016914",0,0,0,0,0,0,1,0,0]
["flumequine","flumequine","C012976",0,0,0,0,0,0,1,0,0]
["fluometuron","fluometuron","C005015",0,0,0,0,0,0,1,0,0]
["fluoranthene","fluoranthene","C007738",9,0,0,0,0,0,5,0,0]
["fluorescein isothiocyanate dextran","fluorescein isothiocyanate dextran","C015219",0,0,0,0,0,3,0,0,0]
["Fluorescein-5-isothiocyanate","Fluorescein-5-isothiocyanate","D016650",0,0,0,0,1,5,0,0,0]
["Fluoxymesterone","Fluoxymesterone","D005474",0,1,0,0,0,0,0,0,0]
["fluparoxan","fluparoxan","C065161",0,0,0,0,0,0,1,0,0]
["flupyrazofos","flupyrazofos","C116965",0,0,0,0,0,0,2,0,0]
["Flutamide","Flutamide","D005485",4,0,0,0,0,2,3,0,0]
["Fluvoxamine","Fluvoxamine","D016666",0,0,0,0,0,0,3,0,0]
["FOE 3440 A","FOE 3440 A","C062107",0,0,0,0,0,0,1,0,0]
["fomepizole","fomepizole","C010238",0,0,0,0,0,0,2,0,0]
["fomocain","fomocain","C100275",0,0,0,0,0,0,1,0,0]
["formic acid","formic acid","C030544",0,0,0,0,0,0,0,2,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2756,B2756)","v":"fostamatinib"},"fostamatinib","C523665",0,0,0,0,0,1,0,0,0]
["FR 111142","FR 111142","C074363",0,0,0,0,0,2,0,0,0]
["FR 145237","FR 145237","C097564",0,0,0,0,0,2,0,0,0]
["FR 186485","FR 186485","C115433",0,0,0,0,0,1,0,0,0]
["FR 190809","FR 190809","C115432",0,0,0,0,0,1,0,0,0]
["FR171456","FR171456","C487953",0,0,0,0,0,1,0,0,0]
["FR901512","FR901512","C487955",0,0,0,0,0,1,0,0,0]
["fractogel TSK HW 40S","fractogel TSK HW 40S","C049226",0,1,0,0,0,1,0,0,0]
["fraxetin","fraxetin","C105671",0,0,0,0,0,1,0,0,0]
["Fructosamine","Fructosamine","D019270",0,0,0,0,0,6,0,0,0]
["fructose-1,6-diphosphate","fructose-1,6-diphosphate","C029063",0,0,0,1,0,0,0,0,0]
["furafylline","furafylline","C050131",0,0,0,0,0,0,4,0,0]
["Furaldehyde","Furaldehyde","D005662",0,0,0,0,0,1,0,0,0]
["furametpyr","furametpyr","C417978",0,0,0,0,0,0,1,0,0]
["Furazolidone","Furazolidone","D005664",0,0,0,0,0,0,2,0,0]
["Fusidic Acid","Fusidic Acid","D005672",0,0,0,0,0,1,0,0,0]
["G(A1) ganglioside","G(A1) ganglioside","C011258",0,1,0,0,0,1,0,0,0]
["G(M1) Ganglioside","G(M1) Ganglioside","D005677",0,0,0,0,0,1,0,0,0]
["G(M3) Ganglioside","G(M3) Ganglioside","D005679",0,0,0,0,0,2,0,0,0]
["Gabexate","Gabexate","D016670",0,1,0,0,0,0,0,0,0]
["gadofluorine M","gadofluorine M","C517961",0,0,0,0,0,1,0,0,0]
["gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate","gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate","C050823",0,0,0,0,1,0,0,0,0]
["gadolinium stearylamide DTPA","gadolinium stearylamide DTPA","C077628",0,0,0,0,0,2,0,0,0]
["galactaric acid","galactaric acid","C000090",0,0,0,0,0,1,0,0,0]
["galangin","galangin","C037032",7,0,0,0,0,0,3,0,0]
["galaxolide","galaxolide","C033119",0,0,0,0,0,0,1,0,0]
["galgeun-tang","galgeun-tang","C000598417",0,0,0,0,0,0,1,0,0]
["gallocatechin gallate","gallocatechin gallate","C417940",0,0,0,0,0,1,0,0,0]
["gallocatechin-7-gallate","gallocatechin-7-gallate","C544617",0,0,0,0,0,1,0,0,0]
["gallocatechol","gallocatechol","C057580",1,0,0,0,0,2,1,0,0]
["Gallopamil","Gallopamil","D005711",0,0,0,0,0,1,0,0,0]
["gamma-cyclodextrin","gamma-cyclodextrin","C023792",0,1,0,0,0,1,0,0,0]
["gamma-linolenoyl-3-eicosapentaenoylpropanediol","gamma-linolenoyl-3-eicosapentaenoylpropanediol","C121195",0,0,0,0,0,0,0,2,0]
["gamma-terpinene","gamma-terpinene","C018669",0,0,0,0,0,1,0,0,0]
["ganglio-N-triaosylceramide","ganglio-N-triaosylceramide","C038244",0,1,0,0,0,1,0,0,0]
["ganglioside, GD1a","ganglioside, GD1a","C021298",0,0,0,0,0,2,0,0,0]
["garcinol","garcinol","C054597",0,0,0,0,0,1,0,0,0]
["garugamblin-3","garugamblin-3","C509356",0,0,0,0,0,1,0,0,0]
["Gd-AA2TAC17","Gd-AA2TAC17","C526378",0,0,0,0,0,3,0,0,0]
["Gd-DO3A-diph","Gd-DO3A-diph","C526379",0,0,0,0,0,3,0,0,0]
["GEA 3162","GEA 3162","C082874",0,0,0,0,0,2,0,0,0]
["gefitinib","gefitinib","C419708",0,0,0,0,0,0,3,0,0]
["Gemfibrozil","Gemfibrozil","D015248",0,42,0,0,0,58,2,7,0]
["geniposidic acid","geniposidic acid","C058966",0,0,0,0,0,1,0,0,0]
["genistin","genistin","C040641",2,0,0,0,0,2,1,0,0]
["gentiopicroside","gentiopicroside","C012997",0,0,0,1,0,0,0,0,0]
["geosmin","geosmin","C001278",0,0,0,0,0,0,1,0,0]
["geranylgeranyl pyrophosphate","geranylgeranyl pyrophosphate","C002963",0,0,0,0,0,0,0,2,0]
["geranylgeranylacetone","geranylgeranylacetone","C031049",1,0,0,0,0,0,1,0,0]
["germacrone","germacrone","C048393",1,0,0,0,0,0,0,0,0]
["gerontoxanthone B","gerontoxanthone B","C000621756",3,0,0,0,0,0,0,0,0]
["Gestodene","Gestodene","C033273",0,0,0,0,0,3,0,0,0]
["Gestrinone","Gestrinone","D005867",4,0,0,0,0,1,1,0,0]
["gilvocarcin V","gilvocarcin V","C031781",0,0,0,0,0,1,0,0,0]
["Ginkgo biloba extract","Ginkgo biloba extract","C063170",2,0,0,0,0,8,0,0,0]
["ginkgolide B","ginkgolide B","C045856",0,0,0,0,0,5,0,0,0]
["ginkgolide C","ginkgolide C","C058295",0,0,0,0,0,0,1,0,0]
["ginsenoside Rb3","ginsenoside Rb3","C044463",0,0,0,0,0,1,0,0,0]
["ginsenoside Rg1","ginsenoside Rg1","C035054",2,0,0,0,0,0,2,0,0]
["glabridin","glabridin","C107601",0,0,0,0,1,12,0,0,0]
["Glipizide","Glipizide","D005913",0,1,0,1,0,1,0,0,0]
["globotriaosylceramide","globotriaosylceramide","C018549",0,0,0,0,0,1,0,0,0]
["glucobrassicin","glucobrassicin","C048308",0,0,0,0,0,0,1,0,0]
["glucoerucin","glucoerucin","C119493",1,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2820,B2820)","v":"glucosaminoglycans"},"glucosaminoglycans","C020341",0,1,0,0,0,0,0,0,0]
["Glucose-6-Phosphate","Glucose-6-Phosphate","D019298",0,1,0,0,0,0,0,0,0]
["glucosyl hesperidin","glucosyl hesperidin","C487382",0,2,0,0,0,1,0,0,0]
["Glucuronic Acid","Glucuronic Acid","D020723",0,0,0,0,0,0,1,0,0]
["glucuronyl glucosamine glycan sulfate","glucuronyl glucosamine glycan sulfate","C007858",0,1,0,0,0,1,0,0,0]
["glutaric acid","glutaric acid","C035736",0,0,1,0,0,0,0,44,0]
["Glutethimide","Glutethimide","D005984",0,1,0,0,0,1,0,0,0]
["glyceollin","glyceollin","C017343",0,0,0,0,0,1,1,0,0]
["glyceric acid","glyceric acid","C042971",0,0,0,3,0,0,0,0,0]
["glycerophosphoethanolamine","glycerophosphoethanolamine","C002449",0,0,0,0,0,1,0,0,0]
["glycidyl trimethylammonium","glycidyl trimethylammonium","C045006",0,0,0,0,0,1,0,0,0]
["glycol-chitosan","glycol-chitosan","C118638",0,0,0,0,0,1,0,0,0]
["glycyrol","glycyrol","C531349",0,0,0,0,0,0,1,0,0]
["Glyoxal","Glyoxal","D006037",0,0,0,0,0,5,0,0,0]
["glyoxylic acid","glyoxylic acid","C031150",0,0,0,1,0,0,0,0,0]
["glyteen","glyteen","C007876",1,0,0,0,0,0,1,0,0]
["gossypetin","gossypetin","C059922",0,0,0,0,0,3,0,0,0]
["gossypin","gossypin","C022944",0,0,0,0,0,1,0,0,0]
["Gossypol","Gossypol","D006072",0,1,0,0,0,1,0,0,0]
["Gosyuyu","Gosyuyu","C406544",0,0,0,0,0,0,1,0,0]
["GQ-177","GQ-177","C000612421",0,0,0,0,0,1,0,0,0]
["Granisetron","Granisetron","D017829",0,0,0,0,0,0,2,0,0]
["Grape Seed Proanthocyanidins","Grape Seed Proanthocyanidins","C511402",0,3,0,0,1,2,0,0,0]
["Griseofulvin","Griseofulvin","D006118",0,0,0,0,0,0,0,5,0]
["GSK 993","GSK 993","C546024",0,0,0,0,0,0,0,1,0]
["gualou xiebai baijiutang","gualou xiebai baijiutang","C488004",0,0,0,0,0,1,0,0,0]
["Guanabenz","Guanabenz","D006143",0,1,0,0,0,1,0,0,0]
["guggulu extract","guggulu extract","C018562",0,0,0,0,0,3,0,0,0]
["guizhi decoction","guizhi decoction","C528663",0,0,0,0,0,1,0,0,0]
["guluronic acid","guluronic acid","C007896",0,0,0,0,0,1,0,0,0]
["GW 532","GW 532","C442819",0,0,0,0,0,2,0,0,0]
["GW 707","GW 707","C442817",0,0,0,0,0,3,0,0,0]
["GWC20","GWC20","C470988",0,0,0,0,0,2,0,0,0]
["gypenoside IX","gypenoside IX","C077955",0,0,0,0,0,1,0,0,0]
["halimane","halimane","C000610653",0,0,0,0,0,1,0,0,0]
["halofantrine","halofantrine","C023768",0,0,0,0,0,2,0,0,0]
["haloperidol decanoate","haloperidol decanoate","C033563",0,0,0,0,0,1,0,0,0]
["halowax 1051","halowax 1051","C571106",2,0,0,0,0,0,1,0,0]
["hamamelitannin","hamamelitannin","C093412",0,0,0,0,0,0,1,0,0]
["Harmaline","Harmaline","D006246",1,0,0,0,0,0,2,0,0]
["harmalol","harmalol","C007904",1,0,0,0,0,0,1,0,0]
["harman","harman","C005010",1,0,0,0,0,0,3,0,0]
["Harmine","Harmine","D006247",1,0,0,0,0,0,6,0,0]
["harmol","harmol","C001326",0,0,0,0,0,0,2,0,0]
["helenalin","helenalin","C001329",0,0,0,0,0,0,1,0,0]
["helvolic acid","helvolic acid","C011267",0,0,0,0,0,1,0,0,0]
["hematein","hematein","C007915",0,0,0,0,0,1,0,0,0]
["Hematoporphyrin Derivative","Hematoporphyrin Derivative","D017324",0,0,0,0,0,4,0,0,0]
["hematoporphyrin dipentyl ether","hematoporphyrin dipentyl ether","C067528",0,0,0,0,0,1,0,0,0]
["Hemin","Hemin","D006427",0,0,0,0,0,14,1,0,0]
["Heparitin Sulfate","Heparitin Sulfate","D006497",0,15,0,0,1,32,0,0,0]
["Heptachlor","Heptachlor","D006533",0,0,0,1,0,0,0,0,0]
["herboxidiene","herboxidiene","C076087",0,0,0,0,0,2,0,0,0]
["hesperetin","hesperetin","C013015",1,0,0,0,0,3,3,1,0]
["heteronemin","heteronemin","C493748",0,0,0,0,0,0,1,0,0]
["hexa(beta-glucopyranosyl)glucitol","hexa(beta-glucopyranosyl)glucitol","C042659",0,0,0,0,0,3,0,0,0]
["hexabrominated diphenyl ether 153","hexabrominated diphenyl ether 153","C517828",0,0,0,0,0,0,1,0,0]
["hexabromobenzene","hexabromobenzene","C017363",0,0,0,0,0,0,2,0,0]
["hexabromocyclododecane","hexabromocyclododecane","C089796",1,0,0,0,0,0,5,0,0]
["Hexachlorobenzene","Hexachlorobenzene","D006581",19,0,0,0,0,0,17,0,0]
["hexadecenoic acid","hexadecenoic acid","C093821",0,0,0,0,0,0,0,6,0]
["hexanoic acid","hexanoic acid","C037652",0,0,0,0,0,0,0,2,0]
["hexanoylcarnitine","hexanoylcarnitine","C061301",0,0,0,0,0,0,0,4,0]
["Heymann Nephritis Antigenic Complex","Heymann Nephritis Antigenic Complex","D026541",0,2,0,0,0,54,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2884,B2884)","v":"hinokiresinol"},"hinokiresinol","C119821",0,0,0,0,0,1,0,0,0]
["hippuric acid","hippuric acid","C030514",0,1,0,0,0,0,1,0,0]
["hispidin","hispidin","C007946",0,0,0,0,0,1,0,0,0]
["HOE 402","HOE 402","C081893",0,1,0,0,0,5,0,0,0]
["horminone","horminone","C045490",0,0,0,0,0,0,1,0,0]
["human platelet antigen 1b","human platelet antigen 1b","C083451",0,0,0,0,1,0,0,0,0]
["humulene","humulene","C042686",0,0,0,0,0,1,0,0,0]
["hydracrylic acid","hydracrylic acid","C031601",0,0,0,0,0,0,0,2,0]
["Hydralazine","Hydralazine","D006830",0,0,0,0,0,2,0,0,0]
["Hydrogel, Polyethylene Glycol Dimethacrylate","Hydrogel, Polyethylene Glycol Dimethacrylate","D020136",0,0,0,0,0,0,2,0,0]
["hydroquinone","hydroquinone","C031927",1,0,0,0,0,0,0,0,0]
["hydroxide ion","hydroxide ion","C031356",0,0,0,0,0,1,0,0,0]
["Hydroxychloroquine","Hydroxychloroquine","D006886",0,0,0,0,0,3,0,0,0]
["hydroxyethyl methacrylate","hydroxyethyl methacrylate","C005044",1,0,0,0,0,0,0,0,0]
["hydroxyhydroquinone","hydroxyhydroquinone","C013038",0,0,1,0,0,0,0,0,0]
["Hydroxyl Radical","Hydroxyl Radical","D017665",0,0,0,0,0,13,0,0,0]
["Hydroxylamine","Hydroxylamine","D019811",0,0,0,0,0,1,0,0,0]
["hydroxysafflor yellow A","hydroxysafflor yellow A","C085278",0,0,0,0,0,1,0,0,0]
["hydroxytamoxifen","hydroxytamoxifen","C475919",0,0,0,0,0,0,1,0,0]
["hyodeoxycholic acid","hyodeoxycholic acid","C010471",0,0,0,0,0,4,0,1,0]
["Hypercholanemia, Familial","Hypercholanemia, Familial","C564336",0,0,0,0,0,1,0,0,0]
["hyperforin","hyperforin","C001654",0,0,0,0,0,2,0,0,0]
["hypericin","hypericin","C004965",0,0,0,0,1,10,0,2,0]
["hypobromous acid","hypobromous acid","C027664",0,0,0,0,0,2,0,0,0]
["Hypochlorous Acid","Hypochlorous Acid","D006997",0,1,0,0,6,55,0,0,0]
["hypoglycin","hypoglycin","C041757",0,0,0,0,0,0,0,4,0]
["hypotaurine","hypotaurine","C003949",0,0,0,0,0,3,0,0,0]
["hypothiocyanous acid","hypothiocyanous acid","C517667",0,0,0,0,0,2,0,0,0]
["ibandronic acid","ibandronic acid","C073007",0,0,0,0,1,2,0,0,0]
["icariin","icariin","C056599",0,0,0,0,1,3,0,0,0]
["icaritin","icaritin","C499403",2,0,0,0,0,0,1,0,0]
["icodextrin","icodextrin","C105834",0,1,0,0,0,0,0,0,0]
["idebenone","idebenone","C036619",0,0,0,0,0,3,0,0,0]
["idescarpin","idescarpin","C584753",0,0,0,0,0,0,0,1,0]
["Ifosfamide","Ifosfamide","D007069",1,0,0,0,0,0,1,0,0]
["ikarugamycin","ikarugamycin","C074292",0,0,0,0,0,3,0,0,0]
["ilexgenin A","ilexgenin A","C468850",0,0,0,0,0,1,0,0,0]
["Iloprost","Iloprost","D016285",0,0,0,0,0,1,0,0,0]
["ILX237553","ILX237553","C428283",0,0,0,0,1,0,0,0,0]
["IMA-07101","IMA-07101","C000619834",3,0,0,0,0,0,1,0,0]
["IMA-08401","IMA-08401","C000619833",3,0,0,0,0,0,1,0,0]
["Imatinib Mesylate","Imatinib Mesylate","D000068877",0,0,0,0,0,1,2,0,0]
["imidapril","imidapril","C065166",0,0,0,0,0,1,0,0,0]
["imidaprilat","imidaprilat","C078006",0,0,0,0,0,1,0,0,0]
["imiquimod","imiquimod","C056493",1,0,0,0,1,0,0,2,0]
["imperatorin","imperatorin","C031534",0,0,0,0,0,1,1,0,0]
["implitapide","implitapide","C443181",0,1,0,0,0,1,0,0,0]
["Indapamide","Indapamide","D007190",0,0,0,0,0,3,0,0,0]
["indenoindole","indenoindole","C057286",5,0,0,0,0,0,0,0,0]
["Indican","Indican","D007200",21,0,0,0,0,1,0,0,0]
["indicaxanthin","indicaxanthin","C469628",0,0,0,0,0,1,0,0,0]
["Indigo Carmine","Indigo Carmine","D007203",2,0,0,0,0,0,0,0,0]
["Indinavir","Indinavir","D019469",0,0,0,0,0,3,0,0,0]
["indirubin","indirubin","C027185",15,0,0,0,0,0,4,0,0]
["indirubin-3'-monoxime","indirubin-3'-monoxime","C474021",6,0,0,0,0,0,1,0,0]
["indium DTPA-bis(stearylamide)","indium DTPA-bis(stearylamide)","C099575",0,0,0,0,0,2,0,0,0]
["indium oxine","indium oxine","C032950",0,0,0,0,0,1,0,0,0]
["indol-3-yl pyruvic acid","indol-3-yl pyruvic acid","C008122",3,0,0,0,0,0,0,0,0]
["indole","indole","C030374",2,0,0,0,0,0,0,0,0]
["indole-2-carboxylic acid","indole-2-carboxylic acid","C058980",0,0,0,0,0,1,0,0,0]
["indoleacetic acid","indoleacetic acid","C030737",2,0,0,0,0,0,0,2,0]
["indolo(3,2-b)carbazole","indolo(3,2-b)carbazole","C075954",10,0,0,0,0,0,6,0,0]
["Indoramin","Indoramin","D007217",0,1,0,0,0,1,0,0,0]
["indoxam","indoxam","C119389",0,0,0,0,0,2,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C2948,B2948)","v":"Inositol 1,4,5-Trisphosphate"},"Inositol 1,4,5-Trisphosphate","D015544",1,0,0,0,0,3,0,0,0]
["Inositol Niacinate","Inositol Niacinate","C005193",0,0,0,0,0,1,0,0,0]
["inositol phosphate glycan","inositol phosphate glycan","C028039",0,0,0,5,0,0,0,0,0]
["INTERCEED","INTERCEED","C060002",0,0,0,0,0,1,0,0,0]
["iodixanol","iodixanol","C044834",0,0,0,0,0,2,0,0,0]
["Iodoquinol","Iodoquinol","D004103",0,0,0,0,0,1,0,0,0]
["ipriflavone","ipriflavone","C018986",0,0,0,0,0,0,1,0,0]
["iprodione","iprodione","C033148",3,0,0,0,0,0,2,0,0]
["IRFI 005","IRFI 005","C073918",0,0,0,0,0,2,0,0,0]
["iron(II)-ascorbic acid complex","iron(II)-ascorbic acid complex","C051140",0,0,0,0,0,0,1,0,0]
["iron(III)-deuteroporphyrin","iron(III)-deuteroporphyrin","C042990",0,0,0,0,0,2,0,0,0]
["Iron-Dextran Complex","Iron-Dextran Complex","D007505",0,0,0,0,0,1,0,0,0]
["irsogladine","irsogladine","C041836",0,0,0,0,0,0,1,0,0]
["Isatin","Isatin","D007510",0,0,0,0,0,1,0,0,0]
["isatin isothiosemicarbazone","isatin isothiosemicarbazone","C019440",0,0,0,0,0,1,0,0,0]
["isoeugenol","isoeugenol","C036643",4,0,0,0,0,1,3,0,0]
["isoferulic acid","isoferulic acid","C008180",0,0,0,1,0,0,0,0,0]
["isoflavanone","isoflavanone","C065753",0,0,0,0,0,1,0,0,0]
["isoimperatorin","isoimperatorin","C055542",0,0,0,0,0,0,2,0,0]
["isoindigotin","isoindigotin","C049010",2,0,0,0,0,0,0,0,0]
["isolaulimalide","isolaulimalide","C117306",0,0,0,0,0,0,1,0,0]
["isoluminol","isoluminol","C032487",0,0,0,0,0,1,0,0,0]
["Isoorientin-6-O-glucoside","Isoorientin-6-O-glucoside","C110612",0,0,0,0,0,1,0,0,0]
["isopimpinellin","isopimpinellin","C015304",0,0,0,0,0,0,1,0,0]
["isoprene","isoprene","C005059",0,0,0,0,0,1,1,0,0]
["isopropyl 4,4'-dibromobenzilate","isopropyl 4,4'-dibromobenzilate","C038267",0,0,0,0,0,0,1,0,0]
["isopropyl 8-fluoro-1,1-dimethyl-3-(4-(3-morpholin-4-ylpropoxy)benzoyl)-1,2,3,6-tetrahydroazepino(4,5-b)indole-5-carboxylate","isopropyl 8-fluoro-1,1-dimethyl-3-(4-(3-morpholin-4-ylpropoxy)benzoyl)-1,2,3,6-tetrahydroazepino(4,5-b)indole-5-carboxylate","C547955",0,0,0,0,0,1,0,0,0]
["isopropyl-9H-thioxanthen-9-one","isopropyl-9H-thioxanthen-9-one","C518329",3,0,0,0,0,0,1,0,0]
["isoprostane F2alpha III","isoprostane F2alpha III","C438786",0,0,0,0,0,1,0,0,0]
["isoquinoline","isoquinoline","C039109",0,0,0,0,1,1,0,0,0]
["isorhapontigenin","isorhapontigenin","C432307",0,0,0,0,0,1,0,0,0]
["isosafrole","isosafrole","C015959",4,0,0,0,0,0,6,0,0]
["Isosorbide Dinitrate","Isosorbide Dinitrate","D007548",0,0,0,0,0,1,0,0,0]
["isotorachrysone","isotorachrysone","C102504",0,0,0,0,0,1,0,0,0]
["isovaleric acid","isovaleric acid","C008216",0,0,0,0,0,0,0,2,0]
["Isradipine","Isradipine","D017275",0,0,0,0,0,12,0,0,0]
["Itraconazole","Itraconazole","D017964",4,0,0,0,0,1,1,0,0]
["ITX-5061","ITX-5061","C583499",0,0,0,0,0,1,0,0,0]
["IY 80843","IY 80843","C096848",0,0,0,0,0,0,1,0,0]
["IY 80845","IY 80845","C096847",0,0,0,0,0,0,1,0,0]
["jacaric acid","jacaric acid","C579118",0,0,0,0,0,0,0,1,0]
["jaceosidin","jaceosidin","C477508",0,0,0,0,0,1,0,0,0]
["jasmonic acid","jasmonic acid","C011006",0,0,0,0,0,0,0,18,0]
["jatrorrhizine","jatrorrhizine","C055785",0,0,0,0,0,4,1,0,0]
["JM 1591","JM 1591","C087531",0,0,0,0,0,1,0,0,0]
["JM 1596","JM 1596","C087530",0,0,0,0,0,1,0,0,0]
["JM 2820","JM 2820","C087529",0,0,0,0,0,1,0,0,0]
["JM 3100","JM 3100","C088327",0,0,0,0,0,1,0,0,0]
["jojoba wax","jojoba wax","C034743",0,0,0,0,0,1,0,0,0]
["JP8 aviation fuel","JP8 aviation fuel","C098607",1,0,0,0,0,0,1,0,0]
["K-85 fish oil preparation","K-85 fish oil preparation","C092589",0,1,0,0,0,1,0,0,0]
["K-877 compound","K-877 compound","C000603947",0,0,0,0,0,1,0,0,0]
["kaempferide","kaempferide","C449720",0,0,0,0,0,0,1,0,0]
["kaempferide 3-O-glucopyranosyl-1-2-O-(rhamnopyranosyl-1-6)glucopyranoside","kaempferide 3-O-glucopyranosyl-1-2-O-(rhamnopyranosyl-1-6)glucopyranoside","C430221",0,0,0,0,0,0,1,0,0]
["kaempferol","kaempferol","C006552",5,0,0,0,2,9,4,0,0]
["Kangxin","Kangxin","C521630",0,0,0,0,0,1,0,0,0]
["kavain","kavain","C011889",0,0,0,0,0,1,0,0,0]
["kefir grain polysaccharide","kefir grain polysaccharide","C050180",0,1,0,0,0,0,0,0,0]
["Ketanserin","Ketanserin","D007650",0,0,0,0,0,4,0,0,0]
["ketoconazole oleate","ketoconazole oleate","C066633",0,0,0,0,0,1,0,0,0]
["Khellin","Khellin","D007666",1,2,0,0,0,3,1,0,0]
["khelloside","khelloside","C047312",0,1,0,0,0,0,0,0,0]
["kifunensine","kifunensine","C065629",0,0,0,0,0,3,0,0,0]
["Kinetin","Kinetin","D007701",1,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3012,B3012)","v":"KL001"},"KL001","C574808",0,0,0,1,0,0,0,0,0]
["kojic acid","kojic acid","C011890",0,0,0,0,0,2,0,0,0]
["KR 30450","KR 30450","C096762",0,0,0,0,0,2,0,0,0]
["KR 31372","KR 31372","C419651",0,0,0,0,0,1,0,0,0]
["KR-31543","KR-31543","C473251",0,0,0,0,0,1,0,0,0]
["KRP-203","KRP-203","C501899",0,0,0,0,0,1,0,0,0]
["kryptopyrrole","kryptopyrrole","C011891",0,0,0,0,0,0,0,3,0]
["Kynurenic Acid","Kynurenic Acid","D007736",7,0,0,0,0,0,1,0,0]
["L 659989","L 659989","C054893",0,0,0,0,0,1,0,0,0]
["Labetalol","Labetalol","D007741",0,1,0,0,0,0,0,0,0]
["lacidipine","lacidipine","C060285",0,0,0,0,0,10,0,0,0]
["lactosamine","lactosamine","C032233",0,0,0,0,0,2,0,0,0]
["laminaran","laminaran","C008247",0,0,0,0,0,2,0,0,0]
["Lanosterol","Lanosterol","D007810",0,0,0,0,0,6,0,0,0]
["Lansoprazole","Lansoprazole","D064747",4,0,0,0,0,0,6,0,0]
["lapatinib","lapatinib","C490728",0,1,0,0,0,0,0,0,0]
["laquinimod","laquinimod","C476223",4,0,0,0,0,0,1,0,0]
["laulimalide","laulimalide","C117305",0,0,0,0,0,0,1,0,0]
["laurdan","laurdan","C065580",0,1,0,0,0,3,0,0,0]
["lauric acid","lauric acid","C030358",0,0,0,0,0,3,1,3,0]
["LCO-Tyr-GalNAc3","LCO-Tyr-GalNAc3","C507464",0,0,0,0,0,1,0,0,0]
["lead acetate","lead acetate","C008261",0,1,0,1,0,1,4,0,0]
["lecanoric acid","lecanoric acid","C008263",1,0,0,0,0,0,0,0,0]
["lecimibide","lecimibide","C084073",0,1,0,0,0,0,0,0,0]
["lercanidipine","lercanidipine","C060343",0,0,0,0,0,3,0,0,0]
["lesquerolic acid","lesquerolic acid","C105775",0,0,0,0,0,0,0,2,0]
["letrozole","letrozole","C067431",0,0,0,0,0,0,1,0,0]
["Leucovorin","Leucovorin","D002955",0,0,0,0,0,1,0,0,0]
["Leukotriene A4","Leukotriene A4","D017572",1,0,0,0,0,0,0,0,0]
["leukotriene B5","leukotriene B5","C040212",0,0,0,0,1,0,0,0,0]
["Leukotriene E4","Leukotriene E4","D017999",0,0,0,0,0,0,0,4,0]
["levan","levan","C072599",0,0,0,0,0,0,1,0,0]
["Levonorgestrel","Levonorgestrel","D016912",0,8,0,0,0,13,0,0,0]
["levuglandin E2","levuglandin E2","C047684",0,0,0,0,0,2,0,0,0]
["lewisite","lewisite","C035965",0,0,0,0,0,0,1,0,0]
["LG 100268","LG 100268","C095104",0,2,0,0,0,0,0,0,0]
["licochalcone A","licochalcone A","C070840",0,0,0,0,0,0,1,0,0]
["lifibrol","lifibrol","C059343",0,0,0,0,0,4,0,0,0]
["Lignin","Lignin","D008031",0,0,0,0,0,0,1,3,0]
["lignocellulose","lignocellulose","C036909",0,0,0,0,0,0,0,1,0]
["lignoceric acid","lignoceric acid","C010210",0,0,0,0,0,1,0,0,0]
["ligustilide","ligustilide","C027820",1,0,0,0,0,0,1,0,0]
["linalool","linalool","C018584",0,0,0,0,0,1,0,0,0]
["Linezolid","Linezolid","D000069349",0,0,0,0,0,1,0,0,0]
["linoleic acid hydroperoxide","linoleic acid hydroperoxide","C008285",0,0,0,0,0,7,0,0,0]
["linsidomine","linsidomine","C002385",0,1,0,0,0,12,0,0,0]
["Linuron","Linuron","D008044",3,0,0,0,0,0,1,0,0]
["Lipid A","Lipid A","D008050",0,0,0,0,0,4,0,0,0]
["lipoarabinomannan","lipoarabinomannan","C050016",0,0,0,0,1,0,0,0,0]
["Lipofundin","Lipofundin","C008288",0,1,0,0,0,0,0,0,0]
["lipopolysaccharide B","lipopolysaccharide B","C036757",0,0,0,0,0,1,0,0,0]
["liposomal amphotericin B","liposomal amphotericin B","C068538",0,0,0,0,0,3,0,0,0]
["lipoteichoic acid","lipoteichoic acid","C009900",0,2,0,0,5,1,0,0,0]
["lipoxin A4","lipoxin A4","C040527",3,0,0,0,0,0,1,0,0]
["liquiritin","liquiritin","C512196",0,0,0,0,0,0,1,0,0]
["lissamine-rhodamine-phosphatidylethanolamine","lissamine-rhodamine-phosphatidylethanolamine","C046703",0,0,0,0,1,0,0,0,0]
["lithospermate B","lithospermate B","C061091",0,0,0,0,0,1,0,0,0]
["locust bean gum","locust bean gum","C017471",0,1,0,0,0,1,0,0,0]
["loganic acid","loganic acid","C002947",0,0,0,0,0,1,0,0,0]
["longxuetongluo","longxuetongluo","C000624399",0,0,0,0,0,1,0,0,0]
["Lopinavir","Lopinavir","D061466",0,1,0,0,1,7,0,0,0]
["lopinavir-ritonavir drug combination","lopinavir-ritonavir drug combination","C558899",0,0,0,0,0,2,0,0,0]
["Loratadine","Loratadine","D017336",0,0,0,0,0,0,1,0,0]
["Lorenzo's oil","Lorenzo's oil","C079420",0,0,0,0,0,0,0,2,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3076,B3076)","v":"LR 16"},"LR 16","C056904",0,0,0,0,0,1,0,0,0]
["LR-90","LR-90","C485003",0,0,0,0,0,1,0,0,0]
["LU 224332","LU 224332","C113044",0,0,0,0,0,1,0,0,0]
["lubazodone hydrochloride","lubazodone hydrochloride","C105748",0,0,0,0,0,0,1,0,0]
["LUF6281","LUF6281","C578191",0,1,0,0,0,0,0,0,0]
["LUF6283","LUF6283","C578192",0,1,0,0,0,0,0,0,0]
["Luminol","Luminol","D008165",0,0,0,0,0,2,0,0,0]
["luotonin A","luotonin A","C480761",0,0,0,0,0,0,1,0,0]
["luteolin-7-glucoside","luteolin-7-glucoside","C066408",0,0,0,0,0,2,0,0,0]
["luteolin-7-glucuronide methyl ester","luteolin-7-glucuronide methyl ester","C467205",0,0,0,0,0,1,0,0,0]
["luteolinidin","luteolinidin","C518537",0,0,0,0,0,1,0,0,0]
["Lutheran Blood-Group System","Lutheran Blood-Group System","D008188",0,1,0,0,0,0,0,0,0]
["LY 117018","LY 117018","C025430",0,0,0,0,0,1,0,0,0]
["LY 295427","LY 295427","C107473",0,0,0,0,0,4,0,0,0]
["LY2584702","LY2584702","C588151",0,0,0,0,0,1,0,0,0]
["Ly-6C antigen, mouse","Ly-6C antigen, mouse","C494192",0,0,0,0,0,2,0,0,0]
["Ly6G antigen, mouse","Ly6G antigen, mouse","C480309",0,0,0,0,0,1,0,0,0]
["lyapolate","lyapolate","C008959",0,0,0,0,0,1,0,0,0]
["Lynestrenol","Lynestrenol","D008234",0,0,0,0,0,1,0,0,0]
["lyoniside","lyoniside","C011015",0,0,0,0,0,1,0,0,0]
["Lysergic Acid","Lysergic Acid","D008237",0,0,0,0,0,1,0,0,0]
["lysophosphatidylserine","lysophosphatidylserine","C025059",0,0,0,0,0,1,0,0,0]
["lysoplasmalogens","lysoplasmalogens","C021215",0,0,0,0,0,1,0,0,0]
["M 50367","M 50367","C119626",4,0,0,0,0,0,0,0,0]
["M&B 1714","M&B 1714","C044720",0,0,0,3,0,0,0,0,0]
["M40401","M40401","C426066",0,0,0,0,0,1,0,0,0]
["M50354","M50354","C506997",4,0,0,0,0,0,0,0,0]
["machilin A","machilin A","C539438",0,0,0,0,0,0,1,0,0]
["machilin D","machilin D","C446120",0,0,0,0,0,2,0,0,0]
["Macular Pigment","Macular Pigment","D065348",0,0,0,0,0,1,0,0,0]
["Magnesium Hydroxide","Magnesium Hydroxide","D008276",0,0,0,0,0,1,0,0,0]
["Magnesium Oxide","Magnesium Oxide","D008277",0,0,0,0,0,3,0,0,0]
["Magnesium Sulfate","Magnesium Sulfate","D008278",0,0,0,0,0,2,0,0,0]
["magnoflorine","magnoflorine","C001670",0,0,0,0,0,1,0,0,0]
["malachite green","malachite green","C005095",0,0,0,0,0,0,1,0,0]
["malassezin","malassezin","C436511",9,0,0,0,0,0,2,0,0]
["malic acid","malic acid","C030298",0,0,0,3,0,0,0,0,0]
["malonic semialdehyde","malonic semialdehyde","C039786",0,0,0,0,0,0,0,2,0]
["maltol","maltol","C008316",1,0,0,0,0,0,2,0,0]
["malvidin","malvidin","C065861",0,0,0,0,0,1,0,0,0]
["manganese mesoporphyrin","manganese mesoporphyrin","C067090",0,0,0,0,0,1,0,0,0]
["manganese sulfate","manganese sulfate","C039798",0,0,0,0,0,1,0,0,0]
["manganese(III) porphyrin","manganese(III) porphyrin","C027155",0,0,0,0,0,1,0,0,0]
["Mangifera indica extract","Mangifera indica extract","C501277",0,0,0,0,0,0,1,0,0]
["manidipine","manidipine","C054218",0,0,0,0,0,2,0,0,0]
["Mannoheptulose","Mannoheptulose","D008356",0,0,0,1,0,0,0,0,0]
["mannose-6-phosphate","mannose-6-phosphate","C027693",0,0,0,0,2,3,0,0,0]
["Manure","Manure","D008372",1,0,0,0,0,0,1,0,0]
["manzamine A","manzamine A","C078290",0,0,0,0,0,1,0,0,0]
["marchantin H","marchantin H","C102015",0,0,0,0,0,1,0,0,0]
["marchantinquinone","marchantinquinone","C097634",0,0,0,0,0,1,0,0,0]
["margaric acid","margaric acid","C013102",0,0,0,0,0,0,0,2,0]
["Martius scarlet blue trichrome","Martius scarlet blue trichrome","C042643",0,0,0,0,0,1,0,0,0]
["Mastic Resin","Mastic Resin","D000069997",0,0,0,0,0,1,0,0,0]
["Materia Medica","Materia Medica","D008419",0,0,0,0,0,2,0,0,0]
["maxacalcitol","maxacalcitol","C051883",0,0,0,0,0,2,0,0,0]
["Maxepa","Maxepa","C045153",0,2,0,0,0,3,0,0,0]
["MDL 29311","MDL 29311","C071022",0,2,0,0,0,0,0,0,0]
["mead acid","mead acid","C010944",0,0,0,0,0,0,0,5,0]
["Mebendazole","Mebendazole","D008463",0,0,0,2,0,0,3,0,0]
["Mecamylamine","Mecamylamine","D008464",0,0,0,0,0,0,2,0,0]
["Medazepam","Medazepam","D008472",0,0,0,0,0,0,1,0,0]
["Medetomidine","Medetomidine","D020926",0,0,0,0,0,0,4,0,0]
["MEDICA 16","MEDICA 16","C056166",0,3,0,0,0,3,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3140,B3140)","v":"Medrogestone"},"Medrogestone","D008524",0,0,0,0,0,2,0,0,0]
["Megestrol","Megestrol","D008535",0,1,0,0,0,1,0,0,0]
["Megestrol Acetate","Megestrol Acetate","D019290",0,1,0,0,0,1,0,0,0]
["melagatran","melagatran","C109573",0,0,0,0,0,1,0,0,0]
["melarsen","melarsen","C008345",0,0,0,3,0,0,0,0,0]
["melarsen oxide","melarsen oxide","C044719",0,0,0,3,0,0,0,0,0]
["menaquinone 9","menaquinone 9","C073355",0,0,0,0,0,1,0,0,0]
["menatetrenone","menatetrenone","C030814",0,0,0,0,0,1,0,0,0]
["Mephenytoin","Mephenytoin","D008617",0,0,0,0,0,0,1,0,0]
["mepindolol","mepindolol","C015340",0,0,0,0,0,1,0,0,0]
["mepitiostane","mepitiostane","C006242",0,1,0,0,0,0,0,0,0]
["Mercuric Chloride","Mercuric Chloride","D008627",0,0,0,0,0,0,1,0,0]
["Mersalyl","Mersalyl","D008634",0,0,0,1,0,0,0,0,0]
["meso-zeaxanthin","meso-zeaxanthin","C584722",0,0,0,0,0,1,1,0,0]
["Mesterolone","Mesterolone","D008655",0,0,0,0,0,2,0,0,0]
["metamitron","metamitron","C047758",0,0,0,0,0,0,1,0,0]
["metanil yellow","metanil yellow","C005108",0,0,0,0,0,0,1,0,0]
["methacrylic acid","methacrylic acid","C008384",0,0,0,0,0,1,0,0,0]
["Methane","Methane","D008697",0,2,0,0,0,1,1,0,0]
["Methapyrilene","Methapyrilene","D008701",0,0,0,0,0,0,1,0,0]
["Methaqualone","Methaqualone","D008702",0,1,0,0,0,0,0,0,0]
["methidathion","methidathion","C005828",0,0,0,0,0,0,1,0,0]
["Methimazole","Methimazole","D008713",2,0,0,0,0,1,0,0,0]
["Methoxsalen","Methoxsalen","D008730",2,0,0,0,0,3,4,0,0]
["Methoxychlor","Methoxychlor","D008731",3,0,0,0,0,0,6,0,0]
["methyl 2-tetradecylglycidate","methyl 2-tetradecylglycidate","C017522",0,0,0,0,0,0,0,4,0]
["methyl arachidonylfluorophosphonate","methyl arachidonylfluorophosphonate","C104810",0,0,0,0,0,1,0,0,0]
["methyl cellosolve","methyl cellosolve","C005219",0,0,0,0,1,0,0,0,0]
["methyl coelenterazine","methyl coelenterazine","C412044",0,0,0,0,0,0,2,0,0]
["methyl ferulate","methyl ferulate","C530806",0,0,0,0,0,1,0,0,0]
["Methyl Methanesulfonate","Methyl Methanesulfonate","D008741",0,0,0,0,0,0,1,0,0]
["methyl sterculate","methyl sterculate","C023396",0,0,0,0,0,0,0,3,0]
["methyl-9-hydroxy-10-mercaptostearate","methyl-9-hydroxy-10-mercaptostearate","C102437",0,0,0,0,0,1,0,0,0]
["methylamine","methylamine","C027451",0,0,0,0,0,5,0,0,0]
["methyl-beta-cyclodextrin","methyl-beta-cyclodextrin","C108732",0,0,0,0,4,3,0,0,0]
["Methyldimethylaminoazobenzene","Methyldimethylaminoazobenzene","D008749",1,0,0,2,0,0,1,0,0]
["Methylenebis(chloroaniline)","Methylenebis(chloroaniline)","D008753",0,0,0,0,0,0,2,0,0]
["Methylmalonic Acid","Methylmalonic Acid","D008764",0,0,0,0,0,0,0,2,0]
["methylmercuric chloride","methylmercuric chloride","C004925",0,0,0,0,0,0,1,0,0]
["methylprednisolone acetate","methylprednisolone acetate","C000873",0,0,0,0,0,1,0,0,0]
["Methylprednisolone Hemisuccinate","Methylprednisolone Hemisuccinate","D008776",0,0,0,0,0,1,0,0,0]
["methysticin","methysticin","C076881",3,0,0,0,0,1,1,0,0]
["Metipranolol","Metipranolol","D014290",0,0,0,0,0,1,0,0,0]
["metolachlor","metolachlor","C051786",0,0,0,0,0,0,2,0,0]
["Metoprolol","Metoprolol","D008790",1,3,0,0,0,6,1,0,0]
["metribuzin","metribuzin","C009235",0,0,0,0,0,0,1,0,0]
["mevalonolactone","mevalonolactone","C015367",0,1,0,0,0,1,0,0,0]
["mevastatin","mevastatin","C012258",0,7,0,0,1,47,0,1,0]
["Mexiletine","Mexiletine","D008801",0,0,0,0,0,0,2,0,0]
["mezerein","mezerein","C011309",0,0,0,0,0,3,0,0,0]
["MF 152","MF 152","C544974",0,0,0,0,0,0,0,2,0]
["MF 438","MF 438","C548713",0,0,0,0,0,0,0,2,0]
["Mibefradil","Mibefradil","D020748",0,0,0,0,0,1,0,0,0]
["Miconazole","Miconazole","D008825",0,1,0,0,0,1,1,0,0]
["midostaurin","midostaurin","C059539",0,0,0,0,0,1,0,0,0]
["miglustat","miglustat","C059896",0,0,0,0,0,2,0,0,0]
["miltirone","miltirone","C068880",0,0,0,0,0,1,0,0,0]
["Minocycline","Minocycline","D008911",0,0,0,0,0,1,0,0,0]
["Miocamycin","Miocamycin","D015644",0,0,0,0,0,0,1,0,0]
["mirodenafil","mirodenafil","C528396",0,0,0,0,0,0,1,0,0]
["miroestrol","miroestrol","C571572",0,0,0,0,0,0,1,0,0]
["mitiglinide","mitiglinide","C087255",0,0,0,0,0,1,0,0,0]
["Mitomycin","Mitomycin","D016685",0,0,0,0,0,1,1,2,0]
["mitopodozide","mitopodozide","C003170",0,0,0,0,0,2,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3204,B3204)","v":"Mitotane"},"Mitotane","D008939",0,2,0,0,0,2,0,0,0]
["MK-0524","MK-0524","C518174",0,0,0,0,0,2,0,0,0]
["Molsidomine","Molsidomine","D008981",0,2,0,0,0,13,0,0,0]
["monastrol","monastrol","C400223",0,0,0,0,0,0,1,0,0]
["monatepil","monatepil","C067818",0,0,0,0,0,4,0,0,0]
["Monensin","Monensin","D008985",0,3,0,0,0,10,0,1,0]
["mono-(2-ethylhexyl)phthalate","mono-(2-ethylhexyl)phthalate","C016599",4,0,0,1,0,0,1,0,0]
["monocyte-macrophage differentiation antigen","monocyte-macrophage differentiation antigen","C036763",0,0,0,0,1,0,0,0,0]
["monogalactosyldiacylglycerol","monogalactosyldiacylglycerol","C009909",0,0,0,0,0,0,0,4,0]
["monomethoxypolyethyleneglycol-polylactide block copolymer","monomethoxypolyethyleneglycol-polylactide block copolymer","C542623",0,0,0,0,0,1,0,0,0]
["monomethylarsonous acid","monomethylarsonous acid","C406082",1,0,0,0,0,0,1,0,0]
["monoolein","monoolein","C005953",0,2,0,0,1,0,0,2,0]
["monorden","monorden","C035359",1,0,0,0,0,0,0,0,0]
["montelukast","montelukast","C093875",0,0,0,0,0,2,0,0,0]
["morelloflavone","morelloflavone","C105620",0,0,0,0,0,2,0,0,0]
["Moricizine","Moricizine","D016293",0,0,0,0,0,1,0,0,0]
["moxifloxacin","moxifloxacin","C104727",0,0,0,0,0,0,1,0,0]
["moxonidine","moxonidine","C043482",0,0,0,0,0,1,0,0,0]
["muconaldehyde","muconaldehyde","C034476",0,0,0,0,0,0,1,0,0]
["musk","musk","C008563",0,0,0,0,0,0,2,0,0]
["musk ketone","musk ketone","C031448",0,0,0,0,0,0,2,0,0]
["musk xylene","musk xylene","C031447",0,0,0,0,0,0,5,0,0]
["Muzolimine","Muzolimine","D009156",0,0,0,0,0,1,0,0,0]
["Mycophenolic Acid","Mycophenolic Acid","D009173",0,0,0,0,0,2,0,0,0]
["myoseverin","myoseverin","C407365",0,0,0,0,0,1,0,0,0]
["myricitrin","myricitrin","C008577",0,0,0,0,0,2,0,0,0]
["myrigalone B","myrigalone B","C100377",0,0,0,0,0,3,0,0,0]
["myristicin","myristicin","C005246",1,0,0,0,0,0,1,0,0]
["N-((tris-O-(galactopyranosyl)methyl)methyl)-N(alpha)-(4-(5-cholesten-3-yloxy)succinyl)glycinamide","N-((tris-O-(galactopyranosyl)methyl)methyl)-N(alpha)-(4-(5-cholesten-3-yloxy)succinyl)glycinamide","C094119",0,0,0,0,0,1,0,0,0]
["N(1)-methylnicotinamide","N(1)-methylnicotinamide","C024058",0,0,0,0,0,2,0,0,0]
["N'-(10H-indolo(3,2-b)quinolin-11-yl)-N,N-dimethylpropane-1,3-diamine","N'-(10H-indolo(3,2-b)quinolin-11-yl)-N,N-dimethylpropane-1,3-diamine","C521094",0,0,0,0,0,0,1,0,0]
["N-(11-(1-pyrene)sulfonylaminoundecanoyl)sphingomyelin","N-(11-(1-pyrene)sulfonylaminoundecanoyl)sphingomyelin","C068391",0,0,0,0,0,1,0,0,0]
["N-(12-((1-pyrenesulfonyl)amido)dodecanoyl)sphingosylphosphorylcholine","N-(12-((1-pyrenesulfonyl)amido)dodecanoyl)sphingosylphosphorylcholine","C057744",0,0,0,0,0,1,0,0,0]
["N-(2-(3H-indol-3-yl)ethyl)-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine","N-(2-(3H-indol-3-yl)ethyl)-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine","C560625",3,0,0,0,0,0,0,0,0]
["N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide","N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide","C063509",0,0,0,0,0,2,0,0,0]
["N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-3,5-di-tert-butyl-4-hydroxybenzamide","N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-3,5-di-tert-butyl-4-hydroxybenzamide","C470989",0,0,0,0,0,3,0,0,0]
["N-(2-guanidinoethyl)-5-isoquinolinesulfonamide","N-(2-guanidinoethyl)-5-isoquinolinesulfonamide","C043204",0,0,0,0,0,1,0,0,0]
["N-(2-heptyl)-propargylamine","N-(2-heptyl)-propargylamine","C435297",0,0,0,0,0,0,1,0,0]
["N-(3-(1-pyrene)propenoyl)sphingomyelin","N-(3-(1-pyrene)propenoyl)sphingomyelin","C068461",0,0,0,0,0,1,0,0,0]
["N-(3-(oleoyloxy)androst-5-en-17-yl(pentyloxycarbonyl))-N-N-bis(2-chloroethyl)amine","N-(3-(oleoyloxy)androst-5-en-17-yl(pentyloxycarbonyl))-N-N-bis(2-chloroethyl)amine","C053328",0,0,0,0,0,3,0,0,0]
["N-(3-phenoxycinnamyl)acetohydroxamic acid","N-(3-phenoxycinnamyl)acetohydroxamic acid","C056614",0,0,0,0,0,1,0,0,0]
["N-(4-(3-((4-fluorophenyl)hydroxymethyl)-4-hydroxyphenoxy)-3,5-dimethylphenyl) malonamic acid sodium","N-(4-(3-((4-fluorophenyl)hydroxymethyl)-4-hydroxyphenoxy)-3,5-dimethylphenyl) malonamic acid sodium","C496199",0,0,0,0,1,0,0,0,0]
["N-(4-(4-tert-butoxycarbonylpiperazin-1-yl)phenyl)-(2-chloro-5-nitrophenyl)carboxamide","N-(4-(4-tert-butoxycarbonylpiperazin-1-yl)phenyl)-(2-chloro-5-nitrophenyl)carboxamide","C521768",0,0,0,0,2,0,0,0,0]
["N(4)-acetylsulfamethoxazole","N(4)-acetylsulfamethoxazole","C021282",0,1,0,0,0,0,0,0,0]
["N-(4,6-dimethyl-1-pentylindolin-7-yl)-2,2-dimethylpropanamide","N-(4,6-dimethyl-1-pentylindolin-7-yl)-2,2-dimethylpropanamide","C483406",0,0,0,0,0,2,0,0,0]
["N-(4-methoxyphenyl)retinamide","N-(4-methoxyphenyl)retinamide","C058346",0,0,0,0,0,0,0,1,0]
["N-(4-methyl-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)phenyl)-N'-phenylurea","N-(4-methyl-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)phenyl)-N'-phenylurea","C534914",0,0,0,0,0,1,0,0,0]
["N-(5-(5,7-dimethyl Bodipy)-1-pentanoyl)-erythro-sphingosylphosphorylcholine","N-(5-(5,7-dimethyl Bodipy)-1-pentanoyl)-erythro-sphingosylphosphorylcholine","C105705",0,0,0,0,0,1,0,0,0]
["N-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin","N-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin","C496281",0,0,0,0,0,1,0,0,0]
["N-(6-(4-fluorobenzylidene)aminooxyhexyl)maleimide","N-(6-(4-fluorobenzylidene)aminooxyhexyl)maleimide","C518594",0,0,0,0,0,1,0,0,0]
["N-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine","N-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine","C037974",0,0,0,0,0,4,0,0,0]
["N-(7-nitrobenz-2-oxa-1,3-diazole)-23,24-dinor-5-cholen-22-amine-3beta-ol","N-(7-nitrobenz-2-oxa-1,3-diazole)-23,24-dinor-5-cholen-22-amine-3beta-ol","C031654",0,0,0,0,0,1,0,0,0]
["N(8)-bromoacetyl-N(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane","N(8)-bromoacetyl-N(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane","C057316",0,0,0,0,0,1,0,0,0]
["N-(alpha-methylbenzyl)azelaamic acid","N-(alpha-methylbenzyl)azelaamic acid","C050451",0,0,0,0,0,0,0,2,0]
["N-(hexanoyl)ethanolamine","N-(hexanoyl)ethanolamine","C499478",0,0,0,0,0,1,0,0,0]
["N-(N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-epsilon-aminohexanoyl)sphingosylphosphorylcholine","N-(N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-epsilon-aminohexanoyl)sphingosylphosphorylcholine","C081708",0,0,0,0,0,2,0,0,0]
["N-(p-coumaroyl)serotonin","N-(p-coumaroyl)serotonin","C114774",0,0,0,0,0,2,0,0,0]
["N-(tris((beta-galactopyranosyloxy)methyl)methyl)-N(alpha)-(4-(5-cholesten-3 beta-yloxy)succinyl)glycinamide","N-(tris((beta-galactopyranosyloxy)methyl)methyl)-N(alpha)-(4-(5-cholesten-3 beta-yloxy)succinyl)glycinamide","C042924",0,0,0,0,0,7,0,0,0]
["N,N,N-(3-carbazolylpropyl)-(p-methoxyphenylethyl)methylamine","N,N,N-(3-carbazolylpropyl)-(p-methoxyphenylethyl)methylamine","C493192",0,0,0,0,0,1,0,0,0]
["N,N'-bis(2-hydroxyperoxy-2-methoxyethyl)-1,4,5,8-naphthalenetetracarboxylic diimide","N,N'-bis(2-hydroxyperoxy-2-methoxyethyl)-1,4,5,8-naphthalenetetracarboxylic diimide","C067580",0,0,0,0,0,1,0,0,0]
["N,N-dimethylaniline","N,N-dimethylaniline","C015157",0,0,0,1,0,0,0,0,0]
["N,N-dimethylsphingosine","N,N-dimethylsphingosine","C061800",0,0,0,0,0,1,0,0,0]
["N-1-(hydroxy(3-oxo-2-phenyl-1-cyclopropen-1-yl)methyl)-2-methylpropyl-2-benzenesulfonylamino-4-methylpentanamide","N-1-(hydroxy(3-oxo-2-phenyl-1-cyclopropen-1-yl)methyl)-2-methylpropyl-2-benzenesulfonylamino-4-methylpentanamide","C572617",0,0,0,0,0,1,0,0,0]
["N-acetyldopamine","N-acetyldopamine","C006374",0,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3268,B3268)","v":"N-acetylsphingosine"},"N-acetylsphingosine","C064769",1,0,0,0,0,0,0,0,0]
["Nadroparin","Nadroparin","D017762",0,0,0,0,0,1,0,0,0]
["nafamostat","nafamostat","C032855",0,0,0,0,0,2,0,0,0]
["nafazatrom","nafazatrom","C018845",0,0,0,0,0,1,0,0,0]
["Nafenopin","Nafenopin","D009255",0,0,0,0,0,1,0,0,0]
["Nafoxidine","Nafoxidine","D009256",0,1,0,0,0,0,0,0,0]
["Naka isoantigen, human","Naka isoantigen, human","C062601",0,0,0,0,4,0,0,0,0]
["naloxonazine","naloxonazine","C034643",0,0,0,1,0,0,0,0,0]
["NanoGel","NanoGel","C413692",0,0,0,0,0,2,0,0,0]
["naoxintong","naoxintong","C571443",0,0,0,0,0,1,0,0,0]
["naphthalene","naphthalene","C031721",2,0,0,0,0,0,11,0,0]
["naphthenic acid","naphthenic acid","C046170",1,0,0,0,0,0,3,0,0]
["narciclasine","narciclasine","C010753",0,0,0,0,0,0,1,0,0]
["Natamycin","Natamycin","D010866",0,0,0,0,0,0,1,0,0]
["NB 598","NB 598","C066059",0,0,0,0,0,1,0,0,0]
["N-benzyl-1-aminobenzotriazole","N-benzyl-1-aminobenzotriazole","C067013",0,0,0,0,0,0,5,0,0]
["NBI-74330","NBI-74330","C501976",0,0,0,0,0,1,0,0,0]
["n-butyl-3-(18-(2-butylcarbamoyl-ethyl)-3,7,12,17-tetramethyl-18,13-divinyl-22,24-dihydro-porphin-2-yl)propionamide","n-butyl-3-(18-(2-butylcarbamoyl-ethyl)-3,7,12,17-tetramethyl-18,13-divinyl-22,24-dihydro-porphin-2-yl)propionamide","C466065",0,0,0,0,0,3,0,0,0]
["n-butylamine","n-butylamine","C032462",0,0,0,0,0,0,0,2,0]
["N-caproylsphingosine","N-caproylsphingosine","C101954",0,0,0,0,0,2,0,0,0]
["N''-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N'-benzylguanidine","N''-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N'-benzylguanidine","C438686",0,0,0,0,0,0,1,0,0]
["N-dehydroxyethylmirodenafil","N-dehydroxyethylmirodenafil","C528397",0,0,0,0,0,0,1,0,0]
["Nebivolol","Nebivolol","D000068577",0,0,0,0,0,3,0,0,0]
["nefazodone","nefazodone","C051752",0,0,0,0,0,0,1,0,0]
["neferine","neferine","C057222",0,0,0,0,0,1,0,0,0]
["neocuproine","neocuproine","C002701",0,0,0,0,0,1,0,0,0]
["neoglucobrassicin","neoglucobrassicin","C555404",2,0,0,0,0,0,1,0,0]
["neoquassin","neoquassin","C539436",0,0,0,0,0,0,1,0,0]
["nervonic acid","nervonic acid","C013147",0,0,0,0,0,0,0,3,0]
["N-ethyl-5-phenylisoxazolium-3'-sulfonate","N-ethyl-5-phenylisoxazolium-3'-sulfonate","C009686",0,0,0,1,0,0,0,0,0]
["netoglitazone","netoglitazone","C115174",0,0,0,0,1,0,0,0,0]
["neutral lipid, phosphatidylcholine, phosphatidylethanolamine drug combination","neutral lipid, phosphatidylcholine, phosphatidylethanolamine drug combination","C046637",0,0,0,0,0,1,0,0,0]
["Nevirapine","Nevirapine","D019829",0,0,0,0,0,1,0,0,0]
["N-feruloylserotonin","N-feruloylserotonin","C512561",0,0,0,0,0,2,0,0,0]
["n-heptane","n-heptane","C028618",0,1,0,0,0,2,0,0,0]
["n-hexanal","n-hexanal","C010463",0,0,0,0,0,3,0,0,0]
["n-hexane","n-hexane","C026385",0,0,0,0,0,0,1,0,0]
["Nicardipine","Nicardipine","D009529",0,0,0,0,0,2,1,5,0]
["Niceritrol","Niceritrol","D009531",0,7,0,0,0,5,0,0,0]
["Nicotinyl Alcohol","Nicotinyl Alcohol","D009540",0,2,0,0,0,3,0,0,0]
["nilvadipine","nilvadipine","C035100",0,0,0,0,0,2,0,0,0]
["N-isobutyl-5-(3,4-methylenedioxyphenyl)-2,4-pentadienamine","N-isobutyl-5-(3,4-methylenedioxyphenyl)-2,4-pentadienamine","C576583",0,0,0,0,0,1,0,0,0]
["nitecapone","nitecapone","C057364",0,0,0,0,0,1,0,0,0]
["Nitrilotriacetic Acid","Nitrilotriacetic Acid","D009571",0,0,0,0,0,0,1,0,0]
["Nitroblue Tetrazolium","Nitroblue Tetrazolium","D009580",0,1,0,0,0,2,0,0,0]
["Nitrogen Dioxide","Nitrogen Dioxide","D009585",0,0,0,0,1,6,0,0,0]
["Nitroglycerin","Nitroglycerin","D005996",0,0,0,0,0,4,0,0,0]
["Nitroprusside","Nitroprusside","D009599",0,0,0,0,0,5,0,0,0]
["nitrosobenzylmethylamine","nitrosobenzylmethylamine","C014707",0,0,0,0,0,0,1,0,0]
["Nitrous Oxide","Nitrous Oxide","D009609",0,0,0,0,0,1,0,0,0]
["N-methoxy-6-(5-(4-(N-methoxyamidino)phenyl)furan-2-yl)nicotinamidine","N-methoxy-6-(5-(4-(N-methoxyamidino)phenyl)furan-2-yl)nicotinamidine","C504230",0,0,0,0,0,0,1,0,0]
["N-methoxyindole-3-carbinol","N-methoxyindole-3-carbinol","C410766",0,0,0,0,0,0,1,0,0]
["N-Methyl-3,4-methylenedioxyamphetamine","N-Methyl-3,4-methylenedioxyamphetamine","D018817",0,0,0,0,0,0,1,2,0]
["N-methyl-7H-dibenzo(c,g)carbazole","N-methyl-7H-dibenzo(c,g)carbazole","C041150",0,0,0,0,0,0,2,0,0]
["N-nitrosopiperidine","N-nitrosopiperidine","C002743",0,0,0,0,0,0,3,0,0]
["N-nitroso-tris-chloroethylurea","N-nitroso-tris-chloroethylurea","C572573",0,0,0,0,0,0,1,0,0]
["Nocodazole","Nocodazole","D015739",1,1,0,0,0,0,1,0,0]
["N-octanoylsphinganine","N-octanoylsphinganine","C108139",0,0,0,0,0,0,0,2,0]
["noduliprevenone","noduliprevenone","C535033",0,0,0,0,0,0,2,0,0]
["N-oleyl-daunorubicin","N-oleyl-daunorubicin","C000599289",0,0,0,0,0,1,0,0,0]
["Nonidet P-40","Nonidet P-40","C010615",0,0,0,0,0,1,0,0,0]
["Nonoxynol","Nonoxynol","D017137",0,0,0,0,0,0,1,0,0]
["norbuprenorphine","norbuprenorphine","C043585",1,0,0,0,0,0,0,0,0]
["Nordazepam","Nordazepam","D003708",0,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3332,B3332)","v":"Norethindrone"},"Norethindrone","D009640",0,15,0,0,0,24,1,0,0]
["norethindrone acetate","norethindrone acetate","C024262",0,3,0,0,0,4,0,0,0]
["norethindrone enanthate","norethindrone enanthate","C024319",0,1,0,0,0,3,0,0,0]
["Norfloxacin","Norfloxacin","D009643",0,0,0,0,0,0,3,0,0]
["norflurazone","norflurazone","C008677",0,0,0,0,0,0,0,6,0]
["norgestimate","norgestimate","C017576",0,0,0,0,0,1,0,0,0]
["Norgestrel","Norgestrel","D009644",0,16,0,0,0,19,0,0,0]
["norharman","norharman","C010262",0,0,0,0,0,0,1,0,0]
["norisoboldine","norisoboldine","C464745",2,0,0,0,0,0,1,0,0]
["notoginsenoside R1","notoginsenoside R1","C072936",0,0,0,0,0,1,0,0,0]
["Novobiocin","Novobiocin","D009675",0,0,0,0,0,0,2,0,0]
["N-palmitoylsphingosine","N-palmitoylsphingosine","C097760",0,1,0,0,0,0,0,0,0]
["NSC 674495","NSC 674495","C122062",3,0,0,0,0,0,5,0,0]
["N-stearoylethanolamine","N-stearoylethanolamine","C408368",0,1,0,0,0,1,0,2,0]
["N-succinimidyl-4-fluorobenzoate","N-succinimidyl-4-fluorobenzoate","C075713",0,0,0,0,0,1,0,0,0]
["N-succinyl-chitosan","N-succinyl-chitosan","C118639",0,0,0,0,0,2,0,0,0]
["N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine","N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine","C089665",0,0,0,0,0,1,0,0,0]
["N-terbutyl-N'-(2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl)urea","N-terbutyl-N'-(2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl)urea","C475768",0,0,0,0,0,2,0,0,0]
["nutrient mixture F-10 Ham","nutrient mixture F-10 Ham","C083923",0,0,0,0,0,1,0,0,0]
["N-vinyl-2-pyrrolidinone","N-vinyl-2-pyrrolidinone","C042670",0,0,0,0,0,1,0,0,0]
["Nylidrin","Nylidrin","D009756",0,0,0,0,0,1,0,0,0]
["O-(11-(5-cholesten-3-yloxy)3,6,9-trioxaundecyl) O-(2-(galactopyranosyloxy)ethyl) phosphorothioate","O-(11-(5-cholesten-3-yloxy)3,6,9-trioxaundecyl) O-(2-(galactopyranosyloxy)ethyl) phosphorothioate","C077516",0,0,0,0,0,1,0,0,0]
["O-(4-diazo-3-iodobenzoyl)sucrose","O-(4-diazo-3-iodobenzoyl)sucrose","C044133",0,0,0,0,0,1,0,0,0]
["O-(6)-methylguanine","O-(6)-methylguanine","C008449",1,0,0,0,0,0,1,0,0]
["O,O,S-trimethyl phosphorothioate","O,O,S-trimethyl phosphorothioate","C019123",0,0,0,0,0,0,1,0,0]
["O,O,S-trimethylphosphorodithionate","O,O,S-trimethylphosphorodithionate","C065349",0,0,0,0,0,0,1,0,0]
["O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate","O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate","C009618",0,0,0,0,0,1,0,0,0]
["o,p'-DDT","o,p'-DDT","C016340",3,0,0,0,0,0,1,0,0]
["O,S,S-trimethyl phosphorodithioate","O,S,S-trimethyl phosphorodithioate","C033125",0,0,0,0,0,0,1,0,0]
["o-Aminoazotoluene","o-Aminoazotoluene","D009762",0,0,0,0,0,0,5,0,0]
["ochratoxin A","ochratoxin A","C025589",2,0,0,7,0,0,0,0,0]
["octa-2,4,6-trienoic acid","octa-2,4,6-trienoic acid","C062198",0,0,0,0,0,0,0,2,0]
["octachlorostyrene","octachlorostyrene","C014138",1,0,0,0,0,0,3,0,0]
["octadecadienoic acid","octadecadienoic acid","C027369",0,0,0,0,0,1,0,2,0]
["octamethylcyclotetrasiloxane","octamethylcyclotetrasiloxane","C024064",0,0,0,0,0,0,2,0,0]
["octanoylcarnitine","octanoylcarnitine","C008698",0,0,0,0,0,0,0,6,0]
["octimibate","octimibate","C054659",0,0,0,0,0,2,0,0,0]
["Octoxynol","Octoxynol","D017830",0,0,0,0,0,0,1,0,0]
["O-deacetyl platelet activating factor","O-deacetyl platelet activating factor","C029271",0,0,0,1,0,5,0,0,0]
["Okadaic Acid","Okadaic Acid","D019319",1,0,0,4,0,0,1,0,0]
["oleocanthal","oleocanthal","C503534",0,0,0,0,0,1,0,0,0]
["oligo(2-(2-ethoxy)-ethoxyethyl)guanidinium-chloride","oligo(2-(2-ethoxy)-ethoxyethyl)guanidinium-chloride","C584298",0,0,0,0,0,1,0,0,0]
["Oligopin","Oligopin","C587735",0,0,0,0,0,1,0,0,0]
["Olmesartan Medoxomil","Olmesartan Medoxomil","D000068557",0,0,0,0,0,3,0,0,0]
["omapatrilat","omapatrilat","C106266",0,0,0,0,0,1,0,0,0]
["omega-(4-iodophenyl)pentadecanoic acid","omega-(4-iodophenyl)pentadecanoic acid","C025391",0,0,0,0,1,0,0,0,0]
["Omeprazole","Omeprazole","D009853",40,0,0,0,1,1,29,0,0]
["omeprazole sulfide","omeprazole sulfide","C040449",1,0,0,0,0,0,0,0,0]
["OPC 33509","OPC 33509","C116725",0,0,0,0,1,0,0,0,0]
["o-Phthalaldehyde","o-Phthalaldehyde","D009764",3,0,0,3,0,0,1,0,0]
["oracine","oracine","C103439",0,0,0,0,0,0,1,0,0]
["Org 13061","Org 13061","C109126",0,0,0,0,0,1,0,0,0]
["osajin","osajin","C485800",0,0,0,0,0,0,1,0,0]
["osteum","osteum","C013173",0,1,0,0,0,3,0,0,0]
["Ouabain","Ouabain","D010042",0,0,0,0,2,0,0,0,0]
["oval cell marker OV-6","oval cell marker OV-6","C115011",0,0,0,0,0,1,0,0,0]
["oxalyl phosphate","oxalyl phosphate","C064555",0,0,0,1,0,0,0,0,0]
["Oxandrolone","Oxandrolone","D010074",0,6,0,0,0,3,0,0,0]
["oxatomide","oxatomide","C015408",0,0,0,0,0,0,1,0,0]
["Oxazepam","Oxazepam","D010076",0,0,0,0,0,0,1,0,0]
["oxcarbazepine","oxcarbazepine","C036006",0,0,0,0,0,0,1,0,0]
["oxfendazole","oxfendazole","C011030",1,0,0,0,0,0,0,0,0]
["oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine","oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine","C472349",0,0,0,0,0,7,0,0,0]
["oxomonastrol","oxomonastrol","C000616961",0,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3396,B3396)","v":"Oxprenolol"},"Oxprenolol","D010096",0,1,0,0,0,2,0,0,0]
["oxybenzone","oxybenzone","C005290",1,0,0,0,0,0,0,0,0]
["Oxymetholone","Oxymetholone","D010110",0,1,0,0,0,0,0,0,0]
["Oxyquinoline","Oxyquinoline","D015125",0,0,0,0,0,1,0,0,0]
["Ozone","Ozone","D010126",4,1,0,0,1,5,3,3,0]
["PAcein","PAcein","C002313",0,0,0,0,0,1,0,0,0]
["Paclitaxel","Paclitaxel","D017239",0,0,0,0,0,14,4,4,0]
["Pactamycin","Pactamycin","D010142",0,0,0,1,0,0,0,0,0]
["pactimibe","pactimibe","C509302",0,0,0,0,0,1,0,0,0]
["palmatine","palmatine","C005413",1,0,0,0,0,2,2,0,0]
["palmidrol","palmidrol","C005958",0,0,0,0,0,1,0,0,0]
["palmiwon","palmiwon","C000606987",0,0,0,0,0,1,0,0,0]
["PAMAM Starburst","PAMAM Starburst","C104700",0,0,0,0,0,1,0,0,0]
["p-Aminoazobenzene","p-Aminoazobenzene","D010128",0,0,0,0,0,0,1,0,0]
["p-Aminohippuric Acid","p-Aminohippuric Acid","D010130",3,0,0,1,0,0,2,0,0]
["Panax quinquefolium saponin","Panax quinquefolium saponin","C079995",0,0,0,0,0,4,0,0,0]
["Paraffin","Paraffin","D010232",0,0,0,0,0,0,1,0,0]
["parbendazole","parbendazole","C100292",0,1,0,0,0,0,0,0,0]
["Pargyline","Pargyline","D010293",0,0,0,0,0,0,1,0,0]
["parinaric acid","parinaric acid","C013641",0,0,0,0,0,1,0,0,0]
["Patulin","Patulin","D010365",1,0,0,0,0,0,0,0,0]
["PCB 180","PCB 180","C410127",1,0,0,0,0,0,2,0,0]
["PD 128042","PD 128042","C069304",0,0,0,0,0,1,0,0,0]
["Peanut Oil","Peanut Oil","D000074241",0,1,0,0,0,1,0,2,0]
["pectenotoxin 2","pectenotoxin 2","C098380",1,0,0,0,0,0,0,0,0]
["pectin","pectin","C030121",0,4,0,0,0,7,0,0,0]
["PEG-PAMAM","PEG-PAMAM","C522249",0,0,0,0,0,1,0,0,0]
["pelargonic acid","pelargonic acid","C008776",3,0,0,0,0,0,0,0,0]
["pelargonidin","pelargonidin","C066957",4,0,0,0,0,1,2,0,0]
["pendimethalin","pendimethalin","C030856",0,0,0,0,0,0,1,0,0]
["pentachlorobenzene","pentachlorobenzene","C003060",0,0,0,0,0,0,1,0,0]
["Pentachlorophenol","Pentachlorophenol","D010416",2,0,0,0,0,0,9,0,0]
["pentanal","pentanal","C046012",0,0,0,0,0,1,0,0,0]
["pentoxyresorufin","pentoxyresorufin","C044943",0,0,0,0,0,0,2,0,0]
["Perazine","Perazine","D010464",0,0,0,0,0,0,1,0,0]
["perfluorodecanoic acid","perfluorodecanoic acid","C036567",0,0,0,0,0,0,1,4,0]
["perfluorosuccinic acid","perfluorosuccinic acid","C060763",0,0,0,3,0,0,0,0,0]
["perfluorotributylamine","perfluorotributylamine","C008807",0,1,0,0,0,1,0,0,0]
["Perhexiline","Perhexiline","D010480",0,0,0,0,0,1,0,0,0]
["perhexiline maleate","perhexiline maleate","C023470",0,0,0,0,0,1,0,0,0]
["perhydroxyl radical","perhydroxyl radical","C049375",0,1,0,0,0,14,0,0,0]
["perillaldehyde","perillaldehyde","C033342",0,0,0,0,0,1,0,0,0]
["perillyl alcohol","perillyl alcohol","C032208",0,0,0,0,0,2,2,0,0]
["Permethrin","Permethrin","D026023",0,0,0,0,0,0,0,1,0]
["peroxovanadate","peroxovanadate","C069276",0,0,0,1,0,0,0,0,0]
["peroxynitric acid","peroxynitric acid","C039642",0,3,0,0,1,31,0,0,0]
["Perylene","Perylene","D010569",5,0,0,0,1,10,1,2,0]
["petunidin-3-glucoside","petunidin-3-glucoside","C455107",0,0,0,0,0,1,0,0,0]
["PF-06424439","PF-06424439","C000603793",0,0,0,0,0,1,0,0,0]
["PF-429242","PF-429242","C570314",0,0,0,0,0,1,0,0,0]
["Phenacetin","Phenacetin","D010615",0,0,0,0,0,0,4,0,0]
["phenanthrene","phenanthrene","C031181",4,0,0,0,0,0,15,0,0]
["phenarsazine chloride","phenarsazine chloride","C010283",0,0,0,0,0,0,1,0,0]
["Phencyclidine","Phencyclidine","D010622",0,0,0,0,0,0,2,0,0]
["Phenelzine","Phenelzine","D010624",0,0,0,3,0,0,0,0,0]
["phenethyl isothiocyanate","phenethyl isothiocyanate","C058305",1,0,0,0,0,0,6,0,0]
["Phenindione","Phenindione","D010630",0,0,0,0,0,1,0,0,0]
["phenolic acid","phenolic acid","C017616",1,0,0,0,0,8,0,0,0]
["phenoxazinone","phenoxazinone","C020456",0,0,0,0,0,0,1,0,0]
["phenoxy radical","phenoxy radical","C042329",0,0,0,0,0,2,0,0,0]
["Phentermine","Phentermine","D010645",0,0,0,0,0,2,1,0,0]
["phentin acetate","phentin acetate","C011978",0,0,0,0,0,0,2,0,0]
["phenyl 2-acetamido-2-deoxy-4-O-sulfonatogalactopyranoside","phenyl 2-acetamido-2-deoxy-4-O-sulfonatogalactopyranoside","C504597",0,0,0,0,0,1,0,0,0]
["phenylacetylene","phenylacetylene","C044736",0,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3460,B3460)","v":"Phenylephrine"},"Phenylephrine","D010656",0,0,0,1,0,1,0,3,0]
["Phenylglyoxal","Phenylglyoxal","D010658",0,0,0,3,0,0,0,0,0]
["phenylisothiocyanate","phenylisothiocyanate","C005441",0,0,0,0,0,0,2,0,0]
["Phenylmercuric Acetate","Phenylmercuric Acetate","D010662",0,0,0,0,0,0,0,2,0]
["phenylmethylpyrazolone","phenylmethylpyrazolone","C005435",0,0,0,0,0,3,0,0,0]
["Phenylmethylsulfonyl Fluoride","Phenylmethylsulfonyl Fluoride","D010664",0,0,0,1,0,0,0,0,0]
["Phenylthiourea","Phenylthiourea","D010670",1,0,0,0,0,0,1,3,0]
["pheophorbide a","pheophorbide a","C032623",0,0,0,0,0,1,0,0,0]
["Phloroglucinol","Phloroglucinol","D010696",0,0,0,0,0,5,0,0,0]
["Phorbol 12,13-Dibutyrate","Phorbol 12,13-Dibutyrate","D015240",0,0,0,0,1,2,0,0,0]
["phorbolol myristate acetate","phorbolol myristate acetate","C016658",0,0,0,0,0,1,0,0,0]
["Phortress","Phortress","C492651",0,0,0,0,0,0,3,0,0]
["phosphatidylethanol","phosphatidylethanol","C051521",0,0,0,0,0,1,0,1,0]
["phosphatidylinositol 3,4,5-triphosphate","phosphatidylinositol 3,4,5-triphosphate","C060974",0,1,0,0,0,0,0,0,0]
["Phosphatidylinositol 4,5-Diphosphate","Phosphatidylinositol 4,5-Diphosphate","D019269",0,0,0,0,0,3,0,0,0]
["phosphocitrate","phosphocitrate","C014148",0,0,0,0,0,1,0,0,0]
["phosphoenol-2-ketobutyrate","phosphoenol-2-ketobutyrate","C015443",0,0,0,7,0,0,0,0,0]
["phosphoenol-3-bromopyruvate","phosphoenol-3-bromopyruvate","C036817",0,0,0,1,0,0,0,0,0]
["phosphoenol-3-fluoropyruvate","phosphoenol-3-fluoropyruvate","C041143",0,0,0,2,0,0,0,0,0]
["Phosphoenolpyruvate","Phosphoenolpyruvate","D010728",0,0,0,42,0,0,0,0,0]
["phospholipon 90G","phospholipon 90G","C585968",0,0,0,0,0,1,0,0,0]
["Phosphonoacetic Acid","Phosphonoacetic Acid","D010746",0,0,0,0,0,3,0,0,0]
["phosphoramidite","phosphoramidite","C434331",0,0,0,0,0,1,0,0,0]
["Phosphorylcholine","Phosphorylcholine","D010767",0,1,0,0,1,23,0,0,0]
["phosphorylethanolamine","phosphorylethanolamine","C005448",0,0,0,0,0,1,0,0,0]
["Phosphotungstic Acid","Phosphotungstic Acid","D010772",0,2,0,0,0,1,0,0,0]
["phthalic acid","phthalic acid","C032279",3,0,0,0,0,0,0,0,0]
["phthalocyanine","phthalocyanine","C013647",0,0,0,0,0,4,0,0,0]
["Physostigmine","Physostigmine","D010830",0,0,0,0,0,1,0,0,0]
["phytochlorin","phytochlorin","C062985",0,0,0,0,0,2,0,0,0]
["Phytodolor N","Phytodolor N","C092917",0,0,0,0,0,2,0,0,0]
["phytofluene","phytofluene","C003140",0,0,0,0,0,2,0,2,0]
["phytosphingosine","phytosphingosine","C012491",0,0,0,0,0,0,0,2,0]
["Picibanil","Picibanil","D010844",0,0,0,2,1,0,0,0,0]
["Picloram","Picloram","D010846",0,0,0,0,0,0,2,0,0]
["PicoGreen","PicoGreen","C099476",0,0,0,0,0,1,0,0,0]
["picolinic acid","picolinic acid","C030614",0,0,0,3,1,0,1,0,0]
["Picrotoxin","Picrotoxin","D010852",1,0,0,0,0,0,1,0,0]
["pifithrin-beta","pifithrin-beta","C558699",1,0,0,0,0,0,1,0,0]
["Pilocarpine","Pilocarpine","D010862",0,0,0,0,0,0,1,0,0]
["pimagedine","pimagedine","C004479",0,0,0,0,0,12,0,0,0]
["Pimozide","Pimozide","D010868",0,0,0,0,0,1,0,0,0]
["pinitol","pinitol","C021730",0,1,0,0,0,1,0,0,0]
["pinostilbene","pinostilbene","C522997",1,0,0,0,0,0,2,0,0]
["piperazine-N,N'-bis(2-ethanesulfonic acid)","piperazine-N,N'-bis(2-ethanesulfonic acid)","C008916",0,0,0,0,0,1,0,0,0]
["piperidine","piperidine","C032727",0,0,0,0,0,0,0,1,0]
["piperlactam S","piperlactam S","C415282",0,0,0,0,0,1,0,0,0]
["piperlonguminine","piperlonguminine","C498077",0,0,0,0,0,1,0,0,0]
["Piperonyl Butoxide","Piperonyl Butoxide","D010882",2,0,0,0,0,0,5,0,0]
["Piperoxan","Piperoxan","D010883",0,0,0,0,0,0,1,0,0]
["Piracetam","Piracetam","D010889",0,0,0,0,0,2,1,0,0]
["pirinixil","pirinixil","C016908",0,1,0,0,0,0,0,0,0]
["pirozadil","pirozadil","C015453",0,0,0,0,0,2,0,0,0]
["p-isopentoxyaniline","p-isopentoxyaniline","C112313",0,0,0,0,0,0,0,4,0]
["pityriazepin","pityriazepin","C000598352",3,0,0,0,0,0,0,0,0]
["plant stanol ester","plant stanol ester","C407042",0,3,0,0,1,6,0,0,0]
["plastochromanol 8","plastochromanol 8","C013649",1,1,0,0,0,3,0,3,0]
["plicatin B acrylate","plicatin B acrylate","C098495",0,0,0,0,0,1,0,0,0]
["Podophyllin","Podophyllin","D011033",0,0,0,0,0,2,0,0,0]
["Poloxalene","Poloxalene","D011060",0,3,0,0,0,0,0,0,0]
["Poloxamer","Poloxamer","D020442",0,0,0,0,0,11,0,0,0]
["poly (methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl cyanoacrylate)","poly (methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl cyanoacrylate)","C504655",0,0,0,0,0,1,0,0,0]
["poly(2,8-deaminoneuraminic acid)","poly(2,8-deaminoneuraminic acid)","C099023",0,0,0,0,0,1,0,0,0]
["poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)","poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)","C115940",0,0,1,0,0,0,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3524,B3524)","v":"poly(3-hydroxybutyrate-co-4-hydroxybutyrate)"},"poly(3-hydroxybutyrate-co-4-hydroxybutyrate)","C068056",0,0,0,0,0,1,0,0,0]
["polyacrylamide","polyacrylamide","C016679",0,0,0,0,0,1,0,0,0]
["polyacrylamide gels","polyacrylamide gels","C016680",0,0,0,0,0,1,0,0,0]
["Polyanetholesulfonate","Polyanetholesulfonate","D011074",0,1,0,0,0,0,0,0,0]
["polyanions","polyanions","C009791",0,0,0,0,0,3,0,0,0]
["poly-beta-hydroxybutyrate","poly-beta-hydroxybutyrate","C003182",0,2,0,0,0,1,0,0,0]
["polycaprolactone-g-polyethylene glycol","polycaprolactone-g-polyethylene glycol","C000617025",0,0,0,0,0,1,0,0,0]
["polychlorodibenzofuran","polychlorodibenzofuran","C016068",4,0,0,0,0,0,8,0,0]
["polydiacetylene","polydiacetylene","C082361",0,0,0,0,0,1,0,0,0]
["Polyethylene","Polyethylene","D020959",0,0,0,0,0,0,1,0,0]
["polyethylene glycol oleyl ether","polyethylene glycol oleyl ether","C033084",0,0,0,0,1,0,0,0,0]
["Polyethyleneimine","Polyethyleneimine","D011094",0,0,0,0,0,3,0,0,0]
["polyhexamethyleneguanidine","polyhexamethyleneguanidine","C060540",0,0,0,0,0,1,0,0,0]
["polymethacrylic acid","polymethacrylic acid","C030613",0,0,0,0,0,2,0,0,0]
["polyphenon B","polyphenon B","C506663",0,0,0,0,0,0,1,0,0]
["polysialic acid","polysialic acid","C021319",0,0,0,0,1,0,0,0,0]
["polysulfone P 1700","polysulfone P 1700","C017662",0,0,0,0,0,2,0,0,0]
["Polyvinyl Alcohol","Polyvinyl Alcohol","D011142",0,1,0,0,0,5,0,0,0]
["polyvinyl sulfate","polyvinyl sulfate","C019050",0,1,0,0,0,4,0,0,0]
["Polyvinylpyridine N-Oxide","Polyvinylpyridine N-Oxide","D011144",0,0,0,0,0,1,0,0,0]
["pomiferin","pomiferin","C474837",0,0,0,0,0,0,1,0,0]
["ponatinib","ponatinib","C545373",0,0,0,0,0,0,1,0,0]
["potassium bicarbonate","potassium bicarbonate","C026329",0,0,0,0,0,1,0,0,0]
["potassium borohydride","potassium borohydride","C028371",0,0,0,0,0,1,0,0,0]
["potassium bromide","potassium bromide","C039004",0,2,0,0,0,3,0,0,0]
["potassium cyanate","potassium cyanate","C024835",0,0,0,0,0,1,0,0,0]
["Potassium Dichromate","Potassium Dichromate","D011192",0,2,0,0,0,0,0,0,0]
["potassium phosphate","potassium phosphate","C013216",1,1,0,0,0,1,0,0,0]
["Potassium, Dietary","Potassium, Dietary","D017419",0,0,0,1,0,1,0,0,0]
["Prazosin","Prazosin","D011224",0,12,0,0,0,11,0,0,0]
["Prednimustine","Prednimustine","D011238",0,0,0,0,0,1,0,0,0]
["pregna-4,17-diene-3,16-dione","pregna-4,17-diene-3,16-dione","C023617",0,0,0,0,0,4,0,0,0]
["Pregnenolone Carbonitrile","Pregnenolone Carbonitrile","D011285",6,0,0,0,0,0,0,0,0]
["Prenylamine","Prenylamine","D011299",0,0,0,0,0,1,0,0,0]
["Primaquine","Primaquine","D011319",1,0,0,0,0,0,1,0,0]
["pristane","pristane","C009042",0,0,0,0,0,0,1,0,0]
["proanthocyanidin","proanthocyanidin","C013221",0,1,0,0,0,9,1,0,0]
["prochloraz","prochloraz","C045362",3,0,0,0,0,0,5,0,0]
["procyanidin B2","procyanidin B2","C479580",0,0,0,0,0,6,0,0,0]
["procyanidin B3","procyanidin B3","C479581",0,0,0,0,0,2,0,0,0]
["profenofos","profenofos","C024273",0,0,0,0,0,1,0,0,0]
["proglycosyn","proglycosyn","C060944",0,1,0,0,0,0,0,0,0]
["Prometryne","Prometryne","D011400",1,0,0,0,0,0,1,0,0]
["Propane","Propane","D011407",2,0,0,0,0,2,2,0,0]
["propane-1,3-diyl bis(4-aminobenzoate)","propane-1,3-diyl bis(4-aminobenzoate)","C061700",0,0,0,0,0,0,1,0,0]
["Propanil","Propanil","D011411",3,0,0,0,0,0,1,0,0]
["propiconazole","propiconazole","C045950",0,0,0,0,0,0,1,0,0]
["propionaldehyde","propionaldehyde","C005556",0,0,0,0,0,1,0,0,0]
["propionylcarnitine","propionylcarnitine","C003223",0,1,0,0,0,3,0,0,0]
["Propyl Gallate","Propyl Gallate","D011435",0,0,0,0,0,1,2,4,0]
["propylparaben","propylparaben","C006068",0,0,0,0,0,0,1,0,0]
["prostacyclin synthesis stimulating plasma factor","prostacyclin synthesis stimulating plasma factor","C057670",0,0,0,0,0,1,0,0,0]
["Prostaglandin D2","Prostaglandin D2","D015230",0,0,0,0,6,7,0,0,0]
["Prostaglandins E","Prostaglandins E","D011458",0,2,0,1,0,10,0,5,0]
["Prostaglandins F","Prostaglandins F","D011460",0,0,0,0,0,3,0,0,0]
["Prostaglandins F, Synthetic","Prostaglandins F, Synthetic","D011461",0,0,0,0,0,2,0,0,0]
["Prostaglandins I","Prostaglandins I","D044062",0,0,0,0,0,1,0,0,0]
["protopine","protopine","C009093",1,0,0,0,0,0,1,0,0]
["przewaquinone D","przewaquinone D","C043165",0,0,0,0,0,1,0,0,0]
["pseudoberberine","pseudoberberine","C578968",0,0,0,0,0,1,0,0,0]
["pseudohypericin","pseudohypericin","C056602",0,0,0,0,0,2,0,0,0]
["Psyllium","Psyllium","D011620",0,3,0,0,0,9,0,0,0]
["pterostilbene","pterostilbene","C107773",0,0,0,0,0,2,1,0,0]
["pullulan","pullulan","C009109",0,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3588,B3588)","v":"punicalin"},"punicalin","C115643",0,0,0,0,0,0,1,0,0]
["punicic acid","punicic acid","C519714",0,0,0,0,0,0,0,2,0]
["purpurin","purpurin","C511975",0,0,0,0,0,0,2,0,0]
["Putrescine","Putrescine","D011700",0,0,0,0,0,0,2,0,0]
["pyralene","pyralene","C013226",0,0,0,0,0,0,1,0,0]
["pyrene","pyrene","C030984",4,0,0,0,0,0,18,0,0]
["pyridazine","pyridazine","C062482",0,0,0,0,0,0,0,2,0]
["pyridine","pyridine","C023666",2,0,0,0,0,0,9,0,0]
["pyridine N-oxide","pyridine N-oxide","C013229",1,0,0,0,0,0,3,0,0]
["Pyridinolcarbamate","Pyridinolcarbamate","D011727",0,0,0,0,0,3,0,0,0]
["Pyridostigmine Bromide","Pyridostigmine Bromide","D011729",0,0,0,0,0,0,0,1,0]
["Pyridoxamine","Pyridoxamine","D011733",0,0,0,1,1,2,0,0,0]
["pyripyropene A","pyripyropene A","C082792",0,1,0,0,0,2,0,0,0]
["Pyrogallol","Pyrogallol","D011748",0,0,0,0,0,0,1,0,0]
["pyropheophorbide a","pyropheophorbide a","C040298",0,0,0,0,0,2,0,0,0]
["pyrrolidine dithiocarbamic acid","pyrrolidine dithiocarbamic acid","C020972",0,0,0,0,1,0,0,0,0]
["Qingdai compound","Qingdai compound","C530990",2,0,0,0,0,0,0,0,0]
["Quartz","Quartz","D011791",1,0,0,0,0,0,3,0,0]
["quassin","quassin","C010317",0,0,0,0,0,0,1,0,0]
["quercetin 3-(6-malonylglucoside)","quercetin 3-(6-malonylglucoside)","C500753",0,0,0,0,0,1,0,0,0]
["quercetin 3-O-glucopyranoside","quercetin 3-O-glucopyranoside","C110309",0,0,0,0,0,1,0,0,0]
["quercetin 3-O-glucuronide","quercetin 3-O-glucuronide","C443401",0,0,0,0,0,2,0,0,0]
["quercetin 3'-sulfate","quercetin 3'-sulfate","C531389",0,0,0,0,0,0,1,0,0]
["quercetin 4'-O-glucopyranoside","quercetin 4'-O-glucopyranoside","C110310",0,0,0,0,0,1,0,0,0]
["quercetin 7-O-glucopyranoside","quercetin 7-O-glucopyranoside","C110311",0,0,0,0,0,1,0,0,0]
["quercetin-3-O-rutinoside","quercetin-3-O-rutinoside","C404204",1,0,0,0,0,0,1,0,0]
["quercetin-6-C-beta-D-glucopyranoside","quercetin-6-C-beta-D-glucopyranoside","C558502",3,0,0,0,0,0,0,0,0]
["quercitrin","quercitrin","C012526",0,0,0,0,1,3,1,0,0]
["Quetiapine Fumarate","Quetiapine Fumarate","D000069348",0,1,0,0,0,0,1,0,0]
["Quinacrine","Quinacrine","D011796",0,0,0,0,0,0,1,0,0]
["quinapril","quinapril","C041125",0,0,0,0,0,3,0,0,0]
["quinaprilat","quinaprilat","C054501",0,0,0,0,0,1,0,0,0]
["Quinic Acid","Quinic Acid","D011801",0,0,0,0,0,4,0,0,0]
["Quinidine","Quinidine","D011802",0,3,0,0,0,4,2,0,0]
["quinoline","quinoline","C037219",0,0,0,0,0,1,1,0,0]
["Quinolinic Acid","Quinolinic Acid","D017378",0,0,0,6,0,0,0,0,0]
["quinone","quinone","C004532",1,0,0,0,0,1,0,2,0]
["R-154716","R-154716","C521770",0,0,0,0,2,0,0,0,0]
["Rabeprazole","Rabeprazole","D064750",0,0,0,0,0,0,2,0,0]
["ractopamine","ractopamine","C060897",0,0,0,0,0,0,0,1,0]
["Ramipril","Ramipril","D017257",0,1,0,0,1,5,0,0,0]
["Raxofelast","Raxofelast","C071049",0,0,0,0,0,2,0,0,0]
["reinioside C","reinioside C","C530274",0,0,0,0,0,3,0,0,0]
["remacemide","remacemide","C067553",0,0,0,0,0,0,1,0,0]
["resiniferatoxin","resiniferatoxin","C024353",0,0,0,0,0,1,0,0,0]
["resorufin","resorufin","C014180",0,0,0,0,0,0,5,0,0]
["resveratrol-4'-O-glucuronide","resveratrol-4'-O-glucuronide","C499731",0,0,0,0,0,1,0,0,0]
["retene","retene","C447880",2,0,0,0,0,0,12,0,0]
["retinol acetate","retinol acetate","C009166",0,0,0,0,0,1,1,0,0]
["Rhamnose","Rhamnose","D012210",0,0,0,0,0,1,0,0,0]
["Rh-Hr Blood-Group System","Rh-Hr Blood-Group System","D012204",0,0,0,0,0,1,0,0,0]
["rhizobitoxine","rhizobitoxine","C041618",0,0,0,0,0,0,0,2,0]
["rhodamine 110","rhodamine 110","C049025",0,0,0,0,0,0,1,0,0]
["Rhodamine 123","Rhodamine 123","D020112",0,0,0,0,0,1,0,0,0]
["rhodoquinone","rhodoquinone","C003304",0,0,0,0,0,0,0,2,0]
["Ribose","Ribose","D012266",0,0,0,1,0,4,0,0,0]
["ricinoleic acid","ricinoleic acid","C030521",0,0,0,0,0,0,0,4,0]
["Rifabutin","Rifabutin","D017828",0,0,0,0,0,0,1,0,0]
["Riluzole","Riluzole","D019782",0,0,0,0,0,0,1,0,0]
["Risedronate Sodium","Risedronate Sodium","D000068296",0,0,0,0,0,1,0,0,0]
["ritetronium","ritetronium","C012121",0,0,0,0,1,5,0,0,0]
["Ritodrine","Ritodrine","D012312",0,1,0,0,0,2,0,0,0]
["Ro 22-0654","Ro 22-0654","C041812",0,1,0,0,0,0,0,0,0]
["Ro 48-8071","Ro 48-8071","C105726",0,0,0,0,0,2,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3652,B3652)","v":"RO 5066852"},"RO 5066852","C557082",0,0,0,0,0,1,0,0,0]
["robinin","robinin","C005183",0,0,0,0,0,1,0,0,0]
["rofecoxib","rofecoxib","C116926",0,0,0,0,0,1,0,0,0]
["rolafagrel","rolafagrel","C066217",0,0,0,0,0,2,0,0,0]
["rosmanol","rosmanol","C465581",0,0,0,0,0,1,0,0,0]
["rosmarinic acid","rosmarinic acid","C041376",0,0,0,1,0,1,1,0,0]
["Roxithromycin","Roxithromycin","D015575",0,0,0,0,0,0,3,0,0]
["royal jelly","royal jelly","C058787",0,0,0,0,0,1,0,0,0]
["RP 73163","RP 73163","C092200",0,1,0,0,0,0,0,0,0]
["RPR 102359","RPR 102359","C100991",0,0,0,0,0,1,0,0,0]
["RPR 200765A","RPR 200765A","C431783",0,0,0,0,0,0,2,0,0]
["rubimaillin","rubimaillin","C046245",0,0,0,0,0,0,1,0,0]
["rutecarpine","rutecarpine","C028632",4,0,0,0,0,2,7,0,0]
["RV 538","RV 538","C033110",0,0,0,0,0,1,0,0,0]
["Ryanodine","Ryanodine","D012433",0,0,0,0,0,1,0,0,0]
["S 12340","S 12340","C085571",0,0,0,0,0,2,0,0,0]
["S 16020-2","S 16020-2","C101591",2,0,0,0,0,0,1,0,0]
["S 20478","S 20478","C105958",0,0,0,0,0,1,0,0,0]
["S 3483","S 3483","C113180",0,0,0,3,0,0,0,0,0]
["S-(1,2-dichlorovinyl)-3-mercaptopropionic acid","S-(1,2-dichlorovinyl)-3-mercaptopropionic acid","C007354",0,0,0,0,0,0,0,2,0]
["Saccharin","Saccharin","D012439",0,1,0,0,0,2,0,0,0]
["Safrole","Safrole","D012451",4,0,0,0,0,0,7,0,0]
["saikogenin A","saikogenin A","C009198",0,0,0,0,0,0,1,0,0]
["saiko-ka-ryukotsu-borei-to","saiko-ka-ryukotsu-borei-to","C095444",0,0,0,0,0,3,0,0,0]
["salicylamide","salicylamide","C031060",1,0,0,0,0,0,0,0,0]
["salicylhydroxamic acid","salicylhydroxamic acid","C005703",0,0,0,0,0,0,0,3,0]
["Saline Solution, Hypertonic","Saline Solution, Hypertonic","D012462",0,0,0,0,0,1,0,0,0]
["salmon oil","salmon oil","C030341",0,0,0,0,0,2,0,0,0]
["salmonella toxin","salmonella toxin","C027952",0,1,0,1,0,1,0,0,0]
["Salvia extract","Salvia extract","C528662",0,0,0,0,0,1,1,0,0]
["salvianolic acid A","salvianolic acid A","C066201",0,0,0,0,0,3,0,0,0]
["SAN 58035","SAN 58035","C040256",0,1,0,0,0,16,0,0,0]
["sanguinarine","sanguinarine","C005705",5,0,0,0,0,0,6,0,0]
["San'o-shashin-to","San'o-shashin-to","C405263",0,0,0,0,0,1,0,0,0]
["sappanchalcone","sappanchalcone","C044363",0,0,0,0,0,1,0,0,0]
["sapropterin","sapropterin","C003402",0,0,0,0,0,9,0,2,0]
["SAR224","SAR224","C583200",0,0,0,0,0,0,0,1,0]
["SAR707","SAR707","C584534",0,0,0,0,0,0,0,1,0]
["sarpogrelate","sarpogrelate","C064294",0,0,0,0,0,1,0,0,0]
["saururin A","saururin A","C446119",0,0,0,0,0,1,0,0,0]
["Saxitoxin","Saxitoxin","D012530",0,0,0,0,0,0,1,0,0]
["SB 203580","SB 203580","C093642",3,0,0,0,0,0,3,0,0]
["SB 209995","SB 209995","C088570",0,0,0,0,0,1,0,0,0]
["SB 211475","SB 211475","C086740",0,0,0,0,0,1,0,0,0]
["SB 216763","SB 216763","C417521",3,0,0,0,0,0,1,0,0]
["SB 222657","SB 222657","C118636",0,0,0,0,0,1,0,0,0]
["SC 26196","SC 26196","C120986",0,0,0,0,0,0,0,8,0]
["SC 560","SC 560","C115461",0,0,0,0,0,1,0,0,0]
["schisanhenol","schisanhenol","C045309",0,0,0,0,0,2,0,0,0]
["schizandrol B","schizandrol B","C033585",0,0,0,0,0,1,0,0,0]
["schizandrol D","schizandrol D","C000614640",0,0,0,0,0,1,0,0,0]
["scorbamic acid","scorbamic acid","C017945",0,0,0,0,0,1,0,0,0]
["scyphostatin","scyphostatin","C121123",0,0,0,0,0,1,0,0,0]
["sebacic acid","sebacic acid","C011107",0,0,0,0,0,0,0,8,0]
["secoisolariciresinol","secoisolariciresinol","C060283",0,0,0,0,0,0,1,0,0]
["Semaxinib","Semaxinib","C116890",3,0,0,0,0,0,1,0,0]
["Sepharose","Sepharose","D012685",0,2,0,0,0,3,0,0,0]
["sergolexole","sergolexole","C054583",0,0,0,0,0,1,0,0,0]
["Sertraline","Sertraline","D020280",0,0,0,0,0,2,0,0,0]
["sesaminol","sesaminol","C066016",0,0,0,0,0,2,0,0,0]
["sesamodil","sesamodil","C064356",0,0,0,0,0,1,1,0,0]
["Sewage","Sewage","D012722",9,0,0,0,0,0,19,0,0]
["SGA 360","SGA 360","C551534",4,0,0,0,0,0,0,0,0]
["shanzha","shanzha","C544212",0,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3716,B3716)","v":"shikonin"},"shikonin","C016101",0,0,0,0,0,1,0,1,0]
["shogaol","shogaol","C040115",1,0,0,0,1,1,1,0,0]
["shosaikoto-go-keishika-shakuyakuto","shosaikoto-go-keishika-shakuyakuto","C461321",0,0,0,0,0,3,0,0,0]
["shugan qingzhi","shugan qingzhi","C533615",0,0,0,0,0,1,0,0,0]
["sigetin","sigetin","C001770",0,1,0,0,0,1,0,0,0]
["Sildenafil Citrate","Sildenafil Citrate","D000068677",0,0,0,0,1,0,0,0,0]
["silsosangami","silsosangami","C487854",0,0,0,0,0,2,0,0,0]
["SIM 6080","SIM 6080","C063868",0,1,0,0,0,3,0,0,0]
["simvastatin acid","simvastatin acid","C063287",0,0,0,0,0,4,0,0,0]
["sinapinic acid","sinapinic acid","C073734",0,0,0,0,0,2,0,0,0]
["sinapyl 9-O-(beta-D-apiofuranosyl(1-6))-O-beta-D-glucopyranoside","sinapyl 9-O-(beta-D-apiofuranosyl(1-6))-O-beta-D-glucopyranoside","C497296",0,0,0,0,0,1,0,0,0]
["sinensetin","sinensetin","C059295",0,0,0,0,0,0,1,0,0]
["Singlet Oxygen","Singlet Oxygen","D026082",0,0,0,0,0,2,0,0,0]
["sinomenine","sinomenine","C009271",3,0,0,0,0,0,1,0,0]
["siphonaxanthin","siphonaxanthin","C003314",0,0,0,0,0,0,0,1,0]
["sirtinol","sirtinol","C439060",0,0,0,0,0,0,1,0,0]
["Sitosterolemia","Sitosterolemia","C537345",0,4,0,0,0,0,0,0,0]
["SK&F 104976","SK&F 104976","C071375",0,0,0,0,0,2,0,0,0]
["Skatole","Skatole","D012862",3,0,0,0,0,0,2,0,0]
["Smallpox Vaccine","Smallpox Vaccine","D012900",0,0,0,0,0,0,1,0,0]
["SMP-797","SMP-797","C508738",0,0,0,0,0,4,0,0,0]
["S-nitrosomercaptoethanol","S-nitrosomercaptoethanol","C032635",0,0,0,0,0,2,0,0,0]
["SNX 2112","SNX 2112","C534922",0,0,0,0,0,0,1,0,0]
["Sodium Azide","Sodium Azide","D019810",0,1,0,0,0,1,0,0,0]
["sodium bromide","sodium bromide","C027938",0,1,0,0,0,5,0,0,0]
["sodium citrate","sodium citrate","C102006",0,0,0,0,0,1,0,0,0]
["Sodium Dodecyl Sulfate","Sodium Dodecyl Sulfate","D012967",0,0,0,0,0,3,0,0,0]
["Sodium Hypochlorite","Sodium Hypochlorite","D012973",0,1,0,0,0,9,1,0,0]
["Sodium Selenite","Sodium Selenite","D018038",0,0,0,0,0,1,1,0,0]
["sofalcone","sofalcone","C035032",0,0,0,0,1,0,0,0,0]
["Soil","Soil","D012987",8,0,0,0,0,0,2,2,0]
["Solid Waste","Solid Waste","D062611",1,0,0,0,0,0,0,0,0]
["Solutol HS 15","Solutol HS 15","C067028",0,0,0,0,0,1,0,0,0]
["Soot","Soot","D053260",0,0,0,0,0,1,0,0,0]
["sophoricoside","sophoricoside","C120642",0,0,0,0,0,1,0,0,0]
["soraphen A","soraphen A","C086151",0,0,0,0,0,0,0,2,0]
["Sorbic Acid","Sorbic Acid","D013011",0,0,0,1,0,0,0,2,0]
["sorbinil","sorbinil","C026411",0,0,0,0,0,1,0,0,0]
["Sorbose","Sorbose","D013013",0,1,0,0,0,1,0,0,0]
["sorgoleone","sorgoleone","C113738",0,0,0,0,0,0,0,4,0]
["Sotalol","Sotalol","D013015",0,1,0,0,0,1,0,0,0]
["soybean oil, phospholipid emulsion","soybean oil, phospholipid emulsion","C545823",0,1,0,0,0,0,0,0,0]
["spermine nitric oxide complex","spermine nitric oxide complex","C091861",0,0,0,0,0,1,0,0,0]
["sphingosine phosphorylcholine","sphingosine phosphorylcholine","C005356",0,0,0,0,0,1,0,0,0]
["squalestatin 1","squalestatin 1","C075117",0,0,0,0,0,2,0,0,0]
["SR 12813","SR 12813","C100355",0,0,0,0,0,2,0,0,0]
["SRM 1597","SRM 1597","C518872",0,0,0,0,0,0,2,0,0]
["SRS-A","SRS-A","D013189",0,0,0,0,0,0,0,4,0]
["S-sulindac","S-sulindac","C539817",1,0,0,0,0,0,1,0,0]
["stachybotramide","stachybotramide","C095377",0,1,0,0,0,1,0,0,0]
["stannous chloride","stannous chloride","C023599",0,0,0,0,0,1,0,0,0]
["stannous sulfate","stannous sulfate","C058882",0,0,0,0,0,1,0,0,0]
["Staurosporine","Staurosporine","D019311",0,0,0,3,0,2,1,0,0]
["stearoyl alpha-lysolecithin","stearoyl alpha-lysolecithin","C026564",0,0,0,0,0,6,0,0,0]
["stearoylethanolamide","stearoylethanolamide","C466089",0,0,0,0,0,0,0,1,0]
["stearylamine","stearylamine","C009317",0,0,0,0,0,1,0,0,0]
["StemRegenin 1","StemRegenin 1","C552240",6,0,0,0,0,0,0,0,0]
["sterculic acid","sterculic acid","C003345",0,0,0,0,0,0,0,9,0]
["Sterigmatocystin","Sterigmatocystin","D013241",0,0,0,0,0,0,3,2,0]
["steviol","steviol","C012042",1,0,0,0,0,0,0,0,0]
["stevioside","stevioside","C012043",0,0,0,0,0,0,0,1,0]
["stigmastanol","stigmastanol","C021255",0,0,0,0,0,1,0,0,0]
["stigmastanyl-phosphorylcholine","stigmastanyl-phosphorylcholine","C072347",0,0,0,0,0,1,0,0,0]
["stilbene oxide","stilbene oxide","C025906",1,0,0,0,0,0,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3780,B3780)","v":"STO 609"},"STO 609","C458525",3,0,0,0,0,0,1,0,0]
["Streptonigrin","Streptonigrin","D013308",0,0,0,3,0,0,0,0,0]
["strictinin","strictinin","C496786",0,0,0,0,0,2,0,0,0]
["Strychnine","Strychnine","D013331",0,0,0,0,0,0,1,0,0]
["suberic acid","suberic acid","C005738",0,0,0,0,0,0,0,6,0]
["succinobucol","succinobucol","C471047",0,0,0,0,0,1,0,0,0]
["sucrose polyester","sucrose polyester","C013692",0,0,0,0,0,2,0,0,0]
["sudan cholesteryl oleate","sudan cholesteryl oleate","C043632",0,0,0,0,0,2,0,0,0]
["sudan III","sudan III","C033006",1,0,0,0,0,0,1,0,0]
["Sulavajrini Vatika","Sulavajrini Vatika","C584239",0,1,0,0,0,1,0,0,0]
["Sulfinpyrazone","Sulfinpyrazone","D013442",0,1,0,0,0,2,0,0,0]
["sulfoglycolipids","sulfoglycolipids","C011117",0,0,0,0,0,1,0,0,0]
["sulfo-N-succinimidyl oleate","sulfo-N-succinimidyl oleate","C120556",0,0,0,0,6,1,0,0,0]
["sulfo-N-succinimidyl palmitate","sulfo-N-succinimidyl palmitate","C097197",0,0,0,0,1,0,0,0,0]
["sulfoxaflor","sulfoxaflor","C560328",0,0,0,0,0,0,1,0,0]
["Sulindac","Sulindac","D013467",4,0,0,0,0,0,4,2,0]
["sulindac sulfide","sulindac sulfide","C025462",0,0,0,0,0,0,0,2,0]
["Suloctidil","Suloctidil","D013468",0,0,0,0,0,3,0,0,0]
["Sulpiride","Sulpiride","D013469",0,0,0,0,1,0,0,0,0]
["sunitinib","sunitinib","C473478",5,0,0,0,0,0,5,0,0]
["SuperEPA","SuperEPA","C056974",0,1,0,0,0,0,0,0,0]
["Superose 6b","Superose 6b","C043127",0,1,0,0,0,1,0,0,0]
["surfomer","surfomer","C025487",0,0,0,0,0,1,0,0,0]
["suxiao jiuxinwan","suxiao jiuxinwan","C543119",0,0,0,0,0,1,0,0,0]
["sweroside","sweroside","C049412",0,0,0,1,0,0,0,0,0]
["syringaldehyde","syringaldehyde","C069665",0,0,0,1,0,0,0,0,0]
["T 2591","T 2591","C109001",0,0,0,0,0,1,0,0,0]
["T-2 Toxin","T-2 Toxin","D013605",1,0,0,0,0,0,3,0,0]
["T-3764518","T-3764518","C000622938",0,0,0,0,0,0,0,3,0]
["Tacrine","Tacrine","D013619",0,0,0,0,0,0,3,0,0]
["tagatose","tagatose","C030192",0,0,0,0,0,1,0,0,0]
["TAK 779","TAK 779","C119369",0,0,0,0,0,1,0,0,0]
["Talaporfin","Talaporfin","C053434",1,0,0,0,0,0,0,0,0]
["tallow","tallow","C013698",0,3,0,0,0,2,0,1,0]
["tamibarotene","tamibarotene","C061133",0,0,0,0,1,0,0,0,0]
["TAN 1607A","TAN 1607A","C098501",0,0,0,0,0,1,0,0,0]
["tanespimycin","tanespimycin","C112765",2,0,0,0,0,1,1,0,0]
["tangeretin","tangeretin","C059006",0,1,0,0,1,1,3,0,0]
["tanshinol","tanshinol","C585969",0,0,0,0,0,1,0,0,0]
["tanshinone","tanshinone","C021751",1,0,0,0,1,12,3,0,0]
["tanshinone II A sodium sulfonate","tanshinone II A sodium sulfonate","C024894",0,0,0,0,0,1,0,0,0]
["taprostene","taprostene","C039188",0,0,0,0,0,1,0,0,0]
["tartronic acid","tartronic acid","C032973",0,0,0,3,0,0,0,0,0]
["Taurodeoxycholic Acid","Taurodeoxycholic Acid","D013657",0,0,0,1,0,0,0,0,0]
["taurohyodeoxycholic acid","taurohyodeoxycholic acid","C083510",0,0,0,1,0,0,0,0,0]
["tazasubrate","tazasubrate","C041008",0,1,0,0,0,0,0,0,0]
["tebufelone","tebufelone","C064268",0,0,0,0,0,0,1,0,0]
["tectochrysin","tectochrysin","C402729",0,0,0,0,0,0,1,0,0]
["telithromycin","telithromycin","C106791",0,0,0,0,0,0,1,0,0]
["temocapril hydrochloride","temocapril hydrochloride","C055603",0,0,0,0,0,2,0,0,0]
["temoporfin","temoporfin","C072269",0,2,0,0,0,1,0,0,0]
["TEMPO","TEMPO","C003959",0,1,0,0,0,1,1,0,0]
["Terazosin","Terazosin","C041226",0,1,0,0,0,1,0,0,0]
["terbinafine","terbinafine","C041359",0,0,0,0,0,1,0,0,0]
["Terbutaline","Terbutaline","D013726",0,1,0,0,0,1,0,0,0]
["terics","terics","C021754",0,0,0,0,0,0,2,0,0]
["teriflunomide","teriflunomide","C527525",1,0,0,0,0,0,0,0,0]
["terpinolene","terpinolene","C027009",0,0,0,0,0,2,0,0,0]
["tert-amyl alcohol","tert-amyl alcohol","C032765",0,0,0,0,0,0,0,1,0]
["tert-Butyl Alcohol","tert-Butyl Alcohol","D020002",0,1,0,0,0,0,1,0,0]
["tert-nitrosobutane","tert-nitrosobutane","C034526",0,0,0,0,0,1,0,0,0]
["tesaglitazar","tesaglitazar","C501413",0,0,0,0,0,2,0,0,0]
["tesmilifene","tesmilifene","C043062",0,1,0,0,0,2,0,0,0]
["tetcyclacis","tetcyclacis","C053723",0,0,0,0,0,0,1,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3844,B3844)","v":"tetrabromobisphenol A-bisallylether"},"tetrabromobisphenol A-bisallylether","C471350",0,0,0,0,0,0,1,0,0]
["tetracalcium phosphate","tetracalcium phosphate","C485830",0,0,0,1,0,0,0,0,0]
["tetracosahexaenoic acid","tetracosahexaenoic acid","C099831",0,0,0,0,0,0,0,2,0]
["tetracosapentaenoic acid","tetracosapentaenoic acid","C099830",0,0,0,0,0,0,0,3,0]
["tetradecabromodiphenoxybenzene","tetradecabromodiphenoxybenzene","C582340",1,0,0,0,0,0,0,0,0]
["Tetradecanoylphorbol Acetate","Tetradecanoylphorbol Acetate","D013755",8,0,0,5,2,21,9,2,0]
["tetradecylselenoacetic acid","tetradecylselenoacetic acid","C410666",0,0,0,0,0,1,0,0,0]
["tetrahydrocurcumin","tetrahydrocurcumin","C096277",0,0,0,0,0,1,1,0,0]
["tetrahydrodaidzein","tetrahydrodaidzein","C433164",0,0,0,0,0,1,0,0,0]
["tetrahydrofuran","tetrahydrofuran","C018674",0,0,0,0,0,1,1,0,0]
["tetrahydrogestrinone","tetrahydrogestrinone","C479553",4,0,0,0,0,0,1,0,0]
["tetrahydroneopterin","tetrahydroneopterin","C023455",0,0,0,0,0,1,0,0,0]
["tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex","tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex","C050950",0,0,0,0,0,2,0,0,0]
["tetrandrine","tetrandrine","C009438",6,0,0,0,0,0,1,0,0]
["tetraphenylporphine","tetraphenylporphine","C049692",0,0,0,0,0,1,0,0,0]
["tetraphenylporphine sulfonate","tetraphenylporphine sulfonate","C016136",0,0,0,0,0,3,0,0,0]
["thalifendine","thalifendine","C477156",0,0,0,0,0,1,2,0,0]
["theaflavin digallate","theaflavin digallate","C077197",0,0,0,0,0,1,0,0,0]
["Thiabendazole","Thiabendazole","D013827",1,0,0,0,0,0,5,0,0]
["thiamorpholine","thiamorpholine","C028971",0,0,0,0,0,1,0,0,0]
["thiazolidine-2,4-dione","thiazolidine-2,4-dione","C500090",0,0,0,0,0,1,0,0,0]
["thiazolyl blue","thiazolyl blue","C022616",0,0,0,0,1,0,1,0,0]
["thiocarlide","thiocarlide","C100189",0,0,0,0,0,0,0,3,0]
["thiocholesterol","thiocholesterol","C002297",0,0,0,0,0,2,0,0,0]
["thiocyanate","thiocyanate","C031760",0,0,0,0,0,2,0,0,0]
["thiopalmitic acid","thiopalmitic acid","C091863",0,0,0,0,0,1,0,0,0]
["Thiophanate","Thiophanate","D013875",0,0,0,0,0,0,2,0,0]
["tiadenol","tiadenol","C004568",0,1,0,0,0,0,0,3,0]
["tibolone","tibolone","C027385",0,1,0,0,0,3,0,0,0]
["Ticrynafen","Ticrynafen","D013989",0,0,0,0,0,1,1,0,0]
["Tiletamine","Tiletamine","D013992",0,0,0,0,0,0,1,0,0]
["tiletamine, zolazepam drug combination","tiletamine, zolazepam drug combination","C006131",0,0,0,0,0,0,1,0,0]
["tilianin","tilianin","C426884",0,0,0,0,0,2,0,0,0]
["tiliroside","tiliroside","C052083",0,0,0,0,0,1,0,0,0]
["tiludronic acid","tiludronic acid","C058651",0,0,0,0,0,2,0,0,0]
["timefurone","timefurone","C046829",0,3,0,0,0,1,0,0,0]
["tiplaxtinin","tiplaxtinin","C488103",0,0,0,0,0,1,0,0,0]
["tiqueside","tiqueside","C080606",0,0,0,0,0,1,0,0,0]
["TMC 49A","TMC 49A","C111759",0,0,0,0,0,2,0,0,0]
["TMK 688","TMK 688","C087493",0,0,0,0,0,0,1,0,0]
["TMK 777","TMK 777","C061008",0,0,0,0,0,0,1,0,0]
["Tocainide","Tocainide","D016677",0,0,0,0,0,0,1,0,0]
["Tocomin","Tocomin","C570135",0,0,0,0,0,1,0,0,0]
["tocopheroxy radical","tocopheroxy radical","C066323",0,0,0,0,0,1,0,0,0]
["tocopherylquinone","tocopherylquinone","C002421",0,0,0,0,0,1,1,2,0]
["tocotrienol, alpha","tocotrienol, alpha","C082032",0,0,0,0,0,3,0,0,0]
["tofacitinib","tofacitinib","C479163",0,0,0,0,0,1,0,0,0]
["toltrazuril","toltrazuril","C036670",0,0,0,0,0,0,1,0,0]
["Toluene 2,4-Diisocyanate","Toluene 2,4-Diisocyanate","D014051",0,0,0,0,0,0,2,0,0]
["tongxinluo","tongxinluo","C513941",0,0,0,0,0,2,0,0,0]
["topiramate","topiramate","C052342",0,1,0,0,2,5,0,0,0]
["Topotecan","Topotecan","D019772",1,0,0,0,0,0,0,0,0]
["torcetrapib","torcetrapib","C483909",0,9,0,0,1,4,0,0,0]
["Toxaphene","Toxaphene","D014112",2,0,0,0,0,1,2,0,0]
["trabectedin","trabectedin","C099150",0,0,0,0,0,0,1,0,0]
["Tramadol","Tramadol","D014147",0,0,0,1,0,0,0,0,0]
["trandolapril","trandolapril","C052035",0,0,0,0,0,1,0,0,0]
["trans-1,2-dihydro-1,2-naphthalenediol","trans-1,2-dihydro-1,2-naphthalenediol","C507866",0,0,0,0,0,0,1,0,0]
["trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride","trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride","D001371",0,0,0,0,0,4,0,0,0]
["Trapidil","Trapidil","D014192",0,0,0,0,0,6,0,0,0]
["trecresanum","trecresanum","C473969",0,0,0,0,0,2,0,0,0]
["Trenbolone Acetate","Trenbolone Acetate","D014204",0,0,0,1,0,0,0,0,0]
["trequinsin","trequinsin","C035964",0,0,0,0,0,1,0,0,0]
["Triamcinolone","Triamcinolone","D014221",0,0,0,6,0,0,0,2,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3908,B3908)","v":"Triamcinolone Acetonide"},"Triamcinolone Acetonide","D014222",0,0,0,5,0,0,0,0,0]
["tricaine","tricaine","C003636",3,0,0,0,0,0,1,0,0]
["tricaprin","tricaprin","C010800",0,1,0,0,0,0,0,0,0]
["tricaprylin","tricaprylin","C003637",0,0,1,0,1,0,0,0,0]
["trichostatin A","trichostatin A","C012589",2,0,0,0,1,4,4,0,0]
["triclocarban","triclocarban","C009540",1,0,0,0,0,0,2,0,0]
["Triclosan","Triclosan","D014260",2,0,0,0,0,0,7,0,0]
["tricyclodecane-9-yl-xanthogenate","tricyclodecane-9-yl-xanthogenate","C046498",0,0,0,0,0,1,0,0,0]
["tridentatol A","tridentatol A","C121186",0,0,0,0,0,1,0,0,0]
["tridihomo-gamma-linolenoylglycerol","tridihomo-gamma-linolenoylglycerol","C081568",0,0,0,0,0,0,0,2,0]
["trierucate","trierucate","C030774",0,0,0,0,0,0,0,2,0]
["trikatu","trikatu","C540456",0,0,0,0,0,2,0,0,0]
["triladyl","triladyl","C503302",0,0,0,0,0,1,0,0,0]
["trilinolein","trilinolein","C009564",0,0,0,0,0,2,0,3,0]
["trimethylamine","trimethylamine","C023336",0,0,0,0,0,1,0,0,0]
["trimethylarsine oxide","trimethylarsine oxide","C052920",2,0,0,0,0,0,1,0,0]
["trimethyltin","trimethyltin","C046488",0,0,0,0,0,0,1,0,0]
["trimyristin","trimyristin","C036694",0,0,0,0,0,1,0,0,0]
["trinitrophenyl-lipopolysaccharide","trinitrophenyl-lipopolysaccharide","C048761",3,0,0,0,0,0,0,0,0]
["tripalmitin","tripalmitin","C005859",0,2,0,0,0,2,0,1,0]
["Triparanol","Triparanol","D014308",0,0,0,0,0,1,0,0,0]
["triphenyl phosphate","triphenyl phosphate","C005445",0,0,0,0,0,1,0,0,0]
["triphenylethylene","triphenylethylene","C037749",0,0,0,0,0,1,0,0,0]
["triphenylphosphine","triphenylphosphine","C061896",1,0,0,0,0,0,1,0,0]
["triphenyltin","triphenyltin","C030665",0,0,0,0,0,0,1,0,0]
["triphenyltin fluoride","triphenyltin fluoride","C033303",0,1,0,0,0,0,0,0,0]
["tris(1,3-dichloro-2-propyl)phosphate","tris(1,3-dichloro-2-propyl)phosphate","C016805",1,0,0,0,0,0,0,0,0]
["tris(2-butoxyethyl) phosphate","tris(2-butoxyethyl) phosphate","C013320",1,0,0,0,0,0,0,0,0]
["tris(2-carboxyethyl)phosphine","tris(2-carboxyethyl)phosphine","C080938",0,0,0,0,0,1,0,0,0]
["tris(porphinato)zinc(II)","tris(porphinato)zinc(II)","C503228",0,0,0,0,0,1,0,0,0]
["trisodium citrate","trisodium citrate","C514290",0,0,0,0,0,1,0,0,0]
["tristearin","tristearin","C022618",0,1,0,0,0,2,0,0,0]
["TRK 820","TRK 820","C111212",0,0,0,0,0,0,1,0,0]
["Troleandomycin","Troleandomycin","D014217",0,0,0,0,0,1,1,0,0]
["tryolobibenzyl D","tryolobibenzyl D","C466769",0,0,0,0,0,0,1,0,0]
["tryptamine","tryptamine","C030820",0,0,0,0,0,1,0,0,0]
["tryptanthrine","tryptanthrine","C046243",3,0,0,0,0,0,0,0,0]
["tung oil","tung oil","C009612",0,0,0,0,0,0,0,2,0]
["tungstate","tungstate","C045951",0,0,0,1,0,0,0,0,0]
["turmeric extract","turmeric extract","C012596",0,0,0,0,1,4,0,0,0]
["tyloxapol","tyloxapol","C016811",0,2,0,0,0,4,0,0,0]
["Tyramine","Tyramine","D014439",0,1,0,0,1,6,0,0,0]
["tyramine-cellobiose adduct","tyramine-cellobiose adduct","C038394",0,0,0,0,0,3,0,0,0]
["tyrphostin 47","tyrphostin 47","C060152",0,0,0,0,0,1,1,0,0]
["U 74389F","U 74389F","C074965",0,0,0,0,0,1,1,0,0]
["U 74500A","U 74500A","C053356",0,0,0,0,0,3,0,0,0]
["UAB 30","UAB 30","C112106",1,0,0,0,0,0,0,0,0]
["ubiquinol","ubiquinol","C003741",0,2,0,0,0,6,0,0,0]
["ubiquinol-10","ubiquinol-10","C026663",0,0,0,0,0,9,0,0,0]
["Ubiquinone Q2","Ubiquinone Q2","C025204",0,1,0,0,0,4,0,0,0]
["Ugilec 141","Ugilec 141","C063736",0,0,0,0,0,0,1,0,0]
["Ultrafine","Ultrafine","C043595",1,0,0,0,0,0,1,0,0]
["UM171 compound","UM171 compound","C000592665",2,0,0,0,0,0,0,0,0]
["Unithiol","Unithiol","D014494",0,0,0,0,0,1,0,0,0]
["urapidil","urapidil","C015568",0,1,0,0,0,0,0,0,0]
["Urocanic Acid","Urocanic Acid","D014560",0,0,0,0,0,1,0,0,0]
["V 70","V 70","C109522",0,0,0,0,0,1,0,0,0]
["VAF347","VAF347","C509596",4,0,0,0,0,0,0,0,0]
["valrubicin","valrubicin","C016163",0,0,0,0,0,3,0,0,0]
["vanadium pentoxide","vanadium pentoxide","C066075",0,0,0,0,0,2,0,0,0]
["vanadyl sulfate","vanadyl sulfate","C034028",0,0,0,2,0,1,0,0,0]
["Varenicline","Varenicline","D000068580",0,0,0,0,1,1,0,0,0]
["Venlafaxine Hydrochloride","Venlafaxine Hydrochloride","D000069470",0,0,0,0,0,0,1,0,0]
["ventol","ventol","C521065",0,0,0,0,0,1,0,0,0]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3972,B3972)","v":"Verapamil"},"Verapamil","D014700",0,5,0,0,0,16,2,0,0]
["Veratridine","Veratridine","D014701",0,0,0,0,0,0,1,0,0]
["verlukast","verlukast","C059141",0,0,0,0,0,0,1,0,0]
["vermiculite","vermiculite","C003760",0,0,0,0,0,1,0,0,0]
["vernolic acid","vernolic acid","C081136",0,0,0,0,0,0,0,2,0]
["verteporfin","verteporfin","C098350",0,0,0,0,0,1,0,0,0]
["vicine","vicine","C009661",0,0,0,1,0,0,0,0,0]
["Vinblastine","Vinblastine","D014747",0,3,0,0,1,1,0,0,0]
["vinclozolin","vinclozolin","C025643",2,0,0,0,0,0,2,0,0]
["vinorelbine","vinorelbine","C030852",0,0,0,0,1,0,0,0,0]
["vinpocetine","vinpocetine","C013983",0,0,0,0,0,2,0,0,0]
["vinylidene chloride","vinylidene chloride","C029297",0,0,0,0,0,0,2,0,0]
["vinylphosphonic acid","vinylphosphonic acid","C433467",0,0,0,0,0,1,0,0,0]
["vinyltoluene","vinyltoluene","C027142",0,0,0,0,0,0,1,0,0]
["virolin","virolin","C446121",0,0,0,0,0,1,0,0,0]
["visnagin","visnagin","C044999",1,0,0,0,0,0,1,0,0]
["Vitamin K 2","Vitamin K 2","D024482",0,0,0,0,0,1,0,0,0]
["Vitamin K 3","Vitamin K 3","D024483",3,0,0,0,0,0,4,0,0]
["vitexin","vitexin","C032731",0,0,0,0,0,1,0,0,0]
["voglibose","voglibose","C102817",0,0,0,0,0,1,0,0,0]
["vorinostat","vorinostat","C111237",2,0,0,0,0,1,0,0,0]
["W 7","W 7","C017967",0,1,0,0,0,0,0,0,0]
["Warfarin","Warfarin","D014859",0,0,0,0,0,3,1,0,0]
["warfarin hexadecyl ether","warfarin hexadecyl ether","C094088",0,0,0,0,0,1,0,0,0]
["Waste Water","Waste Water","D062065",5,0,0,0,0,0,6,0,0]
["WAY-169916","WAY-169916","C499198",6,0,0,0,0,0,0,0,0]
["WB 4291","WB 4291","C066486",0,0,0,0,0,1,0,0,0]
["We 201","We 201","C006065",0,0,0,0,0,6,0,0,0]
["WEB 2086","WEB 2086","C052518",0,0,0,0,0,3,0,0,0]
["WHI P131","WHI P131","C116180",0,0,0,0,0,0,1,0,0]
["Win 55212-2","Win 55212-2","C070417",0,0,0,0,0,2,0,0,0]
["wortmannin","wortmannin","C009687",0,0,0,1,0,0,0,0,0]
["Wu-Hu-Tang","Wu-Hu-Tang","C105819",0,0,0,0,0,0,1,0,0]
["Xanthinol Niacinate","Xanthinol Niacinate","D014971",0,4,0,0,0,3,0,0,0]
["xanthone","xanthone","C009689",0,0,0,0,0,1,0,0,0]
["xanthurenic acid","xanthurenic acid","C028330",0,0,0,0,0,1,0,0,0]
["xiaoxianggou","xiaoxianggou","C000613729",0,0,0,0,0,1,0,0,0]
["ximenynic acid","ximenynic acid","C053760",0,0,0,0,0,0,0,2,0]
["xiongshao","xiongshao","C528128",0,0,0,0,0,1,0,0,0]
["xylenol orange","xylenol orange","C016833",0,0,0,0,0,2,0,0,0]
["xyloketal A","xyloketal A","C438053",0,0,0,0,0,1,0,0,0]
["xylosides","xylosides","C010807",0,0,0,0,0,1,0,0,0]
["YH 439","YH 439","C098009",1,0,0,0,0,0,1,0,0]
["YM17E","YM17E","C080390",0,1,0,0,0,2,0,0,0]
["yuehchukene","yuehchukene","C047409",2,0,0,0,0,0,1,0,0]
["zanoterone","zanoterone","C060492",0,0,0,0,0,0,2,0,0]
["zearalenol","zearalenol","C029659",0,0,0,0,0,1,1,0,0]
["Zearalenone","Zearalenone","D015025",3,0,0,0,0,0,1,2,0]
["zederone","zederone","C586942",1,0,0,0,0,0,0,0,0]
["Zeranol","Zeranol","D015029",0,0,0,0,0,2,1,0,0]
["zerumbone","zerumbone","C403304",0,0,0,0,0,1,0,0,0]
["zinc phthalocyanine sulfonate","zinc phthalocyanine sulfonate","C064328",0,0,0,0,0,1,0,0,0]
["Zinc Sulfate","Zinc Sulfate","D019287",0,0,0,0,0,0,0,1,0]
["zinc(II)-tetradibenzobarrelenooctabutoxyphthalocyanine","zinc(II)-tetradibenzobarrelenooctabutoxyphthalocyanine","C092992",0,0,0,0,0,1,0,0,0]
["ZINC32101539","ZINC32101539","C000612733",0,0,0,0,0,0,1,0,0]
["ZINC33468944","ZINC33468944","C000612732",0,0,0,0,0,0,1,0,0]
["ZK 112993","ZK 112993","C064879",0,0,0,0,0,1,0,0,0]
["Zn(II)-phthalocyanine","Zn(II)-phthalocyanine","C052159",0,1,0,0,0,5,0,0,0]
["Zolazepam","Zolazepam","D015041",0,0,0,0,0,0,1,0,0]
["zolpidem","zolpidem","C049109",2,0,0,0,0,0,0,0,0]
["Zoxazolamine","Zoxazolamine","D015049",0,0,0,0,0,0,1,0,0]
["Zyflamend","Zyflamend","C519312",1,0,0,0,0,0,1,0,0]
["Zymosan","Zymosan","D015054",0,0,0,0,0,6,0,0,0]

{"sheet":"Detail","index":1,"n_rows":33944,"n_cols":18,"rows_kept":4500,"cut":true,"hidden":false,"merged":[],"bounds":{"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0}}
["Detail - AOP "]
["Chemical MeSH Name (hyperlinked)","ChemName","chemuid","catord","event_id","event_order","Event Process","Event Action","MeSH term (hyperlinked)","uid","MeSHterm","basescore","Score","Pub Yr","pmid","Title","LinkPMID","aop_id"]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3,B3)","v":"(1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea)"},"(1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea)","C496792","7_KE",54,7,"CD36","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J3,K3)","v":"CD36 Antigens"},"D018955","CD36 Antigens",1,1,2004,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q3,Q3)","v":"15102890"},"Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide.","15102890",57]
["(1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea)","(1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea)","C496792","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2005,"15866482","Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI.","15866482",57]
["(1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea)","(1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea)","C496792","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15866482","Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI.","15866482",57]
["(1-(chloromethyl)-1,2-dihydropyrrolo(3,2-e)indol-3(6H)-yl)(5-methoxy-1H-indol-2-yl)methanone","(1-(chloromethyl)-1,2-dihydropyrrolo(3,2-e)indol-3(6H)-yl)(5-methoxy-1H-indol-2-yl)methanone","C581919","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23033491","Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.","23033491",57]
["(1-6)-alpha-glucomannan","(1-6)-alpha-glucomannan","C022901","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"28169529","Deacetylated Konjac Glucomannan Is Less Effective in Reducing Dietary-Induced Hyperlipidemia and Hepatic Steatosis in C57BL/6 Mice.","28169529",57]
["(1-6)-alpha-glucomannan","(1-6)-alpha-glucomannan","C022901","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1988,"3253184","[Antihypercholesterolemic and antisteatotic effect of Konjac-polysaccharide in rats fed high cholesterol diet].","3253184",57]
["(1-6)-alpha-glucomannan","(1-6)-alpha-glucomannan","C022901","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,1995,"7627263","Long-term effects of dietary fiber supplementation on serum glucose and lipoprotein levels in diabetic rats fed a high cholesterol diet.","7627263",57]
["(1-6)-alpha-glucomannan","(1-6)-alpha-glucomannan","C022901","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7627263","Long-term effects of dietary fiber supplementation on serum glucose and lipoprotein levels in diabetic rats fed a high cholesterol diet.","7627263",57]
["(1-6)-alpha-glucomannan","(1-6)-alpha-glucomannan","C022901","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1995,"7627263","Long-term effects of dietary fiber supplementation on serum glucose and lipoprotein levels in diabetic rats fed a high cholesterol diet.","7627263",57]
["(1-6)-alpha-glucomannan","(1-6)-alpha-glucomannan","C022901","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"28169529","Deacetylated Konjac Glucomannan Is Less Effective in Reducing Dietary-Induced Hyperlipidemia and Hepatic Steatosis in C57BL/6 Mice.","28169529",57]
["(1-hydroxy-2-oxo-3-(N-methyl-3-aminopropyl)-3-methyl-3-aminopropyl)-3-methyl-1-triazene","(1-hydroxy-2-oxo-3-(N-methyl-3-aminopropyl)-3-methyl-3-aminopropyl)-3-methyl-1-triazene","C100973","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1996,"8946952","Nitric oxide released from zwitterionic polyamine/NO adducts inhibits Cu2+-induced low density lipoprotein oxidation.","8946952",57]
["(2-(2',3'-dihydrobenzo(1,4)dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethylethyl)nonanoic acid amide","(2-(2',3'-dihydrobenzo(1,4)dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethylethyl)nonanoic acid amide","C520404","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19444873","Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.","19444873",57]
["(2,2-bis(docosyloxymethyl)propyl-5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium oxysulfonyl)glycero-alpha-galacto-2-nonulopyranosid)onate","(2,2-bis(docosyloxymethyl)propyl-5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium oxysulfonyl)glycero-alpha-galacto-2-nonulopyranosid)onate","C413863","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2004,"15542636","Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer.","15542636",57]
["(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid","(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid","C487689","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"28591717","Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet.","28591717",57]
["(3,4-dihydroxyphenylamino)-2-imidazoline","(3,4-dihydroxyphenylamino)-2-imidazoline","C011775","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11278710","The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide.","11278710",57]
["(3,4-dihydroxyphenylamino)-2-imidazoline","(3,4-dihydroxyphenylamino)-2-imidazoline","C011775","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2001,"11278710","The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide.","11278710",57]
["(3,5,6-trimethylpyrazin-2-yl)methyl 2-(4-(2-methylpropyl)phenyl)propanoate","(3,5,6-trimethylpyrazin-2-yl)methyl 2-(4-(2-methylpropyl)phenyl)propanoate","C495410","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16545771","A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo.","16545771",57]
["(3,5,6-trimethylpyrazin-2-yl)methyl 2-(4-(2-methylpropyl)phenyl)propanoate","(3,5,6-trimethylpyrazin-2-yl)methyl 2-(4-(2-methylpropyl)phenyl)propanoate","C495410","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16545771","A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo.","16545771",57]
["(5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine","(5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine","C502305","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15792786","Effects of KR-32570, a new Na+/H+ exchanger inhibitor, on functional and metabolic impairments produced by global ischemia and reperfusion in the perfused rat heart.","15792786",57]
["(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid","(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid","C561635","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2011,"21642745","Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors.","21642745",57]
["(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid","(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid","C561635","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2011,"21661758","Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.","21661758",57]
["(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine","(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine","C516138","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21963507","meso-Dihydroguaiaretic acid inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells.","21963507",57]
["(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine","(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine","C516138","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21963507","meso-Dihydroguaiaretic acid inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells.","21963507",57]
["(9Z, 11E)-tetradecadienyl acetate","(9Z, 11E)-tetradecadienyl acetate","C505894","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2017,"28349297","Molecular identification of differential expression genes associated with sex pheromone biosynthesis in Spodoptera exigua.","28349297",57]
["(all-E) phytoene","(all-E) phytoene","C100185","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2008,"18443908","A carotenoid algal preparation containing phytoene and phytofluene inhibited LDL oxidation in vitro.","18443908",57]
["(cyano-C)(diphenyl(aminomethyl)phosphonate-N)dihydroboron","(cyano-C)(diphenyl(aminomethyl)phosphonate-N)dihydroboron","C076461","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1518770","Hypolipidaemic activity in rodents of boron analogs of phosphonoacetates and cyanoborane adducts of dialkyl aminomethylphosphonates.","1518770",57]
["(methylcarboxy-C)(triethylphosphonate-P)dihydroboron","(methylcarboxy-C)(triethylphosphonate-P)dihydroboron","C076462","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1518770","Hypolipidaemic activity in rodents of boron analogs of phosphonoacetates and cyanoborane adducts of dialkyl aminomethylphosphonates.","1518770",57]
["(R)-3-hydroxybutyl (R)-3-hydroxybutyrate","(R)-3-hydroxybutyl (R)-3-hydroxybutyrate","C576699","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,2015,"26498829","An Ester of β-Hydroxybutyrate Regulates Cholesterol Biosynthesis in Rats and a Cholesterol Biomarker in Humans.","26498829",57]
["(Z)-N-(2-hydroxyethyl) docos-13-enamide","(Z)-N-(2-hydroxyethyl) docos-13-enamide","C583814","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"23227559","[The hypolipidemic and liver protective effect of (Z)-N-(2-hydroxyethyl) docos-13-enamide on hyperlipidemic golden hamsters].","23227559",57]
["1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid","1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid","C466644","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18587443","Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions.","18587443",57]
["1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid","1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid","C466644","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2003,"12679152","Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.","12679152",57]
["1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid","1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid","C466644","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2003,"12839864","Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.","12839864",57]
["1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine, monohydrochloride","1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine, monohydrochloride","C569631","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22225957","Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.","22225957",57]
["1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea","1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea","C561574","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22331760","Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats.","22331760",57]
["1-(1,4-benzodioxan-6-ylcarbonyl)piperidine","1-(1,4-benzodioxan-6-ylcarbonyl)piperidine","C443080","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19605837","Memory and the NMDA receptors.","19605837",57]
["1-(1H-indol-3-yl)-3-(3H-indol-3-ylidene)propan-2-one","1-(1H-indol-3-yl)-3-(3H-indol-3-ylidene)propan-2-one","C547593","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2009,"19860415","D-amino acid oxidase generates agonists of the aryl hydrocarbon receptor from D-tryptophan.","19860415",57]
["1-(1H-indol-3-yl)-9H-pyrido(3,4-b)indole","1-(1H-indol-3-yl)-9H-pyrido(3,4-b)indole","C561449","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21722628","Discovery and biological characterization of 1-(1H-indol-3-yl)-9H-pyrido[3,4-b]indole as an aryl hydrocarbon receptor activator generated by photoactivation of tryptophan by sunlight.","21722628",57]
["1-(1H-indol-3-yl)-9H-pyrido(3,4-b)indole","1-(1H-indol-3-yl)-9H-pyrido(3,4-b)indole","C561449","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2011,"21722628","Discovery and biological characterization of 1-(1H-indol-3-yl)-9H-pyrido[3,4-b]indole as an aryl hydrocarbon receptor activator generated by photoactivation of tryptophan by sunlight.","21722628",57]
["1-(1H-indol-3-yl)-9H-pyrido(3,4-b)indole","1-(1H-indol-3-yl)-9H-pyrido(3,4-b)indole","C561449","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21722628","Discovery and biological characterization of 1-(1H-indol-3-yl)-9H-pyrido[3,4-b]indole as an aryl hydrocarbon receptor activator generated by photoactivation of tryptophan by sunlight.","21722628",57]
["1-(1-propynyl)pyrene","1-(1-propynyl)pyrene","C402363","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10581206","Metabolism-based polycyclic aromatic acetylene inhibition of CYP1B1 in 10T1/2 cells potentiates aryl hydrocarbon receptor activity.","10581206",57]
["1-(1-propynyl)pyrene","1-(1-propynyl)pyrene","C402363","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,1999,"10581206","Metabolism-based polycyclic aromatic acetylene inhibition of CYP1B1 in 10T1/2 cells potentiates aryl hydrocarbon receptor activity.","10581206",57]
["1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide","1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide","C554616","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2015,"25656402","A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.","25656402",57]
["1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole","1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole","C472829","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2003,"12855660","The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.","12855660",57]
["1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one","1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one","C000603962","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"26354992","Inhibition of mitogen-activated protein kinases/nuclear factor κB-dependent inflammation by a novel chalcone protects the kidney from high fat diet-induced injuries in mice.","26354992",57]
["1-(3-trifluoromethylphenyl)-2-(N-(2-hydroxyethyl)amino)propane","1-(3-trifluoromethylphenyl)-2-(N-(2-hydroxyethyl)amino)propane","C073864","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1991,"1666560","The liver metabolite S-422 of the hypolipidaemic drug benfluorex decreases cholesterol esterification in fibroblasts and monocyte-like cells.","1666560",57]
["1-(4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)butyl)-4-aza-1-azoniabicyclo(2.2.2)octane","1-(4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)butyl)-4-aza-1-azoniabicyclo(2.2.2)octane","C466800","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2003,"12562847","Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.","12562847",57]
["1-(4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)butyl)-4-aza-1-azoniabicyclo(2.2.2)octane","1-(4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)butyl)-4-aza-1-azoniabicyclo(2.2.2)octane","C466800","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2003,"12562847","Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.","12562847",57]
["1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone","1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone","C517943","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26475489","G protein-coupled receptor 30 ligand G-1 increases aryl hydrocarbon receptor signalling by inhibition of tubulin assembly and cell cycle arrest in human MCF-7 cells.","26475489",57]
["1-(4-chlorophenyl)-benzo-2,5-quinone","1-(4-chlorophenyl)-benzo-2,5-quinone","C000597136","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25668756","Ligand-independent activation of aryl hydrocarbon receptor signaling in PCB3-quinone treated HaCaT human keratinocytes.","25668756",57]
["1-(4-chlorophenyl)-benzo-2,5-quinone","1-(4-chlorophenyl)-benzo-2,5-quinone","C000597136","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25668756","Ligand-independent activation of aryl hydrocarbon receptor signaling in PCB3-quinone treated HaCaT human keratinocytes.","25668756",57]
["1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide","1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide","C481758","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2008,"18816293","The influence of acetylcholinesterase reactivators on selected hepatic functions in rats.","18816293",57]
["1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine","1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine","D019307","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2017,"28223486","Serum-borne bioactivity caused by pulmonary multiwalled carbon nanotubes induces neuroinflammation via blood-brain barrier impairment.","28223486",57]
["1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine","1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine","D019307","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2005,"15840411","Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice.","15840411",57]
["1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione","1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione","C060229","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2013,"23468551","The phospholipase C inhibitor U73122 attenuates trans-10, cis-12 conjugated linoleic acid-mediated inflammatory signaling and insulin resistance in human adipocytes.","23468551",57]
["1'-(6-(5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl)pyridazin-3-yl)-5-(trifluoromethyl)-3,4-dihydrospiro(chromene-2,4'-piperidine)","1'-(6-(5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl)pyridazin-3-yl)-5-(trifluoromethyl)-3,4-dihydrospiro(chromene-2,4'-piperidine)","C548720","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2010,"20006498","Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine].","20006498",57]
["1-(beta-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetra-hydroisoquinoline","1-(beta-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetra-hydroisoquinoline","C495109","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27343380","(S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.","27343380",57]
["1-(carboxyethylthio)tetradecane","1-(carboxyethylthio)tetradecane","C062077","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2016,"26846427","Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice.","26846427",57]
["1-(carboxyethylthio)tetradecane","1-(carboxyethylthio)tetradecane","C062077","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26846427","Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice.","26846427",57]
["1-(carboxymethylthio)tetradecane","1-(carboxymethylthio)tetradecane","C062078","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1998,"9973177","Early modulation of genes encoding peroxisomal and mitochondrial beta-oxidation enzymes by 3-thia fatty acids.","9973177",57]
["1-(carboxymethylthio)tetradecane","1-(carboxymethylthio)tetradecane","C062078","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10832068","Tetradecylthioacetic acid and tetradecylselenoacetic acid inhibit lipid peroxidation and interact with superoxide radical.","10832068",57]
["1-(carboxymethylthio)tetradecane","1-(carboxymethylthio)tetradecane","C062078","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11684079","Sustained retention of tetradecylthioacetic acid after local delivery reduces angioplasty-induced coronary stenosis in the minipig.","11684079",57]
["1-(carboxymethylthio)tetradecane","1-(carboxymethylthio)tetradecane","C062078","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11931845","Inhibition of rat lipoprotein oxidation after tetradecylthioacetic acid feeding.","11931845",57]
["1-(carboxymethylthio)tetradecane","1-(carboxymethylthio)tetradecane","C062078","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9409320","Tetradecylthioacetic acid inhibits the oxidative modification of low density lipoprotein and 8-hydroxydeoxyguanosine formation in vitro.","9409320",57]
["1-(carboxymethylthio)tetradecane","1-(carboxymethylthio)tetradecane","C062078","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"11931845","Inhibition of rat lipoprotein oxidation after tetradecylthioacetic acid feeding.","11931845",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C67,B67)","v":"1-(carboxymethylthio)tetradecane"},"1-(carboxymethylthio)tetradecane","C062078","2_KE",450,2,"VLDL secretion","Suppression",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J67,K67)","v":"Lipoproteins, VLDL"},"D008079","Lipoproteins, VLDL",1,1,1997,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q67,Q67)","v":"9101436"},"Up-regulated delta 9-desaturase gene expression by hypolipidemic peroxisome-proliferating fatty acids results in increased oleic acid content in liver and VLDL: accumulation of a delta 9-desaturated metabolite of tetradecylthioacetic acid.","9101436",57]
["1-(carboxymethylthio)tetradecane","1-(carboxymethylthio)tetradecane","C062078","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2006,"16971150","Effects of 3-thia fatty acids on expression of some lipid related genes in Atlantic salmon (Salmo salar L.).","16971150",57]
["1-(carboxymethylthio)tetradecane","1-(carboxymethylthio)tetradecane","C062078","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,1997,"9101436","Up-regulated delta 9-desaturase gene expression by hypolipidemic peroxisome-proliferating fatty acids results in increased oleic acid content in liver and VLDL: accumulation of a delta 9-desaturated metabolite of tetradecylthioacetic acid.","9101436",57]
["1,1,1,2-tetrafluoro-2-chloroethane","1,1,1,2-tetrafluoro-2-chloroethane","C072959","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2001,"11548120","Investigations on the liver toxicity of a blend of HCFC-123 (2,2-dichloro-1,1,1-trifluoroethane) and HCFC-124 (2-chloro-1,1,1,2-tetrafluoroethane) in guinea-pigs.","11548120",57]
["1,1,1-trichloroethane","1,1,1-trichloroethane","C024566","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1991,"1953241","1,1,1-trichloroethane and the liver.","1953241",57]
["1,1,1-trichloroethane","1,1,1-trichloroethane","C024566","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1989,"2669664","Liver disease associated with exposure to 1,1,1-trichloroethane.","2669664",57]
["1,1,2,2-tetrahydroheptadecafluorodecanol-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol","1,1,2,2-tetrahydroheptadecafluorodecanol-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol","C505284","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2006,"16880635","Effects of 8-2 fluorotelomer alcohol on oleic acid formation in the liver of rats.","16880635",57]
["1,1,3,3-tetramethylurea","1,1,3,3-tetramethylurea","C004168","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"7444342","Studies on the protein composition of human serum very low density lipoproteins with particular reference to the presence or absence of late pre-beta lipoprotein (Lp beta).","7444342",57]
["1,10-bis(carboxymethylthiodecane)","1,10-bis(carboxymethylthiodecane)","C062079","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1998,"9973177","Early modulation of genes encoding peroxisomal and mitochondrial beta-oxidation enzymes by 3-thia fatty acids.","9973177",57]
["1,10-bis(carboxymethylthiodecane)","1,10-bis(carboxymethylthiodecane)","C062079","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1993,"8218098","Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis.","8218098",57]
["1,10-phenanthroline","1,10-phenanthroline","C025205","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27180721","Mixed-ligand copper(II) complexes activate aryl hydrocarbon receptor AhR and induce CYP1A genes expression in human hepatocytes and human cell lines.","27180721",57]
["1,10-phenanthroline","1,10-phenanthroline","C025205","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2016,"27180721","Mixed-ligand copper(II) complexes activate aryl hydrocarbon receptor AhR and induce CYP1A genes expression in human hepatocytes and human cell lines.","27180721",57]
["1,12-benzoperylene","1,12-benzoperylene","C006718","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11141357","Benzo[g,h,i]perylene synergistically transactivates benzo[a]pyrene-induced CYP1A1 gene expression by aryl hydrocarbon receptor pathway.","11141357",57]
["1,12-benzoperylene","1,12-benzoperylene","C006718","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2001,"11141357","Benzo[g,h,i]perylene synergistically transactivates benzo[a]pyrene-induced CYP1A1 gene expression by aryl hydrocarbon receptor pathway.","11141357",57]
["1,12-benzoperylene","1,12-benzoperylene","C006718","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2016,"27234499","Benzo[ghi]perylene activates the AHR pathway to exert biological effects on the NL-20 human bronchial cell line.","27234499",57]
["1,1-bis(3'-indolyl)-1-(4-t-butylphenyl)methane","1,1-bis(3'-indolyl)-1-(4-t-butylphenyl)methane","C505816","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2008,"18501502","Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs.","18501502",57]
["1,1-bis(3'-indolyl)methane","1,1-bis(3'-indolyl)methane","C512018","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26712945","Dietary Indoles Suppress Delayed-Type Hypersensitivity by Inducing a Switch from Proinflammatory Th17 Cells to Anti-Inflammatory Regulatory T Cells through Regulation of MicroRNA.","26712945",57]
["1,1-dichloroethane","1,1-dichloroethane","C501196","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11606809","Acute, subacute, and subchronic oral toxicity studies of 1,1-dichloroethane in rats: application to risk evaluation.","11606809",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2000,"11063915","Antioxidant properties of di-tert-butylhydroxylated flavonoids.","11063915",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10403533","Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies.","10403533",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10597884","Ibuprofen protects low density lipoproteins against oxidative modification.","10597884",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10600174","Inhibitory effect of quercetin metabolites and their related derivatives on copper ion-induced lipid peroxidation in human low-density lipoprotein.","10600174",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10832068","Tetradecylthioacetic acid and tetradecylselenoacetic acid inhibit lipid peroxidation and interact with superoxide radical.","10832068",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11137086","Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.","11137086",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11814152","Antioxidant ability of various flavonoids against DPPH radicals and LDL oxidation.","11814152",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2002,"11842320","Antioxidant effects of 1,5-anhydro-D-fructose, a new natural sugar, in vitro.","11842320",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11929315","Comparison of radical scavenging effect, inhibition of microsomal oxygen free radical generation, and serum lipoprotein oxidation of several natural antioxidants.","11929315",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1279277","In vitro and ex vivo inhibition of the modification of low-density lipoprotein by indapamide.","1279277",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15080652","Screening for antioxidant activity in edible plant products: comparison of low-density lipoprotein oxidation assay, DPPH radical scavenging assay, and Folin-Ciocalteu assay.","15080652",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15736921","Hypochlorous acid scavenging properties of local Mediterranean plant foods.","15736921",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7670947","Paracetamol inhibits copper ion-induced, azo compound-initiated, and mononuclear cell-mediated oxidative modification of LDL.","7670947",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8827529","Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein.","8827529",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9032944","Beta-blockers inhibit the modification of low-density lipoproteins by sodium hypochlorite in vitro.","9032944",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9395251","Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests.","9395251",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9280299","Antioxidant role of melatonin in lipid peroxidation of human LDL.","9280299",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9461249","Isoorientin-6\"-O-glucoside, a water-soluble antioxidant isolated from Gentiana arisanensis.","9461249",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9514418","Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza.","9514418",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9630680","Antioxidant properties of butein isolated from Dalbergia odorifera.","9630680",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9641259","Structural aspects of the inhibitory effect of glabridin on LDL oxidation.","9641259",57]
["1,1-diphenyl-2-picrylhydrazyl","1,1-diphenyl-2-picrylhydrazyl","C004931","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1999,"10375392","Oxidative modification of apolipoprotein E in human very-low-density lipoprotein and its inhibition by glycosaminoglycans.","10375392",57]
["1,2,3,4,4a,7,8,8a-octahydro-4,4a-methano-7-methyl-8-(2-(2,4-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthyl 2-methylbutanoate","1,2,3,4,4a,7,8,8a-octahydro-4,4a-methano-7-methyl-8-(2-(2,4-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthyl 2-methylbutanoate","C120872","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10400160","Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration.","10400160",57]
["1,2,3,4,5,6-hexachloronaphthalene","1,2,3,4,5,6-hexachloronaphthalene","C049022","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"19783048","Toxicity of hexachloronaphthalene (HxCN) and induction of CYP 1A in rats.","19783048",57]
["1,2,3,4,5,6-hexachloronaphthalene","1,2,3,4,5,6-hexachloronaphthalene","C049022","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"26403959","Developmental toxicity of hexachloronaphthalene in Wistar rats. A role of CYP1A1 expression.","26403959",57]
["1,2,3,4,5,6-hexachloronaphthalene","1,2,3,4,5,6-hexachloronaphthalene","C049022","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2018,"29663608","The effects of hexachloronaphthalene on selected parameters of heme biosynthesis and systemic toxicity in female wistar rats after 90-day oral exposure.","29663608",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11510945","Kinetics and inductive potency of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (H7CDD) in rats.","11510945",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12030841","Structure-activity relationships and dose responses of polychlorinated dibenzo-p-dioxins for short-term effects in 2,3,7,8-tetrachlorodibenzo-p-dioxin-resistant and -sensitive rat strains.","12030841",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1992,"1332652","Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part III: Structure-activity relationship with increased plasma tryptophan levels, but no relationship to hepatic ethoxyresorufin o-deethylase activity.","1332652",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"7850387","Subchronic (13-week) toxicity of heptachlorodibenzo-p-dioxin in male Sprague-Dawley rats.","7850387",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9344889","Subchronic/chronic toxicity of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD) in rats. Part II. Biochemical effects.","9344889",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9705888","Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. II. Biochemical effects.","9705888",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1992,"1359853","Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part II: Structure-activity relationships with inhibition of hepatic phosphoenolpyruvate carboxykinase, pyruvate carboxylase, and gamma-glutamyl transpeptidase activities.","1359853",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1994,"7850387","Subchronic (13-week) toxicity of heptachlorodibenzo-p-dioxin in male Sprague-Dawley rats.","7850387",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1998,"9705888","Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. II. Biochemical effects.","9705888",57]
["1,2,3,4,6,7,8-heptachlorodibenzodioxin","1,2,3,4,6,7,8-heptachlorodibenzodioxin","C046839","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1992,"1332652","Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part III: Structure-activity relationship with increased plasma tryptophan levels, but no relationship to hepatic ethoxyresorufin o-deethylase activity.","1332652",57]
["1,2,3,4,6,7-hexachlorinated naphthalene","1,2,3,4,6,7-hexachlorinated naphthalene","C412791","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22813907","Repeated dose toxicity and relative potency of 1,2,3,4,6,7-hexachloronaphthalene (PCN 66) 1,2,3,5,6,7-hexachloronaphthalene (PCN 67) compared to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for induction of CYP1A1, CYP1A2 and thymic atrophy in female Harlan Sprague-Dawley rats.","22813907",57]
["1,2,3,4,7,8-hexachlorodibenzodioxin","1,2,3,4,7,8-hexachlorodibenzodioxin","C078219","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1992,"1332652","Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part III: Structure-activity relationship with increased plasma tryptophan levels, but no relationship to hepatic ethoxyresorufin o-deethylase activity.","1332652",57]
["1,2,3,4,7,8-hexachlorodibenzodioxin","1,2,3,4,7,8-hexachlorodibenzodioxin","C078219","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2007,"17448584","Differences in acute toxicity syndromes of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin in rats.","17448584",57]
["1,2,3,4,7,8-hexachlorodibenzodioxin","1,2,3,4,7,8-hexachlorodibenzodioxin","C078219","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1992,"1359853","Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part II: Structure-activity relationships with inhibition of hepatic phosphoenolpyruvate carboxykinase, pyruvate carboxylase, and gamma-glutamyl transpeptidase activities.","1359853",57]
["1,2,3,4,7,8-hexachlorodibenzodioxin","1,2,3,4,7,8-hexachlorodibenzodioxin","C078219","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1992,"1332652","Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part III: Structure-activity relationship with increased plasma tryptophan levels, but no relationship to hepatic ethoxyresorufin o-deethylase activity.","1332652",57]
["1,2,3,4,7,8-hexachlorodibenzodioxin","1,2,3,4,7,8-hexachlorodibenzodioxin","C078219","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2007,"17448584","Differences in acute toxicity syndromes of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin in rats.","17448584",57]
["1,2,3,4-tetrachlorodibenzodioxin","1,2,3,4-tetrachlorodibenzodioxin","C092155","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11737705","Effect of lactational exposure to 1,2,3,4- tetrachlorodibenzo-p-dioxin on cytochrome P-450 1A1 mRNA in the neonatal rat liver: quantitative analysis by the competitive RT-PCR method.","11737705",57]
["1,2,3,4-tetrachlorodibenzodioxin","1,2,3,4-tetrachlorodibenzodioxin","C092155","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1996,"8792845","Stimulation of calcium uptake in cultured rat hippocampal neurons by 2,3,7,8-tetrachlorodibenzo-p-dioxin.","8792845",57]
["1,2,3,5,6,7-hexachloronaphthalene","1,2,3,5,6,7-hexachloronaphthalene","C575652","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22813907","Repeated dose toxicity and relative potency of 1,2,3,4,6,7-hexachloronaphthalene (PCN 66) 1,2,3,5,6,7-hexachloronaphthalene (PCN 67) compared to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for induction of CYP1A1, CYP1A2 and thymic atrophy in female Harlan Sprague-Dawley rats.","22813907",57]
["1,2,3,6,7,8-hexachlorodibenzodioxin","1,2,3,6,7,8-hexachlorodibenzodioxin","C046838","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12030841","Structure-activity relationships and dose responses of polychlorinated dibenzo-p-dioxins for short-term effects in 2,3,7,8-tetrachlorodibenzo-p-dioxin-resistant and -sensitive rat strains.","12030841",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C131,B131)","v":"1,2,3,6,7,8-hexachlorodibenzodioxin"},"1,2,3,6,7,8-hexachlorodibenzodioxin","C046838","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J131,K131)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,1998,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q131,Q131)","v":"9705888"},"Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. II. Biochemical effects.","9705888",57]
["1,2,3,6,7,8-hexachlorodibenzodioxin","1,2,3,6,7,8-hexachlorodibenzodioxin","C046838","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1998,"9705888","Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. II. Biochemical effects.","9705888",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10487418","Metabolism of polychlorinated dibenzo-p-dioxins by rat liver microsomes.","10487418",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12030841","Structure-activity relationships and dose responses of polychlorinated dibenzo-p-dioxins for short-term effects in 2,3,7,8-tetrachlorodibenzo-p-dioxin-resistant and -sensitive rat strains.","12030841",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1992,"1332652","Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part III: Structure-activity relationship with increased plasma tryptophan levels, but no relationship to hepatic ethoxyresorufin o-deethylase activity.","1332652",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1455422","Absence of interactions on hepatic retention and 7-ethoxyresorufin-O-deethylation activity after co-administration of 1,2,3,7,8-pentachlorodibenzo-p-dioxin and 2,4,5,2',4',5'-hexachlorobiphenyl.","1455422",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"14736496","Evaluation of toxic equivalency factors for induction of cytochromes P450 CYP1A1 and CYP1A2 enzyme activity by dioxin-like compounds.","14736496",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16929009","In utero exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin induces amphiregulin gene expression in the developing mouse ureter.","16929009",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19607907","Factorial design applied for multiple endpoint toxicity evaluation in Atlantic salmon (Salmo salar L.) hepatocytes.","19607907",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21458559","Development of a co-culture model for in vitro toxicological studies in Atlantic salmon.","21458559",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1989,"2545344","Structure-dependent induction of aryl hydrocarbon hydroxylase in human breast cancer cell lines and characterization of the Ah receptor.","2545344",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1992,"1359853","Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part II: Structure-activity relationships with inhibition of hepatic phosphoenolpyruvate carboxykinase, pyruvate carboxylase, and gamma-glutamyl transpeptidase activities.","1359853",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1992,"1332652","Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part III: Structure-activity relationship with increased plasma tryptophan levels, but no relationship to hepatic ethoxyresorufin o-deethylase activity.","1332652",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"16929009","In utero exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin induces amphiregulin gene expression in the developing mouse ureter.","16929009",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1990,"2154986","2,3,7,8-Tetrachlorodibenzo-p-dioxin as an antiestrogen: effect on rat uterine peroxidase activity.","2154986",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1989,"2545344","Structure-dependent induction of aryl hydrocarbon hydroxylase in human breast cancer cell lines and characterization of the Ah receptor.","2545344",57]
["1,2,3,7,8-pentachlorodibenzo-p-dioxin","1,2,3,7,8-pentachlorodibenzo-p-dioxin","C051452","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1987,"3029898","Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic and uterine estrogen receptor levels in rats.","3029898",57]
["1,2,4,5-tetrabromobenzene","1,2,4,5-tetrabromobenzene","C110818","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2004,"15683155","Effect of repeated administration of hexabromobenzene and 1,2,4,5-tetrabromobenzene on the levels of selected cytochromes in rat liver.","15683155",57]
["1,2,4,5-tetrachlorobenzene","1,2,4,5-tetrachlorobenzene","C018673","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1983,"6413203","Maternal hepatic effects of 1,2,4,5-tetrachlorobenzene in the rat.","6413203",57]
["1,2,4-triazine","1,2,4-triazine","C093444","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22414679","Synthesis and structure elucidation of novel fused 1,2,4-triazine derivatives as potent inhibitors targeting CYP1A1 activity.","22414679",57]
["1,2,4-trichlorobenzene","1,2,4-trichlorobenzene","C009947","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20961080","Development of a partition-controlled dosing system for cell assays.","20961080",57]
["1,2,4-trichlorobenzene","1,2,4-trichlorobenzene","C009947","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1983,"6605599","Differential induction of hepatic drug metabolizing enzymes in Japanese quail by 1,2,4-trichlorobenzene.","6605599",57]
["1,2,4-trichlorodibenzo-1,4-dioxin","1,2,4-trichlorodibenzo-1,4-dioxin","C090523","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20655778","Specific interactions between aryl hydrocarbon receptor and dioxin congeners: ab initio fragment molecular orbital calculations.","20655778",57]
["1,2,5,6-dibenzanthracene","1,2,5,6-dibenzanthracene","C026486","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26744022","Use of the Integrated Biomarker Response to Measure the Effect of Short-term Exposure to Dibenz[a,h]anthracene in Common carp (Cyprinus carpio).","26744022",57]
["1,2,5,6-dibenzanthracene","1,2,5,6-dibenzanthracene","C026486","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1984,"6322977","Binding of benzo(a)pyrene and dibenz(a,h)anthracene to the Ah receptor in mouse and rat hepatic cytosols.","6322977",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15934323","Detection of interaction of binding affinity of aromatic hydrocarbon receptor to the specific DNA by exonuclease protection mediated PCR assay.","15934323",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16545771","A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo.","16545771",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20420201","The effect of TCDD dioxin on the rat liver in biochemical and histological assessment.","20420201",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"26600472","Determination of Heavy Metal Concentrations in Normal and Pathological Human Endometrial Biopsies and In Vitro Regulation of Gene Expression by Metals in the Ishikawa and Hec-1b Endometrial Cell Line.","26600472",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2002,"12062155","cDNA cloning and characterization of an aryl hydrocarbon receptor from the harbor seal (Phoca vitulina): a biomarker of dioxin susceptibility?","12062155",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2005,"15792965","Activation of the aryl hydrocarbon receptor increases pulmonary neutrophilia and diminishes host resistance to influenza A virus.","15792965",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15934323","Detection of interaction of binding affinity of aromatic hydrocarbon receptor to the specific DNA by exonuclease protection mediated PCR assay.","15934323",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16545771","A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo.","16545771",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19371626","Transgenic mouse lines expressing rat AH receptor variants--a new animal model for research on AH receptor function and dioxin toxicity mechanisms.","19371626",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21048045","Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier.","21048045",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22230337","2,3,7,8-Tetrachlorodibenzo-p-dioxin treatment alters eicosanoid levels in several organs of the mouse in an aryl hydrocarbon receptor-dependent fashion.","22230337",57]
["1,2,7,8-tetrachlorodibenzo-p-dioxin","1,2,7,8-tetrachlorodibenzo-p-dioxin","C445379","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26600472","Determination of Heavy Metal Concentrations in Normal and Pathological Human Endometrial Biopsies and In Vitro Regulation of Gene Expression by Metals in the Ishikawa and Hec-1b Endometrial Cell Line.","26600472",57]
["1,25-dihydroxyvitamin D","1,25-dihydroxyvitamin D","C097949","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2009,"19667238","1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus.","19667238",57]
["1,25-dihydroxyvitamin D","1,25-dihydroxyvitamin D","C097949","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19667238","1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus.","19667238",57]
["1,25-dihydroxyvitamin D","1,25-dihydroxyvitamin D","C097949","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25684936","Vitamin D: a new player in non-alcoholic fatty liver disease?","25684936",57]
["1,25-dihydroxyvitamin D","1,25-dihydroxyvitamin D","C097949","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25906757","1,25(OH)2D3 downregulates the Toll-like receptor 4-mediated inflammatory pathway and ameliorates liver injury in diabetic rats.","25906757",57]
["1,25-dihydroxyvitamin D","1,25-dihydroxyvitamin D","C097949","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2015,"26030589","Regulation of Adipogenesis and Key Adipogenic Gene Expression by 1, 25-Dihydroxyvitamin D in 3T3-L1 Cells.","26030589",57]
["1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester","1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester","C070379","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14977048","Induction of lipoprotein lipase gene expression in Chlamydia pneumoniae-infected macrophages is dependent on Ca2+ signaling events.","14977048",57]
["1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid","1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid","C025603","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12086682","Native low-density lipoprotein induces endothelial nitric oxide synthase dysfunction: role of heat shock protein 90 and caveolin-1.","12086682",57]
["1,2-cyclohexanedione","1,2-cyclohexanedione","C018031","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"4067428","Effects of 1,2-cyclohexanedione modification on the metabolism of very low density lipoprotein apolipoprotein B: potential role of receptors in intermediate density lipoprotein catabolism.","4067428",57]
["1,2-cyclohexanedione","1,2-cyclohexanedione","C018031","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"6282270","Degradation by cultured fibroblasts and macrophages of unmodified and 1,2-cyclohexanedione-modified low-density lipoprotein from normal and homozygous familial hypercholesterolaemic subjects.","6282270",57]
["1,2-cyclohexanedione","1,2-cyclohexanedione","C018031","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"4067428","Effects of 1,2-cyclohexanedione modification on the metabolism of very low density lipoprotein apolipoprotein B: potential role of receptors in intermediate density lipoprotein catabolism.","4067428",57]
["1,2-cyclohexanedione","1,2-cyclohexanedione","C018031","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"7308485","The effect of selective modification of the arginyl residues of partially-metabolized very low density lipoproteins on their uptake by the liver.","7308485",57]
["1,2-cyclohexanedione","1,2-cyclohexanedione","C018031","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1985,"4067428","Effects of 1,2-cyclohexanedione modification on the metabolism of very low density lipoprotein apolipoprotein B: potential role of receptors in intermediate density lipoprotein catabolism.","4067428",57]
["1,2-cyclohexanedione","1,2-cyclohexanedione","C018031","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1982,"6282270","Degradation by cultured fibroblasts and macrophages of unmodified and 1,2-cyclohexanedione-modified low-density lipoprotein from normal and homozygous familial hypercholesterolaemic subjects.","6282270",57]
["1,2-diacylglycerol","1,2-diacylglycerol","C011439","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2003,"12798429","Impact of alpha-tocopherol on cardiac hypertrophy due to energy metabolism disorder: the involvement of 1,2-diacylglycerol.","12798429",57]
["1,2-diacylglycerol","1,2-diacylglycerol","C011439","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21480517","Hepatic steatosis by dietary-conjugated linoleic acid is accompanied by accumulation of diacylglycerol and increased membrane-associated protein kinase C ε in mice.","21480517",57]
["1,2-diacylglycerol","1,2-diacylglycerol","C011439","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22560210","Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance.","22560210",57]
["1,2-diacylglycerol","1,2-diacylglycerol","C011439","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1997,"9296524","Hepatic protein kinase C is not activated despite high intracellular 1,2-sn-diacylglycerol in obese Zucker rats.","9296524",57]
["1,2-diacylglycerol","1,2-diacylglycerol","C011439","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22560210","Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance.","22560210",57]
["1,2-dibromo-1,2-dichloroethane","1,2-dibromo-1,2-dichloroethane","C033164","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1981,"6119752","Influence of two haloalkanes on the redox behavior of hepatic microsomal cytochrome b-5 and its possible relationship to stearate desaturase.","6119752",57]
["1,2-dibromo-1,2-dichloroethane","1,2-dibromo-1,2-dichloroethane","C033164","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,1981,"6119752","Influence of two haloalkanes on the redox behavior of hepatic microsomal cytochrome b-5 and its possible relationship to stearate desaturase.","6119752",57]
["1,2-dihydro-1,2-dihydroxy-5-methylchrysene","1,2-dihydro-1,2-dihydroxy-5-methylchrysene","C017229","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18992797","Cytotoxicity and mutagenicity of 5-methylchrysene and its 1,2-dihydrodiol in V79MZ cells modified to express human CYP1A1 or CYP1B1, in the presence or absence of human GSTP1 coexpression.","18992797",57]
["1,2-dihydro-1,2-dihydroxy-6-nitrochrysene","1,2-dihydro-1,2-dihydroxy-6-nitrochrysene","C042316","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23461617","Mechanisms underlying the varied mammary carcinogenicity of the environmental pollutant 6-nitrochrysene and its metabolites (-)-[R,R]- and (+)-[S,S]-1,2-dihydroxy-1,2-dihydro-6-nitrochrysene in the rat.","23461617",57]
["1,2-dilauroylphosphatidylcholine","1,2-dilauroylphosphatidylcholine","C015153","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21614002","A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects.","21614002",57]
["1,2-dilauroylphosphatidylcholine","1,2-dilauroylphosphatidylcholine","C015153","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21697939","Metabolism: A lipid for fat disorders.","21697939",57]
["1,2-Dimethylhydrazine","1,2-Dimethylhydrazine","D019813","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1988,"3388438","DNA alkylation by 1,2-dimethylhydrazine in the rat large intestine and liver: influence of diet and enzyme induction.","3388438",57]
["1,2-Dimethylhydrazine","1,2-Dimethylhydrazine","D019813","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1998,"9683279","Effects of a vegetables-fruit mixture on liver and colonic 1,2-dimethylhydrazine-metabolizing enzyme activities in rats fed low- or high-fat diets.","9683279",57]
["1,2-dioctanoylglycerol","1,2-dioctanoylglycerol","C044295","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1986,"3023368","The effect of phorbol esters and diacylglycerol on expression of the phosphoenolpyruvate carboxykinase (GTP) gene in rat hepatoma H4IIE cells.","3023368",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C195,B195)","v":"1,2-Dipalmitoylphosphatidylcholine"},"1,2-Dipalmitoylphosphatidylcholine","D015060","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J195,K195)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1987,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q195,Q195)","v":"3559547"},"Spectroscopic studies on Zn(II)-phthalocyanine in homogeneous and microheterogeneous systems.","3559547",57]
["1,2-Dipalmitoylphosphatidylcholine","1,2-Dipalmitoylphosphatidylcholine","D015060","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3828467","Interaction of human low density lipoprotein and apolipoprotein B with ternary lipid microemulsion. Physical and functional properties.","3828467",57]
["1,2-Dipalmitoylphosphatidylcholine","1,2-Dipalmitoylphosphatidylcholine","D015060","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2006,"16278220","Model of biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine.","16278220",57]
["1,2-diselenolane-3-pentanoic acid","1,2-diselenolane-3-pentanoic acid","C109588","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9398652","The lipoic acid analogue 1,2-diselenolane-3-pentanoic acid protects human low density lipoprotein against oxidative modification mediated by copper ion.","9398652",57]
["1,2-distearoylphosphatidylethanolamine","1,2-distearoylphosphatidylethanolamine","C038089","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2015,"26517697","Saturated phosphatidic acids mediate saturated fatty acid-induced vascular calcification and lipotoxicity.","26517697",57]
["1,2-dithiol-3-thione","1,2-dithiol-3-thione","C049325","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1992,"1371615","Induction of quinone reductase and glutathione in bone marrow cells by 1,2-dithiole-3-thione: effect on hydroquinone-induced cytotoxicity.","1371615",57]
["1,2-linoleoylphosphatidylcholine","1,2-linoleoylphosphatidylcholine","C002448","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2000,"10996343","Dilinoleoylphosphatidylcholine protects human low density lipoproteins against oxidation.","10996343",57]
["1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril","1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril","C012385","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"12005032","Comparison of two methods for radioiodination on the oxidizability properties of low density lipoprotein.","12005032",57]
["1,3,6,8-tetrachlorodibenzofuran","1,3,6,8-tetrachlorodibenzofuran","C049040","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1986,"3012826","Polychlorinated dibenzofurans as 2,3,7,8-TCDD antagonists: in vitro inhibition of monooxygenase enzyme induction.","3012826",57]
["1,3,6,8-tetrachlorodibenzofuran","1,3,6,8-tetrachlorodibenzofuran","C049040","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1986,"3012826","Polychlorinated dibenzofurans as 2,3,7,8-TCDD antagonists: in vitro inhibition of monooxygenase enzyme induction.","3012826",57]
["1,3,7,8-tetrachlorodibenzo-4-dioxin","1,3,7,8-tetrachlorodibenzo-4-dioxin","C078329","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1992,"1332906","Inhibition of insulin-like growth factor-I responses in MCF-7 cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds.","1332906",57]
["1,3-benzodioxole","1,3-benzodioxole","C040539","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7701515","Computer graphics analysis of the interaction of alkoxy methylenedioxybenzenes with cytochromes P4501.","7701515",57]
["1,3-bis(3,5-dichlorophenyl)urea","1,3-bis(3,5-dichlorophenyl)urea","C577482","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"24376752","COH-SR4 reduces body weight, improves glycemic control and prevents hepatic steatosis in high fat diet-induced obese mice.","24376752",57]
["1,3-butadiene","1,3-butadiene","C031763","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21915069","Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers.","21915069",57]
["1,3-butylene glycol","1,3-butylene glycol","C028491","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1991,"1787195","Metabolic changes in blood and liver of dairy cows during either feed restriction or administration of 1,3-butanediol.","1787195",57]
["1,3-butylene glycol","1,3-butylene glycol","C028491","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1989,"2628443","Metabolic responses of lactating goats to feed restriction and dietary 1,3-butanediol.","2628443",57]
["1,3-di(1H-indol-3-yl)propan-2-one","1,3-di(1H-indol-3-yl)propan-2-one","C547592","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2009,"19860415","D-amino acid oxidase generates agonists of the aryl hydrocarbon receptor from D-tryptophan.","19860415",57]
["1,3-dichloro-2-propanol","1,3-dichloro-2-propanol","C033489","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"25910858","Nonalcoholic fatty liver disease induced by 13-week oral administration of 1,3-dichloro-2-propanol in C57BL/6J mice.","25910858",57]
["1,3-diiopanoate glyceryl ether","1,3-diiopanoate glyceryl ether","C474281","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12732679","Acetylated low-density lipoprotein-encapsulated cholesteryl 1,3-diiopanoate glyceryl ether for the detection of atherosclerosis in rabbits.","12732679",57]
["1,3-dimethyluric acid","1,3-dimethyluric acid","C031274","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18088504","Effects of CYP inducers and inhibitors on the pharmacokinetics of intravenous theophylline in rats: involvement of CYP1A1/2 in the formation of 1,3-DMU.","18088504",57]
["1,3-dinitropyrene","1,3-dinitropyrene","C037413","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11113705","Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1.","11113705",57]
["1,3-dioleoyl-2-(4-pyrenylbutanoyl)glycerol","1,3-dioleoyl-2-(4-pyrenylbutanoyl)glycerol","C046906","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"4043079","Hydrolysis of very-low-density lipoproteins labeled with a fluorescent triacylglycerol: 1,3-dioleoyl-2-(4-pyrenylbutanoyl)glycerol.","4043079",57]
["1,3-dithia-2-thioxocyclopent-4-ene","1,3-dithia-2-thioxocyclopent-4-ene","C111193","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1997,"9442451","Effect of 1,3-dithia-2-thioxo-cyclopent-4-ene and its derivatives on liver injury induced by carbon tetrachloride and orotic acid in rats.","9442451",57]
["1,4-bis(2-(3,5-dichloropyridyloxy))benzene","1,4-bis(2-(3,5-dichloropyridyloxy))benzene","C028474","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2007,"17948939","Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse.","17948939",57]
["1,4-bis(2-(3,5-dichloropyridyloxy))benzene","1,4-bis(2-(3,5-dichloropyridyloxy))benzene","C028474","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2011,"21778422","Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.","21778422",57]
["1,4-bis(2-(3,5-dichloropyridyloxy))benzene","1,4-bis(2-(3,5-dichloropyridyloxy))benzene","C028474","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2010,"20637255","The activated aryl hydrocarbon receptor synergizes mitogen-induced murine liver hyperplasia.","20637255",57]
["1,4-bis(2-(3,5-dichloropyridyloxy))benzene","1,4-bis(2-(3,5-dichloropyridyloxy))benzene","C028474","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2016,"26577535","Age-Specific Regulation of Drug-Processing Genes in Mouse Liver by Ligands of Xenobiotic-Sensing Transcription Factors.","26577535",57]
["1,4-bis(2-(3,5-dichloropyridyloxy))benzene","1,4-bis(2-(3,5-dichloropyridyloxy))benzene","C028474","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2016,"27113289","RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome.","27113289",57]
["1,4-bis(2-(3,5-dichloropyridyloxy))benzene","1,4-bis(2-(3,5-dichloropyridyloxy))benzene","C028474","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"21778422","Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.","21778422",57]
["1,4-butanediol","1,4-butanediol","C039681","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1985,"3911807","Ethanol potentiates the toxic effects of 1,4-butanediol.","3911807",57]
["1,4-dihydropyridine","1,4-dihydropyridine","C038806","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10471444","1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats.","10471444",57]
["1,4-dihydropyridine","1,4-dihydropyridine","C038806","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26881016","1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative Stress.","26881016",57]
["1,4-dihydroxy-2-naphthoic acid","1,4-dihydroxy-2-naphthoic acid","C024023","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2017,"27837168","Editor's Highlight: Microbial-Derived 1,4-Dihydroxy-2-naphthoic Acid and Related Compounds as Aryl Hydrocarbon Receptor Agonists/Antagonists: Structure-Activity Relationships and Receptor Modeling.","27837168",57]
["1,4-dihydroxy-2-naphthoic acid","1,4-dihydroxy-2-naphthoic acid","C024023","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2017,"27837168","Editor's Highlight: Microbial-Derived 1,4-Dihydroxy-2-naphthoic Acid and Related Compounds as Aryl Hydrocarbon Receptor Agonists/Antagonists: Structure-Activity Relationships and Receptor Modeling.","27837168",57]
["1,4-phenylenebis(methylene)selenocyanate","1,4-phenylenebis(methylene)selenocyanate","C074153","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21732699","Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds.","21732699",57]
["1,4-phenylenebis(methylene)selenocyanate","1,4-phenylenebis(methylene)selenocyanate","C074153","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9354437","Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds.","9354437",57]
["1,5-anhydrofructose","1,5-anhydrofructose","C048927","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2002,"11842320","Antioxidant effects of 1,5-anhydro-D-fructose, a new natural sugar, in vitro.","11842320",57]
["1,5-I-AEDANS","1,5-I-AEDANS","C006421","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1991,"1897968","Fluorescent labeling of the nucleotide site in cytosolic rat liver phosphoenolpyruvate carboxykinase.","1897968",57]
["1,6-dinitropyrene","1,6-dinitropyrene","C033309","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11113705","Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1.","11113705",57]
["1,6-di-O-galloyl-beta-D-glucose","1,6-di-O-galloyl-beta-D-glucose","C504375","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15997216","Antiatherogenic effects of phyllanthus emblica associated with corilagin and its analogue.","15997216",57]
["1,7-phenanthroline","1,7-phenanthroline","C053486","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1998,"9849642","Drug-metabolizing enzyme induction by 2,2'-dipyridyl, 1,7-phenanthroline, 7,8-benzoquinoline and oltipraz in mouse.","9849642",57]
["1,7-phenanthroline","1,7-phenanthroline","C053486","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,1999,"9890192","Induction of drug metabolizing enzymes by 1,7-phenanthroline and oltipraz in mice is unrelated to Ah-responsiveness.","9890192",57]
["1,8-dinitropyrene","1,8-dinitropyrene","C033310","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11113705","Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1.","11113705",57]
["1,9-benz-10-anthrone","1,9-benz-10-anthrone","C000609119","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2015,"26141390","Ligand-Specific Transcriptional Mechanisms Underlie Aryl Hydrocarbon Receptor-Mediated Developmental Toxicity of Oxygenated PAHs.","26141390",57]
["10-(6'-ubiquinonyl)decyltriphenylphosphonium bromide","10-(6'-ubiquinonyl)decyltriphenylphosphonium bromide","C476756","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20649545","Animal and human studies with the mitochondria-targeted antioxidant MitoQ.","20649545",57]
["10-(6'-ubiquinonyl)decyltriphenylphosphonium bromide","10-(6'-ubiquinonyl)decyltriphenylphosphonium bromide","C476756","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21520201","Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis.","21520201",57]
["10,12-octadecadienoic acid","10,12-octadecadienoic acid","C094849","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"22242926","Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation.","22242926",57]
["10,12-octadecadienoic acid","10,12-octadecadienoic acid","C094849","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2012,"22242926","Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation.","22242926",57]
["10,12-octadecadienoic acid","10,12-octadecadienoic acid","C094849","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"17678565","Functional effects of eggs, naturally enriched with conjugated linoleic acid, on the blood lipid profile, development of atherosclerosis and composition of atherosclerotic plaque in apolipoprotein E and low-density lipoprotein receptor double-knockout mice (apoE/LDLR-/-).","17678565",57]
["10,12-octadecadienoic acid","10,12-octadecadienoic acid","C094849","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2001,"11396956","Regulation of stearoyl-CoA desaturase activity by the trans-10,cis-12 isomer of conjugated linoleic acid in HepG2 cells.","11396956",57]
["10,12-octadecadienoic acid","10,12-octadecadienoic acid","C094849","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,2,2002,"12061775","Inhibition of stearoyl-CoA desaturase activity by the cis-9,trans-11 isomer and the trans-10,cis-12 isomer of conjugated linoleic acid in MDA-MB-231 and MCF-7 human breast cancer cells.","12061775",57]
["10,12-tetradecadienoic acid","10,12-tetradecadienoic acid","C447625","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2001,"11722204","Synthesis of gem-dideuterated tetradecanoic acids and their use in investigating the enzymatic transformation of (Z)-11-tetradecenoic acid into (E,E)-10,12-tetradecadienoic acid.","11722204",57]
["10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid","10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid","C000591716","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"22520055","Dose-effect and metabolism of docosahexaenoic acid: pathophysiological relevance in blood platelets.","22520055",57]
["10-azabenzo(a)pyrene","10-azabenzo(a)pyrene","C023961","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2002,"12438015","Effect of 10-aza-substitution on benzo[a]pyrene mutagenicity in vivo and in vitro.","12438015",57]
["10-carboxymethyl-9-acridanone","10-carboxymethyl-9-acridanone","C026430","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"22606899","[Efficiency of modern immunoactive preparation cycloferon at coplex therapy of the patients with nonalcoholic steatohepatitis combined with irritable bowel syndrome].","22606899",57]
["10-carboxymethyl-9-acridanone","10-carboxymethyl-9-acridanone","C026430","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"22606899","[Efficiency of modern immunoactive preparation cycloferon at coplex therapy of the patients with nonalcoholic steatohepatitis combined with irritable bowel syndrome].","22606899",57]
["10-chloro-7H-benzimidazo(2,1-a)benzo(de)Isoquinolin-7-one","10-chloro-7H-benzimidazo(2,1-a)benzo(de)Isoquinolin-7-one","C000593972","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24586378","Benzimidazoisoquinolines: a new class of rapidly metabolized aryl hydrocarbon receptor (AhR) ligands that induce AhR-dependent Tregs and prevent murine graft-versus-host disease.","24586378",57]
["10-chloro-7H-benzimidazo(2,1-a)benzo(de)Isoquinolin-7-one","10-chloro-7H-benzimidazo(2,1-a)benzo(de)Isoquinolin-7-one","C000593972","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2016,"26573835","Activation of the Aryl Hydrocarbon Receptor by 10-Cl-BBQ Prevents Insulitis and Effector T Cell Development Independently of Foxp3+ Regulatory T Cells in Nonobese Diabetic Mice.","26573835",57]
["10-hydroxy-2-decenoic acid","10-hydroxy-2-decenoic acid","C055543","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12583195","[The research of 10-hydroxy-2-decenoic acid on experiment hyperlipoidemic rat].","12583195",57]
["10-nitro-oleic acid","10-nitro-oleic acid","C521487","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20167658","Nitro-fatty acids reduce atherosclerosis in apolipoprotein E-deficient mice.","20167658",57]
["11,12-epoxy-5,8,14-eicosatrienoic acid","11,12-epoxy-5,8,14-eicosatrienoic acid","C046783","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14656932","Mechanistic role of cytochrome P450 monooxygenases in oxidized low-density lipoprotein-induced vascular injury: therapy through LOX-1 receptor antagonism?","14656932",57]
["11,12-epoxy-5,8,14-eicosatrienoic acid","11,12-epoxy-5,8,14-eicosatrienoic acid","C046783","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1540175","Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma.","1540175",57]
["11,12-epoxy-5,8,14-eicosatrienoic acid","11,12-epoxy-5,8,14-eicosatrienoic acid","C046783","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24486707","EETs alleviate ox-LDL-induced inflammation by inhibiting LOX-1 receptor expression in rat pulmonary arterial endothelial cells.","24486707",57]
["11,12-epoxy-5,8,14-eicosatrienoic acid","11,12-epoxy-5,8,14-eicosatrienoic acid","C046783","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1540175","Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma.","1540175",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C259,B259)","v":"11,12-epoxy-5,8,14-eicosatrienoic acid"},"11,12-epoxy-5,8,14-eicosatrienoic acid","C046783","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J259,K259)","v":"Receptors, LDL"},"D011973","Receptors, LDL",1,1,2004,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q259,Q259)","v":"14656932"},"Mechanistic role of cytochrome P450 monooxygenases in oxidized low-density lipoprotein-induced vascular injury: therapy through LOX-1 receptor antagonism?","14656932",57]
["11-hexadecenal","11-hexadecenal","C061128","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2016,"26923548","A single aldehyde group can serve as a structural element for recognition by transmembrane protein CD36.","26923548",57]
["11-hexadecenal","11-hexadecenal","C061128","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26923548","A single aldehyde group can serve as a structural element for recognition by transmembrane protein CD36.","26923548",57]
["11-hydroxytetradecanoic acid","11-hydroxytetradecanoic acid","C101376","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1996,"8733624","Synthesis of [14,14,14-2H3] 12-hydroxytetradecanoic acid and [13,14-2H2] 11-hydroxytetradecanoic acid useful as tracers to study a (11E)-desaturation reaction in Spodoptera littoralis.","8733624",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2004,"15173397","Trans10,cis12-18:2 is a more potent inhibitor of de novo fatty acid synthesis and desaturation than cis9,trans11-18:2 in the mammary gland of lactating mice.","15173397",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2007,"17235173","The effect of solids dilution rate and oil source on trans C18:1 and conjugated linoleic acid production by ruminal microbes in continuous culture.","17235173",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2013,"24070791","Trans-vaccenate is Δ13-desaturated by FADS3 in rodents.","24070791",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2017,"27865506","Synthesis of the suspected trans-11,cis-13 conjugated linoleic acid isomer in ruminant mammary tissue by FADS3-catalyzed Δ13-desaturation of vaccenic acid.","27865506",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25962361","Effects of dietary trans-9 octadecenoic acid, trans-11 vaccenic acid and cis-9, trans-11 conjugated linoleic acid in mice.","25962361",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"12197992","Bioconversion of vaccenic acid to conjugated linoleic acid in humans.","12197992",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24775093","Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome.","24775093",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"19923390","Dietary vaccenic acid has antiatherogenic effects in LDLr-/- mice.","19923390",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2004,"15173397","Trans10,cis12-18:2 is a more potent inhibitor of de novo fatty acid synthesis and desaturation than cis9,trans11-18:2 in the mammary gland of lactating mice.","15173397",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,2,2004,"15465769","The anticarcinogenic effect of trans-11 18:1 is dependent on its conversion to cis-9, trans-11 CLA by delta9-desaturase in rats.","15465769",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2006,"16571147","Eicosapentaenoic acid and 3,10 dithia stearic acid inhibit the desaturation of trans-vaccenic acid into cis-9, trans-11-conjugated linoleic acid through different pathways in Caco-2 and T84 cells.","16571147",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2006,"16571155","Trans-11-18 : 1 is effectively Delta9-desaturated compared with trans-12-18 : 1 in humans.","16571155",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2007,"17235173","The effect of solids dilution rate and oil source on trans C18:1 and conjugated linoleic acid production by ruminal microbes in continuous culture.","17235173",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2007,"17449574","Transfer of absorbed cis-9, trans-11 conjugated linoleic acid into milk is biologically more efficient than endogenous synthesis from absorbed vaccenic acid in lactating cows.","17449574",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2008,"18275620","Cis-9, trans-11-conjugated linoleic acid but not its precursor trans-vaccenic acid attenuate inflammatory markers in the human colonic epithelial cell line Caco-2.","18275620",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2008,"18513458","The effect of dietary inclusion of olive tree leaves and grape marc on the content of conjugated linoleic acid and vaccenic acid in the milk of dairy sheep and goats.","18513458",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2010,"20307350","Effects of fish oil and starch added to a diet containing sunflower-seed oil on dairy goat performance, milk fatty acid composition and in vivo delta9-desaturation of [13C]vaccenic acid.","20307350",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2012,"22750019","Vaccenic acid-mediated reduction in cytokine production is independent of c9,t11-CLA in human peripheral blood mononuclear cells.","22750019",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2014,"24518825","trans-11 18:1 vaccenic acid (TVA) has a direct anti-carcinogenic effect on MCF-7 human mammary adenocarcinoma cells.","24518825",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2014,"24909189","Quantitative trait loci mapping for conjugated linoleic acid, vaccenic acid and ∆(9) -desaturase in Italian Brown Swiss dairy cattle using selective DNA pooling.","24909189",57]
["11-octadecenoic acid","11-octadecenoic acid","C050413","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2017,"27865506","Synthesis of the suspected trans-11,cis-13 conjugated linoleic acid isomer in ruminant mammary tissue by FADS3-catalyzed Δ13-desaturation of vaccenic acid.","27865506",57]
["11-tetradecenoic acid","11-tetradecenoic acid","C432948","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2001,"11378415","Stereospecificity of the (Z)-9 desaturase that converts (E)-11-tetradecenoic acid into (Z,E)-9,11-tetradecadienoic acid in the biosynthesis of Spodoptera littoralis sex pheromone.","11378415",57]
["11-tetradecenoic acid","11-tetradecenoic acid","C432948","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2002,"12530216","Moth desaturase characterized that produces both Z and E isomers of delta 11-tetradecenoic acids.","12530216",57]
["11-tetradecenoic acid","11-tetradecenoic acid","C432948","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2001,"11378415","Stereospecificity of the (Z)-9 desaturase that converts (E)-11-tetradecenoic acid into (Z,E)-9,11-tetradecadienoic acid in the biosynthesis of Spodoptera littoralis sex pheromone.","11378415",57]
["12-(1-pyrene)dodecanoylcerebroside sulfate","12-(1-pyrene)dodecanoylcerebroside sulfate","C058912","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8608174","Pyrene lipids as markers of peroxidative processes in different regions of low and high density lipoproteins.","8608174",57]
["12-(3-methoxy-4-(methoxymethoxy) phenyl)-10-oxododec-8-enoic acid ethyl ester","12-(3-methoxy-4-(methoxymethoxy) phenyl)-10-oxododec-8-enoic acid ethyl ester","C579625","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2012,"22963983","Enhanced CD36 expression changes the role of Nrf2 activation from anti-atherogenic to pro-atherogenic in apoE-deficient mice.","22963983",57]
["12-(4-hydroxy-3-methoxyphenyl)-10-oxododec-8-enoic acid ethyl ester","12-(4-hydroxy-3-methoxyphenyl)-10-oxododec-8-enoic acid ethyl ester","C579627","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2012,"22963983","Enhanced CD36 expression changes the role of Nrf2 activation from anti-atherogenic to pro-atherogenic in apoE-deficient mice.","22963983",57]
["12-(9-anthroyloxy)stearic acid","12-(9-anthroyloxy)stearic acid","C026653","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2169900","[Relative location of anthroyl derivatives of stearic acid in low density lipoproteins].","2169900",57]
["12,13-dihydroxyoctadecenoic acid","12,13-dihydroxyoctadecenoic acid","C425204","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,2,2017,"28346411","The cold-induced lipokine 12,13-diHOME promotes fatty acid transport into brown adipose tissue.","28346411",57]
["12,13-dihydroxyoctadecenoic acid","12,13-dihydroxyoctadecenoic acid","C425204","7_KE",54,7,"CD36","Up Regulation","Fatty Acid Transport Proteins","D050612","Fatty Acid Transport Proteins",0,1,2017,"28346411","The cold-induced lipokine 12,13-diHOME promotes fatty acid transport into brown adipose tissue.","28346411",57]
["12,13-epoxy-9-octadecenoic acid","12,13-epoxy-9-octadecenoic acid","C119104","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2000,"11171264","Inhibition of polyunsaturated fatty acid accumulation in plants expressing a fatty acid epoxygenase.","11171264",57]
["12-doxylstearate methyl ester","12-doxylstearate methyl ester","C024283","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"6245076","Mobility of apolar lipids of reconstituted low density lipoprotein as monitored by electron spin resonance spectroscopy.","6245076",57]
["12-hydroxy-4-(2-propenyl)-5-cholest-24-en-3-ol","12-hydroxy-4-(2-propenyl)-5-cholest-24-en-3-ol","C400813","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10498032","Synthesis and in vitro biological activity of 4alpha-(2-propenyl)-5alpha-cholest-24-en-3alpha,12 alpha-diol, a 12alpha-hydroxyl analog of 4alpha-(2-propenyl)-5alpha-cholest-24-en-3alpha-ol: the latter is a potent activator of the low-density lipoprotein receptor promoter.","10498032",57]
["12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","D019377","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18779363","12(R)-Hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid derivative, is an activator of the aryl hydrocarbon receptor.","18779363",57]
["12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","D019377","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"28171546","AHR/CYP1A1 interplay triggers lymphatic barrier breaching in breast cancer spheroids by inducing 12(S)-HETE synthesis.","28171546",57]
["12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","D019377","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2463850","Regulation of 12-hydroxyeicosatetraenoic acid synthesis by acetyl-LDL in mouse peritoneal macrophages.","2463850",57]
["12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","D019377","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2008,"18779363","12(R)-Hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid derivative, is an activator of the aryl hydrocarbon receptor.","18779363",57]
["12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","D019377","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"28171546","AHR/CYP1A1 interplay triggers lymphatic barrier breaching in breast cancer spheroids by inducing 12(S)-HETE synthesis.","28171546",57]
["12-hydroxyellipticine","12-hydroxyellipticine","C517214","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22917556","Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.","22917556",57]
["12-hydroxytetradecanoic acid","12-hydroxytetradecanoic acid","C101377","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1996,"8733624","Synthesis of [14,14,14-2H3] 12-hydroxytetradecanoic acid and [13,14-2H2] 11-hydroxytetradecanoic acid useful as tracers to study a (11E)-desaturation reaction in Spodoptera littoralis.","8733624",57]
["13,14-dihydroprostaglandin E1","13,14-dihydroprostaglandin E1","C069881","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1397039","13,14-Dihydro-prostaglandin E1 decreases low-density lipoprotein influx into rabbit aorta.","1397039",57]
["13,14-dihydroprostaglandin E1","13,14-dihydroprostaglandin E1","C069881","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1993,"7681515","Increase in in vivo low-density lipoprotein (LDL) receptor binding after PGE1 and 13,14-dihydro-PGE1 treatment in rabbits.","7681515",57]
["13,17-bispropanoylaspartic acid-3-ethenyl-8-((N,N',N'', N'''-tetrakis(carboxylmethyl)diethylenetriaminoacetyloxy)methyl-2,7,12,18-tetramethylporphyrinato)manganese(III)","13,17-bispropanoylaspartic acid-3-ethenyl-8-((N,N',N'', N'''-tetrakis(carboxylmethyl)diethylenetriaminoacetyloxy)methyl-2,7,12,18-tetramethylporphyrinato)manganese(III)","C091730","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7757956","Tumor-localizing activity of porphyrin and its affinity to LDL, transferrin.","7757956",57]
["13-hexadecen-11-ynoic acid","13-hexadecen-11-ynoic acid","C524873","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2007,"17921252","A multifunctional desaturase involved in the biosynthesis of the processionary moth sex pheromone.","17921252",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10218641","Lipid hydroperoxides inhibit nitric oxide production in RAW264.7 macrophages.","10218641",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10521368","Vitamin C protects human vascular smooth muscle cells against apoptosis induced by moderately oxidized LDL containing high levels of lipid hydroperoxides.","10521368",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10946007","Lipid peroxides induce expression of catalase in cultured vascular cells.","10946007",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10974056","Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1.","10974056",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1554346","Pro-oxidant effects of lipoxygenase-derived peroxides on the copper-initiated oxidation of low-density lipoprotein.","1554346",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7806971","Predominance of esterified hydroperoxy-linoleic acid in human monocyte-oxidized LDL.","7806971",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7944405","The role of lipid hydroperoxides in the myoglobin-dependent oxidation of LDL.","7944405",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8752616","Inhibition of oxidative modification of proteins by RU486.","8752616",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9065759","Reduction of Cu(II) by lipid hydroperoxides: implications for the copper-dependent oxidation of low-density lipoprotein.","9065759",57]
["13-hydroperoxy-9,11-octadecadienoic acid","13-hydroperoxy-9,11-octadecadienoic acid","C038649","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9500842","Detection of oxidized phospholipid-protein adducts using anti-15-hydroperoxyeicosatetraenoic acid-modified protein antibody: contribution of esterified fatty acid-protein adduct to oxidative modification of LDL.","9500842",57]
["13-hydroperoxylinoleic acid","13-hydroperoxylinoleic acid","C032890","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,1999,"10195919","Uptake of 13-hydroperoxylinoleic acid by cultured cells.","10195919",57]
["13-hydroxy-9,11-octadecadienoic acid","13-hydroxy-9,11-octadecadienoic acid","C024348","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15522824","Translocation of phospholipase A2 to membranes by oxidized LDL and hydroxyoctadecadienoic acid to contribute to cholesteryl ester formation.","15522824",57]
["13-hydroxy-9,11-octadecadienoic acid","13-hydroxy-9,11-octadecadienoic acid","C024348","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7806971","Predominance of esterified hydroperoxy-linoleic acid in human monocyte-oxidized LDL.","7806971",57]
["13-hydroxy-9,11-octadecadienoic acid","13-hydroxy-9,11-octadecadienoic acid","C024348","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9488997","Strong increase in hydroxy fatty acids derived from linoleic acid in human low density lipoproteins of atherosclerotic patients.","9488997",57]
["13-hydroxy-9,11-octadecadienoic acid","13-hydroxy-9,11-octadecadienoic acid","C024348","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9643357","13-hydroxy octadecadienoic acid (13-HODE) inhibits triacylglycerol-rich lipoprotein secretion by CaCo-2 cells.","9643357",57]
["13-hydroxy-9,11-octadecadienoic acid","13-hydroxy-9,11-octadecadienoic acid","C024348","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2002,"12421837","Oxidized fatty acids promote atherosclerosis only in the presence of dietary cholesterol in low-density lipoprotein receptor knockout mice.","12421837",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C323,B323)","v":"13-hydroxyellipticine"},"13-hydroxyellipticine","C517215","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J323,K323)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2012,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q323,Q323)","v":"22917556"},"Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.","22917556",57]
["13-oxo-9,11-octadecadienoic acid","13-oxo-9,11-octadecadienoic acid","C064441","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22347463","Potent PPARα activator derived from tomato juice, 13-oxo-9,11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice.","22347463",57]
["14,15-epoxy-5,8,11-eicosatrienoic acid","14,15-epoxy-5,8,11-eicosatrienoic acid","C046782","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1540175","Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma.","1540175",57]
["14,15-epoxy-5,8,11-eicosatrienoic acid","14,15-epoxy-5,8,11-eicosatrienoic acid","C046782","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24486707","EETs alleviate ox-LDL-induced inflammation by inhibiting LOX-1 receptor expression in rat pulmonary arterial endothelial cells.","24486707",57]
["14,15-epoxy-5,8,11-eicosatrienoic acid","14,15-epoxy-5,8,11-eicosatrienoic acid","C046782","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"26035589","EETs Attenuate Ox-LDL-Induced LTB4 Production and Activity by Inhibiting p38 MAPK Phosphorylation and 5-LO/BLT1 Receptor Expression in Rat Pulmonary Arterial Endothelial Cells.","26035589",57]
["14,15-epoxy-5,8,11-eicosatrienoic acid","14,15-epoxy-5,8,11-eicosatrienoic acid","C046782","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1540175","Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma.","1540175",57]
["14,15-epoxy-5,8,11-eicosatrienoic acid","14,15-epoxy-5,8,11-eicosatrienoic acid","C046782","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25389366","CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice.","25389366",57]
["14'-apolycopen-14'-oic acid","14'-apolycopen-14'-oic acid","C557871","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2011,"21247174","Organic synthesis of new putative lycopene metabolites and preliminary investigation of their cell-signaling effects.","21247174",57]
["14-deoxyandrographolide","14-deoxyandrographolide","C114791","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2014,"24507479","14-Deoxyandrographolide alleviates ethanol-induced hepatosteatosis through stimulation of AMP-activated protein kinase activity in rats.","24507479",57]
["14-tigloylschinlignan D","14-tigloylschinlignan D","C000614641","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"28139296","Lignans from the fruits of Schisandra chinensis (Turcz.) Baill inhibit proprotein convertase subtilisin/kexin type 9 expression.","28139296",57]
["15-deoxy-delta(12,14)-prostaglandin J2","15-deoxy-delta(12,14)-prostaglandin J2","C097240","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2004,"14563653","Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages.","14563653",57]
["15-deoxy-delta(12,14)-prostaglandin J2","15-deoxy-delta(12,14)-prostaglandin J2","C097240","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2007,"17643887","Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2.","17643887",57]
["15-deoxy-delta(12,14)-prostaglandin J2","15-deoxy-delta(12,14)-prostaglandin J2","C097240","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12881207","Oxidized low-density lipoprotein and 15-deoxy-delta 12,14-PGJ2 increase mitochondrial complex I activity in endothelial cells.","12881207",57]
["15-deoxy-delta(12,14)-prostaglandin J2","15-deoxy-delta(12,14)-prostaglandin J2","C097240","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2004,"14668325","Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism.","14668325",57]
["15-deoxyprostaglandin J2","15-deoxyprostaglandin J2","C477819","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2004,"15498928","Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.","15498928",57]
["15-deoxyprostaglandin J2","15-deoxyprostaglandin J2","C477819","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2004,"15665586","Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-g.","15665586",57]
["15-deoxyprostaglandin J2","15-deoxyprostaglandin J2","C477819","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2005,"15769457","Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages.","15769457",57]
["15-deoxyprostaglandin J2","15-deoxyprostaglandin J2","C477819","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2017,"28398824","15-Deoxy-Δ12,14-Prostaglandin J2 Exerts Proresolving Effects Through Nuclear Factor E2-Related Factor 2-Induced Expression of CD36 and Heme Oxygenase-1.","28398824",57]
["15-deoxyprostaglandin J2","15-deoxyprostaglandin J2","C477819","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15665586","Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-g.","15665586",57]
["15-deoxyprostaglandin J2","15-deoxyprostaglandin J2","C477819","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14741709","15d-PGJ2 inhibits oxidized LDL-induced macrophage proliferation by inhibition of GM-CSF production via inactivation of NF-kappaB.","14741709",57]
["15-deoxyprostaglandin J2","15-deoxyprostaglandin J2","C477819","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2004,"15271788","Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells.","15271788",57]
["15-hydroperoxy-5,8,11,13-eicosatetraenoic acid","15-hydroperoxy-5,8,11,13-eicosatetraenoic acid","C025086","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10974056","Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1.","10974056",57]
["15-hydroperoxy-5,8,11,13-eicosatetraenoic acid","15-hydroperoxy-5,8,11,13-eicosatetraenoic acid","C025086","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9500842","Detection of oxidized phospholipid-protein adducts using anti-15-hydroperoxyeicosatetraenoic acid-modified protein antibody: contribution of esterified fatty acid-protein adduct to oxidative modification of LDL.","9500842",57]
["15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid","15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid","D019796","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11133169","Synergistic interaction between thromboxane A2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation.","11133169",57]
["15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid","15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid","D019796","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1716063","Effects of PGE2 and a thromboxane A2 analogue on uptake of IgG complexes and LDL by mesangial cells.","1716063",57]
["15-hydroxy-5,8,11,13-eicosatetraenoic acid","15-hydroxy-5,8,11,13-eicosatetraenoic acid","C025984","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2014,"25152235","ROS-dependent Syk and Pyk2-mediated STAT1 activation is required for 15(S)-hydroxyeicosatetraenoic acid-induced CD36 expression and foam cell formation.","25152235",57]
["15-keto-13,14-dihydroprostaglandin F2alpha","15-keto-13,14-dihydroprostaglandin F2alpha","C008228","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"6278539","Effects of dibutyryl cAMP, LHRH, and aromatase inhibitor on simultaneous outputs of prostaglandin F2 alpha, and 13,14-dihydro-15-keto-prostaglandin F2 alpha by term placental explants.","6278539",57]
["17-(dimethylaminoethylamino)-17-demethoxygeldanamycin","17-(dimethylaminoethylamino)-17-demethoxygeldanamycin","C448659","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2014,"24859453","Inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine alcoholic liver injury.","24859453",57]
["17,18-epoxy-5,8,11,14-eicosatetraenoic acid","17,18-epoxy-5,8,11,14-eicosatetraenoic acid","C070378","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28471490","Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease.","28471490",57]
["17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid","17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid","C062894","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2011,"21421544","Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-α.","21421544",57]
["17-iodoheptadecanoic acid","17-iodoheptadecanoic acid","C027252","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1986,"3760977","17-Iodine-123 iodoheptadecanoic acid for metabolic liver studies in humans.","3760977",57]
["17-iodoheptadecanoic acid","17-iodoheptadecanoic acid","C027252","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1986,"3760977","17-Iodine-123 iodoheptadecanoic acid for metabolic liver studies in humans.","3760977",57]
["17-methylandrost-2-en-17-ol","17-methylandrost-2-en-17-ol","C500374","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27612377","Mission Compromised? Drug-Induced Liver Injury From Prohormone Supplements Containing Anabolic-Androgenic Steroids in Two Deployed U.S. Service Members.","27612377",57]
["18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","C521270","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19752584","Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro.","19752584",57]
["18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","C521270","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19958646","[Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study].","19958646",57]
["18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","C521270","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"28951632","Amelioration of Ethanol-Induced Hepatitis by Magnesium Isoglycyrrhizinate through Inhibition of Neutrophil Cell Infiltration and Oxidative Damage.","28951632",57]
["18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","C521270","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2017,"28500689","Blockade of hedgehog pathway is required for the protective effects of magnesium isoglycyrrhizinate against ethanol-induced hepatocyte steatosis and apoptosis.","28500689",57]
["18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate","C521270","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27220460","Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms.","27220460",57]
["18alpha-glycyrrhetinic acid","18alpha-glycyrrhetinic acid","C119129","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2008,"18452148","Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways.","18452148",57]
["18alpha-glycyrrhetinic acid","18alpha-glycyrrhetinic acid","C119129","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2014,"24687644","18β-glycyrrhetinic acid attenuates anandamide-induced adiposity and high-fat diet induced obesity.","24687644",57]
["1a alloantigen, human","1a alloantigen, human","C039231","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,1993,"7505078","Lack of binding of peptides carrying the human platelet antigen 1 (HPA-1) dimorphism to purified HLA-DRw52a molecules.","7505078",57]
["1a alloantigen, human","1a alloantigen, human","C039231","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,1996,"8885154","Evidence for an expression of blood group A antigen on platelet glycoproteins IV and V.","8885154",57]
["1-acetyl-4-phenyl-1,2,4-triazolidine-3,5-dione","1-acetyl-4-phenyl-1,2,4-triazolidine-3,5-dione","C078499","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1333628","Effects of isoxazolidine or triazolidine on rat serum lipids in vivo and LDL and HDL binding and degradation in human and rodent cultured cells in vitro.","1333628",57]
["1-acetyl-4-phenyl-1,2,4-triazolidine-3,5-dione","1-acetyl-4-phenyl-1,2,4-triazolidine-3,5-dione","C078499","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1992,"1333628","Effects of isoxazolidine or triazolidine on rat serum lipids in vivo and LDL and HDL binding and degradation in human and rodent cultured cells in vitro.","1333628",57]
["1-acyl-2-acetyl-sn-glycero-3-phosphocholine","1-acyl-2-acetyl-sn-glycero-3-phosphocholine","C069030","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8280775","1 Acyl-2 acetyl-sn-glycero-3 phosphocholine decreases the susceptibility of low-density lipoprotein to oxidative modification by copper ions, monocytes or endothelial cells.","8280775",57]
["1-alkyl-2-acyl-sn-glycero-3-phosphocholine","1-alkyl-2-acyl-sn-glycero-3-phosphocholine","C036761","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1932343","[1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine: acetylhydrolase is associated primarily with low density lipoproteins in human blood].","1932343",57]
["1-amino-3,7,8-trichlorodibenzo-4-dioxin","1-amino-3,7,8-trichlorodibenzo-4-dioxin","C014981","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1986,"3021141","1-amino-3,7,8-trichlorodibenzo-p-dioxin: a specific antagonist for TCDD-induced myelotoxicity.","3021141",57]
["1-aminobenzotriazole","1-aminobenzotriazole","C033020","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10640292","Potentiation of oxygen-induced lung injury in rats by the mechanism-based cytochrome P-450 inhibitor, 1-aminobenzotriazole.","10640292",57]
["1-aminobenzotriazole","1-aminobenzotriazole","C033020","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"2276091","N-aralkylated derivatives of 1-aminobenzotriazole as isozyme-selective, mechanism-based inhibitors of guinea pig hepatic cytochrome P-450 dependent monooxygenase activity.","2276091",57]
["1-aminobenzotriazole","1-aminobenzotriazole","C033020","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1985,"4045721","Inactivation of rabbit pulmonary cytochrome P-450 in microsomes and isolated perfused lungs by the suicide substrate 1-aminobenzotriazole.","4045721",57]
["1-aminobenzotriazole","1-aminobenzotriazole","C033020","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8050632","A 13-week toxicologic and pathologic evaluation of prolonged cytochromes P450 inhibition by 1-aminobenzotriazole in male rats.","8050632",57]
["1-aminobenzotriazole","1-aminobenzotriazole","C033020","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1993,"8246152","Mechanism-based inactivation of cytochrome P450 1A1 by N-aralkyl-1-aminobenzotriazoles in guinea pig kidney in vivo and in vitro: minimal effects on metabolism of arachidonic acid by renal P450-dependent monooxygenases.","8246152",57]
["1-aminobenzotriazole","1-aminobenzotriazole","C033020","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19606393","Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice.","19606393",57]
["1-benzylimidazole","1-benzylimidazole","C017062","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12685719","Induction of CYP1A by the N-imidazole derivative, 1-benzylimidazole.","12685719",57]
["1-benzylimidazole","1-benzylimidazole","C017062","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1988,"2840913","Effect of 1-benzylimidazole on cytochromes P-450 induction and on the activities of epoxide hydrolases and UDP-glucuronosyltransferases in rat liver.","2840913",57]
["1-Butanol","1-Butanol","D020001","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2011,"21569861","Metabolic engineering of cyanobacteria for 1-butanol production from carbon dioxide.","21569861",57]
["1-chloropyrene","1-chloropyrene","C040345","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26252339","Identification and characterization of oxidative metabolites of 1-chloropyrene.","26252339",57]
["1-cyano-2-hydroxy-3-butene","1-cyano-2-hydroxy-3-butene","C055903","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2004,"15207647","Crambene, a bioactive nitrile derived from glucosinolate hydrolysis, acts via the antioxidant response element to upregulate quinone reductase alone or synergistically with indole-3-carbinol.","15207647",57]
["1-cyano-3,4-epithiobutane","1-cyano-3,4-epithiobutane","C062529","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10439337","Protection from 1-cyano-3,4-epithiobutane nephrotoxicity by aminooxyacetic acid and effect on xenobiotic-metabolizing enzymes in male Fischer 344 rats.","10439337",57]
["1-Deoxynojirimycin","1-Deoxynojirimycin","D017485","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2015,"25445511","1-deoxynojirimycin isolated from Bacillus subtilis improves hepatic lipid metabolism and mitochondrial function in high-fat-fed mice.","25445511",57]
["1-Deoxynojirimycin","1-Deoxynojirimycin","D017485","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"26927057","1-Deoxynojirimycin Alleviates Liver Injury and Improves Hepatic Glucose Metabolism in db/db Mice.","26927057",57]
["1-Deoxynojirimycin","1-Deoxynojirimycin","D017485","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15234963","Inhibition of alpha-glucosidases I and II increases the cell surface expression of functional class A macrophage scavenger receptor (SR-A) by extending its half-life.","15234963",57]
["1-Deoxynojirimycin","1-Deoxynojirimycin","D017485","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15890646","Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator.","15890646",57]
["1-Deoxynojirimycin","1-Deoxynojirimycin","D017485","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28349245","Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.","28349245",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C387,B387)","v":"1-Deoxynojirimycin"},"1-Deoxynojirimycin","D017485","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J387,K387)","v":"Receptors, LDL"},"D011973","Receptors, LDL",1,1,2010,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q387,Q387)","v":"20167657"},"Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice.","20167657",57]
["1-ethynylpyrene","1-ethynylpyrene","C042881","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10581206","Metabolism-based polycyclic aromatic acetylene inhibition of CYP1B1 in 10T1/2 cells potentiates aryl hydrocarbon receptor activity.","10581206",57]
["1-ethynylpyrene","1-ethynylpyrene","C042881","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8069946","Interaction of 1-ethynylpyrene and hepatic CYPIA1 from rainbow trout.","8069946",57]
["1-ethynylpyrene","1-ethynylpyrene","C042881","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8448348","Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene.","8448348",57]
["1-ethynylpyrene","1-ethynylpyrene","C042881","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,1999,"10581206","Metabolism-based polycyclic aromatic acetylene inhibition of CYP1B1 in 10T1/2 cells potentiates aryl hydrocarbon receptor activity.","10581206",57]
["1-furan-2-yl-3-pyridin-2-yl-propenone","1-furan-2-yl-3-pyridin-2-yl-propenone","C508534","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18255114","Chemopreventive effects of Furan-2-yl-3-pyridin-2-yl-propenone against 7,12-dimethylbenz[a]anthracene-inducible genotoxicity.","18255114",57]
["1-furan-2-yl-3-pyridin-2-yl-propenone","1-furan-2-yl-3-pyridin-2-yl-propenone","C508534","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18255114","Chemopreventive effects of Furan-2-yl-3-pyridin-2-yl-propenone against 7,12-dimethylbenz[a]anthracene-inducible genotoxicity.","18255114",57]
["1-hexacosanol","1-hexacosanol","C051942","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"28676202","Hexacosanol reduces plasma and hepatic cholesterol by activation of AMP-activated protein kinase and suppression of sterol regulatory element-binding protein-2 in HepG2 and C57BL/6J mice.","28676202",57]
["1-hexadecyl-2-acetyl-glycero-3-phosphocholine","1-hexadecyl-2-acetyl-glycero-3-phosphocholine","C037145","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2013,"23792041","An endothelin-3-related synthetic biotinylated pentapeptide as a novel inhibitor of platelet-activating factor.","23792041",57]
["1-hydroxyphenanthrene","1-hydroxyphenanthrene","C092102","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24085514","PAH metabolites, GST and EROD in European eel (Anguilla anguilla) as possible indicators for eel habitat quality in German rivers.","24085514",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10753202","CYP1A1 and GSTM1 polymorphisms affect urinary 1-hydroxypyrene levels after PAH exposure.","10753202",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11323399","Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations.","11323399",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11600727","Urinary 1-hydroxypyrene in coke oven workers relative to exposure, alcohol consumption, and metabolic enzymes.","11600727",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11641039","Effects of genetic polymorphisms of CYP1A1, CYP2E1, GSTM1, and GSTT1 on the urinary levels of 1-hydroxypyrene and 2-naphthol in aircraft maintenance workers.","11641039",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12698233","Simultaneous analysis of naphthols, phenanthrols, and 1-hydroxypyrene in urine as biomarkers of polycyclic aromatic hydrocarbon exposure: intraindividual variance in the urinary metabolite excretion profiles caused by intervention with beta-naphthoflavone induction in the rat.","12698233",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12807751","Genetic effects on urinary 1-hydroxypyrene levels in a Korean population.","12807751",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12919719","Susceptibility and exposure biomarkers in people exposed to PAHs from diesel exhaust.","12919719",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12919721","Influence of genetic polymorphisms of CYP1A1 and GSTM1 on the urinary levels of 1-hydroxypyrene.","12919721",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"14646291","Effects of genetic polymorphisms in metabolic enzymes on the relationships between 8-hydroxydeoxyguanosine levels in human leukocytes and urinary 1-hydroxypyrene and 2-naphthol concentrations.","14646291",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15016593","Identification of cytochrome P450 isoforms involved in 1-hydroxylation of pyrene.","15016593",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"15027695","[Influence of genetic polymorphism of CYP1A1 and GSTM1 on the levels of urinary 1-hydroxypyrene].","15027695",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15355699","[Effect of genetic polymorphisms of microsomal epoxide hydrolase on urinary 1-hydroxypyrene levels in coke oven workers].","15355699",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16914185","Effects of genetic polymorphisms CYP1A1, GSTM1, GSTT1 and GSTP1 on urinary 1-hydroxypyrene levels in sugarcane workers.","16914185",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17618724","Pyrene-induced CYP1A2 and SULT1A1 may be regulated by CAR and not by AhR.","17618724",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17908297","Primary DNA damage and genetic polymorphisms for CYP1A1, EPHX and GSTM1 in workers at a graphite electrode manufacturing plant.","17908297",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2008,"18083245","Humic substances modify accumulation but not biotransformation of pyrene in salmon yolk-sac fry.","18083245",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19538838","[Relationship between CYP1A1 gene polymorphisms and urinary 1-hydroxypyrene levels in coke oven workers].","19538838",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21351293","EROD activity in peripheral blood lymphocytes and 1-hydroxypyrene in urine and milk as biomarkers of PAH exposure in dairy ruminants.","21351293",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21787681","The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentration in Thai bus drivers.","21787681",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24085514","PAH metabolites, GST and EROD in European eel (Anguilla anguilla) as possible indicators for eel habitat quality in German rivers.","24085514",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26247835","Oxidation of pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13.","26247835",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9752993","Cytochrome P450 1A1 MspI polymorphism and urinary 1-hydroxypyrene concentrations in coke-oven workers.","9752993",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2007,"17498780","The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers.","17498780",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2007,"17618724","Pyrene-induced CYP1A2 and SULT1A1 may be regulated by CAR and not by AhR.","17618724",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18302886","[Relationship between aryl hydrocarbon receptor G1661A gene polymorphism and level of urinary 1-hydroxypyrene of coke oven workers].","18302886",57]
["1-hydroxypyrene","1-hydroxypyrene","C033146","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18628420","Association of aryl hydrocarbon receptor gene polymorphisms and urinary 1-hydroxypyrene in polycyclic aromatic hydrocarbon-exposed workers.","18628420",57]
["1-hydroxypyrene-glucuronide","1-hydroxypyrene-glucuronide","C093851","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"16864595","The influence of genetic polymorphisms in Ahr, CYP1A1, CYP1A2, CYP1B1, GST M1, GST T1 and UGT1A1 on urine 1-hydroxypyrene glucuronide concentrations in healthy subjects from Rio Grande do Sul, Brazil.","16864595",57]
["1-hydroxypyrene-glucuronide","1-hydroxypyrene-glucuronide","C093851","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2007,"16864595","The influence of genetic polymorphisms in Ahr, CYP1A1, CYP1A2, CYP1B1, GST M1, GST T1 and UGT1A1 on urine 1-hydroxypyrene glucuronide concentrations in healthy subjects from Rio Grande do Sul, Brazil.","16864595",57]
["1-isopropyl-3,5-bis((pyridine-3-yl)methylene)piperidine-4-one","1-isopropyl-3,5-bis((pyridine-3-yl)methylene)piperidine-4-one","C000622636","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"28601309","The aryl hydrocarbon receptor as an antitumor target of synthetic curcuminoids in colorectal cancer.","28601309",57]
["1-methyl-3,5-bis((4-pyridyl)methylidene)-4-piperidone","1-methyl-3,5-bis((4-pyridyl)methylidene)-4-piperidone","C579034","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"28601309","The aryl hydrocarbon receptor as an antitumor target of synthetic curcuminoids in colorectal cancer.","28601309",57]
["1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","D015632","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2009,"19526281","Mutant alpha-synuclein overexpression mediates early proinflammatory activity.","19526281",57]
["1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","D015632","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1468127","Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its toxic metabolites on the physicochemical property of the liposomal membrane in relation to their cytochrome P-450 inhibition.","1468127",57]
["1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","D015632","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18374908","Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.","18374908",57]
["1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","D015632","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1991,"1881637","1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by beta-naphthoflavone-pretreatment.","1881637",57]
["1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","D015632","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1989,"2785364","Studies on the interactions of MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with the cytochrome P-450 enzyme system--clues to a possible aetiological factor in Parkinson's disease.","2785364",57]
["1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","D015632","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2015,"25677261","Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease via mitochondrial stabilization.","25677261",57]
["1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","D015632","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22155743","The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain.","22155743",57]
["1-methyl-4-phenyl-2,3-dihydropyridinium","1-methyl-4-phenyl-2,3-dihydropyridinium","C044755","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1468127","Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its toxic metabolites on the physicochemical property of the liposomal membrane in relation to their cytochrome P-450 inhibition.","1468127",57]
["1-Methyl-4-phenylpyridinium","1-Methyl-4-phenylpyridinium","D015655","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1468127","Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its toxic metabolites on the physicochemical property of the liposomal membrane in relation to their cytochrome P-450 inhibition.","1468127",57]
["1-Methyl-4-phenylpyridinium","1-Methyl-4-phenylpyridinium","D015655","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10727637","Protective effect of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum.","10727637",57]
["1-methylphenanthrene","1-methylphenanthrene","C041507","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23553963","CYP1A expression in liver and gills of roach (Rutilus rutilus) after waterborne exposure to two phenanthrene derivatives, 1-methylphenanthrene and 4-methylphenanthrene.","23553963",57]
["1-N-5-iodovaleramido-3,7,8-trichlorodibenzo-4-dioxin","1-N-5-iodovaleramido-3,7,8-trichlorodibenzo-4-dioxin","C042433","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1984,"6086542","A screening assay for the tetrachlorodibenzo-p-dioxin receptor using the [125I]iodovaleramide derivative of trichlorodibenzo-p-dioxin as the binding ligand.","6086542",57]
["1-naphthoic acid","1-naphthoic acid","C085312","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18433798","Differential developmental toxicity of naphthoic acid isomers in medaka (Oryzias latipes) embryos.","18433798",57]
["1-naphthoic acid","1-naphthoic acid","C085312","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2008,"18433798","Differential developmental toxicity of naphthoic acid isomers in medaka (Oryzias latipes) embryos.","18433798",57]
["1-Naphthylisothiocyanate","1-Naphthylisothiocyanate","D015058","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18187559","Protective response of the Ah receptor to ANIT-induced biliary epithelial cell toxicity in see-through medaka.","18187559",57]
["1-Naphthylisothiocyanate","1-Naphthylisothiocyanate","D015058","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11018467","Accumulation of cholestatic lipoproteins in ANIT-treated human apolipoprotein A-I transgenic rats is diminished through dose-dependent apolipoprotein A-I activation of LCAT.","11018467",57]
["1-Naphthylisothiocyanate","1-Naphthylisothiocyanate","D015058","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,4,2008,"18187559","Protective response of the Ah receptor to ANIT-induced biliary epithelial cell toxicity in see-through medaka.","18187559",57]
["1-nitronaphthalene","1-nitronaphthalene","C016614","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"2384072","Protection against chemical-induced lung injury by inhibition of pulmonary cytochrome P-450.","2384072",57]
["1-nitropyrene","1-nitropyrene","C032668","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11113705","Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1.","11113705",57]
["1-nitropyrene","1-nitropyrene","C032668","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16280210","Suppressive effect of 1-nitropyrene on benzo[a]pyrene-induced CYP1A1 protein expression in HepG2 cells.","16280210",57]
["1-nitropyrene","1-nitropyrene","C032668","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19961161","1-Nitropyrene stabilizes the mRNA of cytochrome P450 1a1, a carcinogen-metabolizing enzyme, via the Akt pathway.","19961161",57]
["1-nitropyrene","1-nitropyrene","C032668","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"22044530","2,3,7,8-Tetrachlorodibenzo-p-dioxin's suppression of 1-nitropyrene-induced p53 expression is mediated by cytochrome P450 1A1.","22044530",57]
["1-nitropyrene","1-nitropyrene","C032668","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26247835","Oxidation of pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13.","26247835",57]
["1-nitropyrene","1-nitropyrene","C032668","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19961161","1-Nitropyrene stabilizes the mRNA of cytochrome P450 1a1, a carcinogen-metabolizing enzyme, via the Akt pathway.","19961161",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C451,B451)","v":"1-nitropyrene"},"1-nitropyrene","C032668","1_MIE",18,1,"AHR","Activation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J451,K451)","v":"Receptors, Aryl Hydrocarbon"},"D018336","Receptors, Aryl Hydrocarbon",1,3,2011,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q451,Q451)","v":"22044530"},"2,3,7,8-Tetrachlorodibenzo-p-dioxin's suppression of 1-nitropyrene-induced p53 expression is mediated by cytochrome P450 1A1.","22044530",57]
["1-nitropyrene","1-nitropyrene","C032668","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2011,"21872649","Mechanisms involved in lipid accumulation and apoptosis induced by 1-nitropyrene in Hepa1c1c7 cells.","21872649",57]
["1-octyl-3-methylimidazolium","1-octyl-3-methylimidazolium","C528768","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"24094773","Expression alterations of cytochromes P4501A1, 2E1, and 3A, and their receptors AhR and PXR caused by 1-octyl-3-methylimidazolium chloride in mouse mammary carcinoma cells.","24094773",57]
["1-octyl-3-methylimidazolium","1-octyl-3-methylimidazolium","C528768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"24094773","Expression alterations of cytochromes P4501A1, 2E1, and 3A, and their receptors AhR and PXR caused by 1-octyl-3-methylimidazolium chloride in mouse mammary carcinoma cells.","24094773",57]
["1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine","1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine","C043051","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11031211","Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position.","11031211",57]
["1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine","1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine","C043051","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11829739","Induction of glutathione synthesis by oxidized low-density lipoprotein and 1-palmitoyl-2-arachidonyl phosphatidylcholine: protection against quinone-mediated oxidative stress.","11829739",57]
["1-palmitoyl-2-(1'-pyreneoctanoyl)glycero-3-phosphochine","1-palmitoyl-2-(1'-pyreneoctanoyl)glycero-3-phosphochine","C062484","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2606101","Lateral diffusion of phospholipids in the lipid surface of human low-density lipoprotein measured with a pyrenyl phospholipid probe.","2606101",57]
["1-palmitoyl-2-(5-oxovaleroyl)phosphatidylcholine","1-palmitoyl-2-(5-oxovaleroyl)phosphatidylcholine","C119546","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10339590","Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells.","10339590",57]
["1-palmitoyl-2-(5-oxovaleroyl)phosphatidylcholine","1-palmitoyl-2-(5-oxovaleroyl)phosphatidylcholine","C119546","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10339590","Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells.","10339590",57]
["1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","C400184","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2012,"22934615","Design and synthesis of a stable oxidized phospholipid mimic with specific binding recognition for macrophage scavenger receptors.","22934615",57]
["1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","C400184","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11031211","Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position.","11031211",57]
["1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","C400184","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16904371","The oxidized phospholipids POVPC and PGPC inhibit growth and induce apoptosis in vascular smooth muscle cells.","16904371",57]
["1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","C400184","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22333180","Uptake and protein targeting of fluorescent oxidized phospholipids in cultured RAW 264.7 macrophages.","22333180",57]
["1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","C400184","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23936132","Oxidized phospholipids induce ceramide accumulation in RAW 264.7 macrophages: role of ceramide synthases.","23936132",57]
["1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine","C400184","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25219896","Chemical recognition of oxidation-specific epitopes in low-density lipoproteins by a nanoparticle based concept for trapping, enrichment, and liquid chromatography-tandem mass spectrometry analysis of oxidative stress biomarkers.","25219896",57]
["1-palmitoyl-2-(6-(N-(7-nitrobenz)-2-oxa-1,3-diazol-4-yl)aminocaproyl)phosphatidylcholine","1-palmitoyl-2-(6-(N-(7-nitrobenz)-2-oxa-1,3-diazol-4-yl)aminocaproyl)phosphatidylcholine","C044745","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1576162","The use of C6-NBD-PC for assaying phospholipase A2-activity: scope and limitations.","1576162",57]
["1-palmitoyl-2-(9-oxononanoyl)-sn-glycero-3-phosphocholine","1-palmitoyl-2-(9-oxononanoyl)-sn-glycero-3-phosphocholine","C097369","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25219896","Chemical recognition of oxidation-specific epitopes in low-density lipoproteins by a nanoparticle based concept for trapping, enrichment, and liquid chromatography-tandem mass spectrometry analysis of oxidative stress biomarkers.","25219896",57]
["1-palmitoyl-2-arachidonyl-3-phosphorylcholine","1-palmitoyl-2-arachidonyl-3-phosphorylcholine","C468114","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2003,"12775576","Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2.","12775576",57]
["1-palmitoyl-2-arachidonyl-3-phosphorylcholine","1-palmitoyl-2-arachidonyl-3-phosphorylcholine","C468114","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2003,"12777373","Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein.","12777373",57]
["1-palmitoyl-2-arachidonyl-3-phosphorylcholine","1-palmitoyl-2-arachidonyl-3-phosphorylcholine","C468114","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12777373","Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein.","12777373",57]
["1-palmitoyl-2-arachidonyl-3-phosphorylcholine","1-palmitoyl-2-arachidonyl-3-phosphorylcholine","C468114","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14520236","Antibodies against platelet-activating factor and platelet-activating factor-like lipids are raised in women with primary recurrent abortion.","14520236",57]
["1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","C400185","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11031211","Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position.","11031211",57]
["1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","C400185","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16904371","The oxidized phospholipids POVPC and PGPC inhibit growth and induce apoptosis in vascular smooth muscle cells.","16904371",57]
["1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","C400185","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22333180","Uptake and protein targeting of fluorescent oxidized phospholipids in cultured RAW 264.7 macrophages.","22333180",57]
["1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine","C400185","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23936132","Oxidized phospholipids induce ceramide accumulation in RAW 264.7 macrophages: role of ceramide synthases.","23936132",57]
["1-palmitoyl-2-linoleoylphosphatidylcholine","1-palmitoyl-2-linoleoylphosphatidylcholine","C055402","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10569945","CTP:phosphocholine cytidylyltransferase activation by oxidized phosphatidylcholines correlates with a decrease in lipid order: a 2H NMR analysis.","10569945",57]
["1-palmitoyl-2-linoleoylphosphatidylcholine","1-palmitoyl-2-linoleoylphosphatidylcholine","C055402","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8619631","Reaction of phosphatidylcholine hydroperoxide in human plasma: the role of peroxidase and lecithin:cholesterol acyltransferase.","8619631",57]
["1-palmitoyl-2-lysophosphatidylcholine","1-palmitoyl-2-lysophosphatidylcholine","C089215","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15805546","Chemical modification of proteins during peroxidation of phospholipids.","15805546",57]
["1-palmitoyl-2-oleoylphosphatidylcholine","1-palmitoyl-2-oleoylphosphatidylcholine","C028694","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10569945","CTP:phosphocholine cytidylyltransferase activation by oxidized phosphatidylcholines correlates with a decrease in lipid order: a 2H NMR analysis.","10569945",57]
["1-palmitoyl-2-oleoylphosphatidylcholine","1-palmitoyl-2-oleoylphosphatidylcholine","C028694","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17655300","Tetrahydro-1,8-naphthyridinol analogues of alpha-tocopherol as antioxidants in lipid membranes and low-density lipoproteins.","17655300",57]
["1-palmitoyl-2-oleoylphosphatidylcholine","1-palmitoyl-2-oleoylphosphatidylcholine","C028694","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23828780","Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.","23828780",57]
["1-palmitoyl-2-oleoylphosphatidylcholine","1-palmitoyl-2-oleoylphosphatidylcholine","C028694","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2013,"23828780","Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.","23828780",57]
["1-palmitoyl-2-pyrenedecanoylphosphatidylcholine","1-palmitoyl-2-pyrenedecanoylphosphatidylcholine","C021248","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8608174","Pyrene lipids as markers of peroxidative processes in different regions of low and high density lipoproteins.","8608174",57]
["1-phenylazo-2-naphthol","1-phenylazo-2-naphthol","C024336","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12384524","Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes.","12384524",57]
["1-phenylazo-2-naphthol","1-phenylazo-2-naphthol","C024336","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15766589","Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers.","15766589",57]
["1-phenylazo-2-naphthol","1-phenylazo-2-naphthol","C024336","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"17159775","Modulation of CYP1A1-mediated oxidation of carcinogenic azo dye Sudan I and its binding to DNA by cytochrome b5.","17159775",57]
["1-phenylazo-2-naphthol","1-phenylazo-2-naphthol","C024336","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23289503","Induced expression of cytochrome P450 1A and NAD(P)H:quinone oxidoreductase determined at mRNA, protein, and enzyme activity levels in rats exposed to the carcinogenic azo dye 1-phenylazo-2-naphthol (Sudan I).","23289503",57]
["1-phenylimidazole","1-phenylimidazole","C037738","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2007,"17521864","Induction of EROD activity by 1-phenylimidazole and beta-naphthoflavone in rainbow trout cultured hepatocytes: a comparative study.","17521864",57]
["1-phenylimidazole","1-phenylimidazole","C037738","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2007,"17521864","Induction of EROD activity by 1-phenylimidazole and beta-naphthoflavone in rainbow trout cultured hepatocytes: a comparative study.","17521864",57]
["1-phenylpropanol","1-phenylpropanol","C439395","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15563769","Natural phenylpropanoids inhibit lipoprotein-induced endothelin-1 secretion by endothelial cells.","15563769",57]
["1-Propanol","1-Propanol","D000433","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"14308132","ENCEPHALOPATHY, HEPATITIS AND FAT ACCUMULATION IN VISCERA.","14308132",57]
["1-Propanol","1-Propanol","D000433","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1974,"4140561","Effects of chronic ingestion of some lower aliphatic alcohols in rats.","4140561",57]
["1-Propanol","1-Propanol","D000433","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1974,"4457159","Effect of an intoxicating dose of ethanol or isopropanol on the incorporation of [1-14C] palmitate into rat liver and blood lipids.","4457159",57]
["1-Propanol","1-Propanol","D000433","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1972,"4631967","[Effect of isopropanol on palmitate 1-C14 incorporation in hepatic triglycerides and phospholipids in rats].","4631967",57]
["1-Propanol","1-Propanol","D000433","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1973,"4756119","Studies on the mechanisms involved in the isopropanol-induced fatty liver.","4756119",57]
["1-Propanol","1-Propanol","D000433","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1969,"5375483","[Toxic influence of the choleretics dehydrocholic acid, phenylpropanol and hydroxyphenylsalicylamide on the regenerating rat liver].","5375483",57]
["1-Propanol","1-Propanol","D000433","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1977,"79372","[Comparison of the effect of acetone and isopropanol on lipid metabolism in rats].","79372",57]
["1-Propanol","1-Propanol","D000433","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10963937","The EPR study of LDL perturbed by alcohols with different molecular architecture.","10963937",57]
["1-Propanol","1-Propanol","D000433","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24769351","Synthesis of new N-acryl-1-amino-2-phenylethanol and N-acyl-1-amino-3-aryloxypropanols and evaluation of their antihyperlipidemic, LDL-oxidation and antioxidant activity.","24769351",57]
["1-Propanol","1-Propanol","D000433","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6631250","Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B.","6631250",57]
["1-Propanol","1-Propanol","D000433","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1979,"222494","Comparative effects of ethanol, n-propranol and isopropanol on lipid disposal by rat liver.","222494",57]
["1-Propanol","1-Propanol","D000433","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1983,"6631250","Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B.","6631250",57]
["1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine","1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine","C027891","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18005671","Phospholipid chlorohydrin induces leukocyte adhesion to ApoE-/- mouse arteries via upregulation of P-selectin.","18005671",57]
["2-((2,4-dihydroxyphenyl)sulfonyl)isoindoline-4,6-diol","2-((2,4-dihydroxyphenyl)sulfonyl)isoindoline-4,6-diol","C588035","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24356970","Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.","24356970",57]
["2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester","2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester","C520611","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19276279","Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells.","19276279",57]
["2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester","2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester","C520611","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19276279","Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells.","19276279",57]
["2-(1-((2,3-dihydro-1H-imidazol-2-yl)methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo(d)imidazole","2-(1-((2,3-dihydro-1H-imidazol-2-yl)methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo(d)imidazole","C000622243","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28671460","Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.","28671460",57]
["2-(10H-phenothiazin-2-yloxy)-N,N-dimethylethanamine","2-(10H-phenothiazin-2-yloxy)-N,N-dimethylethanamine","C073191","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1542098","Phenothiazines as lipid peroxidation inhibitors and cytoprotective agents.","1542098",57]
["2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C584446","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23851185","An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells.","23851185",57]
["2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C584446","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23851185","An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells.","23851185",57]
["2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C584446","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2014,"24475139","ITE and TCDD differentially regulate the vascular remodeling of rat placenta via the activation of AhR.","24475139",57]
["2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C548651","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22572380","Effects of AhR ligands on the production of immunoglobulins in purified mouse B cells.","22572380",57]
["2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C548651","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2002,"12409613","A ligand for the aryl hydrocarbon receptor isolated from lung.","12409613",57]
["2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C548651","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"19933214","TCDD and a putative endogenous AhR ligand, ITE, elicit the same immediate changes in gene expression in mouse lung fibroblasts.","19933214",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C515,B515)","v":"2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester"},"2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C548651","1_MIE",18,1,"AHR","Activation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J515,K515)","v":"Receptors, Aryl Hydrocarbon"},"D018336","Receptors, Aryl Hydrocarbon",1,1,2011,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q515,Q515)","v":"21406171"},"The aryl hydrocarbon receptor ligand ITE inhibits TGFβ1-induced human myofibroblast differentiation.","21406171",57]
["2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C548651","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2012,"22572380","Effects of AhR ligands on the production of immunoglobulins in purified mouse B cells.","22572380",57]
["2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester","C548651","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2014,"24514067","An aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress the Th17 response in allergic rhinitis patients.","24514067",57]
["2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid","2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid","C483845","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2009,"18971352","Tissue-specific postprandial clearance is the major determinant of PPARgamma-induced triglyceride lowering in the rat.","18971352",57]
["2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid","2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid","C559288","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"23108115","Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice.","23108115",57]
["2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid","2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid","C559288","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2015,"25897794","FABP4 inhibition suppresses PPARγ activity and VLDL-induced foam cell formation in IL-4-polarized human macrophages.","25897794",57]
["2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid","2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid","C559288","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2013,"23108115","Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice.","23108115",57]
["2-(2,2,3,3,3-pentafluoropropoxy)-3-(4-(2,2,2-trifluoroethoxy)phenyl)-5,7-dihydro-3H-pyrrolo(2,3-d)pyrimidine-4,6-dione","2-(2,2,3,3,3-pentafluoropropoxy)-3-(4-(2,2,2-trifluoroethoxy)phenyl)-5,7-dihydro-3H-pyrrolo(2,3-d)pyrimidine-4,6-dione","C000621111","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2016,"27832159","A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet-Induced Obese C57BL/6J Mice.","27832159",57]
["2-(2',4'-dibromophenoxy)-3,5-dibromoanisole","2-(2',4'-dibromophenoxy)-3,5-dibromoanisole","C496823","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25565004","Bioaccumulation, biotransformation, and toxicity of BDE-47, 6-OH-BDE-47, and 6-MeO-BDE-47 in early life-stages of zebrafish (Danio rerio).","25565004",57]
["2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","C585906","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23703580","Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.","23703580",57]
["2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","C585906","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23787705","Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism.","23787705",57]
["2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","C585906","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23703580","Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.","23703580",57]
["2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","C585906","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23787705","Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism.","23787705",57]
["2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","C585906","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28637104","[Treatment Options in Non-alcoholic Fatty Liver Disease].","28637104",57]
["2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","C585906","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"25164277","GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.","25164277",57]
["2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid","C585906","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26874076","Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.","26874076",57]
["2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","C093973","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1999,"10426807","Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor.","10426807",57]
["2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","C093973","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16393856","CCAAT/enhancer binding protein activation by PD98059 contributes to the inhibition of AhR-mediated 3-methylcholanthrene induction of CYP1A1.","16393856",57]
["2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","C093973","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1999,"10426807","Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor.","10426807",57]
["2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","C093973","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"16393856","CCAAT/enhancer binding protein activation by PD98059 contributes to the inhibition of AhR-mediated 3-methylcholanthrene induction of CYP1A1.","16393856",57]
["2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one","C093973","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1998,"9495809","PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase.","9495809",57]
["2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide","2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide","C096011","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"21372297","Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.","21372297",57]
["2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol","2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol","C529054","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2017,"28244693","Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.","28244693",57]
["2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione","2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione","C074534","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1333628","Effects of isoxazolidine or triazolidine on rat serum lipids in vivo and LDL and HDL binding and degradation in human and rodent cultured cells in vitro.","1333628",57]
["2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione","2-(3,4,5-trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione","C074534","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1992,"1333628","Effects of isoxazolidine or triazolidine on rat serum lipids in vivo and LDL and HDL binding and degradation in human and rodent cultured cells in vitro.","1333628",57]
["2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole","2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole","C507816","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21831963","CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells.","21831963",57]
["2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole","2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole","C507816","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22734839","Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1.","22734839",57]
["2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole","2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole","C507816","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18666770","Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648).","18666770",57]
["2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino)ethanol","2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino)ethanol","C532995","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22459073","Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.","22459073",57]
["2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid","2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid","C079315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2007,"17928652","BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice.","17928652",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11311068","Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.","11311068",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12592376","DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.","12592376",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"14707267","Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.","14707267",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15078163","The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate.","15078163",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15634650","In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.","15634650",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18074135","BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity.","18074135",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19088497","Preclinical toxicokinetic evaluation of phortress [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride] in two rodent species.","19088497",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2009,"19265716","2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole is a ligand and shows species-specific partial agonism of the aryl hydrocarbon receptor.","19265716",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22734839","Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1.","22734839",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23696052","Biomarkers of sensitivity to potent and selective antitumor 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F203) in ovarian cancer.","23696052",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24446378","Molecular dynamics simulation studies for DNA sequence recognition by reactive metabolites of anticancer compounds.","24446378",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"26474663","Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F203 hydrogels for local delivery.","26474663",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2003,"12592376","DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.","12592376",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15655410","The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.","15655410",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2009,"19265716","2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole is a ligand and shows species-specific partial agonism of the aryl hydrocarbon receptor.","19265716",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25781201","Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human Breast Cancer Cells.","25781201",57]
["2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole","C425784","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2017,"28471540","In Vitro Antitumor Effects of AHR Ligands Aminoflavone (AFP 464) and Benzothiazole (5F 203) in Human Renal Carcinoma Cells.","28471540",57]
["2-(4-aminophenyl)benzothiazole","2-(4-aminophenyl)benzothiazole","C111133","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10901382","Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).","10901382",57]
["2-(4-aminophenyl)benzothiazole","2-(4-aminophenyl)benzothiazole","C111133","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2006,"16787373","2-(4-aminophenyl) benzothiazole: a potent and selective pharmacophore with novel mechanistic action towards various tumour cell lines.","16787373",57]
["2-(4-aminophenyl)benzothiazole","2-(4-aminophenyl)benzothiazole","C111133","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16787373","2-(4-aminophenyl) benzothiazole: a potent and selective pharmacophore with novel mechanistic action towards various tumour cell lines.","16787373",57]
["2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol","2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol","C405041","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10691687","Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity.","10691687",57]
["2-(4-bromophenyl)-N-(4-fluorophenyl)-3-propyl-3H-imidazo(4,5-b)pyridin-5-amine","2-(4-bromophenyl)-N-(4-fluorophenyl)-3-propyl-3H-imidazo(4,5-b)pyridin-5-amine","C576502","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22715131","Hepatic differentiation of rat mesenchymal stem cells by a small molecule.","22715131",57]
["2-(4-hydroxy-3-methoxyphenyl)benzothiazole","2-(4-hydroxy-3-methoxyphenyl)benzothiazole","C000602051","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"25403352","2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.","25403352",57]
["2-(4-hydroxyphenoxy)acetic acid-formaldehyde polymer","2-(4-hydroxyphenoxy)acetic acid-formaldehyde polymer","C090697","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11427199","Effects of the heparin-mimicking compound RG-13577 on lipoprotein lipase and on lipase mediated binding of LDL to cells.","11427199",57]
["2-(4-hydroxyphenoxy)acetic acid-formaldehyde polymer","2-(4-hydroxyphenoxy)acetic acid-formaldehyde polymer","C090697","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2001,"11427199","Effects of the heparin-mimicking compound RG-13577 on lipoprotein lipase and on lipase mediated binding of LDL to cells.","11427199",57]
["2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","C085911","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10927021","Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated aryl hydrocarbon receptor transformation and CYP1A1 induction by the phosphatidylinositol 3-kinase inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002).","10927021",57]
["2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","C085911","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2007,"17848630","Polyphenolic compounds from Artemisia dracunculus L. inhibit PEPCK gene expression and gluconeogenesis in an H4IIE hepatoma cell line.","17848630",57]
["2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","C085911","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"10927021","Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated aryl hydrocarbon receptor transformation and CYP1A1 induction by the phosphatidylinositol 3-kinase inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002).","10927021",57]
["2-(6-(4-(2-chloro-5-fluorophenoxy)piperidin-1-yl)pyridazin-3-yl)-5-methyl-1,3,4-oxadiazole","2-(6-(4-(2-chloro-5-fluorophenoxy)piperidin-1-yl)pyridazin-3-yl)-5-methyl-1,3,4-oxadiazole","C531040","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2007,"17530838","Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.","17530838",57]
["2-(7-methoxy-4-methylquinazolin-2-yl)guanidine","2-(7-methoxy-4-methylquinazolin-2-yl)guanidine","C000622242","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28671460","Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.","28671460",57]
["2-(indol-3-ylmethyl)-3,3'-diindolylmethane","2-(indol-3-ylmethyl)-3,3'-diindolylmethane","C120667","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1999,"10449193","Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3'-diindolylmethane, a major in vivo product of dietary indole-3-carbinol.","10449193",57]
["2-(N-ethylperfluorooctanesulfonamido)ethyl alcohol","2-(N-ethylperfluorooctanesulfonamido)ethyl alcohol","C435127","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2002,"11879971","Perfluorooctanoate, perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis.","11879971",57]
["2-(omega-carboxyethyl)pyrrole","2-(omega-carboxyethyl)pyrrole","C000602461","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2015,"25966710","Receptor-Mediated Mechanism Controlling Tissue Levels of Bioactive Lipid Oxidation Products.","25966710",57]
["2-(omega-carboxyethyl)pyrrole","2-(omega-carboxyethyl)pyrrole","C000602461","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25966710","Receptor-Mediated Mechanism Controlling Tissue Levels of Bioactive Lipid Oxidation Products.","25966710",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C579,B579)","v":"2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene"},"2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene","C054919","2_KE",450,2,"VLDL secretion","Suppression",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J579,K579)","v":"Lipoproteins, IDL"},"D053419","Lipoproteins, IDL",1,1,2016,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q579,Q579)","v":"26671975"},"Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.","26671975",57]
["2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene","2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene","C054919","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26671975","Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.","26671975",57]
["2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene","2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene","C054919","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2016,"26671975","Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.","26671975",57]
["2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid","2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid","C054917","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,2016,"26671975","Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.","26671975",57]
["2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid","2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid","C054917","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26671975","Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.","26671975",57]
["2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid","2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid","C054917","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2016,"26671975","Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.","26671975",57]
["2,2'-(hydroxynitrosohydrazono)bis-ethanamine","2,2'-(hydroxynitrosohydrazono)bis-ethanamine","C094210","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25347994","M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice.","25347994",57]
["2,2',3,4,4',5,5'-heptachloro-3'-hydroxybiphenyl","2,2',3,4,4',5,5'-heptachloro-3'-hydroxybiphenyl","C000602900","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"26148434","Hydroxyl metabolite of PCB 180 induces DNA damage signaling and enhances the DNA damaging effect of benzo[a]pyrene.","26148434",57]
["2,2',3,5',6-pentachlorobiphenyl","2,2',3,5',6-pentachlorobiphenyl","C032904","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1997,"9291493","Ortho-substituted 2,2',3,5',6-pentachlorobiphenyl (PCB 95) alters rat hippocampal ryanodine receptors and neuroplasticity in vitro: evidence for altered hippocampal function.","9291493",57]
["2,2',4,4',5-brominated diphenyl ether","2,2',4,4',5-brominated diphenyl ether","C477694","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15840429","Common viral infection affects pentabrominated diphenyl ether (PBDE) distribution and metabolic and hormonal activities in mice.","15840429",57]
["2,2',4,4',5-brominated diphenyl ether","2,2',4,4',5-brominated diphenyl ether","C477694","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17964053","Coxsackievirus B3 infection and PBDE exposure causes organ-specific effects on CYP-gene expression in the mouse.","17964053",57]
["2,2',4,4',5-brominated diphenyl ether","2,2',4,4',5-brominated diphenyl ether","C477694","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17964055","Viral infection and PBDE exposure interact on CYP gene expression and enzyme activities in the mouse liver.","17964055",57]
["2,2',4,4',5-brominated diphenyl ether","2,2',4,4',5-brominated diphenyl ether","C477694","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"25180441","Effects of BDE-209 and its mixtures with BDE-47 and BDE-99 on multiple biomarkers in Carassius auratus.","25180441",57]
["2,2',4,4',5-brominated diphenyl ether","2,2',4,4',5-brominated diphenyl ether","C477694","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27343407","BDE-99, but not BDE-47, is a transient aryl hydrocarbon receptor agonist in zebrafish liver cells.","27343407",57]
["2,2',4,4',5-brominated diphenyl ether","2,2',4,4',5-brominated diphenyl ether","C477694","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2016,"27343407","BDE-99, but not BDE-47, is a transient aryl hydrocarbon receptor agonist in zebrafish liver cells.","27343407",57]
["2,2',4,4',5-pentachlorodiphenyl ether","2,2',4,4',5-pentachlorodiphenyl ether","C058905","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1997,"9231697","Maternal and developmental toxicity of polychlorinated diphenyl ethers (PCDEs) in Swiss-Webster mice and Sprague-Dawley rats.","9231697",57]
["2,2',4,4',6,6'-hexabromobiphenyl","2,2',4,4',6,6'-hexabromobiphenyl","C508511","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16291824","Genetic differences in lethality of newborn mice treated in utero with coplanar versus non-coplanar hexabromobiphenyl.","16291824",57]
["2,2',4,4',6,6'-hexabromobiphenyl","2,2',4,4',6,6'-hexabromobiphenyl","C508511","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"16291824","Genetic differences in lethality of newborn mice treated in utero with coplanar versus non-coplanar hexabromobiphenyl.","16291824",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11861977","Developmental exposure to brominated diphenyl ethers results in thyroid hormone disruption.","11861977",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12135626","Polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs) and chlorinated paraffins (CPs) in rats-testing interactions and mechanisms for thyroid hormone effects.","12135626",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16280385","Impact of repeated exposure on the toxicokinetics of BDE 47 in mice.","16280385",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18485829","Biomonitoring of polybrominated diphenyl ether (PBDE) pollution: a field study.","18485829",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20074802","Growth and transcriptional effect of dietary 2,2',4,4'-tetrabromodiphenyl ether (PBDE-47) exposure in developing zebrafish (Danio rerio).","20074802",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"25180441","Effects of BDE-209 and its mixtures with BDE-47 and BDE-99 on multiple biomarkers in Carassius auratus.","25180441",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27343407","BDE-99, but not BDE-47, is a transient aryl hydrocarbon receptor agonist in zebrafish liver cells.","27343407",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2017,"28300557","High-fat diet aggravates 2,2',4,4'-tetrabromodiphenyl ether-inhibited testosterone production via DAX-1 in Leydig cells in rats.","28300557",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23933504","Global DNA hypermethylation is associated with high serum levels of persistent organic pollutants in an elderly population.","23933504",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25565004","Bioaccumulation, biotransformation, and toxicity of BDE-47, 6-OH-BDE-47, and 6-MeO-BDE-47 in early life-stages of zebrafish (Danio rerio).","25565004",57]
["2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether","C511295","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2016,"27343407","BDE-99, but not BDE-47, is a transient aryl hydrocarbon receptor agonist in zebrafish liver cells.","27343407",57]
["2,2',4,4'-tetrahydroxybenzophenone","2,2',4,4'-tetrahydroxybenzophenone","C035476","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2004,"15458797","Effects of estradiol, benzophenone-2 and benzophenone-3 on the expression pattern of the estrogen receptors (ER) alpha and beta, the estrogen receptor-related receptor 1 (ERR1) and the aryl hydrocarbon receptor (AhR) in adult ovariectomized rats.","15458797",57]
["2,2',4,6,6'-pentachlorobiphenyl","2,2',4,6,6'-pentachlorobiphenyl","C417207","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17511620","Co-planar 3,3',4,4',5-pentachlorinated biphenyl and non-co-planar 2,2',4,6,6'-pentachlorinated biphenyl differentially induce recruitment of oestrogen receptor alpha to aryl hydrocarbon receptor target genes.","17511620",57]
["2,2',4,6,6'-pentachlorobiphenyl","2,2',4,6,6'-pentachlorobiphenyl","C417207","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19549508","PCB-induced endothelial cell dysfunction: role of poly(ADP-ribose) polymerase.","19549508",57]
["2,2',4,6,6'-pentachlorobiphenyl","2,2',4,6,6'-pentachlorobiphenyl","C417207","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"11076690","2,2',4,6,6'-pentachlorobiphenyl induces apoptosis in human monocytic cells.","11076690",57]
["2,2',4,6,6'-pentachlorobiphenyl","2,2',4,6,6'-pentachlorobiphenyl","C417207","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2007,"17511620","Co-planar 3,3',4,4',5-pentachlorinated biphenyl and non-co-planar 2,2',4,6,6'-pentachlorinated biphenyl differentially induce recruitment of oestrogen receptor alpha to aryl hydrocarbon receptor target genes.","17511620",57]
["2,2',4,6'-tetramethoxystilbene","2,2',4,6'-tetramethoxystilbene","C541980","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19463925","Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene.","19463925",57]
["2,2,4-trimethylpentane","2,2,4-trimethylpentane","C045798","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1997,"9253172","Carrier effects of dosing the H4IIE cells with 3,3',4,4'-tetrachlorobiphenyl (PCB77) in dimethyl sulfoxide or isooctane.","9253172",57]
["2,2',5-trichlorobiphenyl","2,2',5-trichlorobiphenyl","C078449","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1995,"7767025","Uterotropic and enzyme induction effects of 2,2',5-trichlorobiphenyl.","7767025",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10575349","The protective effect on Cu2+- and AAPH-mediated oxidation of human low-density lipoproteins depends on glycosaminoglycan structure.","10575349",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15190934","Application of water-soluble radical initiator, 2,2'-azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride, to a study of oxidative stress.","15190934",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16259790","Interaction and reactivity of urocanic acid towards peroxyl radicals.","16259790",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21620869","Thiosemicarbazone derivate protects from AAPH and Cu2+ -induced LDL oxidation.","21620869",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7670947","Paracetamol inhibits copper ion-induced, azo compound-initiated, and mononuclear cell-mediated oxidative modification of LDL.","7670947",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1994,"8179337","Oxidation-induced aggregation of rabbit low-density lipoprotein by azo initiator.","8179337",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8606614","Morin hydrate inhibits azo-initiator induced oxidation of human low density lipoprotein.","8606614",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8827529","Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein.","8827529",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9378372","A comparison of the kinetics of low-density lipoprotein oxidation initiated by copper or by azobis (2-amidinopropane).","9378372",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9086309","Initiation of LDL oxidation by copper ions or AAPH yields different kinetic parameters which are correlated.","9086309",57]
["2,2'-azobis(2-amidinopropane)","2,2'-azobis(2-amidinopropane)","C046728","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9862277","The isoflavone genistein inhibits copper and peroxyl radical mediated low density lipoprotein oxidation in vitro.","9862277",57]
["2,2-dichloro-1,1,1-trifluoroethane","2,2-dichloro-1,1,1-trifluoroethane","C067411","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2001,"11548120","Investigations on the liver toxicity of a blend of HCFC-123 (2,2-dichloro-1,1,1-trifluoroethane) and HCFC-124 (2-chloro-1,1,1,2-tetrafluoroethane) in guinea-pigs.","11548120",57]
["2,2-difluoro-4-pentenoic acid","2,2-difluoro-4-pentenoic acid","C096093","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1995,"7548749","Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.","7548749",57]
["2,2-dimethyl-5-tert-butyl-1,3-benzodioxole","2,2-dimethyl-5-tert-butyl-1,3-benzodioxole","C037778","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1983,"6845372","Induction of cytochrome P-450 by methylenedioxyphenyl compounds: importance of the methylene carbon.","6845372",57]
["2,2-dimethyl-5-tert-butyl-1,3-benzodioxole","2,2-dimethyl-5-tert-butyl-1,3-benzodioxole","C037778","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1986,"3002384","Cytochrome P-450 induction by 3-methylcholanthrene and its antagonism by 2,2-dimethyl-5-t-butyl-1,3-benzodioxole.","3002384",57]
["2,2'-Dipyridyl","2,2'-Dipyridyl","D015082","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1998,"9849642","Drug-metabolizing enzyme induction by 2,2'-dipyridyl, 1,7-phenanthroline, 7,8-benzoquinoline and oltipraz in mouse.","9849642",57]
["2,2'-methylenebis(4-methyl-6-tert-butylphenol)","2,2'-methylenebis(4-methyl-6-tert-butylphenol)","C008437","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1981,"7245245","Effects of four bisphenolic antioxidants on lipid contents of rat liver.","7245245",57]
["2,2'-methylenebis(ethyl-6-tert-butylphenol)","2,2'-methylenebis(ethyl-6-tert-butylphenol)","C030577","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1981,"7245245","Effects of four bisphenolic antioxidants on lipid contents of rat liver.","7245245",57]
["2,3,3',4,4',5,5'-heptachlor-1'-methyl-1,2'-bipyrrole","2,3,3',4,4',5,5'-heptachlor-1'-methyl-1,2'-bipyrrole","C503289","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15657799","Biological activity and physicochemical parameters of marine halogenated natural products 2,3,3',4,4',5,5'-heptachloro-1'-methyl-1,2'-bipyrrole and 2,4,6-tribromoanisole.","15657799",57]
["2,3,3',4,4',5,5'-heptachlor-1'-methyl-1,2'-bipyrrole","2,3,3',4,4',5,5'-heptachlor-1'-methyl-1,2'-bipyrrole","C503289","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15657799","Biological activity and physicochemical parameters of marine halogenated natural products 2,3,3',4,4',5,5'-heptachloro-1'-methyl-1,2'-bipyrrole and 2,4,6-tribromoanisole.","15657799",57]
["2,3,3',4,4',5-hexabromobiphenyl","2,3,3',4,4',5-hexabromobiphenyl","C029186","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1981,"6258818","Potent induction of rat liver microsomal, drug-metabolizing enzymes by 2,3,3',4,4',5-hexabromobiphenyl, a component of fireMaster.","6258818",57]
["2,3,3',4,4',5-hexachlorobiphenyl","2,3,3',4,4',5-hexachlorobiphenyl","C087667","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7672011","Subchronic effects of 2,3,7,8-TCDD or PCBs on thyroid hormone metabolism: use in risk assessment.","7672011",57]
["2,3,3',4,4',5-hexachlorobiphenyl","2,3,3',4,4',5-hexachlorobiphenyl","C087667","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9356306","Promotion of enzyme altered foci in female rat 2,3,3',4,4',5-hexachlorobiphenyl.","9356306",57]
["2,3,3',4,4',5-hexachlorobiphenyl","2,3,3',4,4',5-hexachlorobiphenyl","C087667","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1995,"7672011","Subchronic effects of 2,3,7,8-TCDD or PCBs on thyroid hormone metabolism: use in risk assessment.","7672011",57]
["2,3,3',4,4'5,6-heptabromobiphenyl","2,3,3',4,4'5,6-heptabromobiphenyl","C029187","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1981,"6258818","Potent induction of rat liver microsomal, drug-metabolizing enzymes by 2,3,3',4,4',5-hexabromobiphenyl, a component of fireMaster.","6258818",57]
["2,3,3',4,4'-pentachlorobiphenyl","2,3,3',4,4'-pentachlorobiphenyl","C067940","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10640525","Induction of aberrant mitosis with PCBs: particular efficiency of 2, 3,3',4,4'-pentachlorobiphenyl and synergism with triphenyltin.","10640525",57]
["2,3,3',4,4'-pentachlorobiphenyl","2,3,3',4,4'-pentachlorobiphenyl","C067940","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"18007995","Polychlorinated biphenyls 105 and 118 form thyroid hormone receptor agonists after cytochrome P4501A1 activation in rat pituitary GH3 cells.","18007995",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C643,B643)","v":"2,3,3',4,4'-pentachlorobiphenyl"},"2,3,3',4,4'-pentachlorobiphenyl","C067940","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J643,K643)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,1997,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q643,Q643)","v":"9090025"},"Toxicity of PCB 105 in the rat liver: an ultrastructural and biochemical study.","9090025",57]
["2,3,3',4,4'-pentachlorobiphenyl","2,3,3',4,4'-pentachlorobiphenyl","C067940","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9772211","Interactive effects of three structurally different polychlorinated biphenyls in a rat liver tumor promotion bioassay.","9772211",57]
["2,3,3',4',5-pentachloro-4-hydroxybiphenyl","2,3,3',4',5-pentachloro-4-hydroxybiphenyl","C111120","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9493316","Hydroxylated polychlorinated biphenyls: placental transfer and effects on thyroxine in the foetal mouse.","9493316",57]
["2',3,3',4',5-pentachloro-4-hydroxybiphenyl","2',3,3',4',5-pentachloro-4-hydroxybiphenyl","C111118","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9493316","Hydroxylated polychlorinated biphenyls: placental transfer and effects on thyroxine in the foetal mouse.","9493316",57]
["2,3,4,2',3',4'-hexachlorobiphenyl","2,3,4,2',3',4'-hexachlorobiphenyl","C014218","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9183382","Subchronic toxicity of 2,2',3,3',4,4'-hexachlorobiphenyl in rats.","9183382",57]
["2,3,4,2',3',4'-hexachlorobiphenyl","2,3,4,2',3',4'-hexachlorobiphenyl","C014218","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"8748700","Species-specific antagonism of Ah receptor action by 2,2',5,5'-tetrachloro- and 2,2',3,3'4,4'-hexachlorobiphenyl.","8748700",57]
["2,3,4,2',3',4'-hexachlorobiphenyl","2,3,4,2',3',4'-hexachlorobiphenyl","C014218","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1995,"8748700","Species-specific antagonism of Ah receptor action by 2,2',5,5'-tetrachloro- and 2,2',3,3'4,4'-hexachlorobiphenyl.","8748700",57]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12604167","Effect of low dose mono-ortho 2,3',4,4',5 pentachlorobiphenyl on thyroid hormone status and EROD activity in rat offspring: consequences for risk assessment.","12604167",57]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"18007995","Polychlorinated biphenyls 105 and 118 form thyroid hormone receptor agonists after cytochrome P4501A1 activation in rat pituitary GH3 cells.","18007995",57]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1991,"1907123","Response of xenobiotic metabolizing enzymes of rainbow trout (Oncorhynchus mykiss) to the mono-ortho substituted polychlorinated PCB congener 2,3',4,4',5-pentachlorobiphenyl, PCB-118, detected by enzyme activities and immunochemical methods.","1907123",57]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24926919","Genetic variation in the CYP1A1 gene is related to circulating PCB118 levels in a population-based sample.","24926919",57]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26519956","2,3',4,4',5-Pentachlorobiphenyl Induces Inflammatory Responses in the Thyroid Through JNK and Aryl Hydrocarbon Receptor-Mediated Pathway.","26519956",57]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9388007","Ethoxyresorufin-O-deethylase (EROD) inducing potencies of planar chlorinated aromatic hydrocarbons in primary cultures of hepatocytes from different developmental stages of the chicken.","9388007",57]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18399641","PCB 118 and Aryl Hydrocarbon Receptor Immunoassays for Screening Dioxins in Retail Fish.","18399641",57]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26519956","2,3',4,4',5-Pentachlorobiphenyl Induces Inflammatory Responses in the Thyroid Through JNK and Aryl Hydrocarbon Receptor-Mediated Pathway.","26519956",57]
["2,3',4,4',5-pentachlorobiphenyl","2,3',4,4',5-pentachlorobiphenyl","C070055","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"27208082","From the Cover: Structural Determinants of the Position of 2,3',4,4',5-Pentachlorobiphenyl (CB118) Hydroxylation by Mammalian Cytochrome P450 Monooxygenases.","27208082",57]
["2',3',4',5'-tetrahydroxystilbene-2-O-beta-D-glucoside","2',3',4',5'-tetrahydroxystilbene-2-O-beta-D-glucoside","C489707","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2007,"17455469","[Blood lipid-regulation of stilbene glycoside from polygonum multiflorum].","17455469",57]
["2,3,4,6-tetra-O-acetyl-1-thioglucopyranose","2,3,4,6-tetra-O-acetyl-1-thioglucopyranose","C508252","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"27884777","Anionic glycosylated polysulfone membranes for the affinity adsorption of low-density lipoprotein via click reactions.","27884777",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"18098034","Pulmonary lesions in female Harlan Sprague-Dawley rats following two-year oral treatment with dioxin-like compounds.","18098034",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19041884","Sequencing and characterization of mixed function monooxygenase genes CYP1A1 and CYP1A2 of Mink (Mustela vison) to facilitate study of dioxin-like compounds.","19041884",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"19884122","Cytochrome P4501A induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin and two chlorinated dibenzofurans in primary hepatocyte cultures of three avian species.","19884122",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20206251","Ethoxyresorufin O-deethylase induction by TCDD, PeCDF and TCDF in ring-necked pheasant and Japanese quail hepatocytes: Time-dependent effects on concentration-response curves.","20206251",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20705892","Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran.","20705892",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20821667","2,3,4,7,8-pentachlorodibenzofuran is a more potent cytochrome P4501A inducer than 2,3,7,8-tetrachlorodibenzo-p-dioxin in herring gull hepatocyte cultures.","20821667",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21703235","Differential ligand-dependent activation and a role for Y322 in aryl hydrocarbon receptor-mediated regulation of gene expression.","21703235",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22865772","Incidence of jaw lesions and activity and gene expression of hepatic P4501A enzymes in mink (Mustela vison) exposed to dietary 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran.","22865772",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24619315","Ethoxyresorufin-O-deethylase (EROD) induction by TCDD, PeCDF and PCB 126 in bobwhite quail hepatocytes.","24619315",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2018,"29091793","Differential sensitivities to dioxin-like compounds PCB 126 and PeCDF between Tg(cyp1a:gfp) transgenic medaka and zebrafish larvae.","29091793",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1988,"3220203","The acute toxicity of 2,3,4,7,8-pentachlorodibenzofuran (4PeCDF) in the male Fischer rat.","3220203",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23519780","Cytochrome P4501A induction in primary cultures of embryonic European starling hepatocytes exposed to TCDD, PeCDF and TCDF.","23519780",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2009,"19041884","Sequencing and characterization of mixed function monooxygenase genes CYP1A1 and CYP1A2 of Mink (Mustela vison) to facilitate study of dioxin-like compounds.","19041884",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20705892","Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran.","20705892",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21703235","Differential ligand-dependent activation and a role for Y322 in aryl hydrocarbon receptor-mediated regulation of gene expression.","21703235",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21724226","Transcriptional profiles induced by the Aryl Hydrocarbon Receptor agonists 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran and 2,3,4,7,8-pentachlorodibenzofuran in primary rat hepatocytes.","21724226",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24434118","Species-specific relative AHR1 binding affinities of 2,3,4,7,8-pentachlorodibenzofuran explain avian species differences in its relative potency.","24434118",57]
["2,3,4,7,8-pentachlorodibenzofuran","2,3,4,7,8-pentachlorodibenzofuran","C038890","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26226675","[Relationships between Half-Lives of Dioxins and SNPs in AhR among Yusho Patients].","26226675",57]
["2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate","2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate","C041942","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2016,"26822063","Allyl isothiocyanate suppresses the proteolytic activation of sterol regulatory element-binding proteins and de novo fatty acid and cholesterol synthesis.","26822063",57]
["2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","C093026","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24680992","In vitro effects of active components of Polygonum Multiflorum Radix on enzymes involved in the lipid metabolism.","24680992",57]
["2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","C093026","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23575939","2,3,4',5-tetrahydroxystilbene-2-O-β-D-glucoside suppresses expression of adhesion molecules in aortic wall of dietary atherosclerotic rats and promonocytic U937 cells.","23575939",57]
["2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","C093026","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25323856","Tetrahydroxystilbene glucoside protects against oxidized LDL-induced endothelial dysfunction via regulating vimentin cytoskeleton and its colocalization with ICAM-1 and VCAM-1.","25323856",57]
["2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","C093026","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27551760","The inhibition of macrophage foam cell formation by tetrahydroxystilbene glucoside is driven by suppressing vimentin cytoskeleton.","27551760",57]
["2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","C093026","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"26474417","Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis.","26474417",57]
["2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside","C093026","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25350237","Effects of tetrahydroxystilbene glucoside on mouse liver cytochrome P450 enzyme expressions.","25350237",57]
["2,3,6,2',3',6'-hexachlorobiphenyl","2,3,6,2',3',6'-hexachlorobiphenyl","C010498","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1985,"3920403","Toxicological manifestations of 2,4,5,2',4',5'-, 2,3,6,2',3',6'-, and 3,4,5,3',4',5'-hexachlorobiphenyl and Aroclor 1254 in mink.","3920403",57]
["2,3,6,7-tetrachlorobiphenylene","2,3,6,7-tetrachlorobiphenylene","C516412","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16759834","Structure-dependent Ah receptor agonist activities of chlorinated biphenylenes.","16759834",57]
["2,3,6,7-tetrachlorobiphenylene","2,3,6,7-tetrachlorobiphenylene","C516412","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16759834","Structure-dependent Ah receptor agonist activities of chlorinated biphenylenes.","16759834",57]
["2,3,6-trichlorobiphenylene","2,3,6-trichlorobiphenylene","C516411","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16759834","Structure-dependent Ah receptor agonist activities of chlorinated biphenylenes.","16759834",57]
["2,3,6-trichlorobiphenylene","2,3,6-trichlorobiphenylene","C516411","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16759834","Structure-dependent Ah receptor agonist activities of chlorinated biphenylenes.","16759834",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"14594946","Suppression by p38 MAP kinase inhibitors (pyridinyl imidazole compounds) of Ah receptor target gene activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin and the possible mechanism.","14594946",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2006,"16540597","Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor.","16540597",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21356177","Retention and maternal transfer of brominated dioxins in zebrafish (Danio rerio) and effects on reproduction, aryl hydrocarbon receptor-regulated genes, and ethoxyresorufin-O-deethylase (EROD) activity.","21356177",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2017,"27604104","Strain differences in the proteome of dioxin-sensitive and dioxin-resistant mice treated with 2,3,7,8-tetrabromodibenzo-p-dioxin.","27604104",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8538369","Tissue distribution after a single subcutaneous administration of 2,3,7,8-tetrabromodibenzo-p-dioxin in comparison with toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Wistar rats.","8538369",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8794239","Induction of cytochromes P450 by dioxins in liver and lung of marmoset monkeys (Callithrix jacchus).","8794239",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2004,"14594946","Suppression by p38 MAP kinase inhibitors (pyridinyl imidazole compounds) of Ah receptor target gene activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin and the possible mechanism.","14594946",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"16540597","Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor.","16540597",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21356177","Retention and maternal transfer of brominated dioxins in zebrafish (Danio rerio) and effects on reproduction, aryl hydrocarbon receptor-regulated genes, and ethoxyresorufin-O-deethylase (EROD) activity.","21356177",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2011,"21889950","Identification of aryl hydrocarbon receptor binding targets in mouse hepatic tissue treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin.","21889950",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2012,"22483799","2,3,7,8-Tetrachlorodibenzo-p-dioxin activates the aryl hydrocarbon receptor and alters sex steroid hormone secretion without affecting growth of mouse antral follicles in vitro.","22483799",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24718703","Liver tumor promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin is dependent on the aryl hydrocarbon receptor and TNF/IL-1 receptors.","24718703",57]
["2,3,7,8-tetrabromodibenzo-4-dioxin","2,3,7,8-tetrabromodibenzo-4-dioxin","C066841","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2017,"27604104","Strain differences in the proteome of dioxin-sensitive and dioxin-resistant mice treated with 2,3,7,8-tetrabromodibenzo-p-dioxin.","27604104",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11032772","Relative contributions of affinity and intrinsic efficacy to aryl hydrocarbon receptor ligand potency.","11032772",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1440615","Dietary 2,3,7,8-tetrachlorodibenzofuran in rainbow trout: accumulation, disposition, and hepatic mixed-function oxidase enzyme induction.","1440615",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19041884","Sequencing and characterization of mixed function monooxygenase genes CYP1A1 and CYP1A2 of Mink (Mustela vison) to facilitate study of dioxin-like compounds.","19041884",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C707,B707)","v":"2,3,7,8-tetrachlorodibenzofuran"},"2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J707,K707)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2009,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q707,Q707)","v":"19607907"},"Factorial design applied for multiple endpoint toxicity evaluation in Atlantic salmon (Salmo salar L.) hepatocytes.","19607907",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"19884122","Cytochrome P4501A induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin and two chlorinated dibenzofurans in primary hepatocyte cultures of three avian species.","19884122",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20206251","Ethoxyresorufin O-deethylase induction by TCDD, PeCDF and TCDF in ring-necked pheasant and Japanese quail hepatocytes: Time-dependent effects on concentration-response curves.","20206251",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20702594","Automated dose-response analysis and comparative toxicogenomic evaluation of the hepatic effects elicited by TCDD, TCDF, and PCB126 in C57BL/6 mice.","20702594",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20705892","Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran.","20705892",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21703235","Differential ligand-dependent activation and a role for Y322 in aryl hydrocarbon receptor-mediated regulation of gene expression.","21703235",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22865772","Incidence of jaw lesions and activity and gene expression of hepatic P4501A enzymes in mink (Mustela vison) exposed to dietary 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran.","22865772",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1995,"7713338","The importance of pharmacokinetics in determining the relative potency of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzofuran.","7713338",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8048062","Regulation of cytochrome P4501A1 in teleosts: sustained induction of CYP1A1 mRNA, protein, and catalytic activity by 2,3,7,8-tetrachlorodibenzofuran in the marine fish Stenotomus chrysops.","8048062",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1993,"8269548","Liver accumulation of 2,3,7,8-tetrachloro-[3H]dibenzofuran in mice: modulation by treatments with polychlorinated biphenyls.","8269548",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8382688","Nonresponsiveness of normal human fibroblasts to dioxin correlates with the presence of a constitutive xenobiotic response element-binding factor.","8382688",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8920757","Bioassay for determining 2,3,7,8-tetrachlorodibenzo-p-dioxin equivalents (TEs) in human hepatoma Hepg2 cells.","8920757",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9011028","Metabolic degradation, inducing potency, and metabolites of fluorinated and chlorinated-fluorinated dibenzodioxins and dibenzofurans.","9011028",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9065741","Halogenated aromatic hydrocarbon-mediated porphyrin accumulation and induction of cytochrome P4501A in chicken embryo hepatocytes.","9065741",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9134672","Derivation of 2,3,7,8-TCDD toxic equivalent factors (TEFs) for selected dioxins, furans and PCBs with rainbow trout and rat liver cell lines and the influence of exposure time.","9134672",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9388007","Ethoxyresorufin-O-deethylase (EROD) inducing potencies of planar chlorinated aromatic hydrocarbons in primary cultures of hepatocytes from different developmental stages of the chicken.","9388007",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9772216","Characterization of 2,3,7,8-tetrachlorodibenzofuran-dependent suppression and AH receptor pathway gene expression in the developing mouse mammary gland.","9772216",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1992,"1315629","The stability of dioxin-receptor ligands influences cytochrome P450IA1 expression in human keratinocytes.","1315629",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23519780","Cytochrome P4501A induction in primary cultures of embryonic European starling hepatocytes exposed to TCDD, PeCDF and TCDF.","23519780",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"11032772","Relative contributions of affinity and intrinsic efficacy to aryl hydrocarbon receptor ligand potency.","11032772",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2009,"19041884","Sequencing and characterization of mixed function monooxygenase genes CYP1A1 and CYP1A2 of Mink (Mustela vison) to facilitate study of dioxin-like compounds.","19041884",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20705892","Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran.","20705892",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21534955","Aryl hydrocarbon receptor-dependent induction of apoptosis by 2,3,7,8-tetrachlorodibenzo-p-dioxin in cerebellar granule cells from mouse.","21534955",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1990,"2169866","Analysis of photoaffinity-labeled aryl hydrocarbon receptor heterogeneity by two-dimensional gel electrophoresis.","2169866",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21703235","Differential ligand-dependent activation and a role for Y322 in aryl hydrocarbon receptor-mediated regulation of gene expression.","21703235",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21724226","Transcriptional profiles induced by the Aryl Hydrocarbon Receptor agonists 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran and 2,3,4,7,8-pentachlorodibenzofuran in primary rat hepatocytes.","21724226",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25768209","Persistent Organic Pollutants Modify Gut Microbiota-Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation.","25768209",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26023891","Metabolomics Reveals that Aryl Hydrocarbon Receptor Activation by Environmental Chemicals Induces Systemic Metabolic Dysfunction in Mice.","26023891",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1981,"6271080","A wire reclamation incinerator as a source of environmental contamination with tetrachlorodibenzo-p-dioxins and tetrachlorodibenzofurans.","6271080",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1993,"8382688","Nonresponsiveness of normal human fibroblasts to dioxin correlates with the presence of a constitutive xenobiotic response element-binding factor.","8382688",57]
["2,3,7,8-tetrachlorodibenzofuran","2,3,7,8-tetrachlorodibenzofuran","C014211","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1998,"9772216","Characterization of 2,3,7,8-tetrachlorodibenzofuran-dependent suppression and AH receptor pathway gene expression in the developing mouse mammary gland.","9772216",57]
["2,3,7,8-tetrachlorophenothiazine","2,3,7,8-tetrachlorophenothiazine","C531157","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17394264","From dioxin to drug lead--the development of 2,3,7,8-tetrachlorophenothiazine.","17394264",57]
["2,3,7,8-tetrachlorothainthrene","2,3,7,8-tetrachlorothainthrene","C112084","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9570110","Elimination kinetics and toxicity of 2,3,7,8-tetrachlorothianthren, a thio analogue of 2,3,7,8-TCDD.","9570110",57]
["2,3,7,8-tetrafluorodibenzodioxin","2,3,7,8-tetrafluorodibenzodioxin","C092566","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11489429","Biochemical and toxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in immature male and female chickens.","11489429",57]
["2,3,7,8-tetrafluorodibenzodioxin","2,3,7,8-tetrafluorodibenzodioxin","C092566","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9011028","Metabolic degradation, inducing potency, and metabolites of fluorinated and chlorinated-fluorinated dibenzodioxins and dibenzofurans.","9011028",57]
["2,3,7,8-tetrafluorodibenzodioxin","2,3,7,8-tetrafluorodibenzodioxin","C092566","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2001,"11408608","Immune-specific up-regulation of adseverin gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin.","11408608",57]
["2,3-bis(4-nitrophenyl)acrylonitrile","2,3-bis(4-nitrophenyl)acrylonitrile","C570603","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22197899","Identification of a new stilbene-derived inducer of paraoxonase 1 and ligand of the Aryl hydrocarbon Receptor.","22197899",57]
["2,3-bis(4-nitrophenyl)acrylonitrile","2,3-bis(4-nitrophenyl)acrylonitrile","C570603","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2012,"22197899","Identification of a new stilbene-derived inducer of paraoxonase 1 and ligand of the Aryl hydrocarbon Receptor.","22197899",57]
["2,3-diaminotoluene","2,3-diaminotoluene","C100420","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1996,"8685904","Interaction with the aromatic hydrocarbon receptor, CYP1A induction, and mutagenicity of a series of diaminotoluenes: implications for their carcinogenicity.","8685904",57]
["2,3-dichlorobiphenylene","2,3-dichlorobiphenylene","C516410","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16759834","Structure-dependent Ah receptor agonist activities of chlorinated biphenylenes.","16759834",57]
["2,3-dichlorobiphenylene","2,3-dichlorobiphenylene","C516410","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16759834","Structure-dependent Ah receptor agonist activities of chlorinated biphenylenes.","16759834",57]
["2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","C106512","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10193574","Antioxidant BO-653 and human macrophage-mediated LDL oxidation.","10193574",57]
["2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","C106512","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12825946","Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.","12825946",57]
["2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","C106512","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16596815","Inhibition of lipoprotein lipid oxidation.","16596815",57]
["2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","C106512","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9344475","Inhibition of oxidation of low-density lipoprotein by a novel antioxidant, BO-653, prepared by theoretical design.","9344475",57]
["2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","C106512","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9707611","Antiatherogenic effects of the antioxidant BO-653 in three different animal models.","9707611",57]
["2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran","C106512","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9707611","Antiatherogenic effects of the antioxidant BO-653 in three different animal models.","9707611",57]
["2,3-dihydroxybenzoic acid","2,3-dihydroxybenzoic acid","C009135","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10722843","The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein.","10722843",57]
["2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2(alpha)","2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2(alpha)","C411579","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15004731","Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers.","15004731",57]
["2,3-dinor-6-ketoprostaglandin F1alpha","2,3-dinor-6-ketoprostaglandin F1alpha","C028290","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2001,"11248083","Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.","11248083",57]
["2,3-dinor-thromboxane B2","2,3-dinor-thromboxane B2","C028965","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2000,"11090066","Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis.","11090066",57]
["2,3-dinor-thromboxane B2","2,3-dinor-thromboxane B2","C028965","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2001,"11248083","Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.","11248083",57]
["2,4,2',4'-tetrachlorobiphenyl","2,4,2',4'-tetrachlorobiphenyl","C035976","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9439713","Multiple roles of polyhalogenated biphenyls in causing increases in cytochrome P450 and uroporphyrin accumulation in cultured hepatocytes.","9439713",57]
["2,4,2',4'-tetrachlorobiphenyl","2,4,2',4'-tetrachlorobiphenyl","C035976","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1987,"3030868","Comparative toxicology of tetrachlorobiphenyls in mink and rats. II. Pathology.","3030868",57]
["2,4,3',5'-tetramethoxystilbene","2,4,3',5'-tetramethoxystilbene","C440850","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21170676","Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland.","21170676",57]
["2,4,3',5'-tetramethoxystilbene","2,4,3',5'-tetramethoxystilbene","C440850","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21669939","The resveratrol analogue, 2,3',4,5'-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene.","21669939",57]
["2,4,4'-trichlorobiphenyl","2,4,4'-trichlorobiphenyl","C081766","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16426774","Tumor promoting potency of PCBs 28 and 101 in rat liver.","16426774",57]
["2,4,4'-trichlorobiphenyl","2,4,4'-trichlorobiphenyl","C081766","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8727071","Subchronic toxicity of 2,4,4'-trichlorobiphenyl in the rat liver: an ultrastructural and biochemical study.","8727071",57]
["2,4,4'-trichlorobiphenyl","2,4,4'-trichlorobiphenyl","C081766","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1996,"8876656","Toxicity of 2,4,4'-trichlorobiphenyl in rats following 90-day dietary exposure.","8876656",57]
["2,4,5,2',4',5'-hexabromobiphenyl","2,4,5,2',4',5'-hexabromobiphenyl","C018566","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2537902","Human lipoprotein influence on the partition of 2,2',4,4',5,5'-hexabromobiphenyl between 3T3L1 adipocytes and culture medium.","2537902",57]
["2,4,5,2',4',5'-hexabromobiphenyl","2,4,5,2',4',5'-hexabromobiphenyl","C018566","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2537902","Human lipoprotein influence on the partition of 2,2',4,4',5,5'-hexabromobiphenyl between 3T3L1 adipocytes and culture medium.","2537902",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10630420","Competitive behavior in the interactive toxicology of halogenated aromatic compounds.","10630420",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10901669","Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in male and female WAG/Rij-rats.","10901669",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11222084","Polychlorinated biphenyl-induced effects on metabolic enzymes, AP-1 binding, vitamin E, and oxidative stress in the rat liver.","11222084",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C771,B771)","v":"2,4,5,2',4',5'-hexachlorobiphenyl"},"2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J771,K771)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2002,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q771,Q771)","v":"12049832"},"Effect of 3,3',4,4'-tetrachlorobiphenyl and 2,2',4,4',5,5'-hexachlorobiphenyl on the induction of hepatic lipid peroxidation and cytochrome P-450 associated enzyme activities in rats.","12049832",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12151633","Comparative responsiveness of hypothyroxinemia and hepatic enzyme induction in Long-Evans rats versus C57BL/6J mice exposed to TCDD-like and phenobarbital-like polychlorinated biphenyl congeners.","12151633",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1455422","Absence of interactions on hepatic retention and 7-ethoxyresorufin-O-deethylation activity after co-administration of 1,2,3,7,8-pentachlorodibenzo-p-dioxin and 2,4,5,2',4',5'-hexachlorobiphenyl.","1455422",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1462349","Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in female germfree WAG/Rij-rats.","1462349",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15223772","Regional induction of CYP1A1 in rat liver following treatment with mixtures of PCB 126 and PCB 153.","15223772",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1539179","Limited PCB antagonism of TCDD-induced malformations in mice.","1539179",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17703865","The effect of dietary glycine on the hepatic tumor promoting activity of polychlorinated biphenyls (PCBs) in rats.","17703865",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19386251","Effect of PCB153 on BaP-induced genotoxicity in HepG2 cells via modulation of metabolic enzymes.","19386251",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2011,"21569787","A possible mechanism for 2,2',4,4',5,5'-hexachlorobiphenyl-mediated decrease in serum thyroxine level in mice.","21569787",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21803134","Gene expression and inducibility of the aryl hydrocarbon receptor-dependent pathway in cultured bovine blood lymphocytes.","21803134",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"23121874","Activation of the Ahr signalling pathway by polychlorobiphenyls causes a marked induction of cytochrome P450 only after depletion of vitellogenin in Sparus aurata.","23121874",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23457121","Biological and tumor-promoting effects of dioxin-like and non-dioxin-like polychlorinated biphenyls in mouse liver after single or combined treatment.","23457121",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24878560","PCB153 and p,p'-DDE disorder thyroid hormones via thyroglobulin, deiodinase 2, transthyretin, hepatic enzymes and receptors.","24878560",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25316167","DDE and PCB 153 independently induce aryl hydrocarbon receptor (AhR) expression in peripheral blood mononuclear cells.","25316167",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25433332","The inflammation and estrogen metabolism impacts of polychlorinated biphenyls on endometrial cancer cells.","25433332",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26752525","Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland.","26752525",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1987,"3031851","Synergistic interactions of 2,3,7,8-TCDD and 2,2',4,4',5,5'-hexachlorobiphenyl in C57BL/6J and DBA/2J mice: role of the Ah receptor.","3031851",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1988,"3149181","Toxicity and 7-ethoxyresorufin O-deethylase-inducing potency of coplanar polychlorinated biphenyls (PCBs) in chick embryos.","3149181",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1985,"3920403","Toxicological manifestations of 2,4,5,2',4',5'-, 2,3,6,2',3',6'-, and 3,4,5,3',4',5'-hexachlorobiphenyl and Aroclor 1254 in mink.","3920403",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7665010","Induction of cytochrome P450 isoenzymes after toxicokinetic interactions between 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2,2',4,4',5,5'-hexachlorobiphenyl in the liver of the mouse.","7665010",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1995,"7767025","Uterotropic and enzyme induction effects of 2,2',5-trichlorobiphenyl.","7767025",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8000188","Multiple dose toxicokinetic influence on the estrogenicity of 2,2',4,4',5,5'-hexachlorobiphenyl.","8000188",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8048058","2,2',4,4',5,5'- and 3,3',4,4',5,5'-hexachlorobiphenyl alteration of uterine progesterone and estrogen receptors coincides with embryotoxicity in mink (Mustela vision).","8048058",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8935785","Toxicity of 2,2',4,4',5,5'-hexachlorobiphenyl in rats: effects following 90-day oral exposure.","8935785",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9169061","Comparative toxicity of polychlorinated biphenyls to Japanese quail (Coturnix c. japonica) and American kestrels (Falco sparverius).","9169061",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1998,"9490328","Interaction of 2,2',4,4',5,5'-hexachlorobiphenyl with hepatic cytochrome P-4501A in rainbow trout (Oncorhynchus mykiss).","9490328",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9772211","Interactive effects of three structurally different polychlorinated biphenyls in a rat liver tumor promotion bioassay.","9772211",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2013,"24121159","PCB-153 and temperature cause restructuring of goldfish membranes: homeoviscous response to a chemical fluidiser.","24121159",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"22686559","Metabolomic analysis of the effects of polychlorinated biphenyls in nonalcoholic fatty liver disease.","22686559",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"23618531","Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens nonalcoholic fatty liver disease in male C57BL6/J mice.","23618531",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3107224","Potential mechanisms for redistribution of polychlorinated biphenyls during pregnancy and lactation.","3107224",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3142100","Transfer of 2,4,5,2',4',5'-hexachlorobiphenyl across the in situ perfused guinea pig placenta.","3142100",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6327254","2,4,5,2',4',5'-Hexachlorobiphenyl-lipoprotein (LDL, HDL, VLDL) interaction and induced lipidosis in cultured skin fibroblasts.","6327254",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6431076","Distribution of 2,4,5,2',4',5'-hexachlorobiphenyl among lipoproteins during pregnancy and lactation in the rat.","6431076",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"6804637","Determination of the binding of 2,4,5,2',4',5'-hexachlorobiphenyl by low density lipoprotein and bovine serum albumin.","6804637",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2007,"16858609","A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice.","16858609",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1986,"3096803","Mechanisms for the release and redistribution of 2,4,5,2',4',5'-hexachlorobiphenyl (6-CB) from hepatic tissues in the rat.","3096803",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1987,"3107224","Potential mechanisms for redistribution of polychlorinated biphenyls during pregnancy and lactation.","3107224",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1988,"3142100","Transfer of 2,4,5,2',4',5'-hexachlorobiphenyl across the in situ perfused guinea pig placenta.","3142100",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1984,"6327254","2,4,5,2',4',5'-Hexachlorobiphenyl-lipoprotein (LDL, HDL, VLDL) interaction and induced lipidosis in cultured skin fibroblasts.","6327254",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1984,"6431076","Distribution of 2,4,5,2',4',5'-hexachlorobiphenyl among lipoproteins during pregnancy and lactation in the rat.","6431076",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2012,"22686559","Metabolomic analysis of the effects of polychlorinated biphenyls in nonalcoholic fatty liver disease.","22686559",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2013,"23618531","Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens nonalcoholic fatty liver disease in male C57BL6/J mice.","23618531",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2000,"10630420","Competitive behavior in the interactive toxicology of halogenated aromatic compounds.","10630420",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"10746932","Differential and non-uniform tissue and brain distribution of two distinct 14C-hexachlorobiphenyls in weanling rats.","10746932",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2005,"16552988","Aromatic hydrocarbon receptor (AhR) in the porcine theca and granulosa cells: effect of TCDD, PCB 126 and PCB 153 on the expression of AhR.","16552988",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"16725033","Dioxin-like activities in serum across European and Inuit populations.","16725033",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18560532","Polychlorinated biphenyl-77 induces adipocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis.","18560532",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20959002","Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: identification of genomic biomarkers of exposure to AhR ligands.","20959002",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21803134","Gene expression and inducibility of the aryl hydrocarbon receptor-dependent pathway in cultured bovine blood lymphocytes.","21803134",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22262711","Inflammatory pathway genes belong to major targets of persistent organic pollutants in adipose cells.","22262711",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"23121874","Activation of the Ahr signalling pathway by polychlorobiphenyls causes a marked induction of cytochrome P450 only after depletion of vitellogenin in Sparus aurata.","23121874",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25316167","DDE and PCB 153 independently induce aryl hydrocarbon receptor (AhR) expression in peripheral blood mononuclear cells.","25316167",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25433332","The inflammation and estrogen metabolism impacts of polychlorinated biphenyls on endometrial cancer cells.","25433332",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1989,"2558429","2,2',4,4',5,5'-hexachlorobiphenyl as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist in C57BL/6J mice.","2558429",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2015,"26415833","Compound- and sex-specific effects on programming of energy and immune homeostasis in adult C57BL/6JxFVB mice after perinatal TCDD and PCB 153.","26415833",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26752525","Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland.","26752525",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1987,"3031851","Synergistic interactions of 2,3,7,8-TCDD and 2,2',4,4',5,5'-hexachlorobiphenyl in C57BL/6J and DBA/2J mice: role of the Ah receptor.","3031851",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1994,"7992314","Additive binding of polychlorinated biphenyls and 2,3,7,8-tetrachlorodibenzo-p-dioxin to the murine hepatic Ah receptor.","7992314",57]
["2,4,5,2',4',5'-hexachlorobiphenyl","2,4,5,2',4',5'-hexachlorobiphenyl","C014024","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1987,"3111474","Uptake of persistent environmental chemicals by cultured human cells.","3111474",57]
["2,4,5,2',5'-pentachlorobiphenyl","2,4,5,2',5'-pentachlorobiphenyl","C009828","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16426774","Tumor promoting potency of PCBs 28 and 101 in rat liver.","16426774",57]
["2,4,5,3',4'-pentabromobiphenyl","2,4,5,3',4'-pentabromobiphenyl","C035354","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1982,"6289491","Liver microsomal enzyme induction and toxicity studies with 2,4,5,3',4'-pentabromobiphenyl.","6289491",57]
["2,4,5-trichlorophenol","2,4,5-trichlorophenol","C009534","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1979,"317704","Induction of the hepatic microsomal and nuclear cytochrome P-450 system by hexachlorobenzene, pentachlorophenol and trichlorophenol.","317704",57]
["2,4,5-Trichlorophenoxyacetic Acid","2,4,5-Trichlorophenoxyacetic Acid","D015085","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24688078","Agent Orange and heart disease: is there a connection?","24688078",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C835,B835)","v":"2,4,6,8-tetrachlorodibenzofuran"},"2,4,6,8-tetrachlorodibenzofuran","C049041","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J835,K835)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,1986,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q835,Q835)","v":"3012826"},"Polychlorinated dibenzofurans as 2,3,7,8-TCDD antagonists: in vitro inhibition of monooxygenase enzyme induction.","3012826",57]
["2,4,6,8-tetrachlorodibenzofuran","2,4,6,8-tetrachlorodibenzofuran","C049041","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1986,"3012826","Polychlorinated dibenzofurans as 2,3,7,8-TCDD antagonists: in vitro inhibition of monooxygenase enzyme induction.","3012826",57]
["2,4,6-tribromoanisole","2,4,6-tribromoanisole","C484217","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15657799","Biological activity and physicochemical parameters of marine halogenated natural products 2,3,3',4,4',5,5'-heptachloro-1'-methyl-1,2'-bipyrrole and 2,4,6-tribromoanisole.","15657799",57]
["2,4,6-tribromoanisole","2,4,6-tribromoanisole","C484217","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15657799","Biological activity and physicochemical parameters of marine halogenated natural products 2,3,3',4,4',5,5'-heptachloro-1'-methyl-1,2'-bipyrrole and 2,4,6-tribromoanisole.","15657799",57]
["2,4,6-trichlorophenyl 4-nitrophenyl ether","2,4,6-trichlorophenyl 4-nitrophenyl ether","C010422","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7749724","Induction of hepatic drug-metabolizing enzymes by chlornitrofen (CNP) and CNP-amino in rats and mice.","7749724",57]
["2,4,6-trichlorophenyl-4'-aminophenyl ether","2,4,6-trichlorophenyl-4'-aminophenyl ether","C067259","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7749724","Induction of hepatic drug-metabolizing enzymes by chlornitrofen (CNP) and CNP-amino in rats and mice.","7749724",57]
["2,4,6-trimethyl-N-((3'-(methylsulfonyl)-4-biphenylyl)methyl)-N-((5-(trifluoromethyl)-2-furanyl)methyl)benzenesulfonamide","2,4,6-trimethyl-N-((3'-(methylsulfonyl)-4-biphenylyl)methyl)-N-((5-(trifluoromethyl)-2-furanyl)methyl)benzenesulfonamide","C549350","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27680310","Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease.","27680310",57]
["2,4,6-triphenyl-1,3-dioxane","2,4,6-triphenyl-1,3-dioxane","C054589","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2012,"22296760","Constitutive androstane receptor activation by 2,4,6-triphenyldioxane-1,3 suppresses the expression of the gluconeogenic genes.","22296760",57]
["2,4,6-triphenyl-1-hexene","2,4,6-triphenyl-1-hexene","C533342","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18560529","Styrene trimer may increase thyroid hormone levels via down-regulation of the aryl hydrocarbon receptor (AhR) target gene UDP-glucuronosyltransferase.","18560529",57]
["2,4,6-triphenyl-1-hexene","2,4,6-triphenyl-1-hexene","C533342","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18560529","Styrene trimer may increase thyroid hormone levels via down-regulation of the aryl hydrocarbon receptor (AhR) target gene UDP-glucuronosyltransferase.","18560529",57]
["2,4,8-trichlorodibenzofuran","2,4,8-trichlorodibenzofuran","C063566","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1989,"2631297","6-substituted-1,3,8-trichlorodibenzofurans as 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonists in the rat: structure activity relationships.","2631297",57]
["2,4,8-trihydroxybicyclo(3.2.1)octan-3-one","2,4,8-trihydroxybicyclo(3.2.1)octan-3-one","C571833","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22239689","2,4,8-trihydroxybicyclo [3.2.1]octan-3-one scavenges free radicals and protects against xenobiotic-induced cytotoxicity.","22239689",57]
["2,4-diaminotoluene","2,4-diaminotoluene","C010914","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1996,"8685904","Interaction with the aromatic hydrocarbon receptor, CYP1A induction, and mutagenicity of a series of diaminotoluenes: implications for their carcinogenicity.","8685904",57]
["2,4-Dichlorophenoxyacetic Acid","2,4-Dichlorophenoxyacetic Acid","D015084","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1991,"2048162","Effects of 2,4-dichlorophenoxyacetic acid and picloram on biotransformation, peroxisomal and serum enzyme activities in channel catfish (Ictalurus punctatus).","2048162",57]
["2,4-Dichlorophenoxyacetic Acid","2,4-Dichlorophenoxyacetic Acid","D015084","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2003,"12682048","Arabidopsis mutants in short- and medium-chain acyl-CoA oxidase activities accumulate acyl-CoAs and reveal that fatty acid beta-oxidation is essential for embryo development.","12682048",57]
["2,4-Dichlorophenoxyacetic Acid","2,4-Dichlorophenoxyacetic Acid","D015084","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,1998,"9490742","2,4-Dichlorophenoxybutyric acid-resistant mutants of Arabidopsis have defects in glyoxysomal fatty acid beta-oxidation.","9490742",57]
["2,4-Dichlorophenoxyacetic Acid","2,4-Dichlorophenoxyacetic Acid","D015084","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2001,"11165716","Induction of apoptosis in human lymphocytes by the herbicide 2,4-dichlorophenoxyacetic acid.","11165716",57]
["2,4-Dichlorophenoxyacetic Acid","2,4-Dichlorophenoxyacetic Acid","D015084","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24688078","Agent Orange and heart disease: is there a connection?","24688078",57]
["2',4'-dihydroxy-4-methoxydihydrochalcone","2',4'-dihydroxy-4-methoxydihydrochalcone","C514624","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2007,"17848630","Polyphenolic compounds from Artemisia dracunculus L. inhibit PEPCK gene expression and gluconeogenesis in an H4IIE hepatoma cell line.","17848630",57]
["2,4-Dinitrophenol","2,4-Dinitrophenol","D019297","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"24206666","Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler.","24206666",57]
["2,4-Dinitrophenol","2,4-Dinitrophenol","D019297","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"24304662","Treating fatty liver and insulin resistance.","24304662",57]
["2,4-Dinitrophenol","2,4-Dinitrophenol","D019297","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"24206666","Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler.","24206666",57]
["2,4-Dinitrophenol","2,4-Dinitrophenol","D019297","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24924900","Burn after feeding. An old uncoupler of oxidative phosphorylation is redesigned for the treatment of nonalcoholic fatty liver disease.","24924900",57]
["2,4-Dinitrophenol","2,4-Dinitrophenol","D019297","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25721504","Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.","25721504",57]
["2,4-Dinitrophenol","2,4-Dinitrophenol","D019297","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28754512","Sustained-release mitochondrial protonophore reverses nonalcoholic fatty liver disease in rats.","28754512",57]
["2,4-dinitrophenol methyl ether","2,4-dinitrophenol methyl ether","C000590645","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"24304662","Treating fatty liver and insulin resistance.","24304662",57]
["2,4-dinitrophenylhydrazone","2,4-dinitrophenylhydrazone","C001072","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1618333","Identification of cholesterol-bound aldehydes in copper-oxidized low density lipoprotein.","1618333",57]
["2,4-dinitrotoluene","2,4-dinitrotoluene","C016403","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22209323","Effects of 2,4-dinitrotoluene exposure on enzyme activity, energy reserves and condition factors in common carp (Cyprinus carpio).","22209323",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,2,2003,"12935909","Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARgamma) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism.","12935909",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2000,"11056218","Down-regulation of uncoupling protein-3 and -2 by thiazolidinediones in C2C12 myotubes.","11056218",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19670459","Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.","19670459",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20101743","Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution?","20101743",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2016,"26447327","Mechanisms by which the thiazolidinedione troglitazone protects against sucrose-induced hepatic fat accumulation and hyperinsulinaemia.","26447327",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11351658","[Significance of PPAR gamma (peroxisome proliferator-activated receptor gamma) in atherosclerosis].","11351658",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15071727","Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans.","15071727",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24805140","The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.","24805140",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2001,"11434190","Obesity and free fatty acids: double trouble.","11434190",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,2,2001,"11728630","A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes.","11728630",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2003,"14739073","Regulation of glyceroneogenesis and phosphoenolpyruvate carboxykinase by fatty acids, retinoic acids and thiazolidinediones: potential relevance to type 2 diabetes.","14739073",57]
["2,4-thiazolidinedione","2,4-thiazolidinedione","C089946","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,1999,"10581155","Regulation of stearoyl-CoA desaturase genes: role in cellular metabolism and preadipocyte differentiation.","10581155",57]
["2,5,2',5'-tetrachlorobiphenyl","2,5,2',5'-tetrachlorobiphenyl","C009407","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11048677","In vitro metabolism of polychlorinated biphenyl congeners by beluga whale (Delphinapterus leucas) and pilot whale (Globicephala melas) and relationship to cytochrome P450 expression.","11048677",57]
["2,5,2',5'-tetrachlorobiphenyl","2,5,2',5'-tetrachlorobiphenyl","C009407","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24397434","Complex interactions between dioxin-like and non-dioxin-like compounds for in vitro cellular responses: implications for the identification of dioxin exposure biomarkers.","24397434",57]
["2,5,2',5'-tetrachlorobiphenyl","2,5,2',5'-tetrachlorobiphenyl","C009407","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"8748700","Species-specific antagonism of Ah receptor action by 2,2',5,5'-tetrachloro- and 2,2',3,3'4,4'-hexachlorobiphenyl.","8748700",57]
["2,5,2',5'-tetrachlorobiphenyl","2,5,2',5'-tetrachlorobiphenyl","C009407","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1989,"2558429","2,2',4,4',5,5'-hexachlorobiphenyl as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist in C57BL/6J mice.","2558429",57]
["2,5,2',5'-tetrachlorobiphenyl","2,5,2',5'-tetrachlorobiphenyl","C009407","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1995,"8748700","Species-specific antagonism of Ah receptor action by 2,2',5,5'-tetrachloro- and 2,2',3,3'4,4'-hexachlorobiphenyl.","8748700",57]
["2,5-bis(2-fluoro-6-(trifluoromethyl)benzylidene)cyclopentanone","2,5-bis(2-fluoro-6-(trifluoromethyl)benzylidene)cyclopentanone","C000615599","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27242185","The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice.","27242185",57]
["2,5-diaminotoluene","2,5-diaminotoluene","C007303","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1996,"8685904","Interaction with the aromatic hydrocarbon receptor, CYP1A induction, and mutagenicity of a series of diaminotoluenes: implications for their carcinogenicity.","8685904",57]
["2,5-dihydroxybenzoic acid","2,5-dihydroxybenzoic acid","C010925","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10598750","Association of cytochrome P450 induction with oxidative stress in vivo as evidenced by 3-hydroxylation of salicylate.","10598750",57]
["2,5-dihydroxybenzoic acid","2,5-dihydroxybenzoic acid","C010925","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10381197","Salicylate promotes myeloperoxidase-initiated LDL oxidation: antagonization by its metabolite gentisic acid.","10381197",57]
["2,5-dihydroxybenzoic acid","2,5-dihydroxybenzoic acid","C010925","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10722843","The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein.","10722843",57]
["2,5-dihydroxybenzoic acid","2,5-dihydroxybenzoic acid","C010925","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15862799","Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma.","15862799",57]
["2,5-dihydroxybenzoic acid","2,5-dihydroxybenzoic acid","C010925","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17723224","2,5-Dihydroxybenzoic acid instead of alpha-cyano-4-hydroxycinnamic acid as matrix in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for analyses of in-gel digests of silver-stained proteins.","17723224",57]
["2,6-diaminotoluene","2,6-diaminotoluene","C025235","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1996,"8685904","Interaction with the aromatic hydrocarbon receptor, CYP1A induction, and mutagenicity of a series of diaminotoluenes: implications for their carcinogenicity.","8685904",57]
["2,6-diisopropylphenyl ((4-(3-methoxyphenyl)-1-pyrimidin-2-ylpiperidin-4-yl)carbonyl)sulfamate","2,6-diisopropylphenyl ((4-(3-methoxyphenyl)-1-pyrimidin-2-ylpiperidin-4-yl)carbonyl)sulfamate","C549344","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20356098","A novel class of antihyperlipidemic agents with low density lipoprotein receptor up-regulation via the adaptor protein autosomal recessive hypercholesterolemia.","20356098",57]
["2',7'-dichlorofluorescein","2',7'-dichlorofluorescein","C037631","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9429083","Effects of quercetin on drug metabolizing enzymes and oxidation of 2',7-dichlorofluorescin in HepG2 cells.","9429083",57]
["2,8-dichlorodibenzo-4-dioxin","2,8-dichlorodibenzo-4-dioxin","C068993","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1994,"8168101","Antiestrogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17 beta-estradiol-induced pS2 expression.","8168101",57]
["2016481B compound","2016481B compound","C550230","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2010,"20152792","Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model.","20152792",57]
["2016481B compound","2016481B compound","C550230","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20152792","Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model.","20152792",57]
["2038751B compound","2038751B compound","C550229","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2010,"20152792","Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model.","20152792",57]
["2038751B compound","2038751B compound","C550229","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20152792","Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model.","20152792",57]
["20-hydroxy-5,8,11,14-eicosatetraenoic acid","20-hydroxy-5,8,11,14-eicosatetraenoic acid","C055987","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27179555","Oxidized HDL is a potent inducer of adipogenesis and causes activation of the Ang-II and 20-HETE systems in human obese females.","27179555",57]
["22-hydroxy-25-fluorocholesterol","22-hydroxy-25-fluorocholesterol","C039341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6615863","Prevention of the hyperlipidemic serum or LDL-induced cellular cholesterol ester accumulation by 22-hydroxycholesterol and its analogue.","6615863",57]
["22-hydroxycholesterol","22-hydroxycholesterol","C003585","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2002,"12470667","Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes.","12470667",57]
["22-hydroxycholesterol","22-hydroxycholesterol","C003585","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2015,"25557254","22-S-Hydroxycholesterol protects against ethanol-induced liver injury by blocking the auto/paracrine activation of MCP-1 mediated by LXRα.","25557254",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C899,B899)","v":"22-hydroxycholesterol"},"22-hydroxycholesterol","C003585","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J899,K899)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1983,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q899,Q899)","v":"6615863"},"Prevention of the hyperlipidemic serum or LDL-induced cellular cholesterol ester accumulation by 22-hydroxycholesterol and its analogue.","6615863",57]
["23-valent pneumococcal capsular polysaccharide vaccine","23-valent pneumococcal capsular polysaccharide vaccine","C414006","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22507657","Pneumococcal vaccination may induce anti-oxidized low-density lipoprotein antibodies that have potentially protective effects against cardiovascular disease.","22507657",57]
["24,25-epoxycholesterol","24,25-epoxycholesterol","C028358","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20045741","Low-density lipoprotein and oxysterols suppress the transcription of CTP: Phosphoethanolamine cytidylyltransferase in vitro.","20045741",57]
["24,25-epoxycholesterol","24,25-epoxycholesterol","C028358","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2003,"14512442","Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation.","14512442",57]
["24,25-epoxycholesterol","24,25-epoxycholesterol","C028358","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2003,"14512442","Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation.","14512442",57]
["24-hydroxycholesterol","24-hydroxycholesterol","C044563","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2011,"21272192","Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-β in amplifying neuronal damage in Alzheimer's disease: three partners in crime.","21272192",57]
["24-hydroxycholesterol","24-hydroxycholesterol","C044563","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9630709","Transport of side-chain oxidized oxysterols in the human circulation.","9630709",57]
["24-hydroxycholesterol","24-hydroxycholesterol","C044563","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9630709","Transport of side-chain oxidized oxysterols in the human circulation.","9630709",57]
["24-hydroxycholesterol","24-hydroxycholesterol","C044563","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2006,"16524875","24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux.","16524875",57]
["24-norursodeoxycholic acid","24-norursodeoxycholic acid","C081331","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21115542","Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.","21115542",57]
["24-norursodeoxycholic acid","24-norursodeoxycholic acid","C081331","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2013,"23461012","[Preventive administration of new UDCA derivatives in experimental alcoholic steatohepatitis].","23461012",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11254916","Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols.","11254916",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11378532","Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins.","11378532",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11500175","25-hydroxycholesterol induces lipopolysaccharide-tolerance and decreases a lipopolysaccharide-induced TNF-alpha secretion in macrophages.","11500175",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1313035","The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cells.","1313035",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3036263","The effect of human chorionic gonadotropin, dibutyryl cyclic adenosine 3',5'-monophosphate, prostaglandins, and 25-hydroxycholesterol on acute progesterone secretion by dissociated rabbit luteal cells in vitro: evidence for independent effect of human chorionic gonadotropins and lipoproteins.","3036263",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"7240196","Evidence indicating that inactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by low density lipoprotein or by 25-hydroxycholesterol requires mediator protein(s) with rapid turnover rate.","7240196",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"18317936","7beta-Hydroxycholesterol and 25-hydroxycholesterol-induced interleukin-8 secretion involves a calcium-dependent activation of c-fos via the ERK1/2 signaling pathway in THP-1 cells: oxysterols-induced IL-8 secretion is calcium-dependent.","18317936",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"2005896","Activation of the silent endogenous cholesterol-7-alpha-hydroxylase gene in rat hepatoma cells: a new complementation group having resistance to 25-hydroxycholesterol.","2005896",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2513806","Effect of 25-hydroxycholesterol and bile acids on the regulation of cholesterol metabolism in Hep G2 cells.","2513806",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3707902","Cycloheximide sensitivity in regulation of acyl coenzyme A:cholesterol acyltransferase activity in Chinese hamster ovary cells. 1. Effect of exogenous sterols.","3707902",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3945632","Steroidogenic effects of lipoproteins and 25-hydroxycholesterol on luteal and ovarian cells: a comparison of two pseudopregnant rat models.","3945632",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"6105157","Regulation of cytosolic acetoacetyl coenzyme A thiolase, 3-hydroxy-3-methylglutaryl coenzyme A synthase, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and mevalonate kinase by low density lipoprotein and by 25-hydroxycholesterol in Chinese hamster ovary cells.","6105157",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"6273153","Up-regulation in vascular endothelial cells of binding sites of high density lipoprotein induced by 25-hydroxycholesterol.","6273153",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6478014","Effect of lipoproteins, 25-hydroxycholesterol and luteinizing hormone on in vitro follicular steroidogenesis in the hamster and rat.","6478014",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"6957860","Regulation of synthesis and degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by low density lipoprotein and 25-hydroxycholesterol in UT-1 cells.","6957860",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8391799","Differing effects of three oxysterols on low density lipoprotein metabolism in HepG2 cells.","8391799",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8463321","Induction of basic fibroblast growth factor mRNA and protein synthesis in smooth muscle cells by cholesteryl ester enrichment and 25-hydroxycholesterol.","8463321",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8576635","Effect of a coffee lipid (cafestol) on regulation of lipid metabolism in CaCo-2 cells.","8576635",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"7066085","Distribution of 25-hydroxycholesterol in plasma lipoproteins and its role in atherogenesis. A study in squirrel monkeys.","7066085",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"25072708","Identification of novel regulatory cholesterol metabolite, 5-cholesten, 3β,25-diol, disulfate.","25072708",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1992,"1429619","Expression of 7 alpha-hydroxylase in non-hepatic cells results in liver phenotypic resistance of the low density lipoprotein receptor to cholesterol repression.","1429619",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2006,"16611739","ABCA1 mediates high-affinity uptake of 25-hydroxycholesterol by membrane vesicles and rapid efflux of oxysterol by intact cells.","16611739",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1991,"1673968","Genetic distinction between sterol-mediated transcriptional and posttranscriptional control of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.","1673968",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1989,"2513806","Effect of 25-hydroxycholesterol and bile acids on the regulation of cholesterol metabolism in Hep G2 cells.","2513806",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"26812621","RORα and 25-Hydroxycholesterol Crosstalk Regulates Lipid Droplet Homeostasis in Macrophages.","26812621",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1989,"2745447","Control of low density lipoprotein receptor gene promoter activity. Ketoconazole inhibits serum lipoprotein but not oxysterol suppression of gene transcription.","2745447",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1987,"3030558","42 bp element from LDL receptor gene confers end-product repression by sterols when inserted into viral TK promoter.","3030558",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7595067","Regulation of low density lipoprotein receptor gene expression in HepG2 and Caco2 cells by palmitate, oleate, and 25-hydroxycholesterol.","7595067",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7666011","25-Hydroxycholesterol stimulates sphingomyelin synthesis in Chinese hamster ovary cells.","7666011",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7749852","Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes.","7749852",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1994,"8305487","Ketoconazole and 25-hydroxycholesterol produce reciprocal changes in the rate of transcription of the human LDL receptor gene.","8305487",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"8576635","Effect of a coffee lipid (cafestol) on regulation of lipid metabolism in CaCo-2 cells.","8576635",57]
["25-hydroxycholesterol","25-hydroxycholesterol","C007997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1996,"8820112","Esterification of oxysterols in human serum: effects on distribution and cellular uptake.","8820112",57]
["25-hydroxycholesterol 3-sulfate","25-hydroxycholesterol 3-sulfate","C534977","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"23258548","5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.","23258548",57]
["25-hydroxycholesterol 3-sulfate","25-hydroxycholesterol 3-sulfate","C534977","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2013,"23258548","5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.","23258548",57]
["25-hydroxycholesterol 3-sulfate","25-hydroxycholesterol 3-sulfate","C534977","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"25072708","Identification of novel regulatory cholesterol metabolite, 5-cholesten, 3β,25-diol, disulfate.","25072708",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25304467","Interaction effect of serum 25-hydroxyvitamin D levels and CYP1A1, CYP1B1 polymorphisms on blood pressure in an elderly population.","25304467",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1999,"10518281","Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: variable expressivity of maternal illness during pregnancy and unusual presentation with infantile cholestasis and hypocalcaemia.","10518281",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23415456","Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease.","23415456",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23958268","Independent associations of low 25 hydroxy vitamin D and high parathyroid hormonal levels with nonalcoholic fatty liver disease in Asian Indians residing in north India.","23958268",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"24130687","Low vitamin D status is associated with nonalcoholic Fatty liver disease independent of visceral obesity in Korean adults.","24130687",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"24306155","Low 25-hydroxyvitamin D level is associated with insulin sensitivity in obese adolescents with non-alcoholic fatty liver disease.","24306155",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24412930","Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease.","24412930",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"28814531","Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation.","28814531",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24835432","Vitamin D supplementation and lipid profile: what does the best available evidence show?","24835432",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25922846","Relationship between serum 25-hydroxyvitamin D and lower extremity arterial disease in type 2 diabetes mellitus patients and the analysis of the intervention of vitamin D.","25922846",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27020528","Effects of vitamin D on serum lipid profile in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.","27020528",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"27865973","Hypertension and other cardiovascular risk factors are associated with vitamin D deficiency in an urban Chinese population: A short report.","27865973",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23415456","Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease.","23415456",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23958268","Independent associations of low 25 hydroxy vitamin D and high parathyroid hormonal levels with nonalcoholic fatty liver disease in Asian Indians residing in north India.","23958268",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2013,"24130687","Low vitamin D status is associated with nonalcoholic Fatty liver disease independent of visceral obesity in Korean adults.","24130687",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"24306155","Low 25-hydroxyvitamin D level is associated with insulin sensitivity in obese adolescents with non-alcoholic fatty liver disease.","24306155",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24412930","Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease.","24412930",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C963,B963)","v":"25-hydroxyvitamin D"},"25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J963,K963)","v":"Non-alcoholic Fatty Liver Disease"},"D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q963,Q963)","v":"24611991"},"Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity.","24611991",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24647335","Role of vitamin D in children with hepatosteatosis.","24647335",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26713058","Vitamin D Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease.","26713058",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26787197","Severe Vitamin D Deficiency Is Not Associated with Liver Damage in Morbidly Obese Patients.","26787197",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26825918","Combined Association of Vitamin D and Sex Hormone Binding Globulin With Nonalcoholic Fatty Liver Disease in Men and Postmenopausal Women: A Cross-Sectional Study.","26825918",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27284686","Vitamin D Levels Are Inversely Associated with Liver Fat Content and Risk of Non-Alcoholic Fatty Liver Disease in a Chinese Middle-Aged and Elderly Population: The Shanghai Changfeng Study.","27284686",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"27796814","Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease.","27796814",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"28219837","Chronic maternal calcium and 25-hydroxyvitamin D deficiency in Wistar rats programs abnormal hepatic gene expression leading to hepatic steatosis in female offspring.","28219837",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28274829","Vitamin D and histologic severity of nonalcoholic fatty liver disease: A systematic review and meta-analysis.","28274829",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"28685131","Relationship between Nonalcoholic Fatty Liver Disease and Vitamin D Nutritional Status in Extreme Obesity.","28685131",57]
["25-hydroxyvitamin D","25-hydroxyvitamin D","C104450","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28814531","Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation.","28814531",57]
["25-Hydroxyvitamin D 2","25-Hydroxyvitamin D 2","D015652","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"27089408","Low 25-hydroxyvitamin D level is not an independent risk factor for hepatosteatosis in obese children.","27089408",57]
["26-aminocholesterol","26-aminocholesterol","C058194","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"2850793","Cholesterol metabolism. Effect of 26-thiacholesterol and 26-aminocholesterol, analogues of 26-hydroxycholesterol, on cholesterol synthesis and low-density-lipoprotein-receptor binding.","2850793",57]
["26-aminocholesterol","26-aminocholesterol","C058194","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7749852","Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes.","7749852",57]
["26-thiacholesterol","26-thiacholesterol","C058193","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"2850793","Cholesterol metabolism. Effect of 26-thiacholesterol and 26-aminocholesterol, analogues of 26-hydroxycholesterol, on cholesterol synthesis and low-density-lipoprotein-receptor binding.","2850793",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2011,"21272192","Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-β in amplifying neuronal damage in Alzheimer's disease: three partners in crime.","21272192",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2016,"26669587","Oxysterol mixture and, in particular, 27-hydroxycholesterol drive M2 polarization of human macrophages.","26669587",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23041327","The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice.","23041327",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11254916","Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols.","11254916",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11378532","Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins.","11378532",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20056921","FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages.","20056921",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"24269812","27-Hydroxycholesterol induces recruitment of monocytic cells by enhancing CCL2 production.","24269812",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25281859","Hematopoietic overexpression of Cyp27a1 reduces hepatic inflammation independently of 27-hydroxycholesterol levels in Ldlr(-/-) mice.","25281859",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8405424","27-Hydroxycholesterol modulation of low density lipoprotein metabolism in cultured human hepatic and extrahepatic cells.","8405424",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9630709","Transport of side-chain oxidized oxysterols in the human circulation.","9630709",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9630709","Transport of side-chain oxidized oxysterols in the human circulation.","9630709",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23041327","The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice.","23041327",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25281859","Hematopoietic overexpression of Cyp27a1 reduces hepatic inflammation independently of 27-hydroxycholesterol levels in Ldlr(-/-) mice.","25281859",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23041327","The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice.","23041327",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"28167099","27-Hydroxycholesterol regulates cholesterol synthesis and transport in C6 glioma cells.","28167099",57]
["27-hydroxycholesterol","27-hydroxycholesterol","C076996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7749852","Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes.","7749852",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11888708","Acute cytotoxicity of the chemical carcinogen 2-acetylaminofluorene in cultured rat liver epithelial cells.","11888708",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9183562","Evaluation of the developmental toxicity of benzo[a]pyrene and 2-acetylaminofluorene using Xenopus: modes of biotransformation. Stover Group.","9183562",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"2167182","Competitive binding affinity of carcinogenic aromatic amines to the rat hepatic aromatic hydrocarbon (Ah) receptor in vitro and potency to induce monooxygenase activity in vivo.","2167182",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1986,"3488741","Induction of cytochrome P-450 and related drug-metabolizing activities in the livers of different rodent species by 2-acetylaminofluorene or by 3-methylcholanthrene.","3488741",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1986,"3943517","Induction of different isozymes of cytochrome P-450 and of microsomal epoxide hydrolase in rat liver by 2-acetylaminofluorene and structurally related compounds.","3943517",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1983,"6850990","Characterization of drug-metabolizing systems in hyperplastic nodules from the livers of rats receiving 2-acetylaminofluorene in their diet.","6850990",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7875126","Metabolic activation of carcinogenic aromatic amines by fish exposed to environmental pollutants.","7875126",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9332696","Control of the mutagenicity of aromatic amines by protein kinases and phosphatases. I. The protein phosphatase inhibitors okadaic acid and ortho-vanadate drastically reduce the mutagenicity of aromatic amines.","9332696",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9585267","Mutagenic activation of aromatic amines by molluscs as a biomarker of marine pollution.","9585267",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9784024","Influence of 2-acetylaminofluorene (2-AAF) on biotransformation and lipid peroxidation in salivary glands and liver from male rats.","9784024",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1990,"2167182","Competitive binding affinity of carcinogenic aromatic amines to the rat hepatic aromatic hydrocarbon (Ah) receptor in vitro and potency to induce monooxygenase activity in vivo.","2167182",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1989,"2548720","Decreased activation of carcinogens in the liver of carcinogen-resistant rats.","2548720",57]
["2-Acetylaminofluorene","2-Acetylaminofluorene","D015073","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1993,"8397005","The mutagenicity and interactions of 2- and 4-(acetylamino)fluorene with cytochrome P450 and the aromatic hydrocarbon receptor may explain the difference in their carcinogenic potency.","8397005",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26091049","Synergistic and Antagonistic Mutation Responses of Human MCL-5 Cells to Mixtures of Benzo[a]pyrene and 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]pyridine: Dose-Related Variation in the Joint Effects of Common Dietary Carcinogens.","26091049",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"10050262","Inhibition of DNA adduct formation of PhIP in female F344 rats by dietary conjugated linoleic acid.","10050262",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"10920929","[Chemoprevention of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine-induced carcinogen-DNA adducts by Chinese cabbage in rats].","10920929",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10964100","Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue.","10964100",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11162778","Lack of UGT1 isoforms in Gunn rats changes metabolic ratio and facilitates excretion of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo.","11162778",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16167840","Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2.","16167840",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16394512","Inhibitory effects of beer on mutation in the Ames test and DNA adduct formation in mouse organs induced by 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).","16394512",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16527260","Cytochrome P450 expression and metabolic activation of cooked food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in MCF10A breast epithelial cells.","16527260",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"1702369","Effects of the food mutagens MeIQx and PhIP on the expression of cytochrome P450IA proteins in various tissues of male and female rats.","1702369",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17052995","Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).","17052995",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19301197","Role of human CYP1A1 and NAT2 in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mutagenicity and DNA adducts.","19301197",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21081470","Rapid induction of colon carcinogenesis in CYP1A-humanized mice by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate.","21081470",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25733458","Apiaceous vegetable consumption decreases PhIP-induced DNA adducts and increases methylated PhIP metabolites in the urine metabolome in rats.","25733458",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27801952","Human T lymphocytes bioactivate heterocyclic aromatic amines by forming DNA adducts.","27801952",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8361949","Bioactivation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine by liver microsomes from three different rat strains.","8361949",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8403195","Cytochrome P450 forms in the rodent lung involved in the metabolic activation of food-derived heterocyclic amines.","8403195",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8472319","Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP.","8472319",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9434884","Cancer chemoprevention from the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine: reconsideration of the evidence.","9434884",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9855011","Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1.","9855011",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1990,"1702369","Effects of the food mutagens MeIQx and PhIP on the expression of cytochrome P450IA proteins in various tissues of male and female rats.","1702369",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1027,B1027)","v":"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine"},"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","1_MIE",18,1,"AHR","Activation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1027,K1027)","v":"Receptors, Aryl Hydrocarbon"},"D018336","Receptors, Aryl Hydrocarbon",1,1,2010,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1027,Q1027)","v":"20816883"},"Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines.","20816883",57]
["2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C049584","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23208499","Long interspersed element-1 is differentially regulated by food-borne carcinogens via the aryl hydrocarbon receptor.","23208499",57]
["2-amino-3-(3,5-dibromo-4-(4-hydroxy-3-(6-oxo-1,6-dihydro-pyridazin-3-ylmethyl)-phenoxyl)-phenyl)-propionic acid","2-amino-3-(3,5-dibromo-4-(4-hydroxy-3-(6-oxo-1,6-dihydro-pyridazin-3-ylmethyl)-phenoxyl)-phenyl)-propionic acid","C113777","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9698096","Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression.","9698096",57]
["2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide","2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide","C492908","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23249949","Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction.","23249949",57]
["2-amino-3,4-dimethylimidazo(4,5-f)quinoline","2-amino-3,4-dimethylimidazo(4,5-f)quinoline","C036989","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11473383","Recombinant human P450 forms 1A1, 1A2, and 1B1 catalyze the bioactivation of heterocyclic amine mutagens in Escherichia coli lacZ strains.","11473383",57]
["2-amino-3,4-dimethylimidazo(4,5-f)quinoline","2-amino-3,4-dimethylimidazo(4,5-f)quinoline","C036989","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11752233","Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1.","11752233",57]
["2-amino-3,4-dimethylimidazo(4,5-f)quinoline","2-amino-3,4-dimethylimidazo(4,5-f)quinoline","C036989","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1617633","2-Amino-3,4-dimethylimidazo[4,5-f]quinoline induces and inhibits cytochrome P450 from the IA subfamily in chick and rat hepatocytes.","1617633",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11473383","Recombinant human P450 forms 1A1, 1A2, and 1B1 catalyze the bioactivation of heterocyclic amine mutagens in Escherichia coli lacZ strains.","11473383",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12680239","Effect of high sucrose diet on cytochrome P450 1A and heterocyclic amine mutagenesis.","12680239",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"1702369","Effects of the food mutagens MeIQx and PhIP on the expression of cytochrome P450IA proteins in various tissues of male and female rats.","1702369",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17627018","2-Amino-3,8-dimethylimidazo-[4,5-f]quinoxaline-induced DNA adduct formation and mutagenesis in DNA repair-deficient Chinese hamster ovary cells expressing human cytochrome P4501A1 and rapid or slow acetylator N-acetyltransferase 2.","17627018",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20448087","2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)-induced hepatocarcinogenesis is not enhanced by CYP1A inducers, alpha- and beta-naphthoflavone: relationship to intralobular distribution of CYP1A expression.","20448087",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27801952","Human T lymphocytes bioactivate heterocyclic aromatic amines by forming DNA adducts.","27801952",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8403195","Cytochrome P450 forms in the rodent lung involved in the metabolic activation of food-derived heterocyclic amines.","8403195",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1990,"1702369","Effects of the food mutagens MeIQx and PhIP on the expression of cytochrome P450IA proteins in various tissues of male and female rats.","1702369",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20816883","Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines.","20816883",57]
["2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline","C036990","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23208499","Long interspersed element-1 is differentially regulated by food-borne carcinogens via the aryl hydrocarbon receptor.","23208499",57]
["2-amino-3-methyl-9H-pyrido(2,3-b)indole","2-amino-3-methyl-9H-pyrido(2,3-b)indole","C017821","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12753413","Impact of five cytochrome p450 enzymes on the metabolism of two heterocyclic aromatic amines, 2-amino-9H-pyrido[2,3-b]indole (AalphaC) and 2-amino-3-methyl-9H-pyrido[2,3-b]indole (MeAalphaC).","12753413",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10828274","Prenatal toxicity and lack of carcinogenicity of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) following transplacental exposure.","10828274",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12680239","Effect of high sucrose diet on cytochrome P450 1A and heterocyclic amine mutagenesis.","12680239",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15721198","Characterization of antimutagenic mechanism of 3-allyl-5-substituted 2-thiohydantoins against 2-amino-3-methylimidazo[4,5-f]quinoline.","15721198",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16496416","The expression of xenobiotic-metabolizing enzymes in human prostate and in prostate epithelial cells (PECs) derived from primary cultures.","16496416",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20570348","Toxicokinetics of the food-toxin IQ in human placental perfusion is not affected by ABCG2 or xenobiotic metabolism.","20570348",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7586161","Inhibitory effect of dietary 4-ipomeanol on DNA adduct formation by the food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in male CDF1 mice.","7586161",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1993,"8114061","Specific induction of hepatic cytochrome P4501a-2 in C57BL/6 and DBA/2 mice treated with 2-amino-3-methylimidazo[4,5-f]quinoline (IQ).","8114061",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8201941","The structure-activity relationships of flavonoids as inhibitors of cytochrome P-450 enzymes in rat liver microsomes and the mutagenicity of 2-amino-3-methyl-imidazo[4,5-f]quinoline.","8201941",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8514213","Effect of 3-methylcholanthrene induction on the distribution and DNA adduction of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in F344 rats.","8514213",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8706244","Protection by green tea, black tea, and indole-3-carbinol against 2-amino-3-methylimidazo[4,5-f]quinoline-induced DNA adducts and colonic aberrant crypts in the F344 rat.","8706244",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9330619","The inhibition by flavonoids of 2-amino-3-methylimidazo[4,5-f]quinoline metabolic activation to a mutagen: a structure-activity relationship study.","9330619",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9395215","Inhibition of 2-amino-3-methylimidazo[4,5-f]quinoline-DNA adducts by indole-3-carbinol: dose-response studies in the rat colon.","9395215",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1995,"7606725","DNA adducts of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in colon, bladder, and kidney of congenic mice differing in Ah responsiveness and N-acetyltransferase genotype.","7606725",57]
["2-amino-3-methylimidazo(4,5-f)quinoline","2-amino-3-methylimidazo(4,5-f)quinoline","C029216","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1996,"8622637","Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.","8622637",57]
["2-amino-9H-pyrido(2,3-b)indole","2-amino-9H-pyrido(2,3-b)indole","C017822","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12753413","Impact of five cytochrome p450 enzymes on the metabolism of two heterocyclic aromatic amines, 2-amino-9H-pyrido[2,3-b]indole (AalphaC) and 2-amino-3-methyl-9H-pyrido[2,3-b]indole (MeAalphaC).","12753413",57]
["2-amino-9H-pyrido(2,3-b)indole","2-amino-9H-pyrido(2,3-b)indole","C017822","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27801952","Human T lymphocytes bioactivate heterocyclic aromatic amines by forming DNA adducts.","27801952",57]
["2-aminodiphenyl","2-aminodiphenyl","C014970","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1999,"10469630","CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice.","10469630",57]
["2-aminofluorene","2-aminofluorene","C012177","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9332696","Control of the mutagenicity of aromatic amines by protein kinases and phosphatases. I. The protein phosphatase inhibitors okadaic acid and ortho-vanadate drastically reduce the mutagenicity of aromatic amines.","9332696",57]
["2-anthramine","2-anthramine","C006593","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16006184","The spectrum of enzymes involved in activation of 2-aminoanthracene varies with the metabolic system applied.","16006184",57]
["2-anthramine","2-anthramine","C006593","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7875126","Metabolic activation of carcinogenic aromatic amines by fish exposed to environmental pollutants.","7875126",57]
["2-anthramine","2-anthramine","C006593","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"8545829","Aminoanthracene is a mechanism-based inactivator of CYP1A in channel catfish hepatic tissue.","8545829",57]
["2-anthramine","2-anthramine","C006593","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9332696","Control of the mutagenicity of aromatic amines by protein kinases and phosphatases. I. The protein phosphatase inhibitors okadaic acid and ortho-vanadate drastically reduce the mutagenicity of aromatic amines.","9332696",57]
["2-anthramine","2-anthramine","C006593","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9585267","Mutagenic activation of aromatic amines by molluscs as a biomarker of marine pollution.","9585267",57]
["2-anthramine","2-anthramine","C006593","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1998,"9744548","Induction of hepatic CYP1A in channel catfish increases binding of 2-aminoanthracene to DNA in vitro and in vivo.","9744548",57]
["2-azido-3-iodo-7,8-dibromodibenzo-1,4-dioxin","2-azido-3-iodo-7,8-dibromodibenzo-1,4-dioxin","C054916","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2004,"15213304","Use of 2-azido-3-[125I]iodo-7,8-dibromodibenzo-p-dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells.","15213304",57]
["2-azido-3-iodo-7,8-dibromodibenzo-1,4-dioxin","2-azido-3-iodo-7,8-dibromodibenzo-1,4-dioxin","C054916","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1991,"1654604","Detection of the Ah receptor in rainbow trout: use of 2-azido-3-[125I]iodo-7,8-dibromodibenzo-p-dioxin in cell culture.","1654604",57]
["2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one","2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one","C587262","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"23995519","The new aryl hydrocarbon receptor antagonist E/Z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one protects against UVB-induced signal transduction.","23995519",57]
["2-bromopalmitate","2-bromopalmitate","C022776","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1997,"9374121","Inhibition of sex pheromone production in female lepidopteran moths by 2-halofatty acids.","9374121",57]
["2-butenal","2-butenal","C012796","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1987,"3103627","Inhibition of microsomal cytochrome c reductase activity by a series of alpha, beta-unsaturated aldehydes.","3103627",57]
["2-chloro-5-nitrobenzanilide","2-chloro-5-nitrobenzanilide","C457499","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2004,"15007093","Lysophosphatidic acid induces neointima formation through PPARgamma activation.","15007093",57]
["2-chloro-5-nitrobenzanilide","2-chloro-5-nitrobenzanilide","C457499","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15007093","Lysophosphatidic acid induces neointima formation through PPARgamma activation.","15007093",57]
["2-chloroethyl ethyl sulfide","2-chloroethyl ethyl sulfide","C031278","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20561902","Inhibition of NADPH cytochrome P450 reductase by the model sulfur mustard vesicant 2-chloroethyl ethyl sulfide is associated with increased production of reactive oxygen species.","20561902",57]
["2-chlorosyringaldehyde","2-chlorosyringaldehyde","C103515","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9515087","The effects of exposure duration and feeding status on fish bile metabolites: implications for biomonitoring.","9515087",57]
["2-cresol","2-cresol","C034047","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8579380","Habitual and genetic factors that affect urinary background levels of biomarkers for organic solvent exposure.","8579380",57]
["2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid","2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid","C116817","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2003,"12855660","The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.","12855660",57]
["2-cyclopentyl-N-(2,4-dichloro-3-((isoquinolin-5-yloxy)methyl)phenyl)-N-methylacetamide","2-cyclopentyl-N-(2,4-dichloro-3-((isoquinolin-5-yloxy)methyl)phenyl)-N-methylacetamide","C555068","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2010,"20655898","Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice.","20655898",57]
["2-dichlorobenzene","2-dichlorobenzene","C004726","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20961080","Development of a partition-controlled dosing system for cell assays.","20961080",57]
["2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione","2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione","C581182","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27941348","Protective Effects of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Isolated from Averrhoa Carambola L. (Oxalidaceae) Roots on High-Fat Diet-Induced Obesity and Insulin Resistance in Mice.","27941348",57]
["2-ethynylnaphthalene","2-ethynylnaphthalene","C065012","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1510726","Suicide inhibitors of cytochrome P450 1A1 and P450 2B1.","1510726",57]
["2-fluoro-2-propyl-4-pentenoic acid","2-fluoro-2-propyl-4-pentenoic acid","C096095","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1995,"7548749","Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.","7548749",57]
["2-heptylformononetin","2-heptylformononetin","C584672","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"23738334","2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice.","23738334",57]
["2-hexadecynoic acid","2-hexadecynoic acid","C031203","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2013,"24062307","Diversity of Δ12 fatty acid desaturases in santalaceae and their role in production of seed oil acetylenic fatty acids.","24062307",57]
["2'-hydroxy dihydroguaiaretic acid","2'-hydroxy dihydroguaiaretic acid","C497853","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15482936","Antioxidant activities of a new lignan and a neolignan from Saururus chinensis.","15482936",57]
["2-hydroxy-1,3,7,8-tetrachlorodibenzo-4-dioxin","2-hydroxy-1,3,7,8-tetrachlorodibenzo-4-dioxin","C049089","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2014,"24475139","ITE and TCDD differentially regulate the vascular remodeling of rat placenta via the activation of AhR.","24475139",57]
["2'-hydroxy-4-methoxychalcone","2'-hydroxy-4-methoxychalcone","C031742","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22157260","2-hydroxy-4'-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma.","22157260",57]
["2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C060533","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10964100","Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue.","10964100",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1091,B1091)","v":"2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline"},"2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline","C032012","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1091,K1091)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2006,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1091,Q1091)","v":"16496416"},"The expression of xenobiotic-metabolizing enzymes in human prostate and in prostate epithelial cells (PECs) derived from primary cultures.","16496416",57]
["2-hydroxyatorvastatin","2-hydroxyatorvastatin","C518963","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2011,"22164412","[The composition of blood lipoproteins of donors 2 hours later after single atorvastatin intake].","22164412",57]
["2-hydroxyatorvastatin","2-hydroxyatorvastatin","C518963","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23575262","Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein.","23575262",57]
["2-hydroxyatorvastatin","2-hydroxyatorvastatin","C518963","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2013,"23575262","Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein.","23575262",57]
["2'-hydroxychalcone","2'-hydroxychalcone","C013031","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14565769","Inhibition of peroxynitrite-mediated LDL oxidation by prenylated flavonoids: the alpha,beta-unsaturated keto functionality of 2'-hydroxychalcones as a novel antioxidant pharmacophore.","14565769",57]
["2-hydroxyethylhydrazine","2-hydroxyethylhydrazine","C037834","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23774039","Repeated treatment with furazolidone induces multiple cytochrome p450-related activities in chicken liver, but not in rat liver.","23774039",57]
["2-hydroxyoleic acid","2-hydroxyoleic acid","C483229","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2013,"23360770","The role of membrane fatty acid remodeling in the antitumor mechanism of action of 2-hydroxyoleic acid.","23360770",57]
["2-Hydroxypropyl-beta-cyclodextrin","2-Hydroxypropyl-beta-cyclodextrin","D000073738","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8910326","Hydroxypropyl-beta-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells.","8910326",57]
["2-Hydroxypropyl-beta-cyclodextrin","2-Hydroxypropyl-beta-cyclodextrin","D000073738","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2011,"21494673","Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. [corrected].","21494673",57]
["2-Hydroxypropyl-beta-cyclodextrin","2-Hydroxypropyl-beta-cyclodextrin","D000073738","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"26404254","Weekly Treatment of 2-Hydroxypropyl-β-cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice.","26404254",57]
["2-hydroxyursolic acid","2-hydroxyursolic acid","C412810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2006,"17136324","Ursane triterpenoids inhibit atherosclerosis and xanthoma in LDL receptor knockout mice.","17136324",57]
["2-iodo-3,7,8-trichlorodibenzo-4-dioxin","2-iodo-3,7,8-trichlorodibenzo-4-dioxin","C060352","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1989,"2546045","[125I]2-iodo-3,7,8-trichlorodibenzo-p-dioxin-binding species in mouse liver induced by agonists for the Ah receptor: characterization and identification.","2546045",57]
["2-iodo-3,7,8-trichlorodibenzo-4-dioxin","2-iodo-3,7,8-trichlorodibenzo-4-dioxin","C060352","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1989,"2546046","Stimulation of in vivo hepatic uptake and in vitro hepatic binding of [125I]2-lodo-3,7,8-trichlorodibenzo-p-dioxin by the administration of agonist for the Ah receptor.","2546046",57]
["2-iodo-7,8-dibromodibenzo-1,4-dioxin","2-iodo-7,8-dibromodibenzo-1,4-dioxin","C056902","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1991,"1654803","In situ and in vitro photoaffinity labeling of the nuclear aryl hydrocarbon receptor from transformed rodent and human cell lines.","1654803",57]
["2-iodo-7,8-dibromodibenzo-1,4-dioxin","2-iodo-7,8-dibromodibenzo-1,4-dioxin","C056902","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1990,"2156826","2,3,7,8-Tetrachlorodibenzo-p-dioxin-inducible, Ah receptor-mediated bending of enhancer DNA.","2156826",57]
["2-iodo-7,8-dibromodibenzo-1,4-dioxin","2-iodo-7,8-dibromodibenzo-1,4-dioxin","C056902","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1988,"2842655","Kinetic and equilibrium studies of Ah receptor-ligand binding: use of [125I]2-iodo-7,8-dibromodibenzo-p-dioxin.","2842655",57]
["2-mercaptoacetate","2-mercaptoacetate","C017487","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1999,"10627078","Conditioned taste aversion produced by inhibitors of fatty acid oxidation in rats.","10627078",57]
["2-mercaptoacetate","2-mercaptoacetate","C017487","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1983,"6661181","Inhibition in vitro of acyl-CoA dehydrogenases by 2-mercaptoacetate in rat liver mitochondria.","6661181",57]
["2-mercaptoacetate","2-mercaptoacetate","C017487","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1997,"9374805","Development of independent ingestive responding to blockade of fatty acid oxidation in rats.","9374805",57]
["2-mercaptoacetate","2-mercaptoacetate","C017487","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1983,"6313642","Characterization of the binding site on thioglycolate-stimulated mouse peritoneal macrophages that mediates the uptake of very low density lipoproteins.","6313642",57]
["2-mercaptoacetate","2-mercaptoacetate","C017487","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2008,"18480247","Mercaptoacetate inhibition of fatty acid beta-oxidation attenuates the oral acceptance of fat in BALB/c mice.","18480247",57]
["2-mercaptoacetate","2-mercaptoacetate","C017487","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1983,"6313642","Characterization of the binding site on thioglycolate-stimulated mouse peritoneal macrophages that mediates the uptake of very low density lipoproteins.","6313642",57]
["2-mercaptobenzimidazole","2-mercaptobenzimidazole","C030698","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10103034","Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells.","10103034",57]
["2-methyl-1-(2,4,6-trihydroxy-3-(3-methyl2-butenyl)phenyl)-1-propanone","2-methyl-1-(2,4,6-trihydroxy-3-(3-methyl2-butenyl)phenyl)-1-propanone","C572891","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22259110","Prenylated acylphloroglucinol derivatives: isoprenomics-based design, syntheses and antioxidative activities.","22259110",57]
["2-methyl-1-(2,4,6-trihydroxy-3,5-di(3-methyl-2-butenyl)phenyl)-1-propanone","2-methyl-1-(2,4,6-trihydroxy-3,5-di(3-methyl-2-butenyl)phenyl)-1-propanone","C572889","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22259110","Prenylated acylphloroglucinol derivatives: isoprenomics-based design, syntheses and antioxidative activities.","22259110",57]
["2-methyl-1-(2,4,6-trihydroxyphenyl)-1-propanone","2-methyl-1-(2,4,6-trihydroxyphenyl)-1-propanone","C572890","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22259110","Prenylated acylphloroglucinol derivatives: isoprenomics-based design, syntheses and antioxidative activities.","22259110",57]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2006,"16540597","Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor.","16540597",57]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27020609","Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1.","27020609",57]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27020609","Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1.","27020609",57]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"16540597","Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor.","16540597",57]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20634293","CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor.","20634293",57]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"21967751","Development of novel CH223191-based antagonists of the aryl hydrocarbon receptor.","21967751",57]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23321324","When one is better than two.","23321324",57]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23321333","T-cell potential of human adult and cord blood hemopoietic stem cells expanded with the use of aryl hydrocarbon receptor antagonists.","23321333",57]
["2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide","C511621","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"27020609","Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1.","27020609",57]
["2-methyl-3-(2-((4-nitrooxybutyloxy)carbonyl)vinyl)phenyl ursodeoxycholic acid ester","2-methyl-3-(2-((4-nitrooxybutyloxy)carbonyl)vinyl)phenyl ursodeoxycholic acid ester","C433771","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2007,"17487265","Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity.","17487265",57]
["2-methyl-5-tert-butyl-1,3-benzodioxole","2-methyl-5-tert-butyl-1,3-benzodioxole","C037777","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1983,"6845372","Induction of cytochrome P-450 by methylenedioxyphenyl compounds: importance of the methylene carbon.","6845372",57]
["2-methylisoborneol","2-methylisoborneol","C005536","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10441633","Toxicological effects of geosmin and 2-methylisoborneol on rainbow trout hepatocytes.","10441633",57]
["2-morpholinomethyl-2',3',4'-trimethoxyacrylophenone","2-morpholinomethyl-2',3',4'-trimethoxyacrylophenone","C075405","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1617635","Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells.","1617635",57]
["2-morpholinomethyl-2',3',4'-trimethoxyacrylophenone","2-morpholinomethyl-2',3',4'-trimethoxyacrylophenone","C075405","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1992,"1617635","Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells.","1617635",57]
["2-naphthaldehyde","2-naphthaldehyde","C018686","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16083846","Evaluation of alpha-cyano ethers as fluorescent substrates for assay of cytochrome P450 enzyme activity.","16083846",57]
["2-naphthol","2-naphthol","C028405","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11323399","Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations.","11323399",57]
["2-naphthol","2-naphthol","C028405","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11641039","Effects of genetic polymorphisms of CYP1A1, CYP2E1, GSTM1, and GSTT1 on the urinary levels of 1-hydroxypyrene and 2-naphthol in aircraft maintenance workers.","11641039",57]
["2-naphthol","2-naphthol","C028405","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"14646291","Effects of genetic polymorphisms in metabolic enzymes on the relationships between 8-hydroxydeoxyguanosine levels in human leukocytes and urinary 1-hydroxypyrene and 2-naphthol concentrations.","14646291",57]
["2-naphthol orange","2-naphthol orange","C014722","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8045463","Effect of metanil yellow, orange II and their blend on hepatic xenobiotic metabolizing enzymes in rats.","8045463",57]
["2-Naphthylamine","2-Naphthylamine","D015081","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11076531","Estradiol enhances the resistance of LDL to oxidation by stabilizing apoB-100 conformation.","11076531",57]
["2-Naphthylamine","2-Naphthylamine","D015081","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11425493","Loss of apoB-100 secondary structure and conformation in hydroperoxide rich, electronegative LDL(-).","11425493",57]
["2-Naphthylamine","2-Naphthylamine","D015081","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11994361","Glycated low density lipoproteins modify platelet properties: a compositional and functional study.","11994361",57]
["2-Naphthylamine","2-Naphthylamine","D015081","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8369288","Acrylodan can label amino as well as sulfhydryl groups: results with low-density lipoprotein, lipoprotein[a], and lipid-free proteins.","8369288",57]
["2-Naphthylamine","2-Naphthylamine","D015081","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"11841825","Effect of human Apo AIV against lipid peroxidation of very low density lipoproteins.","11841825",57]
["2-Naphthylamine","2-Naphthylamine","D015081","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18989657","Synergism of aromatic amines and benzo[a]pyrene in induction of Ah receptor-dependent genes.","18989657",57]
["2-nitro-6H-dibenzo(b,d)pyran-6-one","2-nitro-6H-dibenzo(b,d)pyran-6-one","C097142","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9093392","Mutagenicity of the atmospheric transformation products 2-nitrofluoranthene and 2-nitrodibenzopyranone in Salmonella and human cell forward mutation assays.","9093392",57]
["2-nitrofluoranthene","2-nitrofluoranthene","C049030","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9093392","Mutagenicity of the atmospheric transformation products 2-nitrofluoranthene and 2-nitrodibenzopyranone in Salmonella and human cell forward mutation assays.","9093392",57]
["2-nonenal","2-nonenal","C013166","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9502761","In vivo absorption, metabolism, and urinary excretion of alpha,beta-unsaturated aldehydes in experimental animals. Relevance to the development of cardiovascular diseases by the dietary ingestion of thermally stressed polyunsaturate-rich culinary oils.","9502761",57]
["2-nonenal","2-nonenal","C013166","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9502761","In vivo absorption, metabolism, and urinary excretion of alpha,beta-unsaturated aldehydes in experimental animals. Relevance to the development of cardiovascular diseases by the dietary ingestion of thermally stressed polyunsaturate-rich culinary oils.","9502761",57]
["2-O-(9-octadecenyl)glycerol","2-O-(9-octadecenyl)glycerol","C084967","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1993,"8262928","In vivo desaturation of cis-delta 9-monounsaturated to cis-delta 9,12-diunsaturated alkenylether glycerolipids.","8262928",57]
["2-octynoic acid","2-octynoic acid","C060855","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1999,"10381140","Pitfalls in the use of 2-octynoic acid as an in vivo model of medium-chain acyl-coenzyme A dehydrogenase deficiency: ketone turnover and metabolite studies in the rat.","10381140",57]
["2-oxohexyl isothiocyanate","2-oxohexyl isothiocyanate","C524315","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19202560","Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzo[a]pyrene.","19202560",57]
["2-oxohexyl isothiocyanate","2-oxohexyl isothiocyanate","C524315","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2009,"19362136","The effect of isothiocyanates on CYP1A1 and CYP1A2 activities induced by polycyclic aromatic hydrocarbons in Mcf7 cells.","19362136",57]
["2-oxohexyl isothiocyanate","2-oxohexyl isothiocyanate","C524315","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19202560","Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzo[a]pyrene.","19202560",57]
["2-parinarolyllecithin","2-parinarolyllecithin","C030048","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2765542","Parinaroyl and pyrenyl phospholipids as probes for the lipid surface layer of human low density lipoproteins.","2765542",57]
["2-pentenal","2-pentenal","C064599","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9502761","In vivo absorption, metabolism, and urinary excretion of alpha,beta-unsaturated aldehydes in experimental animals. Relevance to the development of cardiovascular diseases by the dietary ingestion of thermally stressed polyunsaturate-rich culinary oils.","9502761",57]
["2-pentenal","2-pentenal","C064599","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9502761","In vivo absorption, metabolism, and urinary excretion of alpha,beta-unsaturated aldehydes in experimental animals. Relevance to the development of cardiovascular diseases by the dietary ingestion of thermally stressed polyunsaturate-rich culinary oils.","9502761",57]
["2-phenyl-2-(1-piperidinyl)propane","2-phenyl-2-(1-piperidinyl)propane","C412835","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2000,"10901699","Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.","10901699",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1155,B1155)","v":"2-phenylchromone"},"2-phenylchromone","C525486","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1155,K1155)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2007,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1155,Q1155)","v":"17950758"},"Inhibition of estrogen action by 2-phenylchromone as AhR agonist in MCF-7 cells.","17950758",57]
["2-phenylchromone","2-phenylchromone","C525486","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2007,"17950758","Inhibition of estrogen action by 2-phenylchromone as AhR agonist in MCF-7 cells.","17950758",57]
["2-phenylphenanthridinone","2-phenylphenanthridinone","C089169","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8080264","2-Phenylphenanthridinone and related compounds: aryl hydrocarbon receptor agonists and suicide inactivators of P4501A1.","8080264",57]
["2-phenylphenanthridinone","2-phenylphenanthridinone","C089169","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1994,"8080264","2-Phenylphenanthridinone and related compounds: aryl hydrocarbon receptor agonists and suicide inactivators of P4501A1.","8080264",57]
["2-propenyl-5,6-secocholestan-3-ol","2-propenyl-5,6-secocholestan-3-ol","C113842","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9589554","Synthesis of 4 alpha-(2-propenyl)-5,6-secocholestan-3 alpha-ol, a novel B-ring seco analog of the hypocholesterolemic agent 4 alpha-(2-propenyl)-5 alpha-cholestan-3 alpha-ol.","9589554",57]
["2-propyl-4-pentenoic acid","2-propyl-4-pentenoic acid","C045022","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1995,"7548749","Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.","7548749",57]
["2-pyrazinoylguanidine","2-pyrazinoylguanidine","C056104","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1487552","Pyrazinoylguanidine: antihypertensive, hypocholesterolemic, and renin effects.","1487552",57]
["2-tert-butylhydroquinone","2-tert-butylhydroquinone","C018855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15608132","tert-Butylhydroquinone is a novel aryl hydrocarbon receptor ligand.","15608132",57]
["2-tert-butylhydroquinone","2-tert-butylhydroquinone","C018855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16581943","Regulation of CYP1A1 gene expression by the antioxidant tert-butylhydroquinone.","16581943",57]
["2-tert-butylhydroquinone","2-tert-butylhydroquinone","C018855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2003,"12948865","Contribution of the Ah receptor to the phenolic antioxidant-mediated expression of human and rat UDP-glucuronosyltransferase UGT1A6 in Caco-2 and rat hepatoma 5L cells.","12948865",57]
["2-tert-butylhydroquinone","2-tert-butylhydroquinone","C018855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15608132","tert-Butylhydroquinone is a novel aryl hydrocarbon receptor ligand.","15608132",57]
["2-tert-butylhydroquinone","2-tert-butylhydroquinone","C018855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2006,"16581943","Regulation of CYP1A1 gene expression by the antioxidant tert-butylhydroquinone.","16581943",57]
["2-tert-butylhydroquinone","2-tert-butylhydroquinone","C018855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2013,"23329125","Differential sensitivity to pro-oxidant exposure in two populations of killifish (Fundulus heteroclitus).","23329125",57]
["2-tert-butylhydroquinone","2-tert-butylhydroquinone","C018855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,4,1995,"8615869","Response of [Ah] battery genes to compounds that protect against menadione toxicity.","8615869",57]
["2-tetradecylglycidic acid","2-tetradecylglycidic acid","C021756","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"7287708","Increased secretion of very low density lipoprotein triglyceride following inhibition of long chain fatty acid oxidation in isolated rat liver.","7287708",57]
["2-toluidine","2-toluidine","C023622","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12604171","Effect of naturally occurring plant phenolics on the induction of drug metabolizing enzymes by o-toluidine.","12604171",57]
["3-((2,4-dimethylpyrrol-5-yl)methylidenyl)-2-indolinone","3-((2,4-dimethylpyrrol-5-yl)methylidenyl)-2-indolinone","C549241","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20171196","TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes.","20171196",57]
["3-((2,4-dimethylpyrrol-5-yl)methylidenyl)-2-indolinone","3-((2,4-dimethylpyrrol-5-yl)methylidenyl)-2-indolinone","C549241","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2010,"20171196","TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes.","20171196",57]
["3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid","3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid","C526273","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23651850","Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways.","23651850",57]
["3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid","3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid","C526273","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23651850","Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways.","23651850",57]
["3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate","3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate","C028213","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3407929","Analytical isoelectric focusing of apolipoprotein B of human plasma low-density lipoproteins in the presence of a nonionic and a zwitterionic detergent.","3407929",57]
["3-((3-phenoxyphenyl)((3-(1,1,2,2-tetrafluoroethoxy)phenyl)methyl)amino)-1,1,1-trifluoro-2-propanol","3-((3-phenoxyphenyl)((3-(1,1,2,2-tetrafluoroethoxy)phenyl)methyl)amino)-1,1,1-trifluoro-2-propanol","C465459","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12190312","Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein.","12190312",57]
["3-((3-phenoxyphenyl)((3-(1,1,2,2-tetrafluoroethoxy)phenyl)methyl)amino)-1,1,1-trifluoro-2-propanol","3-((3-phenoxyphenyl)((3-(1,1,2,2-tetrafluoroethoxy)phenyl)methyl)amino)-1,1,1-trifluoro-2-propanol","C465459","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"12190312","Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein.","12190312",57]
["3-(1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl)propanoic acid","3-(1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl)propanoic acid","C000593222","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26699145","ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.","26699145",57]
["3-(2-(2,4,6-trimethylphenyl)thioethyl)-4-methylsydnone","3-(2-(2,4,6-trimethylphenyl)thioethyl)-4-methylsydnone","C048192","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7763287","Inactivation of chick embryo hepatic cytochrome P450 1A, 2H and 3A following in ovo administration of 3,5-diethoxycarbonyl-1,4-dihydro-2,6-dimethyl-4-ethylpyridine and 3-[2-(2,4,6-trimethylphenyl)thioethyl]-4-methylsydnone.","7763287",57]
["3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid","3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid","C487112","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"24750664","The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.","24750664",57]
["3-(2,2,2-trimethylhydrazine)propionate","3-(2,2,2-trimethylhydrazine)propionate","C050147","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25177814","[Using meldonium to improve the adaptation of patients with cardiovascular disease to the effects of heat and correction of associated oxidative stress].","25177814",57]
["3-(2,2,2-trimethylhydrazine)propionate","3-(2,2,2-trimethylhydrazine)propionate","C050147","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2003,"14671546","[The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].","14671546",57]
["3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H,2,4-triazol","3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H,2,4-triazol","C543497","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19694183","Inhibitive effect of diphenytriazol on rat cytochrome P450 enzyme in vitro.","19694183",57]
["3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole","3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole","C030266","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15013813","In vitro metabolism and inductive or inhibitive effect of DL111 on rat cytochrome P4501A enzyme.","15013813",57]
["3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole","3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole","C030266","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15066225","Induction of diphenytriazol on cytochrome CYP1A.","15066225",57]
["3-(2-hydroxyethoxy)-4-methoxy-N-(5-(3-trifluoromethylbenzyl)thiazol-2-yl)benzamide","3-(2-hydroxyethoxy)-4-methoxy-N-(5-(3-trifluoromethylbenzyl)thiazol-2-yl)benzamide","C545364","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2009,"19540759","Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.","19540759",57]
["3-(2-hydroxyethoxy)-4-methoxy-N-(5-(3-trifluoromethylbenzyl)thiazol-2-yl)benzamide","3-(2-hydroxyethoxy)-4-methoxy-N-(5-(3-trifluoromethylbenzyl)thiazol-2-yl)benzamide","C545364","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2009,"19541482","Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.","19541482",57]
["3-(3,4,5-trimethoxyphenyl)-1-oxo-2-propene","3-(3,4,5-trimethoxyphenyl)-1-oxo-2-propene","C520655","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2017,"29138024","(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.","29138024",57]
["3-(3,4,5-trimethoxyphenyl)-1-oxo-2-propene","3-(3,4,5-trimethoxyphenyl)-1-oxo-2-propene","C520655","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"29138024","(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.","29138024",57]
["3-(3,5-dichlorophenyl)-2,4-thiazolidinedione","3-(3,5-dichlorophenyl)-2,4-thiazolidinedione","C532666","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18621092","Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.","18621092",57]
["3-(4-(2-carbazol-9-ylethoxy)phenyl)-2-ethoxypropionic acid","3-(4-(2-carbazol-9-ylethoxy)phenyl)-2-ethoxypropionic acid","C448626","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2006,"16456093","Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.","16456093",57]
["3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine","3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine","C579035","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"26264980","Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity.","26264980",57]
["3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine","3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine","C579035","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"26670228","The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.","26670228",57]
["3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine","3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine","C579035","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"28260070","A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice.","28260070",57]
["3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide","3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide","C548780","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22234485","Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.","22234485",57]
["3-(4-hydroxy-3-(3-oxo-but-1-enyl)-phenyl)-acrylic acid","3-(4-hydroxy-3-(3-oxo-but-1-enyl)-phenyl)-acrylic acid","C110594","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10800636","Antiapoptotic effects of propolis extract and propol on human macrophages exposed to minimally modified low density lipoprotein.","10800636",57]
["3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid","3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid","C526155","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2014,"25010893","Kimchi methanol extract and the kimchi active compound, 3'-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid, downregulate CD36 in THP-1 macrophages stimulated by oxLDL.","25010893",57]
["3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid","3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid","C526155","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25010893","Kimchi methanol extract and the kimchi active compound, 3'-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid, downregulate CD36 in THP-1 macrophages stimulated by oxLDL.","25010893",57]
["3-(4-methylphenylsulfonyl)-2-propenenitrile","3-(4-methylphenylsulfonyl)-2-propenenitrile","C434003","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2004,"14694442","The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells.","14694442",57]
["3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","C090937","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27938560","[Effect of targeted inhibition of hypoxia-inducible factor-1α by 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole on the progression of non-alcoholic fatty liver disease in rats].","27938560",57]
["3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","C090937","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18197143","YC-1 induces heat shock protein 70 expression and prevents oxidized LDL-mediated apoptosis in vascular smooth muscle cells.","18197143",57]
["3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","C090937","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26767504","YC-1 induces lipid droplet formation in RAW 264.7 macrophages.","26767504",57]
["3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole","C090937","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27938560","[Effect of targeted inhibition of hypoxia-inducible factor-1α by 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole on the progression of non-alcoholic fatty liver disease in rats].","27938560",57]
["3-(alpha,alpha-dimethylallyl)psoralen","3-(alpha,alpha-dimethylallyl)psoralen","C020740","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23257392","Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin.","23257392",57]
["3-(carboxymethyl)-5-(6-(2,4-dichlorophenyl)hexyl)-3-hydroxytetrahydrofuran-2-one","3-(carboxymethyl)-5-(6-(2,4-dichlorophenyl)hexyl)-3-hydroxytetrahydrofuran-2-one","C114594","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9733484","ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.","9733484",57]
["3-(N-phenylamino)-1,2-propanediol 1,2-dioleoyl ester","3-(N-phenylamino)-1,2-propanediol 1,2-dioleoyl ester","C092835","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16343824","Endocytosis and intracellular trafficking of fatty acid esters of phenylaminopropanediol, the putative etiologic agents of the toxic oil syndrome (TOS).","16343824",57]
["3,3',4,4',5,5'-hexabromobiphenyl","3,3',4,4',5,5'-hexabromobiphenyl","C032790","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16291824","Genetic differences in lethality of newborn mice treated in utero with coplanar versus non-coplanar hexabromobiphenyl.","16291824",57]
["3,3',4,4',5,5'-hexabromobiphenyl","3,3',4,4',5,5'-hexabromobiphenyl","C032790","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1985,"2994254","Toxicity of 3,4,5,3',4',5'-hexabrominated biphenyl and 3,4,3',4'-tetrabrominated biphenyl.","2994254",57]
["3,3',4,4',5,5'-hexabromobiphenyl","3,3',4,4',5,5'-hexabromobiphenyl","C032790","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1985,"2994255","Studies on the structure-activity relationships for the metabolism of polybrominated biphenyls by rat liver microsomes.","2994255",57]
["3,3',4,4',5,5'-hexabromobiphenyl","3,3',4,4',5,5'-hexabromobiphenyl","C032790","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"16291824","Genetic differences in lethality of newborn mice treated in utero with coplanar versus non-coplanar hexabromobiphenyl.","16291824",57]
["3,3',4,4',5,5'-hexabromobiphenyl","3,3',4,4',5,5'-hexabromobiphenyl","C032790","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1985,"2994254","Toxicity of 3,4,5,3',4',5'-hexabrominated biphenyl and 3,4,3',4'-tetrabrominated biphenyl.","2994254",57]
["3,3',4,4'-tetrabromobiphenyl","3,3',4,4'-tetrabromobiphenyl","C036685","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1985,"2994254","Toxicity of 3,4,5,3',4',5'-hexabrominated biphenyl and 3,4,3',4'-tetrabrominated biphenyl.","2994254",57]
["3,3',4,4'-tetrabromobiphenyl","3,3',4,4'-tetrabromobiphenyl","C036685","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1985,"2994255","Studies on the structure-activity relationships for the metabolism of polybrominated biphenyls by rat liver microsomes.","2994255",57]
["3,3',4,4'-tetrabromobiphenyl","3,3',4,4'-tetrabromobiphenyl","C036685","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1985,"2994254","Toxicity of 3,4,5,3',4',5'-hexabrominated biphenyl and 3,4,3',4'-tetrabrominated biphenyl.","2994254",57]
["3,3',4',5,6,7,8-heptamethoxyflavone","3,3',4',5,6,7,8-heptamethoxyflavone","C059294","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23370792","Effects of citrus flavonoids, 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone and 3,5,6,7,8,3',4'-heptamethoxyflavone, on the activities of macrophage scavenger receptors and the hepatic LDL receptor.","23370792",57]
["3,3',4',5,6,7,8-heptamethoxyflavone","3,3',4',5,6,7,8-heptamethoxyflavone","C059294","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23370792","Effects of citrus flavonoids, 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone and 3,5,6,7,8,3',4'-heptamethoxyflavone, on the activities of macrophage scavenger receptors and the hepatic LDL receptor.","23370792",57]
["3,3',4',5-tetrachloro-4-hydroxybiphenyl","3,3',4',5-tetrachloro-4-hydroxybiphenyl","C111117","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9493316","Hydroxylated polychlorinated biphenyls: placental transfer and effects on thyroxine in the foetal mouse.","9493316",57]
["3,3',4,5'-tetrahydroxystilbene","3,3',4,5'-tetrahydroxystilbene","C041525","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2013,"23838580","PP2 and piceatannol inhibit PrP106-126-induced iNOS activation mediated by CD36 in BV2 microglia.","23838580",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1219,B1219)","v":"3,3',4,5'-tetrahydroxystilbene"},"3,3',4,5'-tetrahydroxystilbene","C041525","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1219,K1219)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2007,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1219,Q1219)","v":"19356012"},"In vitro inhibition of rat CYP1A1 and CYP1A2 by piceatannol, a hydroxylated metabolite of trans-resveratrol.","19356012",57]
["3,3',4,5'-tetrahydroxystilbene","3,3',4,5'-tetrahydroxystilbene","C041525","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20846786","Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells.","20846786",57]
["3,3',4,5'-tetrahydroxystilbene","3,3',4,5'-tetrahydroxystilbene","C041525","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27792146","Piceatannol Exerts Anti-Obesity Effects in C57BL/6 Mice through Modulating Adipogenic Proteins and Gut Microbiota.","27792146",57]
["3,3',4,5'-tetrahydroxystilbene","3,3',4,5'-tetrahydroxystilbene","C041525","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20846786","Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells.","20846786",57]
["3,3'-Dichlorobenzidine","3,3'-Dichlorobenzidine","D015101","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1977,"892292","Synergistic effect of urinary bladder carcinogenesis in rats treated with N-butyl-n-(4-hydroxybutyl)nitrosamine, N-(4-(5-nitro-2-furyl)-2-thiazolyl)formamide,N-2-fluorenylacetamide, and 3,3'-dichlorobenzidine.","892292",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2001,"11294972","2,3,7,8-Tetrachlorodibenzo-p-dioxin and diindolylmethanes differentially induce cytochrome P450 1A1, 1B1, and 19 in H295R human adrenocortical carcinoma cells.","11294972",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11765009","Concurrent flavin-containing monooxygenase down regulation and cytochrome P450 induction by dietary indoles in the rat: implication for drug-drug interactions.","11765009",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18486294","Inhibitory effects of a dietary phytochemical 3,3'-diindolylmethane on the phenobarbital-induced hepatic CYP mRNA expression and CYP-catalyzed reactions in female rats.","18486294",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"19022961","3,3'-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.","19022961",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1991,"1954658","Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro.","1954658",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21617870","Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C?","21617870",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22592002","A selective aryl hydrocarbon receptor modulator 3,3'-Diindolylmethane inhibits gastric cancer cell growth.","22592002",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26476840","Selective Aryl Hydrocarbon Receptor Modulator 3,3'-Diindolylmethane Impairs AhR and ARNT Signaling and Protects Mouse Neuronal Cells Against Hypoxia.","26476840",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7867998","Regulation of hepatic cytochrome P4501A by indole-3-carbinol: transient induction with continuous feeding in rainbow trout.","7867998",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8384853","Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation.","8384853",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"8568833","The anticarcinogen 3,3'-diindolylmethane is an inhibitor of cytochrome P-450.","8568833",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9771935","Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane.","9771935",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,"25281898","3, 3'-Diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg/Th17 cells to Treg dominance.","25281898",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2013,"23586923","Indoles mitigate the development of experimental autoimmune encephalomyelitis by induction of reciprocal differentiation of regulatory T cells and Th17 cells.","23586923",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2001,"11294972","2,3,7,8-Tetrachlorodibenzo-p-dioxin and diindolylmethanes differentially induce cytochrome P450 1A1, 1B1, and 19 in H295R human adrenocortical carcinoma cells.","11294972",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2001,"11437101","Methyl-substituted diindolylmethanes as inhibitors of estrogen-induced growth of T47D cells and mammary tumors in rats.","11437101",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"16488130","Estrogen receptor alpha as a target for indole-3-carbinol.","16488130",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2007,"17515958","Interplay of genes regulated by estrogen and diindolylmethane in breast cancer cell lines.","17515958",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19056653","Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast cancer cells.","19056653",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22592002","A selective aryl hydrocarbon receptor modulator 3,3'-Diindolylmethane inhibits gastric cancer cell growth.","22592002",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23085552","3,3'-Diindolylmethane alleviates oxazolone-induced colitis through Th2/Th17 suppression and Treg induction.","23085552",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26476840","Selective Aryl Hydrocarbon Receptor Modulator 3,3'-Diindolylmethane Impairs AhR and ARNT Signaling and Protects Mouse Neuronal Cells Against Hypoxia.","26476840",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1993,"8384853","Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation.","8384853",57]
["3,3'-diindolylmethane","3,3'-diindolylmethane","C016392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1998,"9771935","Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane.","9771935",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1526197","Three probe flow cytometry of a human foam-cell forming macrophage.","1526197",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15767207","Suitability of LLC-PK1 pig kidney cells for the study of drug action on renal cell cholesterol uptake: identification and characterization of low-density lipoprotein receptors.","15767207",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1917780","Toxicity in vital fluorescence microscopy: effect of dimethylsulfoxide, rhodamine-123, and DiI-low density lipoprotein on fibroblast growth in vitro.","1917780",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"3939385","Metabolism of lipoproteins labeled with fluorescent indocarbocyanine dyes for in vitro studies of atherogenesis.","3939385",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"6270157","Fluorescent low density lipoprotein for observation of dynamics of individual receptor complexes on cultured human fibroblasts.","6270157",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6688438","Identification of macrophages in sections of rabbit lung using acetoacetylated lipoproteins.","6688438",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8381454","Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL.","8381454",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1992,"1526197","Three probe flow cytometry of a human foam-cell forming macrophage.","1526197",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,2005,"15767207","Suitability of LLC-PK1 pig kidney cells for the study of drug action on renal cell cholesterol uptake: identification and characterization of low-density lipoprotein receptors.","15767207",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1981,"6270157","Fluorescent low density lipoprotein for observation of dynamics of individual receptor complexes on cultured human fibroblasts.","6270157",57]
["3,3'-dioctadecylindocarbocyanine","3,3'-dioctadecylindocarbocyanine","C024286","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1993,"8381454","Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL.","8381454",57]
["3,3'-iminodipropionitrile","3,3'-iminodipropionitrile","C008110","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,2,2015,"25424614","Maternal exposure to 3,3'-iminodipropionitrile targets late-stage differentiation of hippocampal granule cell lineages to affect brain-derived neurotrophic factor signaling and interneuron subpopulations in rat offspring.","25424614",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10462547","Oxidative inactivation of cytochrome P-450 1A (CYP1A) stimulated by 3,3',4,4'-tetrachlorobiphenyl: production of reactive oxygen by vertebrate CYP1As.","10462547",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10630420","Competitive behavior in the interactive toxicology of halogenated aromatic compounds.","10630420",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10665414","Accumulation pattern and biotransformation enzyme induction in rainbow trout embryos exposed to sublethal aqueous concentrations of 3,3',4,4'-tetrachlorobiphenyl.","10665414",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10788563","Effect of micelle fatty acid composition and 3,4,3', 4'-tetrachlorobiphenyl (TCB) exposure on intestinal [(14)C]-TCB bioavailability and biotransformation in channel catfish in situ preparations.","10788563",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11048677","In vitro metabolism of polychlorinated biphenyl congeners by beluga whale (Delphinapterus leucas) and pilot whale (Globicephala melas) and relationship to cytochrome P450 expression.","11048677",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11222084","Polychlorinated biphenyl-induced effects on metabolic enzymes, AP-1 binding, vitamin E, and oxidative stress in the rat liver.","11222084",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11572610","Vitamin and thyroid status in arctic grayling (Thymallus arcticus) exposed to doses of 3,3',4,4'-tetrachlorobiphenyl that induce the phase I enzyme system.","11572610",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2000,"11790349","3,3',4,4'-Tetrachlorobiphenyl oxidation in fish, bird and reptile species: relationship to cytochrome P450 1A inactivation and reactive oxygen production.","11790349",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12049832","Effect of 3,3',4,4'-tetrachlorobiphenyl and 2,2',4,4',5,5'-hexachlorobiphenyl on the induction of hepatic lipid peroxidation and cytochrome P-450 associated enzyme activities in rats.","12049832",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12970578","Dietary flavonoids modulate PCB-induced oxidative stress, CYP1A1 induction, and AhR-DNA binding activity in vascular endothelial cells.","12970578",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16291559","Gene expression patterns in estrogen (nonylphenol) and aryl hydrocarbon receptor agonists (PCB-77) interaction using rainbow trout (Oncorhynchus Mykiss) primary hepatocyte culture.","16291559",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2006,"16313980","Comparison of hepatic and extra hepatic induction of cytochrome P4501A by graded doses of aryl hydrocarbon receptor agonists in Atlantic tomcod from two populations.","16313980",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16364462","Intestinal bioavailability and biotransformation of 3,3',4,4'-tetrachlorobiphenyl (CB 77) in in situ preparations of channel catfish following dietary induction of CYP1A.","16364462",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17703865","The effect of dietary glycine on the hepatic tumor promoting activity of polychlorinated biphenyls (PCBs) in rats.","17703865",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18373956","Hepatic biotransformation responses in Atlantic salmon exposed to retinoic acids and 3,3',4,4'-tetrachlorobiphenyl (PCB congener 77).","18373956",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18423858","Reductive dechlorination of 3,3',4,4'-tetrachlorobiphenyl (PCB77) using palladium or palladium/iron nanoparticles and assessment of the reduction in toxic potency in vascular endothelial cells.","18423858",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18640730","PCB77 (3,3',4,4'-tetrachlorobiphenyl) co-exposure prolongs CYP1A induction, and sustains oxidative stress in B(a)P-exposed turbot, Scophthalmus maximus, in a long-term study.","18640730",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18657580","The suitability of cytochrome-P4501A1 as a biomarker for PCB contamination in European eel (Anguilla anguilla).","18657580",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18786521","Coplanar polychlorinated biphenyl-induced CYP1A1 is regulated through caveolae signaling in vascular endothelial cells.","18786521",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20176134","Differential sensitivity of CYP1A to 3,3',4',4-tetrachlorobiphenyl and benzo(a)pyrene in two Lepomis species.","20176134",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21803134","Gene expression and inducibility of the aryl hydrocarbon receptor-dependent pathway in cultured bovine blood lymphocytes.","21803134",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22410624","Effects of polychlorinated biphenyls on whole animal energy mobilization and hepatic cellular respiration in rainbow trout, Oncorhynchus mykiss.","22410624",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"22776768","Lack of CYP1A responsiveness in species inhabiting chronically contaminated habitats: two varieties of resistance?","22776768",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1283,B1283)","v":"3,4,3',4'-tetrachlorobiphenyl"},"3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1283,K1283)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,1989,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1283,Q1283)","v":"2497554"},"Effects of ortho- and non-ortho-substituted polychlorinated biphenyl congeners on the hepatic monooxygenase system in scup (Stenotomus chrysops).","2497554",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26752525","Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland.","26752525",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2018,"29316220","Interactive effects of hypoxia and PCB co-exposure on expression of CYP1A and its potential regulators in Atlantic croaker liver.","29316220",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7618351","beta-Naphthoflavone- and self-induced metabolism of 3,3',4,4'-tetrachlorobiphenyl in hepatic microsomes of the male, pregnant female and foetal rat.","7618351",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7624895","Effects of gestational and lactational exposure to coplanar polychlorinated biphenyl (PCB) congeners or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on thyroid hormone concentrations in weanling rats.","7624895",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1995,"7697753","Metabolism and biochemical effects of 3,3',4,4'-tetrachlorobiphenyl in pregnant and fetal rats.","7697753",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"7843859","Detection and localization of 3,3',4,4'-tetrachlorobiphenyl-induced P4501A protein in avian primary immune tissues.","7843859",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"7992318","Inhibition of intercellular communication by 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like PCBs in mouse hepatoma cells (Hepa1c1c7): involvement of the Ah receptor.","7992318",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8039554","In vitro metabolism of 3,3',4,4'-tetrachlorobiphenyl in relation to ethoxyresorufin-O-deethylase activity in liver microsomes of some wildlife species and rat.","8039554",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8378931","Interference of polychlorinated biphenyls in hepatic and brain thyroid hormone metabolism in fetal and neonatal rats.","8378931",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8498074","Induction of 7-ethoxyresorufin-O-deethylase (EROD) activity in mice foetuses by the PCB-congener 3,3',4,4'-tetrachlorobiphenyl.","8498074",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"8552139","DNA adducts and P450 induction in human, rat and avian liver cells after exposure to polychlorobiphenyls.","8552139",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"8577641","3,3',4,4'-tetrachlorobiphenyl effects on antioxidant enzymes and glutathione status in different tissues of rainbow trout.","8577641",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8653380","Temporal induction pattern of hepatic cytochrome P450 1A in thermally acclimated dab (Limanda limanda) treated with 3,3',4,4'-tetrachlorobiphenyl (CB77).","8653380",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8665401","P450 induction by Aroclor 1254 and 3,3',4,4'-tetrachlorobiphenyl in cultured hepatocytes from rat, quail and man: interspecies comparison.","8665401",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1996,"8739034","Glutathione regulates 3,3',4,4'-tetrachlorobiphenyl induced cytochrome P450 metabolism: evidence for a cross-talk between the two major detoxication pathways.","8739034",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"8748700","Species-specific antagonism of Ah receptor action by 2,2',5,5'-tetrachloro- and 2,2',3,3'4,4'-hexachlorobiphenyl.","8748700",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8975768","In vivo/in vitro comparison of the pharmacokinetics and pharmacodynamics of 3,3',4,4'-tetrachlorobiphenyl (PCB77).","8975768",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9134684","Tissue distribution, toxicokinetics and induction of hepatic drug metabolizing enzymes in male rats after a single s.c. dose of 3,4,3',4'-tetrachlorobiphenyl (PCB-77).","9134684",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9152595","Metabolism of the aryl hydrocarbon receptor agonist 3,3',4,4'-tetrachlorobiphenyl by the marine fish scup (Stenotomus chrysops) in vivo and in vitro.","9152595",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9174117","Induction and post-transcriptional suppression of hepatic cytochrome P450 1A1 by 3,3',4,4'-tetrachlorobiphenyl.","9174117",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9297809","Regulation of 3,3',4,4'-tetrachlorobiphenyl induced cytochrome P450 metabolism by thiols in tissues of rainbow trout.","9297809",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9439713","Multiple roles of polyhalogenated biphenyls in causing increases in cytochrome P450 and uroporphyrin accumulation in cultured hepatocytes.","9439713",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2003,"12970578","Dietary flavonoids modulate PCB-induced oxidative stress, CYP1A1 induction, and AhR-DNA binding activity in vascular endothelial cells.","12970578",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2000,"10630420","Competitive behavior in the interactive toxicology of halogenated aromatic compounds.","10630420",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,4,2000,"11790349","3,3',4,4'-Tetrachlorobiphenyl oxidation in fish, bird and reptile species: relationship to cytochrome P450 1A inactivation and reactive oxygen production.","11790349",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2004,"15556062","Prior PCB exposure suppresses hypoxia-induced up-regulation of glycolytic enzymes in Fundulus heteroclitus.","15556062",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16291559","Gene expression patterns in estrogen (nonylphenol) and aryl hydrocarbon receptor agonists (PCB-77) interaction using rainbow trout (Oncorhynchus Mykiss) primary hepatocyte culture.","16291559",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16313980","Comparison of hepatic and extra hepatic induction of cytochrome P4501A by graded doses of aryl hydrocarbon receptor agonists in Atlantic tomcod from two populations.","16313980",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18560532","Polychlorinated biphenyl-77 induces adipocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis.","18560532",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18786521","Coplanar polychlorinated biphenyl-induced CYP1A1 is regulated through caveolae signaling in vascular endothelial cells.","18786521",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2009,"19265715","Up-regulation of endothelial monocyte chemoattractant protein-1 by coplanar PCB77 is caveolin-1-dependent.","19265715",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1990,"2154336","3,3',4,4'-tetrachlorobiphenyl: metabolism by the chick embryo in ovo and toxicity of hydroxylated metabolites.","2154336",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21803134","Gene expression and inducibility of the aryl hydrocarbon receptor-dependent pathway in cultured bovine blood lymphocytes.","21803134",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21979385","Developmental effects related to angiogenesis and osteogenic differentiation in Salmon larvae continuously exposed to dioxin-like 3,3',4,4'-tetrachlorobiphenyl (congener 77).","21979385",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"24231106","Resveratrol protects against polychlorinated biphenyl-mediated impairment of glucose homeostasis in adipocytes.","24231106",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25734695","Effects of Adipocyte Aryl Hydrocarbon Receptor Deficiency on PCB-Induced Disruption of Glucose Homeostasis in Lean and Obese Mice.","25734695",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26752525","Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland.","26752525",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1988,"2833182","Potentially hazardous residues of non-ortho chlorine substituted coplanar PCBs in human adipose tissue.","2833182",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1988,"2905963","Differences between chick and turkey embryos in sensitivity to 3,3',4,4'-tetrachloro-biphenyl and in concentration/affinity of the hepatic receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin.","2905963",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1986,"3024358","Ah receptor mediated suppression of the antibody response in mice is primarily dependent on the Ah phenotype of lymphoid tissue.","3024358",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1987,"3030868","Comparative toxicology of tetrachlorobiphenyls in mink and rats. II. Pathology.","3030868",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1994,"7826668","Proliferation inhibition and CD4/CD8 thymocyte subset skewing by in vivo exposure of C57BL/6 mice to Ah receptor-binding 3,3',4,4'-tetrachlorobiphenyl.","7826668",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1994,"7992314","Additive binding of polychlorinated biphenyls and 2,3,7,8-tetrachlorodibenzo-p-dioxin to the murine hepatic Ah receptor.","7992314",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1994,"7992318","Inhibition of intercellular communication by 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like PCBs in mouse hepatoma cells (Hepa1c1c7): involvement of the Ah receptor.","7992318",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1994,"8077682","Thymic stroma exposed to arylhydrocarbon receptor-binding xenobiotics fails to support proliferation of early thymocytes but induces differentiation.","8077682",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1995,"8748700","Species-specific antagonism of Ah receptor action by 2,2',5,5'-tetrachloro- and 2,2',3,3'4,4'-hexachlorobiphenyl.","8748700",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,1997,"9152595","Metabolism of the aryl hydrocarbon receptor agonist 3,3',4,4'-tetrachlorobiphenyl by the marine fish scup (Stenotomus chrysops) in vivo and in vitro.","9152595",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18786521","Coplanar polychlorinated biphenyl-induced CYP1A1 is regulated through caveolae signaling in vascular endothelial cells.","18786521",57]
["3,4,3',4'-tetrachlorobiphenyl","3,4,3',4'-tetrachlorobiphenyl","C028451","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2009,"19265715","Up-regulation of endothelial monocyte chemoattractant protein-1 by coplanar PCB77 is caveolin-1-dependent.","19265715",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15369848","Evaluation of relative potencies of PCB126 and PCB169 for the immunotoxicities in ovalbumin (OVA)-immunized mice.","15369848",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2006,"16313980","Comparison of hepatic and extra hepatic induction of cytochrome P4501A by graded doses of aryl hydrocarbon receptor agonists in Atlantic tomcod from two populations.","16313980",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21374784","Adverse effects of neonatal exposure to 3,3',4,4',5,5'-hexachlorobiphenyl on hormone levels and testicular function in male Sprague-Dawley rats.","21374784",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1985,"3920403","Toxicological manifestations of 2,4,5,2',4',5'-, 2,3,6,2',3',6'-, and 3,4,5,3',4',5'-hexachlorobiphenyl and Aroclor 1254 in mink.","3920403",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"7992318","Inhibition of intercellular communication by 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like PCBs in mouse hepatoma cells (Hepa1c1c7): involvement of the Ah receptor.","7992318",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8048058","2,2',4,4',5,5'- and 3,3',4,4',5,5'-hexachlorobiphenyl alteration of uterine progesterone and estrogen receptors coincides with embryotoxicity in mink (Mustela vision).","8048058",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8378931","Interference of polychlorinated biphenyls in hepatic and brain thyroid hormone metabolism in fetal and neonatal rats.","8378931",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9439713","Multiple roles of polyhalogenated biphenyls in causing increases in cytochrome P450 and uroporphyrin accumulation in cultured hepatocytes.","9439713",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"10746932","Differential and non-uniform tissue and brain distribution of two distinct 14C-hexachlorobiphenyls in weanling rats.","10746932",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16313980","Comparison of hepatic and extra hepatic induction of cytochrome P4501A by graded doses of aryl hydrocarbon receptor agonists in Atlantic tomcod from two populations.","16313980",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1987,"2825945","Nonadditive interactive effects of polychlorinated biphenyl congeners in rats: role of the 2,3,7,8-tetrachlorodibenzo-p-dioxin receptor.","2825945",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1988,"2833182","Potentially hazardous residues of non-ortho chlorine substituted coplanar PCBs in human adipose tissue.","2833182",57]
["3,4,5,3',4',5'-hexachlorobiphenyl","3,4,5,3',4',5'-hexachlorobiphenyl","C027309","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1994,"7992318","Inhibition of intercellular communication by 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like PCBs in mouse hepatoma cells (Hepa1c1c7): involvement of the Ah receptor.","7992318",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2012,"22824115","N-acetylcysteine (NAC) diminishes the severity of PCB 126-induced fatty liver in male rodents.","22824115",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1347,B1347)","v":"3,4,5,3',4'-pentachlorobiphenyl"},"3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1347,K1347)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2002,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1347,Q1347)","v":"11991632"},"Circulating lysozyme and hepatic CYP1A activities during a chronic dietary exposure to tributyltin (TBT) and 3,3',4,4',5-pentachlorobiphenyl (PCB-126) mixtures in channel catfish, Ictalurus punctatus.","11991632",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17316808","The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.","17316808",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11005680","CYP1A-dependent activation of xenobiotics in endothelial linings of the chorioallantoic membrane (CAM) in birds.","11005680",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11164533","Induction and suppression of cytochrome P450 1A by 3,3',4,4',5-pentachlorobiphenyl and its relationship to oxidative stress in the marine fish scup (Stenotomus chrysops).","11164533",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11312653","Role of oxidative stress and antioxidant defense in 3,3',4,4',5-pentachlorobiphenyl-induced toxicity and species-differential sensitivity in chicken and duck embryos.","11312653",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11351408","Immunohistochemical localization of cytochrome P4501A induced by 3,3',4,4',5-pentachlorobiphenyl (PCB 126) in multiple organs of northern leopard frogs, Rana pipiens.","11351408",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11831221","Cytochrome P4501A induction and testosterone hydroxylation in cultured hepatocytes of four fish species.","11831221",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11847979","MFO induction potential of fish species native to the Swan-Canning Estuary, Western Australia.","11847979",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12127732","Dietary accumulation and biochemical responses of juvenile rainbow trout (Oncorhynchus mykiss) to 3,3',4,4',5-pentachlorobiphenyl (PCB 126).","12127732",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12151633","Comparative responsiveness of hypothyroxinemia and hepatic enzyme induction in Long-Evans rats versus C57BL/6J mice exposed to TCDD-like and phenobarbital-like polychlorinated biphenyl congeners.","12151633",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12223198","Metabolic disturbances in fish exposed to sodium pentachlorophenate (NaPCP) and 3,3',4,4',5-pentachlorobiphenyl (PCB126), individually or combined.","12223198",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2002,"12408577","Effects of single and combined exposures to benzo(a)pyrene and 3,3'4,4'5-pentachlorobiphenyl on EROD activity and development in Fundulus heteroclitus.","12408577",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12408627","Patterns of heritability of decreased EROD activity and resistance to PCB 126-induced teratogenesis in laboratory-reared offspring of killifish (Fundulus heteroclitus) from a creosote-contaminated site in the Elizabeth River, VA, USA.","12408627",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12781204","Effects of 3,3',4,4',5-pentachlorobiphenyl, a coplanar polychlorinated biphenyl congener, on cultured neonatal mouse testis.","12781204",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"14984707","3,3',4,4',5-Pentachlorobiphenyl (PCB 126) impacts hepatic lipid peroxidation, membrane fluidity and beta-adrenoceptor kinetics in chick embryos.","14984707",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15014209","Induction of CYP1A1 in primary rat hepatocytes by 3,3',4,4',5-pentachlorobiphenyl: evidence for a switch circuit element.","15014209",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15223772","Regional induction of CYP1A1 in rat liver following treatment with mixtures of PCB 126 and PCB 153.","15223772",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15369848","Evaluation of relative potencies of PCB126 and PCB169 for the immunotoxicities in ovalbumin (OVA)-immunized mice.","15369848",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15642632","Cultured gill epithelial cells from tilapia (Oreochromis niloticus): a new in vitro assay for toxicants.","15642632",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15908097","CYP1 and AhR expression in 7,12-dimethylbenz[a]anthracene-induced mammary carcinoma of rats prenatally exposed to 3,3',4,4',5-pentachlorobiphenyl.","15908097",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"15990133","Prenatal 3,3',4,4',5-pentachlorobiphenyl exposure modulates induction of rat hepatic CYP 1A1, 1B1, and AhR by 7,12-dimethylbenz[a]anthracene.","15990133",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16219370","Effects of 17beta-estradiol, 4-nonylphenol and PCB 126 on the estrogenic activity and phase 1 and 2 biotransformation enzymes in male sea bass (Dicentrarchus labrax).","16219370",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16289341","The chlorinated AHR ligand 3,3',4,4',5-pentachlorobiphenyl (PCB126) promotes reactive oxygen species (ROS) production during embryonic development in the killifish (Fundulus heteroclitus).","16289341",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2006,"16313980","Comparison of hepatic and extra hepatic induction of cytochrome P4501A by graded doses of aryl hydrocarbon receptor agonists in Atlantic tomcod from two populations.","16313980",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16339789","Effect of PCB 126 on hepatic metabolism of thyroxine and perturbations in the hypothalamic-pituitary-thyroid axis in the rat.","16339789",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16749683","Effects of deBDE and PCB-126 on hepatic concentrations of PBDEs and methoxy-PBDEs in Atlantic tomcod.","16749683",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16983182","Effects of vertically transferred 3,3',4,4',5-pentachlorobiphenyl (PCB-126) on the reproductive development of female rats.","16983182",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"17089722","Exposure to 3,3',4,4',5-pentachlorobiphenyl during embryonic development has a minimal effect on the cytochrome P4501A response to 2,3,7,8-tetrachlorodibenzo-p-dioxin in cultured chicken embryo hepatocytes.","17089722",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17445853","Basal and 3,3',4,4',5-pentachlorobiphenyl-induced expression of cytochrome P450 1A, 1B and 1C genes in zebrafish.","17445853",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17446141","Activity patterns of biotransformation enzymes in juvenile chickens after in ovo dosage of PCB126.","17446141",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17511620","Co-planar 3,3',4,4',5-pentachlorinated biphenyl and non-co-planar 2,2',4,6,6'-pentachlorinated biphenyl differentially induce recruitment of oestrogen receptor alpha to aryl hydrocarbon receptor target genes.","17511620",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17557910","Tumor necrosis factor-alpha modulates effects of aryl hydrocarbon receptor ligands on cell proliferation and expression of cytochrome P450 enzymes in rat liver \"stem-like\" cells.","17557910",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"17763880","Effects of diazinon on mummichog (Fundulus heteroclitus) larvae produced from eggs differentially treated with PCB126.","17763880",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"18098034","Pulmonary lesions in female Harlan Sprague-Dawley rats following two-year oral treatment with dioxin-like compounds.","18098034",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18786521","Coplanar polychlorinated biphenyl-induced CYP1A1 is regulated through caveolae signaling in vascular endothelial cells.","18786521",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19103147","Cytochrome P450 1D1: a novel CYP1A-related gene that is not transcriptionally activated by PCB126 or TCDD.","19103147",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19553035","PCB126 enhanced the genotoxicity of BaP in HepG2 cells by modulating metabolic enzyme and DNA repair activities.","19553035",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20170748","Effects of the dioxin-like PCB 126 on larval summer flounder (Paralichthys dentatus).","20170748",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20702594","Automated dose-response analysis and comparative toxicogenomic evaluation of the hepatic effects elicited by TCDD, TCDF, and PCB126 in C57BL/6 mice.","20702594",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20819910","Analysis of the CYP1A1 mRNA dose-response in human keratinocytes indicates that relative potencies of dioxins, furans, and PCBs are species and congener specific.","20819910",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"20946947","Precision-Cut Liver Slices of Salmo salar as a tool to investigate the oxidative impact of CYP1A-mediated PCB 126 and 3-methylcholanthrene metabolism.","20946947",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21258071","Structural basis of species differences between human and experimental animal CYP1A1s in metabolism of 3,3',4,4',5-pentachlorobiphenyl.","21258071",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21349578","Embryonic exposure to environmentally relevant concentrations of PCB126 affect prey capture ability of Fundulus heteroclitus larvae.","21349578",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21354474","Cytochrome P450 1A, 1B, and 1C mRNA induction patterns in three-spined stickleback exposed to a transient and a persistent inducer.","21354474",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21543048","Characterization and expression of cytochrome P4501A in Atlantic sturgeon and shortnose sturgeon experimentally exposed to coplanar PCB 126 and TCDD.","21543048",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21803134","Gene expression and inducibility of the aryl hydrocarbon receptor-dependent pathway in cultured bovine blood lymphocytes.","21803134",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21865291","Dietary selenium as a modulator of PCB 126-induced hepatotoxicity in male Sprague-Dawley rats.","21865291",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22410624","Effects of polychlorinated biphenyls on whole animal energy mobilization and hepatic cellular respiration in rainbow trout, Oncorhynchus mykiss.","22410624",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22521609","EGCG protects endothelial cells against PCB 126-induced inflammation through inhibition of AhR and induction of Nrf2-regulated genes.","22521609",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"23036320","Ahr2-dependence of PCB126 effects on the swim bladder in relation to expression of CYP1 and cox-2 genes in developing zebrafish.","23036320",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"23121874","Activation of the Ahr signalling pathway by polychlorobiphenyls causes a marked induction of cytochrome P450 only after depletion of vitellogenin in Sparus aurata.","23121874",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23314333","Relative potency of PCB126 to TCDD for sublethal embryotoxicity in the mummichog (Fundulus heteroclitus).","23314333",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23457121","Biological and tumor-promoting effects of dioxin-like and non-dioxin-like polychlorinated biphenyls in mouse liver after single or combined treatment.","23457121",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"23644946","Dietary antioxidants (selenium and N-acetylcysteine) modulate paraoxonase 1 (PON1) in PCB 126-exposed rats.","23644946",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"24003986","Compound- and mixture-specific differences in resistance to polycyclic aromatic hydrocarbons and PCB-126 among Fundulus heteroclitus subpopulations throughout the Elizabeth River estuary (Virginia, USA).","24003986",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24355420","Hypoxia perturbs aryl hydrocarbon receptor signaling and CYP1A1 expression induced by PCB 126 in human skin and liver-derived cell lines.","24355420",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24619315","Ethoxyresorufin-O-deethylase (EROD) induction by TCDD, PeCDF and PCB 126 in bobwhite quail hepatocytes.","24619315",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24773490","Ethoxyresorufin-O-deethylase (EROD) activity modulation of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 3,3',4,4',5-pentachlorobiphenyl (PCB 126) in the presence of aqueous suspensions of nano-C60.","24773490",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"25099626","Developmental toxicity, EROD, and CYP1A mRNA expression in zebrafish embryos exposed to dioxin-like PCB126.","25099626",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"25116688","Epigenetic determinants of CYP1A1 induction by the aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl (PCB 126).","25116688",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2015,"25304490","PCB126 inhibits adipogenesis of human preadipocytes.","25304490",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25433332","The inflammation and estrogen metabolism impacts of polychlorinated biphenyls on endometrial cancer cells.","25433332",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26752525","Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland.","26752525",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26803990","Exposure to sublethal levels of PCB-126 impacts fuel metabolism and swimming performance in rainbow trout.","26803990",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1411,B1411)","v":"3,4,5,3',4'-pentachlorobiphenyl"},"3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1411,K1411)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2018,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1411,Q1411)","v":"29091793"},"Differential sensitivities to dioxin-like compounds PCB 126 and PeCDF between Tg(cyp1a:gfp) transgenic medaka and zebrafish larvae.","29091793",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7624895","Effects of gestational and lactational exposure to coplanar polychlorinated biphenyl (PCB) congeners or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on thyroid hormone concentrations in weanling rats.","7624895",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7672011","Subchronic effects of 2,3,7,8-TCDD or PCBs on thyroid hormone metabolism: use in risk assessment.","7672011",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8048064","Toxic potency of 3,3',4,4',5-pentachlorobiphenyl relative to and in combination with 2,3,7,8-tetrachlorodibenzo-p-dioxin in a subchronic feeding study in the rat.","8048064",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9169061","Comparative toxicity of polychlorinated biphenyls to Japanese quail (Coturnix c. japonica) and American kestrels (Falco sparverius).","9169061",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9388007","Ethoxyresorufin-O-deethylase (EROD) inducing potencies of planar chlorinated aromatic hydrocarbons in primary cultures of hepatocytes from different developmental stages of the chicken.","9388007",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9772103","Tributyltin modulates 3,3',4,4',5-pentachlorobiphenyl (PCB-126)-induced hepatic CYP1A activity in channel catfish, Ictalurus punctatus.","9772103",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9772211","Interactive effects of three structurally different polychlorinated biphenyls in a rat liver tumor promotion bioassay.","9772211",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9829560","Interaction of tributyltin with 3,3',4,4',5-pentachlorobiphenyl-induced ethoxyresorufin O-deethylase activity in rat hepatoma cells.","9829560",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1999,"10604864","A highly toxic coplanar polychlorinated biphenyl compound suppresses Delta5 and Delta6 desaturase activities which play key roles in arachidonic acid synthesis in rat liver.","10604864",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"22824115","N-acetylcysteine (NAC) diminishes the severity of PCB 126-induced fatty liver in male rodents.","22824115",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2016,"26396156","PCB126-Induced Disruption in Gluconeogenesis and Fatty Acid Oxidation Precedes Fatty Liver in Male Rats.","26396156",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2015,"26410179","Progression of micronutrient alteration and hepatotoxicity following acute PCB126 exposure.","26410179",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"27796995","Liver metabolic disruption induced after a single exposure to PCB126 in rats.","27796995",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2017,"28163111","A compromised liver alters polychlorinated biphenyl-mediated toxicity.","28163111",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,1999,"10604864","A highly toxic coplanar polychlorinated biphenyl compound suppresses Delta5 and Delta6 desaturase activities which play key roles in arachidonic acid synthesis in rat liver.","10604864",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2007,"16858609","A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice.","16858609",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,1995,"7628801","[Alteration of peroxisomal enzyme activities in the liver of guinea pigs caused by coplanar PCB].","7628801",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2016,"26396156","PCB126-Induced Disruption in Gluconeogenesis and Fatty Acid Oxidation Precedes Fatty Liver in Male Rats.","26396156",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2004,"15014209","Induction of CYP1A1 in primary rat hepatocytes by 3,3',4,4',5-pentachlorobiphenyl: evidence for a switch circuit element.","15014209",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15908097","CYP1 and AhR expression in 7,12-dimethylbenz[a]anthracene-induced mammary carcinoma of rats prenatally exposed to 3,3',4,4',5-pentachlorobiphenyl.","15908097",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"15990133","Prenatal 3,3',4,4',5-pentachlorobiphenyl exposure modulates induction of rat hepatic CYP 1A1, 1B1, and AhR by 7,12-dimethylbenz[a]anthracene.","15990133",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2006,"16313980","Comparison of hepatic and extra hepatic induction of cytochrome P4501A by graded doses of aryl hydrocarbon receptor agonists in Atlantic tomcod from two populations.","16313980",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2005,"16552988","Aromatic hydrocarbon receptor (AhR) in the porcine theca and granulosa cells: effect of TCDD, PCB 126 and PCB 153 on the expression of AhR.","16552988",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"16983182","Effects of vertically transferred 3,3',4,4',5-pentachlorobiphenyl (PCB-126) on the reproductive development of female rats.","16983182",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2007,"17316808","The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.","17316808",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2007,"17511620","Co-planar 3,3',4,4',5-pentachlorinated biphenyl and non-co-planar 2,2',4,6,6'-pentachlorinated biphenyl differentially induce recruitment of oestrogen receptor alpha to aryl hydrocarbon receptor target genes.","17511620",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2007,"17557910","Tumor necrosis factor-alpha modulates effects of aryl hydrocarbon receptor ligands on cell proliferation and expression of cytochrome P450 enzymes in rat liver \"stem-like\" cells.","17557910",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2007,"17686920","Role of AHR2 in the expression of novel cytochrome P450 1 family genes, cell cycle genes, and morphological defects in developing zebra fish exposed to 3,3',4,4',5-pentachlorobiphenyl or 2,3,7,8-tetrachlorodibenzo-p-dioxin.","17686920",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2008,"18155262","Activation of estrogen receptor signaling by the dioxin-like aryl hydrocarbon receptor agonist, 3,3',4,4',5-pentachlorobiphenyl (PCB126) in salmon in vitro system.","18155262",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2008,"18378297","Estrogenic effect of dioxin-like aryl hydrocarbon receptor (AhR) agonist (PCB congener 126) in salmon hepatocytes.","18378297",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18786521","Coplanar polychlorinated biphenyl-induced CYP1A1 is regulated through caveolae signaling in vascular endothelial cells.","18786521",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2009,"19515436","New cytochrome P450 1B1, 1C2 and 1D1 genes in the killifish Fundulus heteroclitus: Basal expression and response of five killifish CYP1s to the AHR agonist PCB126.","19515436",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2009,"19692669","Divergent transcriptomic responses to aryl hydrocarbon receptor agonists between rat and human primary hepatocytes.","19692669",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20605646","AHR2 mediates cardiac teratogenesis of polycyclic aromatic hydrocarbons and PCB-126 in Atlantic killifish (Fundulus heteroclitus).","20605646",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20959002","Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: identification of genomic biomarkers of exposure to AhR ligands.","20959002",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"20965207","New CYP1 genes in the frog Xenopus (Silurana) tropicalis: induction patterns and effects of AHR agonists during development.","20965207",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21330491","Mechanistic basis of resistance to PCBs in Atlantic tomcod from the Hudson River.","21330491",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21354474","Cytochrome P450 1A, 1B, and 1C mRNA induction patterns in three-spined stickleback exposed to a transient and a persistent inducer.","21354474",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21513769","Effects of PCB126 and 17β-oestradiol on endothelium-derived vasoactive factors in human endothelial cells.","21513769",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21613231","Genetic architecture of susceptibility to PCB126-induced developmental cardiotoxicity in zebrafish.","21613231",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"21733895","Common mechanism underlies repeated evolution of extreme pollution tolerance.","21733895",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21803134","Gene expression and inducibility of the aryl hydrocarbon receptor-dependent pathway in cultured bovine blood lymphocytes.","21803134",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21865291","Dietary selenium as a modulator of PCB 126-induced hepatotoxicity in male Sprague-Dawley rats.","21865291",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21970748","Species difference in the regulation of cytochrome P450 2S1: lack of induction in rats by the aryl hydrocarbon receptor agonist PCB126.","21970748",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22262711","Inflammatory pathway genes belong to major targets of persistent organic pollutants in adipose cells.","22262711",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22521609","EGCG protects endothelial cells against PCB 126-induced inflammation through inhibition of AhR and induction of Nrf2-regulated genes.","22521609",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22615911","PCB 126 and other dioxin-like PCBs specifically suppress hepatic PEPCK expression via the aryl hydrocarbon receptor.","22615911",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2012,"22824115","N-acetylcysteine (NAC) diminishes the severity of PCB 126-induced fatty liver in male rodents.","22824115",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2012,"23036320","Ahr2-dependence of PCB126 effects on the swim bladder in relation to expression of CYP1 and cox-2 genes in developing zebrafish.","23036320",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"23121874","Activation of the Ahr signalling pathway by polychlorobiphenyls causes a marked induction of cytochrome P450 only after depletion of vitellogenin in Sparus aurata.","23121874",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"23644946","Dietary antioxidants (selenium and N-acetylcysteine) modulate paraoxonase 1 (PON1) in PCB 126-exposed rats.","23644946",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23933504","Global DNA hypermethylation is associated with high serum levels of persistent organic pollutants in an elderly population.","23933504",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23994337","Comparisons of differential gene expression elicited by TCDD, PCB126, βNF, or ICZ in mouse hepatoma Hepa1c1c7 cells and C57BL/6 mouse liver.","23994337",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"24003986","Compound- and mixture-specific differences in resistance to polycyclic aromatic hydrocarbons and PCB-126 among Fundulus heteroclitus subpopulations throughout the Elizabeth River estuary (Virginia, USA).","24003986",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"24084256","Knockdown of AHR1A but not AHR1B exacerbates PAH and PCB-126 toxicity in zebrafish (Danio rerio) embryos.","24084256",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24355420","Hypoxia perturbs aryl hydrocarbon receptor signaling and CYP1A1 expression induced by PCB 126 in human skin and liver-derived cell lines.","24355420",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24530184","Application of lipid extracts from Solidago canadensis to phytomonitoring of PCB126 in transgenic Arabidopsis plants.","24530184",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"25060310","Role of AHR, AHRR and ARNT in response to dioxin-like PCBs in Spaurus aurata.","25060310",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2014,"25116688","Epigenetic determinants of CYP1A1 induction by the aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl (PCB 126).","25116688",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"25209921","Amino acid sequence of the AhR1 ligand-binding domain predicts avian sensitivity to dioxin like compounds: in vivo verification in European starlings.","25209921",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25216468","Dose- and time-dependent expression of aryl hydrocarbon receptor (AhR) and aryl hydrocarbon receptor nuclear translocator (ARNT) in PCB-, B[a]P-, and TBT-exposed intertidal copepod Tigriopus japonicus.","25216468",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25433332","The inflammation and estrogen metabolism impacts of polychlorinated biphenyls on endometrial cancer cells.","25433332",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26325326","Regulation of Ahr signaling by Nrf2 during development: Effects of Nrf2a deficiency on PCB126 embryotoxicity in zebrafish (Danio rerio).","26325326",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1475,B1475)","v":"3,4,5,3',4'-pentachlorobiphenyl"},"3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1475,K1475)","v":"Receptors, Aryl Hydrocarbon"},"D018336","Receptors, Aryl Hydrocarbon",1,1,2015,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1475,Q1475)","v":"26363503"},"Effect of PCB 126 on aryl hydrocarbon receptor 1 (AHR1) and AHR1 nuclear translocator 1 (ARNT1) mRNA expression and CYP1 monooxygenase activity in chicken (Gallus domesticus) ovarian follicles.","26363503",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26396156","PCB126-Induced Disruption in Gluconeogenesis and Fatty Acid Oxidation Precedes Fatty Liver in Male Rats.","26396156",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2015,"26410179","Progression of micronutrient alteration and hepatotoxicity following acute PCB126 exposure.","26410179",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26449762","Absorption of PCB126 by upper airways impairs G protein-coupled receptor-mediated immune response.","26449762",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2016,"26616910","Delayed effects of developmental exposure to low levels of the aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl (PCB126) on adult zebrafish behavior.","26616910",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26752525","Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland.","26752525",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26967026","Assessment of the Mitigative Capacity of Dietary Zinc on PCB126 Hepatotoxicity and the Contribution of Zinc to Toxicity.","26967026",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1988,"2833182","Potentially hazardous residues of non-ortho chlorine substituted coplanar PCBs in human adipose tissue.","2833182",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1995,"7672011","Subchronic effects of 2,3,7,8-TCDD or PCBs on thyroid hormone metabolism: use in risk assessment.","7672011",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1998,"9772103","Tributyltin modulates 3,3',4,4',5-pentachlorobiphenyl (PCB-126)-induced hepatic CYP1A activity in channel catfish, Ictalurus punctatus.","9772103",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1998,"9829560","Interaction of tributyltin with 3,3',4,4',5-pentachlorobiphenyl-induced ethoxyresorufin O-deethylase activity in rat hepatoma cells.","9829560",57]
["3,4,5,3',4'-pentachlorobiphenyl","3,4,5,3',4'-pentachlorobiphenyl","C023035","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18786521","Coplanar polychlorinated biphenyl-induced CYP1A1 is regulated through caveolae signaling in vascular endothelial cells.","18786521",57]
["3,4-dichloroaniline","3,4-dichloroaniline","C014464","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20398795","Effects of 3,4-dichloroaniline on expression of ahr2 and cyp1a1 in zebrafish adults and embryos.","20398795",57]
["3,4-dichloroaniline","3,4-dichloroaniline","C014464","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20398795","Effects of 3,4-dichloroaniline on expression of ahr2 and cyp1a1 in zebrafish adults and embryos.","20398795",57]
["3',4'-dihydroxy-5,6,7,8-tetramethoxyflavone","3',4'-dihydroxy-5,6,7,8-tetramethoxyflavone","C547849","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2010,"19833227","Nobiletin metabolite, 3',4'-dihydroxy-5,6,7,8-tetramethoxyflavone, inhibits LDL oxidation and down-regulates scavenger receptor expression and activity in THP-1 cells.","19833227",57]
["3',4'-dihydroxy-5,6,7,8-tetramethoxyflavone","3',4'-dihydroxy-5,6,7,8-tetramethoxyflavone","C547849","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"19833227","Nobiletin metabolite, 3',4'-dihydroxy-5,6,7,8-tetramethoxyflavone, inhibits LDL oxidation and down-regulates scavenger receptor expression and activity in THP-1 cells.","19833227",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2017,"28395666","Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice.","28395666",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,2017,"28395666","Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice.","28395666",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11929315","Comparison of radical scavenging effect, inhibition of microsomal oxygen free radical generation, and serum lipoprotein oxidation of several natural antioxidants.","11929315",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15168036","Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial.","15168036",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17683140","New insights into controversies on the antioxidant potential of the olive oil antioxidant hydroxytyrosol.","17683140",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20045462","Human absorption of a supplement containing purified hydroxytyrosol, a natural antioxidant from olive oil, and evidence for its transient association with low-density lipoproteins.","20045462",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20516254","Antioxidant activities of hydroxytyrosol main metabolites do not contribute to beneficial health effects after olive oil ingestion.","20516254",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"26434322","Differential partitioning of antioxidants, including hydroxytyrosol, in human plasma and LDL: implications for their antioxidant activity in vivo.","26434322",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27006237","Hydroxytyrosol in functional hydroxytyrosol-enriched biscuits is highly bioavailable and decreases oxidised low density lipoprotein levels in humans.","27006237",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27648880","Effects of hydroxytyrosol on cardiovascular biomarkers in experimental diabetes mellitus.","27648880",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7514253","Protection of low-density lipoprotein from oxidation by 3,4-dihydroxyphenylethanol.","7514253",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26807847","Effects of Silicon vs. Hydroxytyrosol-Enriched Restructured Pork on Liver Oxidation Status of Aged Rats Fed High-Saturated/High-Cholesterol Diets.","26807847",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27012627","Hydroxytyrosol prevents metabolic impairment reducing hepatic inflammation and restoring duodenal integrity in a rat model of NAFLD.","27012627",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28386616","Molecular adaptations underlying the beneficial effects of hydroxytyrosol in the pathogenic alterations induced by a high-fat diet in mouse liver: PPAR-α and Nrf2 activation, and NF-κB down-regulation.","28386616",57]
["3,4-dihydroxyphenylethanol","3,4-dihydroxyphenylethanol","C005975","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"28395666","Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice.","28395666",57]
["3,4-dihydroxyphenyllactic acid","3,4-dihydroxyphenyllactic acid","C035055","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2016,"27514857","Danshensu Promotes Cholesterol Efflux in RAW264.7 Macrophages.","27514857",57]
["3,4-dihydroxyphenyllactic acid","3,4-dihydroxyphenyllactic acid","C035055","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19623993","[Effects of danshensu on function of EPCs which were damaged by Ox-LDL and study its possible mechanism].","19623993",57]
["3,4-dihydroxyphenyllactic acid","3,4-dihydroxyphenyllactic acid","C035055","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27514857","Danshensu Promotes Cholesterol Efflux in RAW264.7 Macrophages.","27514857",57]
["3',4'-dimethoxy-alpha-naphthoflavone","3',4'-dimethoxy-alpha-naphthoflavone","C557505","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2011,"21127131","Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3',4'-dimethoxy-α-naphthoflavone.","21127131",57]
["3',4'-dimethoxy-alpha-naphthoflavone","3',4'-dimethoxy-alpha-naphthoflavone","C557505","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22553215","Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure.","22553215",57]
["3',4'-dimethoxyflavone","3',4'-dimethoxyflavone","C509288","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16484233","Inhibition of benzo[a]pyrene-activating enzymes and DNA binding in human bronchial epithelial BEAS-2B cells by methoxylated flavonoids.","16484233",57]
["3',4'-dimethoxyflavone","3',4'-dimethoxyflavone","C509288","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20466593","Aryl hydrocarbon receptor antagonists attenuate the deleterious effects of benzo[a]pyrene on isolated rat follicle development.","20466593",57]
["3,4-di-O-caffeoylquinic acid","3,4-di-O-caffeoylquinic acid","C478100","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2005,"16176146","In vivo antihepatotoxic effects of Ligularia fischeri var. spiciformis and the identification of the active component, 3,4-dicaffeoylquinic acid.","16176146",57]
["3,4-dixydroxyphenylethanol elenolic acid","3,4-dixydroxyphenylethanol elenolic acid","C121925","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1999,"10496414","Antioxidant activity of 3,4-DHPEA-EA and protocatechuic acid: a comparative assessment with other olive oil biophenols.","10496414",57]
["3,5 dimethylpyrazole-peroxy-vanadate","3,5 dimethylpyrazole-peroxy-vanadate","C000621804","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2017,"28072841","A Small Insulinomimetic Molecule Also Improves Insulin Sensitivity in Diabetic Mice.","28072841",57]
["3,5,3',4',5'-pentamethoxystilbene","3,5,3',4',5'-pentamethoxystilbene","C494914","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15513897","Potent inhibition of recombinant human cytochrome p-450 1A1 by pentamethoxystilbene.","15513897",57]
["3,5-dibromo-2-(2,4-dibromophenoxy)phenol","3,5-dibromo-2-(2,4-dibromophenoxy)phenol","C085794","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2012,"22954249","Dioxin-like potency of HO- and MeO- analogues of PBDEs' the potential risk through consumption of fish from eastern China.","22954249",57]
["3,5-dibromo-4-nitrosobenzenesulfonate","3,5-dibromo-4-nitrosobenzenesulfonate","C048757","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1322177","Direct modification of low density lipoprotein by the spin trap 3,5-dibromo-4-nitrosobenzenesulfonic acid.","1322177",57]
["3,5-dibromo-4-nitrosobenzenesulfonate","3,5-dibromo-4-nitrosobenzenesulfonate","C048757","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8804984","A water soluble C-nitroso-aromatic spin-trap-3,5-dibromo-4-nitrosobenzenesulphonic acid. \"The Perkins spin-trap'.","8804984",57]
["3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine","3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine","C030826","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7763287","Inactivation of chick embryo hepatic cytochrome P450 1A, 2H and 3A following in ovo administration of 3,5-diethoxycarbonyl-1,4-dihydro-2,6-dimethyl-4-ethylpyridine and 3-[2-(2,4,6-trimethylphenyl)thioethyl]-4-methylsydnone.","7763287",57]
["3,5-diethoxycarbonyl-1,4-dihydrocollidine","3,5-diethoxycarbonyl-1,4-dihydrocollidine","C530773","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"22449798","Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model.","22449798",57]
["3,5-dihydroxy-4'-methoxystilbene","3,5-dihydroxy-4'-methoxystilbene","C439024","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17440990","Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers.","17440990",57]
["3,5-dihydroxystilbene","3,5-dihydroxystilbene","C510000","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2011,"20464549","In vivo and in vitro mixed-function oxygenase activity and vitellogenin induction in fish and in fish and rat liver cells by stilbenes isolated from scotch pine (Pinus sylvestris).","20464549",57]
["3,5-dimethylpyrazole","3,5-dimethylpyrazole","C027635","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2009,"19419245","Stimulation of autophagy by antilipolytic drugs may rescue rodents from age-associated hypercholesterolemia.","19419245",57]
["3,5-di-O-galloyl-4-O-digalloylquinic acid","3,5-di-O-galloyl-4-O-digalloylquinic acid","C061725","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12747734","Antioxidant activity of galloyl quinic derivatives isolated from P. lentiscus leaves.","12747734",57]
["3,5-di-O-galloyl-4-O-digalloylquinic acid","3,5-di-O-galloyl-4-O-digalloylquinic acid","C061725","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16809011","Antioxidant activity of caffeoyl quinic acid derivatives from the roots of Dipsacus asper Wall.","16809011",57]
["3,6,24-trihydroxy-24,24-bis(trifluoromethyl)cholane","3,6,24-trihydroxy-24,24-bis(trifluoromethyl)cholane","C532886","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18723776","Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.","18723776",57]
["3,6,24-trihydroxy-24,24-bis(trifluoromethyl)cholane","3,6,24-trihydroxy-24,24-bis(trifluoromethyl)cholane","C532886","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2008,"18723776","Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.","18723776",57]
["3,6,24-trihydroxy-24,24-bis(trifluoromethyl)cholane","3,6,24-trihydroxy-24,24-bis(trifluoromethyl)cholane","C532886","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18723776","Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.","18723776",57]
["3,6,9,12,15-octadecapentaenoic acid","3,6,9,12,15-octadecapentaenoic acid","C432384","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2001,"11269695","Cultured fish cells metabolize octadecapentaenoic acid (all-cis delta3,6,9,12,15-18:5) to octadecatetraenoic acid (all-cis delta6,9,12,15-18:4) via its 2-trans intermediate (trans delta2, all-cis delta6,9,12,15-18:5).","11269695",57]
["3,6-dichlorocarbazole","3,6-dichlorocarbazole","C558653","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"20890770","Degradative fate of 3-chlorocarbazole and 3,6-dichlorocarbazole in soil.","20890770",57]
["3,6-dichlorocarbazole","3,6-dichlorocarbazole","C558653","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27479457","The fingerprints of dioxin-like bromocarbazoles and chlorocarbazoles in selected forest soils in Germany.","27479457",57]
["3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one","3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one","C026423","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19469472","Dissimilar in vitro and in vivo effects of ellagic acid and its microbiota-derived metabolites, urolithins, on the cytochrome P450 1A1.","19469472",57]
["3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one","3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one","C026423","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27060359","Urolithin A attenuates ox-LDL-induced endothelial dysfunction partly by modulating microRNA-27 and ERK/PPAR-γ pathway.","27060359",57]
["3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","C019132","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10967320","Toxicity of Trp-P-2 to cultured human and rat keratinocytes.","10967320",57]
["3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","C019132","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11005680","CYP1A-dependent activation of xenobiotics in endothelial linings of the chorioallantoic membrane (CAM) in birds.","11005680",57]
["3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","C019132","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8187073","Metabolic activation of the food mutagen 3-amino-1,4-dimethyl-5H-pyrido-[4,3-b]indole (Trp-P-1) in endothelial cells of cytochrome P-450-induced mice.","8187073",57]
["3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","C019132","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9708879","Induction of ethoxyresorufin O-deethylase (EROD) and endothelial activation of the heterocyclic amine Trp-P-1 in bird embryo hearts.","9708879",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1539,B1539)","v":"3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole"},"3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole","C019132","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1539,K1539)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,1998,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1539,Q1539)","v":"9772093"},"Localization of cytochrome P4501A1 and covalent binding of a mutagenic heterocyclic amine in blood vessel endothelia of rodents.","9772093",57]
["3-amino-1-methyl-5H-pyrido(4,3-b)indole","3-amino-1-methyl-5H-pyrido(4,3-b)indole","C019133","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11473383","Recombinant human P450 forms 1A1, 1A2, and 1B1 catalyze the bioactivation of heterocyclic amine mutagens in Escherichia coli lacZ strains.","11473383",57]
["3-amino-1-methyl-5H-pyrido(4,3-b)indole","3-amino-1-methyl-5H-pyrido(4,3-b)indole","C019133","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12680239","Effect of high sucrose diet on cytochrome P450 1A and heterocyclic amine mutagenesis.","12680239",57]
["3-amino-1-methyl-5H-pyrido(4,3-b)indole","3-amino-1-methyl-5H-pyrido(4,3-b)indole","C019133","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12744663","Protection against Trp-P-2 DNA adduct formation in C57bl6 mice by purpurin is accompanied by induction of cytochrome P450.","12744663",57]
["3-amino-2-oxazolidinone","3-amino-2-oxazolidinone","C000209","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23774039","Repeated treatment with furazolidone induces multiple cytochrome p450-related activities in chicken liver, but not in rat liver.","23774039",57]
["3-aminobenzamide","3-aminobenzamide","C025160","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1988,"2829739","3-Aminobenzamide inhibits poly(ADP ribose) synthetase activity and induces phosphoenolpyruvate carboxykinase (GTP) in H4IIE hepatoma cells.","2829739",57]
["3-aminobenzamide","3-aminobenzamide","C025160","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1998,"9578465","Repression of phosphoenolpyruvate carboxykinase gene activity by insulin is blocked by 3-aminobenzamide but not by PD128763, a selective inhibitor of poly(ADP-ribose) polymerase.","9578465",57]
["3-aminobenzanthrone","3-aminobenzanthrone","C475568","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15310241","3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2.","15310241",57]
["3-aminobenzanthrone","3-aminobenzanthrone","C475568","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17477947","The environmental carcinogen 3-nitrobenzanthrone and its main metabolite 3-aminobenzanthrone enhance formation of reactive oxygen intermediates in human A549 lung epithelial cells.","17477947",57]
["3-aminobenzanthrone","3-aminobenzanthrone","C475568","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2008,"18329153","The environmental pollutant and carcinogen 3-nitrobenzanthrone induces cytochrome P450 1A1 and NAD(P)H:quinone oxidoreductase in rat lung and kidney, thereby enhancing its own genotoxicity.","18329153",57]
["3-aminobenzanthrone","3-aminobenzanthrone","C475568","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19398038","3-aminobenzanthrone, a human metabolite of the carcinogenic environmental pollutant 3-nitrobenzanthrone, induces biotransformation enzymes in rat kidney and lung.","19398038",57]
["3-aminobenzanthrone","3-aminobenzanthrone","C475568","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21167309","Induction of biotransformation enzymes by the carcinogenic air-pollutant 3-nitrobenzanthrone in liver, kidney and lung, after intra-tracheal instillation in rats.","21167309",57]
["3-aminobenzanthrone","3-aminobenzanthrone","C475568","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"19941874","3-Nitrobenzanthrone and 3-aminobenzanthrone induce DNA damage and cell signalling in Hepa1c1c7 cells.","19941874",57]
["3-aminopicolinic acid","3-aminopicolinic acid","C018451","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1985,"4004920","Effects of the hyperglycaemic agent 3-aminopicolinate on amino acid release by rat muscle in vitro.","4004920",57]
["3-aminopicolinic acid","3-aminopicolinic acid","C018451","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1984,"6725275","3-Aminopicolinate inhibits phosphoenolpyruvate carboxykinase in hepatocytes and increases release of gluconeogenic precursors from peripheral tissues.","6725275",57]
["3-aminopicolinic acid","3-aminopicolinic acid","C018451","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1981,"7271880","Effect of 3-aminopicolinic acid on renal ammoniagenesis in the rat.","7271880",57]
["3-aminopicolinic acid","3-aminopicolinic acid","C018451","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1980,"7362645","Phosphoenolpyruvate carboxykinase: effects of the hyperglycaemic agent 3-aminopicolinic acid.","7362645",57]
["3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one","3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one","C553471","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24980430","An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E⁻/⁻ mice.","24980430",57]
["3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine","3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine","C511179","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16603125","Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells.","16603125",57]
["3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","C006261","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8827526","Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol transport.","8827526",57]
["3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","C006261","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1991,"1885589","Characterization of Chinese hamster ovary cells that are resistant to 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one inhibition of low density lipoprotein-derived cholesterol metabolism.","1885589",57]
["3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","C006261","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1989,"2745416","The intracellular transport of low density lipoprotein-derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one.","2745416",57]
["3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one","C006261","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1999,"9973239","U18666A inhibits intracellular cholesterol transport and neurotransmitter release in human neuroblastoma cells.","9973239",57]
["3-carboxy-11-(2,4-dichlorophenyl)-3,5-dihydroxyundecanoic acid","3-carboxy-11-(2,4-dichlorophenyl)-3,5-dihydroxyundecanoic acid","C114593","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9733484","ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.","9733484",57]
["3-chloro-2-methyl-N-(4-(2-(4-methyl-1-piperazinyl)-2-oxoethyl)-1,3-thiazol-2-yl)benzenesulfonamide","3-chloro-2-methyl-N-(4-(2-(4-methyl-1-piperazinyl)-2-oxoethyl)-1,3-thiazol-2-yl)benzenesulfonamide","C474501","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2002,"12436336","Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice.","12436336",57]
["3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone","3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone","C054121","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7624869","Altered enzyme activities of xenobiotic biotransformation in kidneys after subchronic administration of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) to rats.","7624869",57]
["3-chlorocarbazole","3-chlorocarbazole","C558654","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"20890770","Degradative fate of 3-chlorocarbazole and 3,6-dichlorocarbazole in soil.","20890770",57]
["3-chlorocarbazole","3-chlorocarbazole","C558654","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27479457","The fingerprints of dioxin-like bromocarbazoles and chlorocarbazoles in selected forest soils in Germany.","27479457",57]
["3'-demethylnobiletin","3'-demethylnobiletin","C515880","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2007,"18806314","Suppressive effects of demethylated metabolites of nobiletin on phorbol ester-induced expression of scavenger receptor genes in THP-1 human monocytic cells.","18806314",57]
["3'-deoxy-4-O-methylepisappanol","3'-deoxy-4-O-methylepisappanol","C548568","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20105050","Antioxidant properties of benzylchroman derivatives from Caesalpinia sappan L. against oxidative stress evaluated in vitro.","20105050",57]
["3-deoxyglycero-galacto-nonulosonic acid","3-deoxyglycero-galacto-nonulosonic acid","C050008","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9860259","Unconventional antigen retrieval for carbohydrate and protein antigens.","9860259",57]
["3-hydroxy-2-(4-(trifluoromethyl)phenyl)(1,2,3)triazolo(1,5-a)quinolinium","3-hydroxy-2-(4-(trifluoromethyl)phenyl)(1,2,3)triazolo(1,5-a)quinolinium","C587352","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2012,"23000282","Fused mesoionic heterocyclic compounds are a new class of aryl hydrocarbon receptor (AhR) agonist of exceptional potency.","23000282",57]
["3-hydroxy-3-methyl-1(3H)-isobenzofuranone","3-hydroxy-3-methyl-1(3H)-isobenzofuranone","C104226","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1999,"10532684","Up-regulation of low density lipoprotein receptor by a novel isobenzofranone derivative, MD-700.","10532684",57]
["3-hydroxy-3-methyl-1(3H)-isobenzofuranone","3-hydroxy-3-methyl-1(3H)-isobenzofuranone","C104226","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,2,1999,"10532684","Up-regulation of low density lipoprotein receptor by a novel isobenzofranone derivative, MD-700.","10532684",57]
["3-hydroxy-3-methyl-1(3H)-isobenzofuranone","3-hydroxy-3-methyl-1(3H)-isobenzofuranone","C104226","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10532684","Up-regulation of low density lipoprotein receptor by a novel isobenzofranone derivative, MD-700.","10532684",57]
["3-hydroxy-3-methylbutene","3-hydroxy-3-methylbutene","C027250","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2012,"22194447","Bacterial degradation of tert-amyl alcohol proceeds via hemiterpene 2-methyl-3-buten-2-ol by employing the tertiary alcohol desaturase function of the Rieske nonheme mononuclear iron oxygenase MdpJ.","22194447",57]
["3-hydroxy-5-cholestenoic acid","3-hydroxy-5-cholestenoic acid","C029435","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9630709","Transport of side-chain oxidized oxysterols in the human circulation.","9630709",57]
["3-hydroxy-5-cholestenoic acid","3-hydroxy-5-cholestenoic acid","C029435","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9630709","Transport of side-chain oxidized oxysterols in the human circulation.","9630709",57]
["3-Hydroxyanthranilic Acid","3-Hydroxyanthranilic Acid","D015095","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2012,"22711758","The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice.","22711758",57]
["3-Hydroxyanthranilic Acid","3-Hydroxyanthranilic Acid","D015095","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8955104","3-Hydroxyanthranilic acid is an efficient, cell-derived co-antioxidant for alpha-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation.","8955104",57]
["3-Hydroxyanthranilic Acid","3-Hydroxyanthranilic Acid","D015095","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1975,"1153021","Inhibition of gluconeogenesis in rat renal cortex slices by metabolites of L-tryptophan in vitro.","1153021",57]
["3-hydroxybenzoic acid","3-hydroxybenzoic acid","C032948","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22434674","3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes.","22434674",57]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2008,"18417958","Effect of carnitine deprivation on carnitine homeostasis and energy metabolism in mice with systemic carnitine deficiency.","18417958",57]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"26773702","Serum Beta Hydroxybutyrate Concentrations in Cats with Chronic Kidney Disease, Hyperthyroidism, or Hepatic Lipidosis.","26773702",57]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1983,"6684351","Blood composition and liver fat in post parturient dairy cows.","6684351",57]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2005,"15847825","The relationship of a high level of serum beta-hydroxybutyrate to cause of death.","15847825",57]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2011,"21251339","Young women partition fatty acids towards ketone body production rather than VLDL-TAG synthesis, compared with young men.","21251339",57]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"7150254","Regulation of 3-hydroxybutyrate formation and secretion of very-low-density-lipoprotein triacylglycerol by perfused livers from fed and starved rats.","7150254",57]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2003,"12694916","Enhanced production of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) via manipulating the fatty acid beta-oxidation pathway in E. coli.","12694916",57]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1994,"7907092","Overexpression of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase in transgenic mice causes hepatic hyperketogenesis.","7907092",57]
["3-Hydroxybutyric Acid","3-Hydroxybutyric Acid","D020155","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,2015,"26498829","An Ester of β-Hydroxybutyrate Regulates Cholesterol Biosynthesis in Rats and a Cholesterol Biomarker in Humans.","26498829",57]
["3-hydroxydodecanoic acid","3-hydroxydodecanoic acid","C022145","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,2,2010,"20399795","Disturbance of mitochondrial energy homeostasis caused by the metabolites accumulating in LCHAD and MTP deficiencies in rat brain.","20399795",57]
["3-hydroxydodecanoic acid","3-hydroxydodecanoic acid","C022145","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2014,"24946182","Mitochondrial bioenergetics deregulation caused by long-chain 3-hydroxy fatty acids accumulating in LCHAD and MTP deficiencies in rat brain: a possible role of mPTP opening as a pathomechanism in these disorders?","24946182",57]
["3-hydroxyflavone","3-hydroxyflavone","C041477","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24375494","Analysis of flavonoids regulating the expression of UGT1A1 via xenobiotic receptors in intestinal epithelial cells.","24375494",57]
["3-hydroxyisovalerylcarnitine","3-hydroxyisovalerylcarnitine","C098116","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2001,"11849623","Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS.","11849623",57]
["3-hydroxylanost-7-en-15-one","3-hydroxylanost-7-en-15-one","C091763","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7840615","15-substituted lanosterols: post-transcriptional suppressors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.","7840615",57]
["3-hydroxylanost-7-en-15-one 15-oxime","3-hydroxylanost-7-en-15-one 15-oxime","C091764","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7840615","15-substituted lanosterols: post-transcriptional suppressors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.","7840615",57]
["3-hydroxypalmitic acid","3-hydroxypalmitic acid","C108229","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2010,"20381565","Long-chain 3-hydroxy fatty acids accumulating in LCHAD and MTP deficiencies induce oxidative stress in rat brain.","20381565",57]
["3-hydroxypalmitic acid","3-hydroxypalmitic acid","C108229","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2014,"24946182","Mitochondrial bioenergetics deregulation caused by long-chain 3-hydroxy fatty acids accumulating in LCHAD and MTP deficiencies in rat brain: a possible role of mPTP opening as a pathomechanism in these disorders?","24946182",57]
["3-hydroxypalmitic acid","3-hydroxypalmitic acid","C108229","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2015,"26408230","Deregulation of mitochondrial functions provoked by long-chain fatty acid accumulating in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial permeability transition deficiencies in rat heart--mitochondrial permeability transition pore opening as a potential contributing pathomechanism of cardiac alterations in these disorders.","26408230",57]
["3-hydroxypalmitic acid","3-hydroxypalmitic acid","C108229","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2016,"27371118","Disturbance of mitochondrial functions provoked by the major long-chain 3-hydroxylated fatty acids accumulating in MTP and LCHAD deficiencies in skeletal muscle.","27371118",57]
["3-hydroxypyridine","3-hydroxypyridine","C023500","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10860547","Comparative induction of CYP1A1 expression by pyridine and its metabolites.","10860547",57]
["3-hydroxypyridine","3-hydroxypyridine","C023500","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12147272","CYP1A1 induction by pyridine and its metabolites in HepG2 cells.","12147272",57]
["3-hydroxypyridine","3-hydroxypyridine","C023500","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8644130","Comparison of the effects of pyridine and its metabolites on rat liver and kidney.","8644130",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1603,B1603)","v":"3-hydroxypyridine"},"3-hydroxypyridine","C023500","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1603,K1603)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,2005,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1603,Q1603)","v":"16250637"},"Lipid-soluble 3-pyridinol antioxidants spare alpha-tocopherol and do not efficiently mediate peroxidation of cholesterol esters in human low-density lipoprotein.","16250637",57]
["3-hydroxypyridine","3-hydroxypyridine","C023500","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"10860547","Comparative induction of CYP1A1 expression by pyridine and its metabolites.","10860547",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1990,"2221921","Inhibition of phosphoenolpyruvate carboxykinase from Trypanosoma (Schizotrypanum) cruzi epimastigotes by 3-mercaptopicolinic acid: in vitro and in vivo studies.","2221921",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1990,"2405699","Glucose kinetics in gluconeogenesis-inhibited rats during rest and exercise.","2405699",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,2015,"26322521","Inhibition and Allosteric Regulation of Monomeric Phosphoenolpyruvate Carboxykinase by 3-Mercaptopicolinic Acid.","26322521",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,2016,"27391465","Inhibition of Pig Phosphoenolpyruvate Carboxykinase Isoenzymes by 3-Mercaptopicolinic Acid and Novel Inhibitors.","27391465",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1985,"2992516","Hormonal regulation of fat esterification &amp; oxidation in hepatocytes from fed rats: modulation by 3-mercaptopicolinate.","2992516",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1983,"6225676","Fasciola hepatica: inhibition of phosphoenolpyruvate carboxykinase, and end-product formation by quinolinic acid and 3-mercaptopicolinic acid.","6225676",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1984,"6469453","3-Mercaptopicolinic acid and energy metabolism in the liver fluke, Fasciola hepatica.","6469453",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1983,"6619135","3-Mercaptopicolinate. A reversible active site inhibitor of avian liver phosphoenolpyruvate carboxykinase.","6619135",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1983,"6679346","Direction of carbon flux in starvation and after refeeding: in vitro and in vivo effects of 3-mercaptopicolinate.","6679346",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1981,"7213768","Inhibition of phosphoenolpyruvate carboxykinase, glyceroneogenesis and fatty acid synthesis in rat adipose tissue by quinolinate and 3-mercaptopicolinate.","7213768",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1981,"7306575","The disposition of citric acid cycle intermediates by isolated rat heart mitochondria.","7306575",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1980,"7407681","Inhibition of renal gluconeogenesis and phosphoenolpyruvate carboxykinase activity by 3-mercaptopicolinic acid: studies in rat, guinea pig, dog, rabbit, and man.","7407681",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1995,"7654019","Hypoglycemia with glycerol salvage: a role in anti-neoplastic therapy?","7654019",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1993,"8246682","The indirect pathway of hepatic glycogen synthesis and reduction of food intake by metabolic inhibitors.","8246682",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1993,"8398068","Inhibition of glucose-6-phosphate phosphohydrolase by 3-mercaptopicolinate and two analogs is metabolically directive.","8398068",57]
["3-mercaptopicolinic acid","3-mercaptopicolinic acid","C008363","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1998,"9671114","Effects of 3-mercaptopicolinic acid and a derivative of chlorogenic acid (S-3483) on hepatic and islet glucose-6-phosphatase activity.","9671114",57]
["3-methoxy-4-aminoazobenzene","3-methoxy-4-aminoazobenzene","C044436","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1987,"3302669","Co-induction of cytochrome P-450 isozymes in rat liver by 2,4,5,2',4',5'-hexachlorobiphenyl or 3-methoxy-4-aminoazobenzene.","3302669",57]
["3-methoxy-4'-methylthiostilbene","3-methoxy-4'-methylthiostilbene","C000601815","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18435436","Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities.","18435436",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17324381","beta-Naphthoflavone and 3'-methoxy-4'-nitroflavone exert ambiguous effects on Ah receptor-dependent cell proliferation and gene expression in rat liver 'stem-like' cells.","17324381",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1999,"10426807","Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor.","10426807",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10825463","Effect of 3'-methoxy-4'-nitroflavone on benzo[a]pyrene toxicity. Aryl hydrocarbon receptor-dependent and -independent mechanisms.","10825463",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2003,"12859983","3'-methoxy-4'-nitroflavone, a reported aryl hydrocarbon receptor antagonist, enhances Cyp1a1 transcription by a dioxin responsive element-dependent mechanism.","12859983",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7840652","Identification of 3'-methoxy-4'-nitroflavone as a pure aryl hydrocarbon (Ah) receptor antagonist and evidence for more than one form of the nuclear Ah receptor in MCF-7 human breast cancer cells.","7840652",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8866830","Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists.","8866830",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2003,"12859983","3'-methoxy-4'-nitroflavone, a reported aryl hydrocarbon receptor antagonist, enhances Cyp1a1 transcription by a dioxin responsive element-dependent mechanism.","12859983",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1999,"10426807","Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor.","10426807",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"10825463","Effect of 3'-methoxy-4'-nitroflavone on benzo[a]pyrene toxicity. Aryl hydrocarbon receptor-dependent and -independent mechanisms.","10825463",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2001,"11353134","In vivo antagonism of AhR-mediated gene induction by 3'-methoxy-4'-nitroflavone in TCDD-responsive lacZ mice.","11353134",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2003,"12668121","The aryl hydrocarbon receptor antagonist, 3'methoxy-4'nitroflavone, attenuates 2,3,7,8-tetrachlorodibenzo-p-dioxin-dependent regulation of growth factor signaling and apoptosis in the MCF-10A cell line.","12668121",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2007,"17324381","beta-Naphthoflavone and 3'-methoxy-4'-nitroflavone exert ambiguous effects on Ah receptor-dependent cell proliferation and gene expression in rat liver 'stem-like' cells.","17324381",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2008,"18294953","Molecular determinants of species-specific agonist and antagonist activity of a substituted flavone towards the aryl hydrocarbon receptor.","18294953",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,1995,"7840652","Identification of 3'-methoxy-4'-nitroflavone as a pure aryl hydrocarbon (Ah) receptor antagonist and evidence for more than one form of the nuclear Ah receptor in MCF-7 human breast cancer cells.","7840652",57]
["3'-methoxy-4'-nitroflavone","3'-methoxy-4'-nitroflavone","C091768","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,1996,"8866830","Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists.","8866830",57]
["3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid","3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid","C049113","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,2,2013,"22676331","Thromboxane inhibitors attenuate inflammatory and fibrotic changes in rat liver despite continued ethanol administrations.","22676331",57]
["3-methyladenine","3-methyladenine","C025946","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27906187","Systemic application of 3-methyladenine markedly inhibited atherosclerotic lesion in ApoE-/- mice by modulating autophagy, foam cell formation and immune-negative molecules.","27906187",57]
["3-methylethergalangin","3-methylethergalangin","C480203","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12808299","3-Methylethergalangin isolated from Alpinia officinarum inhibits pancreatic lipase.","12808299",57]
["3-methylquercetin","3-methylquercetin","C047368","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16963021","Isorhamnetin prevent endothelial cell injuries from oxidized LDL via activation of p38MAPK.","16963021",57]
["3-methylquercetin","3-methylquercetin","C047368","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16968106","Absorption of flavonols derived from sea buckthorn (Hippophaë rhamnoides L.) and their effect on emerging risk factors for cardiovascular disease in humans.","16968106",57]
["3-methylquercetin","3-methylquercetin","C047368","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17918439","[Inhibitory effect of Isorhamnetin and Hesperidin on LDL oxidation induced by Cu2+].","17918439",57]
["3-methylquercetin","3-methylquercetin","C047368","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2001,"12600108","[The effects of quercetin and isorhamnetin on oxidative modification of VLDL induced by Cu2+].","12600108",57]
["3-methylquercetin","3-methylquercetin","C047368","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26775807","Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency.","26775807",57]
["3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate","3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate","C441128","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"28899902","Pharmacological inhibition of protein tyrosine phosphatase 1B protects against atherosclerotic plaque formation in the LDLR-/- mouse model of atherosclerosis.","28899902",57]
["3-nitrobenzanthrone","3-nitrobenzanthrone","C117220","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15310241","3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2.","15310241",57]
["3-nitrobenzanthrone","3-nitrobenzanthrone","C117220","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17477947","The environmental carcinogen 3-nitrobenzanthrone and its main metabolite 3-aminobenzanthrone enhance formation of reactive oxygen intermediates in human A549 lung epithelial cells.","17477947",57]
["3-nitrobenzanthrone","3-nitrobenzanthrone","C117220","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2008,"18329153","The environmental pollutant and carcinogen 3-nitrobenzanthrone induces cytochrome P450 1A1 and NAD(P)H:quinone oxidoreductase in rat lung and kidney, thereby enhancing its own genotoxicity.","18329153",57]
["3-nitrobenzanthrone","3-nitrobenzanthrone","C117220","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19398038","3-aminobenzanthrone, a human metabolite of the carcinogenic environmental pollutant 3-nitrobenzanthrone, induces biotransformation enzymes in rat kidney and lung.","19398038",57]
["3-nitrobenzanthrone","3-nitrobenzanthrone","C117220","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21167309","Induction of biotransformation enzymes by the carcinogenic air-pollutant 3-nitrobenzanthrone in liver, kidney and lung, after intra-tracheal instillation in rats.","21167309",57]
["3-nitrobenzanthrone","3-nitrobenzanthrone","C117220","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"19941874","3-Nitrobenzanthrone and 3-aminobenzanthrone induce DNA damage and cell signalling in Hepa1c1c7 cells.","19941874",57]
["3-nitroperylene","3-nitroperylene","C035987","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1984,"6329540","Short-term bioassays of nitro derivatives of benzo[a]pyrene and perylene.","6329540",57]
["3-O-(1-hexadecyl)cholesterol","3-O-(1-hexadecyl)cholesterol","C035237","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,2,2003,"12456719","Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse J774 macrophages: role of scavenger receptors, classes A and B.","12456719",57]
["3'-O-methylepicatechin","3'-O-methylepicatechin","C424450","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11237853","Epicatechin and its in vivo metabolite, 3'-O-methyl epicatechin, protect human fibroblasts from oxidative-stress-induced cell death involving caspase-3 activation.","11237853",57]
["3-phenoxybenzoic acid","3-phenoxybenzoic acid","C017618","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9973180","The metabolism of the xenobiotic triacylglycerols, rac-1- and sn-2- (3-phenoxybenzoyl)-dipalmitoylglycerol, following intravenous administration to the rat.","9973180",57]
["3-phenylpropyl isothiocyanate","3-phenylpropyl isothiocyanate","C093849","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1996,"9042227","Effects of isothiocyanates on cytochrome P-450 1A1 and 1A2 activity and on the mutagenicity of heterocyclic amines.","9042227",57]
["3-xylene","3-xylene","C031285","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1994,"8296328","Effects of m-xylene on rat nasal cytochrome P450 mixed function oxidase activities.","8296328",57]
["4-(((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)-2-(trifluoromethyl)-3-pyridinyl)methylamino)methyl)benzoic acid","4-(((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)-2-(trifluoromethyl)-3-pyridinyl)methylamino)methyl)benzoic acid","C000598201","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22918042","Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.","22918042",57]
["4-(1-(4-tert-butylphenyl)-2-oxo-4-pyrrolidinyl)methoxybenzoic acid","4-(1-(4-tert-butylphenyl)-2-oxo-4-pyrrolidinyl)methoxybenzoic acid","C482648","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,3,2003,"12809954","Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E.","12809954",57]
["4-(1,1'-biphenyl)-2-hydroxytetronic acid","4-(1,1'-biphenyl)-2-hydroxytetronic acid","C113935","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9714311","Potent inhibitory activities of hydrophobic aci-reductones (2-hydroxytetronic acid analogs) against membrane and human low-density lipoprotein oxidation.","9714311",57]
["4-(1-adamantyloxy)aniline","4-(1-adamantyloxy)aniline","C018807","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"7131490","Hypobetalipoproteinemic agents. 3. Variation of the polycyclic portion of 4-(1-adamantyloxy)aniline.","7131490",57]
["4-(2-(2-(4-chlorophenyl)-5,6-difluorobenzoimidazol-1-yl)-2-cyclohexylacetylamino)-3-fluorobenzoic acid","4-(2-(2-(4-chlorophenyl)-5,6-difluorobenzoimidazol-1-yl)-2-cyclohexylacetylamino)-3-fluorobenzoic acid","C558287","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"21269824","Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.","21269824",57]
["4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid","4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid","C000598200","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22918042","Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.","22918042",57]
["4-(2,4-dichlorophenoxy)butyric acid","4-(2,4-dichlorophenoxy)butyric acid","C004764","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2003,"12682048","Arabidopsis mutants in short- and medium-chain acyl-CoA oxidase activities accumulate acyl-CoAs and reveal that fatty acid beta-oxidation is essential for embryo development.","12682048",57]
["4-(2,4-dichlorophenoxy)butyric acid","4-(2,4-dichlorophenoxy)butyric acid","C004764","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,1998,"9490742","2,4-Dichlorophenoxybutyric acid-resistant mutants of Arabidopsis have defects in glyoxysomal fatty acid beta-oxidation.","9490742",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1667,B1667)","v":"4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol"},"4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol","C556295","1_MIE",18,1,"AHR","Activation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1667,K1667)","v":"Receptors, Aryl Hydrocarbon"},"D018336","Receptors, Aryl Hydrocarbon",1,1,2016,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1667,Q1667)","v":"27183630"},"ERβ in CD4+ T Cells Is Crucial for Ligand-Mediated Suppression of Central Nervous System Autoimmunity.","27183630",57]
["4-(2-propenyl)cholest-24-en-3-ol","4-(2-propenyl)cholest-24-en-3-ol","C121236","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10400383","Synthesis and in vitro biological activity of 4alpha-(2-propenyl)-5alpha-cholest-24-en-3alpha-ol: a 24,25-dehydro analog of the hypocholesterolemic agent 4alpha-(2-propenyl)-5alpha-cholestan-3alpha-ol.","10400383",57]
["4-(2-propenyl)cholest-24-en-3-ol","4-(2-propenyl)cholest-24-en-3-ol","C121236","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10498032","Synthesis and in vitro biological activity of 4alpha-(2-propenyl)-5alpha-cholest-24-en-3alpha,12 alpha-diol, a 12alpha-hydroxyl analog of 4alpha-(2-propenyl)-5alpha-cholest-24-en-3alpha-ol: the latter is a potent activator of the low-density lipoprotein receptor promoter.","10498032",57]
["4-(2-succinimidyloxycarbonylethyl)phenyl-10-methylacridinium-9-carboxylate","4-(2-succinimidyloxycarbonylethyl)phenyl-10-methylacridinium-9-carboxylate","C053333","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8250504","Use of a chemiluminescent acridinium ester label for cellular uptake assay of low density lipoprotein.","8250504",57]
["4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid","4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid","C520164","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2009,"19766624","PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice.","19766624",57]
["4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one","4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one","C557982","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"27885461","Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models.","27885461",57]
["4-(4-(2-(n-butoxy)ethoxy)-5-methylthiazol-2-yl)-2-fluorobenzoic acid","4-(4-(2-(n-butoxy)ethoxy)-5-methylthiazol-2-yl)-2-fluorobenzoic acid","C507711","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27271256","A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.","27271256",57]
["4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","C524106","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2011,"21418994","[Effects of soluble epoxide hydrolase inhibitors on lipid metabolism and secretive functions of adipocytes].","21418994",57]
["4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","C524106","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21078594","Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.","21078594",57]
["4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","C524106","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21418994","[Effects of soluble epoxide hydrolase inhibitors on lipid metabolism and secretive functions of adipocytes].","21418994",57]
["4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","C524106","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24225128","A potent soluble epoxide hydrolase inhibitor, t-AUCB, modulates cholesterol balance and oxidized low density lipoprotein metabolism in adipocytes in vitro.","24225128",57]
["4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid","C524106","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"25733327","Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis.","25733327",57]
["4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol","4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol","C040692","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"23106957","In vitro characterization of the oxidation of a pyridinium metabolite of haloperidol by human placenta: the effect of smoking.","23106957",57]
["4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol","4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol","C525025","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"25801013","SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet.","25801013",57]
["4-(4,6-diphenyl-1,3-dioxan-2-yl)-N,N-dimethylaniline","4-(4,6-diphenyl-1,3-dioxan-2-yl)-N,N-dimethylaniline","C000592353","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2013,"23231652","The constitutive androstane receptor activator 4-[(4R,6R)-4,6-diphenyl-1,3-dioxan-2-yl]-N,N-dimethylaniline inhibits the gluconeogenic genes PEPCK and G6Pase through the suppression of HNF4α and FOXO1 transcriptional activity.","23231652",57]
["4-(4'-chloro-1,1'-biphenyl)-2-hydroxytetronic acid","4-(4'-chloro-1,1'-biphenyl)-2-hydroxytetronic acid","C113938","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9714311","Potent inhibitory activities of hydrophobic aci-reductones (2-hydroxytetronic acid analogs) against membrane and human low-density lipoprotein oxidation.","9714311",57]
["4-(4'-chlorobenzyloxy)benzyl nicotinate","4-(4'-chlorobenzyloxy)benzyl nicotinate","C042413","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"4033362","Effect of KCD-232, a new hypolipidemic agent, on serum lipoprotein changes in hepatoma-bearing rats.","4033362",57]
["4-(4'-chlorobenzyloxy)benzyl nicotinate","4-(4'-chlorobenzyloxy)benzyl nicotinate","C042413","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"4033362","Effect of KCD-232, a new hypolipidemic agent, on serum lipoprotein changes in hepatoma-bearing rats.","4033362",57]
["4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine","4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine","C101091","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1997,"9217286","Metabolic defects caused by treatment with the tetrahydropyridine analog of haloperidol (HPTP), in baboons.","9217286",57]
["4-(4-chlorophenyl)-2-hydroxytetronic acid","4-(4-chlorophenyl)-2-hydroxytetronic acid","C060438","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2747427","Serum lipoprotein and apoprotein concentrations in 4-(4-chlorophenyl)-2-hydroxytetronic acid and clofibrate-treated cholesterol and cholic acid-fed rats.","2747427",57]
["4-(4-chlorophenyl)-2-hydroxytetronic acid","4-(4-chlorophenyl)-2-hydroxytetronic acid","C060438","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9714311","Potent inhibitory activities of hydrophobic aci-reductones (2-hydroxytetronic acid analogs) against membrane and human low-density lipoprotein oxidation.","9714311",57]
["4-(4-chlorophenyl)-2-hydroxytetronic acid","4-(4-chlorophenyl)-2-hydroxytetronic acid","C060438","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2747427","Serum lipoprotein and apoprotein concentrations in 4-(4-chlorophenyl)-2-hydroxytetronic acid and clofibrate-treated cholesterol and cholic acid-fed rats.","2747427",57]
["4-(4-fluorophenyl)-1,3-dithia-2-thioxocyclopent-4-ene","4-(4-fluorophenyl)-1,3-dithia-2-thioxocyclopent-4-ene","C111195","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1997,"9442451","Effect of 1,3-dithia-2-thioxo-cyclopent-4-ene and its derivatives on liver injury induced by carbon tetrachloride and orotic acid in rats.","9442451",57]
["4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole","4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole","C090942","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"14594946","Suppression by p38 MAP kinase inhibitors (pyridinyl imidazole compounds) of Ah receptor target gene activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin and the possible mechanism.","14594946",57]
["4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole","4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole","C090942","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2004,"14594946","Suppression by p38 MAP kinase inhibitors (pyridinyl imidazole compounds) of Ah receptor target gene activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin and the possible mechanism.","14594946",57]
["4-(5-thioxo-5H-1,2-dithiol-3-yl)-phenyl 2-acetoxybenzoate","4-(5-thioxo-5H-1,2-dithiol-3-yl)-phenyl 2-acetoxybenzoate","C571292","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22209714","Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo.","22209714",57]
["4-(6-hydroxy-7-tricyclo(3.3.1.13,7)dec-1-yl-2-naphthalenyl)benzoic acid","4-(6-hydroxy-7-tricyclo(3.3.1.13,7)dec-1-yl-2-naphthalenyl)benzoic acid","C000591478","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27271256","A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.","27271256",57]
["4-(benzylamino)-2-((2-(3-chloro-4-hydroxyphenyl)ethyl)amino)pyrimidine-5-carboxamide","4-(benzylamino)-2-((2-(3-chloro-4-hydroxyphenyl)ethyl)amino)pyrimidine-5-carboxamide","C544923","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2018,"29510393","A STAT6 Inhibitor AS1517499 Reduces Preventive Effects of Apoptotic Cell Instillation on Bleomycin-Induced Lung Fibrosis by Suppressing PPARγ.","29510393",57]
["4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone","4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone","C016583","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27728767","Dihydromethysticin (DHM) Blocks Tobacco Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-Induced O6-Methylguanine in a Manner Independent of the Aryl Hydrocarbon Receptor (AhR) Pathway in C57BL/6 Female Mice.","27728767",57]
["4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone","4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone","C016583","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,2,2015,"25618784","Potential contributions of the tobacco nicotine-derived nitrosamine ketone (NNK) in the pathogenesis of steatohepatitis in a chronic plus binge rat model of alcoholic liver disease.","25618784",57]
["4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone","4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone","C016583","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"27728767","Dihydromethysticin (DHM) Blocks Tobacco Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-Induced O6-Methylguanine in a Manner Independent of the Aryl Hydrocarbon Receptor (AhR) Pathway in C57BL/6 Female Mice.","27728767",57]
["4,4'-diaminodiphenylmethane","4,4'-diaminodiphenylmethane","C009505","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1989,"2618080","Effects of mutagenic and non-mutagenic aniline derivatives on rat liver drug-metabolizing enzymes.","2618080",57]
["4,4'-diaponeurosporene","4,4'-diaponeurosporene","C091058","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2016,"27276712","4,4'-diaponeurosporene, a C30 carotenoid, effectively activates dendritic cells via CD36 and NF-κB signaling in a ROS independent manner.","27276712",57]
["4,4-difluoro-4-bora-3a,4a-diaza-s-indacene","4,4-difluoro-4-bora-3a,4a-diaza-s-indacene","C095489","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2009,"19224547","In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis.","19224547",57]
["4,4-difluoro-4-bora-3a,4a-diaza-s-indacene","4,4-difluoro-4-bora-3a,4a-diaza-s-indacene","C095489","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14567446","Action of DCFH and BODIPY as a probe for radical oxidation in hydrophilic and lipophilic domain.","14567446",57]
["4,4'-dihydroxy-3,3'-dimethoxy-5,5'-biphenyl-1,1'-(diphthalazin-1-yl)methylhydrazone","4,4'-dihydroxy-3,3'-dimethoxy-5,5'-biphenyl-1,1'-(diphthalazin-1-yl)methylhydrazone","C530304","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18465848","Development of novel antiatherogenic biaryls: design, synthesis, and reactivity.","18465848",57]
["4,4'-methylenebis(2,6-di-tert-butylphenol)","4,4'-methylenebis(2,6-di-tert-butylphenol)","C030593","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1981,"7245245","Effects of four bisphenolic antioxidants on lipid contents of rat liver.","7245245",57]
["4,5-di-O-(E)-caffeoylquinic acid","4,5-di-O-(E)-caffeoylquinic acid","C500583","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16809011","Antioxidant activity of caffeoyl quinic acid derivatives from the roots of Dipsacus asper Wall.","16809011",57]
["4,6-dibromo-2-(2',4'-dibromo)phenoxyanisole","4,6-dibromo-2-(2',4'-dibromo)phenoxyanisole","C471837","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15657799","Biological activity and physicochemical parameters of marine halogenated natural products 2,3,3',4,4',5,5'-heptachloro-1'-methyl-1,2'-bipyrrole and 2,4,6-tribromoanisole.","15657799",57]
["4,6-dibromo-2-(2',4'-dibromo)phenoxyanisole","4,6-dibromo-2-(2',4'-dibromo)phenoxyanisole","C471837","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15657799","Biological activity and physicochemical parameters of marine halogenated natural products 2,3,3',4,4',5,5'-heptachloro-1'-methyl-1,2'-bipyrrole and 2,4,6-tribromoanisole.","15657799",57]
["4,7,10-hexadecatrienoic acid","4,7,10-hexadecatrienoic acid","C094145","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2013,"23790547","Characterization of a trifunctional fatty acid desaturase from oleaginous filamentous fungus Mortierella alpina 1S-4 using a yeast expression system.","23790547",57]
["4',7-dihydroxy-3,4-dihydroisoflavone","4',7-dihydroxy-3,4-dihydroisoflavone","C007610","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18955142","Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes.","18955142",57]
["4',7-dihydroxy-3,4-dihydroisoflavone","4',7-dihydroxy-3,4-dihydroisoflavone","C007610","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12726915","The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification.","12726915",57]
["4',7-dihydroxy-3,4-dihydroisoflavone","4',7-dihydroxy-3,4-dihydroisoflavone","C007610","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10917898","Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development in cholesterol-fed rabbits.","10917898",57]
["4',7-dihydroxy-3,4-dihydroisoflavone","4',7-dihydroxy-3,4-dihydroisoflavone","C007610","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16608210","Antioxidant activity of isoflavones and their major metabolites using different in vitro assays.","16608210",57]
["4',7-dihydroxy-3,4-dihydroisoflavone","4',7-dihydroxy-3,4-dihydroisoflavone","C007610","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19638716","Effects of equol on oxidized low-density lipoprotein-induced apoptosis in endothelial cells.","19638716",57]
["4,9,13,17,21-pentamethyldocosa-2,4,6,8,10,12,14,16,20-nonaenoic Acid","4,9,13,17,21-pentamethyldocosa-2,4,6,8,10,12,14,16,20-nonaenoic Acid","C557870","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2011,"21247174","Organic synthesis of new putative lycopene metabolites and preliminary investigation of their cell-signaling effects.","21247174",57]
["4-acetylaminofluorene","4-acetylaminofluorene","C028676","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1993,"8397005","The mutagenicity and interactions of 2- and 4-(acetylamino)fluorene with cytochrome P450 and the aromatic hydrocarbon receptor may explain the difference in their carcinogenic potency.","8397005",57]
["4-acetylaminostilbene","4-acetylaminostilbene","C028520","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1987,"3036390","Induction of the aromatic hydrocarbon receptor by trans-4-acetylaminostilbene in rat liver. Comparison with other aromatic amines.","3036390",57]
["4-amino-alpha,alpha,2-trimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol","4-amino-alpha,alpha,2-trimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol","C095471","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,1995,"7553223","Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609.","7553223",57]
["4-Aminobenzoic Acid","4-Aminobenzoic Acid","D010129","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1956,"13412963","[Acetylation of PAB in cupridihydroporphyrin-treated rats on steatogenic diet].","13412963",57]
["4-aminodiphenylamine","4-aminodiphenylamine","C031506","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22344700","p-Anilinoaniline enhancement of dioxin-induced CYP1A1 transcription and aryl hydrocarbon receptor occupancy of CYP1A1 promoter: role of the cell cycle.","22344700",57]
["4-aminodiphenylamine","4-aminodiphenylamine","C031506","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2012,"22344700","p-Anilinoaniline enhancement of dioxin-induced CYP1A1 transcription and aryl hydrocarbon receptor occupancy of CYP1A1 promoter: role of the cell cycle.","22344700",57]
["4-aminopyrazolo(3,4-d)pyrimidine","4-aminopyrazolo(3,4-d)pyrimidine","C004420","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1985,"4095713","Ultrastructural studies in 4-aminopyrazolopyrimidine (4-APP)-induced fatty liver.","4095713",57]
["4-aminopyrazolo(3,4-d)pyrimidine","4-aminopyrazolo(3,4-d)pyrimidine","C004420","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28465372","Identification of 4-Aminopyrazolopyrimidine Metabolite That May Contribute to the Hypolipidemic Effects of LY2584702 in Long Evans Diet-Induced Obese Rats.","28465372",57]
["4-aminopyrazolo(3,4-d)pyrimidine","4-aminopyrazolo(3,4-d)pyrimidine","C004420","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"7075531","Effect of low density and high density lipoproteins on progesterone secretion by dispersed corpora luteal cells from rats treated with aminopyrazolo-(3,4-d)pyrimidine.","7075531",57]
["4-aminopyrazolo(3,4-d)pyrimidine","4-aminopyrazolo(3,4-d)pyrimidine","C004420","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"7075531","Effect of low density and high density lipoproteins on progesterone secretion by dispersed corpora luteal cells from rats treated with aminopyrazolo-(3,4-d)pyrimidine.","7075531",57]
["4-aminopyrazolo(3,4-d)pyrimidine","4-aminopyrazolo(3,4-d)pyrimidine","C004420","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1996,"8864965","Effect of hypocholesterolemic doses of 17 alpha-ethinyl estradiol on cholesterol balance in liver and extrahepatic tissues.","8864965",57]
["4-aminoquinoline","4-aminoquinoline","C001920","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22594779","Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands.","22594779",57]
["4-biphenylamine","4-biphenylamine","C006757","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19682468","Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutations.","19682468",57]
["4-biphenylamine","4-biphenylamine","C006757","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18989657","Synergism of aromatic amines and benzo[a]pyrene in induction of Ah receptor-dependent genes.","18989657",57]
["4-bromocrotonic acid","4-bromocrotonic acid","C034444","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1982,"7068598","4-Bromocrotonic acid, an effective inhibitor of fatty acid oxidation and ketone body degradation in rat heart mitochondria. On the rate-determining step of beta-oxidation and ketone body degradation in heart.","7068598",57]
["4'-bromoflavone","4'-bromoflavone","C117304","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"9973203","Cancer chemopreventive activity mediated by 4'-bromoflavone, a potent inducer of phase II detoxification enzymes.","9973203",57]
["4-bromomethaqualone","4-bromomethaqualone","C102576","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2001,"11347150","[Microsomal triglyceride transfer protein inhibitor].","11347150",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1731,B1731)","v":"4-bromotiglic acid"},"4-bromotiglic acid","C115522","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1731,K1731)","v":"Mitochondrial Trifunctional Protein"},"D063991","Mitochondrial Trifunctional Protein",1,3,1998,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1731,Q1731)","v":"9799519"},"4-bromotiglic acid, a novel inhibitor of thiolases and a tool for assessing the cooperation between the membrane-bound and soluble beta-oxidation systems of rat liver mitochondria.","9799519",57]
["4-Butyrolactone","4-Butyrolactone","D015107","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24588654","Z-Ligustilide inhibits benzo(a)pyrene-induced CYP1A1 upregulation in cultured human keratinocytes via ROS-dependent Nrf2 activation.","24588654",57]
["4-Butyrolactone","4-Butyrolactone","D015107","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2004,"14736702","Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass.","14736702",57]
["4-Butyrolactone","4-Butyrolactone","D015107","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21836061","Paraoxonase-2 modulates stress response of endothelial cells to oxidized phospholipids and a bacterial quorum-sensing molecule.","21836061",57]
["4-Butyrolactone","4-Butyrolactone","D015107","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24980430","An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E⁻/⁻ mice.","24980430",57]
["4-Butyrolactone","4-Butyrolactone","D015107","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24588654","Z-Ligustilide inhibits benzo(a)pyrene-induced CYP1A1 upregulation in cultured human keratinocytes via ROS-dependent Nrf2 activation.","24588654",57]
["4-Chloro-7-nitrobenzofurazan","4-Chloro-7-nitrobenzofurazan","D009327","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12721293","Uptake and metabolism of low density lipoproteins with elevated ceramide content by human microvascular endothelial cells: implications for the regulation of apoptosis.","12721293",57]
["4-Chloro-7-nitrobenzofurazan","4-Chloro-7-nitrobenzofurazan","D009327","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11971953","High-precision fluorescence assay for sphingomyelinase activity of isolated enzymes and cell lysates.","11971953",57]
["4-Chloro-7-nitrobenzofurazan","4-Chloro-7-nitrobenzofurazan","D009327","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14617145","Internalization of OspA in rsCD14 complex and aggregated forms.","14617145",57]
["4-Chloro-7-nitrobenzofurazan","4-Chloro-7-nitrobenzofurazan","D009327","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"26239480","Characterization of fluorescent NBD‑cholesterol efflux in THP‑1‑derived macrophages.","26239480",57]
["4-Chloro-7-nitrobenzofurazan","4-Chloro-7-nitrobenzofurazan","D009327","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"7276743","Low density lipoproteins reconstituted with steroids containing the nitrobenzoxadiazole fluorophore.","7276743",57]
["4-Chloro-7-nitrobenzofurazan","4-Chloro-7-nitrobenzofurazan","D009327","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8376460","The End2 mutation in CHO cells slows the exit of transferrin receptors from the recycling compartment but bulk membrane recycling is unaffected.","8376460",57]
["4-Chloro-7-nitrobenzofurazan","4-Chloro-7-nitrobenzofurazan","D009327","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8509447","Sorting of membrane components from endosomes and subsequent recycling to the cell surface occurs by a bulk flow process.","8509447",57]
["4-Chloro-7-nitrobenzofurazan","4-Chloro-7-nitrobenzofurazan","D009327","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2003,"12721293","Uptake and metabolism of low density lipoproteins with elevated ceramide content by human microvascular endothelial cells: implications for the regulation of apoptosis.","12721293",57]
["4-chlorobiphenyl","4-chlorobiphenyl","C006983","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16949219","Induction of cytochromes P450, caspase-3 and DNA damage by PCB3 and its hydroxylated metabolites in porcine ovary.","16949219",57]
["4-chlorobiphenyl","4-chlorobiphenyl","C006983","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18953099","A low halogenated biphenyl (PCB3) increases CYP1A1 expression and activity via the estrogen receptor beta in the porcine ovary.","18953099",57]
["4-chlorobiphenyl","4-chlorobiphenyl","C006983","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2008,"18953099","A low halogenated biphenyl (PCB3) increases CYP1A1 expression and activity via the estrogen receptor beta in the porcine ovary.","18953099",57]
["4'-chloroflavone","4'-chloroflavone","C083064","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8866830","Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists.","8866830",57]
["4'-chloroflavone","4'-chloroflavone","C083064","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,1996,"8866830","Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists.","8866830",57]
["4'-demethylnobiletin","4'-demethylnobiletin","C515881","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2007,"18806314","Suppressive effects of demethylated metabolites of nobiletin on phorbol ester-induced expression of scavenger receptor genes in THP-1 human monocytic cells.","18806314",57]
["4-dichlorobenzene","4-dichlorobenzene","C018511","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17593412","Antiestrogenic effect of paradichlorobenzene in immature mice and rats.","17593412",57]
["4-dichlorobenzene","4-dichlorobenzene","C018511","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2007,"17593412","Antiestrogenic effect of paradichlorobenzene in immature mice and rats.","17593412",57]
["4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","C082137","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2006,"16807312","NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs.","16807312",57]
["4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","C082137","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2004,"14767881","Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats.","14767881",57]
["4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","C082137","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2007,"17350593","Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis.","17350593",57]
["4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide","C082137","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16807312","NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs.","16807312",57]
["4-hydroperoxy-2-nonenal","4-hydroperoxy-2-nonenal","C547259","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2016,"26923548","A single aldehyde group can serve as a structural element for recognition by transmembrane protein CD36.","26923548",57]
["4-hydroperoxy-2-nonenal","4-hydroperoxy-2-nonenal","C547259","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21690609","4-Hydroperoxy-2-nonenal is not just an intermediate but a reactive molecule that covalently modifies proteins to generate unique intramolecular oxidation products.","21690609",57]
["4-hydroperoxy-2-nonenal","4-hydroperoxy-2-nonenal","C547259","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26923548","A single aldehyde group can serve as a structural element for recognition by transmembrane protein CD36.","26923548",57]
["4-hydroxy-2-ethyl-5-methyl-3(2H)-furanone","4-hydroxy-2-ethyl-5-methyl-3(2H)-furanone","C112945","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10864016","Inhibition of iron ion-induced oxidative damage of erythrocyte membranes and low density lipoprotein by a Maillard product, 4-hydroxy-2(or 5)-ethyl-5(or 2)-methyl-3(2H)-furanone (HEMF).","10864016",57]
["4-hydroxy-2-hexenal","4-hydroxy-2-hexenal","C045934","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14729859","Protein-bound 4-hydroxy-2-hexenal as a marker of oxidized n-3 polyunsaturated fatty acids.","14729859",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2002,"12127421","Damaged interlobular bile ducts in primary biliary cirrhosis show reduced expression of glutathione-S-transferase-pi and aberrant expression of 4-hydroxynonenal.","12127421",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2007,"17581812","Identification of a serum component that regulates cyclooxygenase-2 gene expression in cooperation with 4-hydroxy-2-nonenal.","17581812",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2009,"19135147","4-Hydroxynonenal enhances CD36 expression on murine macrophages via p38 MAPK-mediated activation of 5-lipoxygenase.","19135147",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2012,"22981873","Potentiation of amyloid-β peptide neurotoxicity in human dental-pulp neuron-like cells by the membrane lipid peroxidation product 4-hydroxynonenal.","22981873",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2014,"25250848","Effects of toxicologically relevant xenobiotics and the lipid-derived electrophile 4-hydroxynonenal on macrophage cholesterol efflux: silencing carboxylesterase 1 has paradoxical effects on cholesterol uptake and efflux.","25250848",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24722988","Identification of 5' AMP-activated kinase as a target of reactive aldehydes during chronic ingestion of high concentrations of ethanol.","24722988",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1997,"9303495","Acetaldehyde-modified and 4-hydroxynonenal-modified proteins in the livers of rats with alcoholic liver disease.","9303495",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10401613","Presence of aldehydic epitopes on a minor low-density lipoprotein fraction.","10401613",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10812084","Detection of lipofuscin-like fluorophore in oxidized human low-density lipoprotein. 4-hydroxy-2-nonenal as a potential source of fluorescent chromophore.","10812084",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10813658","Polyclonal antibodies to a fluorescent 4-hydroxy-2-nonenal (HNE)-derived lysine-lysine cross-link: characterization and application to HNE-treated protein and in vitro oxidized low-density lipoprotein.","10813658",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10898587","HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques.","10898587",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10946210","Role of reactive aldehyde in cardiovascular diseases.","10946210",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11306075","Involvement of aldose reductase in the metabolism of atherogenic aldehydes.","11306075",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11583712","Identification of biochemical pathways for the metabolism of oxidized low-density lipoprotein derived aldehyde-4-hydroxy trans-2-nonenal in vascular smooth muscle cells.","11583712",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12588771","Phospholipid hydroxyalkenals: biological and chemical properties of specific oxidized lipids present in atherosclerotic lesions.","12588771",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1280111","Studies on epitopes on low-density lipoprotein modified by 4-hydroxynonenal. Biochemical characterization and determination.","1280111",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15353344","Mechanisms of alcohol liver damage: aldehydes, scavenger receptors, and autoimmunity.","15353344",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16270277","4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis.","16270277",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16876267","Acceleration of matrix metalloproteinase-1 production and activation of platelet-derived growth factor receptor beta in human coronary smooth muscle cells by oxidized LDL and 4-hydroxynonenal.","16876267",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17581812","Identification of a serum component that regulates cyclooxygenase-2 gene expression in cooperation with 4-hydroxy-2-nonenal.","17581812",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"17643134","Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors.","17643134",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18483467","A lipid-derived endogenous inducer of COX-2: a bridge between inflammation and oxidative stress.","18483467",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1997735","Macrophage uptake of low-density lipoprotein modified by 4-hydroxynonenal. An ultrastructural study.","1997735",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22077443","Identification of 4-hydroxy-2-nonenal-histidine adducts that serve as ligands for human lectin-like oxidized LDL receptor-1.","22077443",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27478848","Oxidative Damage to the Salivary Glands of Rats with Streptozotocin-Induced Diabetes-Temporal Study: Oxidative Stress and Diabetic Salivary Glands.","27478848",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2751482","Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages.","2751482",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28040472","Proatherogenic effects of 4-hydroxynonenal.","28040472",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28057601","Oxysterols and 4-hydroxy-2-nonenal contribute to atherosclerotic plaque destabilization.","28057601",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28192229","HNE as an inducer of COX-2.","28192229",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28456641","Low-density lipoprotein oxidation biomarkers in human health and disease and effects of bioactive compounds.","28456641",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3010955","Interaction of 4-hydroxynonenal-modified low-density lipoproteins with the fibroblast apolipoprotein B/E receptor.","3010955",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3510062","Modification of human low-density lipoprotein by the lipid peroxidation product 4-hydroxynonenal.","3510062",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7626094","4-Hydroxy-2-nonenal-trapping ELISA: direct evidence for the release of a cytotoxic aldehyde from oxidized low density lipoproteins.","7626094",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1795,B1795)","v":"4-hydroxy-2-nonenal"},"4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1795,K1795)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1995,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1795,Q1795)","v":"7668347"},"Biosynthesis and metabolism of 4-hydroxynonenal in canine ceroid-lipofuscinosis.","7668347",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7710102","Quantitative measurement of 4-hydroxyalkenals in oxidized low-density lipoprotein by gas chromatography-mass spectrometry.","7710102",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7749848","Lysine modification of LDL or lipoprotein(a) by 4-hydroxynonenal or malondialdehyde decreases platelet serotonin secretion without affecting platelet aggregability and eicosanoid formation.","7749848",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7918471","Michael addition-type 4-hydroxy-2-nonenal adducts in modified low-density lipoproteins: markers for atherosclerosis.","7918471",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1993,"8371068","Structural and functional changes in LDL after modification with both 4-hydroxynonenal and malondialdehyde.","8371068",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8690078","Cytotoxic and chemotactic potencies of several aldehydic components of oxidised low density lipoprotein for human monocyte-macrophages.","8690078",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8885333","Monoclonal antibodies for detection of 4-hydroxynonenal modified proteins.","8885333",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9733221","The role of (E)-4-hydroxy-2-nonenal in platelet activation by low density lipoprotein and iron.","9733221",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9078279","Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein.","9078279",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2007,"17382197","The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).","17382197",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,"25180626","Binge alcohol consumption aggravates oxidative stress and promotes pathogenesis of NASH from obesity-induced simple steatosis.","25180626",57]
["4-hydroxy-2-nonenal","4-hydroxy-2-nonenal","C027576","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1989,"2751482","Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages.","2751482",57]
["4-hydroxy-2-octenal","4-hydroxy-2-octenal","C046538","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8690078","Cytotoxic and chemotactic potencies of several aldehydic components of oxidised low density lipoprotein for human monocyte-macrophages.","8690078",57]
["4-hydroxyatorvastatin","4-hydroxyatorvastatin","C518964","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2011,"22164412","[The composition of blood lipoproteins of donors 2 hours later after single atorvastatin intake].","22164412",57]
["4-hydroxybutyric acid","4-hydroxybutyric acid","C111420","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1999,"10207820","Treatment of alcoholic fatty liver: is the metabolic effect of metadoxine the only reason for improved liver function?","10207820",57]
["4-hydroxydebrisoquin","4-hydroxydebrisoquin","C012359","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1984,"6391252","Oxidation phenotyping in alcoholics with liver disease of varying severity.","6391252",57]
["4-hydroxyhexenal","4-hydroxyhexenal","C063409","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7710102","Quantitative measurement of 4-hydroxyalkenals in oxidized low-density lipoprotein by gas chromatography-mass spectrometry.","7710102",57]
["4-hydroxyhexenal","4-hydroxyhexenal","C063409","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8690078","Cytotoxic and chemotactic potencies of several aldehydic components of oxidised low density lipoprotein for human monocyte-macrophages.","8690078",57]
["4-hydroxyphenylacetaldehyde","4-hydroxyphenylacetaldehyde","C097891","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11104675","Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions.","11104675",57]
["4-hydroxyphenylacetaldehyde","4-hydroxyphenylacetaldehyde","C097891","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10744670","p-hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima.","10744670",57]
["4-hydroxyphenylacetaldehyde","4-hydroxyphenylacetaldehyde","C097891","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11172805","p-Hydroxyphenylacetaldehyde, the major product of tyrosine oxidation by the activated myeloperoxidase system can act as an antioxidant in LDL.","11172805",57]
["4-hydroxyphenylacetaldehyde","4-hydroxyphenylacetaldehyde","C097891","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1999,"10323775","Modification of type III VLDL, their remnants, and VLDL from ApoE-knockout mice by p-hydroxyphenylacetaldehyde, a product of myeloperoxidase activity, causes marked cholesteryl ester accumulation in macrophages.","10323775",57]
["4-hydroxyphenylethanol","4-hydroxyphenylethanol","C011867","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25496362","Olive oil and its phenolic constituent tyrosol attenuates dioxin-induced toxicity in peripheral blood mononuclear cells via an antioxidant-dependent mechanism.","25496362",57]
["4-hydroxyphenylethanol","4-hydroxyphenylethanol","C011867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1999,"10395586","Tyrosol, the major olive oil biophenol, protects against oxidized-LDL-induced injury in Caco-2 cells.","10395586",57]
["4-hydroxyphenylethanol","4-hydroxyphenylethanol","C011867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15168036","Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial.","15168036",57]
["4-hydroxyphenylethanol","4-hydroxyphenylethanol","C011867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"16928436","Tyrosol, the major extra virgin olive oil compound, restored intracellular antioxidant defences in spite of its weak antioxidative effectiveness.","16928436",57]
["4-hydroxypropranolol","4-hydroxypropranolol","C001422","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14569064","Potent antioxidant properties of 4-hydroxyl-propranolol.","14569064",57]
["4-hydroxypropranolol","4-hydroxypropranolol","C001422","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"4011620","Competitive binding of quinidine, propranolol, and 4-OH-propranolol to human plasma very low-density (VLDL) and low-density (LDL) lipoproteins.","4011620",57]
["4-hydroxypropranolol","4-hydroxypropranolol","C001422","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"4011620","Competitive binding of quinidine, propranolol, and 4-OH-propranolol to human plasma very low-density (VLDL) and low-density (LDL) lipoproteins.","4011620",57]
["4-hydroxypyrazole","4-hydroxypyrazole","C014606","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1998,"9657280","Induction of CYP2A5 by pyrazole and its derivatives in mouse primary hepatocytes.","9657280",57]
["4'-iodoflavone","4'-iodoflavone","C099018","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8866830","Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists.","8866830",57]
["4'-iodoflavone","4'-iodoflavone","C099018","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2002,"12481305","Use of [125I]4'-iodoflavone as a tool to characterize ligand-dependent differences in Ah receptor behavior.","12481305",57]
["4'-iodoflavone","4'-iodoflavone","C099018","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,1996,"8866830","Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists.","8866830",57]
["4-iodopyrazole","4-iodopyrazole","C010201","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1998,"9657280","Induction of CYP2A5 by pyrazole and its derivatives in mouse primary hepatocytes.","9657280",57]
["4-ipomeanol","4-ipomeanol","C001470","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"2384072","Protection against chemical-induced lung injury by inhibition of pulmonary cytochrome P-450.","2384072",57]
["4-ipomeanol","4-ipomeanol","C001470","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7586161","Inhibitory effect of dietary 4-ipomeanol on DNA adduct formation by the food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in male CDF1 mice.","7586161",57]
["4'-MeSO(2)-2,2',4,5,5'-pentachlorobiphenyl","4'-MeSO(2)-2,2',4,5,5'-pentachlorobiphenyl","C472352","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12377985","In vitro antiestrogenic effects of aryl methyl sulfone metabolites of polychlorinated biphenyls and 2,2-bis(4-chlorophenyl)-1,1-dichloroethene on 17beta-estradiol-induced gene expression in several bioassay systems.","12377985",57]
["4'-MeSO(2)-2,2',4,5'-tetrachlorobiphenyl","4'-MeSO(2)-2,2',4,5'-tetrachlorobiphenyl","C472353","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12377985","In vitro antiestrogenic effects of aryl methyl sulfone metabolites of polychlorinated biphenyls and 2,2-bis(4-chlorophenyl)-1,1-dichloroethene on 17beta-estradiol-induced gene expression in several bioassay systems.","12377985",57]
["4'-methoxyflavone","4'-methoxyflavone","C487850","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17709371","Bioavailable flavonoids: cytochrome P450-mediated metabolism of methoxyflavones.","17709371",57]
["4-methyl-7-ethoxycoumarin","4-methyl-7-ethoxycoumarin","C115983","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9784028","Induction of cytochrome P450 1A1 in rat liver slices by 7-ethoxycoumarin and 4-methyl-7-ethoxycoumarin.","9784028",57]
["4-methylene-2-octyl-5-oxofuran-3-carboxylic acid","4-methylene-2-octyl-5-oxofuran-3-carboxylic acid","C406734","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2004,"14736702","Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass.","14736702",57]
["4-nitrophenol","4-nitrophenol","C024836","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2017,"27172127","4-Nitrophenol exposure alters the AhR signaling pathway and related gene expression in the rat liver.","27172127",57]
["4-nitrophenol","4-nitrophenol","C024836","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27235926","Effects of 4-nitrophenol on expression of the ER-α and AhR signaling pathway-associated genes in the small intestine of rats.","27235926",57]
["4-nitrophenol","4-nitrophenol","C024836","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2006,"16510927","[Influence of 4-nitrophenol on some biochemical and morphological indices of rat blood].","16510927",57]
["4-nitrophenol","4-nitrophenol","C024836","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"27878751","Assessment of the relationship between serum paraoxonase activity and epicardial adipose tissue in hemodialysis patients.","27878751",57]
["4-nitrophenol","4-nitrophenol","C024836","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26563031","Long-term p-nitrophenol exposure can disturb liver metabolic cytochrome P450 genes together with aryl hydrocarbon receptor in Japanese quail.","26563031",57]
["4-nitrophenol","4-nitrophenol","C024836","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"27172127","4-Nitrophenol exposure alters the AhR signaling pathway and related gene expression in the rat liver.","27172127",57]
["4-nitrophenol","4-nitrophenol","C024836","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"27235926","Effects of 4-nitrophenol on expression of the ER-α and AhR signaling pathway-associated genes in the small intestine of rats.","27235926",57]
["4-nitrophenyl butyrate","4-nitrophenyl butyrate","C033592","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"4043407","Heparin binding to lipoprotein lipase and low density lipoproteins.","4043407",57]
["4-nitrophenylglucuronide","4-nitrophenylglucuronide","C002730","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10606751","Different induction of gulonolactone oxidase in aromatic hydrocarbon-responsive or -unresponsive mouse strains.","10606751",57]
["4-nitrophenylglucuronide","4-nitrophenylglucuronide","C002730","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1999,"10606751","Different induction of gulonolactone oxidase in aromatic hydrocarbon-responsive or -unresponsive mouse strains.","10606751",57]
["4-nonylphenol","4-nonylphenol","C041594","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2001,"11248424","Suppression of CYP1A1 expression by 4-nonylphenol in murine Hepa-1c1c7 cells.","11248424",57]
["4-nonylphenol","4-nonylphenol","C041594","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15589249","Sparus aurata L. liver EROD and GST activities, plasma cortisol, lactate, glucose and erythrocytic nuclear anomalies following short-term exposure either to 17beta-estradiol (E2) or E2 combined with 4-nonylphenol.","15589249",57]
["4-nonylphenol","4-nonylphenol","C041594","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16219370","Effects of 17beta-estradiol, 4-nonylphenol and PCB 126 on the estrogenic activity and phase 1 and 2 biotransformation enzymes in male sea bass (Dicentrarchus labrax).","16219370",57]
["4-nonylphenol","4-nonylphenol","C041594","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16406821","The xenoestrogen 4-nonylphenol modulates hepatic gene expression of pregnane X receptor, aryl hydrocarbon receptor, CYP3A and CYP1A1 in juvenile Atlantic salmon (Salmo salar).","16406821",57]
["4-nonylphenol","4-nonylphenol","C041594","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23866175","Effects of 4-nonylphenol on hepatic gene expression of peroxisome proliferator-activated receptors and cytochrome P450 isoforms (CYP1A1 and CYP3A4) in juvenile sole (Solea solea).","23866175",57]
["4-nonylphenol","4-nonylphenol","C041594","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23621474","A common environmental pollutant, 4-nonylphenol, promotes allergic lung inflammation in a murine model of asthma.","23621474",57]
["4-nonylphenol","4-nonylphenol","C041594","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2006,"16406821","The xenoestrogen 4-nonylphenol modulates hepatic gene expression of pregnane X receptor, aryl hydrocarbon receptor, CYP3A and CYP1A1 in juvenile Atlantic salmon (Salmo salar).","16406821",57]
["4-octylphenol","4-octylphenol","C080417","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11460683","Modulation of trout 7-ethoxyresorufin-O-deethylase (EROD) activity by estradiol and octylphenol.","11460683",57]
["4-octylphenol","4-octylphenol","C080417","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23555028","Interactions between urinary 4-tert-octylphenol levels and metabolism enzyme gene variants on idiopathic male infertility.","23555028",57]
["4-O-deacetyl vinorelbine","4-O-deacetyl vinorelbine","C520600","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2016,"26629767","Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells.","26629767",57]
["4-O-methylhonokiol","4-O-methylhonokiol","C542058","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24991305","The magnolia bioactive constituent 4-O-methylhonokiol protects against high-fat diet-induced obesity and systemic insulin resistance in mice.","24991305",57]
["4-oxofenretinide","4-oxofenretinide","C494898","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2017,"28448568","Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.","28448568",57]
["4-pentenoic acid","4-pentenoic acid","C009785","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1981,"7305999","Metabolism of pent-4-enoate in rat heart. Reduction of the double bond.","7305999",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1859,B1859)","v":"4-pentenoic acid"},"4-pentenoic acid","C009785","12_KE",462,12,"SCD-1","Increased",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1859,K1859)","v":"Fatty Acid Desaturases"},"D044943","Fatty Acid Desaturases",2,2,1980,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1859,Q1859)","v":"7396904"},"In vivo induction of 4-enoyl-CoA reductase by clofibrate in liver mitochondria and its effect on pent-4-enoate metabolism.","7396904",57]
["4-pentenoic acid","4-pentenoic acid","C009785","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1980,"7461116","Increased 4-enoyl-CoA reductase activity in liver mitochondria of rats fed high-fed diets and its effect on fatty acid oxidation and the inhibitory action of pent-4-enoate.","7461116",57]
["4-pentenoic acid","4-pentenoic acid","C009785","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1990,"2240462","The effect of L-carnitine supplementation in 4 pentenoic acid treated rats.","2240462",57]
["4-pentenoic acid","4-pentenoic acid","C009785","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1990,"2260472","Microvesicular fatty liver in rats with resembling Reye's syndrome induced by 4-pentenoic acid.","2260472",57]
["4-pentenoic acid","4-pentenoic acid","C009785","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1984,"6712730","Inhibition of mitochondrial fatty acid oxidation in pentenoic acid-induced fatty liver. A possible model for Reye's syndrome.","6712730",57]
["4-pentenoic acid","4-pentenoic acid","C009785","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1995,"7548749","Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.","7548749",57]
["4-phenyl-1,3-dithia-2-thioxocyclopent-4-ene","4-phenyl-1,3-dithia-2-thioxocyclopent-4-ene","C111194","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1997,"9442451","Effect of 1,3-dithia-2-thioxo-cyclopent-4-ene and its derivatives on liver injury induced by carbon tetrachloride and orotic acid in rats.","9442451",57]
["4-phenyl-3-butyn-2-one","4-phenyl-3-butyn-2-one","C454401","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11901095","Reductive metabolism of an alpha,beta-ketoalkyne, 4-phenyl-3-butyn-2-one, by rat liver preparations.","11901095",57]
["4-phenyl-5,5-dicarbethoxy-2-pyrrolidinone","4-phenyl-5,5-dicarbethoxy-2-pyrrolidinone","C041986","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1992,"1329835","The effects on lipid metabolism of 4-phenyl-5,5-dicarbethoxy-2-pyrrolidenone in Sprague Dawley rats.","1329835",57]
["4-phenylbutyric acid","4-phenylbutyric acid","C075773","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19502591","Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis.","19502591",57]
["4-phenylbutyric acid","4-phenylbutyric acid","C075773","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"24042997","The chemical chaperon 4-phenylbutyric acid ameliorates hepatic steatosis through inhibition of de novo lipogenesis in high-fructose-fed rats.","24042997",57]
["4-phenylbutyric acid","4-phenylbutyric acid","C075773","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,2007,"17408384","4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor.","17408384",57]
["4-phenylbutyric acid","4-phenylbutyric acid","C075773","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"29024862","4-phenylbutyrate and valproate treatment attenuates the progression of atherosclerosis and stabilizes existing plaques.","29024862",57]
["4-tert-octylphenol","4-tert-octylphenol","C105260","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23555028","Interactions between urinary 4-tert-octylphenol levels and metabolism enzyme gene variants on idiopathic male infertility.","23555028",57]
["4'-trifluoromethyl-2,3,4,5-tetrachlorobiphenyl","4'-trifluoromethyl-2,3,4,5-tetrachlorobiphenyl","C091911","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"7853359","Differential modulation of hepatic cytochrome P-450 enzymes in rat and Syrian hamster by 4'-trifluoromethyl-2,3,4,5-tetrachlorobiphenyl.","7853359",57]
["4-trifluoromethyl-7,8-pyranocoumarin","4-trifluoromethyl-7,8-pyranocoumarin","C000602647","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2015,"26222195","A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2.","26222195",57]
["4-vinyl-1-cyclohexene dioxide","4-vinyl-1-cyclohexene dioxide","C012606","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15710172","Differences between rats and mice in the involvement of the aryl hydrocarbon receptor in 4-vinylcyclohexene diepoxide-induced ovarian follicle loss.","15710172",57]
["4-vinylcyclohexene","4-vinylcyclohexene","C013733","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2003,"12488331","Bax, caspase-2, and caspase-3 are required for ovarian follicle loss caused by 4-vinylcyclohexene diepoxide exposure of female mice in vivo.","12488331",57]
["4-vinylphenyl boronic acid","4-vinylphenyl boronic acid","C427523","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12460405","In vitro evaluation of newly developed adsorbent for selective removal of glycosylated low-density lipoprotein.","12460405",57]
["4-xylene","4-xylene","C031286","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"2384072","Protection against chemical-induced lung injury by inhibition of pulmonary cytochrome P-450.","2384072",57]
["5-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid","5-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid","C524722","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"19122336","Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68.","19122336",57]
["5-((5-bromo-1H-indol-3-yl)methylene)-3-(4-chlorobenzyl)thiazolidine-2,4-dione","5-((5-bromo-1H-indol-3-yl)methylene)-3-(4-chlorobenzyl)thiazolidine-2,4-dione","C583084","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"25869519","New indole-thiazolidine attenuates atherosclerosis in LDLr(-/-) mice.","25869519",57]
["5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol","5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol","C571829","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2017,"28595996","Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.","28595996",57]
["5-(3,4-dihydroxyphenyl)-1-piperidin-1-yl-penta-2,4-dien-1-one","5-(3,4-dihydroxyphenyl)-1-piperidin-1-yl-penta-2,4-dien-1-one","C000607169","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"26214461","Effect of GBOT on blood lipid and blood glucose metabolism in rats with atherosclerosis.","26214461",57]
["5-(3,5-di-tert-butyl-4-hydroxybenzylidene)thiazolidine-2,4-dione","5-(3,5-di-tert-butyl-4-hydroxybenzylidene)thiazolidine-2,4-dione","C507175","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20684827","Anti-atherogenic effect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice.","20684827",57]
["5-(3-methyl-1-triazeno)imidazole-4-carboxamide","5-(3-methyl-1-triazeno)imidazole-4-carboxamide","C010243","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10473105","Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1.","10473105",57]
["5-(4-(1-(4-(difluoromethoxy)benzoyl)piperidin-4-yloxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione","5-(4-(1-(4-(difluoromethoxy)benzoyl)piperidin-4-yloxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione","C577950","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"23025244","Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.","23025244",57]
["5-(4-(1-(4-(difluoromethoxy)benzoyl)piperidin-4-yloxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione","5-(4-(1-(4-(difluoromethoxy)benzoyl)piperidin-4-yloxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione","C577950","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2012,"23025244","Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.","23025244",57]
["5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","C581247","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25875942","LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).","25875942",57]
["5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","C581247","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27349145","Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).","27349145",57]
["5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","C581247","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"22795892","Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR(-/-)).","22795892",57]
["5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","C581247","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"25875942","LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).","25875942",57]
["5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","5-(4-chlorobenzylidene)-3-(4-methylbenzyl)thiazolidine-2,4-dione","C581247","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"27693798","Chronic LPSF/GQ-02 treatment attenuates inflammation and atherosclerosis development in LDLr-/- mice.","27693798",57]
["5-(4-dimethylaminobenzoyl)-aminovaleric acid hydroxamate","5-(4-dimethylaminobenzoyl)-aminovaleric acid hydroxamate","C521334","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18358644","Differential effects of hydroxamate histone deacetylase inhibitors on cellular functionality and gap junctions in primary cultures of mitogen-stimulated hepatocytes.","18358644",57]
["5-(4-hydroxy-2,5-dimethylphenoxy)-2,2-dimethyl pentanoic acid","5-(4-hydroxy-2,5-dimethylphenoxy)-2,2-dimethyl pentanoic acid","C407182","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10778872","Gemfibrozil metabolite inhibits in vitro low-density lipoprotein (LDL) oxidation and diminishes cytotoxicity induced by oxidized LDL.","10778872",57]
["5-(5-bromo-2-methoxybenzylidene)-3-(4-methyl-benzyl)thiazolidine-2,4-dione","5-(5-bromo-2-methoxybenzylidene)-3-(4-methyl-benzyl)thiazolidine-2,4-dione","C576055","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"22795892","Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR(-/-)).","22795892",57]
["5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline","5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline","C517687","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24648300","M30 does not predict the severity of hepatosteatosis, whereas adiponectin level declined with increase of ALT and the severity of hepatic steatosis.","24648300",57]
["5,10,15,20-tetrakis(4-methoxyphenyl)porphyrin","5,10,15,20-tetrakis(4-methoxyphenyl)porphyrin","C445706","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12504271","Physiological parameters and biodistribution of 5,10,15,20-tetra (4-methoxyphenyl) porphyrin in rats.","12504271",57]
["5,10,15,20-tetraphenyl-1-3-(4-(4-aminobutyl)-7-chloroquinoline)propioamidoporphine","5,10,15,20-tetraphenyl-1-3-(4-(4-aminobutyl)-7-chloroquinoline)propioamidoporphine","C064271","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1990,"2111393","Synthesis, cellular uptake of, and cell photosensitization by a porphyrin bearing a quinoline group.","2111393",57]
["5,11-methenyltetrahydrohomofolate","5,11-methenyltetrahydrohomofolate","C032418","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2005,"15957251","Effect of homocysteine, folates, and cobalamin on endothelial cell- and copper-induced LDL oxidation.","15957251",57]
["5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate","5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate","C434605","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18981301","Inhibition of protein kinase Cbeta prevents foam cell formation by reducing scavenger receptor A expression in human macrophages.","18981301",57]
["5,5'-bis-trifluoromethyl-2,2'-dichlorobiphenyl","5,5'-bis-trifluoromethyl-2,2'-dichlorobiphenyl","C107005","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9217306","Modulation of cytochrome P450 by 5,5'-bis-trifluoromethyl-2,2'-dichlorobiphenyl, a unique environmental contaminant.","9217306",57]
["5,5'-dibutoxy-2,2'-bifuran","5,5'-dibutoxy-2,2'-bifuran","C530807","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18481011","Heterocyclic compounds from Chrysanthemum coronarium L. and their inhibitory activity on hACAT-1, hACAT-2, and LDL-oxidation.","18481011",57]
["5,6,11,12,17,18-hexahydrocyclononatriindole","5,6,11,12,17,18-hexahydrocyclononatriindole","C074140","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7867998","Regulation of hepatic cytochrome P4501A by indole-3-carbinol: transient induction with continuous feeding in rainbow trout.","7867998",57]
["5,6,11,12,17,18-hexahydrocyclononatriindole","5,6,11,12,17,18-hexahydrocyclononatriindole","C074140","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"10653634","The major cyclic trimeric product of indole-3-carbinol is a strong agonist of the estrogen receptor signaling pathway.","10653634",57]
["5,6-epoxycholesterol","5,6-epoxycholesterol","C119784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10371147","Major differences in oxysterol formation in human low density lipoproteins (LDLs) oxidized by *OH/O2*- free radicals or by copper.","10371147",57]
["5,6-secosterol","5,6-secosterol","C479527","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14605372","Evidence for ozone formation in human atherosclerotic arteries.","14605372",57]
["5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one","5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one","C080669","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2018,"29476730","Oroxylin A prevents alcohol-induced hepatic steatosis through inhibition of hypoxia inducible factor 1alpha.","29476730",57]
["5,7-dimethoxyflavone","5,7-dimethoxyflavone","C060298","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15661813","5,7-Dimethoxyflavone downregulates CYP1A1 expression and benzo[a]pyrene-induced DNA binding in Hep G2 cells.","15661813",57]
["5,7-dimethoxyflavone","5,7-dimethoxyflavone","C060298","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16484233","Inhibition of benzo[a]pyrene-activating enzymes and DNA binding in human bronchial epithelial BEAS-2B cells by methoxylated flavonoids.","16484233",57]
["5,7-dimethoxyflavone","5,7-dimethoxyflavone","C060298","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17709371","Bioavailable flavonoids: cytochrome P450-mediated metabolism of methoxyflavones.","17709371",57]
["5,7-dimethoxyflavone","5,7-dimethoxyflavone","C060298","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27828718","5,7-Dimethoxyflavone Attenuates Obesity by Inhibiting Adipogenesis in 3T3-L1 Adipocytes and High-Fat Diet-Induced Obese C57BL/6J Mice.","27828718",57]
["5,8,11,14-Eicosatetraynoic Acid","5,8,11,14-Eicosatetraynoic Acid","D015117","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1979,"106197","The effect of 5,8,11,14-eicosatetraynoic acid on lipid metabolism.","106197",57]
["5,8,11,14-Eicosatetraynoic Acid","5,8,11,14-Eicosatetraynoic Acid","D015117","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2000,"10827210","Regulation of hepatic delta-6 desaturase expression and its role in the polyunsaturated fatty acid inhibition of fatty acid synthase gene expression in mice.","10827210",57]
["5,8,11,14-Eicosatetraynoic Acid","5,8,11,14-Eicosatetraynoic Acid","D015117","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,2000,"10827210","Regulation of hepatic delta-6 desaturase expression and its role in the polyunsaturated fatty acid inhibition of fatty acid synthase gene expression in mice.","10827210",57]
["5,8-tetradecadienoic acid","5,8-tetradecadienoic acid","C108157","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1997,"9250615","Conversion of arachidonic acid to tetradecadienoic acid by peroxisomal oxidation.","9250615",57]
["5,9,12-octadecatrienoic acid","5,9,12-octadecatrienoic acid","C034302","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2006,"16267098","A front-end desaturase from Chlamydomonas reinhardtii produces pinolenic and coniferonic acids by omega13 desaturation in methylotrophic yeast and tobacco.","16267098",57]
["5,9,12-octadecatrienoic acid","5,9,12-octadecatrienoic acid","C034302","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2004,"15357026","Selective increase in pinolenic acid (all-cis-5,9,12-18:3) in Korean pine nut oil by crystallization and its effect on LDL-receptor activity.","15357026",57]
["5,9,12-octadecatrienoic acid","5,9,12-octadecatrienoic acid","C034302","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"27084371","Pinolenic Acid Downregulates Lipid Anabolic Pathway in HepG2 Cells.","27084371",57]
["5,9,12-octadecatrienoic acid","5,9,12-octadecatrienoic acid","C034302","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2016,"27084371","Pinolenic Acid Downregulates Lipid Anabolic Pathway in HepG2 Cells.","27084371",57]
["5,9-dimethyldibenzo(c,g)carbazole","5,9-dimethyldibenzo(c,g)carbazole","C039387","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16406433","7H-Dibenzo[c,g]carbazole and 5,9-dimethyldibenzo[c,g]carbazole exert multiple toxic events contributing to tumor promotion in rat liver epithelial 'stem-like' cells.","16406433",57]
["5,9-dimethyldibenzo(c,g)carbazole","5,9-dimethyldibenzo(c,g)carbazole","C039387","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21809388","Genotoxicity of 7H-dibenzo[c,g]carbazole and its tissue-specific derivatives in human hepatoma HepG2 cells is related to CYP1A1/1A2 expression.","21809388",57]
["5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid","5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid","C553926","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,2010,"20736318","Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice.","20736318",57]
["5-carboxamidotryptamine","5-carboxamidotryptamine","C047087","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15505500","Low-density lipoprotein inhibits receptor-mediated prostaglandin synthesis without affecting calcium and arachidonic acid mobilization in human endothelial cells.","15505500",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1923,B1923)","v":"5-diphosphomevalonic acid"},"5-diphosphomevalonic acid","C046285","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1923,K1923)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1991,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1923,Q1923)","v":"1917936"},"Negative regulation of cell proliferation by mevalonate or one of the mevalonate phosphates.","1917936",57]
["5-diphosphomevalonic acid","5-diphosphomevalonic acid","C046285","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2211719","Inhibition by 6-fluoromevalonate demonstrates that mevalonate or one of the mevalonate phosphates is necessary for lymphocyte proliferation.","2211719",57]
["5-ethyl-5-phenyloxazolidinedione","5-ethyl-5-phenyloxazolidinedione","C080851","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8477010","Pharmacodynamics of cytochrome P450 2B induction by phenobarbital, 5-ethyl-5-phenylhydantoin, and 5-ethyl-5-phenyloxazolidinedione in the male rat liver or in cultured rat hepatocytes.","8477010",57]
["5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone","5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone","C521815","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23370792","Effects of citrus flavonoids, 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone and 3,5,6,7,8,3',4'-heptamethoxyflavone, on the activities of macrophage scavenger receptors and the hepatic LDL receptor.","23370792",57]
["5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone","5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone","C521815","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23370792","Effects of citrus flavonoids, 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone and 3,5,6,7,8,3',4'-heptamethoxyflavone, on the activities of macrophage scavenger receptors and the hepatic LDL receptor.","23370792",57]
["5-hydroxy-6,8,11,14,17-eicosapentaenoic acid","5-hydroxy-6,8,11,14,17-eicosapentaenoic acid","C058722","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28471490","Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease.","28471490",57]
["5-hydroxy-6-formyl-7-norcholesterol","5-hydroxy-6-formyl-7-norcholesterol","C479528","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14605372","Evidence for ozone formation in human atherosclerotic arteries.","14605372",57]
["5-hydroxymethylfurfural","5-hydroxymethylfurfural","C008046","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"24168404","Isolation of bioactive phytoconstituent from Alpinia galanga L. with anti-hyperlipidemic activity.","24168404",57]
["5-methoxypsoralen","5-methoxypsoralen","C022909","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11297873","The psoralens adversely affect reproductive function in male wistar rats.","11297873",57]
["5-methoxypsoralen","5-methoxypsoralen","C022909","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12746176","Reproductive toxicity of the psoralens.","12746176",57]
["5-methoxypsoralen","5-methoxypsoralen","C022909","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15769128","Antioxidant activity of citrus limonoids, flavonoids, and coumarins.","15769128",57]
["5-methoxypsoralen","5-methoxypsoralen","C022909","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6732778","Binding of 5-methoxypsoralen to human serum low density lipoproteins.","6732778",57]
["5-methoxysterigmatocystin","5-methoxysterigmatocystin","C578082","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"23756242","Metabolic detoxification pathways for 5-methoxy-sterigmatocystin in primary tracheal epithelial cells.","23756242",57]
["5-methylchrysene","5-methylchrysene","C008422","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18992797","Cytotoxicity and mutagenicity of 5-methylchrysene and its 1,2-dihydrodiol in V79MZ cells modified to express human CYP1A1 or CYP1B1, in the presence or absence of human GSTP1 coexpression.","18992797",57]
["5-methylchrysene","5-methylchrysene","C008422","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18407395","Effects of methylated chrysenes on AhR-dependent and -independent toxic events in rat liver epithelial cells.","18407395",57]
["5-Methylcytosine","5-Methylcytosine","D044503","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1990,"1697983","5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes.","1697983",57]
["5-methyltetrahydrofolate","5-methyltetrahydrofolate","C005984","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11749673","Folate protects against oxidative modification of human LDL.","11749673",57]
["5-methyltetrahydrofolate","5-methyltetrahydrofolate","C005984","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17367704","5-methyltetrahydrofolic acid stimulates endothelin-1 production in low density lipoprotein-treated human endothelial cells.","17367704",57]
["5-methyltetrahydrofolate","5-methyltetrahydrofolate","C005984","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7731991","Folate receptors targeted to clathrin-coated pits cannot regulate vitamin uptake.","7731991",57]
["5-octadecenoic acid","5-octadecenoic acid","C114874","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2015,"25701799","Influence of the cis-9, cis-12 and cis-15 double bond position in octadecenoic acid (18:1) isomers on the rat FADS2-catalyzed Δ6-desaturation.","25701799",57]
["5-oxovaaleroyl cholesterol","5-oxovaaleroyl cholesterol","C120394","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10393209","Macrophage-enhanced formation of cholesteryl ester-core aldehydes during oxidation of low density lipoprotein.","10393209",57]
["5-oxovaaleroyl cholesterol","5-oxovaaleroyl cholesterol","C120394","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12663661","Covalent binding of oxidized cholesteryl esters to protein: implications for oxidative modification of low density lipoprotein and atherosclerosis.","12663661",57]
["5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione","5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione","C505144","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18268153","Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes.","18268153",57]
["5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid","5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid","C499823","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19211925","Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins.","19211925",57]
["5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid","5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid","C499823","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"22336459","[Resolvin E1 protects against ox-LDL-induced injury on vascular endothelial cells].","22336459",57]
["5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid","5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid","C499823","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25681756","Resolvin E1 and chemerin C15 peptide do not improve rodent non-alcoholic steatohepatitis.","25681756",57]
["5-tert-butyl-1,3-benzodioxole","5-tert-butyl-1,3-benzodioxole","C037776","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1983,"6845372","Induction of cytochrome P-450 by methylenedioxyphenyl compounds: importance of the methylene carbon.","6845372",57]
["6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid","6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid","C000595150","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,"24858947","The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats.","24858947",57]
["6-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid","6-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid","C000607197","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"26568144","Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.","26568144",57]
["6-(4-(2-methylbenzoyl)piperidin-1-yl)pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide","6-(4-(2-methylbenzoyl)piperidin-1-yl)pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide","C549137","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2010,"19926281","Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats.","19926281",57]
["6-(4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl)pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide","6-(4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl)pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide","C583719","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2013,"23446987","Pharmacological inhibition of stearoyl CoA desaturase in the skin induces atrophy of the sebaceous glands.","23446987",57]
["6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione","6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione","C454039","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11710520","Induction of cytochrome P450 1A1 gene expression by a vitamin K3 analog in mouse hepatoma Hepa-1c1c7 cells.","11710520",57]
["6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione","6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione","C454039","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2001,"11710520","Induction of cytochrome P450 1A1 gene expression by a vitamin K3 analog in mouse hepatoma Hepa-1c1c7 cells.","11710520",57]
["6-(5-(4-amidinophenyl)furan-2-yl)nicotinamidine","6-(5-(4-amidinophenyl)furan-2-yl)nicotinamidine","C504229","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24186380","CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangement.","24186380",57]
["6,12-diformylindolo(3,2-b)carbazole","6,12-diformylindolo(3,2-b)carbazole","C111854","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9566724","Rapid and transient induction of CYP1A1 gene expression in human cells by the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole.","9566724",57]
["6,12-diformylindolo(3,2-b)carbazole","6,12-diformylindolo(3,2-b)carbazole","C111854","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1998,"9566724","Rapid and transient induction of CYP1A1 gene expression in human cells by the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole.","9566724",57]
["6,2',4'-trimethoxyflavone","6,2',4'-trimethoxyflavone","C546607","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2010,"19828881","Antagonism of aryl hydrocarbon receptor signaling by 6,2',4'-trimethoxyflavone.","19828881",57]
["6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)","6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)","C011923","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1982,"7150502","Biochemical markers in carbon-tetrachloride-and galactosamine-induced acute liver injuries: the effects of dihydroquinoline-type antioxidants.","7150502",57]
["6,6'-methylenebis(2,2-dimethyl-4-methanesulfonic acid-1,2-dihydroquinoline)","6,6'-methylenebis(2,2-dimethyl-4-methanesulfonic acid-1,2-dihydroquinoline)","C044964","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1984,"6532129","Liver lipid peroxidation induced by cholesterol and its treatment with a dihydroquinoline type free radical scavenger in rabbits.","6532129",57]
["6,6'-methylenebis(2,2-dimethyl-4-methanesulfonic acid-1,2-dihydroquinoline)","6,6'-methylenebis(2,2-dimethyl-4-methanesulfonic acid-1,2-dihydroquinoline)","C044964","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6532129","Liver lipid peroxidation induced by cholesterol and its treatment with a dihydroquinoline type free radical scavenger in rabbits.","6532129",57]
["6,9,12,15,18-heneicosapentaenoic acid","6,9,12,15,18-heneicosapentaenoic acid","C108158","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1997,"9252958","Heneicosapentaenoate (21:5n-3): its incorporation into lipids and its effects on arachidonic acid and eicosanoid synthesis.","9252958",57]
["6,9,12,15,18-heneicosapentaenoic acid","6,9,12,15,18-heneicosapentaenoic acid","C108158","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,1997,"9252958","Heneicosapentaenoate (21:5n-3): its incorporation into lipids and its effects on arachidonic acid and eicosanoid synthesis.","9252958",57]
["6,9,12,15-octadecatetraenoic acid","6,9,12,15-octadecatetraenoic acid","C432383","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2001,"11269695","Cultured fish cells metabolize octadecapentaenoic acid (all-cis delta3,6,9,12,15-18:5) to octadecatetraenoic acid (all-cis delta6,9,12,15-18:4) via its 2-trans intermediate (trans delta2, all-cis delta6,9,12,15-18:5).","11269695",57]
["6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine","6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine","C541593","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19362839","Protective effects of a benzoxazine derivative against oxidized LDL-induced apoptosis and the increases of integrin beta4, ROS, NF-kappaB and P53 in human umbilical vein endothelial cells.","19362839",57]
["6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine","6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine","C541593","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"24052074","Targeting annexin A7 by a small molecule suppressed the activity of phosphatidylcholine-specific phospholipase C in vascular endothelial cells and inhibited atherosclerosis in apolipoprotein E⁻/⁻mice.","24052074",57]
["6-amino-2-mercapto-5-methylpyrimidine-4-carboxylic acid","6-amino-2-mercapto-5-methylpyrimidine-4-carboxylic acid","C070934","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8429494","Hypolipidemic effects of 6-amino-2-mercapto-5-methylpyrimidine-4-carboxylic acid in rats and tissue culture cells.","8429494",57]
["6-amino-4-(N-(4-chlorophenyl)-N-(1H-imidazol-2ylmethyl)amino)-3-hydroxyl-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran","6-amino-4-(N-(4-chlorophenyl)-N-(1H-imidazol-2ylmethyl)amino)-3-hydroxyl-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran","C000595877","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"25446077","HL-217, a new topical anti-angiogenic agent, inhibits retinal vascular leakage and pathogenic subretinal neovascularization in Vldlr⁻/⁻ mice.","25446077",57]
["6-aminocholesterol","6-aminocholesterol","C095995","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11347151","[CETP inhibitor].","11347151",57]
["6-Aminonicotinamide","6-Aminonicotinamide","D015120","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1959,"13820823","[The nature and prevention of hepatic steatosis caused by massive doses of nicotinamide and 6-aminonicotinamide].","13820823",57]
["6-bromoflavone","6-bromoflavone","C099934","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"9973203","Cancer chemopreventive activity mediated by 4'-bromoflavone, a potent inducer of phase II detoxification enzymes.","9973203",57]
["6-carboxyfluorescein","6-carboxyfluorescein","C024098","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"6895324","Phase transition release, a new approach to the interaction of proteins with lipid vesicles. Application to lipoproteins.","6895324",57]
["6-chloromercuricholesterol","6-chloromercuricholesterol","C049524","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11347151","[CETP inhibitor].","11347151",57]
["6-chrysenamine","6-chrysenamine","C100101","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1993,"8396278","Mutagenicity of chrysene, its methyl and benzo derivatives, and their interactions with cytochromes P-450 and the Ah-receptor; relevance to their carcinogenic potency.","8396278",57]
["6-demethoxycapillarisin","6-demethoxycapillarisin","C514569","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2007,"17848630","Polyphenolic compounds from Artemisia dracunculus L. inhibit PEPCK gene expression and gluconeogenesis in an H4IIE hepatoma cell line.","17848630",57]
["6-dimethylamino-2-naphthaldehyde","6-dimethylamino-2-naphthaldehyde","C506914","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16083846","Evaluation of alpha-cyano ethers as fluorescent substrates for assay of cytochrome P450 enzyme activity.","16083846",57]
["6-ethyl-24-norcholane-3,7,23-triol-23 sulfate","6-ethyl-24-norcholane-3,7,23-triol-23 sulfate","C000602622","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28442273","The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.","28442273",57]
["6-fluoromevalonolactone","6-fluoromevalonolactone","C045174","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1917936","Negative regulation of cell proliferation by mevalonate or one of the mevalonate phosphates.","1917936",57]
["6-fluoromevalonolactone","6-fluoromevalonolactone","C045174","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2211719","Inhibition by 6-fluoromevalonate demonstrates that mevalonate or one of the mevalonate phosphates is necessary for lymphocyte proliferation.","2211719",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11097181","Regulation of CYP1A1 transcription via the metabolism of the tryptophan-derived 6-formylindolo[3,2-b]carbazole.","11097181",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15788723","Identification of the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole, in cell culture medium, as a factor that controls the background aryl hydrocarbon receptor activity.","15788723",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17020875","Effects of tryptophan photoproducts in the circadian timing system: searching for a physiological role for aryl hydrocarbon receptor.","17020875",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2011,"21883026","Influence of light on aryl hydrocarbon receptor signaling and consequences in drug metabolism, physiology and disease.","21883026",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24194396","Differential consequences of two distinct AhR ligands on innate and adaptive immune responses to influenza A virus.","24194396",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26686552","Evidence for New Light-Independent Pathways for Generation of the Endogenous Aryl Hydrocarbon Receptor Agonist FICZ.","26686552",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C1987,B1987)","v":"6-formylindolo(3,2-b)carbazole"},"6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J1987,K1987)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2016,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q1987,Q1987)","v":"26861731"},"The AhR is involved in the regulation of LoVo cell proliferation through cell cycle-associated proteins.","26861731",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27112072","Biological effects of 6-formylindolo[3,2-b]carbazole (FICZ) in vivo are enhanced by loss of CYP1A function in an Ahr2-dependent manner.","27112072",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27301797","Time-dependent transcriptomic and biochemical responses of 6-formylindolo[3,2-b]carbazole (FICZ) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) are explained by AHR activation time.","27301797",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2018,"29680209","6-formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression.","29680209",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9566724","Rapid and transient induction of CYP1A1 gene expression in human cells by the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole.","9566724",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2003,"12527705","Characterization of in vitro metabolites of the aryl hydrocarbon receptor ligand 6-formylindolo[3,2-b]carbazole by liquid chromatography-mass spectrometry and NMR.","12527705",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2004,"15501436","Metabolic fate of the Ah receptor ligand 6-formylindolo[3,2-b]carbazole.","15501436",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2005,"15788723","Identification of the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole, in cell culture medium, as a factor that controls the background aryl hydrocarbon receptor activity.","15788723",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2007,"17020875","Effects of tryptophan photoproducts in the circadian timing system: searching for a physiological role for aryl hydrocarbon receptor.","17020875",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2009,"19054769","The suggested physiologic aryl hydrocarbon receptor activator and cytochrome P4501 substrate 6-formylindolo[3,2-b]carbazole is present in humans.","19054769",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19615353","The tryptophan photoproduct 6-formylindolo[3,2-b]carbazole (FICZ) binds multiple AHRs and induces multiple CYP1 genes via AHR2 in zebrafish.","19615353",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"19799885","Responsiveness of a Xenopus laevis cell line to the aryl hydrocarbon receptor ligands 6-formylindolo[3,2-b]carbazole (FICZ) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).","19799885",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20852066","Induction of long interspersed nucleotide element-1 (L1) retrotransposition by 6-formylindolo[3,2-b]carbazole (FICZ), a tryptophan photoproduct.","20852066",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2010,"20944064","The tryptophan photoproduct 6-formylindolo[3,2-b]carbazole helps genes jump.","20944064",57]
["6-formylindolo(3,2-b)carbazole","6-formylindolo(3,2-b)carbazole","C111855","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21883026","Influence of light on aryl hydrocarbon receptor signaling and consequences in drug metabolism, physiology and disease.","21883026",57]
["6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid","6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid","C010643","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16484048","Fibrinogen is a co-antioxidant that supplements the vitamin E analog trolox in a model system.","16484048",57]
["6-Ketoprostaglandin F1 alpha","6-Ketoprostaglandin F1 alpha","D015121","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1991,"1941177","Plasma very low density lipoproteins from male rats fed casein or soybean protein diets: a comparison of fatty acid composition and influence on prostanoid production.","1941177",57]
["6-methyl-1,3,8-trichlorodibenzofuran","6-methyl-1,3,8-trichlorodibenzofuran","C054923","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8390116","Mechanism of action of alpha-naphthoflavone as an Ah receptor antagonist in MCF-7 human breast cancer cells.","8390116",57]
["6-prenylnaringenin","6-prenylnaringenin","C521871","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27269377","Hop (Humulus lupulus L.) Extract and 6-Prenylnaringenin Induce P450 1A1 Catalyzed Estrogen 2-Hydroxylation.","27269377",57]
["7,7-azocholestanol","7,7-azocholestanol","C472706","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12177179","Synthesis and biochemical properties of a new photoactivatable cholesterol analog 7,7-azocholestanol and its linoleate ester in Chinese hamster ovary cell lines.","12177179",57]
["7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide","7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide","D015123","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"22809837","BPDE-like DNA adduct level in oral tissue may act as a risk biomarker of oral cancer.","22809837",57]
["7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide","7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide","D015123","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"8525499","Metabolism of (+)-trans-benzo[a]pyrene-7,8-dihydrodiol by 3-methylcholanthrene-induced rat liver homogenates.","8525499",57]
["7,8-dihydroneopterin","7,8-dihydroneopterin","C000976","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2010,"20408759","Oxidant production, oxLDL uptake, and CD36 levels in human monocyte–derived macrophages are downregulated by the macrophage-generated antioxidant 7,8-dihydroneopterin.","20408759",57]
["7-chlorobenz(a)anthracene","7-chlorobenz(a)anthracene","C046094","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8310461","Regioselective metabolism of benzo[a]pyrene and 7-chlorobenz[a]anthracene by fish liver microsomes.","8310461",57]
["7H-dibenzo(c,g)carbazole","7H-dibenzo(c,g)carbazole","C013478","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23639521","Sustained induction of cytochrome P4501A1 in human hepatoma cells by co-exposure to benzo[a]pyrene and 7H-dibenzo[c,g]carbazole underlies the synergistic effects on DNA adduct formation.","23639521",57]
["7-ketocholesterol","7-ketocholesterol","C003001","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11239823","7-Ketocholesterol delivered to mice in chylomicron remnant-like particles is rapidly metabolised, excreted and does not accumulate in aorta.","11239823",57]
["7-ketocholesterol","7-ketocholesterol","C003001","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25742736","THP1 macrophages oxidized cholesterol, generating 7-derivative oxysterols specifically released by HDL.","25742736",57]
["7-ketocholesteryl-9-carboxynonanoate","7-ketocholesteryl-9-carboxynonanoate","C510905","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28377266","The lipid moiety 7-ketocholesteryl-9-carboxynonanoate mediates binding interaction of oxLDL to LOX-1 and upregulates ABCA1 expression through PPARγ.","28377266",57]
["8,11,14-Eicosatrienoic Acid","8,11,14-Eicosatrienoic Acid","D015126","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1991,"1906979","Inhibition of arachidonate biosynthesis in hepatoma tissue culture cells by 11-deoxycorticosterone-induced factor.","1906979",57]
["8,11,14-Eicosatrienoic Acid","8,11,14-Eicosatrienoic Acid","D015126","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1993,"8177224","Delta 5 desaturase activity in rat kidney microsomes.","8177224",57]
["8,11,14-Eicosatrienoic Acid","8,11,14-Eicosatrienoic Acid","D015126","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6377563","Dihomo-gamma-linolenic acid in patients with atherosclerosis: effects on platelet aggregation, plasma lipids and low-density lipoprotein-induced inhibition of prostacyclin generation.","6377563",57]
["8-epi-prostaglandin F2alpha","8-epi-prostaglandin F2alpha","C075750","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10882184","LDL-apheresis decreases plasma levels and urinary excretion of 8-epi-PGF2alpha.","10882184",57]
["8-epi-prostaglandin F2alpha","8-epi-prostaglandin F2alpha","C075750","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2000,"11073849","Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy.","11073849",57]
["9-(4-(2,5-dimethyl-4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1H-benzimidazol-1-yl)butyl)-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide","9-(4-(2,5-dimethyl-4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1H-benzimidazol-1-yl)butyl)-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide","C424429","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11300866","A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors.","11300866",57]
["9,10-Dimethyl-1,2-benzanthracene","9,10-Dimethyl-1,2-benzanthracene","D015127","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12224597","Baicalein inhibits DMBA-DNA adduct formation by modulating CYP1A1 and CYP1B1 activities.","12224597",57]
["9,10-Dimethyl-1,2-benzanthracene","9,10-Dimethyl-1,2-benzanthracene","D015127","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21787703","Chokeberry (Aronia melanocarpa) juice modulates 7,12-dimethylbenz[a]anthracene induced hepatic but not mammary gland phase I and II enzymes in female rats.","21787703",57]
["9,10-Dimethyl-1,2-benzanthracene","9,10-Dimethyl-1,2-benzanthracene","D015127","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19065662","Aryl hydrocarbon receptor polymorphism modulates DMBA-induced inflammation and carcinogenesis in phenotypically selected mice.","19065662",57]
["9,10-Dimethyl-1,2-benzanthracene","9,10-Dimethyl-1,2-benzanthracene","D015127","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"20521247","Aryl hydrocarbon receptor activation during pregnancy, and in adult nulliparous mice, delays the subsequent development of DMBA-induced mammary tumors.","20521247",57]
["9,11-linoleic acid","9,11-linoleic acid","C046938","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20924169","Trans-10,cis-12-CLA-caused lipodystrophy is associated with profound changes of fatty acid profiles of liver, white adipose tissue and erythrocytes in mice: possible link to tissue-specific alterations of fatty acid desaturation.","20924169",57]
["9-hydroxy-10,12-octadecadienoic acid","9-hydroxy-10,12-octadecadienoic acid","C024347","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10558912","Regulation of ferritin light chain gene expression by oxidized low-density lipoproteins in human monocytic THP-1 cells.","10558912",57]
["9-hydroxy-10,12-octadecadienoic acid","9-hydroxy-10,12-octadecadienoic acid","C024347","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9219348","Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis.","9219348",57]
["A2-E (N-retinylidene-N-retinylethanolamine)","A2-E (N-retinylidene-N-retinylethanolamine)","C112040","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10067978","Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin.","10067978",57]
["Acarbose","Acarbose","D020909","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18230353","The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.","18230353",57]
["acenaphthene","acenaphthene","C042552","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8001243","Aryl hydrocarbon (Ah) receptor-independent induction of Cyp1a2 gene expression by acenaphthylene and related compounds in B6C3F1 mice.","8001243",57]
["Acetaldehyde","Acetaldehyde","D000079","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1996,"8691329","Hepatotoxicity and absorption of extrahepatic acetaldehyde in rats.","8691329",57]
["Acetaldehyde","Acetaldehyde","D000079","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3821381","Acetaldehyde binding increases the catabolism of rat serum low-density lipoproteins.","3821381",57]
["Acetaminophen","Acetaminophen","D000082","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"18798224","Effects of choline-deprivation on paracetamol- or phenobarbital-induced rat liver metabolic response.","18798224",57]
["Acetaminophen","Acetaminophen","D000082","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2008,"18501395","Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate.","18501395",57]
["Acetaminophen","Acetaminophen","D000082","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21240014","Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease.","21240014",57]
["Acetic Acid","Acetic Acid","D019342","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1987,"3619695","Effect of acetate administration on rats with chronic uremia.","3619695",57]
["Acetone","Acetone","D000096","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2010,"19856260","Chronic acetonemia alters liver oxidative balance and lipid content in rats. A model of NASH?","19856260",57]
["Acetylcholine","Acetylcholine","D000109","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25031153","Oxidation-induced loss of the ability of HDL to counteract the inhibitory effect of oxidized LDL on vasorelaxation.","25031153",57]
["Acetylglucosamine","Acetylglucosamine","D000117","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27318140","Effects of caloric restriction on O-GlcNAcylation, Ca(2+) signaling, and learning impairment in the hippocampus of ob/ob mice.","27318140",57]
["acetylhydrazine","acetylhydrazine","C014949","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1986,"3737601","[Effect of monoacetylhydrazine on the rat liver].","3737601",57]
["acipimox","acipimox","C027696","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1990,"2306305","Lipoprotein changes and increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia.","2306305",57]
["Acrolein","Acrolein","D000171","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22716039","Quantitative analysis of acrolein-specific adducts generated during lipid peroxidation-modification of proteins in vitro: identification of N(τ)-(3-propanal)histidine as the major adduct.","22716039",57]
["acrylic acid","acrylic acid","C036658","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22976475","Development of poly(vinyl acetate-methylacrylic acid)/chitosan/Fe3O4 nanoparticles for the diagnosis of non-alcoholic steatohepatitis with magnetic resonance imaging.","22976475",57]
["acylcarnitine","acylcarnitine","C116917","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2003,"14512887","Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis.","14512887",57]
["Adamantane","Adamantane","D000218","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1977,"189153","Response to the hypobetalipoproteinemic agent adamantyloxyphenyl piperidine in hyperlipemic rats.","189153",57]
["Adenine","Adenine","D000225","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14247621","PERIPORTAL FATTY LIVER IN THE RAT INDUCED BY HIGH PROTEIN OROTIC ACID DIETS.","14247621",57]
["Adenine","Adenine","D000225","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,1997,"9270978","Correlation of suppressed linoleic acid metabolism with the hypocholesterolemic action of eritadenine in rats.","9270978",57]
["adrenic acid","adrenic acid","C011395","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28456640","Adrenic acid as an inflammation enhancer in non-alcoholic fatty liver disease.","28456640",57]
["Aflatoxin B1","Aflatoxin B1","D016604","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"2108694","Stable expression of human cytochrome P450IA2 cDNA in a human lymphoblastoid cell line: role of the enzyme in the metabolic activation of aflatoxin B1.","2108694",57]
["Aflatoxin B1","Aflatoxin B1","D016604","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9839019","Mechanism of biochemical action of substituted 4-methylbenzopyran-2-ones. Part II: Mechanism-based inhibition of rat liver microsome-mediated aflatoxin B1-DNA binding by the candidate antimutagen 7,8-diacetoxy-4-methylcoumarin.","9839019",57]
["Aflatoxin B1","Aflatoxin B1","D016604","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"21994236","Effect of aflatoxin B1 on nuclear receptors PXR, CAR, and AhR and their target cytochromes P450 mRNA expression in primary cultures of human hepatocytes.","21994236",57]
["AL 0670","AL 0670","C088267","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1994,"7996482","A possible mechanism of action of a new potassium channel opener, AL0671, on lipid metabolism in obese Zucker rats.","7996482",57]
["aliskiren","aliskiren","C446481","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21358304","Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension.","21358304",57]
["alitretinoin","alitretinoin","C103303","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11378441","Low synthesis of retinoic acid due to impaired cytochrome P450 1a1 expression in mouse xeroderma pigmentosum fibroblasts.","11378441",57]
["Allopurinol","Allopurinol","D000493","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1983,"6862346","[Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].","6862346",57]
["Allopurinol","Allopurinol","D000493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14687901","Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy.","14687901",57]
["allyl sulfide","allyl sulfide","C038491","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12575903","The combined effects of garlic oil and fish oil on the hepatic antioxidant and drug-metabolizing enzymes of rats.","12575903",57]
["alpha-carotene","alpha-carotene","C041635","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10620353","Interaction of peroxynitrite with carotenoids in human low density lipoproteins.","10620353",57]
["alpha-cyclodextrin","alpha-cyclodextrin","C032613","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1991,"1873912","Lipoprotein-cyclodextrin interaction.","1873912",57]
["alpha-ketoglutaric acid","alpha-ketoglutaric acid","C029743","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"24675715","Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease.","24675715",57]
["alpha-Linolenic Acid","alpha-Linolenic Acid","D017962","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2004,"15549653","Molecular cloning and functional characterization of fatty acyl desaturase and elongase cDNAs involved in the production of eicosapentaenoic and docosahexaenoic acids from alpha-linolenic acid in Atlantic salmon (Salmo salar).","15549653",57]
["alpha-Linolenic Acid","alpha-Linolenic Acid","D017962","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2012,"22378946","Identification and evaluation of ω-3 fatty acid desaturase genes for hyperfortifying α-linolenic acid in transgenic rice seed.","22378946",57]
["alpha-Linolenic Acid","alpha-Linolenic Acid","D017962","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2013,"23579035","Comparative effects of well-balanced diets enriched in α-linolenic or linoleic acids on LC-PUFA metabolism in rat tissues.","23579035",57]
["alpha-Linolenic Acid","alpha-Linolenic Acid","D017962","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2017,"27960561","Dietary essential α-linolenic acid and linoleic acid differentially modulate TNFα-induced NFκB activity in FADS2-deficient HEK-293 cells.","27960561",57]
["alpha-Linolenic Acid","alpha-Linolenic Acid","D017962","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23746194","Oils rich in α-linolenic acid independently protect against characteristics of fatty liver disease in the Δ6-desaturase null mouse.","23746194",57]
["alpha-Linolenic Acid","alpha-Linolenic Acid","D017962","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,1989,"2570573","Age-related changes in linoleate and alpha-linolenate desaturation by rat liver microsomes.","2570573",57]
["alpha-Linolenic Acid","alpha-Linolenic Acid","D017962","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,2,2005,"16317123","The dietary alpha-linolenic acid to linoleic acid ratio does not affect the serum lipoprotein profile in humans.","16317123",57]
["alpha-Linolenic Acid","alpha-Linolenic Acid","D017962","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2013,"23026492","Effects of ALA, EPA and DHA in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats.","23026492",57]
["alpha-naphthoflavone","alpha-naphthoflavone","C011512","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2007,"17257690","Inhibition of CYP1A enzymes by alpha-naphthoflavone causes both synergism and antagonism of retene toxicity to rainbow trout (Oncorhynchus mykiss).","17257690",57]
["alpha-naphthoflavone","alpha-naphthoflavone","C011512","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1991,"1658599","Alpha-naphthoflavone acts as an antagonist of 2,3,7, 8-tetrachlorodibenzo-p-dioxin by forming an inactive complex with the Ah receptor.","1658599",57]
["alpha-naphthoflavone","alpha-naphthoflavone","C011512","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1993,"8390116","Mechanism of action of alpha-naphthoflavone as an Ah receptor antagonist in MCF-7 human breast cancer cells.","8390116",57]
["alpha-Tocopherol","alpha-Tocopherol","D024502","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2004,"15814462","HIV protease inhibitors-induced atherosclerosis: prevention by alpha-tocopherol.","15814462",57]
["alpha-Tocopherol","alpha-Tocopherol","D024502","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2007,"17537406","Molecular mechanism of alpha-tocopheryl-phosphate transport across the cell membrane.","17537406",57]
["alpha-Tocopherol","alpha-Tocopherol","D024502","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12773456","Concentrations of carotenoids, retinol and alpha-tocopherol in plasma and follicular fluid of women undergoing IVF.","12773456",57]
["alpha-Tocopherol","alpha-Tocopherol","D024502","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14622976","Extent of copper LDL oxidation depends on oxidation time and copper/LDL ratio: chemical characterization.","14622976",57]
["alpha-Tocopherol","alpha-Tocopherol","D024502","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17934234","The coantioxidative effects of carboxyethyl-6-hydroxychromans and alpha-Tocopherol.","17934234",57]
["alpha-Tocopherol","alpha-Tocopherol","D024502","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19661353","Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma.","19661353",57]
["alpha-Tocopherol","alpha-Tocopherol","D024502","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9223282","Alpha-tocopheryl hydroquinone is an efficient multifunctional inhibitor of radical-initiated oxidation of low density lipoprotein lipids.","9223282",57]
["alpha-Tocopherol","alpha-Tocopherol","D024502","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2629612","Alpha-tocopherol as compared with gamma-tocopherol is preferentially secreted in human lipoproteins.","2629612",57]
["alpha-Tocopherol","alpha-Tocopherol","D024502","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2002,"11880569","Alpha-tocopherol metabolism is abnormal in scavenger receptor class B type I (SR-BI)-deficient mice.","11880569",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C3267,B3267)","v":"Alprostadil"},"Alprostadil","D000527","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J3267,K3267)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1992,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q3267,Q3267)","v":"1397039"},"13,14-Dihydro-prostaglandin E1 decreases low-density lipoprotein influx into rabbit aorta.","1397039",57]
["altenusin","altenusin","C095643","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28739572","Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor.","28739572",57]
["aluminum phthalocyanine disulfonate","aluminum phthalocyanine disulfonate","C064331","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17092686","In vitro photodynamic therapy on melanoma cell lines with phthalocyanine.","17092686",57]
["aminoflavone","aminoflavone","C413760","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24885022","Estrogen receptor α and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells.","24885022",57]
["Aminoimidazole Carboxamide","Aminoimidazole Carboxamide","D000620","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2009,"19480562","Effects of AMPK activators on the sub-cellular distribution of fatty acid transporters CD36 and FABPpm.","19480562",57]
["Aminopyrine","Aminopyrine","D000632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1988,"3220177","The 30-minute aminopyrine breath test: optimization of sampling times after intravenous administration of 14C-aminopyrine.","3220177",57]
["Aminopyrine","Aminopyrine","D000632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1979,"550765","[An unusual type of hepatic lesion caused by aminophenazone].","550765",57]
["Amiodarone","Amiodarone","D000638","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2005,"16237810","Fatty liver and drugs.","16237810",57]
["Amiodarone","Amiodarone","D000638","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21475067","Acute amiodarone hepatotoxicity after liver transplantation.","21475067",57]
["Amlodipine","Amlodipine","D017311","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18087679","Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction.","18087679",57]
["amlodipine, atorvastatin drug combination","amlodipine, atorvastatin drug combination","C487936","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2010,"20108992","Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.","20108992",57]
["Ammonia","Ammonia","D000641","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1973,"4727750","Comparison of the effect of various amino acids upon the blood ammonia concentration of patients with liver disease.","4727750",57]
["Ammonia","Ammonia","D000641","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1983,"6864069","Influence of phosphoenolpyruvate carboxykinase inhibition on the response of NH3 production to acute acidosis.","6864069",57]
["ammonium metavanadate","ammonium metavanadate","C101036","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20599494","Modulation of NAD(P)H:quinone oxidoreductase by vanadium in human hepatoma HepG2 cells.","20599494",57]
["Amphotericin B","Amphotericin B","D000666","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7840573","The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B.","7840573",57]
["Amylopectin","Amylopectin","D000687","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21736804","A high-amylopectin diet caused hepatic steatosis associated with more lipogenic enzymes and increased serum insulin concentration.","21736804",57]
["anandamide","anandamide","C078814","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2016,"27014939","Bisphenol A Induces Fatty Liver by an Endocannabinoid-Mediated Positive Feedback Loop.","27014939",57]
["andrographolide","andrographolide","C030419","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26817235","Andrographolide Ameliorates Beta-Naphthoflavone-Induced CYP1A Enzyme Activity and Lipid Peroxidation in Hamsters with Acute Opisthorchiasis.","26817235",57]
["ankaflavin","ankaflavin","C499916","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26663010","Ankaflavin ameliorates steatotic liver ischemia-reperfusion injury in mice.","26663010",57]
["Antipyrine","Antipyrine","D000983","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1986,"3463183","Morphological changes in the liver due to phenazone and its derivatives.","3463183",57]
["APD668","APD668","C000617192","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"29203247","Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet.","29203247",57]
["apocarotenal","apocarotenal","C004984","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9101553","Effects of provitamin A or non-provitamin A carotenoids on liver xenobiotic-metabolizing enzymes in mice.","9101553",57]
["Arachidonic Acid","Arachidonic Acid","D016718","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2002,"12479587","Surface expression of fatty acid translocase (FAT/CD36) on platelets in myeloproliferative disorders and non-insulin dependent diabetes mellitus: effect on arachidonic acid uptake.","12479587",57]
["Arachidonic Acid","Arachidonic Acid","D016718","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2010,"19944063","Decrease in uptake of arachidonic acid by indomethacin in LS174T human colon cancer cells; a novel cyclooxygenase-2-inhibition-independent effect.","19944063",57]
["Arachidonic Acid","Arachidonic Acid","D016718","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2003,"12600866","Arachidonic acid status during pregnancy is associated with polychlorinated biphenyl exposure.","12600866",57]
["Arachidonic Acid","Arachidonic Acid","D016718","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2007,"17470538","Characterization of prostaglandin E2 production by Candida albicans.","17470538",57]
["Arachidonic Acid","Arachidonic Acid","D016718","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2013,"24075244","Dietary arachidonic acid and docosahexaenoic acid regulate liver fatty acid desaturase (FADS) alternative transcript expression in suckling piglets.","24075244",57]
["Arachidonic Acid","Arachidonic Acid","D016718","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1993,"8316052","Mechanism of decreased arachidonic acid in the renal cortex of rats with diabetes mellitus.","8316052",57]
["Arachidonic Acid","Arachidonic Acid","D016718","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2009,"18947440","Arachidonic acid prevents fatty liver induced by conjugated linoleic acid in mice.","18947440",57]
["Arachidonic Acid","Arachidonic Acid","D016718","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,2,2011,"21457203","Regulation of stearoyl-coenzyme A desaturase and fatty acid delta-6 desaturase-2 expression by linoleic acid and arachidonic acid in human sebocytes leads to enhancement of proinflammatory activity but does not affect lipogenesis.","21457203",57]
["Arachidonic Acid","Arachidonic Acid","D016718","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16254615","Kinetics of fatty acid oxidation in low density lipoproteins evaluated by registration of the oxidizer consumption and reaction product yield.","16254615",57]
["Arachidonic Acid","Arachidonic Acid","D016718","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9409317","Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions.","9409317",57]
["Arachidonic Acid","Arachidonic Acid","D016718","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1991,"1714117","A new role for the low density lipoprotein receptor.","1714117",57]
["Arachidonic Acid","Arachidonic Acid","D016718","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,1994,"7987266","Induction of stearoyl-CoA desaturase 2 gene expression correlates with fatty acid changes in phosphatidylcholine.","7987266",57]
["argan oil","argan oil","C555574","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"26101142","Consumption of Argan Oil Improves Anti-Oxidant and Lipid Status in Hemodialysis Patients.","26101142",57]
["aristolochic acid I","aristolochic acid I","C000228","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23981375","Tanshinone I protects mice from aristolochic acid I-induced kidney injury by induction of CYP1A.","23981375",57]
["aroclor 1242","aroclor 1242","C027423","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1360369","Comparative effects of the polychlorinated biphenyl mixture, Aroclor 1242, on porphyrin and xenobiotic metabolism in kidney of Japanese quail and rat.","1360369",57]
["arsenite","arsenite","C015001","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2006,"17038550","Arsenite modulates cardiac substrate preference by translocation of GLUT4, but not CD36, independent of mitogen-activated protein kinase signaling.","17038550",57]
["arsenite","arsenite","C015001","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15630080","Arsenite inhibition of CYP1A1 induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin is independent of cell cycle arrest.","15630080",57]
["arsenite","arsenite","C015001","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2012,"22535251","Differential modulation of aryl hydrocarbon receptor regulated enzymes by arsenite in the kidney, lung, and heart of C57BL/6 mice.","22535251",57]
["Ascorbic Acid","Ascorbic Acid","D001205","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"17582584","Protective effects of isothiocyanates alone or in combination with vitamin C towards N-nitrosodibutylamine or N-nitrosopiperidine-induced oxidative DNA damage in the single-cell gel electrophoresis (SCGE)/HepG2 assay.","17582584",57]
["Ascorbic Acid","Ascorbic Acid","D001205","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"22375551","Amelioration of diet-induced nonalcoholic steatohepatitis in rats by Mn-salen complexes via reduction of oxidative stress.","22375551",57]
["Ascorbic Acid","Ascorbic Acid","D001205","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10479466","Antioxidant vitamins and prevention of cardiovascular disease: laboratory, epidemiological and clinical trial data.","10479466",57]
["Ascorbic Acid","Ascorbic Acid","D001205","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11430772","Iron loading and large doses of intravenous ascorbic acid promote lipid peroxidation in whole serum in guinea pigs.","11430772",57]
["Ascorbic Acid","Ascorbic Acid","D001205","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1512641","Dietary ascorbic acid depresses plasma and low density lipoprotein lipid peroxidation in genetically scorbutic rats.","1512641",57]
["Ascorbic Acid","Ascorbic Acid","D001205","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"17049479","Ascorbate does not protect macrophages against apoptosis induced by oxidised low density lipoprotein.","17049479",57]
["Ascorbic Acid","Ascorbic Acid","D001205","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2013,"23279831","Antioxidant effects of vitamins C and e on the low-density lipoprotein oxidation mediated by myeloperoxidase.","23279831",57]
["Ascorbic Acid","Ascorbic Acid","D001205","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7867194","Protection from oxidized LDL-induced leukocyte adhesion to microvascular and macrovascular endothelium in vivo by vitamin C but not by vitamin E.","7867194",57]
["Ascorbic Acid","Ascorbic Acid","D001205","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9179545","The effect of vitamin C in high doses on plasma and biliary lipid composition in patients with cholesterol gallstones: prolongation of the nucleation time.","9179545",57]
["Ascorbic Acid","Ascorbic Acid","D001205","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2004,"15228221","Effect of L-ascorbic acid on the oxidative modification of apolipoprotein E in human very-low-density lipoprotein.","15228221",57]
["asphalt","asphalt","C006647","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12167208","Alteration of pulmonary cytochrome p-450 system: effects of asphalt fume condensate exposure.","12167208",57]
["Aspirin","Aspirin","D001241","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1985,"4015815","[Reye's syndrome and the administration of acetylsalicylic acid in children].","4015815",57]
["Aspirin","Aspirin","D001241","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3036591","Aspirin induces alterations in low-density lipoprotein and decreases its catabolism by cultured human fibroblasts.","3036591",57]
["Aspirin","Aspirin","D001241","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1979,"217724","Studies on the progression and regression of coronary and peripheral atherosclerosis in the cynomolgus monkey. I. Effects of dipyridamole and aspirin.","217724",57]
["Aspirin","Aspirin","D001241","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2002,"12208806","Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice.","12208806",57]
["Aspirin","Aspirin","D001241","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2002,"12209007","Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice.","12209007",57]
["Atenolol","Atenolol","D001262","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1983,"6873132","Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects.","6873132",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2007,"17643887","Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2.","17643887",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2010,"19932590","Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.","19932590",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,2002,"11994377","Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.","11994377",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2001,"11685905","Effects of atorvastatin (and blood pressure lowering comparing amlodipide-based therapy with beta-blocker-based therapy) on serum variables of cholesterol synthesis and absorption, thrombogenicity and on low-density lipoprotein oxidation in vivo.","11685905",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12606523","Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.","12606523",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2004,"15146369","Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.","15146369",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16285605","A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin.","16285605",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18087679","Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction.","18087679",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2010,"20540635","Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.","20540635",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"21956776","Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IκBα degradation, and COX-2 expression in murine macrophages.","21956776",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24163116","Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.","24163116",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27402817","Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.","27402817",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,2,2001,"11472706","Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.","11472706",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2006,"16893378","Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.","16893378",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21212755","Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?","21212755",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21684478","Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.","21684478",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2000,"10856535","Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.","10856535",57]
["Atorvastatin Calcium","Atorvastatin Calcium","D000069059","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1997,"9409231","Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.","9409231",57]
["atractylenolide I","atractylenolide I","C424804","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28274716","Atractylenolide I restores HO-1 expression and inhibits Ox-LDL-induced VSMCs proliferation, migration and inflammatory responses in vitro.","28274716",57]
["aucubin","aucubin","C006650","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24586300","Eucommia ulmoides cortex, geniposide and aucubin regulate lipotoxicity through the inhibition of lysosomal BAX.","24586300",57]
["avenanthramide-2C","avenanthramide-2C","C514463","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2018,"29298067","High Levels of Avenanthramides in Oat-Based Diet Further Suppress High Fat Diet-Induced Atherosclerosis in Ldlr-/- Mice.","29298067",57]
["azobenzene","azobenzene","C009850","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1994,"8020164","Mutagenicity and CYP1A induction by azobenzenes correlates with their carcinogenicity.","8020164",57]
["baicalin","baicalin","C038044","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21391433","A novel therapeutic regimen for hepatic fibrosis using the combination of mesenchymal stem cells and baicalin.","21391433",57]
["BCG Vaccine","BCG Vaccine","D001500","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23653002","Isocitrate lyase encoding plasmids in BCG cause increased survival in ApoB100-only LDLR-/- mice.","23653002",57]
["benfluorex","benfluorex","C001584","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1993,"8240408","Effects of chronic benfluorex treatment on the activities of key enzymes of hepatic carbohydrate metabolism in old Sprague-Dawley rats.","8240408",57]
["Benzene","Benzene","D001554","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17161514","Investigating the role of the aryl hydrocarbon receptor in benzene-initiated toxicity in vitro.","17161514",57]
["Benzene","Benzene","D001554","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20070208","Advances in understanding benzene health effects and susceptibility.","20070208",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"26148434","Hydroxyl metabolite of PCB 180 induces DNA damage signaling and enhances the DNA damaging effect of benzo[a]pyrene.","26148434",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10357794","Metabolic proficiency and benzo[a]pyrene DNA adduct formation in APCMin mouse adenomas and uninvolved mucosa.","10357794",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11854143","Induction of CYP1A1 and CYP1B1 in T-47D human breast cancer cells by benzo[a]pyrene is diminished by arsenite.","11854143",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12067567","Protective effects of Brussels sprouts towards B[a]P-induced DNA damage: a model study with the single-cell gel electrophoresis (SCGE)/Hep G2 assay.","12067567",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12787821","Inhibition of clastogenicity of benzo[a]pyrene and of its trans-7,8-dihydrodiol in mice in vivo by fruits, vegetables, and flavonoids.","12787821",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15095903","Cytological changes in association with ethoxyresorufin o-deethylase induction in fish upon dietary exposure to benzo[a]pyrene.","15095903",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2004,"15519607","Benzo[a]pyrene-induced immunotoxicity in Japanese medaka (Oryzias latipes): relationship between lymphoid CYP1A activity and humoral immune suppression.","15519607",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16316927","Effect of polymeric black tea polyphenols on benzo(a)pyrene [B(a)P]-induced cytochrome P4501A1 and 1A2 in mice.","16316927",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17525473","Protective efficacy of hGSTM1-1 against B[a]P and (+)- or (-)-B[a]P-7,8-dihydrodiol cytotoxicity, mutagenicity, and macromolecular adducts in V79 cells coexpressing hCYP1A1.","17525473",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18569596","Miniaturization of primary porcine urinary bladder epithelial cell cultures and application for gene expression studies after exposure to benzo[a]pyrene.","18569596",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19216581","Biotransformation of benzo[a]pyrene in Ahr knockout mice is dependent on time and route of exposure.","19216581",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"19879933","Importance of CYP1A1 and CYP1B1 in bioactivation of benzo[a]pyrene in human lung cell lines.","19879933",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20888851","Role of retinoic acid in the modulation of benzo(a)pyrene-DNA adducts in human hepatoma cells: implications for cancer prevention.","20888851",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2011,"21978865","Aryl hydrocarbon receptor-mediated Cyp1a1 expression is modulated in a CLOCK-dependent circadian manner.","21978865",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23237588","Biochemical responses in seabream (Sparus aurata) caged in-field or exposed to benzo(a)pyrene and paraquat. Characterization of glutathione S-transferases.","23237588",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"24095716","The relationship between DNA adduct formation by benzo[a]pyrene and expression of its activation enzyme cytochrome P450 1A1 in rat.","24095716",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"25259779","Benzo(a)pyrene exposure causes adaptive changes in p53 and CYP1A gene expression in Brown bullhead (Ameiurus nebulosus).","25259779",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27162022","Resveratrol ameliorates benzo(a)pyrene-induced testicular dysfunction and apoptosis: involvement of p38 MAPK/ATF2/iNOS signaling.","27162022",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2017,"28800488","Benzo(a)pyrene-induced a mitochondria-independent apoptosis of liver in juvenile Chinese rare minnows (Gobiocypris rarus).","28800488",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8061947","Effects of in vivo benzo(a)pyrene treatment on liver microsomal mixed-function oxidase activities of gilthead seabream (Sparus aurata).","8061947",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8422652","Modulation of cytochrome P-450IA1-mediated mutagenicity, DNA binding and metabolism of benzo[a]pyrene by Chinese medicinal herbs.","8422652",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"6265078","Effect of low-density lipoprotein on the incorporation of benzo(a)pyrene by cultured cells.","6265078",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"10639156","Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor.","10639156",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2006,"16934955","Assessment of the DNA damaging potency and chemopreventive effects towards BaP-induced genotoxicity in human derived cells by Monimiastrum globosum, an endemic Mauritian plant.","16934955",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2007,"17944540","AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines.","17944540",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19486938","Inhibition of human mesenchymal stem cell-derived adipogenesis by the environmental contaminant benzo(a)pyrene.","19486938",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21604763","Toxic effects of methylated benzo[a]pyrenes in rat liver stem-like cells.","21604763",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22167199","Induction of intracellular calcium concentration by environmental benzo(a)pyrene involves a β2-adrenergic receptor/adenylyl cyclase/Epac-1/inositol 1,4,5-trisphosphate pathway in endothelial cells.","22167199",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2015,"25251150","Constitutive expression of the AHR signaling pathway in a bovine mammary epithelial cell line and modulation by dioxin-like PCB and other AHR ligands.","25251150",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"27989697","Developmental benzo[a]pyrene (B[a]P) exposure impacts larval behavior and impairs adult learning in zebrafish.","27989697",57]
["Benzo(a)pyrene","Benzo(a)pyrene","D001564","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"28882572","Identification of essential transcription factors for adequate DNA damage response after benzo(a)pyrene and aflatoxin B1 exposure by combining transcriptomics with functional genomics.","28882572",57]
["benzo(a)pyrene 7,8-dihydrodiol","benzo(a)pyrene 7,8-dihydrodiol","C017228","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8222063","Effects of benzo[a]pyrene and (+-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene on mitosis in Chinese hamster V79 cells with stable expression of rat cytochrome P4501A1 or 1A2.","8222063",57]
["benzo(e)pyrene","benzo(e)pyrene","C026487","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1992,"1325293","Benzo[e]pyrene elicits changes in the biochemical activities and chromatographic behavior of murine hepatic cytochromes P-450 that are distinct from those induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin.","1325293",57]
["benzo(k)fluoranthene","benzo(k)fluoranthene","C022921","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11749126","In vivo and in vitro inhibition of CYP1A-dependent activity in Fundulus heteroclitus by the polynuclear aromatic hydrocarbon fluoranthene.","11749126",57]
["benzotriazole","benzotriazole","C012771","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25383696","Benzotriazole ultraviolet stabilizers show potent activities as human aryl hydrocarbon receptor ligands.","25383696",57]
["benzotript","benzotript","C013841","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1996,"8827458","A new inhibitor of mitochondrial fatty acid oxidation.","8827458",57]
["Bepridil","Bepridil","D015764","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11137086","Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.","11137086",57]
["Berberine","Berberine","D001599","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2008,"18520050","Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats.","18520050",57]
["Berberine","Berberine","D001599","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"21061468","Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL.","21061468",57]
["Berberine","Berberine","D001599","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25623289","Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles.","25623289",57]
["Berberine","Berberine","D001599","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21130434","Berberine reduces insulin resistance: the roles for glucocorticoid receptor and aryl hydrocarbon receptor.","21130434",57]
["Berberine","Berberine","D001599","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20939176","[Advances of the mechanism study on berberine in the control of blood glucose and lipid as well as metabolism disorders].","20939176",57]
["bergamottin","bergamottin","C068337","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22705772","Bergamottin is a competitive inhibitor of CYP1A1 and is antimutagenic in the Ames test.","22705772",57]
["beta Carotene","beta Carotene","D019207","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2008,"18806102","A 9-cis beta-carotene-enriched diet inhibits atherogenesis and fatty liver formation in LDL receptor knockout mice.","18806102",57]
["beta Carotene","beta Carotene","D019207","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12804012","Protection of endogenous beta-carotene in LDL oxidized by oxygen free radicals in the presence of supraphysiological concentrations of melatonin.","12804012",57]
["beta Carotene","beta Carotene","D019207","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7562097","Distributions of carotenoids and alpha-tocopherol among lipoproteins do not change when human plasma is incubated in vitro.","7562097",57]
["beta Carotene","beta Carotene","D019207","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8467013","Preferential inhibition of LDL oxidation by the all-trans isomer of beta-carotene in comparison with 9-cis beta-carotene.","8467013",57]
["beta Carotene","beta Carotene","D019207","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1990,"2251860","Parenteral beta-carotene administration to cows: effect on plasma levels, lipoprotein distribution and secretion in the milk.","2251860",57]
["beta Carotene","beta Carotene","D019207","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"27916814","Low-Density Lipoprotein Receptor Contributes to β-Carotene Uptake in the Maternal Liver.","27916814",57]
["beta-hydroxyisovalerylshikonin","beta-hydroxyisovalerylshikonin","C118460","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2016,"26865314","AMPK and SREBP-1c mediate the anti-adipogenic effect of β-hydroxyisovalerylshikonin.","26865314",57]
["Betaine","Betaine","D001622","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14200504","[ACTION OF BETAINE CITRATE ON HEPATIC STEATOSIS OF ALIMENTARY ORIGIN IN RATS].","14200504",57]
["Betaine","Betaine","D001622","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19501665","The effects of dietary betaine supplementation on fatty liver performance, serum parameters, histological changes, methylation status and the mRNA expression level of Spot14alpha in Landes goose fatty liver.","19501665",57]
["Betaine","Betaine","D001622","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24456734","Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet.","24456734",57]
["Betaine","Betaine","D001622","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2003,"12730887","Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice.","12730887",57]
["Betaine","Betaine","D001622","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23861108","Betaine protects against high-fat-diet-induced liver injury by inhibition of high-mobility group box 1 and Toll-like receptor 4 expression in rats.","23861108",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9217270","Handling stress does not affect the expression of hepatic heat shock protein 70 and conjugation enzymes in rainbow trout treated with beta-naphthoflavone.","9217270",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"11460681","Lack of effect of beta-naphthoflavone on induction of Nramp genes in adult rainbow trout Oncorhynchus mykiss.","11460681",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15178098","Effects of beta-naphthoflavone on hepatic biotransformation and glutathione biosynthesis in largemouth bass (Micropterus salmoides).","15178098",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18304588","Molecular cloning and beta-naphthoflavone-induced expression of a cytochrome P450 1A (CYP1A) gene from an anadromous river pufferfish, Takifugu obscurus.","18304588",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22495716","Activation of aryl hydrocarbon receptor suppresses invasion of esophageal squamous  cell carcinoma cell lines.","22495716",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25948055","Physiological response of alligator gar juveniles (Atractosteus spatula) exposed to sub-lethal doses of pollutants.","25948055",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"7811300","Pretranslational induction of cytochrome P4501A enzymes by beta-naphthoflavone and 3-methylcholanthrene occurs in different liver zones.","7811300",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"9890445","Differential in vivo effects of alpha-naphthoflavone and beta-naphthoflavone on CYP1A1 and CYP2E1 in rat liver, lung, heart, and kidney.","9890445",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2005,"16308268","Beta-naphthoflavone inhibits the induction of hepatic oestrogen-dependent proteins by 17alpha-ethynylestradiol in mosquitofish (Gambusia holbrooki).","16308268",57]
["beta-Naphthoflavone","beta-Naphthoflavone","D019324","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2012,"22495716","Activation of aryl hydrocarbon receptor suppresses invasion of esophageal squamous  cell carcinoma cell lines.","22495716",57]
["beta-penta-O-galloyl-glucose","beta-penta-O-galloyl-glucose","C013185","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"26322417","The polyphenol PGG enhances expression of SR-BI and ABCA1 in J774 and THP-1 macrophages.","26322417",57]
["Bezafibrate","Bezafibrate","D001629","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1993,"8250965","Fibrates modify rat hepatic fatty acid chain elongation and desaturation in vitro.","8250965",57]
["Bezafibrate","Bezafibrate","D001629","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1999,"10348023","Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.","10348023",57]
["Bezafibrate","Bezafibrate","D001629","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2004,"14687899","Influence of fibrate treatment on malondialdehyde-modified LDL concentration.","14687899",57]
["Bezafibrate","Bezafibrate","D001629","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6825604","[Bezafibrate and delayed action etofibrate in hyperlipidemia].","6825604",57]
["Bezafibrate","Bezafibrate","D001629","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"7060720","The effect of bezafibrate and clofibrate on cholesterol ester metabolism in 3T3 cells in smooth muscle cells in tissue culture.","7060720",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C5699,B5699)","v":"Bezafibrate"},"Bezafibrate","D001629","2_KE",450,2,"VLDL secretion","Suppression",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J5699,K5699)","v":"Lipoproteins, VLDL"},"D008079","Lipoproteins, VLDL",1,1,1992,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q5699,Q5699)","v":"1523145"},"[Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].","1523145",57]
["Bezafibrate","Bezafibrate","D001629","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1983,"6685498","Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.","6685498",57]
["Bezafibrate","Bezafibrate","D001629","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18712055","Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.","18712055",57]
["bifenthrin","bifenthrin","C099952","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23994515","Exposure of maternal mice to cis-bifenthrin enantioselectively disrupts the transcription of genes related to testosterone synthesis in male offspring.","23994515",57]
["Bilirubin","Bilirubin","D001663","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1977,"408935","Serum hepatic enzyme and bilirubin elevations during parenteral nutrition.","408935",57]
["Bilirubin","Bilirubin","D001663","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1968,"5707324","[Liver function test after nicotinic acid loading. I. A clinical study].","5707324",57]
["Bilirubin","Bilirubin","D001663","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8201841","Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox.","8201841",57]
["Bilirubin","Bilirubin","D001663","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1996,"8982266","Bilirubin sensitized photooxidation of human plasma low density lipoprotein.","8982266",57]
["Biopterin","Biopterin","D001708","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2000,"11589366","Tetrahydrobiopterin inhibits copper-induced oxidation of low density lipoprotein.","11589366",57]
["Biotin","Biotin","D001710","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2013,"23291771","A synthetic peptide-based assay system for detecting binding between CD36 and an oxidized low-density lipoprotein.","23291771",57]
["Biotin","Biotin","D001710","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1974,"4434154","The effect of biotin on the fatty liver and kidney syndrome.","4434154",57]
["Biotin","Biotin","D001710","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"4052026","Detection of the low-density-lipoprotein receptor with biotin-low-density lipoprotein. A rapid new method for ligand blotting.","4052026",57]
["Biotin","Biotin","D001710","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1978,"82516","Effects of biotin deficiency on serum proteins and plasma amino acids.","82516",57]
["bis(monoacylglyceryl)phosphate","bis(monoacylglyceryl)phosphate","C012786","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17146116","Anti-bis(monoacylglycero)phosphate antibody accumulates acetylated LDL-derived cholesterol in cultured macrophages.","17146116",57]
["bisphenol A","bisphenol A","C006780","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27314163","Efficacy of UV-C photolysis of bisphenol A on transcriptome alterations of genes in zebrafish embryos.","27314163",57]
["bisphenol A","bisphenol A","C006780","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23123408","Review: Endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms.","23123408",57]
["Blood Glucose","Blood Glucose","D001786","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1991,"1828360","Glucose: a fuel for thought!","1828360",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1968,"5732400","[The behavior of glucose, pyruvic acid and nonesterified fatty acids following i.v. tolbutamide loading in fatty liver].","5732400",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19381124","Association between type two diabetes and non-alcoholic fatty liver disease in youth.","19381124",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21642744","Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis.","21642744",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22809960","Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance.","22809960",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2015,"24817112","Anti-diabetic effects of the ethanol extract of a functional formula diet in mice fed with a fructose/fat-rich combination diet.","24817112",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2018,"29561981","MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.","29561981",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1984,"6238316","[Disturbances in glycoregulation and plasma amino acids in alcoholic hepatopathies. Study using the arginine test].","6238316",57]
["Blood Glucose","Blood Glucose","D001786","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14668345","Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance.","14668345",57]
["Blood Glucose","Blood Glucose","D001786","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17341567","In vitro glycoxidized low-density lipoproteins and low-density lipoproteins isolated from type 2 diabetic patients activate platelets via p38 mitogen-activated protein kinase.","17341567",57]
["Blood Glucose","Blood Glucose","D001786","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"2045466","Deterioration in carbohydrate metabolism and lipoprotein changes induced by modern, high fat diet in Pima Indians and Caucasians.","2045466",57]
["Blood Glucose","Blood Glucose","D001786","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1979,"225125","Short-term immobilization of healthy men: right ventricular function and metabolism during graded exercise.","225125",57]
["Blood Glucose","Blood Glucose","D001786","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"23285758","[Melatonin as a regulator of metabolism].","23285758",57]
["Blood Glucose","Blood Glucose","D001786","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"26665406","EFFECT OF-GYMNEMA SYLVESTRE, CITRULLUS COLOCYNTHIS AND ARTEMISIA ABSINTHIUM ON BLOOD GLUCOSE AND LIPID PROFILE IN DIABETIC HUMAN.","26665406",57]
["Blood Glucose","Blood Glucose","D001786","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1973,"4361071","[Clinico-biochemical studies of patients with hypothalamic pathology in the practice of occupation medicine].","4361071",57]
["Blood Glucose","Blood Glucose","D001786","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9622282","Effects of a cardioselective beta-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middle-aged men with modestly increased cardiovascular risk.","9622282",57]
["Blood Glucose","Blood Glucose","D001786","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2004,"14668345","Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance.","14668345",57]
["Blood Glucose","Blood Glucose","D001786","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"2989169","Effect of whole buckwheat (Fagopyrum esculentum) flour supplementation on lipid profile &amp; glucose tolerance.","2989169",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"20880682","Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children.","20880682",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2012,"23057494","Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.","23057494",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"25059108","Metabolically healthy and unhealthy obese--the 2013 Stock Conference report.","25059108",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27761469","Effect of Alkaloids from Nelumbinis Plumula against Insulin Resistance of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.","27761469",57]
["Blood Glucose","Blood Glucose","D001786","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28592311","The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.","28592311",57]
["Blood Glucose","Blood Glucose","D001786","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2010,"20655933","Parenteral 17beta-estradiol decreases fasting blood glucose levels in non-obese mice with short-term ovariectomy.","20655933",57]
["Blood Glucose","Blood Glucose","D001786","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1982,"6284365","[Glycides after prolonged fasting in rats (author's transl)].","6284365",57]
["Blood Glucose","Blood Glucose","D001786","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1980,"7362645","Phosphoenolpyruvate carboxykinase: effects of the hyperglycaemic agent 3-aminopicolinic acid.","7362645",57]
["BM 15766","BM 15766","C047457","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1996,"8690417","Blocking late cholesterol biosynthesis inhibits the growth of transplanted Morris hepatomas (7288CTC) in rats.","8690417",57]
["borage oil","borage oil","C079363","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2015,"25921305","Botanical oils enriched in n-6 and n-3 FADS2 products are equally effective in preventing atherosclerosis and fatty liver.","25921305",57]
["borage oil","borage oil","C079363","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1995,"8577782","Diets rich in eicosapentaenoic acid and gamma-linolenic acid affect phospholipid fatty acid composition and production of prostaglandins E1, E2 and E3 in turbot (Scophthalmus maximus), a species deficient in delta 5 fatty acid desaturase.","8577782",57]
["Brefeldin A","Brefeldin A","D020126","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9473518","Reduced expression of the macrophage scavenger receptors in macrophage-like cell mutants resistant to brefeldin A.","9473518",57]
["Bromocriptine","Bromocriptine","D001971","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1989,"2499727","Effects of bromocriptine on hepatic cytochrome P-450 monooxygenase system.","2499727",57]
["Bupropion","Bupropion","D016642","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27321734","Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet.","27321734",57]
["Butylated Hydroxytoluene","Butylated Hydroxytoluene","D002084","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12659720","Effects of dietary butylated hydroxytoluene on aflatoxin B1-relevant metabolic enzymes in turkeys.","12659720",57]
["Butylhydroxybutylnitrosamine","Butylhydroxybutylnitrosamine","D002085","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"19880377","Suppression of AhR signaling pathway is associated with the down-regulation of UDP-glucuronosyltransferases during BBN-induced urinary bladder carcinogenesis in mice.","19880377",57]
["butyrylcarnitine","butyrylcarnitine","C427065","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2002,"12084849","Analysis of mitochondrial fatty acid oxidation intermediates by tandem mass spectrometry from intact mitochondria prepared from homogenates of cultured fibroblasts, skeletal muscle cells, and fresh muscle.","12084849",57]
["Cadmium Chloride","Cadmium Chloride","D019256","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"7824600","Cadmium-induced sexual dysfunction does not involve increased hepatic metabolism of testosterone nor increased circulating levels of corticosterone.","7824600",57]
["cafestol","cafestol","C053400","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2000,"10845871","Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.","10845871",57]
["caffeic acid","caffeic acid","C040048","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20075335","Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages.","20075335",57]
["Caffeine","Caffeine","D002110","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1991,"1676053","Selective in-vitro inhibition of hepatic oxidative metabolism by quinolones: 7-ethoxyresorufin and caffeine as model substrates.","1676053",57]
["Caffeine","Caffeine","D002110","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21557768","Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test.","21557768",57]
["Caffeine","Caffeine","D002110","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2000,"10767400","Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation.","10767400",57]
["caffeoylquinic acid","caffeoylquinic acid","C472707","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16809011","Antioxidant activity of caffeoyl quinic acid derivatives from the roots of Dipsacus asper Wall.","16809011",57]
["Calcimycin","Calcimycin","D000001","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6437867","Effects of the calcium ionophore A 23187 on low-density lipoprotein processing and lipid metabolism in cultured human fibroblasts.","6437867",57]
["Calcitriol","Calcitriol","D002117","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1995,"8546749","1,25-Dihydroxyvitamin D3-induced HL-60 macrophages: regulation of cholesterol and LDL metabolism.","8546749",57]
["Calcitriol","Calcitriol","D002117","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1995,"8546749","1,25-Dihydroxyvitamin D3-induced HL-60 macrophages: regulation of cholesterol and LDL metabolism.","8546749",57]
["calcium phosphate, dibasic, anhydrous","calcium phosphate, dibasic, anhydrous","C485829","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2003,"12731090","Incorporation of calcium phosphate enhances recombinant adeno-associated virus-mediated gene therapy in diabetic mice.","12731090",57]
["calphostin C","calphostin C","C058819","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1992,"1384714","Rapid regulation of albumin transcription by insulin and phorbol esters in rat hepatoma cells.","1384714",57]
["Camptothecin","Camptothecin","D002166","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2008,"17764887","Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.","17764887",57]
["candesartan","candesartan","C081643","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2006,"17380850","Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension.","17380850",57]
["Canola Oil","Canola Oil","D000074262","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"22214788","Role of hepatic de novo lipogenesis in the development of fasting-induced fatty liver in the American mink (Neovison vison).","22214788",57]
["Canola Oil","Canola Oil","D000074262","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2011,"21257056","Effects of feeding rapeseed oil, soybean oil, or linseed oil on stearoyl-CoA desaturase expression in the mammary gland of dairy cows.","21257056",57]
["caraway oil","caraway oil","C104525","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11050701","Nigella sativa L. oil protects against induced hepatotoxicity and improves serum lipid profile in rats.","11050701",57]
["Carbamazepine","Carbamazepine","D002220","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,2,2013,"23339953","Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice.","23339953",57]
["carbazole","carbazole","C041514","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"26226543","Characterization and Biological Potency of Mono- to Tetra-Halogenated Carbazoles.","26226543",57]
["Carbimazole","Carbimazole","D002231","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21106332","[Hepatic and cutaneous affections induced by antithyroid drugs revealing haemochromatosis and porphyria cutanea tarda].","21106332",57]
["Carbon Dioxide","Carbon Dioxide","D002245","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1977,"913603","Evidence for reassimilation of CO2 released from C4 acids by PEP carboxylase in leaves of C4 plants.","913603",57]
["Carbon Dioxide","Carbon Dioxide","D002245","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1974,"4463360","[The influence of heterotrophic carbon dioxide fixation on enzyme activity in Candida yeasts during growth on n-alkanes and glucose].","4463360",57]
["Carbon Disulfide","Carbon Disulfide","D002246","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25579033","[Effects of carbon disulfide inhalation on lipid levels of ApoE gene knockout mice and C57BL/6J mice].","25579033",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1991,"1883371","Post-translational reduction of cytochrome P450IIE by CCl4, its substrate.","1883371",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1958,"13609399","[Importance of lecithin in fat metabolism &amp; experimental fatty liver in rat].","13609399",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1959,"13654317","Biochemical changes in carbon tetrachloride fatty liver: separation of fatty changes from mitochondrial degeneration.","13654317",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1963,"14059232","[ON THE EFFECT OF SMALL DOSES OF SELENITE ON TOXIC FATTY LIVER DEGENERATION].","14059232",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14210548","[ACTION OF ADENOSINE MONOPHOSPHORIC ACID ON CARBON TETRACHLORIDE-INDUCED TOXIC HEPATITIS].","14210548",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1971,"4948844","Biochemical pathology.","4948844",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2008,"17897764","Genotoxic effects of tanshinones from Hyptis martiusii in V79 cell line.","17897764",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1990,"2273452","[Pharmacological studies on puerariae flos. II. The effects of puerariae flos on alcohol-induced unusual metabolism and experimental liver injury in mice].","2273452",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1973,"4142675","The liver-pathogenic role of spleen suspension of rats treated with carbon tetrachloride.","4142675",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1972,"4638598","Pyrazole blockade of carbon tetrachloride activation and liver necrosis.","4638598",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1967,"5286304","[Hepatotoxic reactions caused by drugs].","5286304",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1970,"5436244","Reticuloendothelial activity in choline-deficient or carbon tetrachloride-treated rats.","5436244",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1965,"5824989","Relation between release of free fatty acid from the adipose tissue and carbon tetrachloride-induced fatty infiltration in the liver.","5824989",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1966,"5931987","A mechanism of the acute ethanol-induced fatty liver and the modification of liver injury by antioxidants.","5931987",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1982,"6753061","[Hepatitis caused by drugs. I].","6753061",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C7107,B7107)","v":"Carbon Tetrachloride"},"Carbon Tetrachloride","D002251","13_AO",455,13,"Accumulation, Liver lipid",null,{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J7107,K7107)","v":"Fatty Liver, Alcoholic"},"D005235","Fatty Liver, Alcoholic",1,1,1985,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q7107,Q7107)","v":"3906270"},"Lipid peroxidation and cellular damage in toxic liver injury.","3906270",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"3915301","Pathological mechanisms in carbon tetrachloride hepatotoxicity.","3915301",57]
["Carbon Tetrachloride","Carbon Tetrachloride","D002251","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1980,"7423545","Involvement of glucocorticoids in the stimulation of rat kidney phosphoenolpyruvate carboxykinase activity after liver intoxication by carbon tetrachloride.","7423545",57]
["carbopol 940","carbopol 940","C006903","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3178519","Selective removal of low-density lipoproteins from plasma by polyacrylate-coated Fractogel in vitro and in experimental extracorporeal perfusion.","3178519",57]
["Carboxymethylcellulose Sodium","Carboxymethylcellulose Sodium","D002266","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28499201","Folate-functionalized assembly of low density lipoprotein/sodium carboxymethyl cellulose nanoparticles for targeted delivery.","28499201",57]
["Carnitine","Carnitine","D002331","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1990,"2172644","Progressive fatal pancytopenia, psychomotor retardation and muscle carnitine deficiency in a child with ethylmalonic aciduria and ethylmalonic acidaemia.","2172644",57]
["Carnitine","Carnitine","D002331","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1993,"8463904","Effect of treatment with glycine and L-carnitine in medium-chain acyl-coenzyme A dehydrogenase deficiency.","8463904",57]
["Carnitine","Carnitine","D002331","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2003,"14688515","L-carnitine ameliorates abnormal vulnerability of steatotic rat livers to cold ischemic preservation.","14688515",57]
["Carnitine","Carnitine","D002331","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20661589","Post-mortem MRI reveals CPT2 deficiency after sudden infant death.","20661589",57]
["Carnitine","Carnitine","D002331","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1987,"3683188","L-carnitine treatment in the hyperlipidemic rabbit.","3683188",57]
["Carnitine","Carnitine","D002331","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1984,"6424429","Ameliorating effects of carnitine and its precursors on alcohol-induced fatty liver.","6424429",57]
["Carnitine","Carnitine","D002331","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1994,"7875055","L-propionyl carnitine protects erythrocytes and low density lipoproteins against peroxidation.","7875055",57]
["Carnitine","Carnitine","D002331","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2003,"12971428","A case of mitochondrial trifunctional protein deficiency diagnosed by acylcarnitine profile and DNA analysis in a dried blood spot of a 4-day-old boy.","12971428",57]
["carprofen","carprofen","C007005","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25771063","Adipose and liver gene expression profiles in response to treatment with a nonsteroidal antiinflammatory drug after calving in grazing dairy cows.","25771063",57]
["carvedilol","carvedilol","C043211","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8047557","A potent antioxidant, SB209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity.","8047557",57]
["Catechin","Catechin","D002392","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"14558788","A combination of tea (Camellia senensis) catechins is required for optimal inhibition of induced CYP1A expression by green tea extract.","14558788",57]
["Catechin","Catechin","D002392","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2014,"23981577","Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions.","23981577",57]
["Catechin","Catechin","D002392","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1983,"6634856","Biochemical mode of action of a hepatoprotective drug: observations on (+)-catechin.","6634856",57]
["Catechin","Catechin","D002392","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15640470","Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men.","15640470",57]
["Catechin","Catechin","D002392","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15763958","In vitro antioxidative activity of (-)-epicatechin glucuronide metabolites present in human and rat plasma.","15763958",57]
["Catechin","Catechin","D002392","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23922881","PIMT prevents the apoptosis of endothelial cells in response to glycated low density lipoproteins and protective effects of grape seed procyanidin B2.","23922881",57]
["Catechin","Catechin","D002392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2000,"11064004","Comparative studies on the effects of green tea extracts and individual tea catechins on human CYP1A gene expression.","11064004",57]
["Catechin","Catechin","D002392","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19113837","(-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor.","19113837",57]
["catechol","catechol","C034221","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9219504","Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics.","9219504",57]
["CD68 antigen, human","CD68 antigen, human","C067980","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"28951310","Glucose regulated protein 78 is potentially an important player in the development of nonalcoholic steatohepatitis.","28951310",57]
["CDV-085","CDV-085","C574298","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22406426","Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLR(-/-) and ApoE(-/-) mice.","22406426",57]
["Celecoxib","Celecoxib","D000068579","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27397427","Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.","27397427",57]
["Cellulose","Cellulose","D002482","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9734273","A fish hepatoma cell line (PLHC-1) as a tool to study cytotoxicity and CYP1A induction properties of cellulose and wood chip extracts.","9734273",57]
["Cellulose","Cellulose","D002482","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10648671","Dextran sulphate cellulose columns for the treatment of nephrotic syndrome due to inactive lupus nephritis.","10648671",57]
["Cellulose","Cellulose","D002482","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1987,"2825766","Effect of pectin, wheat bran and cellulose on serum lipids and lipoproteins in rats fed on a low- or high-fat diet.","2825766",57]
["cerivastatin","cerivastatin","C086276","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12958617","Platelet hyperactivity after statin treatment discontinuation.","12958617",57]
["Ceroid","Ceroid","D002566","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7811710","Lipid oxidation, lipoprotein cell-association and ceroid accumulation in P388D1 macrophage-like cells.","7811710",57]
["Cerulenin","Cerulenin","D002569","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"24086674","Cerulenin blockade of fatty acid synthase reverses hepatic steatosis in ob/ob mice.","24086674",57]
["Chenodeoxycholic Acid","Chenodeoxycholic Acid","D002635","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1976,"1278058","[Dissolution of cholesterol calculi using chenodeoxycholic acid].","1278058",57]
["Chenodeoxycholic Acid","Chenodeoxycholic Acid","D002635","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1974,"4138590","Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia.","4138590",57]
["Chenodeoxycholic Acid","Chenodeoxycholic Acid","D002635","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1975,"170347","The effect of chenodeoxycholic acid feeding on bile acid kinetics and fecal neutral steroid excretion in patients with hyperlipoproteinemia types II and IV.","170347",57]
["Chenodeoxycholic Acid","Chenodeoxycholic Acid","D002635","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25421586","NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?","25421586",57]
["Chenodeoxycholic Acid","Chenodeoxycholic Acid","D002635","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"27939613","Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system.","27939613",57]
["Chitin","Chitin","D002686","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15274435","Chitosan adsorbents carrying amino acids for selective removal of low density lipoprotein.","15274435",57]
["Chitosan","Chitosan","D048271","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"27008163","Binary-copolymer system base on low-density lipoprotein-coupled N-succinyl chitosan lipoic acid micelles for co-delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug.","27008163",57]
["Chloramphenicol","Chloramphenicol","D002701","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14114004","HEPATIC REACTIONS TO TETRACYCLINE.","14114004",57]
["Chlormadinone Acetate","Chlormadinone Acetate","D002715","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"6157258","[Changes in the serum triglyceride levels following treatment with ovulation inhibitors in tall girls].","6157258",57]
["Chlorodiphenyl (54% Chlorine)","Chlorodiphenyl (54% Chlorine)","D020111","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1459375","Alkoxyresorufin metabolism in white-footed mice at relevant environmental concentrations of Aroclor 1254.","1459375",57]
["Chlorodiphenyl (54% Chlorine)","Chlorodiphenyl (54% Chlorine)","D020111","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8560483","Modulation by iron of hepatic microsomal and nuclear cytochrome P450, and cytosolic glutathione S-transferase and peroxidase in C57BL/10ScSn mice induced with polychlorinated biphenyls (Aroclor 1254).","8560483",57]
["Chloroform","Chloroform","D002725","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10550481","Time dependence of chloroform-induced metabolic alterations in the liver and kidney of B6C3F1 mice.","10550481",57]
["Chlorogenic Acid","Chlorogenic Acid","D002726","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28088946","Effects of chlorogenic acid on intracellular calcium regulation in lysophosphatidylcholine-treated endothelial cells.","28088946",57]
["Chloroquine","Chloroquine","D002738","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16153718","Ecotoxicological evaluation of the antimalarial drug chloroquine.","16153718",57]
["Chloroquine","Chloroquine","D002738","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1994,"7700578","Apolipoprotein E uptake and degradation via chloroquine-sensitive pathway in cultivated monkey cells overexpressing low density lipoprotein receptor.","7700578",57]
["Chlorpropamide","Chlorpropamide","D002747","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1971,"4257742","[Effects of a hypoglycemic sulfonamide on the regression of lipid disorders and evolution of arterial lesions in rabbits after cessation of a cholesterol rich diet].","4257742",57]
["Chlortetracycline","Chlortetracycline","D002751","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1951,"14860396","Fatty liver following aureomycin and terramycin therapy in chronic hepatic disease.","14860396",57]
["Chlorthalidone","Chlorthalidone","D002752","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"7374438","Increased serum low-density lipoprotein cholesterol in men treated short-term with the diuretic chlorthalidone.","7374438",57]
["Chlorzoxazone","Chlorzoxazone","D002753","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16393464","Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats.","16393464",57]
["Cholecalciferol","Cholecalciferol","D002762","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1979,"216261","Nutrition imbalance and angiotoxins as dietary risk factors in coronary heart disease.","216261",57]
["cholest-5-ene-3 beta,26-diol","cholest-5-ene-3 beta,26-diol","C007042","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3595864","Regulation of low density lipoprotein metabolism by 26-hydroxycholesterol in human fibroblasts.","3595864",57]
["cholest-8(14)-en-3-ol-15-one","cholest-8(14)-en-3-ol-15-one","C015073","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2720860","Inhibitors of sterol synthesis. Metabolism of [2,4-3H]5 alpha-cholest-8(14)-en-3 beta-ol-15-one after oral administration to a nonhuman primate.","2720860",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,2,2008,"18331615","Oxidation as a crucial reaction for cholesterol to induce tissue degeneration: CD36 overexpression in human promonocytic cells treated with a biologically relevant oxysterol mixture.","18331615",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2000,"10896940","Scavenger receptor-BI inhibits ATP-binding cassette transporter 1- mediated cholesterol efflux in macrophages.","10896940",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2002,"11786985","HDL receptor SR-BI and cholesterol gallstones.","11786985",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2002,"12207878","Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages.","12207878",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2003,"12819036","Acute tubular injury causes dysregulation of cellular cholesterol transport proteins.","12819036",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2004,"15210845","SR-BI- and ABCA1-mediated cholesterol efflux to serum from patients with Alagille syndrome.","15210845",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2006,"16479608","Ezetimib influences the expression of raft-associated antigens in human monocytes.","16479608",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2009,"19074161","Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages.","19074161",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2010,"20398376","Pharmacogenetic interaction between dexamethasone and Cd36-deficient segment of spontaneously hypertensive rat chromosome 4 affects triacylglycerol and cholesterol distribution into lipoprotein fractions.","20398376",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2012,"22302708","Chitosan oligosaccharides promote reverse cholesterol transport and expression of scavenger receptor BI and CYP7A1 in mice.","22302708",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2014,"23672804","Lipid content in hepatic and gonadal adipose tissue parallel aortic cholesterol accumulation in mice fed diets with different omega-6 PUFA to EPA plus DHA ratios.","23672804",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2015,"25833688","Micellar lipid composition affects micelle interaction with class B scavenger receptor extracellular loops.","25833688",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2015,"25868845","Increased DNA methylation of scavenger receptor class B type I contributes to inhibitory effects of prenatal caffeine ingestion on cholesterol uptake and steroidogenesis in fetal adrenals.","25868845",57]
["Cholesterol","Cholesterol","D002784","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2017,"29149604","NRF1 Is an ER Membrane Sensor that Is Central to Cholesterol Homeostasis.","29149604",57]
["Cholesterol","Cholesterol","D002784","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1992,"1537328","The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene.","1537328",57]
["Cholesterol","Cholesterol","D002784","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1997,"9270978","Correlation of suppressed linoleic acid metabolism with the hypocholesterolemic action of eritadenine in rats.","9270978",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1975,"1147830","Cholesterol fatty liver. Morphological changes in the course of its development in rabbits.","1147830",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1962,"13934540","[The form of steatosis of the human liver and its etiology].","13934540",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1963,"14168175","EFFECTS OF PALMITIC, OLEIC, AND LINOLEIC ACIDS ON HEPATIC AND VASCULAR LIPID DEPOSITS.","14168175",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"14289002","EFFECTS OF UNSATURATED FATS ON DIETARY-INDUCED CIRRHOSIS IN THE RAT.","14289002",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2010,"20143458","Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?","20143458",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2006,"16831521","Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease.","16831521",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2007,"18330098","Statins in hepatobiliary diseases: effects, indications and risks.","18330098",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19116776","Diet-induced alterations in intestinal and extrahepatic lipid metabolism in liver fatty acid binding protein knockout mice.","19116776",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2010,"20489159","A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.","20489159",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21218508","Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.","21218508",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22112382","Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.","22112382",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22446927","Features, diagnosis, and treatment of nonalcoholic fatty liver disease.","22446927",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"22878918","Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets.","22878918",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"23448543","Paraoxonase-1 deficiency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: a metabolomic approach.","23448543",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"24222095","Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.","24222095",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2015,"25887406","Transcriptomic analysis of hepatic responses to testosterone deficiency in miniature pigs fed a high-cholesterol diet.","25887406",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"28511152","[Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].","28511152",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1979,"500001","Cholesterol and triglycerides of the liver after administration of a chromatographic fraction of thymus: variations in tissue and blood.","500001",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1966,"6006480","[Studies on mechanism of cholesterol esterification. 1. Mechanism of cholesterol esterification in liver cell sap].","6006480",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1996,"9032585","Serum cholesterol and chronic hepatitis C.","9032585",57]
["Cholesterol","Cholesterol","D002784","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,2013,"24324720","Fish oil replacement in current aquaculture feed: is cholesterol a hidden treasure for fish nutrition?","24324720",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,2008,"18546884","[Remnant lipoprotein cholesterol level measured by homogeneous assay reflects the quantity of intermediate-density lipoprotein].","18546884",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,1994,"7696442","Recovery of cholesterol and triacylglycerol in very-fast ultracentrifugation of human lipoproteins in a large range of concentrations.","7696442",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10691687","Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity.","10691687",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15694369","Low density lipoprotein stimulation of human macrophage proteoglycan secretion.","15694369",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10224152","Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36.","10224152",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1999,"10464782","Effect of virgin olive oil phenolic compounds on in vitro oxidation of human low density lipoproteins.","10464782",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10631147","A cholesterol-lowering gene maps to chromosome 13q.","10631147",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10639163","ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport.","10639163",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10924733","Statin treatment increases the sialic acid content of LDL in hypercholesterolemic patients.","10924733",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10955072","[Cholesterol oxidation, macrophage foam cells and atherosclerosis: importance of antioxidants and paraoxonase].","10955072",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2001,"11160563","Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling.","11160563",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2001,"11321864","Is a statin a statin?","11321864",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11522112","Plant sterol-enriched margarine lowers plasma LDL in hyperlipidemic subjects with low cholesterol intake: effect of fibrate treatment.","11522112",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2001,"11587157","Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.","11587157",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11912548","Increased levels of anti-oxidized low-density lipoprotein antibodies are associated with reduced levels of cholesterol in the general population.","11912548",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11971952","A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC.","11971952",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12161156","Synthesis of cholesterol-carborane conjugate for targeted drug delivery.","12161156",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"12532844","[Relationship between oxysterols and atherosclerosis].","12532844",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C8835,B8835)","v":"Cholesterol"},"Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J8835,K8835)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,2003,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q8835,Q8835)","v":"12879839"},"How effective is simvastatin 10 mg?","12879839",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"12940070","[Effect of oxLDL on the uptake and clearance rate of cholesterol in vascular smooth muscle cells originated from human apoAI transgenic mice].","12940070",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1960,"13685407","[Statistical study of the variations of cholesterol bound to the beta-lipoprotein fraction of the blood in subjects of myocardial infarct with normal cholesterolemia].","13685407",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1390855","Effects of membrane lipids and -proteins and cytoskeletal proteins on the kinetics of cholesterol exchange between high density lipoprotein and human red blood cells, ghosts and microvesicles.","1390855",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1962,"13976308","[Action of beta-benzalbutyramide on the blood level of cholesterol and beta-lipoproteins in the rat fed a low-protein diet].","13976308",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1965,"14248273","HEPARIN AND THE ELECTROPHORETIC MOBILITY OF BETA-LIPOPROTEIN IN CORONARY DISEASE.","14248273",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14518572","Lipid-lowering: can ezetimibe help close the treatment gap?","14518572",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14698043","Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression.","14698043",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15103515","Serum pro-oxidant-antioxidant balance and low-density lipoprotein oxidation in healthy subjects with different cholesterol levels.","15103515",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15319426","Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein.","15319426",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1576122","Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima.","1576122",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16013454","Cholesterol regulation of genes involved in sterol trafficking in human THP-1 macrophages.","16013454",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16272774","Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy.","16272774",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1975,"164111","Mechanisms of cholesterol accumulation in the arterial wall.","164111",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16596807","Lipid and non-lipid effects of statins.","16596807",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16715393","The in vitro plasma distribution of a novel cholesteryl ester transfer protein inhibitor, torcetrapib, is influenced by differences in plasma lipid concentrations.","16715393",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1709885","Apolipoprotein E synthesis by cultured human ovarian granulosa cells: regulation by human chorionic gonadotropin and cholesterol.","1709885",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25661161","Chylomicron remnant model emulsions induce intracellular cholesterol accumulation and cell death due to lysosomal destabilization.","25661161",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3818885","High density lipoprotein and low density lipoprotein utilization by human granulosa cells for progesterone synthesis in serum-free culture: respective contributions of free and esterified cholesterol.","3818885",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8334820","The regulation of post-prandial cellular cholesterol metabolism in type 2 diabetic and non-diabetic subjects.","8334820",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1730049","Hepatic uptake and processing of cholesterol and cholesteryl ester from chylomicron remnants: an in vivo study in the rat.","1730049",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1730591","Low density lipoprotein modification by cholesterol oxidase induces enhanced uptake and cholesterol accumulation in cells.","1730591",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17565701","Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.","17565701",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1991,"1764540","Dual effect of lovastatin and simvastatin on LDL-macrophage interaction.","1764540",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1777220","Coenzyme Q10, alpha-tocopherol and free cholesterol in HDL and LDL fractions.","1777220",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1976,"179302","Mechanism of inhibition of cholesterol uptake by the arterial wall.","179302",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18281279","Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss.","18281279",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18427282","Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway.","18427282",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1976,"186857","Diffusible cholesterol as a risk factor in the biochemical stage of atherosclerosis.","186857",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1892896","Acyl-CoA: cholesterol acyltransferase in HT 29 cell subpopulations. Defect of activity in the undifferentiated cells.","1892896",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1977,"191212","Stimulation of cholesterol esterification in rhesus monkey arterial smooth muscle cells.","191212",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19217514","Other therapies for reducing low-density lipoprotein cholesterol: medications in development.","19217514",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19383063","Association between cholesterols, homocysteine and silent brain infarcts.","19383063",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1977,"195625","Regulation of lipid synthesis by low density lipoproteins in cultured skin fibroblasts in homozygous familial hypercholesterolemia.","195625",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19758344","Haptoglobin binds the antiatherogenic protein apolipoprotein E - impairment of apolipoprotein E stimulation of both lecithin:cholesterol acyltransferase activity and cholesterol uptake by hepatocytes.","19758344",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1977,"200098","Relationships between plasma lipoprotein cholesterol concentrations and the pool size and metabolism of cholesterol in man.","200098",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1977,"202092","[Cholesterol metabolism in rabbits with resistance to experimental atherosclerosis acquired by immunological treatment].","202092",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1978,"202222","New insights into cholesterol dynamics.","202222",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20506155","Anti-atherogenic effect of berberine on LXRalpha-ABCA1-dependent cholesterol efflux in macrophages.","20506155",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20625867","Phenotypic high-throughput screening in atherosclerosis research: focus on macrophages.","20625867",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1978,"208187","Evidence for high-density lipoprotein-free cholesterol as the primary precursor for bile-acid synthesis in man.","208187",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1978,"210780","Location and interactions of phospholipid and cholesterol in human low density lipoprotein from 31P nuclear magnetic resonance.","210780",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21250691","Cholesterol metabolism is modulated by quercetin in rats.","21250691",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21463617","Polysorbates as novel lipid-modulating candidates for reducing serum total cholesterol and low-density lipoprotein levels in hyperlipidemic C57BL/6J mice and rats.","21463617",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21670382","Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.","21670382",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C9539,B9539)","v":"Cholesterol"},"Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J9539,K9539)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,2011,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q9539,Q9539)","v":"21816466"},"Dual use of amphiphilic macromolecules as cholesterol efflux triggers and inhibitors of macrophage athero-inflammation.","21816466",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21940512","Dietary ellagic acid attenuates oxidized LDL uptake and stimulates cholesterol efflux in murine macrophages.","21940512",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22100058","Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.","22100058",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2011,"22164412","[The composition of blood lipoproteins of donors 2 hours later after single atorvastatin intake].","22164412",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1979,"223600","Dietary fiber and cholesterol metabolism in rats fed a high cholesterol diet.","223600",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1979,"225948","Unexpected decrease in plasma high density lipoprotein cholesterol with weight loss.","225948",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22682430","Differential mRNA expression of seven genes involved in cholesterol metabolism and transport in the liver of atherosclerosis-susceptible and -resistant Japanese quail strains.","22682430",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2289643","A study of the correlation between serum total cholesterol and low-density lipoproteins (LDL) in Chinese.","2289643",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22904031","Gene-environment interaction in Alzheimer's disease.","22904031",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2310768","Cellular cholesterol metabolism in mitogen-stimulated lymphocytes--requirement for de novo synthesis.","2310768",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1979,"233552","Cholesterol accumulation in the arterial cells and in the extracellular spaces.","233552",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2363705","Evidence for reverse cholesterol transport in vivo from liver endothelial cells to parenchymal cells and bile by high-density lipoprotein.","2363705",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23975928","Discovery of the cellular and molecular basis of cholesterol control.","23975928",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"24302809","Effect of surgical treatment on lipid peroxidation parameters and antioxidant status in the serum of patients with peripheral arterial disease.","24302809",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24528684","Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.","24528684",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24920391","Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis.","24920391",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25172365","Evolving targets for lipid-modifying therapy.","25172365",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25528964","RIP140 contributes to foam cell formation and atherosclerosis by regulating cholesterol homeostasis in macrophages.","25528964",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25803666","Effects of Nordic Walking and Pilates exercise programs on blood glucose and lipid profile in overweight and obese postmenopausal women in an experimental, nonrandomized, open-label, prospective controlled trial.","25803666",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25998247","Lysophosphatidylcholine promotes SREBP-2 activation via rapid cholesterol efflux and SREBP-2-independent cytokine release in human endothelial cells.","25998247",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"26399924","Oxidized low-density lipoprotein promotes macrophage lipid accumulation via the toll-like receptor 4-Src pathway.","26399924",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2664966","[Cholesterol in 1989].","2664966",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27100504","Paradoxical impact of cholesterol on lipid packing and cell stiffness.","27100504",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27416363","The pathophysiological role of oxidized cholesterols in epicardial fat accumulation and cardiac dysfunction: a study in swine fed a high caloric diet with an inhibitor of intestinal cholesterol absorption, ezetimibe.","27416363",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27644038","Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol.","27644038",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2770245","A role for intracellular traffic of high-density lipoproteins in cholesterol metabolism.","2770245",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28098515","A Randomized Open-Label Trial to Assess the Effect of Plant Sterols Associated with Ezetimibe in Low-Density Lipoprotein Levels in Patients with Coronary Artery Disease on Statin Therapy.","28098515",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"2845980","Cyclic AMP decreases LDL catabolism and cholesterol synthesis in the human hepatoma cell line HepG2.","2845980",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"2982384","Prostaglandins and cyclic nucleotides. Modulators of arterial cholesterol metabolism.","2982384",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3023738","Role of the high density lipoprotein-receptor cycle in macrophage-cholesterol metabolism.","3023738",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3200122","Increased amounts of cholesterol precursors in lipoproteins after ileal exclusion.","3200122",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3365597","Smoking, alcohol consumption, lipid and lipoprotein levels.","3365597",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3579724","Accumulation of cholesteryl ester and lipid droplets in macrophages after uptake of cholesterol-rich necrotic products.","3579724",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3680287","Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts.","3680287",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"3906334","Cholesterol transport and uptake in miniature swine fed vegetable and animal fats and proteins. 1. Plasma lipoproteins and LDL clearance.","3906334",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3946457","Cholesterol and coronary artery disease. What do clinicians do now?","3946457",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"4052443","Inhibition, post-hydroxymethylglutaryl-CoA regulation and relation to cell growth of cholesterol biosynthesis in cultured human skin fibroblasts.","4052443",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1972,"4339341","Influence of dietary fat on the concentration of long-chain unsaturated fatty acid families in rat tissues.","4339341",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1972,"4345054","Hypolipidemic effect of pregnancy in the rabbit.","4345054",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1974,"4361700","Plasma vitamin E and cholesterol relationship in Western Canadian Indians.","4361700",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1973,"4361804","Altered bile acid metabolism during treatment with phenobarbitone.","4361804",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1974,"4369163","Separate estimation of serum beta-lipoprotein cholesterol and pre-beta-lipoprotein cholesterol: clinical aspects.","4369163",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6099617","Effects of catechol estrogen methyl ethers on lipid metabolism in prepubertal rats.","6099617",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6147694","Metabolic study of variation in plasma cholesterol level in normal men.","6147694",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"6250789","The regulation of de novo synthesis of cholesterol in the human fetal adrenal gland by low density lipoprotein and adrenocorticotropin.","6250789",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"6276267","Interaction of lipoproteins with macrophages.","6276267",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6317039","Regulation of hepatic receptor-dependent degradation of LDL by mevinolin in rabbits with hypercholesterolemia induced by a wheat starch-casein diet.","6317039",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6366488","The lipid hypothesis is proven.","6366488",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6435409","Regulation of low density lipoprotein uptake and degradation in different animals species.","6435409",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6491537","Cholesterol metabolism in pigeon aortic smooth muscle cells lacking a functional low density lipoprotein receptor pathway.","6491537",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6574521","The effect of growth hormone administration on lipids and lipoproteins in growth hormone-deficient patients.","6574521",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6592957","Regulation of LDL receptors in vivo.","6592957",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6665516","Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics.","6665516",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6694557","Primary and familial hypoalphalipoproteinemia.","6694557",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"6750834","The Program on the Surgical Control of the Hyperlipidemias: a status report.","6750834",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6825228","Summary estimates of cholesterol used to predict coronary heart disease.","6825228",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6848509","The dual role of mevalonate in the cell cycle.","6848509",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6870997","Red blood cell cholesterol levels, plasma cholesterol esterification rate and serum lipids and lipoproteins in men with hypercholesterolaemia and normal men during 16 weeks physical training.","6870997",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"6944284","Lipoprotein-cholesterol in coronary-heart-disease (CHD) patients with and without exercise training.","6944284",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"6954844","Cholesterol turnover in human plasma lipoproteins: studies with stable and radioactive isotopes.","6954844",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"7048876","Consideration of cholesterol and noncardiovascular mortality.","7048876",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"7081119","Changes in plasma lipid and lipoprotein fractions after alteration in dietary cholesterol, polyunsaturated, saturated, and total fat in free-living normal and hypercholesterolemic children.","7081119",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"7132740","Exercise does not change high-density lipoprotein cholesterol in women after ten weeks of training.","7132740",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"7176708","Cholesterol and cholesteryl ester concentration in different size classes of cultured human fibroblasts: effect of in vitro aging.","7176708",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"7213268","Fitness variables and the lipid profile in United States astronauts.","7213268",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"7229037","Effects of ML-236b (compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia.","7229037",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"7289181","[The relationships of HDL- and LDL-cholesterol to cerebral infarction and to atherosclerosis--clinical and pathological study (author's transl)].","7289181",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"7330649","[Importance of the determination of HDL-cholesterol in the evaluation of arteriopathies of the lower extremities].","7330649",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"7357841","Cholesterol: good and bad.","7357841",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"7401938","Regulation of lung surfactant cholesterol metabolism by serum lipopoteins.","7401938",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"7441801","Serum cholesterol in Libyans.","7441801",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"7448794","Effect of cell density and confluency on cholesterol metabolism in cancer cells in monolayer culture.","7448794",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7503765","Thyronines and probucol inhibition of human capillary endothelial cell-induced low density lipoprotein oxidation.","7503765",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7658161","Psyllium reduces plasma LDL in guinea pigs by altering hepatic cholesterol homeostasis.","7658161",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7705389","Cholesterol biosynthesis in dermal fibroblasts from patients with metabolic disorders of peroxisomal origin.","7705389",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7805879","Pro-oxidant effects of 7-hydroperoxycholest-5-en-3 beta-ol on the copper-initiated oxidation of low density lipoprotein.","7805879",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7917914","Tumours of the central nervous system and concentration of total serum cholesterol and beta-lipoprotein in men and women.","7917914",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8074686","Melatonin inhibits LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes.","8074686",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8206258","Effects of low density lipoprotein of varying composition on cholesterol levels in human monocyte-derived macrophages.","8206258",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8371064","Differential accumulation of cholesterol in Golgi compartments of normal and Niemann-Pick type C fibroblasts incubated with LDL: a cytochemical freeze-fracture study.","8371064",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8485136","Cholesterol is poorly available for free apolipoprotein-mediated cellular lipid efflux from smooth muscle cells.","8485136",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8618929","Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse.","8618929",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8687025","Modification of high- and low-density lipoproteins by cigarette smoke oxidants.","8687025",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8818799","Effects of the callipyge phenotype on serum creatinine, total cholesterol, low-density lipoproteins, very-low-density lipoproteins, high-density lipoproteins, and triacylglycerol in growing lambs.","8818799",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8910497","Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors.","8910497",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8993615","Impaired cholesterol synthesis rate in fibroblasts and reduced cellular uptake of LDLs derived from peroxisome-deficient patients cause cellular cholesterol deficiency in peroxisome-deficient fibroblasts.","8993615",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9105561","Effects of nitric oxide on cholesterol metabolism in macrophages.","9105561",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9210470","Comparison of the uptake and processing of cholesterol from chylomicrons of different fatty acid composition in rats fed high-fat and low-fat diets.","9210470",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9215137","Is lipid oxidation essential for atherogenesis?","9215137",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9405278","Effect of reduced low-density lipoprotein receptor level on HepG2 cell cholesterol metabolism.","9405278",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9456275","Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.","9456275",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9555953","Effect of a coffee lipid (cafestol) on cholesterol metabolism in human skin fibroblasts.","9555953",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9699904","Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects.","9699904",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9840652","Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock.","9840652",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2000,"10953679","Consumption of olive oil has opposite effects on plasma total cholesterol and sphingomyelin concentrations in rats.","10953679",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1999,"10566626","Fasting remnant lipoprotein cholesterol and triglyceride concentrations are elevated in nondiabetic, insulin-resistant, female volunteers.","10566626",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2001,"11387232","Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice.","11387232",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"12105210","Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1.","12105210",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2003,"12700338","Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans.","12700338",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,2,2003,"14569407","Increased binding of LDL and VLDL to apo B,E receptors of hepatic plasma membrane of rats treated with Fibernat.","14569407",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2006,"16528005","Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.","16528005",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1975,"172803","Lipoprotein receptors and genetic control of cholesterol metabolism in cultured human cells.","172803",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1991,"1782727","Independence of myocardial disease in the JCR:LA-corpulent rat on plasma cholesterol concentration.","1782727",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1976,"183081","[Serum lipids and serum lipoproteins in acute hepatitis. A correlation-statistical analysis].","183081",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1976,"183492","Effects of ethanol on bile acid and cholesterol metabolism.","183492",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1977,"191548","Interaction of cholesterol ester and triglyceride in human plasma very low density lipoprotein.","191548",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1990,"1979819","Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.","1979819",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1990,"2087063","Triglycerides and atherosclerosis.","2087063",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2011,"21056113","Regulation of bile acid, cholesterol, and fatty acid synthesis in chicken primary hepatocytes by different concentrations of T0901317, an agonist of liver X receptors.","21056113",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1979,"216259","Dietary fiber and blood lipids: reduction of serum cholesterol in type II hyperlipidemia by guar gum.","216259",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1979,"220351","The effect of glucagon, norepinephrine, and dibutyryl cyclic AMP on cholesterol efflux and on the activity of 3-hydroxy-3-methylglutaryl CoA reductase in rat hepatocytes.","220351",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"4036853","Why do polyunsaturated fatty acids lower serum cholesterol?","4036853",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1979,"228547","The effect of tocopherol on high-density lipoprotein cholesterol. A clinical observation.","228547",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2014,"24299019","Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.","24299019",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2015,"25670366","Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.","25670366",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1986,"3018402","[Principles of cholesterol and bile acid metabolism in the liver and small intestine (I)].","3018402",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1987,"3318456","Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives.","3318456",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1987,"3476234","Effect of phenobarbital upon serum cholesterol lipoprotein fractions of three rodent species.","3476234",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1986,"3524618","Regulation of cholesterol biosynthesis.","3524618",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"3864166","Standardization of lipid and lipoprotein determinations for pediatric screening procedures.","3864166",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"3865475","Serum cholesterol binding reserve percentage in diabetes mellitus.","3865475",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1972,"4337382","Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.","4337382",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1973,"4352458","Hyperlipidemia in coronary heart disease. 3. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction.","4352458",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1974,"4364930","Serum lipids and lipoproteins in hepatosis of pregnancy and pre-eclampsia.","4364930",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1974,"4375013","Changes in plasma lipoprotein lipids in hypercholesterolaemic patients treated with the bile acid-sequestering resin, colestipol.","4375013",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"6277547","Cholesterol transport through the plasma.","6277547",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1984,"6439533","Plasma lipids and lipoprotein cholesterol in undernourished diabetic subjects and adults with protein energy malnutrition.","6439533",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1983,"6574998","Lack of effect of ingestion of vitamin E on lipoprotein-cholesterol fractions in healthy adults.","6574998",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1984,"6591217","Effect of pectin on cholesterol distribution in the lipoproteins of streptozotocin-diabetic rats fed cholesterol diet.","6591217",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,3,1983,"6677890","[Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].","6677890",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"6794547","Serum reserve cholesterol binding capacity (SRCBC): the relative importance of different lipoprotein classes.","6794547",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"6944414","High resolution plasma lipoprotein cholesterol profiles by a rapid, high volume semi-automated method.","6944414",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"6951174","Regulation of serum apolipoprotein E metabolism: role of chylomicron metabolism.","6951174",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"6992525","Cholesterol metabolism in clinical hyperlipidemias.","6992525",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"7181672","Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.","7181672",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"7231186","Hypertriglyceridemia and hypoalphalipoproteinemia in azoospermic and oligospermic young men: relationships of endogenous testosterone to triglyceride and high density lipoprotein cholesterol metabolism.","7231186",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"7295182","Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides. Association with adiposity and the consumption of ethanol, tobacco, and beverages containing caffeine.","7295182",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"7303638","[Ester-bound cholesterol composition in high-density lipoproteins].","7303638",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"7407227","Net mass transfer of esterified cholesterol from human low density lipoproteins to very low density lipoproteins incubated in vitro.","7407227",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1995,"7657828","Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.","7657828",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1994,"7786684","Cholesterol oxides in plasma and lipoproteins of magnesium-deficient rabbits and effects of their lipoproteins on endothelial barrier function.","7786684",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1993,"8246769","Cholesterol and fatty acid metabolism in piglets fed sow milk or infant formula with or without addition of cholesterol.","8246769",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1979,"86108","Serum-lipoprotein-cholesterol distribution in healthy men with high serum-cholesterol concentrations: Extrapolation to clofibrate trial.","86108",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1997,"9270980","Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.","9270980",57]
["Cholesterol","Cholesterol","D002784","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9630709","Transport of side-chain oxidized oxysterols in the human circulation.","9630709",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21181211","Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis.","21181211",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22806626","Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia.","22806626",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23900008","The inhibitory effect of black soybean on hepatic cholesterol accumulation in high cholesterol and high fat diet-induced non-alcoholic fatty liver disease.","23900008",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24849447","[Effect of probucol in improving hepatic steatosis in rats with non-alcoholic steatohepatitis and the mechanism].","24849447",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25605429","miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.","25605429",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26129791","The NASH drug dash.","26129791",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28358980","Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.","28358980",57]
["Cholesterol","Cholesterol","D002784","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28404639","Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH.","28404639",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2001,"11352979","Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP.","11352979",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1989,"2513806","Effect of 25-hydroxycholesterol and bile acids on the regulation of cholesterol metabolism in Hep G2 cells.","2513806",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C11971,B11971)","v":"Cholesterol"},"Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J11971,K11971)","v":"Receptors, LDL"},"D011973","Receptors, LDL",1,1,1999,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q11971,Q11971)","v":"10224158"},"Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice.","10224158",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10574653","Mechanisms mediating lipoprotein responses to diets with medium-chain triglyceride and lauric acid.","10574653",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10872459","Charting the fate of the \"good cholesterol\": identification and characterization of the high-density lipoprotein receptor SR-BI.","10872459",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2000,"11215376","[Aggregation of human blood platelets by remnant-like lipoprotein particles].","11215376",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2001,"11701705","Hepatic lipogenesis and cholesterol synthesis in hyperthyroid patients.","11701705",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2002,"12007578","HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice.","12007578",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2002,"12296605","Familial hypercholesterolaemia: optimum treatment strategies.","12296605",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1993,"1343450","The Gordon Wilson Lecture. Plasma cholesterol: atherogenesis and mortality.","1343450",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2004,"14738906","Naringin alters the cholesterol biosynthesis and antioxidant enzyme activities in LDL receptor-knockout mice under cholesterol fed condition.","14738906",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2004,"15093185","Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy.","15093185",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2005,"15780535","A comparative study of efficacy of tibolone and simvastatin on atherosclerosis in ovariectomized cholesterol-fed rabbits.","15780535",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2005,"16299127","Mouse models may provide new insight into the relation between cholesterol and age related macular degeneration.","16299127",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2006,"16549444","Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux.","16549444",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1991,"1674974","[Lipid metabolism in man--new knowledge on molecular level gives hope for better therapy].","1674974",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,2006,"16946405","PPAR gamma ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2.","16946405",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,2007,"17420587","Hypocholesterolemic mechanism of Chlorella: Chlorella and its indigestible fraction enhance hepatic cholesterol catabolism through up-regulation of cholesterol 7alpha-hydroxylase in rats.","17420587",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18032697","Hormonal regulation of testicular steroid and cholesterol homeostasis.","18032697",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18496813","Apple polyphenols inhibit plasma CETP activity and reduce the ratio of non-HDL to HDL cholesterol.","18496813",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18836590","Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.","18836590",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2009,"19283084","Cholesterol-dependent anaplasma phagocytophilum exploits the low-density lipoprotein uptake pathway.","19283084",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2009,"19718435","LRP1 controls cPLA2 phosphorylation, ABCA1 expression and cellular cholesterol export.","19718435",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1991,"2001802","Hepatic metabolism of cholesterol in Crohn's disease. Effect of partial resection of ileum.","2001802",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20412743","[Cholesterol metabolism and beta-cell function].","20412743",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"21105984","Plasmodium salvages cholesterol internalized by LDL and synthesized de novo in the liver.","21105984",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"21538857","Hypocholesterolemic and hypoglycemic effects of enzymatically modified carbohydrates from rice in high-fat-fed C57BL/6J mice.","21538857",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"21864647","Sphingosine-1-phosphate rapidly increases cortisol biosynthesis and the expression of genes involved in cholesterol uptake and transport in H295R adrenocortical cells.","21864647",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22362817","Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis.","22362817",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22669020","Autosomal recessive hypercholesterolaemia in a Morrocan family due to a mutation of the G266C LDL receptor.","22669020",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22956784","Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation.","22956784",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22964999","Inhibition of PCSK9:  is this the way forward for managing residual risk?","22964999",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23333824","Reciprocal regulation of cholesterol excretion in apolipoprotein E-null mice by angiotensin II type 1 and type 2 receptor deficiency.","23333824",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23645541","Diet supplementation with beta-carotene improves the serum lipid profile in rats fed a cholesterol-enriched diet.","23645541",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"24025543","ATP-binding cassette transporter A1 in lipoprotein metabolism and atherosclerosis: a new piece of the complex puzzle.","24025543",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2014,"24468153","Cholesterol-induced hepatic inflammation does not contribute to the development of insulin resistance in male LDL receptor knockout mice.","24468153",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2014,"24917546","Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering.","24917546",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2014,"25035345","Transmembrane protein 55B is a novel regulator of cellular cholesterol metabolism.","25035345",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"25749868","Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.","25749868",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"26118540","Chandipura virus perturbs cholesterol homeostasis leading to neuronal apoptosis.","26118540",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"26281596","[Regulatory effect of coptisine on key genes involved in cholesterol metabolism].","26281596",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"26628375","GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation.","26628375",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,2016,"27133571","Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.","27133571",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"27821400","Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio.","27821400",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"28003730","Accumulation of cholesterol and increased demand for zinc in serum-deprived RPE cells.","28003730",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"28522295","Reversal of adipose tissue loss by probucol in mice with deficiency of both scavenger receptor class B type 1 and LDL receptor on high fat diet.","28522295",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C12675,B12675)","v":"Cholesterol"},"Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J12675,K12675)","v":"Receptors, LDL"},"D011973","Receptors, LDL",1,1,2017,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q12675,Q12675)","v":"29190422"},"Structure-specific effects of short-chain fatty acids on plasma cholesterol concentration in male Syrian hamsters.","29190422",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1987,"3104128","Biliary excretion of apolipoprotein B by the isolated perfused rat liver. Relationship to receptor-mediated uptake of human low-density lipoprotein and biliary lipid secretion.","3104128",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1988,"3377878","The antidiabetic drug metformin decreases cholesterol metabolism in cultured human fibroblasts.","3377878",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1987,"3571495","Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol loading of cultured macrophages.","3571495",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1985,"3856094","The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia.","3856094",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1981,"6262757","Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.","6262757",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1983,"6309907","Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.","6309907",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1983,"6388097","Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.","6388097",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7601197","1994 Mack-Forster Award Lecture. Review. Studies on the regulation of hepatic cholesterol metabolism in humans.","7601197",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7749852","Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes.","7749852",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1994,"7918302","Potent cholesterol-lowering effect by human granulocyte-macrophage colony-stimulating factor in rabbits. Possible implications of enhancement of macrophage functions and an increase in mRNA for VLDL receptor.","7918302",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1993,"8292099","The effects of hypercholesterolaemia, simvastatin and dietary fat on the low density lipoprotein receptor of unstimulated mononuclear cells.","8292099",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1993,"8489131","Soybean protein diet and plasma cholesterol: from therapy to molecular mechanisms.","8489131",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1996,"8728316","Cholesterol homeostasis is modulated by amphiphiles at transcriptional and post-transcriptional loci.","8728316",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1997,"9075692","Effects of reduced maternal lipoprotein-cholesterol availability on placental progesterone biosynthesis in the baboon.","9075692",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1997,"9281617","Beneficial effects of a novel thyromimetic on lipoprotein metabolism.","9281617",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1997,"9458274","Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.","9458274",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9538248","Hypocholesterolemic effects of the LDL receptor gene transcriptional upregulator CP-230821.","9538248",57]
["Cholesterol","Cholesterol","D002784","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9698096","Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression.","9698096",57]
["Cholesterol","Cholesterol","D002784","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2008,"18620774","Fish oil fed prior to ethanol administration prevents acute ethanol-induced fatty liver in mice.","18620774",57]
["Cholesterol","Cholesterol","D002784","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2014,"25147951","Cartilage-specific ablation of site-1 protease in mice results in the endoplasmic reticulum entrapment of type IIb procollagen and down-regulation of cholesterol and lipid homeostasis.","25147951",57]
["cholesterol alpha-oxide","cholesterol alpha-oxide","C002415","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17994574","Death-signaling pathways in human myeloid cells by oxLDL and its cytotoxic components 7beta-hydroxycholesterol and cholesterol-5beta,6beta-epoxide.","17994574",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,3,1992,"1491012","Fatty acid composition and properties of the liver microsomal membrane of rats fed diets enriched with cholesterol.","1491012",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2008,"18666236","Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis.","18666236",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20512524","Differential response of two models of genetically modified mice fed with high fat and cholesterol diets: relationship to the study of non-alcoholic steatohepatitis.","20512524",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"22806923","Excess cholesterol and fat in the diet: a dangerous liaison for energy expenditure and the liver.","22806923",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27432221","Prolonged feeding with green tea polyphenols exacerbates cholesterol-induced fatty liver disease in mice.","27432221",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1973,"4806036","Exercise and liver injury induced by high cholesterol diet.","4806036",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,1996,"8923254","Effects of diets containing tallow and soybean oil with and without cholesterol on hepatic metabolism of lipids and lipoproteins in the preruminant calf.","8923254",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12030378","Dietary fat source and cholesterol interactions alter plasma lipids and tissue susceptibility to oxidation in spontaneously hypertensive (SHR) and normotensive Wistar Kyoto (WKY) rats.","12030378",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12616810","Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: possible role of oxidised LDL.","12616810",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1976,"179305","Phylogenetic variability of serum lipids and lipoproteins in non-human primates fed diets with different contents of dietary cholesterol.","179305",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19728895","Effect of seaweed and cholesterol-enriched diets on postprandial lipoproteinaemia in rats.","19728895",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"19892353","Low-carbohydrate diets reduce lipid accumulation and arterial inflammation in guinea pigs fed a high-cholesterol diet.","19892353",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2231018","Pectin isolated from prickly pear (Opuntia sp.) modifies low density lipoprotein metabolism in cholesterol-fed guinea pigs.","2231018",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25242170","Noninvasive metabolic syndrome model using an extremely small minipig, the microminipig.","25242170",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3216380","Diet can lower cholesterol and reduce heart disease.","3216380",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1972,"4342426","Characterization of guinea pig plasma lipoproteins: the appearance of new lipoproteins in response to dietary cholesterol.","4342426",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6142348","Ingestion of egg raises plasma low density lipoproteins in free-living subjects.","6142348",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6683911","Regression of casein and cholesterol-induced hypercholesterolaemia in rabbits.","6683911",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"7259536","Alimentary induced changes in the plasma and the liver lipoproteins.","7259536",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7627263","Long-term effects of dietary fiber supplementation on serum glucose and lipoprotein levels in diabetic rats fed a high cholesterol diet.","7627263",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8915394","Antihypercholesterolemic action of taurine on streptozotocin-diabetic rats or on rats fed a high cholesterol diet.","8915394",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1552367","Hyperresponsiveness to dietary cholesterol in inbred rabbits is not associated with enhanced reduction in binding of beta-VLDL to liver membranes.","1552367",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1976,"182200","Atherogenic hyperlipoproteinemia induced by cholesterol feeding the Patas monkey.","182200",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1977,"200093","A comparative study of the effect of dietary cholesterol on plasma lipoproteins in nonhuman primates.","200093",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2585141","Effect of dietary restriction on receptor-mediated and independent catabolism of beta-very low density lipoproteins in cholesterol-fed rabbits.","2585141",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1986,"3460081","Molecular cloning of partial cDNAs for rabbit liver apolipoprotein B and the regulation of its mRNA levels by dietary cholesterol.","3460081",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"3986014","Secretion of cholesteryl ester-enriched very low density lipoproteins by the liver of cholesterol-fed rabbits.","3986014",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1974,"4359181","The very low density lipoproteins of cholesterol-fed rabbits. A study of their structure and in vivo changes in plasma.","4359181",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1984,"6591217","Effect of pectin on cholesterol distribution in the lipoproteins of streptozotocin-diabetic rats fed cholesterol diet.","6591217",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"7040843","Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol.","7040843",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1994,"8185606","Effects of dietary cholesterol on hepatic metabolism of free fatty acid and secretion of VLDL in the hamster.","8185606",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1996,"8915394","Antihypercholesterolemic action of taurine on streptozotocin-diabetic rats or on rats fed a high cholesterol diet.","8915394",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2013,"23697659","A novel antihypoglycemic role of inducible nitric oxide synthase in liver inflammatory response induced by dietary cholesterol and endotoxemia.","23697659",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10074493","The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae.","10074493",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2003,"14681047","Dual benefit of reduced Cx43 on atherosclerosis in LDL receptor-deficient mice.","14681047",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1991,"1683257","In vivo regulation of low-density lipoprotein receptor and apolipoprotein B gene expressions by dietary fat and cholesterol in inbred strains of mice.","1683257",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20189995","Improved insulin sensitivity in high fat- and high cholesterol-fed Ldlr-/- mice with macrophage-specific transgenic expression of cholesteryl ester hydrolase: role of macrophage inflammation and infiltration into adipose tissue.","20189995",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23846497","Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.","23846497",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"26847248","High dietary cholesterol intake during lactation promotes development of fatty liver in offspring of mice.","26847248",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7848292","Increased response to cholesterol feeding in apolipoprotein C1-deficient mice.","7848292",57]
["Cholesterol, Dietary","Cholesterol, Dietary","D002791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1997,"9194759","Alcohol increases plasma levels of cholesterol diet-induced atherogenic lipoproteins and aortic atherosclerosis in rabbits.","9194759",57]
["cholesteryl 1,12-dicarba-closo-dodecaboranel-carboxylate","cholesteryl 1,12-dicarba-closo-dodecaboranel-carboxylate","C496891","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2004,"15290868","Uptake of the carborane derivative of cholesteryl ester by glioma cancer cells is mediated through LDL receptors.","15290868",57]
["cholesteryl hexyl ether","cholesteryl hexyl ether","C048982","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12801606","Inhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: role of electrostatic interactions.","12801606",57]
["cholesteryl iopanoate","cholesteryl iopanoate","C039133","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10213374","Radiolabeled cholesteryl iopanoate/acetylated low density lipoprotein as a potential probe for visualization of early atherosclerotic lesions in rabbits.","10213374",57]
["cholesteryl linoleate","cholesteryl linoleate","C021976","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"7306561","Role of lipoprotein lipase in the uptake of cholesteryl ester by rat lactating mammary gland in vivo.","7306561",57]
["cholesteryl oleate","cholesteryl oleate","C014409","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2693568","In vitro incorporation of radiolabeled cholesteryl esters into high and low density lipoproteins.","2693568",57]
["cholesteryl oleate","cholesteryl oleate","C014409","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2005,"15790455","Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma.","15790455",57]
["cholesteryl sulfate","cholesteryl sulfate","C007045","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8954138","Inhibition of cholesteryl ester transfer protein by apolipoproteins, lipopolysaccharides, and cholesteryl sulfate.","8954138",57]
["Cholestyramine Resin","Cholestyramine Resin","D002792","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1730048","Effects of cholestyramine on lipoprotein levels and metabolism in Syrian hamsters.","1730048",57]
["Cholestyramine Resin","Cholestyramine Resin","D002792","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"2893044","Bile acid sequestrants and hyperlipidaemia.","2893044",57]
["Cholestyramine Resin","Cholestyramine Resin","D002792","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1977,"63709","Dose-effect relation of cholestryamine in children and young adults with familial hypercholesterolaemia.","63709",57]
["Cholestyramine Resin","Cholestyramine Resin","D002792","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1997,"9366812","The influence of age on low density lipoprotein metabolism: effects of cholestyramine treatment in young and old healthy male subjects.","9366812",57]
["Cholestyramine Resin","Cholestyramine Resin","D002792","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"6214264","Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia.","6214264",57]
["Cholestyramine Resin","Cholestyramine Resin","D002792","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1980,"6253466","Effects of cholestyramine on receptor-mediated plasma clearance and tissue uptake of human low density lipoproteins in the rabbit.","6253466",57]
["Cholic Acid","Cholic Acid","D019826","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1988,"2850353","Soluble oat fiber tends to normalize lipoprotein composition in cholesterol-fed rats.","2850353",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1955,"13259736","[Action of lipotropic factors on hepatic steatosis in experimental hypoxia].","13259736",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1952,"13107674","[Liver fatty degeneration inhibiting factors of foodstuffs].","13107674",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14185046","INFLUENCE OF LACTOSE ON AMOUNT OF LIVER-FAT IN FATTY LIVERS.","14185046",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"14289002","EFFECTS OF UNSATURATED FATS ON DIETARY-INDUCED CIRRHOSIS IN THE RAT.","14289002",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1971,"4107960","Lipotropic activity of inositol and chlortetracycline alone and in various combinations of choline, vitamin B 12  and folic acid. Activity of three liver extracts with assays for these substances.","4107960",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1991,"1941213","Dietary management of idiopathic feline hepatic lipidosis with a liquid diet supplemented with citrulline and choline.","1941213",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"23481610","Persistent fibrosis in the liver of choline-deficient and iron-supplemented L-amino acid-defined diet-induced nonalcoholic steatohepatitis rat due to continuing oxidative stress after choline supplementation.","23481610",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1969,"5376845","[Effect of choline on certain indices of fat-lipid metabolism in experimental thyroid toxicosis].","5376845",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"5897492","Fatty cirrhosis in the rat. 8. Effect of dietary fat.","5897492",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1996,"8987099","Hybrid ducks overfed with boiled corn develop an acute hepatic steatosis with decreased choline and polyunsaturated fatty acid level in phospholipids.","8987099",57]
["Choline","Choline","D002794","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2738069","Head group specificity in the requirement of phosphatidylcholine biosynthesis for very low density lipoprotein secretion from cultured hepatocytes.","2738069",57]
["Choline","Choline","D002794","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26880573","Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease.","26880573",57]
["Chondroitin","Chondroitin","D002807","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3142452","Biosynthesis of chondroitin sulfate proteoglycan by P388D1 macrophage-like cell line.","3142452",57]
["chrysene","chrysene","C031180","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2017,"27627846","The detoxification responses, damage effects and bioaccumulation in the scallop Chlamys farreri exposed to single and mixtures of benzo[a]pyrene and chrysene.","27627846",57]
["chrysin","chrysin","C043561","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"26515162","Aryl hydrocarbon receptor-dependent apoptotic cell death induced by the flavonoid chrysin in human colorectal cancer cells.","26515162",57]
["cilostazol","cilostazol","C045645","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2015,"26362727","Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis.","26362727",57]
["cinnamamide","cinnamamide","C411088","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2015,"26384859","Cinnamamides, Novel Liver X Receptor Antagonists that Inhibit Ligand-Induced Lipogenesis and Fatty Liver.","26384859",57]
["ciprofibrate","ciprofibrate","C019304","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2007,"17519077","The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.","17519077",57]
["Ciprofloxacin","Ciprofloxacin","D002939","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21787699","Effects of cytochrome P450 1A substrate (difloxacin) on enzyme gene expression and pharmacokinetics in crucian carp (hybridized Prussian carp).","21787699",57]
["Cisplatin","Cisplatin","D002945","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2003,"12810637","Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.","12810637",57]
["Cisplatin","Cisplatin","D002945","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2003,"12845662","Enhanced susceptibility of oral squamous cell carcinoma cell lines to FAS-mediated apoptosis by cisplatin and 5-fluorouracil.","12845662",57]
["cleomiscosin A","cleomiscosin A","C041934","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17424931","Antioxidant activity of cleomiscosins A and C isolated from Acer okamotoanum.","17424931",57]
["Clofibrate","Clofibrate","D002994","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"2390105","Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.","2390105",57]
["Clofibrate","Clofibrate","D002994","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,3,1994,"7852859","Mitochondrial 2,4-dienoyl-CoA reductases in the rat: differential responses to clofibrate treatment.","7852859",57]
["Clofibrate","Clofibrate","D002994","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1975,"173015","Effect of treatment with a bile-sequestering agent (Secholex) on intestinal absorption, duodenal bile acids, and plasma lipids.","173015",57]
["Clofibrate","Clofibrate","D002994","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1978,"206826","[Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].","206826",57]
["Clofibrate","Clofibrate","D002994","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1975,"215986","Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.","215986",57]
["Clofibrate","Clofibrate","D002994","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1972,"4341290","Change of lipoprotein pattern by clofibrate in hyperglyceridaemia and mixed hyperlipidaemia.","4341290",57]
["Clofibrate","Clofibrate","D002994","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6368883","Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.","6368883",57]
["Clofibrate","Clofibrate","D002994","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6832340","The effect of bezafibrate and clofibrate on cholesterol ester metabolism in rabbit peritoneal macrophages stimulated with acetylated low density lipoproteins.","6832340",57]
["Clofibrate","Clofibrate","D002994","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1975,"164312","Effects of clofibrate and a fat-modified diet on serum lipids.","164312",57]
["Clofibrate","Clofibrate","D002994","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1977,"195201","[Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].","195201",57]
["Clofibrate","Clofibrate","D002994","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1978,"203832","[Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].","203832",57]
["Clofibrate","Clofibrate","D002994","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1973,"4353773","Mechanism of the hypolipemic effect of clofibrate in postabsorptive man.","4353773",57]
["Clofibrate","Clofibrate","D002994","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"6951582","Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.","6951582",57]
["Clofibrate","Clofibrate","D002994","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2001,"11162472","Effects of polyunsaturated fatty acids and clofibrate on chicken stearoyl-coA desaturase 1 gene expression.","11162472",57]
["Clofibrate","Clofibrate","D002994","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,1982,"6129897","Increased activity of stearoyl-CoA desaturation in liver from rat fed clofibric acid.","6129897",57]
["Clofibric Acid","Clofibric Acid","D002995","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1986,"2874791","Alterations by peroxisome proliferators of acyl composition of hepatic phosphatidylcholine in rats, mice and guinea-pigs. Role of stearoyl-CoA desaturase.","2874791",57]
["Clofibric Acid","Clofibric Acid","D002995","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19144670","Fibrates: where are we now?","19144670",57]
["Clofibric Acid","Clofibric Acid","D002995","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8831912","The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.","8831912",57]
["Clofibric Acid","Clofibric Acid","D002995","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2004,"15127182","PPARalpha-dependent modulation of hepatic CYP1A by clofibric acid in rats.","15127182",57]
["Clomiphene","Clomiphene","D002996","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1973,"4780276","[Relationships between clomiphene and experimental hepatopathies].","4780276",57]
["Clove Oil","Clove Oil","D045783","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24611461","Protective effect of clove oil and eugenol microemulsions on fatty liver and dyslipidemia as components of metabolic syndrome.","24611461",57]
["Coal","Coal","D003031","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"7944555","Characterization of cytochrome P4501A induction in medaka (Oryzias latipes) by samples generated from the extraction and processing of coal.","7944555",57]
["Cocaine","Cocaine","D003042","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10409439","Cocaine-induced increase in the permeability function of human vascular endothelial cell monolayers.","10409439",57]
["Coconut Oil","Coconut Oil","D000074263","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1993,"7906638","Effect of dietary coconut oil on lipoprotein composition of young chick (Gallus domesticus).","7906638",57]
["coenzyme Q10","coenzyme Q10","C024989","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10612557","Measurement and stability of plasma reduced, oxidized and total coenzyme Q10 in humans.","10612557",57]
["coenzyme Q10","coenzyme Q10","C024989","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16388100","Effect of coenzyme Q10 on catalase activity and other antioxidant parameters in streptozotocin-induced diabetic rats.","16388100",57]
["coenzyme Q10","coenzyme Q10","C024989","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9733025","Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners.","9733025",57]
["Coffee","Coffee","D003069","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21357676","Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption.","21357676",57]
["Coffee","Coffee","D003069","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"22378327","Coffee extract attenuates changes in cardiovascular and hepatic structure and function without decreasing obesity in high-carbohydrate, high-fat diet-fed male rats.","22378327",57]
["Coffee","Coffee","D003069","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"1971319","Effect of a lipid-rich fraction from boiled coffee on serum cholesterol.","1971319",57]
["Coffee","Coffee","D003069","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19886342","Does ingestion of regular coffee influence serum lipid profile in dialysis patients?","19886342",57]
["Coffee","Coffee","D003069","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24199670","Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection?","24199670",57]
["Coke","Coke","D003077","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15355699","[Effect of genetic polymorphisms of microsomal epoxide hydrolase on urinary 1-hydroxypyrene levels in coke oven workers].","15355699",57]
["Coke","Coke","D003077","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23439269","Association of aryl hydrocarbon receptor gene polymorphism with the neurobehavioral function and autonomic nervous system function changes induced by benzo[a]pyrene exposure in coke oven workers.","23439269",57]
["Colesevelam Hydrochloride","Colesevelam Hydrochloride","D000069472","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22836068","Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus.","22836068",57]
["Colestipol","Colestipol","D003084","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6375337","Low-dose colestipol plus probucol for hypercholesterolemia.","6375337",57]
["Colestipol","Colestipol","D003084","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"7464555","Plasma lipid concentrations and lecithin:cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol.","7464555",57]
["coniferonic acid","coniferonic acid","C432390","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2006,"16267098","A front-end desaturase from Chlamydomonas reinhardtii produces pinolenic and coniferonic acids by omega13 desaturation in methylotrophic yeast and tobacco.","16267098",57]
["Copper Sulfate","Copper Sulfate","D019327","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8825967","Joint effects of copper sulphate and methidathion on rainbow trout (Oncorhynchus mykiss) EROD and AChE activities.","8825967",57]
["Copper Sulfate","Copper Sulfate","D019327","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1999,"10375392","Oxidative modification of apolipoprotein E in human very-low-density lipoprotein and its inhibition by glycosaminoglycans.","10375392",57]
["coriandrin","coriandrin","C063218","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8831817","Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins.","8831817",57]
["Corn Oil","Corn Oil","D003314","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1987,"3102555","Effect of dietary fat saturation on plasma lipoproteins and high density lipoprotein metabolism of the rhesus monkey.","3102555",57]
["Cottonseed Oil","Cottonseed Oil","D003369","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2000,"11288706","Genetic modification of cotton seed oil using inverted-repeat gene-silencing techniques.","11288706",57]
["CP 060","CP 060","C115426","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10447958","Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 2. Structure-activity relationships of thiazolidinone derivatives.","10447958",57]
["cremophor EL","cremophor EL","C000515","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7648425","Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteins.","7648425",57]
["crocin","crocin","C029036","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"22948795","Effect of crocin on the insulin resistance and lipid profile of streptozotocin-induced diabetic rats.","22948795",57]
["Cromolyn Sodium","Cromolyn Sodium","D004205","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23880180","Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice.","23880180",57]
["Curcumin","Curcumin","D003474","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2014,"24401215","Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice.","24401215",57]
["Curcumin","Curcumin","D003474","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24501322","Curcumin implants, not curcumin diet, inhibit estrogen-induced mammary carcinogenesis in ACI rats.","24501322",57]
["Curcumin","Curcumin","D003474","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23303639","Curcumin and liver disease.","23303639",57]
["Curcumin","Curcumin","D003474","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"11593527","Effects of Curcuma Longa on proliferation of cultured bovine smooth muscle cells and on expression of low density lipoprotein receptor in cells.","11593527",57]
["Curcumin","Curcumin","D003474","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24211897","Effect of curcumin on down-expression of thrombospondin-4 induced by oxidized low-density lipoprotein in mouse macrophages.","24211897",57]
["Curcumin","Curcumin","D003474","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26905192","The role of curcumin in streptozotocin-induced hepatic damage and the trans-differentiation of hepatic stellate cells.","26905192",57]
["Curcumin","Curcumin","D003474","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28770225","PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-γ/CD36 Pathway.","28770225",57]
["Curcumin","Curcumin","D003474","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18704882","Curcumin up-regulates LDL receptor expression via the sterol regulatory element pathway in HepG2 cells.","18704882",57]
["cyanidin 3-O-glucoside","cyanidin 3-O-glucoside","C114438","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23735880","Effects of anthocyanins on the AhR-CYP1A1 signaling pathway in human hepatocytes and human cancer cell lines.","23735880",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C15107,B15107)","v":"Cycloheximide"},"Cycloheximide","D003513","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J15107,K15107)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2004,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q15107,Q15107)","v":"15385644"},"Superinduction of CYP1A1 in MCF10A cultures by cycloheximide, anisomycin, and puromycin: a process independent of effects on protein translation and unrelated to suppression of aryl hydrocarbon receptor proteolysis by the proteasome.","15385644",57]
["Cycloheximide","Cycloheximide","D003513","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1973,"4350002","Assembly and secretion of very low density lipoproteins by rat liver following inhibition of protein synthesis with cycloheximide.","4350002",57]
["Cyclophosphamide","Cyclophosphamide","D003520","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6681321","Lipoprotein metabolism in the extravascular space. Cyclophosphamide inhibits modification of low-density lipoproteins in interstitial inflammatory fluid of the rabbit.","6681321",57]
["cypermethrin","cypermethrin","C017160","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27853314","Imprinting of cerebral cytochrome P450s in offsprings prenatally exposed to cypermethrin augments toxicity on rechallenge.","27853314",57]
["Cyproterone Acetate","Cyproterone Acetate","D017373","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3033444","Benefits and risks of different hormonal replacement therapies in post-menopausal women.","3033444",57]
["Cysteamine","Cysteamine","D003543","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21395631","Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease.","21395631",57]
["Cytochalasin B","Cytochalasin B","D003571","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1977,"562772","Studies on fatty liver with isolated hepatocytes. I. The action of colchicine, phalloidin, cytochalasin B, and cyclohexamide on protein and triglyceride synthesis and secretion.","562772",57]
["Dacarbazine","Dacarbazine","D003606","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21816953","Application of homology modeling to generate CYP1A1 mutants with enhanced activation of the cancer chemotherapeutic prodrug dacarbazine.","21816953",57]
["daidzein","daidzein","C004742","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9501223","Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance.","9501223",57]
["daisaikoto","daisaikoto","C051121","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1997,"9128330","Autoimmune hepatitis triggered by administration of an herbal medicine.","9128330",57]
["dan-shen root extract","dan-shen root extract","C028972","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2008,"18676239","[Effect of a compound Danshen preparation in preventing long-term gastric lipid emulsion administration-induced nonalcoholic steatohepatitis in rats].","18676239",57]
["Daunorubicin","Daunorubicin","D003630","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1969,"5305804","[Enzymatic variations and myocardial lesions in the rabbit after an administration of rubidomycin].","5305804",57]
["DDT","DDT","D003634","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1372805","A pleiotropic response to phenobarbital-type enzyme inducers in the F344/NCr rat. Effects of chemicals of varied structure.","1372805",57]
["DDT","DDT","D003634","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1979,"466732","The effects of 1,1-di(p-chlorophenyl)-2-chloroethylene on plasma enzymes and blood constituents in the Japanese quail.","466732",57]
["decabromobiphenyl ether","decabromobiphenyl ether","C010902","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"19449387","In vivo and in vitro toxicity of decabromodiphenyl ethane, a flame retardant.","19449387",57]
["deferasirox","deferasirox","C415250","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21372165","Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.","21372165",57]
["dehydroabietic acid","dehydroabietic acid","C013913","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9469877","Induction of EROD activity and genotoxic effects by polycyclic aromatic hydrocarbons and resin acids on the juvenile eel (Anguilla anguilla L.).","9469877",57]
["dehydroergosterol","dehydroergosterol","C010905","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20070610","Selective visualization of fluorescent sterols in Caenorhabditis elegans by bleach-rate-based image segmentation.","20070610",57]
["demethoxycurcumin","demethoxycurcumin","C050229","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2013,"23386263","Curcuminoids distinctly exhibit antioxidant activities and regulate expression of scavenger receptors and heme oxygenase-1.","23386263",57]
["Deoxycholic Acid","Deoxycholic Acid","D003840","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14613963","Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774.","14613963",57]
["Deoxyglucose","Deoxyglucose","D003847","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2010,"20375272","Differential regulation of cardiac glucose and fatty acid uptake by endosomal pH and actin filaments.","20375272",57]
["desferricoprogen","desferricoprogen","C047664","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18646004","Fungal siderophores function as protective agents of LDL oxidation and are promising anti-atherosclerotic metabolites in functional food.","18646004",57]
["Desmosterol","Desmosterol","D003897","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23447451","Desmosterol in human nonalcoholic steatohepatitis.","23447451",57]
["Dexamethasone","Dexamethasone","D003907","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"17552871","An evidence for regulatory cross-talk between aryl hydrocarbon receptor and glucocorticoid receptor in HepG2 cells.","17552871",57]
["Dexamethasone","Dexamethasone","D003907","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2018,"29100118","In vitro effects of diosmin, naringenin, quercetin and indole-3-carbinol on fish hepatic CYP1A1 in the presence of clotrimazole and dexamethasone.","29100118",57]
["Dexamethasone","Dexamethasone","D003907","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1984,"6142710","Modulation by dexamethasone of the fatty acyl-CoA desaturase system in Tetrahymena microsomes.","6142710",57]
["Dexamethasone","Dexamethasone","D003907","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28406431","Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.","28406431",57]
["Dexamethasone","Dexamethasone","D003907","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1999,"10484287","Consequences of treatment with dexamethasone in rats on the susceptibility of total plasma and isolated lipoprotein fractions to copper oxidation.","10484287",57]
["Dexamethasone","Dexamethasone","D003907","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2003,"12560325","Glucocorticoids repress transcription of phosphoenolpyruvate carboxykinase (GTP) gene in adipocytes by inhibiting its C/EBP-mediated activation.","12560325",57]
["Dexamethasone","Dexamethasone","D003907","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2016,"28005982","Depot Dependent Effects of Dexamethasone on Gene Expression in Human Omental and Abdominal Subcutaneous Adipose Tissues from Obese Women.","28005982",57]
["Dexamethasone","Dexamethasone","D003907","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1974,"4150434","Interaction between hormones and cyclic AMP in regulating specific hepatic enzyme synthesis.","4150434",57]
["Dexamethasone","Dexamethasone","D003907","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2008,"17552871","An evidence for regulatory cross-talk between aryl hydrocarbon receptor and glucocorticoid receptor in HepG2 cells.","17552871",57]
["dexamethasone acetate","dexamethasone acetate","C018038","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28406431","Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.","28406431",57]
["Dextran Sulfate","Dextran Sulfate","D016264","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"10078241","Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column.","10078241",57]
["Dextran Sulfate","Dextran Sulfate","D016264","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8576081","Receptor-mediated interaction of the low-density lipoprotein complex with dextran sulfate: potential as a multi-biological coupler.","8576081",57]
["DH 990","DH 990","C012656","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1984,"6696430","The effect of hypolipidemic drugs WY14643 and DH990, and lysophospholipids on the metabolism of oleate in plants.","6696430",57]
["diallyl trisulfide","diallyl trisulfide","C042577","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20229525","Diallyl disulfide and diallyl trisulfide protect endothelial nitric oxide synthase against damage by oxidized low-density lipoprotein.","20229525",57]
["Diazepam","Diazepam","D003975","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2007,"17604610","Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins.","17604610",57]
["dibenzazepine","dibenzazepine","C527817","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"19846240","Synthesis and antioxidant properties of some novel 5H-dibenz[b,f]azepine derivatives in different in vitro model systems.","19846240",57]
["dibenzo(a,l)pyrene","dibenzo(a,l)pyrene","C041517","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9860506","Metabolic activation of racemic and enantiomeric trans-8, 9-dihydroxy-8,9-dihydrodibenzo[a,l]pyrene (dibenzo[def,p]chrysene) to dibenzo[a,l]pyrene-bis-dihydrodiols by induced rat liver microsomes and a recombinant human P450 1A1 system: the role of the K-region-derived metabolic intermediates in the formation of dibenzo[a,l]pyrene-DNA adducts.","9860506",57]
["dibenzothiophene","dibenzothiophene","C016366","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1994,"7961424","Characterization of the desulfurization genes from Rhodococcus sp. strain IGTS8.","7961424",57]
["dichlorfop-methyl","dichlorfop-methyl","C012891","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2002,"12053478","[Effect of diclofop on the activity of some drug-metabolizing enzymes in the liver of male Wistar rats].","12053478",57]
["Dichlorodiphenyl Dichloroethylene","Dichlorodiphenyl Dichloroethylene","D003633","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"22358094","Effects of two isomers of DDT and their metabolite DDE on CYP1A1 and AhR function in human placental cells.","22358094",57]
["Dicumarol","Dicumarol","D001728","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1985,"2579331","Measurement of cytochrome P-450 dependent dealkylation of alkoxyphenoxazones in hepatic S9s and hepatocyte homogenates: effects of dicumarol.","2579331",57]
["Dietary Fiber","Dietary Fiber","D004043","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21530803","The soluble fiber complex PolyGlycopleX lowers serum triglycerides and reduces hepatic steatosis in high-sucrose-fed rats.","21530803",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C15811,B15811)","v":"Dietary Fiber"},"Dietary Fiber","D004043","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J15811,K15811)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1992,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q15811,Q15811)","v":"1322033"},"Psyllium husk. II: Effect on the metabolism of apolipoprotein B in African green monkeys.","1322033",57]
["Dietary Fiber","Dietary Fiber","D004043","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"2834942","Dietary fiber decreases fasting blood glucose levels and plasma LDL concentration in noninsulin-dependent diabetes mellitus patients.","2834942",57]
["Dietary Fiber","Dietary Fiber","D004043","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8886324","Soybean hull and its effect on atherosclerosis in non-human primates (Macaca fascicularis).","8886324",57]
["Dietary Fiber","Dietary Fiber","D004043","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"2989169","Effect of whole buckwheat (Fagopyrum esculentum) flour supplementation on lipid profile &amp; glucose tolerance.","2989169",57]
["Dietary Fiber","Dietary Fiber","D004043","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18640007","Microdispersed Oxidized Cellulose as a novel potential substance with hypolipidemic properties.","18640007",57]
["Diethylhexyl Phthalate","Diethylhexyl Phthalate","D004051","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1986,"3527064","Effect of the peroxisomal proliferator di(2-ethylhexyl)phthalate on component reactions of the rat hepatic microsomal fatty acid chain elongation system and on other hepatic lipogenic enzymes.","3527064",57]
["Diethylhexyl Phthalate","Diethylhexyl Phthalate","D004051","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,2014,"24564399","In utero exposure to the endocrine disruptor di-(2-ethylhexyl) phthalate induces long-term changes in gene expression in the adult male adrenal gland.","24564399",57]
["Diethylnitrosamine","Diethylnitrosamine","D004052","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2008,"18282651","Repression of Ah receptor and induction of transforming growth factor-beta genes in DEN-induced mouse liver tumors.","18282651",57]
["Diethylstilbestrol","Diethylstilbestrol","D004054","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"6783468","Estrogen regulation of yolk and non-yolk protein synthesis in the avian liver. An immunocytochemical study.","6783468",57]
["Diethylstilbestrol","Diethylstilbestrol","D004054","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"7378356","Apolipoprotein B of avian very low density lipoprotein: characteristics of its regulation in nonstimulated and estrogen-stimulated rooster.","7378356",57]
["Dihydralazine","Dihydralazine","D004078","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1992,"1513326","Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug.","1513326",57]
["dihydroceramide","dihydroceramide","C109343","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"29066349","Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model.","29066349",57]
["dihydronicotinamide","dihydronicotinamide","C015145","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26881016","1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative Stress.","26881016",57]
["diisopropyl 1,3-dithiol-2-ylidenemalonate","diisopropyl 1,3-dithiol-2-ylidenemalonate","C024808","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1985,"3934440","Action of malotilate on reduced serum cholesterol level in rats with carbon tetrachloride-induced liver damage.","3934440",57]
["Dimethyl Sulfoxide","Dimethyl Sulfoxide","D004121","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1991,"1768275","Primary culture of rat hepatocytes in the presence of dimethyl sulphoxide. A system to investigate the regulation of cytochrome P450 IA.","1768275",57]
["dimethylamine","dimethylamine","C034516","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8332077","Genotoxic and biochemical effects of dimethylamine.","8332077",57]
["Dinoprost","Dinoprost","D015237","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2006,"17074020","Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane.","17074020",57]
["Dinoprost","Dinoprost","D015237","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2337625","Regulation of the corpus luteum by protein kinase C. II. Inhibition of lipoprotein-stimulated steroidogenesis by prostaglandin F2 alpha.","2337625",57]
["Dinoprost","Dinoprost","D015237","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9184579","8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo.","9184579",57]
["Dinoprostone","Dinoprostone","D015232","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20231854","Activation of the aryl hydrocarbon receptor pathway may ameliorate dextran sodium sulfate-induced colitis in mice.","20231854",57]
["Dinoprostone","Dinoprostone","D015232","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3036263","The effect of human chorionic gonadotropin, dibutyryl cyclic adenosine 3',5'-monophosphate, prostaglandins, and 25-hydroxycholesterol on acute progesterone secretion by dissociated rabbit luteal cells in vitro: evidence for independent effect of human chorionic gonadotropins and lipoproteins.","3036263",57]
["Dinoprostone","Dinoprostone","D015232","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15863442","The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts.","15863442",57]
["Diosgenin","Diosgenin","D004144","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26666021","[Preliminary study on hepatotoxicity induced by dioscin and its possible mechanism].","26666021",57]
["diphenyldiselenide","diphenyldiselenide","C061132","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25038571","Diphenyl diselenide protects endothelial cells against oxidized low density lipoprotein-induced injury: Involvement of mitochondrial function.","25038571",57]
["diphenyldiselenide","diphenyldiselenide","C061132","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23590714","Molecular effects of diphenyl diselenide on cholesterol and glucose cell metabolism.","23590714",57]
["Dipyridamole","Dipyridamole","D004176","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1397066","Antihypercholesterolemic effect of dipyridamole in chickens.","1397066",57]
["Diuron","Diuron","D004237","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18835618","In vitro screening for aryl hydrocarbon receptor agonistic activity in 200 pesticides using a highly sensitive reporter cell line, DR-EcoScreen cells, and in vivo mouse liver cytochrome P450-1A induction by propanil, diuron and linuron.","18835618",57]
["docosapentaenoic acid","docosapentaenoic acid","C026219","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2003,"12848296","Effect of the delta6-desaturase inhibitor SC-26196 on PUFA metabolism in human cells.","12848296",57]
["dodecylthioacetic acid","dodecylthioacetic acid","C064348","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2006,"16971150","Effects of 3-thia fatty acids on expression of some lipid related genes in Atlantic salmon (Salmo salar L.).","16971150",57]
["Dopamine","Dopamine","D004298","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2010,"20113368","The Toll-like receptor 2 (TLR2) ligand FSL-1 is internalized via the clathrin-dependent endocytic pathway triggered by CD14 and CD36 but not by TLR2.","20113368",57]
["Doxazosin","Doxazosin","D017292","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8292100","Effects of doxazosin, an alpha 1-adrenergic inhibitor, on plasma lipid and lipoprotein levels, low density lipoprotein metabolism and cholesterol absorption in cynomolgus monkeys.","8292100",57]
["Doxorubicin","Doxorubicin","D004317","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21711568","The effect of oxidized low-density lipoprotein combined with adriamycin on the proliferation of Eca-109 cell line.","21711568",57]
["Doxorubicin","Doxorubicin","D004317","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"20946921","A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.","20946921",57]
["Dronabinol","Dronabinol","D013759","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1975,"240663","The use of zonal ultracentrifugation in the investigation of the binding of delta9-tetrahydrocannabinol by plasma lipoproteins.","240663",57]
["Dust","Dust","D004391","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2008,"18338287","Crystalline silica is a negative modifier of pulmonary cytochrome P-4501A1 induction.","18338287",57]
["Dust","Dust","D004391","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"27814953","Dioxin-like activities, halogenated flame retardants, organophosphate esters and chlorinated paraffins in dust from Australia, the United Kingdom, Canada, Sweden and China.","27814953",57]
["ecteinascidin 729","ecteinascidin 729","C100350","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12231541","Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.","12231541",57]
["eflucimibe","eflucimibe","C418062","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2001,"11291309","Overexpression of SR-BI in hamsters treated with a novel ACAT inhibitor (F12511).","11291309",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16153604","Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns.","16153604",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2003,"12834302","Microbial synthesis of trans isomer of eicosapentaenoic acid (EPA) from the chemically synthesized trans isomer of linolenic acid by a delta12 desaturase-defective mutant of Mortierella alpina 1S-4.","12834302",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2013,"23528573","Use of radiolabeled substrates to determine the desaturase and elongase activities involved in eicosapentaenoic acid and docosahexaenoic acid biosynthesis in the marine microalga Pavlova lutheri.","23528573",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2013,"23912207","The desaturase OPIN17 from Phytophthora infestans converts arachidonic acid to eicosapentaenoic acid in CHO cells.","23912207",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2010,"20542418","Cide-a and Cide-c are induced in the progression of hepatic steatosis and inhibited by eicosapentaenoic acid.","20542418",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2015,"25451662","Liver biopsy for the selection of patients with nonalcoholic steatohepatitis for clinical trials.","25451662",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1999,"10505695","Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients.","10505695",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19763135","Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome.","19763135",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"2852878","[Effect of eicosapentaenoic acid on lipid metabolism in rabbits with experimental atherosclerosis].","2852878",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2014,"24299019","Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.","24299019",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23702094","Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.","23702094",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2018,"29345914","Comparative analysis of EPA/DHA-PL forage and liposomes in orotic acid-induced non-alcoholic fatty liver rats and their related mechanisms.","29345914",57]
["Eicosapentaenoic Acid","Eicosapentaenoic Acid","D015118","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2014,"24375980","Cardiometabolic risk factors are influenced by Stearoyl-CoA Desaturase (SCD) -1 gene polymorphisms and n-3 polyunsaturated fatty acid supplementation.","24375980",57]
["elaidic acid","elaidic acid","C011459","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1995,"8538375","Structural importance of the cis-5 ethylenic bond in the endogenous desaturation product of dietary elaidic acid, cis-5,trans-9 18:2 acid, for the acylation of rat mitochondria phosphatidylinositol.","8538375",57]
["Ellagic Acid","Ellagic Acid","D004610","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23583377","Ellagic acid improves hepatic steatosis and serum lipid composition through reduction of serum resistin levels and transcriptional activation of hepatic ppara in obese, diabetic KK-A(y) mice.","23583377",57]
["ellipticine","ellipticine","C034192","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"25547492","The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.","25547492",57]
["Emodin","Emodin","D004642","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2006,"17569351","[Experimental study on effects of emodin on nonalcoholic fatty liver induced by high fat diet in rats].","17569351",57]
["endothelium-dependent hyperpolarization factor","endothelium-dependent hyperpolarization factor","C067410","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2012,"22465673","Functional alterations in endothelial NO, PGI₂ and EDHF pathways in aorta in ApoE/LDLR-/- mice.","22465673",57]
["enrofloxacin","enrofloxacin","C052904","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27490210","Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio.","27490210",57]
["EP2302","EP2302","C500325","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16545796","Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis.","16545796",57]
["EP2306","EP2306","C500324","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16545796","Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis.","16545796",57]
["epigallocatechin gallate","epigallocatechin gallate","C045651","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12670496","In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1.","12670496",57]
["epigallocatechin gallate","epigallocatechin gallate","C045651","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2006,"16227197","Epigallocatechin gallate increases the formation of cytosolic lipid droplets and decreases the secretion of apoB-100 VLDL.","16227197",57]
["epigallocatechin gallate","epigallocatechin gallate","C045651","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"26300331","Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice.","26300331",57]
["epigallocatechin gallate","epigallocatechin gallate","C045651","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2005,"15738931","Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation.","15738931",57]
["Epinephrine","Epinephrine","D004837","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,1993,"8332117","[Influence of epinephrine infusion on the metabolism of exogenous lipid emulsions after 70% hepatectomy in the rat].","8332117",57]
["Epinephrine","Epinephrine","D004837","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6192689","Increased beta-thromboglobulin in essential hypertension: interactions between arterial plasma adrenaline, platelet function and blood lipids.","6192689",57]
["Epoprostenol","Epoprostenol","D011464","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"22936708","Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways.","22936708",57]
["Epoprostenol","Epoprostenol","D011464","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2106424","Modification of prostacyclin-stimulatory activity in sera by glucose, insulin, low density lipoprotein, linoleic acid and linoleic acid hydroperoxide.","2106424",57]
["Epoprostenol","Epoprostenol","D011464","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"3911954","Low density lipoproteins of male donors decrease prostacyclin (PGI2) and enhance thromboxane (TXA2) release from rat aortas perfused under pulsatile pressure.","3911954",57]
["Epoprostenol","Epoprostenol","D011464","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6424692","The effect of lipoproteins on the synthesis of prostacyclin, von Willebrand factor and apolipoproteins A-I and A-II in cultured human endothelial cells.","6424692",57]
["Epoprostenol","Epoprostenol","D011464","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2004,"15550624","COX-2-derived prostacyclin confers atheroprotection on female mice.","15550624",57]
["Ergosterol","Ergosterol","D004875","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14769046","Cholesterol crystal nucleation from enzymatically modified low-density lipoproteins: combined effect of sphingomyelinase and cholesterol esterase.","14769046",57]
["eriocitrin","eriocitrin","C114706","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24424211","Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis.","24424211",57]
["Erythromycin","Erythromycin","D004917","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2002,"11956054","Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells.","11956054",57]
["Erythromycin","Erythromycin","D004917","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2003,"14679752","[Suppression of rhinovirus infections with macrolide antibiotics].","14679752",57]
["Etanidazole","Etanidazole","D017341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"21372297","Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.","21372297",57]
["Ethanol","Ethanol","D000431","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2001,"11505055","Effect of ethanol on polyunsaturated fatty acid biosynthesis in hepatocytes from spontaneously hypertensive rats.","11505055",57]
["Ethanol","Ethanol","D000431","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1980,"7374380","Effect of ethanol administration on fatty acid desaturation.","7374380",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1975,"1174154","Alcohol and malnutrition in the pathogenesis of liver disease..","1174154",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14192514","STUDIES ON THE PATHOGENESIS OF THE ETHANOL-INDUCED FATTY LIVER. II. EFFECT OF ETHANOL ON PALMITATE-1-C-14 METABOLISM BY THE ISOLATED PERFUSED RAT LIVER.","14192514",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1970,"4922062","[Effects of alcohol on the liver].","4922062",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2006,"16835711","Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats.","16835711",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2008,"18722787","Fat diet and alcohol-induced steatohepatitis after LPS challenge in mice: role of bioactive TNF and Th1 type cytokines.","18722787",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2010,"20800122","Fructose: metabolic, hedonic, and societal parallels with ethanol.","20800122",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21930289","Chronic ethanol consumption induces histopathological changes and increases nitric oxide generation in the rat liver.","21930289",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"23465594","Increased dietary fat contributes to dysregulation of the LKB1/AMPK pathway and increased damage in a mouse model of early-stage ethanol-mediated steatosis.","23465594",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24824912","[The intestinal microbioma - more than just bacteria in the gut? a new mechanism in the pathogenesis of NASH?].","24824912",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2015,"26365275","Histone Deacetylase Gene Expression Following Binge Alcohol Consumption in Rats and Humans.","26365275",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1972,"4115472","Recovery from chronic hepatic lesions in rats fed alcohol and a solid super diet.","4115472",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1970,"4316025","Pyrazole and induction of fatty liver by a single dose of ethanol.","4316025",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1969,"4390176","[Alcoholic steatosis of the liver. I. Immediate effects of alcohol, fructose and their association on hepatic concentrations of L-alpha-glycerophosphate and nicotinamide-adenine-dinucleotides, in rat].","4390176",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1974,"4407072","Effect of ethanol on motility of the small intestine.","4407072",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1973,"4748176","Alcohol, nutrition, and the liver.","4748176",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1972,"5023890","Chlorpromazine inhibition of ethanol metabolism without prevention of fatty liver.","5023890",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1970,"5430804","Induction and inhibition of hepatic microsomal and mitochondrial enzymes by ethanol.","5430804",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1971,"5556165","Ethanol-induced fatty liver: the requirement of ethanol metabolism for the development of fatty liver.","5556165",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1968,"5696891","An interaction of disulfiram and ethanol on lipid metabolism.","5696891",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1966,"5929569","Electronmicroscopic autoradiography of 3H-glycerol labeled lipid in ethanol induced fatty liver.","5929569",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1967,"6051326","Role of lipid peroxidation in the pathogenesis of the ethanol-induced fatty liver.","6051326",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1980,"7449415","Alcohol, nutrition, and liver disease.","7449415",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1987,"3032013","Hepatic triacylglycerol accumulation induced by ethanol and carbon tetrachloride: interactions with essential fatty acids and prostaglandins.","3032013",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2005,"15940638","Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice.","15940638",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,2,1991,"1813885","[Liver damage in alcoholics].","1813885",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,2,2010,"20116195","The role of ethanol metabolism in development of alcoholic steatohepatitis in the rat.","20116195",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2012,"22269225","Dysregulated phosphorylation and nuclear translocation of cyclic AMP response element binding protein (CREB) in rat liver after chronic ethanol binge.","22269225",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2012,"22320917","Regulation of transglutaminase-mediated hepatic cell death in alcoholic steatohepatitis and non-alcoholic steatohepatitis.","22320917",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,2,2014,"24483773","PKCε contributes to chronic ethanol-induced steatosis in mice but not inflammation and necrosis.","24483773",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,2,2015,"26022806","Ethanol-induced hepatic steatosis is modulated by glycogen level in the liver.","26022806",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2017,"28536109","Effect of iron on cholesterol 7α-hydroxylase expression in alcohol-induced hepatic steatosis in mice.","28536109",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1984,"6373167","In vitro effect of ethanol on the synthesis of triacylglycerol in hepatic cytoplasmic lipid droplets.","6373167",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1994,"7894250","Effect of polyunsaturated phosphatidylcholine on lipid structure and cAMP-dependent signal transduction in the liver of rats chronically intoxicated with ethanol.","7894250",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C17539,B17539)","v":"Ethanol"},"Ethanol","D000431","12_KE",462,12,"SCD-1","Increased",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J17539,K17539)","v":"Linoleoyl-CoA Desaturase"},"D050602","Linoleoyl-CoA Desaturase",1,1,1988,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q17539,Q17539)","v":"3358827"},"Role of microsomal ethanol-oxidizing system in regulation of linoleoyl-CoA desaturase activity after long-term ethanol administration.","3358827",57]
["Ethanol","Ethanol","D000431","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1359386","Alcohol delays clearance of lipoproteins from the circulation.","1359386",57]
["Ethanol","Ethanol","D000431","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28442378","Antihyperlipidemic and antiapoptotic potential of zingerone on alcohol induced hepatotoxicity in experimental rats.","28442378",57]
["Ethanol","Ethanol","D000431","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7784463","Fatty acid ethyl esters: non-oxidative metabolites of ethanol.","7784463",57]
["Ethanol","Ethanol","D000431","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1999,"10496411","Is ethanol an important antioxidant in alcoholic beverages associated with risk reduction of cataract and atherosclerosis?","10496411",57]
["Ethanol","Ethanol","D000431","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1986,"3472027","Serum lipid and lipoprotein-cholesterol in rats jointly exposed to carbon disulphide and ethanol.","3472027",57]
["Ethanol","Ethanol","D000431","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1994,"7897309","Dietary ethanol is associated with reduced lipolysis of intestinally derived lipoproteins.","7897309",57]
["Ethanol","Ethanol","D000431","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26551085","Induction of CYP2E1 in non-alcoholic fatty liver diseases.","26551085",57]
["Ethanol","Ethanol","D000431","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22486318","Regulation of the activity and expression of aryl hydrocarbon receptor by ethanol in mouse hepatic stellate cells.","22486318",57]
["Ethanol","Ethanol","D000431","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2017,"28315617","Dietary fructose augments ethanol-induced liver pathology.","28315617",57]
["Ethionamide","Ethionamide","D005000","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1973,"4690648","[Experimental studies on the mechanism of fatty liver formation induced by ethionamide. IV. Incorporation of (2- 14 C) acetate into the liver lipids of ethionamide-administered rats].","4690648",57]
["Ethionamide","Ethionamide","D005000","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1973,"4721388","[Experimental studies on the mechanism of fatty liver formation induced by ethionamide. V. Liver and serum total cholesterol in ethionamide-administered rats].","4721388",57]
["ethyl acetate","ethyl acetate","C007650","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27188742","In Vitro and in Vivo antioxidant activity of ethyl acetate extraction of purple rice.","27188742",57]
["ethyl oleate","ethyl oleate","C033180","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8561300","Low-density lipoprotein reconstituted with fatty acid ethyl esters as a physiological vehicle for ethyl ester delivery to intact cells.","8561300",57]
["Ethylmaleimide","Ethylmaleimide","D005033","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1999,"10188593","Differential effect of N-ethyl maleimide on delta6-desaturase activity in human fetal liver toward fatty acids of the n-6 and n-3 series.","10188593",57]
["Etodolac","Etodolac","D017308","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2004,"15193259","Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma.","15193259",57]
["etonogestrel","etonogestrel","C044815","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7590642","Short- and long-term effects on lipid metabolism of oral contraceptives containing 30 micrograms ethinylestradiol and 150 micrograms desogestrel or 3-keto-desogestrel.","7590642",57]
["Eugenol","Eugenol","D005054","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24611461","Protective effect of clove oil and eugenol microemulsions on fatty liver and dyslipidemia as components of metabolic syndrome.","24611461",57]
["euscaphic acid","euscaphic acid","C007695","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25033392","Triterpenoids from the fruits and leaves of the blackberry (Rubus allegheniensis) and their inhibitory activities on foam cell formation in human monocyte-derived macrophage.","25033392",57]
["evening primrose oil","evening primrose oil","C028498","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,1987,"3625311","Dietary influences of evening primrose and fish oil on the skin of essential fatty acid-deficient guinea pigs.","3625311",57]
["Ezetimibe","Ezetimibe","D000069438","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2010,"20654606","The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels.","20654606",57]
["Ezetimibe","Ezetimibe","D000069438","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20601094","Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?","20601094",57]
["Ezetimibe","Ezetimibe","D000069438","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,2006,"16528005","Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.","16528005",57]
["Ezetimibe","Ezetimibe","D000069438","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19217513","Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.","19217513",57]
["Ezetimibe","Ezetimibe","D000069438","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21959521","Ezetimibe in sirolimus-associated hyperlipidemia: to add or not to add to statins?","21959521",57]
["Ezetimibe","Ezetimibe","D000069438","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"20658156","Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.","20658156",57]
["Ezetimibe","Ezetimibe","D000069438","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2004,"14985510","Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport.","14985510",57]
["Ezetimibe","Ezetimibe","D000069438","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2007,"17130282","The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.","17130282",57]
["Ezetimibe, Simvastatin Drug Combination","Ezetimibe, Simvastatin Drug Combination","D000069499","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23926117","Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.","23926117",57]
["Fenfluramine","Fenfluramine","D005277","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1991,"1666560","The liver metabolite S-422 of the hypolipidaemic drug benfluorex decreases cholesterol esterification in fibroblasts and monocyte-like cells.","1666560",57]
["Fenitrothion","Fenitrothion","D005278","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1974,"4134409","Insecticide and viral interaction as a cause of fatty visceral changes and encephalopathy in the mouse.","4134409",57]
["Fenofibrate","Fenofibrate","D011345","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2006,"16762007","Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.","16762007",57]
["Fenofibrate","Fenofibrate","D011345","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2001,"11410747","Effect of fenofibrate on fatty liver in rats treated with alcohol.","11410747",57]
["Fenofibrate","Fenofibrate","D011345","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12053756","[Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].","12053756",57]
["Fenofibrate","Fenofibrate","D011345","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24618208","Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.","24618208",57]
["Fenofibrate","Fenofibrate","D011345","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6870993","Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.","6870993",57]
["Fenofibrate","Fenofibrate","D011345","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1311585","Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate.","1311585",57]
["Fenofibrate","Fenofibrate","D011345","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2010,"20371660","Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.","20371660",57]
["Fenofibrate","Fenofibrate","D011345","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26973390","Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression.","26973390",57]
["Fenofibrate","Fenofibrate","D011345","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,2,2005,"16099631","Effects of fenofibrate and insulin on the biosynthesis of unsaturated fatty acids in streptozotocin diabetic rats.","16099631",57]
["fenofibric acid","fenofibric acid","C006012","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"3924068","Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia.","3924068",57]
["ferric gluconate","ferric gluconate","C035552","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25936327","TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.","25936327",57]
["ferulic acid","ferulic acid","C004999","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"12212033","[Effect of sodium ferulate on proliferation of rabbit aortic smooth muscle cells induced by oxidized LDL].","12212033",57]
["ferulic acid","ferulic acid","C004999","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12454431","Influence of Angelicae sinensis extract on lipid accumulation in rabbit aortic smooth muscle cells induced by oxidized LDL.","12454431",57]
["ferumoxides","ferumoxides","C065507","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21182129","Liver methylene fraction by dual- and triple-echo gradient-echo imaging at 3.0T: Correlation with proton MR spectroscopy and estimation of robustness after SPIO administration.","21182129",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C18243,B18243)","v":"Filipin"},"Filipin","D005372","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J18243,K18243)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1996,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q18243,Q18243)","v":"8660636"},"Filipin as a fluorescent probe of lipoprotein-derived sterols on thin-layer chromatograms.","8660636",57]
["fisetin","fisetin","C017875","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18662803","Fisetin, morin and myricetin attenuate CD36 expression and oxLDL uptake in U937-derived macrophages.","18662803",57]
["flubendazole","flubendazole","C018945","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15096105","The effects of fenbendazole, flubendazole and mebendazole on activities of hepatic cytochromes P450 in pig.","15096105",57]
["fluoranthene","fluoranthene","C007738","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25412620","AHR2-Mediated transcriptomic responses underlying the synergistic cardiac developmental toxicity of PAHs.","25412620",57]
["Fluorodeoxyglucose F18","Fluorodeoxyglucose F18","D019788","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24326630","Hepatic glucose uptake is increased in association with elevated serum γ-glutamyl transpeptidase and triglyceride.","24326630",57]
["Fluorouracil","Fluorouracil","D005472","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11356943","Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.","11356943",57]
["Fluoxetine","Fluoxetine","D005473","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26800487","Interactive effects of selected pharmaceutical mixtures on bioaccumulation and biochemical status in crucian carp (Carassius auratus).","26800487",57]
["fluvastatin","fluvastatin","C065180","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,1995,"7604788","Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.","7604788",57]
["fluvastatin","fluvastatin","C065180","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11488428","Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages.","11488428",57]
["fluvastatin","fluvastatin","C065180","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16510370","Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes.","16510370",57]
["fluvastatin","fluvastatin","C065180","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9692657","A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia.","9692657",57]
["Fluvoxamine","Fluvoxamine","D016666","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8737959","Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo.","8737959",57]
["Folic Acid","Folic Acid","D005492","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22229957","Serum vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease.","22229957",57]
["Folic Acid","Folic Acid","D005492","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1986,"3945624","Abnormal folate metabolism in feed-related anemia of cultured channel catfish.","3945624",57]
["Folic Acid","Folic Acid","D005492","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"5890210","[Further studies on the prevention of the acute fatty liver induced by ethionine. 4. Effects of vitamine B12 and folic acid upon esterase action and histological aspects of fat in acute fatty liver induced by ethionine].","5890210",57]
["Folic Acid","Folic Acid","D005492","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28499201","Folate-functionalized assembly of low density lipoprotein/sodium carboxymethyl cellulose nanoparticles for targeted delivery.","28499201",57]
["Formaldehyde","Formaldehyde","D005557","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1962,"13956039","[On the relation between the results of the thymol tests, the formaldehyde test, the concentration of beta-lipoproteins, and the protein structure of the blood serum].","13956039",57]
["fractogel TSK HW 40S","fractogel TSK HW 40S","C049226","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3178519","Selective removal of low-density lipoproteins from plasma by polyacrylate-coated Fractogel in vitro and in experimental extracorporeal perfusion.","3178519",57]
["fructooligosaccharide","fructooligosaccharide","C116580","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"28463404","A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota.","28463404",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1999,"10215484","Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS.","10215484",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2009,"19679262","Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease.","19679262",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2010,"20450951","Cissus quadrangularis stem alleviates insulin resistance, oxidative injury and fatty liver disease in rats fed high fat plus fructose diet.","20450951",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21261970","Fructose impairs glucose-induced hepatic triglyceride synthesis.","21261970",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"22749137","Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model.","22749137",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23793849","Fructose-containing sugars, blood pressure, and cardiometabolic risk: a critical review.","23793849",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"24142242","Reply to JS White.","24142242",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"25157382","Chemical composition of Pleurotus eryngii polysaccharides and their inhibitory effects on high-fructose diet-induced insulin resistance and oxidative stress in mice.","25157382",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2016,"27669460","ChREBP regulates fructose-induced glucose production independently of insulin signaling.","27669460",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2017,"28559436","Hepatic FGF21 mediates sex differences in high-fat high-fructose diet-induced fatty liver.","28559436",57]
["Fructose","Fructose","D005632","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28972610","fat-1 mice prevent high-fat plus high-sugar diet-induced non-alcoholic fatty liver disease.","28972610",57]
["Fructose","Fructose","D005632","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2018,"29350757","Hepatoprotective Effects of Sophoricoside against Fructose-Induced Liver Injury via Regulating Lipid Metabolism, Oxidation, and Inflammation in Mice.","29350757",57]
["Fructose","Fructose","D005632","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"4018717","Glucose and fructose feeding lead to alterations in structure and function of very low density lipoproteins.","4018717",57]
["Fructose","Fructose","D005632","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"6989966","Effects of short-term dietary glucose and fructose on rat serum triglyceride concentration.","6989966",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22469071","Review article: fructose in non-alcoholic fatty liver disease.","22469071",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2013,"24033459","Fructose, pregnancy and later life impacts.","24033459",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"25099548","Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults.","25099548",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26476631","A possible link between hepatic mitochondrial dysfunction   and diet-induced insulin resistance.","26476631",57]
["Fructose","Fructose","D005632","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28214020","Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.","28214020",57]
["Fructose","Fructose","D005632","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23269653","Beneficial effects of omega-3 fatty acids on the consequences of a fructose diet are not mediated by PPAR delta or PGC1 alpha.","23269653",57]
["fructose 2,6-diphosphate","fructose 2,6-diphosphate","C027652","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1989,"2558647","Endotoxin increases the liver fructose 2,6-bisphosphate concentration in fasted rats.","2558647",57]
["fucoxanthin","fucoxanthin","C025164","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2013,"23516000","Down-regulation of hepatic stearoyl-CoA desaturase-1 expression by fucoxanthin via leptin signaling in diabetic/obese KK-A(y) mice.","23516000",57]
["Furazolidone","Furazolidone","D005664","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23774039","Repeated treatment with furazolidone induces multiple cytochrome p450-related activities in chicken liver, but not in rat liver.","23774039",57]
["G(A1) ganglioside","G(A1) ganglioside","C011258","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1990,"1702710","Characteristic binding of human plasma apolipoprotein B to gangliotetraosylceramide and gangliotriaosylceramide.","1702710",57]
["Gadolinium DTPA","Gadolinium DTPA","D019786","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23598063","Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.","23598063",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C18947,B18947)","v":"Gadolinium DTPA"},"Gadolinium DTPA","D019786","13_AO",455,13,"Accumulation, Liver lipid",null,{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J18947,K18947)","v":"Non-alcoholic Fatty Liver Disease"},"D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q18947,Q18947)","v":"28062263"},"The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice.","28062263",57]
["gadolinium ethoxybenzyl DTPA","gadolinium ethoxybenzyl DTPA","C073590","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2011,"21237679","The Possibility of differentiation between nonalcoholic steatohepatitis and fatty liver in rabbits on Gd-EOB-DTPA-enhanced open-type MRI scans.","21237679",57]
["galactaric acid","galactaric acid","C000090","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23795777","Nanoscale amphiphilic macromolecules with variable lipophilicity and stereochemistry modulate inhibition of oxidized low-density lipoprotein uptake.","23795777",57]
["Galactosamine","Galactosamine","D005688","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27226100","Effect of protocatechuic acid on lipid profile and DNA damage in D-galactosamine-induced hepatotoxic rats.","27226100",57]
["Galactose","Galactose","D005690","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1972,"5008209","[Oral galactose tolerance test in liver diseases. Studies on technics and on the evaluation of results].","5008209",57]
["Galantamine","Galantamine","D005702","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21738953","Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice.","21738953",57]
["Gallic Acid","Gallic Acid","D005707","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1969,"5345901","Effect of propyl gallate on carbon tetrachloride induced fatty liver.","5345901",57]
["gamma-Linolenic Acid","gamma-Linolenic Acid","D017965","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1999,"10470146","Tissue distribution and metabolism of gamma-linolenoyl-3-eicosapentaenoyl propane diol enterally or intravenously administered to mice bearing human pancreatic carcinomas.","10470146",57]
["gamma-Linolenic Acid","gamma-Linolenic Acid","D017965","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1990,"2162007","[A chance for the prevention of atopic diseases].","2162007",57]
["gamma-Linolenic Acid","gamma-Linolenic Acid","D017965","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1996,"9630958","Expression of a cyanobacterial delta 6-desaturase gene results in gamma-linolenic acid production in transgenic plants.","9630958",57]
["gamma-Linolenic Acid","gamma-Linolenic Acid","D017965","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,2011,"21369993","Molecular cloning and expression analysis of a delta 6-fatty acid desaturase gene from Rhizopus stolonifer strain YF6 which can accumulate high levels of gamma-linolenic acid.","21369993",57]
["gamma-Linolenic Acid","gamma-Linolenic Acid","D017965","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2015,"26092623","Lipidomic analysis reveals a radiosensitizing role of gamma-linolenic acid in glioma cells.","26092623",57]
["gamma-Tocopherol","gamma-Tocopherol","D024504","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,2004,"15753174","The decrease in gamma-tocopherol in plasma and lipoprotein fractions levels off within two days of vitamin E supplementation.","15753174",57]
["gardenoside","gardenoside","C056587","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2015,"26610473","Inhibitory Effect of Gardenoside on Free Fatty Acid-Induced Steatosis in HepG2 Hepatocytes.","26610473",57]
["Gasoline","Gasoline","D005742","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2001,"11355188","Comparison of exhaust emissions from Swedish environmental classified diesel fuel (MK1) and European Program on Emissions, Fuels and Engine Technologies (EPEFE) reference fuel: a chemical and biological characterization, with viewpoints on cancer risk.","11355188",57]
["gefitinib","gefitinib","C419708","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2017,"28652202","Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells.","28652202",57]
["Gemfibrozil","Gemfibrozil","D015248","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1575821","Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins.","1575821",57]
["Gemfibrozil","Gemfibrozil","D015248","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6864730","Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.","6864730",57]
["Gemfibrozil","Gemfibrozil","D015248","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"6935550","The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.","6935550",57]
["Gemfibrozil","Gemfibrozil","D015248","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9690910","Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.","9690910",57]
["Gemfibrozil","Gemfibrozil","D015248","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"3923042","Mechanism of action of gemfibrozil on lipoprotein metabolism.","3923042",57]
["Gemfibrozil","Gemfibrozil","D015248","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1993,"8487651","Treatment of E2E2 homozygous familial dysbetalipoproteinemic subjects with gemfibrozil does not enhance the binding of their d &lt; 1.019 lipoprotein fraction to the low-density lipoprotein receptor.","8487651",57]
["genipin","genipin","C007834","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"23151243","Inhibition of uncoupling protein 2 with genipin exacerbates palmitate-induced hepatic steatosis.","23151243",57]
["Genistein","Genistein","D019833","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"18570695","Genistein protects against polycyclic aromatic hydrocarbon-induced oxidative DNA damage in non-cancerous breast cells MCF-10A.","18570695",57]
["Genistein","Genistein","D019833","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15822912","Genistein reverses changes of the proteome induced by oxidized-LDL in EA.hy 926 human endothelial cells.","15822912",57]
["Genistein","Genistein","D019833","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,"24214843","Genistein alleviates the development of nonalcoholic steatohepatitis in ApoE(-/-) mice fed a high-fat diet.","24214843",57]
["genistin","genistin","C040641","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11866114","Inhibitory effect of isoflavones on peroxynitrite-mediated low-density lipoprotein oxidation.","11866114",57]
["geranylgeranylacetone","geranylgeranylacetone","C031049","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15997774","[Possible candidates for the compound which is expected to attenuate dioxin toxicity].","15997774",57]
["ginkgolide A","ginkgolide A","C477042","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28142119","Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice.","28142119",57]
["ginsenoside Rg1","ginsenoside Rg1","C035054","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2008,"19022240","Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells.","19022240",57]
["glabridin","glabridin","C107601","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2008,"19024795","The effect of an endogenous antioxidant glabridin on oxidized LDL.","19024795",57]
["globotriaosylceramide","globotriaosylceramide","C018549","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"6794884","The glycosphingolipids of human plasma lipoproteins.","6794884",57]
["Glucosamine","Glucosamine","D005944","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11792734","Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL.","11792734",57]
["Glucose","Glucose","D005947","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2001,"11323420","Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy.","11323420",57]
["Glucose","Glucose","D005947","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2004,"15452715","High glucose concentrations stimulate human monocyte sodium/hydrogen exchanger activity and modulate atherosclerosis-related functions.","15452715",57]
["Glucose","Glucose","D005947","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2009,"19073900","Adiponectin resistance precedes the accumulation of skeletal muscle lipids and insulin resistance in high-fat-fed rats.","19073900",57]
["Glucose","Glucose","D005947","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2014,"24895286","Calcium signaling recruits substrate transporters GLUT4 and CD36 to the sarcolemma without increasing cardiac substrate uptake.","24895286",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1957,"13418339","Abnormal glucose tolerance in experimental choline-deficient fatty liver.","13418339",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"22254090","Hepatic oxidative stress in fructose-induced fatty liver is not caused by sulfur amino acid insufficiency.","22254090",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2006,"16890540","Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells.","16890540",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20211973","Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet.","20211973",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22802954","GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis.","22802954",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"23792151","Zonation of glucose and fatty acid metabolism in the liver: mechanism and metabolic consequences.","23792151",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2014,"25158235","Maternal high-fat diet modulates hepatic glucose, lipid homeostasis and gene expression in the PPAR pathway in the early life of offspring.","25158235",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27222533","Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption.","27222533",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1974,"4473648","[Clinical studies of fatty liver--with special reference to glucose metabolism].","4473648",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1996,"9035562","Role of the hypoglycemic plant extract cleome droserifolia in improving glucose and lipid metabolism and its relation to insulin resistance in fatty liver.","9035562",57]
["Glucose","Glucose","D005947","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12605021","Effects of cerivastatin on human arterial smooth muscle cell growth and extracellular matrix expression at varying glucose and low-density lipoprotein levels.","12605021",57]
["Glucose","Glucose","D005947","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8341651","Lipid advanced glycosylation: pathway for lipid oxidation in vivo.","8341651",57]
["Glucose","Glucose","D005947","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21904540","Effect of exposure of human monocyte-derived macrophages to high, versus normal, glucose on subsequent lipid accumulation from glycated and acetylated low-density lipoproteins.","21904540",57]
["Glucose","Glucose","D005947","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2227114","Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose.","2227114",57]
["Glucose","Glucose","D005947","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"4075697","Non-enzymatic glycosylation of plasma lipoproteins in vitro.","4075697",57]
["Glucose","Glucose","D005947","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,3,2004,"15448080","Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin.","15448080",57]
["Glucose","Glucose","D005947","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2006,"16410253","Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction.","16410253",57]
["Glucose","Glucose","D005947","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"4018717","Glucose and fructose feeding lead to alterations in structure and function of very low density lipoproteins.","4018717",57]
["Glucose","Glucose","D005947","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"6989966","Effects of short-term dietary glucose and fructose on rat serum triglyceride concentration.","6989966",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"24378273","Effects of bile acid sequestration on hepatic steatosis in obese mice.","24378273",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,"25385228","NAFLD: Ketogenesis could be a determinant of steatohepatitis.","25385228",57]
["Glucose","Glucose","D005947","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"27693527","Effect of HFD/STZ on expression of genes involved in lipid, cholesterol and glucose metabolism in rats.","27693527",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2002,"12388128","ATP-sensitive potassium channels participate in glucose uptake in skeletal muscle and adipose tissue.","12388128",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,2005,"16308834","Glucagon-stimulated but not isoproterenol-stimulated glucose formation inhibition by interleukin-6 in primary cultured rat hepatocytes.","16308834",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2009,"19268699","Enhanced glucose synthesis in three-dimensional hepatocyte collagen matrix.","19268699",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2013,"23716591","MicroRNA 33 regulates glucose metabolism.","23716591",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2014,"24177027","The mitochondrial isoform of phosphoenolpyruvate carboxykinase (PEPCK-M) and glucose homeostasis: has it been overlooked?","24177027",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1974,"4150923","Enzymes of glucose metabolism in liver of subjects with adult-onset diabetes.","4150923",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1983,"6343080","Control of the activity of phosphoenolpyruvate carboxykinase and the level of its mRNA in livers of newborn rats. Effect of diabetes, glucose load and glucocorticoids.","6343080",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1981,"6457751","High glucose-induced enzyme activity changes in cultured cell lines established from the kidneys of Chinese hamsters with aglycosuria or spontaneous glycosuria.","6457751",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1994,"8051090","Insulin-like actions of tungstate in diabetic rats. Normalization of hepatic glucose metabolism.","8051090",57]
["Glucose","Glucose","D005947","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1998,"9650285","Subcellular localization of enzyme activities in chemostat-grown murine myeloma cells.","9650285",57]
["Glucose","Glucose","D005947","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1996,"8738555","2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) modulates function of human luteinizing granulosa cells via cAMP signaling and early reduction of glucose transporting activity.","8738555",57]
["Glucose","Glucose","D005947","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18996368","Effects of a Western diet versus high glucose on endothelium-dependent relaxation in murine micro- and macro-vasculature.","18996368",57]
["Glucose","Glucose","D005947","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2003,"12627319","Glucose oversupply increases Delta9-desaturase expression and its metabolites in rat skeletal muscle.","12627319",57]
["glucuronyl glucosamine glycan sulfate","glucuronyl glucosamine glycan sulfate","C007858","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"7249572","[Long-term effects of a glycosaminoglycan on plasma lipids].","7249572",57]
["glutaric acid","glutaric acid","C035736","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1984,"6394338","Glutaric aciduria type II: treatment with riboflavine, carnitine and insulin.","6394338",57]
["Glyburide","Glyburide","D005905","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2002,"12469362","Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.","12469362",57]
["glyceric acid","glyceric acid","C042971","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1986,"3800911","The involvement of pyruvate cycling in the metabolism of aspartate and glycerate by the perfused rat kidney.","3800911",57]
["Glycerol","Glycerol","D005990","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12912792","Plaque rupture, lysophosphatidic acid, and thrombosis.","12912792",57]
["Glycerol","Glycerol","D005990","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1976,"181061","Effects of glycerol on VLDL secretion by the isolated rat liver.","181061",57]
["Glycerol","Glycerol","D005990","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2002,"12351427","Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9.","12351427",57]
["Glycerol","Glycerol","D005990","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1981,"7213768","Inhibition of phosphoenolpyruvate carboxykinase, glyceroneogenesis and fatty acid synthesis in rat adipose tissue by quinolinate and 3-mercaptopicolinate.","7213768",57]
["Glycerylphosphorylcholine","Glycerylphosphorylcholine","D005997","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1976,"184377","[Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate].","184377",57]
["Glycogen","Glycogen","D006003","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14175268","[THE LIVER IN DIABETES MELLITUS].","14175268",57]
["Glycogen","Glycogen","D006003","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"27815211","Ablation of PPP1R3G reduces glycogen deposition and mitigates high-fat diet induced obesity.","27815211",57]
["Glycogen","Glycogen","D006003","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2017,"28835389","Dietary Methionine Restriction Alleviates Hyperglycemia in Pigs with Intrauterine Growth Restriction by Enhancing Hepatic Protein Kinase B Signaling and Glycogen Synthesis.","28835389",57]
["Glycyrrhetinic Acid","Glycyrrhetinic Acid","D006034","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2008,"18452148","Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways.","18452148",57]
["Glycyrrhizic Acid","Glycyrrhizic Acid","D019695","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2009,"19958654","[Therapeutic effects of compound glycyrrhizin liposome on fibrosis of the rats with nonalcoholic steatohepatitis].","19958654",57]
["Gold Colloid","Gold Colloid","D017979","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1963,"14089508","[SCINTIGRAPHY OF THE LIVER AND SPLEEN IN CIRRHOSIS].","14089508",57]
["Granisetron","Granisetron","D017829","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27809336","Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting.","27809336",57]
["Guaiacol","Guaiacol","D006139","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24955981","LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver.","24955981",57]
["Guanine","Guanine","D006147","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12127742","Early oxidative damage in primary cultured trout hepatocytes: a time course study.","12127742",57]
["guar gum","guar gum","C007894","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2157450","Metabolic studies on the hypolipidaemic effect of guar gum.","2157450",57]
["GW 4064","GW 4064","C412815","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"23371517","Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance.","23371517",57]
["GW0742","GW0742","C479979","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2005,"15939051","The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice.","15939051",57]
["Halofenate","Halofenate","D006218","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1975,"171574","Potentiation of hypoglycemic effect of sulfonylureas by halofenate.","171574",57]
["Halothane","Halothane","D006221","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1990,"2334622","Halothane metabolism in children.","2334622",57]
["Harmaline","Harmaline","D006246","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22037238","Harmaline and harmalol inhibit the carcinogen-activating enzyme CYP1A1 via transcriptional and posttranslational mechanisms.","22037238",57]
["hematein","hematein","C007915","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11689202","Dietary hematein ameliorates fatty streak lesions in the rabbit by the possible mechanism of reducing VCAM-1 and MCP-1 expression.","11689202",57]
["Heme","Heme","D006418","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12750169","Heme and lipid peroxides in hemoglobin-modified low-density lipoprotein mediate cell survival and adaptation to oxidative stress.","12750169",57]
["Heme","Heme","D006418","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2000,"10828027","Ferriporphyrins and endothelium: a 2-edged sword-promotion of oxidation and induction of cytoprotectants.","10828027",57]
["Hemin","Hemin","D006427","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12391268","Cytochrome P450 CYP1A1 accumulates in the cytosol of kidney and brain and is activated by heme.","12391268",57]
["Heparin","Heparin","D006493","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1955,"13248338","Effects of heparin on development of atherosclerosis and fatty liver; a report of studies on cholesterol-fed rabbits.","13248338",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10619998","Acute effect of H.E.L.P. treatment on radical scavenging enzyme activities, total glutathione concentrations in granulocytes, and selenium in plasma.","10619998",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1337474","Complexoproductive and antiheparin properties of low density lipoproteins (LDL). I. Interaction of isolated low density lipoproteins with heparin of different molecular weight.","1337474",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14663604","[Treatment of sudden hearing loss through Fibrinogen/LDL-apheresis. A prospective, randomized multicenter trial].","14663604",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3773409","[Hyperlipoproteinemia as the cause of increased plasma antiheparin activity in patients with arteriosclerosis].","3773409",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1978,"208351","Conversion of the electrophoretic pattern of type IV hyperlipidaemia to type III by intravenous heparin.","208351",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2248621","Apheresis of low density lipoproteins using a heparin-based sorbent with low antithrombin III binding capacity.","2248621",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3382680","Binding of low-density lipoprotein to heparin-Sepharose: characterization and inhibition by serum high-molecular-weight components.","3382680",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1974,"4370795","Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia.","4370795",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7695220","Heparin inhibits rat peritoneal macrophages to reesterify cholesterol.","7695220",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8154130","[Heparin-induced extracorporeal LDL precipitation (HELP): a new therapeutic intervention in cerebrovascular diseases and peripheral arterial occlusive disease].","8154130",57]
["Heparin","Heparin","D006493","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1976,"182536","Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase.","182536",57]
["Heparin","Heparin","D006493","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"4031650","Purification and characterization of bovine lipoproteins: resolution of high density and low density lipoproteins using heparin-Sepharose chromatography.","4031650",57]
["Heparin","Heparin","D006493","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2764475","Manganese-heparin precipitation of very low-density lipoprotein: screening for type III hyperlipoproteinaemia.","2764475",57]
["Heparin","Heparin","D006493","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1972,"4342606","Effects of heparin on lipoprotein lipase from bovine milk.","4342606",57]
["Heparin","Heparin","D006493","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1995,"7583563","Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women.","7583563",57]
["Heparin","Heparin","D006493","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1989,"2745454","Apolipoprotein E mediates binding of normal very low density lipoprotein to heparin but is not required for high affinity receptor binding.","2745454",57]
["Heparitin Sulfate","Heparitin Sulfate","D006497","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8530367","Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix.","8530367",57]
["Heparitin Sulfate","Heparitin Sulfate","D006497","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1993,"8387492","Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase.","8387492",57]
["Heparitin Sulfate","Heparitin Sulfate","D006497","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1994,"8175773","Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.","8175773",57]
["hesperetin","hesperetin","C013015","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2011,"21345233","Citrus flavonoids repress the mRNA for stearoyl-CoA desaturase, a key enzyme in lipid synthesis and obesity control, in rat primary hepatocytes.","21345233",57]
["Hesperidin","Hesperidin","D006569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"28899694","Anti-atherosclerotic effect of hesperidin in LDLr-/- mice and its possible mechanism.","28899694",57]
["Hexachlorobenzene","Hexachlorobenzene","D006581","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20682327","Highly purified hexachlorobenzene induces cytochrome P4501A in primary cultures of chicken embryo hepatocytes.","20682327",57]
["Hexachlorobenzene","Hexachlorobenzene","D006581","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21205633","Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDA-MB-231 human breast cancer cell line.","21205633",57]
["hexadecenoic acid","hexadecenoic acid","C093821","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2003,"12562851","Conversion of hexadecanoic acid to hexadecenoic acid by rat Delta 6-desaturase.","12562851",57]
["Heymann Nephritis Antigenic Complex","Heymann Nephritis Antigenic Complex","D026541","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1997,"9410908","Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis.","9410908",57]
["Heymann Nephritis Antigenic Complex","Heymann Nephritis Antigenic Complex","D026541","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2000,"11006321","Differential expression of the alpha(2)-macroglobulin receptor and the receptor associated protein in normal human endometrium and endometrial carcinoma.","11006321",57]
["Heymann Nephritis Antigenic Complex","Heymann Nephritis Antigenic Complex","D026541","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1994,"7959795","Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1).","7959795",57]
["Heymann Nephritis Antigenic Complex","Heymann Nephritis Antigenic Complex","D026541","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9574443","Megalin-mediated endocytosis in renal proximal tubule.","9574443",57]
["Histamine","Histamine","D006632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1978,"633778","[Studies on the pre- and posthepatic plasma histamine concentrations and their possible pathophysiological effects in liver cirrhosis (author's transl)].","633778",57]
["Histamine","Histamine","D006632","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1977,"872764","[Endogenous plasma histamine and \"hepatogenic\" peptic ulcer in liver cirrhosis (author's transl)].","872764",57]
["hugan qingzhi","hugan qingzhi","C000594496","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24735863","Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.","24735863",57]
["Hyaluronic Acid","Hyaluronic Acid","D006820","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2012,"22910856","Assessing the responses of cellular proteins induced by hyaluronic acid-modified surfaces utilizing a mass spectrometry-based profiling system: over-expression of CD36, CD44, CDK9, and PP2A.","22910856",57]
["Hyaluronic Acid","Hyaluronic Acid","D006820","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"24388885","Apolipoprotein E4 allele is associated with substantial changes in the plasma lipids and hyaluronic acid content in patients with nonalcoholic fatty liver disease.","24388885",57]
["Hyaluronic Acid","Hyaluronic Acid","D006820","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"22140659","Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.","22140659",57]
["Hydrochlorothiazide","Hydrochlorothiazide","D006852","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16986228","Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial.","16986228",57]
["Hydrochlorothiazide","Hydrochlorothiazide","D006852","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8510087","Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypertension.","8510087",57]
["Hydrogen Peroxide","Hydrogen Peroxide","D006861","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23537653","Hydrogen peroxide impairs autophagic flux in a cell model of nonalcoholic fatty liver disease.","23537653",57]
["Hydrogen Peroxide","Hydrogen Peroxide","D006861","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2001,"11390180","Trimetazidine protects low-density lipoproteins from oxidation and cultured cells exposed to H(2)O(2) from DNA damage.","11390180",57]
["Hydrogen Peroxide","Hydrogen Peroxide","D006861","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8811916","The limitations of an iodometric aerobic assay for peroxides.","8811916",57]
["Hydrogen Sulfide","Hydrogen Sulfide","D006862","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2011,"21321313","Hydrogen sulfide inhibits macrophage-derived foam cell formation.","21321313",57]
["Hydrogen Sulfide","Hydrogen Sulfide","D006862","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28177674","Exercise restores bioavailability of hydrogen sulfide and promotes autophagy influx in livers of mice fed with high-fat diet.","28177674",57]
["Hydroxocobalamin","Hydroxocobalamin","D006879","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"5876880","[Action of cyano- and hydroxy-cobalamin on the steatogenic effects of carbon tetrachloride on rat liver as a function of time].","5876880",57]
["Hydroxyl Radical","Hydroxyl Radical","D017665","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8381274","Generation of hydroxyl radical from lipid hydroperoxides contained in oxidatively modified low-density lipoprotein.","8381274",57]
["hyodeoxycholic acid","hyodeoxycholic acid","C010471","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7619860","Effects of hyodeoxycholic acid and alpha-hyocholic acid, two 6 alpha-hydroxylated bile acids, on cholesterol and bile acid metabolism in the hamster.","7619860",57]
["Hypochlorous Acid","Hypochlorous Acid","D006997","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2003,"12968020","Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein.","12968020",57]
["Hypochlorous Acid","Hypochlorous Acid","D006997","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2015,"25849867","Oxidation by neutrophils-derived HOCl increases immunogenicity of proteins by converting them into ligands of several endocytic receptors involved in antigen uptake by dendritic cells and macrophages.","25849867",57]
["Hypochlorous Acid","Hypochlorous Acid","D006997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11742862","Myeloperoxidase and hypochlorite, but not copper ions, oxidize heparin-bound LDL particles and release them from heparin.","11742862",57]
["Hypochlorous Acid","Hypochlorous Acid","D006997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20701912","Hypochlorite-oxidized LDL induces intraplatelet ROS formation and surface exposure of CD40L--a prominent role of CD36.","20701912",57]
["Hypochlorous Acid","Hypochlorous Acid","D006997","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20018624","Hypochlorous acid: a natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity.","20018624",57]
["Ibuprofen","Ibuprofen","D007052","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17559826","1H NMR investigation on interaction between ibuprofen and lipoproteins.","17559826",57]
["IGL-1 solution","IGL-1 solution","C504757","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"21128318","Insulin like growth factor-1 increases fatty liver preservation in IGL-1 solution.","21128318",57]
["imidaprilat","imidaprilat","C078006","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20093780","MMP-9 inhibition by ACE inhibitor reduces oxidized LDL-mediated foam-cell formation.","20093780",57]
["inchinko-to","inchinko-to","C078038","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24466347","Inhibitory effects of Japanese herbal medicines sho-saiko-to and juzen-taiho-to on nonalcoholic steatohepatitis in mice.","24466347",57]
["Indican","Indican","D007200","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26068716","Indoxyl sulfate suppresses hepatic fetuin-A expression via the aryl hydrocarbon receptor in HepG2 cells.","26068716",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C21379,B21379)","v":"indirubin"},"indirubin","C027185","1_MIE",18,1,"AHR","Activation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J21379,K21379)","v":"Receptors, Aryl Hydrocarbon"},"D018336","Receptors, Aryl Hydrocarbon",1,3,2004,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q21379,Q21379)","v":"15001395"},"Aryl hydrocarbon receptor response to indigoids in vitro and in vivo.","15001395",57]
["Indocyanine Green","Indocyanine Green","D007208","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2001,"11490122","Hepatic indocyanine green uptake and excretion in a rabbit model of steatosis.","11490122",57]
["Indocyanine Green","Indocyanine Green","D007208","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1978,"77927","[Binding of indocyanine green (ICG) to normal human serum protein (author's transl)].","77927",57]
["indole-3-carbinol","indole-3-carbinol","C016517","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15840385","Effects of analogs of indole-3-carbinol cyclic trimerization product in human breast cancer cells.","15840385",57]
["indole-3-carbinol","indole-3-carbinol","C016517","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2017,"28812970","Indole-3-carbinol induces G1 cell cycle arrest and apoptosis through aryl hydrocarbon receptor in THP-1 monocytic cell line.","28812970",57]
["indole-3-carbinol","indole-3-carbinol","C016517","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9771935","Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane.","9771935",57]
["indole-3-carbinol","indole-3-carbinol","C016517","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2017,"28812970","Indole-3-carbinol induces G1 cell cycle arrest and apoptosis through aryl hydrocarbon receptor in THP-1 monocytic cell line.","28812970",57]
["indole-3-carbinol","indole-3-carbinol","C016517","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1993,"8384853","Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation.","8384853",57]
["indolo(3,2-b)carbazole","indolo(3,2-b)carbazole","C075954","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"26856715","The Brassica-derived phytochemical indolo[3,2-b]carbazole protects against oxidative DNA damage by aryl hydrocarbon receptor activation.","26856715",57]
["Industrial Waste","Industrial Waste","D007220","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11804045","Bioavailability to juvenile rainbow trout (Oncorynchus mykiss) of retene and other mixed-function oxygenase-active compounds from sediments.","11804045",57]
["Industrial Waste","Industrial Waste","D007220","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12706388","Chronic stress in cunner, Tautogolabrus adspersus, exposed to municipal and industrial effluents.","12706388",57]
["Industrial Waste","Industrial Waste","D007220","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20483492","Estrogenic and anti-estrogenic effects of wood extractives present in pulp and paper mill effluents on rainbow trout.","20483492",57]
["Inositol","Inositol","D007294","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1970,"4910408","[Inosite: recent experimental and clinical findigs. Review of the literature and therapeutic experience].","4910408",57]
["Inositol","Inositol","D007294","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1979,"458502","myo-Inositol deficiency: studies on the mechanism of lactation-dependent fatty liver formation in the rat.","458502",57]
["Inositol","Inositol","D007294","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6683558","[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].","6683558",57]
["Inulin","Inulin","D007444","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"27623982","Effect of inulin-type fructans on blood lipid profile and glucose level: a systematic review and meta-analysis of randomized controlled trials.","27623982",57]
["Iodoquinol","Iodoquinol","D004103","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1974,"4370834","Acrodermatitis enteropathica. A clinical and biochemical survey.","4370834",57]
["ipragliflozin","ipragliflozin","C572941","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26731267","The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.","26731267",57]
["irbesartan","irbesartan","C081309","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12020687","Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits.","12020687",57]
["Iron, Dietary","Iron, Dietary","D019266","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23399663","Dietary fat level affects tissue iron levels but not the iron regulatory gene HAMP in rats.","23399663",57]
["isoferulic acid","isoferulic acid","C008180","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2000,"10683186","Antihyperglycemic action of isoferulic acid in streptozotocin-induced diabetic rats.","10683186",57]
["Isoniazid","Isoniazid","D007538","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2006,"16545483","Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice.","16545483",57]
["isopropyl-9H-thioxanthen-9-one","isopropyl-9H-thioxanthen-9-one","C518329","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2010,"20558275","AhR-agonistic, anti-androgenic, and anti-estrogenic potencies of 2-isopropylthioxanthone (ITX) as determined by in vitro bioassays and gene expression profiling.","20558275",57]
["isopropyl-9H-thioxanthen-9-one","isopropyl-9H-thioxanthen-9-one","C518329","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"27454205","In silico prediction and in vivo analysis of antiestrogenic potential of 2-isopropylthioxanthone (2-ITX) in juvenile goldfish (Carassius auratus).","27454205",57]
["Isoproterenol","Isoproterenol","D007545","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1996,"9026523","Isoproterenol decreases LDL receptor expression in rat adipose cells: activation of cyclic AMP-dependent proteolysis.","9026523",57]
["isosafrole","isosafrole","C015959","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9972470","Interaction of isosafrole, beta-naphthoflavone and other CYP1A inducers in liver of rainbow trout (Oncorhynchus mykiss) and eelpout (Zoarces viviparus).","9972470",57]
["Isotretinoin","Isotretinoin","D015474","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11747145","Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid.","11747145",57]
["Isradipine","Isradipine","D017275","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1996,"8880894","Prostaglandin I2-mediated upregulation of 125I-LDL-receptor binding by isradipine in normo- and hypercholesterolemic rabbits in vivo.","8880894",57]
["jasmonic acid","jasmonic acid","C011006","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2007,"17716996","Disease resistance against Magnaporthe grisea is enhanced in transgenic rice with suppression of omega-3 fatty acid desaturases.","17716996",57]
["JM 1596","JM 1596","C087530","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8955509","Cellular localization of antiviral polyoxometalates in J774 macrophages.","8955509",57]
["kaempferide 3-O-glucopyranosyl-1-2-O-(rhamnopyranosyl-1-6)glucopyranoside","kaempferide 3-O-glucopyranosyl-1-2-O-(rhamnopyranosyl-1-6)glucopyranoside","C430221","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11792676","Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9.","11792676",57]
["kahweol","kahweol","C053401","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9351383","Effect of coffee lipids (cafestol and kahweol) on regulation of cholesterol metabolism in HepG2 cells.","9351383",57]
["keishibukuryogan","keishibukuryogan","C054593","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20388146","The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease.","20388146",57]
["Ketoconazole","Ketoconazole","D007654","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23434491","Interaction of 17β-estradiol and ketoconazole on endocrine function in goldfish (Carassius auratus).","23434491",57]
["Ketoconazole","Ketoconazole","D007654","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3036162","Effect of ketoconazole on cholesterol synthesis and on HMG-CoA reductase and LDL-receptor activities in Hep G2 cells.","3036162",57]
["Khellin","Khellin","D007666","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"3865654","Hypocholesterolemic effect of khellin and khelloside in female cynomolgus monkeys.","3865654",57]
["kryptopyrrole","kryptopyrrole","C011891","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,1986,"3520252","A new prostaglandin disturbance syndrome in schizophrenia: delta-6-pyroluria.","3520252",57]
["Kynurenic Acid","Kynurenic Acid","D007736","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26013807","Absence of aryl hydrocarbon receptors increases endogenous kynurenic acid levels and protects mouse brain against excitotoxic insult and oxidative stress.","26013807",57]
["Lactic Acid","Lactic Acid","D019344","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2013,"23540683","Lactate increases hepatic secretion of VLDL-triglycerides in humans.","23540683",57]
["Lactic Acid","Lactic Acid","D019344","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"27562716","Metabolic biomarkers for non-alcoholic fatty liver disease induced by high-fat diet: In vivo magnetic resonance spectroscopy of hyperpolarized [1-13C] pyruvate.","27562716",57]
["Lactic Acid","Lactic Acid","D019344","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2013,"23540683","Lactate increases hepatic secretion of VLDL-triglycerides in humans.","23540683",57]
["Lansoprazole","Lansoprazole","D064747","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8900397","Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: evidences of a human-specific signal transduction pathway for CYP1A1 induction.","8900397",57]
["lard","lard","C029310","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22642161","[Effects of dietary fat level on the xenobiotic metabolism enzymes activity and antioxidant enzymes in rats].","22642161",57]
["lard","lard","C029310","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2003,"14506832","Chylomicron and VLDL TAG structures and postprandial lipid response induced by lard and modified lard.","14506832",57]
["lathosterol","lathosterol","C001521","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20693157","Lifibrol as a model compound for a novel lipid-lowering mechanism of action.","20693157",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C22083,B22083)","v":"lathosterol"},"lathosterol","C001521","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J22083,K22083)","v":"Receptors, LDL"},"D011973","Receptors, LDL",1,1,2008,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q22083,Q22083)","v":"18340009"},"Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2.","18340009",57]
["lauryl gallate","lauryl gallate","C008259","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1985,"4002681","[Toxicological study of the long-term effects of the antioxidant dodecyl gallate on albino rats].","4002681",57]
["leflunomide","leflunomide","C045463","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22297608","Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner.","22297608",57]
["Leukotriene B4","Leukotriene B4","D007975","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12376088","Does increased leukotriene B4 in type 1 diabetes result from elevated cholesteryl ester transfer protein activity?","12376088",57]
["levocetirizine","levocetirizine","C472067","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"25064340","Levocetirizine ameliorates high fructose diet-induced insulin resistance, vascular dysfunction and hepatic steatosis in rats.","25064340",57]
["Levonorgestrel","Levonorgestrel","D016912","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"6213375","Comparative effects of the oral contraceptive combinations 0.150 mg desogestrel + 0.030 mg ethinyloestradiol and 0.150 mg levonorgestrel + 0.030 mg ethinyloestradiol on lipid and lipoprotein metabolism in healthy female volunteers.","6213375",57]
["lifibrol","lifibrol","C059343","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20693157","Lifibrol as a model compound for a novel lipid-lowering mechanism of action.","20693157",57]
["Linagliptin","Linagliptin","D000069476","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24048504","Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.","24048504",57]
["Linoleic Acid","Linoleic Acid","D019787","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"9890193","Linoleic acid amplifies polychlorinated biphenyl-mediated dysfunction of endothelial cells.","9890193",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1991,"1657182","Incorporation into liver microsomal lipids of linoleic and stearic acids and of their respective products of delta 6 and delta 9 desaturation, gamma-linolenic and oleic acids: effect of age and of blackcurrant seed oil.","1657182",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2012,"22436184","Linoleic and α-linolenic acid as precursor and inhibitor for the synthesis of long-chain polyunsaturated fatty acids in liver and brain of growing pigs.","22436184",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2012,"23084639","High levels of stearic acid, palmitoleic acid, and dihomo-γ-linolenic acid and low levels of linoleic acid in serum cholesterol ester are associated with high insulin resistance.","23084639",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2017,"29031400","Neither linoleic acid nor arachidonic acid promote white adipose tissue inflammation in Fads2-/- mice fed low fat diets.","29031400",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1993,"8399342","Influence of linoleic acid on desaturation and uptake of deuterium-labeled palmitic and stearic acids in humans.","8399342",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,1992,"1606171","Desaturation of linoleic acid in the small bowel is increased by short-term fasting and by dietary content of linoleic acid.","1606171",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,2011,"21679695","Delta-6 desaturase from borage converts linoleic acid to gamma-linolenic acid in HEK293 cells.","21679695",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,1996,"8547334","Delta 6-desaturase: improved methodology and analysis of the kinetics in a multi-enzyme system.","8547334",57]
["Linoleic Acid","Linoleic Acid","D019787","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12913264","Suppression of free radical-induced DNA strand breaks by linoleic acid and low density lipoprotein in vitro.","12913264",57]
["Linoleic Acid","Linoleic Acid","D019787","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8406127","Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects.","8406127",57]
["Linoleic Acid","Linoleic Acid","D019787","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2014,"25049048","Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation.","25049048",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2002,"12362447","trans-10, cis-12 conjugated linoleic acid decreases lipogenic rates and expression of genes involved in milk lipid synthesis in dairy cows.","12362447",57]
["Linoleic Acid","Linoleic Acid","D019787","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,1991,"1657182","Incorporation into liver microsomal lipids of linoleic and stearic acids and of their respective products of delta 6 and delta 9 desaturation, gamma-linolenic and oleic acids: effect of age and of blackcurrant seed oil.","1657182",57]
["Linseed Oil","Linseed Oil","D008043","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2017,"28112058","A n-3 PUFA depletion applied to rainbow trout fry (Oncorhynchus mykiss) does not modulate its subsequent lipid bioconversion capacity.","28112058",57]
["Linseed Oil","Linseed Oil","D008043","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1796574","[Effect of linseed oil on fatty acid composition of low- and very low density lipoproteins, cholesterol and its fractions in the blood serum of albino rats].","1796574",57]
["linsidomine","linsidomine","C002385","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14569064","Potent antioxidant properties of 4-hydroxyl-propranolol.","14569064",57]
["linsidomine","linsidomine","C002385","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2003,"12729008","Effect of alpha-tocopherol on the oxidative modification of apolipoprotein E in human very-low-density lipoprotein.","12729008",57]
["Lipofuscin","Lipofuscin","D008062","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10067978","Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin.","10067978",57]
["lipoteichoic acid","lipoteichoic acid","C009900","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2008,"18458151","Cellular trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling: role of CD14 and CD36.","18458151",57]
["Lithium Chloride","Lithium Chloride","D018021","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2001,"11334436","Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression.","11334436",57]
["Liver Glycogen","Liver Glycogen","D008112","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1963,"14121880","[FATTY LIVER PATHOGENESIS IN CARASSIUS AURATUS IN GLUCOSE-RICH MEDIUM AND ITS ALTERATION BY N1-N-BUTYLBIGUANIDE AND N'-(4-METHYLBENZOYLSULFONYL)-N'-BUTYLUREA (TOLBUTAMIDE)].","14121880",57]
["Liver Glycogen","Liver Glycogen","D008112","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1971,"5090129","Hepatic glycogen studies in Indian diabetics.","5090129",57]
["Liver Glycogen","Liver Glycogen","D008112","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1974,"4364468","Metabolite levels reflecting changes in liver energy metabolism during the neonatal period.","4364468",57]
["Lopinavir","Lopinavir","D061466","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12646808","Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.","12646808",57]
["Losartan","Losartan","D019808","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21748770","Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.","21748770",57]
["Losartan","Losartan","D019808","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9365870","Use of losartan in FH patients during treatment with DSC-LDL apheresis.","9365870",57]
["Lovastatin","Lovastatin","D008148","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,2,1996,"8687497","Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells.","8687497",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11368995","The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens.","11368995",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"7254297","Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.","7254297",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2268863","Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones.","2268863",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2918845","Regulation of low density lipoprotein apoprotein B metabolism by lovastatin and cholestyramine in miniature pigs: effects on LDL composition and synthesis of LDL subfractions.","2918845",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6388097","Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.","6388097",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1995,"7661876","Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin.","7661876",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7677855","Low-density-lipoprotein apheresis.","7677855",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9070296","Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells.","9070296",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9488197","Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin.","9488197",57]
["Lovastatin","Lovastatin","D008148","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"12119202","Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.","12119202",57]
["Lovastatin","Lovastatin","D008148","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"7189661","The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks.","7189661",57]
["Lovastatin","Lovastatin","D008148","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1994,"8295321","Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin.","8295321",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1992,"1627634","Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.","1627634",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1990,"2317163","Unexpected failure of bile acid malabsorption to stimulate cholesterol synthesis in sitosterolemia with xanthomatosis. Comparison with lovastatin.","2317163",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1981,"6265781","Lowering plasma cholesterol by raising LDL receptors.","6265781",57]
["Lovastatin","Lovastatin","D008148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1993,"8457250","Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.","8457250",57]
["luotonin A","luotonin A","C480761","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"23263815","In vitro inhibitory effect of luotonin A on human CYP1A.","23263815",57]
["Luteolin","Luteolin","D047311","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19100243","The alkyl chain length of 3-alkyl-3',4',5,7-tetrahydroxyflavones modulates effective inhibition of oxidative damage in biological systems: illustration with LDL, red blood cells and human skin keratinocytes.","19100243",57]
["luteolin-7-glucoside","luteolin-7-glucoside","C066408","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9802556","Luteolin-rich artichoke extract protects low density lipoprotein from oxidation in vitro.","9802556",57]
["lycium barbarum polysaccharide","lycium barbarum polysaccharide","C500223","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,"24998389","Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model.","24998389",57]
["lycopene","lycopene","C015329","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10442493","Supplementation with tomato juice increases plasma lycopene but does not alter susceptibility to oxidation of low-density lipoproteins from renal transplant recipients.","10442493",57]
["lycopene","lycopene","C015329","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10784384","Dietary fiber reduces the antioxidative effect of a carotenoid and alpha-tocopherol mixture on LDL oxidation ex vivo in humans.","10784384",57]
["lycopene","lycopene","C015329","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18689558","A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress.","18689558",57]
["lycopene","lycopene","C015329","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8736829","Carotenoid profiles of human plasma lipoproteins.","8736829",57]
["lycopene","lycopene","C015329","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2003,"14652003","Incorporation of lycopene into chylomicron remnant-like particles enhances their induction of lipid accumulation in macrophages.","14652003",57]
["lysophosphatidic acid","lysophosphatidic acid","C032881","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23036978","Lysophosphatidic acid induces increased BACE1 expression and Aβ formation.","23036978",57]
["M 50367","M 50367","C119626","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,4,2008,"18179178","Characterization of the antiallergic drugs 3-[2-(2-phenylethyl) benzoimidazole-4-yl]-3-hydroxypropanoic acid and ethyl 3-hydroxy-3-[2-(2-phenylethyl)benzoimidazol-4-yl]propanoate as full aryl hydrocarbon receptor agonists.","18179178",57]
["magnolol","magnolol","C005498","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2015,"25125496","Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1 c pathway.","25125496",57]
["Malathion","Malathion","D008294","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2015,"25449180","Changes in glucose metabolism and reversion of genes expression in the liver of insulin-resistant rats exposed to malathion. The protective effects of N-acetylcysteine.","25449180",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11325894","Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL.","11325894",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15561333","Insulin resistance increases circulating malondialdehyde-modified LDL and impairs endothelial function in healthy young men.","15561333",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"18840422","Circulating malondialdehyde-modified low-density lipoprotein is strongly associated with very small low-density lipoprotein cholesterol concentrations in healthy men.","18840422",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21683785","Specific recognition of malondialdehyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a.","21683785",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23148723","Follow-ups of metabolic, inflammatory and oxidative stress markers, and brachial-ankle pulse wave velocity in middle-aged subjects without metabolic syndrome.","23148723",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"26139161","Malondialdehyde-Modified LDL IgG Antibody Levels and Indices of Cardiac Function in Valvular Heart and Coronary Artery Disease Patients.","26139161",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28539572","Malondialdehyde-Modified Low Density Lipoprotein as Oxidative-Stress Marker in Vasospastic Angina Patients.","28539572",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1997,"9069519","Lipid peroxidation induced in vivo by hyperhomocysteinaemia in pigs.","9069519",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1981,"6260883","The metabolism of native and malondialdehyde-altered low density lipoproteins by human monocyte-macrophages.","6260883",57]
["Malondialdehyde","Malondialdehyde","D008315","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1984,"6481148","Topography and dynamics of receptors for acetylated and malondialdehyde-modified low-density lipoprotein in the plasma membrane of mouse peritoneal macrophages as visualized by colloidal gold in conjunction with surface replicas.","6481148",57]
["mangiferin","mangiferin","C013592","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27123455","The Compound of Mangiferin-Berberine Salt Has Potent Activities in Modulating Lipid and Glucose Metabolisms in HepG2 Cells.","27123455",57]
["Mannose","Mannose","D008358","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1982,"7138908","Impaired glycosylation in liver microsomes of orotic-acid-fed rats.","7138908",57]
["marchantin H","marchantin H","C102015","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8837734","Marchantin H as a natural antioxidant and free radical scavenger.","8837734",57]
["Martius scarlet blue trichrome","Martius scarlet blue trichrome","C042643","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"28168649","Combined orcein and martius scarlet blue (OMSB) staining for qualitative and quantitative analyses of atherosclerotic plaques in brachiocephalic arteries in apoE/LDLR-/- mice.","28168649",57]
["MCC-950","MCC-950","C000597426","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28167322","NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.","28167322",57]
["Mechlorethamine","Mechlorethamine","D008466","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7578363","Improved cytotoxicity of antitumor compounds deliverable by the LDL pathway.","7578363",57]
["Medroxyprogesterone","Medroxyprogesterone","D008525","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1979,"230695","Lipid metabolic studies in oophorectomized women. Effects of three different progestogens.","230695",57]
["Medroxyprogesterone Acetate","Medroxyprogesterone Acetate","D017258","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9841134","Estradiol inhibits LDL oxidation: do the progestins medroxyprogesterone acetate and norethisterone acetate influence this effect?","9841134",57]
["Meglumine","Meglumine","D008536","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23281287","Concentrations of Gd-BOPTA in cholestatic fatty rat livers: role of transport functions through membrane proteins.","23281287",57]
["Menhaden oil","Menhaden oil","C033266","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1998,"9687962","Lack of protective effect of menhaden oil supplementation on rat liver steatosis induced by a carbohydrate-rich diet.","9687962",57]
["Meprobamate","Meprobamate","D008620","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1969,"5368643","[Pharmacokinetics of meprobamate in chronic liver diseases and drug addiction].","5368643",57]
["Metformin","Metformin","D008687","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2010,"20844250","Genetic downregulation of AMPK-alpha isoforms uncovers the mechanism by which metformin decreases FA uptake and oxidation in skeletal muscle cells.","20844250",57]
["Metformin","Metformin","D008687","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2005,"15801922","A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.","15801922",57]
["Metformin","Metformin","D008687","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"18721166","Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.","18721166",57]
["Metformin","Metformin","D008687","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20955440","Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.","20955440",57]
["Metformin","Metformin","D008687","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21366813","Use of metformin in pediatric age.","21366813",57]
["Metformin","Metformin","D008687","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22676459","Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?","22676459",57]
["Metformin","Metformin","D008687","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2015,"25484077","Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway.","25484077",57]
["Metformin","Metformin","D008687","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"22078152","Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.","22078152",57]
["Metformin","Metformin","D008687","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24840107","The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.","24840107",57]
["Metformin","Metformin","D008687","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1977,"193525","Treatment of hypertriglyceridemia with metformin. Effectiveness and analỳsis of results.","193525",57]
["Metformin","Metformin","D008687","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22519397","Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease.","22519397",57]
["Metformin","Metformin","D008687","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28611274","Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.","28611274",57]
["Metformin","Metformin","D008687","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2001,"11440903","Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin.","11440903",57]
["Methadone","Methadone","D008691","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9020195","Interaction of methadone with substrates of human hepatic cytochrome P450 3A4.","9020195",57]
["Methane","Methane","D008697","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,1998,"9802469","Quantification of plasma lipoprotein fractions by wavelet transform time-domain data processing of the proton nuclear magnetic resonance methylene spectral region.","9802469",57]
["Methotrexate","Methotrexate","D008727","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1974,"4835782","Effects of methotrexate on the liver in psoriasis.","4835782",57]
["Methotrexate","Methotrexate","D008727","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"25185870","End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.","25185870",57]
["Methoxychlor","Methoxychlor","D008731","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2003,"12919727","Hepatic CYP1A, 2B, 2C, 2E and 3A regulation by methoxychlor in male and female rats.","12919727",57]
["Methoxychlor","Methoxychlor","D008731","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22484361","Methoxychlor inhibits growth and induces atresia through the aryl hydrocarbon receptor pathway in mouse ovarian antral follicles.","22484361",57]
["methylamine","methylamine","C027451","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1993,"8232278","Methylamine-treated low density lipoproteins elicit different responses in HepG2 cells and macrophages.","8232278",57]
["methylamine","methylamine","C027451","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1993,"8232278","Methylamine-treated low density lipoproteins elicit different responses in HepG2 cells and macrophages.","8232278",57]
["Methylcholanthrene","Methylcholanthrene","D008748","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11285323","Inducibility of hepatic CYP1A enzymes by 3-methylcholanthrene and isosafrole differs in male rats fed diets containing casein, soy protein isolate or whey from conception to adulthood.","11285323",57]
["Methylcholanthrene","Methylcholanthrene","D008748","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15915147","Estrogen-responsive element (ERE)-like motifs affect the 3-methylcholanthrene induction of eel CYP1A gene.","15915147",57]
["Methylcholanthrene","Methylcholanthrene","D008748","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22900608","Precision-cut liver slices to investigate responsiveness of deep-sea fish to contaminants at high pressure.","22900608",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C23811,B23811)","v":"Methylcholanthrene"},"Methylcholanthrene","D008748","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J23811,K23811)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,1985,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q23811,Q23811)","v":"4012798"},"Foetal and neonatal development of cytochrome P-450 and cytochrome P-448 catalysed mixed function oxidases in the rat: induction by 3-methylcholanthrene.","4012798",57]
["Methylcholanthrene","Methylcholanthrene","D008748","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9669083","Modulation of snake hepatic cytochrome P450 by 3-methylcholanthrene and phenobarbital.","9669083",57]
["Methylcholanthrene","Methylcholanthrene","D008748","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2004,"15621696","Benzo[a]pyrene, 3-methylcholanthrene and beta-naphthoflavone induce oxidative stress in hepatoma hepa 1c1c7 Cells by an AHR-dependent pathway.","15621696",57]
["Methylcholanthrene","Methylcholanthrene","D008748","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20651249","3-methylcholanthrene induces differential recruitment of aryl hydrocarbon receptor to human promoters.","20651249",57]
["Methylcholanthrene","Methylcholanthrene","D008748","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"27442426","3-Methylcholanthrene/Aryl-Hydrocarbon Receptor-Mediated Hypertension Through eNOS Inactivation.","27442426",57]
["Methylcholanthrene","Methylcholanthrene","D008748","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1995,"8747408","Fetal mouse susceptibility to transplacental carcinogenesis: differential influence of Ah receptor phenotype on effects of 3-methylcholanthrene, 12-dimethylbenz[a]anthracene, and benzo[a]pyrene.","8747408",57]
["methylmercuric chloride","methylmercuric chloride","C004925","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23541843","Posttranslational mechanisms modulating the expression of the cytochrome P450 1A1 gene by methylmercury in HepG2 cells: a role of heme oxygenase-1.","23541843",57]
["Methylprednisolone","Methylprednisolone","D008775","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2013,"24312573","Meta-modeling of methylprednisolone effects on glucose regulation in rats.","24312573",57]
["methysticin","methysticin","C076881","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21908763","Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1.","21908763",57]
["Metronidazole","Metronidazole","D008795","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1985,"3923267","A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements.","3923267",57]
["Mevalonic Acid","Mevalonic Acid","D008798","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1974,"4375886","[The effect of desoxymevalonic acid derivatives on basic lipid metabolism paremeters in different species of animals].","4375886",57]
["mevalonolactone","mevalonolactone","C015367","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3004340","Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by reversible phosphorylation: modulation of enzymatic activity by low density lipoprotein, sterols, and mevalonolactone.","3004340",57]
["mevastatin","mevastatin","C012258","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6089762","Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2.","6089762",57]
["mevastatin","mevastatin","C012258","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1983,"6643457","Mutant clone of Chinese hamster ovary cells lacking 3-hydroxy-3 -methylglutaryl coenzyme A reductase.","6643457",57]
["mevastatin","mevastatin","C012258","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2000,"11480454","Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.","11480454",57]
["MF 438","MF 438","C548713","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2010,"20004097","Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).","20004097",57]
["Midazolam","Midazolam","D008874","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20080160","Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines.","20080160",57]
["Miocamycin","Miocamycin","D015644","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10725309","Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.","10725309",57]
["MK-0524","MK-0524","C518174","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24618208","Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.","24618208",57]
["monatepil","monatepil","C067818","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8740082","Inhibition of lipid hydroperoxidation of low density lipoprotein by the Ca(2+)-channel and alpha 1-adrenoceptor antagonist monatepil maleate.","8740082",57]
["Monensin","Monensin","D008985","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1984,"6477962","Lipoprotein synthesis and secretion by cultured rat hepatocytes. Parallel inhibition of secretion of VLDL, HDL and albumin by monensin.","6477962",57]
["monomethoxypolyethyleneglycol-polylactide block copolymer","monomethoxypolyethyleneglycol-polylactide block copolymer","C542623","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"26836197","Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance.","26836197",57]
["morin","morin","C008548","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18662803","Fisetin, morin and myricetin attenuate CD36 expression and oxLDL uptake in U937-derived macrophages.","18662803",57]
["Moxalactam","Moxalactam","D009070","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1986,"3735664","[Disulfiram-like reactions resulting from the administration of cephem antibiotics with methyltetrazolethiol moiety examined by using different doses].","3735664",57]
["musk xylene","musk xylene","C031447","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1996,"8661901","Toxicological and kinetic study of musk xylene in rainbow trout, Oncorhynchus mykiss.","8661901",57]
["myricetin","myricetin","C040015","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1997,"9057040","The effect of various dietary flavonoids on the susceptibility of low density lipoproteins to oxidation in vitro using both metallic and non-metallic oxidising agents.","9057040",57]
["myricitrin","myricitrin","C008577","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25849952","Myricitrin attenuates endothelial cell apoptosis to prevent atherosclerosis: An insight into PI3K/Akt activation and STAT3 signaling pathways.","25849952",57]
["N-((2-hydroxy-3-N,N-dimethylhexadecylammonium)propyl)chitosan chloride","N-((2-hydroxy-3-N,N-dimethylhexadecylammonium)propyl)chitosan chloride","C569571","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21875072","Synthesis of carboxymethylated and quaternized chitosans and their therapeutic effect on nonalcoholic Fatty liver disease.","21875072",57]
["N-((2-hydroxy-3-N,N-dimethylhexadecylammonium)propyl)chitosan chloride","N-((2-hydroxy-3-N,N-dimethylhexadecylammonium)propyl)chitosan chloride","C569571","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"21875072","Synthesis of carboxymethylated and quaternized chitosans and their therapeutic effect on nonalcoholic Fatty liver disease.","21875072",57]
["N-(2-heptyl)-propargylamine","N-(2-heptyl)-propargylamine","C435297","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11454735","Inhibition of rat liver microsomal CYP1A2 and CYP2B1 activity by N-(2-heptyl)-N-methyl-propargylamine and by N-(2-heptyl)-propargylamine.","11454735",57]
["N-(4-methyl-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)phenyl)-N'-phenylurea","N-(4-methyl-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)phenyl)-N'-phenylurea","C534914","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"19033819","Pyrido-pyrimidine derivative CYC10424 inhibits glycosaminoglycan changes on vascular smooth muscle-derived proteoglycans and reduces lipoprotein binding.","19033819",57]
["N-(tris((beta-galactopyranosyloxy)methyl)methyl)-N(alpha)-(4-(5-cholesten-3 beta-yloxy)succinyl)glycinamide","N-(tris((beta-galactopyranosyloxy)methyl)methyl)-N(alpha)-(4-(5-cholesten-3 beta-yloxy)succinyl)glycinamide","C042924","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1327096","A monogalactosylated cholesterol derivative that specifically induces uptake of LDL by the liver.","1327096",57]
["N,N'-diphenyl-4-phenylenediamine","N,N'-diphenyl-4-phenylenediamine","C004845","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1601995","Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine.","1601995",57]
["N-Acetylneuraminic Acid","N-Acetylneuraminic Acid","D019158","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11166760","Influence of sialic acid content of low-density lipoprotein particles on endothelium-dependent vasorelaxation in rabbit aorta.","11166760",57]
["N-Acetylneuraminic Acid","N-Acetylneuraminic Acid","D019158","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1995,"8521599","Sialic acid and oxidizability of low density lipoprotein subfractions of hyperlipidemic patients.","8521599",57]
["N-Acetylneuraminic Acid","N-Acetylneuraminic Acid","D019158","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26315777","Association between Serum Sialic Acid Levels and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.","26315777",57]
["naloxonazine","naloxonazine","C034643","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2001,"11723065","Plasma glucose-lowering effect of tramadol in streptozotocin-induced diabetic rats.","11723065",57]
["naphthalene","naphthalene","C031721","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2002,"12220115","Naphthalene and beta-naphthoflavone effects on Anguilla anguilla L. hepatic metabolism and erythrocytic nuclear abnormalities.","12220115",57]
["naringenin","naringenin","C005273","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"29183361","Naringenin attenuates hepatitis B virus X protein-induced hepatic steatosis.","29183361",57]
["naringin","naringin","C005274","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12878454","Effects of flavonoids on the susceptibility of low-density lipoprotein to oxidative modification.","12878454",57]
["ND-630","ND-630","C000610197","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"26976583","Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.","26976583",57]
["neocuproine","neocuproine","C002701","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11328672","The dose-dependent effect of copper-chelating agents on the kinetics of peroxidation of low-density lipoprotein (LDL).","11328672",57]
["Neopterin","Neopterin","D019798","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1987,"2890855","Potential of urinary neopterin excretion in differentiating chronic non-A, non-B hepatitis from fatty liver.","2890855",57]
["Neostigmine","Neostigmine","D009388","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1989,"2574406","Central nervous system control of glycogenolysis and gluconeogenesis in fed and fasted rat liver.","2574406",57]
["n-heptane","n-heptane","C028618","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1984,"6089835","Activation of fibroblast recognition site in very low density lipoprotein by partial delipidation.","6089835",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C24515,B24515)","v":"Niacin"},"Niacin","D009525","7_KE",54,7,"CD36","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J24515,K24515)","v":"CD36 Antigens"},"D018955","CD36 Antigens",1,1,2010,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q24515,Q24515)","v":"19878707"},"Niacin improves renal lipid metabolism and slows progression in chronic kidney disease.","19878707",57]
["Niacin","Niacin","D009525","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2014,"25040591","Nicotinic acid supplementation in the context of alcoholic liver injury: friend or foe?","25040591",57]
["Niacin","Niacin","D009525","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20625257","Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?","20625257",57]
["Niacin","Niacin","D009525","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2001,"11171611","Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.","11171611",57]
["Niacin","Niacin","D009525","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2014,"24806747","Nicotinic acid effects on insulin sensitivity and hepatic lipid metabolism: an in vivo to in vitro study.","24806747",57]
["Niacinamide","Niacinamide","D009536","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22847887","Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.","22847887",57]
["Nicardipine","Nicardipine","D009529","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1996,"8987667","Nicardipine and nifedipine inhibit fatty acid desaturases in rat liver microsomes.","8987667",57]
["Niceritrol","Niceritrol","D009531","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,3,1980,"7458980","Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.","7458980",57]
["Nicotine","Nicotine","D009538","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24926542","Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.","24926542",57]
["Nicotine","Nicotine","D009538","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"26397391","Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice.","26397391",57]
["Nifedipine","Nifedipine","D009543","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1992,"1513199","Effect of nifedipine and S-adenosylmethionine in the liver of rats treated with CCl4 and ethanol for one month.","1513199",57]
["Nifedipine","Nifedipine","D009543","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1995,"7746159","Inhibition by nifedipine of the efflux of plasma low-density lipoprotein and albumin from the vasculature of the mouse mesentery in vivo.","7746159",57]
["Niridazole","Niridazole","D009560","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1977,"402061","Further studies on the effect of Ambilhar on serum choline esterase and transaminases.","402061",57]
["Nitric Oxide","Nitric Oxide","D009569","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16492979","Modulation of pulmonary cytochrome P4501A1 expression by hyperoxia and inhaled nitric oxide in the newborn rat: implications for lung injury.","16492979",57]
["Nitric Oxide","Nitric Oxide","D009569","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2008,"18578693","Severe liver steatosis correlates with nitrosative and oxidative stress in rats.","18578693",57]
["Nitric Oxide","Nitric Oxide","D009569","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2010,"18986378","Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model.","18986378",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10218641","Lipid hydroperoxides inhibit nitric oxide production in RAW264.7 macrophages.","10218641",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12374614","Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide.","12374614",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1309534","Inactivation of endothelial derived relaxing factor by oxidized lipoproteins.","1309534",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15758251","Phytoestrogen alpha-zearalanol antagonizes oxidized LDL-induced inhibition of nitric oxide production and stimulation of endothelin-1 release in human umbilical vein endothelial cells.","15758251",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18435936","Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits.","18435936",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"2040054","Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide.","2040054",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"24319749","Effects of endogenous regulators of endothelial NO synthase on nitric oxide homeostasis and blood serum lipoproteins during experimental diabetes mellitus.","24319749",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7548764","The antioxidant effect of spermine NONOate in human low-density lipoprotein.","7548764",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7947607","Oxidation of LDL to a biologically active form by derivatives of nitric oxide and nitrite in the absence of superoxide. Dependence on pH and oxygen.","7947607",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1996,"8946952","Nitric oxide released from zwitterionic polyamine/NO adducts inhibits Cu2+-induced low density lipoprotein oxidation.","8946952",57]
["Nitric Oxide","Nitric Oxide","D009569","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9794741","Reduced susceptibility to oxidation of low-density lipoprotein in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome).","9794741",57]
["Nitric Oxide","Nitric Oxide","D009569","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28823369","Remote ischemic preconditioning protects liver ischemia-reperfusion injury by regulating eNOS-NO pathway and liver microRNA expressions in fatty liver rats.","28823369",57]
["Nitric Oxide","Nitric Oxide","D009569","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1996,"8897881","Excessive NO production dose not account for the inhibition of hepatic gluconeogenesis in endotoxemia.","8897881",57]
["nitroaspirin","nitroaspirin","C102148","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12209007","Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice.","12209007",57]
["Nitrogen Dioxide","Nitrogen Dioxide","D009585","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2000,"10772654","Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species.","10772654",57]
["Nitroglycerin","Nitroglycerin","D005996","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15159289","Determinants of arterial nitrate-mediated dilatation in children: role of oxidized low-density lipoprotein, endothelial function, and carotid intima-media thickness.","15159289",57]
["N-nitrosopiperidine","N-nitrosopiperidine","C002743","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2007,"17512695","Protective effect of vitamin C towards N-nitrosamine-induced DNA damage in the single-cell gel electrophoresis (SCGE)/HepG2 assay.","17512695",57]
["nobiletin","nobiletin","C008661","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18567747","The citrus flavonoids hesperetin and nobiletin differentially regulate low density lipoprotein receptor gene transcription in HepG2 liver cells.","18567747",57]
["nonylphenol","nonylphenol","C025256","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16402549","Metabolism of 4-n-nonylphenol by non-modified and CYP1A1- and CYP1A2-transgenic cell cultures of tobacco.","16402549",57]
["Norepinephrine","Norepinephrine","D009638","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1963,"14018700","Lipid metabolism and trauma. II. Studies on the effect of nicotinic acid on norepinephrine induced fatty liver.","14018700",57]
["Norepinephrine","Norepinephrine","D009638","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1976,"192511","Noradrenaline sensitivity of an isolated perfused artery: effects of normal and hypertensive plasma.","192511",57]
["Norethindrone","Norethindrone","D009640","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1979,"230695","Lipid metabolic studies in oophorectomized women. Effects of three different progestogens.","230695",57]
["Norethindrone","Norethindrone","D009640","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9841134","Estradiol inhibits LDL oxidation: do the progestins medroxyprogesterone acetate and norethisterone acetate influence this effect?","9841134",57]
["norethindrone acetate","norethindrone acetate","C024262","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3730329","Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy.","3730329",57]
["Norgestrel","Norgestrel","D009644","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,1989,"2910918","Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in postmenopausal women.","2910918",57]
["Norgestrel","Norgestrel","D009644","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1994,"7820162","A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.","7820162",57]
["Norgestrel","Norgestrel","D009644","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1993,"8449014","A randomized comparative open study of the effects of two oral contraceptives, Triphasil and Ortho 7/7/7, on lipid metabolism.","8449014",57]
["N-stearoylethanolamine","N-stearoylethanolamine","C408368","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2014,"24834723","[The effect of N-stearoylethanolamine on liver phospholipid composition of rats with insulin resistance caused by alimentary obesity].","24834723",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C25219,B25219)","v":"O(2)-vinyl-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate"},"O(2)-vinyl-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate","C107010","13_AO",455,13,"Accumulation, Liver lipid",null,{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J25219,K25219)","v":"Non-alcoholic Fatty Liver Disease"},"D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q25219,Q25219)","v":"25870102"},"Hepatoselective Nitric Oxide (NO) Donors, V-PYRRO/NO and V-PROLI/NO, in Nonalcoholic Fatty Liver Disease: A Comparison of Antisteatotic Effects with the Biotransformation and Pharmacokinetics.","25870102",57]
["o-Aminoazotoluene","o-Aminoazotoluene","D009762","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15863256","o-Aminoazotoluene does induce the enzymes of its own mutagenic activation in mouse liver.","15863256",57]
["obeticholic acid","obeticholic acid","C464660","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28624576","Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.","28624576",57]
["obeticholic acid","obeticholic acid","C464660","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25690590","FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.","25690590",57]
["ochratoxin A","ochratoxin A","C025589","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1986,"2881768","Phosphoenolpyruvate carboxykinase as a selective indicator of ochratoxin A induced nephropathy.","2881768",57]
["octanoic acid","octanoic acid","C031492","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1957,"13470069","Metabolism of octanoate by fatty liver slices.","13470069",57]
["Okadaic Acid","Okadaic Acid","D019319","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1990,"1980466","Influence of okadaic acid on the control of liver mRNA levels.","1980466",57]
["olanzapine","olanzapine","C076029","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2016,"27973621","Chronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin Resistance.","27973621",57]
["Oleanolic Acid","Oleanolic Acid","D009828","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2004,"15570868","[Treatment of nonalcoholic steatohepatitis (NASH)].","15570868",57]
["Oleic Acid","Oleic Acid","D019301","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2012,"22693206","High insulin levels are required for FAT/CD36 plasma membrane translocation and enhanced fatty acid uptake in obese Zucker rat hepatocytes.","22693206",57]
["Oleic Acid","Oleic Acid","D019301","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2017,"28637956","CD36 involvement in the olfactory perception of oleic aldehyde, an odour-active volatile compound, in mice.","28637956",57]
["Oleic Acid","Oleic Acid","D019301","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2008,"18467452","An oleate hydroxylase from the fungus Claviceps purpurea: cloning, functional analysis, and expression in Arabidopsis.","18467452",57]
["Oleic Acid","Oleic Acid","D019301","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2014,"24909647","Stacking of a stearoyl-ACP thioesterase with a dual-silenced palmitoyl-ACP thioesterase and ∆12 fatty acid desaturase in transgenic soybean.","24909647",57]
["Oleic Acid","Oleic Acid","D019301","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"14301352","LIVER LIPIDS IN A CASE OF HYPERVITAMINOSIS A.","14301352",57]
["Oleic Acid","Oleic Acid","D019301","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22058427","Relationship of glucose and oleate metabolism to cardiac function in lipin-1 deficient (fld) mice.","22058427",57]
["Oleic Acid","Oleic Acid","D019301","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1318550","Photosensitization by Photofrin II delivered to WI26VA4 SV40-transformed human fibroblasts by low density lipoproteins: inhibition of lipid synthesis and fatty acid uptake.","1318550",57]
["Oleic Acid","Oleic Acid","D019301","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1482370","Lipoprotein lipase-mediated lipolysis of very low density lipoproteins increases monocyte adhesion to aortic endothelial cells.","1482370",57]
["Oleic Acid","Oleic Acid","D019301","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1480152","Long term incubation of cardiac myocytes with oleic acid and very-low density lipoprotein reduces heparin-releasable lipoprotein lipase activity.","1480152",57]
["Oleic Acid","Oleic Acid","D019301","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1997,"9101436","Up-regulated delta 9-desaturase gene expression by hypolipidemic peroxisome-proliferating fatty acids results in increased oleic acid content in liver and VLDL: accumulation of a delta 9-desaturated metabolite of tetradecylthioacetic acid.","9101436",57]
["Oleic Acid","Oleic Acid","D019301","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1997,"9139669","Normal activity of microsomal triglyceride transfer protein is required for the oleate-induced secretion of very low density lipoproteins containing apolipoprotein B from McA-RH7777 cells.","9139669",57]
["Oleic Acid","Oleic Acid","D019301","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1992,"1515122","Essential fatty acid deficiency lowers the activity of the acetylated low density lipoprotein receptor of rat peritoneal macrophages.","1515122",57]
["Oleic Acid","Oleic Acid","D019301","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2004,"14977874","A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension.","14977874",57]
["Oleic Acid","Oleic Acid","D019301","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2014,"24935936","Allosteric inhibition of a stem cell RNA-binding protein by an intermediary metabolite.","24935936",57]
["oleoylethanolamide","oleoylethanolamide","C488250","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2007,"16902188","Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction.","16902188",57]
["oleuropein","oleuropein","C002769","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21145829","Oleuropein attenuates hepatic steatosis induced by high-fat diet in mice.","21145829",57]
["Olive Oil","Olive Oil","D000069463","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2017,"28701171","Identification and characterization of single nucleotide polymorphism markers in FADS2 gene associated with olive oil fatty acids composition.","28701171",57]
["Olive Oil","Olive Oil","D000069463","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11755938","Effect of meals rich in heated olive and safflower oils on oxidation of postprandial serum in healthy men.","11755938",57]
["Olive Oil","Olive Oil","D000069463","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16397870","Oleocanthal in olive oil: between myth and reality.","16397870",57]
["Olive Oil","Olive Oil","D000069463","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2145305","Experience with fish oil treatment with special emphasis on diabetic nephropathy.","2145305",57]
["Olive Oil","Olive Oil","D000069463","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"9014655","Olive oil and rapeseed oil differ in their effect on plasma low-density lipoprotein metabolism in the guinea-pig.","9014655",57]
["Olive Oil","Olive Oil","D000069463","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"27113292","The innovative \"Bio-Oil Spread\" prevents metabolic disorders and mediates preconditioning-like cardioprotection in rats.","27113292",57]
["olmesartan","olmesartan","C437965","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2008,"18501344","Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.","18501344",57]
["oltipraz","oltipraz","C026209","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19563826","Therapeutic potential of dithiolethiones for hepatic diseases.","19563826",57]
["Omacor","Omacor","C405603","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,3,2016,"27444154","The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.","27444154",57]
["Omeprazole","Omeprazole","D009853","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,1998,"9872517","Effect of combined administration of lansoprazole and sofalcone on microvascular and connective tissue regeneration after ethanol-induced gastric mucosal damage.","9872517",57]
["Omeprazole","Omeprazole","D009853","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17935951","Pharmacokinetic interaction between oltipraz and omeprazole in rats: Competitive inhibition of metabolism of oltipraz by omeprazole via CYP1A1 and 3A2, and of omeprazole by oltipraz via CYP1A1/2, 2D1/2, and 3A1/2.","17935951",57]
["Omeprazole","Omeprazole","D009853","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1993,"8379237","[Omeprazole and cytochrome P450].","8379237",57]
["Omeprazole","Omeprazole","D009853","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24382322","Dephosphorylation of Sp1 at Ser-59 by protein phosphatase 2A (PP2A) is required for induction of CYP1A1 transcription after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or omeprazole.","24382322",57]
["orlistat","orlistat","C055122","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2003,"12738478","Orlistat in the treatment of NASH: a case series.","12738478",57]
["orlistat","orlistat","C055122","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23415432","Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat.","23415432",57]
["Orotic Acid","Orotic Acid","D009963","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1963,"14100994","FACTORS INFLUENCING THE INDUCTION OF FATTY LIVER BY OROTIC ACID.","14100994",57]
["Orotic Acid","Orotic Acid","D009963","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21167679","Study on possible mechanism of orotic acid-induced fatty liver in rats.","21167679",57]
["Orotic Acid","Orotic Acid","D009963","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1973,"4354466","Study of steatosis induced in the rat by orotic acid.","4354466",57]
["Orotic Acid","Orotic Acid","D009963","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1969,"5797388","Vitamin E and hepatotoxic agents. 2. Lipid peroxidation and poisoning with orotic acid, ethanol and thioacetamide in rats.","5797388",57]
["Orotic Acid","Orotic Acid","D009963","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1994,"8123687","Influence of orotic acid and estrogen on hepatic lipid storage and secretion in the goose susceptible to liver steatosis.","8123687",57]
["Orotic Acid","Orotic Acid","D009963","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26775542","Long-term fatty liver-induced insulin resistance in orotic acid-induced nonalcoholic fatty liver rats.","26775542",57]
["osthol","osthol","C046627","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"28448873","Osthole attenuates lipid accumulation, regulates the expression of inflammatory mediators, and increases antioxidants in FL83B cells.","28448873",57]
["oxaliplatin","oxaliplatin","C030110","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2011,"21999595","mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.","21999595",57]
["oxfendazole","oxfendazole","C011030","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1995,"7733914","Evidence for the ligand-independent activation of the AH receptor.","7733914",57]
["oxymatrine","oxymatrine","C037573","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23791610","Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).","23791610",57]
["Ozone","Ozone","D010126","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14605372","Evidence for ozone formation in human atherosclerotic arteries.","14605372",57]
["Ozone","Ozone","D010126","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17053167","Ozonized low density lipoprotein (ozLDL) inhibits NF-kappaB and IRAK-1-associated signaling.","17053167",57]
["paclobutrazol","paclobutrazol","C053370","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25500619","Aryl hydrocarbon receptor 2 mediates the toxicity of Paclobutrazol on the digestive system of zebrafish embryos.","25500619",57]
["paeonol","paeonol","C013638","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2014,"25170865","Paeonol attenuates advanced oxidation protein product-induced oxidative stress injury in THP-1 macrophages.","25170865",57]
["Palm Oil","Palm Oil","D000073878","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"2031937","Dietary fat saturation in rhesus monkeys affects LDL concentrations by modulating the independent production of LDL apolipoprotein B.","2031937",57]
["Palmitic Acid","Palmitic Acid","D019308","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,1999,"10198299","Muscle contractile activity increases fatty acid metabolism and transport and FAT/CD36.","10198299",57]
["Palmitic Acid","Palmitic Acid","D019308","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2012,"22640955","Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis.","22640955",57]
["Palmitic Acid","Palmitic Acid","D019308","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1991,"1770782","Octanoate and palmitate beta-oxidation in human leukocytes: implications for the rapid diagnosis of fatty acid beta-oxidation disorders.","1770782",57]
["Palmitic Acid","Palmitic Acid","D019308","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"14280474","FATTY ACID SYNTHESIS DURING FAT-FREE REFEEDING OF STARVED RATS.","14280474",57]
["Palmitic Acid","Palmitic Acid","D019308","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2009,"19646010","Lipotoxicity: why do saturated fatty acids cause and monounsaturates protect against it?","19646010",57]
["Palmitic Acid","Palmitic Acid","D019308","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"19782984","Palmitic acid enhances lectin-like oxidized LDL receptor (LOX-1) expression and promotes uptake of oxidized LDL in macrophage cells.","19782984",57]
["Palmitic Acid","Palmitic Acid","D019308","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25766252","Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers.","25766252",57]
["Palmitic Acid","Palmitic Acid","D019308","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"7595067","Regulation of low density lipoprotein receptor gene expression in HepG2 and Caco2 cells by palmitate, oleate, and 25-hydroxycholesterol.","7595067",57]
["Palmitic Acid","Palmitic Acid","D019308","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2005,"16186393","Increased fatty acid desaturation and enhanced expression of stearoyl coenzyme A desaturase protects pancreatic beta-cells from lipoapoptosis.","16186393",57]
["palmitoleic acid","palmitoleic acid","C008757","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2011,"21084651","Adipose tissue palmitoleic acid and obesity in humans: does it behave as a lipokine?","21084651",57]
["palmitoleic acid","palmitoleic acid","C008757","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2016,"27627903","Characterization of Stearoyl-CoA Desaturases from a Psychrophilic Antarctic Copepod, Tigriopus kingsejongensis.","27627903",57]
["Pantetheine","Pantetheine","D010204","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2000,"11425046","The effects of pantethine on fatty liver and fat distribution.","11425046",57]
["Pantetheine","Pantetheine","D010204","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"7206301","[Effect of pantethine on the lipoprotein abnormalities in survivors of cerebral infarction (author's transl)].","7206301",57]
["pantoprazole","pantoprazole","C064276","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19236548","Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism.","19236548",57]
["Parathion","Parathion","D010278","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1975,"173478","Serum beta -- lipoproteins: studies in a patient and in guinea pigs after the ingestion of organophosphorus compounds.","173478",57]
["Particulate Matter","Particulate Matter","D052638","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18554780","Genotoxic potential of Polycyclic Aromatic Hydrocarbons-coated onto airborne Particulate Matter (PM 2.5) in human lung epithelial A549 cells.","18554780",57]
["Particulate Matter","Particulate Matter","D052638","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"23900936","Differential proinflammatory responses induced by diesel exhaust particles with contrasting PAH and metal content.","23900936",57]
["Particulate Matter","Particulate Matter","D052638","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9405331","Dioxinlike components in incinerator fly ash: a comparison between chemical analysis data and results from a cell culture bioassay.","9405331",57]
["Particulate Matter","Particulate Matter","D052638","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2013,"23069475","From lung to liver: how does airborne particulate matter trigger NASH and systemic insulin resistance?","23069475",57]
["Particulate Matter","Particulate Matter","D052638","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2015,"25500124","The aryl hydrocarbon receptor-mediated and genotoxic effects of fractionated extract of standard reference diesel exhaust particle material in pulmonary, liver and prostate cells.","25500124",57]
["Particulate Matter","Particulate Matter","D052638","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23564731","Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice.","23564731",57]
["p-Dimethylaminoazobenzene","p-Dimethylaminoazobenzene","D004124","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1987,"2878931","Characterization of endocytic compartments using the horseradish peroxidase-diaminobenzidine density shift technique.","2878931",57]
["pelargonic acid","pelargonic acid","C008776","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2013,"24060765","Induction of thymic stromal lymphopoietin production by nonanoic acid and exacerbation of allergic inflammation in mice.","24060765",57]
["pentabromodiphenyl ether","pentabromodiphenyl ether","C086401","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19420013","Reproductive and developmental toxicity of a pentabrominated diphenyl ether mixture, DE-71, to ranch mink (Mustela vison) and hazard assessment for wild mink in the Great Lakes region.","19420013",57]
["Pentachlorophenol","Pentachlorophenol","D010416","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21503612","Developing a qPCR method to quantify AhR-PCP-DNA complex for detection of environmental trace-level PCP.","21503612",57]
["Pentoxifylline","Pentoxifylline","D010431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2004,"15464239","Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.","15464239",57]
["Pentoxifylline","Pentoxifylline","D010431","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21549113","Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.","21549113",57]
["Pentoxifylline","Pentoxifylline","D010431","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24574727","Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.","24574727",57]
["Pentoxifylline","Pentoxifylline","D010431","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"24605610","[Microcirculatory changes of gastric mucosa in patients with chronic H. pylori-associated erosive gastritis with non-alcoholic steatohepatitis during treatment].","24605610",57]
["perfluorodecanoic acid","perfluorodecanoic acid","C036567","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1988,"2906022","The effects of perfluorodecanoic acid on hepatic stearoyl-coenzyme A desaturase and mixed function oxidase activities in rats.","2906022",57]
["perfluorooctanoic acid","perfluorooctanoic acid","C023036","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"23626681","High fat diet feeding exaggerates perfluorooctanoic acid-induced liver injury in mice via modulating multiple metabolic pathways.","23626681",57]
["perfluorooctanoic acid","perfluorooctanoic acid","C023036","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2011,"21628884","Effects of perfluorinated fatty acids with different carbon chain length on fatty acid profiles of hepatic lipids in mice.","21628884",57]
["perhydroxyl radical","perhydroxyl radical","C049375","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8517860","The role of alpha-tocopherol as a peroxyl radical scavenger in human low density lipoprotein.","8517860",57]
["peroxynitric acid","peroxynitric acid","C039642","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10882565","Modeling the interaction of peroxynitrite with low-density lipoproteins. II: reaction/diffusion model of peroxynitrite in low-density lipoprotein particles.","10882565",57]
["peroxynitric acid","peroxynitric acid","C039642","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1993,"8365489","Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor.","8365489",57]
["Peroxynitrous Acid","Peroxynitrous Acid","D030421","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11811543","Protection by quercetin and quercetin 3-O-beta-D-glucuronide of peroxynitrite-induced antioxidant consumption in human plasma low-density lipoprotein.","11811543",57]
["Peroxynitrous Acid","Peroxynitrous Acid","D030421","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16415107","S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells.","16415107",57]
["Perylene","Perylene","D010569","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2016,"27234499","Benzo[ghi]perylene activates the AHR pathway to exert biological effects on the NL-20 human bronchial cell line.","27234499",57]
["Petroleum","Petroleum","D010578","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12204584","Expression of P-glycoprotein and cytochrome p450 1A in intertidal fish (Anoplarchus purpurescens) exposed to environmental contaminants.","12204584",57]
["Petroleum","Petroleum","D010578","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16788743","Ecotoxicity of sediments contaminated by the oil spill associated with the tanker \"Prestige\" using juveniles of the fish Sparus aurata.","16788743",57]
["Petroleum","Petroleum","D010578","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18495522","Cytogenetic effects induced by Prestige oil on human populations: the role of polymorphisms in genes involved in metabolism and DNA repair.","18495522",57]
["Petroleum","Petroleum","D010578","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"21963215","Modulation of CYP1A and genotoxic effects in European seabass (Dicentrarchus labrax) exposed to weathered oil: a mesocosm study.","21963215",57]
["Petroleum","Petroleum","D010578","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27411537","Influence of the natural Rio Negro water on the toxicological effects of a crude oil and its chemical dispersion to the Amazonian fish Colossoma macropomum.","27411537",57]
["Petroleum","Petroleum","D010578","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2009,"19402757","Specific in vitro toxicity of crude and refined petroleum products. 1. Aryl hydrocarbon receptor-mediated responses.","19402757",57]
["Petroleum","Petroleum","D010578","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24754388","Endocrine and AhR-CYP1A pathway responses to the water-soluble fraction of oil in zebrafish (Danio rerio Hamilton).","24754388",57]
["phenanthrene","phenanthrene","C031181","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"16930669","Cytochrome P4501A, genotoxic and stress responses in golden grey mullet (Liza aurata) following short-term exposure to phenanthrene.","16930669",57]
["Phenelzine","Phenelzine","D010624","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,3,1979,"220986","Inhibition of hepatic gluconeogenesis by phenethylhydrazine (phenelzine).","220986",57]
["Phenobarbital","Phenobarbital","D010634","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"10076545","Induction time course of cytochromes P450 by phenobarbital and 3-methylcholanthrene pretreatment in liver microsomes of Alligator mississippiensis.","10076545",57]
["Phenobarbital","Phenobarbital","D010634","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1989,"2787638","Dependence of the induction of cytochrome P-450 by phenobarbital in primary cultures of adult rat hepatocytes on the composition of the culture medium.","2787638",57]
["Phenobarbital","Phenobarbital","D010634","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1995,"7713363","Effect of nifedipine, verapamil and diltiazem on the enzyme-inducing activity of phenobarbital and beta-naphthoflavone.","7713363",57]
["Phenobarbital","Phenobarbital","D010634","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1968,"4239254","[Effect of phenobarbital and diphenylhydantoin on different lipid fractions of liver].","4239254",57]
["Phenobarbital","Phenobarbital","D010634","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3310014","Stimulation of prostacyclin synthesis in rats treated with phenobarbital.","3310014",57]
["Phenobarbital","Phenobarbital","D010634","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2015,"25489928","Enhanced thyroid hormone breakdown in hepatocytes by mutual induction of the constitutive androstane receptor (CAR, NR1I3) and arylhydrocarbon receptor by benzo[a]pyrene and phenobarbital.","25489928",57]
["phenolic acid","phenolic acid","C017616","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"22417418","Composition of flavonoids and phenolic acids in lychee (Litchi Chinensis Sonn.) Flower extracts and their antioxidant capacities estimated with human LDL, erythrocyte, and blood models.","22417418",57]
["Phenylephrine","Phenylephrine","D010656","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16103260","Vascular sensitivity to phenylephrine in rats submitted to anaerobic training and nandrolone treatment.","16103260",57]
["Phenylethyl Alcohol","Phenylethyl Alcohol","D010626","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"16928436","Tyrosol, the major extra virgin olive oil compound, restored intracellular antioxidant defences in spite of its weak antioxidative effectiveness.","16928436",57]
["phenyl-N-tert-butylnitrone","phenyl-N-tert-butylnitrone","C029217","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2003,"12708470","Effects of phenyl N-tert-butyl nitrone and its derivatives on the early phase of hepatocarcinogenesis in rats fed a choline-deficient, L-amino acid-defined diet.","12708470",57]
["pheophorbide a","pheophorbide a","C032623","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8847142","Uptake by cells and photosensitizing effectiveness of novel pheophorbide derivatives in vitro.","8847142",57]
["Phorbol 12,13-Dibutyrate","Phorbol 12,13-Dibutyrate","D015240","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1992,"1310006","Simultaneous redistribution of mannose 6-phosphate and transferrin receptors by insulin-like growth factors and phorbol ester.","1310006",57]
["Phosphatidylinositol 4,5-Diphosphate","Phosphatidylinositol 4,5-Diphosphate","D019269","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8975883","Maleylated-BSA induces hydrolysis of PIP2, fluxes of Ca2+, NF-kappaB binding, and transcription of the TNF-alpha gene in murine macrophages.","8975883",57]
["Phosphatidylinositol 4,5-Diphosphate","Phosphatidylinositol 4,5-Diphosphate","D019269","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18411250","Dissecting the role of PtdIns(4,5)P2 in endocytosis and recycling of the transferrin receptor.","18411250",57]
["Phosphoenolpyruvate","Phosphoenolpyruvate","D010728","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1987,"3677593","Activities of enzymes associated with phosphoenolpyruvate metabolism in the mudskippers, Boleophthalmus boddaerti and Periophthalmodon schlosseri.","3677593",57]
["Phosphonoacetic Acid","Phosphonoacetic Acid","D010746","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11496949","LDL induced association of anionic liposomes with cells and delivery of contents as shown by the increase in potency of liposome dependent drugs.","11496949",57]
["Phosphorylcholine","Phosphorylcholine","D010767","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15025226","Locally produced anti-phosphorylcholine and anti-oxidized low-density lipoprotein antibodies in gingival crevicular fluid from aggressive periodontitis patients.","15025226",57]
["Phosphorylcholine","Phosphorylcholine","D010767","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1978,"210908","Mechanism of heparin and serum lipoprotein interaction: effects of calcium, phosphorylcholine, and a serum fraction.","210908",57]
["Phytic Acid","Phytic Acid","D010833","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2008,"19083479","Dietary inositol hexakisphosphate, but not myo-inositol, clearly improves hypercholesterolemia in rats fed casein-type amino acid mixtures and 1,1,1-trichloro-2,2-bis (p-chlorophenyl) ethane.","19083479",57]
["pifithrin","pifithrin","C121565","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16258175","Potent inhibition of carcinogen-bioactivating cytochrome P450 1B1 by the p53 inhibitor pifithrin alpha.","16258175",57]
["Pikasol","Pikasol","C077446","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2005,"16007396","In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis.","16007396",57]
["Pindolol","Pindolol","D010869","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2574237","Quantitative comparison of bromoacetylated derivatives of alprenolol and pindolol on beta-adrenergic receptor binding and mobility in S49 cells.","2574237",57]
["pioglitazone","pioglitazone","C060836","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2003,"15017657","Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity.","15017657",57]
["pioglitazone","pioglitazone","C060836","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2007,"17354302","Pioglitazone in nonalcoholic steatohepatitis.","17354302",57]
["pioglitazone","pioglitazone","C060836","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22050199","Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.","22050199",57]
["pioglitazone","pioglitazone","C060836","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2015,"25878378","Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats.","25878378",57]
["pioglitazone","pioglitazone","C060836","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19894406","Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study.","19894406",57]
["pioglitazone","pioglitazone","C060836","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22927782","The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.","22927782",57]
["pioglitazone","pioglitazone","C060836","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26976710","Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.","26976710",57]
["pioglitazone","pioglitazone","C060836","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28751548","Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.","28751548",57]
["pioglitazone","pioglitazone","C060836","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2018,"29428719","Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.","29428719",57]
["pioglitazone","pioglitazone","C060836","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2014,"24938300","A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone.","24938300",57]
["piperine","piperine","C008922","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"26431033","Piperine Induces Hepatic Low-Density Lipoprotein Receptor Expression through Proteolytic Activation of Sterol Regulatory Element-Binding Proteins.","26431033",57]
["Piracetam","Piracetam","D010889","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20502135","Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance.","20502135",57]
["pirinixic acid","pirinixic acid","C006253","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2005,"15824748","Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones.","15824748",57]
["pitavastatin","pitavastatin","C108475","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20140004","Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients.","20140004",57]
["pitavastatin","pitavastatin","C108475","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20163419","Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and low-density lipoprotein on proliferation and migration of keratinocytes.","20163419",57]
["plant stanol ester","plant stanol ester","C407042","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11952809","Relationship of genetic variation in genes encoding apolipoprotein A-IV, scavenger receptor BI, HMG-CoA reductase, CETP and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption.","11952809",57]
["Platelet Activating Factor","Platelet Activating Factor","D010972","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11686003","Oxidized LDL contains inflammatory PAF-like phospholipids.","11686003",57]
["Platelet Activating Factor","Platelet Activating Factor","D010972","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21920519","PAF effects on MCP-1 and IL-6 secretion in U-937 monocytes in comparison with oxLDL and IL-1β effects.","21920519",57]
["Platelet Activating Factor","Platelet Activating Factor","D010972","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8199206","Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated.","8199206",57]
["platensimycin","platensimycin","C510909","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21389266","Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes.","21389266",57]
["policosanol","policosanol","C080710","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2010,"21139538","[Non-alcoholic hepatic steatosis: the role of policosanols in associated hyperlipidemia].","21139538",57]
["poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)","poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)","C115940","3_KE",451,3,"Mitochondrial fatty acid beta-oxidation","Inhibition","Mitochondrial Trifunctional Protein","D063991","Mitochondrial Trifunctional Protein",1,1,2003,"12694916","Enhanced production of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) via manipulating the fatty acid beta-oxidation pathway in E. coli.","12694916",57]
["polyanions","polyanions","C009791","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"6181075","Intralysosomal accumulation of polyanions. II. Polyanion internalization and its influence on lysosomal pH and membrane fluidity.","6181075",57]
["polychlorodibenzofuran","polychlorodibenzofuran","C016068","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1993,"8311686","Toxicokinetic mixture interactions between chlorinated aromatic hydrocarbons in the liver of the C57BL/6J mouse: 2. Polychlorinated dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs) and biphenyls (PCBs).","8311686",57]
["polyene phosphatidylcholine","polyene phosphatidylcholine","C029449","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1989,"2480864","[Alcoholic liver diseases and their treatment].","2480864",57]
["polymethacrylic acid","polymethacrylic acid","C030613","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21289994","Polyacrylate adsorbents for the selective adsorption of cholesterol-rich lipoproteins from plasma or blood.","21289994",57]
["Polyvinyl Alcohol","Polyvinyl Alcohol","D011142","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18470702","Preparation of heparin-immobilized PVA and its adsorption for low-density lipoprotein from hyperlipemia plasma.","18470702",57]
["potassium bromide","potassium bromide","C039004","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7641079","Effect of density-gradients on the binding of photosensitizing agents to plasma proteins.","7641079",57]
["Povidone","Povidone","D011205","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"19932676","Partial filling affinity capillary electrophoresis with cationic poly(vinylpyrrolidone)-based copolymer coatings for studies on human lipoprotein-steroid interactions.","19932676",57]
["Pravastatin","Pravastatin","D017035","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11846628","Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro.","11846628",57]
["Pravastatin","Pravastatin","D017035","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16226163","Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.","16226163",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C27651,B27651)","v":"Pravastatin"},"Pravastatin","D017035","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J27651,K27651)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1989,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q27651,Q27651)","v":"2504855"},"Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.","2504855",57]
["Pravastatin","Pravastatin","D017035","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8476719","Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.","8476719",57]
["Pravastatin","Pravastatin","D017035","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1986,"3096862","Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.","3096862",57]
["Pravastatin","Pravastatin","D017035","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2008,"18261733","Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.","18261733",57]
["Pravastatin","Pravastatin","D017035","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1996,"8774761","The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, between once- and twice-daily treatment regimens in beagle dogs and rabbits.","8774761",57]
["Prazosin","Prazosin","D011224","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1986,"2423798","Comparison of the effect of indoramin and prazosin on blood pressure and lipid profiles in essential hypertension.","2423798",57]
["Prednisolone","Prednisolone","D011239","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14238423","[EFFECT OF PREDNISOLONE ON THE DEVELOPMENT OF FATTY LIVER INDUCED IN CARASSIUS AURATUS BY FEEDING].","14238423",57]
["Prednisone","Prednisone","D011241","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1967,"4233509","[The effect of prednisone and turinabol on the tissue phosphatases in experimental fatty liver in rats].","4233509",57]
["Prednisone","Prednisone","D011241","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1971,"5125099","[Corticoids and fatty liver. II].","5125099",57]
["proanthocyanidin","proanthocyanidin","C013221","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12475295","Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans.","12475295",57]
["proanthocyanidin","proanthocyanidin","C013221","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2015,"25981678","Inhibition of differentiation of monocyte to macrophages in atherosclerosis by oligomeric proanthocyanidins -In-vivo and in-vitro study.","25981678",57]
["Probucol","Probucol","D011341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1569200","Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.","1569200",57]
["Probucol","Probucol","D011341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1992,"1637257","Effects of probucol on low-density lipoprotein catabolism in guinea pigs.","1637257",57]
["Probucol","Probucol","D011341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"17302219","Dietary probucol preserves endothelium-dependent relaxation of arteriovenous fistula in hypercholesterolemic rabbits.","17302219",57]
["Probucol","Probucol","D011341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24997046","The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes.","24997046",57]
["Probucol","Probucol","D011341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3394651","Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions.","3394651",57]
["Probucol","Probucol","D011341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"6169481","On the mechanism of plasma cholesterol reduction in the rat given probucol.","6169481",57]
["Probucol","Probucol","D011341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7971685","Probucol protects low-density lipoproteins from in vitro and in vivo oxidation.","7971685",57]
["Probucol","Probucol","D011341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8905298","Influence of native and modified lipoproteins on migration of mouse peritoneal macrophages and the effect of the antioxidants vitamin E and Probucol.","8905298",57]
["Probucol","Probucol","D011341","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1986,"3637051","Lipoprotein fractions and receptors: a role for probucol?","3637051",57]
["Probucol","Probucol","D011341","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1983,"6882500","Effect of probucol on the composition of lipoproteins and on VLDL apoprotein B turnover.","6882500",57]
["Probucol","Probucol","D011341","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1996,"8842353","The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.","8842353",57]
["procyanidin","procyanidin","C017674","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11400384","Inhibition of in vitro low-density lipoprotein oxidation by oligomeric procyanidins present in chocolate and cocoas.","11400384",57]
["procyanidin","procyanidin","C017674","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21422743","Procyanidins are potent inhibitors of LOX-1: a new player in the French Paradox.","21422743",57]
["procyanidin B3","procyanidin B3","C479581","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12033808","Identification and in vitro biological activities of hop proanthocyanidins: inhibition of nNOS activity and scavenging of reactive nitrogen species.","12033808",57]
["Propane","Propane","D011407","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"29138024","(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.","29138024",57]
["Propofol","Propofol","D015742","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1998,"9875925","Lactic acidemia and bradyarrhythmia in a child sedated with propofol.","9875925",57]
["Propranolol","Propranolol","D011433","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2322324","The antihypertensive drug propranolol enhances LDL catabolism and alters cholesterol metabolism in human cultured fibroblasts.","2322324",57]
["Propranolol","Propranolol","D011433","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2005,"16091787","Effects of hydrochlorothiazide and propranolol treatment on chylomicron metabolism in hypertensive objects.","16091787",57]
["Propyl Gallate","Propyl Gallate","D011435","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17382989","Ecotoxicological effects of the antioxidant additive propyl gallate in five aquatic systems.","17382989",57]
["Prostaglandin D2","Prostaglandin D2","D015230","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2004,"15665586","Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-g.","15665586",57]
["Prostaglandins E","Prostaglandins E","D011458","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3036263","The effect of human chorionic gonadotropin, dibutyryl cyclic adenosine 3',5'-monophosphate, prostaglandins, and 25-hydroxycholesterol on acute progesterone secretion by dissociated rabbit luteal cells in vitro: evidence for independent effect of human chorionic gonadotropins and lipoproteins.","3036263",57]
["protocatechuic acid","protocatechuic acid","C009091","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20799701","Effects of protocatechuic acid on trans fat induced hepatic steatosis in mice.","20799701",57]
["przewaquinone D","przewaquinone D","C043165","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"29287777","Tanshindiol C inhibits oxidized low-density lipoprotein induced macrophage foam cell formation via peroxiredoxin 1 dependent pathway.","29287777",57]
["Psyllium","Psyllium","D011620","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9684749","Hypolipidemic mechanisms of pectin and psyllium in guinea pigs fed high fat-sucrose diets: alterations on hepatic cholesterol metabolism.","9684749",57]
["puerarin","puerarin","C033607","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24708212","Puerarin protects endothelial cells from oxidized low density lipoprotein induced injuries via the suppression of LOX-1 and induction of eNOS.","24708212",57]
["Putrescine","Putrescine","D011700","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9566840","Putrescine decreases cytochrome P450 3A4 levels during liver regeneration in the rat.","9566840",57]
["pyrazole","pyrazole","C031280","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1998,"9657280","Induction of CYP2A5 by pyrazole and its derivatives in mouse primary hepatocytes.","9657280",57]
["pyrene","pyrene","C030984","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17993750","Changes of biomarkers with oral exposure to benzo(a)pyrene, phenanthrene and pyrene in rats.","17993750",57]
["pyridine N-oxide","pyridine N-oxide","C013229","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10860547","Comparative induction of CYP1A1 expression by pyridine and its metabolites.","10860547",57]
["pyridine N-oxide","pyridine N-oxide","C013229","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12147272","CYP1A1 induction by pyridine and its metabolites in HepG2 cells.","12147272",57]
["Pyridoxine","Pyridoxine","D011736","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14130718","THE CHILDREN'S HOSPITAL MEDICAL CENTER, BOSTON, MASS.","14130718",57]
["Pyridoxine","Pyridoxine","D011736","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1990,"2283204","Liver triglyceride accumulation after chronic ethanol administration: a possible protective role of metadoxina and ubiquinone.","2283204",57]
["Pyridoxine","Pyridoxine","D011736","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1990,"2365939","Lack of effect of vitamin B-6 supplementation on the lipoprotein profile of post-menopausal chronic hemodialysis patients.","2365939",57]
["Pyruvaldehyde","Pyruvaldehyde","D011765","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9795211","Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein.","9795211",57]
["qinggan huoxue","qinggan huoxue","C527179","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22500386","[Clinical study of Qinggan Huatan Huoxue Recipe on the treatment of non-alcoholic steatohepatitis].","22500386",57]
["Quercetin","Quercetin","D011794","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2015,"25712622","Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver disease.","25712622",57]
["Quercetin","Quercetin","D011794","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24711995","Effects of quercetin on CYP450 and cytokines in Aroclor 1254 injured endometrial cells of the pregnant rats.","24711995",57]
["Quercetin","Quercetin","D011794","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24622831","Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis.","24622831",57]
["Quercetin","Quercetin","D011794","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15128308","Anti- and pro-oxidant effects of quercetin in copper-induced low density lipoprotein oxidation. Quercetin as an effective antioxidant against pro-oxidant effects of urate.","15128308",57]
["Quercetin","Quercetin","D011794","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"22595451","Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits.","22595451",57]
["Quercetin","Quercetin","D011794","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2001,"12600108","[The effects of quercetin and isorhamnetin on oxidative modification of VLDL induced by Cu2+].","12600108",57]
["Quercetin","Quercetin","D011794","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2011,"21638315","A novel quercetin analogue from a medicinal plant promotes peak bone mass achievement and bone healing after injury and exerts an anabolic effect on osteoporotic bone: the role of aryl hydrocarbon receptor as a mediator of osteogenic action.","21638315",57]
["quercetin 7-O-glucopyranoside","quercetin 7-O-glucopyranoside","C110311","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9448720","Inhibition of mammalian 15-lipoxygenase-dependent lipid peroxidation in low-density lipoprotein by quercetin and quercetin monoglucosides.","9448720",57]
["Quinic Acid","Quinic Acid","D011801","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2007,"17822297","Targeted natural product isolation guided by HPLC-SPE-NMR: constituents of Hubertia species.","17822297",57]
["quinone","quinone","C004532","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1995,"7757062","Characterization of a mutation that abolishes quinone reduction by electron transfer flavoprotein-ubiquinone oxidoreductase.","7757062",57]
["quinone","quinone","C004532","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11829739","Induction of glutathione synthesis by oxidized low-density lipoprotein and 1-palmitoyl-2-arachidonyl phosphatidylcholine: protection against quinone-mediated oxidative stress.","11829739",57]
["Raloxifene Hydrochloride","Raloxifene Hydrochloride","D020849","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2004,"14675981","Raloxifene inhibits cholesterol aortic content but not atherosclerotic plaque size in oophorectomised cholesterol-fed rabbits.","14675981",57]
["Ramipril","Ramipril","D017257","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11882318","Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis.","11882318",57]
["reinioside C","reinioside C","C530274","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19730822","Inhibitory effect of reinioside C on monocyte-endothelial cell adhesion induced by oxidized low-density lipoprotein via inhibiting NADPH oxidase/ROS/NF-kappaB pathway.","19730822",57]
["resiniferatoxin","resiniferatoxin","C024353","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"21908651","Activation of TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis.","21908651",57]
["resveratrol","resveratrol","C059514","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11701226","Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components.","11701226",57]
["resveratrol","resveratrol","C059514","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"20715097","Resveratrol (3,5,4'-trihydroxystilbene) protects pregnant mother and fetus from the immunotoxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin.","20715097",57]
["resveratrol","resveratrol","C059514","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26706021","Beneficial action of resveratrol: How and why?","26706021",57]
["resveratrol","resveratrol","C059514","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"23084643","Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet.","23084643",57]
["resveratrol","resveratrol","C059514","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11934802","The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy.","11934802",57]
["resveratrol","resveratrol","C059514","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19108833","Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells.","19108833",57]
["resveratrol","resveratrol","C059514","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9449561","Gas chromatographic analysis of resveratrol in plasma, lipoproteins and cells after in vitro incubations.","9449561",57]
["resveratrol","resveratrol","C059514","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26134756","Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.","26134756",57]
["resveratrol","resveratrol","C059514","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1999,"10496962","Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity.","10496962",57]
["resveratrol","resveratrol","C059514","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,4,2005,"15634023","Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators.","15634023",57]
["resveratrol","resveratrol","C059514","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"27854074","Resveratrol and its methoxy derivatives modulate the expression of estrogen metabolism enzymes in breast epithelial cells by AhR down-regulation.","27854074",57]
["resveratrol","resveratrol","C059514","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"28279696","Hydroxystilbenes and methoxystilbenes activate human aryl hydrocarbon receptor and induce CYP1A genes in human hepatoma cells and human hepatocytes.","28279696",57]
["retene","retene","C447880","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15883094","Anguilla anguilla L. liver EROD induction and genotoxic responses after retene exposure.","15883094",57]
["retinol palmitate","retinol palmitate","C014794","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1885783","Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.","1885783",57]
["retinol palmitate","retinol palmitate","C014794","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2001,"11599549","Mechanisms of action of the anti-atherogenic effect of magnesium: lessons from a mouse model.","11599549",57]
["rhodamine 110","rhodamine 110","C049025","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18595692","A highly sensitive fluorogenic probe for cytochrome P450 activity in live cells.","18595692",57]
["Riboflavin","Riboflavin","D012256","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"14278632","B-COMPLEX VITAMINS IN LIVER DISEASE OF THE ALCOHOLIC.","14278632",57]
["Ribose","Ribose","D012266","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"25393017","An immunohistochemical analysis to validate the rationale behind the enhanced immunogenicity of D-ribosylated low density lipo-protein.","25393017",57]
["Rifampin","Rifampin","D012293","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9667078","Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver.","9667078",57]
["rifaximin","rifaximin","C042734","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2010,"20627999","Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.","20627999",57]
["rimonabant","rimonabant","C089032","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26078820","Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease.","26078820",57]
["Risperidone","Risperidone","D018967","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2012,"22750665","Omega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: positive association with stearoyl-CoA desaturase.","22750665",57]
["Ritonavir","Ritonavir","D019438","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2003,"12732393","Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?","12732393",57]
["robinin","robinin","C005183","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24295649","Robinin modulates TLR/NF-κB signaling pathway in oxidized LDL induced human peripheral blood mononuclear cells.","24295649",57]
["rosiglitazone","rosiglitazone","C089730","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2007,"17492590","A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.","17492590",57]
["rosiglitazone","rosiglitazone","C089730","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2003,"14512888","Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.","14512888",57]
["rosiglitazone","rosiglitazone","C089730","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2007,"18038714","Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.","18038714",57]
["rosiglitazone","rosiglitazone","C089730","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"20965162","The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats.","20965162",57]
["rosiglitazone","rosiglitazone","C089730","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21748770","Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.","21748770",57]
["rosiglitazone","rosiglitazone","C089730","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11194491","[The importance of syndrome X in daily practice].","11194491",57]
["rosiglitazone","rosiglitazone","C089730","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19010810","Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonists.","19010810",57]
["rosiglitazone","rosiglitazone","C089730","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,"25105443","Thiazolidinedione therapy versus lifestyle recommendation in the treatment of post-liver transplant graft steatosis.","25105443",57]
["rosiglitazone","rosiglitazone","C089730","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,2007,"17170230","Involvement of adipose tissues in the early hypolipidemic action of PPARgamma agonism in the rat.","17170230",57]
["rosiglitazone","rosiglitazone","C089730","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2005,"15855323","Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma.","15855323",57]
["Rosuvastatin Calcium","Rosuvastatin Calcium","D000068718","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2006,"16168995","Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.","16168995",57]
["Rosuvastatin Calcium","Rosuvastatin Calcium","D000068718","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19281922","Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.","19281922",57]
["Rosuvastatin Calcium","Rosuvastatin Calcium","D000068718","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24618208","Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.","24618208",57]
["Rosuvastatin Calcium","Rosuvastatin Calcium","D000068718","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27533947","Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.","27533947",57]
["Rosuvastatin Calcium","Rosuvastatin Calcium","D000068718","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2015,"25816050","Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment.","25816050",57]
["Roxithromycin","Roxithromycin","D015575","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26800487","Interactive effects of selected pharmaceutical mixtures on bioaccumulation and biochemical status in crucian carp (Carassius auratus).","26800487",57]
["rutecarpine","rutecarpine","C028632","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1330548","Certain tryptophan photoproducts are inhibitors of cytochrome P450-dependent mutagenicity.","1330548",57]
["rutecarpine","rutecarpine","C028632","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26859198","Rutaecarpine Reverses the Altered Connexin Expression Pattern Induced by Oxidized Low-density Lipoprotein in Monocytes.","26859198",57]
["S 17092-1","S 17092-1","C118986","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2016,"27760195","Prolyl Oligopeptidase Inhibition Attenuates Steatosis in the L02 Human Liver Cell Line.","27760195",57]
["S 20098","S 20098","C084711","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"23849766","[Agomelatine: fulminant liver failure in a patient with fatty liver].","23849766",57]
["Safflower Oil","Safflower Oil","D012450","12_KE",462,12,"SCD-1","Increased","Linoleoyl-CoA Desaturase","D050602","Linoleoyl-CoA Desaturase",1,1,2012,"22642787","Menhaden oil, but not safflower or soybean oil, aids in restoring the polyunsaturated fatty acid profile in the novel delta-6-desaturase null mouse.","22642787",57]
["Safflower Oil","Safflower Oil","D012450","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2012,"21720434","Hepatic mitochondrial energetics during catch-up fat with high-fat diets rich in lard or safflower oil.","21720434",57]
["Safrole","Safrole","D012451","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1986,"3013439","Induction of cytochrome P-450 in congenic C57BL/6J mice by isosafrole: lack of correlation with the Ah locus.","3013439",57]
["Salicylic Acid","Salicylic Acid","D020156","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2012,"22291202","Loss of function of FATTY ACID DESATURASE7 in tomato enhances basal aphid resistance in a salicylate-dependent manner.","22291202",57]
["salvianolic acid","salvianolic acid","C568740","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"27345365","New insights into salvianolic acid A action: Regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats.","27345365",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C29379,B29379)","v":"salvin"},"salvin","C018381","13_AO",455,13,"Accumulation, Liver lipid",null,{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J29379,K29379)","v":"Non-alcoholic Fatty Liver Disease"},"D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q29379,Q29379)","v":"25348739"},"Carnosic acid attenuates obesity-induced glucose intolerance and hepatic fat accumulation by modulating genes of lipid metabolism in C57BL/6J-ob/ob mice.","25348739",57]
["SAN 58035","SAN 58035","C040256","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1987,"3593342","Inhibition of cellular cholesterol esterification can decrease low density lipoprotein receptor number in human fibroblasts.","3593342",57]
["sapropterin","sapropterin","C003402","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2000,"11589366","Tetrahydrobiopterin inhibits copper-induced oxidation of low density lipoprotein.","11589366",57]
["SB 203580","SB 203580","C093642","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2004,"14594946","Suppression by p38 MAP kinase inhibitors (pyridinyl imidazole compounds) of Ah receptor target gene activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin and the possible mechanism.","14594946",57]
["schizandrin B","schizandrin B","C015499","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"24096833","Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture.","24096833",57]
["sebacic acid","sebacic acid","C011107","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1983,"6634246","On the biologic origin of C6-C10-dicarboxylic and C6-C10-omega-1-hydroxy monocarboxylic acids in human and rat with acyl-CoA dehydrogenation deficiencies: in vitro studies on the omega- and omega-1-oxidation of medium-chain (C6-C12) fatty acids in human and rat liver.","6634246",57]
["Sepharose","Sepharose","D012685","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1980,"7360525","Removal of cholesterol from blood by affinity binding to heparin-agarose: evaluation on treatment in homozygous familial hypercholesterolemia.","7360525",57]
["Serotonin","Serotonin","D012701","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1967,"5601544","[The effect of endoxan and serotonin on the glycogen content and development of fatty degeneration of the liver in rats].","5601544",57]
["Serotonin","Serotonin","D012701","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7968236","Relationships between serum lipids, serotonin, platelet aggregation and some fibrinolytic parameters in humans.","7968236",57]
["Sertraline","Sertraline","D020280","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2008,"18791517","Could sertraline afford protection against atherosclerosis? A medical hypothesis.","18791517",57]
["sesamin","sesamin","C054125","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,3,1992,"1291640","Effects of sesamin and curcumin on delta 5-desaturation and chain elongation of polyunsaturated fatty acid metabolism in primary cultured rat hepatocytes.","1291640",57]
["sesamin","sesamin","C054125","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19951001","Sesamin mitigates inflammation and oxidative stress in endothelial cells exposed to oxidized low-density lipoprotein.","19951001",57]
["sevoflurane","sevoflurane","C009250","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"23725684","Cognitive function and oxidative stress after carotid endarterectomy: comparison of propofol to sevoflurane anesthesia.","23725684",57]
["Sewage","Sewage","D012722","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"2311561","Physiological effects in fish exposed to effluents from mills with six different bleaching processes.","2311561",57]
["shosaikoto-go-keishika-shakuyakuto","shosaikoto-go-keishika-shakuyakuto","C461321","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8889034","Anti-hyperlipidemic and anti-atherosclerotic actions of shosaikoto (kampo medicine).","8889034",57]
["sibutramine","sibutramine","C058254","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21319341","Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study.","21319341",57]
["Silicon Dioxide","Silicon Dioxide","D012822","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22273745","Aryl hydrocarbon receptor (AhR) regulates silica-induced inflammation but not fibrosis.","22273745",57]
["silybin","silybin","C440975","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28652427","A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells.","28652427",57]
["Silymarin","Silymarin","D012838","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"23406957","Silymarin prevents benzo(a)pyrene-induced toxicity in Wistar rats by modulating xenobiotic-metabolizing enzymes.","23406957",57]
["Silymarin","Silymarin","D012838","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"23953934","Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes.","23953934",57]
["Silymarin","Silymarin","D012838","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2004,"15177299","Phenolics-rich extracts from Silybum marianum and Prunella vulgaris reduce a high-sucrose diet induced oxidative stress in hereditary hypertriglyceridemic rats.","15177299",57]
["Silymarin","Silymarin","D012838","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26881746","Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.","26881746",57]
["Simazine","Simazine","D012839","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2000,"11153164","[Liver steatosis and disorders of mitochondrial oxidative phosphorylation after experimental administration of simazine].","11153164",57]
["Simvastatin","Simvastatin","D019821","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19946244","Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.","19946244",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1999,"10217372","Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin.","10217372",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10407494","Differential cholesteryl ester accumulation in two human vascular smooth muscle cell subpopulations exposed to aggregated LDL: effect of PDGF-stimulation and HMG-CoA reductase inhibition.","10407494",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"12643184","Heart protection study: LDL lowering therapy and cardiovascular outcomes in patients with low cholesterol levels or diabetes.","12643184",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16510370","Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes.","16510370",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17719471","Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis.","17719471",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20203299","Simvastatin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs.","20203299",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2245435","[Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].","2245435",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1989,"2507323","Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia.","2507323",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28448973","Downregulations of CD36 and Calpain-1, Inflammation, and Atherosclerosis by Simvastatin in Apolipoprotein E Knockout Mice.","28448973",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8993943","Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.","8993943",57]
["Simvastatin","Simvastatin","D019821","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"12056585","High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.","12056585",57]
["Simvastatin","Simvastatin","D019821","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1993,"8427854","Effects of simvastatin on apoB metabolism and LDL subfraction distribution.","8427854",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1991,"1764540","Dual effect of lovastatin and simvastatin on LDL-macrophage interaction.","1764540",57]
["Simvastatin","Simvastatin","D019821","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"26625143","Simvastatin Attenuates Oxidative Stress, NF-κB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-α and TNF Receptor 1.","26625143",57]
["sinapinic acid","sinapinic acid","C073734","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15053556","4-hydroxycinnamic ethyl ester derivatives and related dehydrodimers: Relationship between oxidation potential and protective effects against oxidation of low-density lipoproteins.","15053556",57]
["siphonaxanthin","siphonaxanthin","C003314","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2015,"25733464","The green algal carotenoid siphonaxanthin inhibits adipogenesis in 3T3-L1 preadipocytes and the accumulation of lipids in white adipose tissue of KK-Ay mice.","25733464",57]
["Sirolimus","Sirolimus","D020123","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2001,"11602850","Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients.","11602850",57]
["Sitagliptin Phosphate","Sitagliptin Phosphate","D000068900","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2011,"21871459","Effects of DPP-4 inhibition on cardiac metabolism and function in mice.","21871459",57]
["Sitagliptin Phosphate","Sitagliptin Phosphate","D000068900","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20103614","Elevated hepatic enzymes potentially associated with sitagliptin.","20103614",57]
["Sitagliptin Phosphate","Sitagliptin Phosphate","D000068900","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28104990","Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.","28104990",57]
["Smallpox Vaccine","Smallpox Vaccine","D012900","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"20613780","Surfing a genetic association interaction network to identify modulators of antibody response to smallpox vaccine.","20613780",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C30083,B30083)","v":"Smoke"},"Smoke","D012906","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J30083,K30083)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,2013,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q30083,Q30083)","v":"23363038"},"Adverse effects of wood smoke PM(2.5) exposure on macrophage functions.","23363038",57]
["Smoke","Smoke","D012906","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2013,"24339911","Association between exposure to environmental tobacco smoke and biomarkers of oxidative stress among patients hospitalised with acute myocardial infarction.","24339911",57]
["Smoke","Smoke","D012906","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2004,"15271786","Effect of exposure to cigarette smoke on carotid artery intimal thickening: the role of inducible NO synthase.","15271786",57]
["Smoke","Smoke","D012906","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23776235","Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes.","23776235",57]
["SNX 2112","SNX 2112","C534922","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24191862","Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS).","24191862",57]
["sodium arsenite","sodium arsenite","C017947","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"16274885","The role of oxidative stress in the modulation of aryl hydrocarbon receptor-regulated genes by As3+, Cd2+, and Cr6+.","16274885",57]
["Sodium Chloride","Sodium Chloride","D012965","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2007,"17071783","Fluidization of membrane lipids enhances the tolerance of Saccharomyces cerevisiae to freezing and salt stress.","17071783",57]
["Sodium Chloride","Sodium Chloride","D012965","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"28266792","The science of salt: A regularly updated systematic review of salt and health outcomes (December 2015-March 2016).","28266792",57]
["Sodium Fluoride","Sodium Fluoride","D012969","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9490002","Activation by sodium fluoride of drug-metabolizing enzymes in rat hepatoma-derived Fa32 cells.","9490002",57]
["Sodium Pertechnetate Tc 99m","Sodium Pertechnetate Tc 99m","D013670","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2000,"11100355","Diagnostic value of 99mTc-labeled red blood cell SPET for a solitary solid liver mass in HBV carrier patients with different echogenicities.","11100355",57]
["Soil","Soil","D012987","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2010,"20938504","Screening of dioxin-like compounds in bio-composts and their materials: chemical analysis and fractionation-directed evaluation of AhR ligand activities using an in vitro bioassay.","20938504",57]
["sorafenib","sorafenib","C471405","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"23998651","Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.","23998651",57]
["Sorbose","Sorbose","D013013","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2247413","Regulation of lipid metabolism by dietary sorbose in laying hens.","2247413",57]
["sorgoleone","sorgoleone","C113738","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2007,"17178719","Functional characterization of desaturases involved in the formation of the terminal double bond of an unusual 16:3Delta(9,12,150) fatty acid isolated from Sorghum bicolor root hairs.","17178719",57]
["Soybean Oil","Soybean Oil","D013024","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11055389","Preventive effect of lactobacillus delbrueckii subsp. bulgaricus on the oxidation of LDL.","11055389",57]
["soybean oil, phospholipid emulsion","soybean oil, phospholipid emulsion","C545823","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2012,"22094472","Effects of moderate exercise on VLDL₁ and Intralipid kinetics in overweight/obese middle-aged men.","22094472",57]
["Sphingosine","Sphingosine","D013110","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18411230","Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate.","18411230",57]
["Sphingosine","Sphingosine","D013110","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"25176316","Oxidized LDL-induced angiogenesis involves sphingosine 1-phosphate: prevention by anti-S1P antibody.","25176316",57]
["Sphingosine","Sphingosine","D013110","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,1997,"9355743","Conversion of dihydroceramide into ceramide: involvement of a desaturase.","9355743",57]
["sphingosine 1-phosphate","sphingosine 1-phosphate","C060506","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15277330","Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation.","15277330",57]
["Spironolactone","Spironolactone","D013148","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2013,"24129399","Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet.","24129399",57]
["Squalene","Squalene","D013185","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28606375","Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.","28606375",57]
["SRM 1597","SRM 1597","C518872","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2007,"17187366","Competitive inhibition of carcinogen-activating CYP1A1 and CYP1B1 enzymes by a standardized complex mixture of PAH extracted from coal tar.","17187366",57]
["stachyose","stachyose","C005695","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27157892","Enhancing the hepatic protective effect of genistein by oral administration with stachyose in mice with chronic high fructose diet consumption.","27157892",57]
["Starch","Starch","D013213","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2008,"18524173","High-carbohydrate diets affect the size and composition of plasma lipoproteins in hamsters (Mesocricetus auratus).","18524173",57]
["stearic acid","stearic acid","C031183","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2012,"23084639","High levels of stearic acid, palmitoleic acid, and dihomo-γ-linolenic acid and low levels of linoleic acid in serum cholesterol ester are associated with high insulin resistance.","23084639",57]
["stearic acid","stearic acid","C031183","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"14302120","FATTY ACID COMPOSITION OF RAT LIVER LIPIDS DURING CHOLINE DEFICIENCY.","14302120",57]
["stearidonic acid","stearidonic acid","C062895","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2015,"26339641","Heterologous Reconstitution of Omega-3 Polyunsaturated Fatty Acids in Arabidopsis.","26339641",57]
["StemRegenin 1","StemRegenin 1","C552240","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"26414401","The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34(+) Hematopoietic Stem and Progenitor Cells.","26414401",57]
["StemRegenin 1","StemRegenin 1","C552240","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"27354634","Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes the Expansion of Human Promyelocytic Leukemia Cell Line, NB4.","27354634",57]
["STO 609","STO 609","C458525","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2008,"18755850","Activation of the aryl hydrocarbon receptor by the calcium/calmodulin-dependent protein kinase kinase inhibitor 7-oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid (STO-609).","18755850",57]
["Streptozocin","Streptozocin","D013311","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1979,"230964","Premature appearance of hepatic phosphoenolpyruvate carboxykinase in fetal rats, not mediated by adenosine 3':5'-monophosphate.","230964",57]
["Succinic Acid","Succinic Acid","D019802","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26051274","Succinate causes α-SMA production through GPR91 activation in hepatic stellate cells.","26051274",57]
["Sucrose","Sucrose","D013395","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2016,"26447327","Mechanisms by which the thiazolidinedione troglitazone protects against sucrose-induced hepatic fat accumulation and hyperinsulinaemia.","26447327",57]
["Sucrose","Sucrose","D013395","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1970,"4353905","Interrelationship between the kinds of dietary carbohydrate and fat in hyperlipoproteinemic patients. 1. Sucrose and starch with polyunsaturated fat.","4353905",57]
["Sucrose","Sucrose","D013395","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1619483","Dietary sucrose but not starch promotes protein-induced differences in rates of VLDL secretion and plasma lipid concentrations in rats.","1619483",57]
["Sucrose","Sucrose","D013395","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"6940954","Blood lipids and their distribution in lipoproteins in hyperinsulinemic subjects fed three different levels of sucrose.","6940954",57]
["sudan cholesteryl oleate","sudan cholesteryl oleate","C043632","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1984,"6499941","Receptor-mediated delivery of photoprotective agents by low-density lipoprotein.","6499941",57]
["Sulfobromophthalein","Sulfobromophthalein","D013448","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1963,"14150806","[EVALUATION OF HEPATIC LESIONS OF VARIOUS ORIGINS BY MEANS OF FUNCTION TESTS. II. TREATMENT WITH STEATOGENIC DIETS].","14150806",57]
["Sulfobromophthalein","Sulfobromophthalein","D013448","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1982,"7177685","BSF compartmental analysis in healthy subjects and in patients with alcoholic liver disease.","7177685",57]
["Sulfur Dioxide","Sulfur Dioxide","D013458","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"16023800","Effect of sulfur dioxide inhalation on CYP1A1 and CYP1A2 in rat liver and lung.","16023800",57]
["Sulindac","Sulindac","D013467","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16531450","Sulindac regulates the aryl hydrocarbon receptor-mediated expression of Phase 1 metabolic enzymes in vivo and in vitro.","16531450",57]
["Sunflower Oil","Sunflower Oil","D000074242","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2005,"16437720","Steatosis recovery after treatment with a balanced sunflower or olive oil-based diet: involvement of perisinusoidal stellate cells.","16437720",57]
["Sunflower Oil","Sunflower Oil","D000074242","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"12010587","Different effects of diets rich in olive oil, rapeseed oil and sunflower-seed oil on postprandial lipid and lipoprotein concentrations and on lipoprotein oxidation susceptibility.","12010587",57]
["sunitinib","sunitinib","C473478","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24247421","Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway.","24247421",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C30787,B30787)","v":"Superose 6b"},"Superose 6b","C043127","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J30787,K30787)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1992,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q30787,Q30787)","v":"1521329"},"Generation of analytic plasma lipoprotein profiles using two prepacked superose 6B columns.","1521329",57]
["T-2 Toxin","T-2 Toxin","D013605","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21453744","T-2 toxin is a cytochrome P450 1A1 inducer and leads to MAPK/p38- but not aryl hydrocarbon receptor-dependent interleukin-8 secretion in the human intestinal epithelial cell line Caco-2.","21453744",57]
["Tacrolimus","Tacrolimus","D016559","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11172391","Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.","11172391",57]
["TAK-652","TAK-652","C506967","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27347680","Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.","27347680",57]
["tallow","tallow","C013698","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,1995,"7858942","Lipid metabolism in pigs fed beef tallow or high-oleic acid sunflower oil.","7858942",57]
["Tamoxifen","Tamoxifen","D013629","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2000,"11032933","Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.","11032933",57]
["Tamoxifen","Tamoxifen","D013629","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2006,"16322887","Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.","16322887",57]
["Tamoxifen","Tamoxifen","D013629","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1998,"9717954","Tamoxifen in early breast cancer.","9717954",57]
["Tamoxifen","Tamoxifen","D013629","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3626776","Tamoxifen-induced modification of serum lipoprotein phospholipids in the cockerel.","3626776",57]
["Tamoxifen","Tamoxifen","D013629","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"26071793","Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients.","26071793",57]
["tanshinol","tanshinol","C585969","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24300390","Syntheses of diacyltanshinol derivatives and their suppressive effects on macrophage foam cell formation by reducing oxidized LDL uptake.","24300390",57]
["tanshinone","tanshinone","C021751","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24716403","Syntheses of tanshinone anhydrides and their suppression on oxidized LDL uptake in macrophages and foam cell formation.","24716403",57]
["Taurine","Taurine","D013654","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21175929","Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study.","21175929",57]
["Taurine","Taurine","D013654","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12908610","Effect of alpha-tocopherol and taurine supplementation on oxidized LDL levels of middle aged Korean women during aerobic exercise.","12908610",57]
["Taurine","Taurine","D013654","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17293168","Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.","17293168",57]
["Taurochenodeoxycholic Acid","Taurochenodeoxycholic Acid","D013655","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22994543","Tauroursodeoxycholic acid affects PPARγ and TLR4 in Steatotic liver transplantation.","22994543",57]
["Taurochenodeoxycholic Acid","Taurochenodeoxycholic Acid","D013655","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2014,"24865256","Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet.","24865256",57]
["tauroursodeoxycholic acid","tauroursodeoxycholic acid","C031655","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2014,"24865256","Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet.","24865256",57]
["Tea","Tea","D013662","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15831081","Inhibitory effect(s) of polymeric black tea polyphenols on the formation of B(a)P-derived DNA adducts in mouse skin.","15831081",57]
["Tea","Tea","D013662","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"24065295","Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study.","24065295",57]
["Tea","Tea","D013662","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11410017","Antioxidative activities of phenylethanoid glycosides from Ligustrum purpurascens.","11410017",57]
["Tea","Tea","D013662","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17991670","Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines.","17991670",57]
["Tea","Tea","D013662","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9455677","Influence of green tea and its three major components upon low-density lipoprotein oxidation.","9455677",57]
["Tea","Tea","D013662","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"27866076","Antioxidant properties of tea blunt ROS-dependent lipogenesis: beneficial effect on hepatic steatosis in a high fat-high sucrose diet NAFLD obese rat model.","27866076",57]
["Tea","Tea","D013662","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2015,"25659129","Pu-erh tea down-regulates sterol regulatory element-binding protein and stearyol-CoA desaturase to reduce fat storage in Caenorhaditis elegans.","25659129",57]
["technetium Tc 99m tin colloid","technetium Tc 99m tin colloid","C033493","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2006,"16531927","Colloid scintigraphy in non-alcoholic steatohepatitis: a conventional diagnostic method for an emerging disease.","16531927",57]
["telmisartan","telmisartan","C084178","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20823643","Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.","20823643",57]
["TEMPO","TEMPO","C003959","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9032943","Nitroxide reduction with ascorbic acid in spin labeled human plasma LDL and VLDL.","9032943",57]
["Terbutaline","Terbutaline","D013726","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1981,"6946283","Terbutaline raises high-density-lipoprotein-cholesterol levels.","6946283",57]
["tetraarsenic tetrasulfide","tetraarsenic tetrasulfide","C534735","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2006,"16875560","[Chronic hepatic damage in acute promyelocytic leukemia patients treated with tetra-arsenic tetra-sulfide].","16875560",57]
["Tetracycline","Tetracycline","D013752","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1975,"1158089","Fatty liver induced by tetracycline in the rat. Dose-response relationships and effect of sex.","1158089",57]
["Tetracycline","Tetracycline","D013752","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1988,"3417225","Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic.","3417225",57]
["Tetracycline","Tetracycline","D013752","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1971,"5127882","Ultrastructure of acute tetracycline induced liver change.","5127882",57]
["Tetracycline","Tetracycline","D013752","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1967,"6026422","Studies on the pathogenesis of tetracycline-induced fatty liver.","6026422",57]
["Tetradecanoylphorbol Acetate","Tetradecanoylphorbol Acetate","D013755","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,2001,"11728381","Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated CYP1A1 and CYP1B1 induction by 12-O-tetradecanoylphorbol-13-acetate: role of transforming growth factor beta and mitogen-activated protein kinases.","11728381",57]
["Tetradecanoylphorbol Acetate","Tetradecanoylphorbol Acetate","D013755","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1992,"1313028","Phorbol esters inhibit the dioxin receptor-mediated transcriptional activation of the mouse Cyp1a-1 and Cyp1a-2 genes by 2,3,7,8-tetrachlorodibenzo-p-dioxin.","1313028",57]
["Tetradecanoylphorbol Acetate","Tetradecanoylphorbol Acetate","D013755","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,1993,"8389299","Regulation of low-density-lipoprotein receptors in the human hepatoma cell line Hep G2. Effect of phorbol 12-myristate 13-acetate and low-density lipoprotein.","8389299",57]
["tetramethylpyrazine","tetramethylpyrazine","C017953","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2017,"27837167","Nrf2 Activation Is Required for Ligustrazine to Inhibit Hepatic Steatosis in Alcohol-Preferring Mice and Hepatocytes.","27837167",57]
["Thalidomide","Thalidomide","D013792","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1997,"9252951","Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat.","9252951",57]
["Theophylline","Theophylline","D013806","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"14980704","Cyp1a2 protects against reactive oxygen production in mouse liver microsomes.","14980704",57]
["Theophylline","Theophylline","D013806","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1976,"177335","[Lipids in pregnant patients with severe course of gestosis treated with xanthinol nicotinate and bufenin hydrochloride].","177335",57]
["Thiabendazole","Thiabendazole","D013827","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"18570159","Effect of butylated hydroxytoluene, curcumin, propyl gallate and thiabendazole on cytochrome P450 forms in cultured human hepatocytes.","18570159",57]
["Thiamine","Thiamine","D013831","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1980,"7448358","Biochemical mechanisms of biotin and thiamin action and relationships to genetic disease.","7448358",57]
["Thioacetamide","Thioacetamide","D013853","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1983,"6138897","Qualitative and quantitative changes in hepatic lipoprotein particles following acute injury of the rat liver induced by thioacetamide.","6138897",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C31491,B31491)","v":"thiobarbituric acid"},"thiobarbituric acid","C029684","13_AO",455,13,"Accumulation, Liver lipid",null,{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J31491,K31491)","v":"Non-alcoholic Fatty Liver Disease"},"D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q31491,Q31491)","v":"21429633"},"Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease.","21429633",57]
["Thioctic Acid","Thioctic Acid","D008063","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23151269","Hepato-protective effects of alpha lipoic acid besides its role in preventing fatty liver disease.","23151269",57]
["Thioctic Acid","Thioctic Acid","D008063","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20307398","Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome.","20307398",57]
["Thioctic Acid","Thioctic Acid","D008063","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22863080","α-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats.","22863080",57]
["Thioctic Acid","Thioctic Acid","D008063","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23634883","Flaxseed oil and alpha-lipoic acid combination ameliorates hepatic oxidative stress and lipid accumulation in comparison to lard.","23634883",57]
["Thromboxane A2","Thromboxane A2","D013928","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2005,"15985541","Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alphaIIbbeta3- and aggregation-independent manner.","15985541",57]
["Thromboxane B2","Thromboxane B2","D013929","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16894405","Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187.","16894405",57]
["Thromboxane B2","Thromboxane B2","D013929","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1991,"1941177","Plasma very low density lipoproteins from male rats fed casein or soybean protein diets: a comparison of fatty acid composition and influence on prostanoid production.","1941177",57]
["tibolone","tibolone","C027385","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1986,"3033444","Benefits and risks of different hormonal replacement therapies in post-menopausal women.","3033444",57]
["Ticrynafen","Ticrynafen","D013989","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10387023","Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.","10387023",57]
["TO-901317","TO-901317","C423915","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"21948338","Activation of liver X receptors attenuates endotoxin-induced liver injury in mice with nonalcoholic fatty liver disease.","21948338",57]
["TO-901317","TO-901317","C423915","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2007,"17418145","T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR.","17418145",57]
["Tobacco Smoke Pollution","Tobacco Smoke Pollution","D014028","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2007,"17566695","Passive smoking, Cyp1A1 gene polymorphism and dysmenorrhea.","17566695",57]
["Tobacco Smoke Pollution","Tobacco Smoke Pollution","D014028","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22851337","450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy.","22851337",57]
["Tobacco Smoke Pollution","Tobacco Smoke Pollution","D014028","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"14749157","Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study.","14749157",57]
["Tobacco Smoke Pollution","Tobacco Smoke Pollution","D014028","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2014,"24752502","Aryl hydrocarbon receptor (AhR) attenuation of subchronic cigarette smoke-induced pulmonary neutrophilia is associated with retention of nuclear RelB and suppression of intercellular adhesion molecule-1 (ICAM-1).","24752502",57]
["tofacitinib","tofacitinib","C479163","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22894574","Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.","22894574",57]
["Tolbutamide","Tolbutamide","D014044","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14166175","HYPERLIPEMIA AND KETOSIS IN THE PREGNANT RAT.","14166175",57]
["Toluene","Toluene","D014050","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2011,"21362431","Biological and chemical studies on aryl hydrocarbon receptor induction by the p53 inhibitor pifithrin-α and its condensation product pifithrin-β.","21362431",57]
["topiramate","topiramate","C052342","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2006,"16934763","The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate.","16934763",57]
["topiramate","topiramate","C052342","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24733016","GABA and topiramate inhibit the formation of human macrophage-derived foam cells by modulating cholesterol-metabolism-associated molecules.","24733016",57]
["Toremifene","Toremifene","D017312","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1994,"8200088","Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat.","8200088",57]
["trans-1,2-dihydro-1,2-naphthalenediol","trans-1,2-dihydro-1,2-naphthalenediol","C507866","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19330882","Differential protection by human glutathione S-transferase P1 against cytotoxicity of benzo[a]pyrene, dibenzo[a,l]pyrene, or their dihydrodiol metabolites, in bi-transgenic cell lines that co-express rat versus human cytochrome P4501A1.","19330882",57]
["trans-10,cis-12-conjugated linoleic acid","trans-10,cis-12-conjugated linoleic acid","C496197","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2010,"20924169","Trans-10,cis-12-CLA-caused lipodystrophy is associated with profound changes of fatty acid profiles of liver, white adipose tissue and erythrocytes in mice: possible link to tissue-specific alterations of fatty acid desaturation.","20924169",57]
["Trehalose","Trehalose","D014199","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"9014327","The use of decapitated insects to study lipid mobilization in adult Manduca sexta: effects of adipokinetic hormone and trehalose on fat body lipase activity.","9014327",57]
["Tretinoin","Tretinoin","D014212","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11378441","Low synthesis of retinoic acid due to impaired cytochrome P450 1a1 expression in mouse xeroderma pigmentosum fibroblasts.","11378441",57]
["Tretinoin","Tretinoin","D014212","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23281105","Retinoids counteract insulin resistance and liver steatosis: what's the potential mechanism?","23281105",57]
["Tretinoin","Tretinoin","D014212","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25948673","Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease.","25948673",57]
["Tretinoin","Tretinoin","D014212","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1998,"9773973","Structural requirements of the glucocorticoid and retinoic acid response units in the phosphoenolpyruvate carboxykinase gene promoter.","9773973",57]
["Tretinoin","Tretinoin","D014212","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2001,"11397803","Regulation of stearoyl coenzyme A desaturase expression in human retinal pigment epithelial cells by retinoic acid.","11397803",57]
["tributyltin","tributyltin","C011559","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11991632","Circulating lysozyme and hepatic CYP1A activities during a chronic dietary exposure to tributyltin (TBT) and 3,3',4,4',5-pentachlorobiphenyl (PCB-126) mixtures in channel catfish, Ictalurus punctatus.","11991632",57]
["tributyltin","tributyltin","C011559","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2015,"25216468","Dose- and time-dependent expression of aryl hydrocarbon receptor (AhR) and aryl hydrocarbon receptor nuclear translocator (ARNT) in PCB-, B[a]P-, and TBT-exposed intertidal copepod Tigriopus japonicus.","25216468",57]
["Trichloroethylene","Trichloroethylene","D014241","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"20136049","Study of genetic polymorphism in solvent exposed population and its correlation to in vitro effect of trichloroethylene on lymphocytes.","20136049",57]
["triclocarban","triclocarban","C009540","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23524099","Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells.","23524099",57]
["Trifluoperazine","Trifluoperazine","D014268","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"3235949","Phenothiazines inhibit cholesteryl ester formation in J 774 monocyte-like cells.","3235949",57]
["triladyl","triladyl","C503302","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15798030","Modifications of bull spermatozoa induced by three extenders: Biociphos, low density lipoprotein and Triladyl, before, during and after freezing and thawing.","15798030",57]
["Trimetazidine","Trimetazidine","D014292","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2006,"16521219","Trimetazidine: is it a promising drug for use in steatotic grafts?","16521219",57]
["trimyristin","trimyristin","C036694","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10477245","Effect of synthetic triglycerides of myristic, palmitic, and stearic acid on serum lipoprotein metabolism.","10477245",57]
["tripalmitin","tripalmitin","C005859","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2000,"10899171","The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1.","10899171",57]
["triphenyltin fluoride","triphenyltin fluoride","C033303","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"7334675","[Triphenyltin fluoride-induced hypertriglyceridemia in rabbits (author's transl)].","7334675",57]
["TRK 820","TRK 820","C111212","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22581509","Identification of human cytochrome P450 enzymes involved in the metabolism of a novel к-opioid receptor agonist, nalfurafine hydrochloride.","22581509",57]
["troglitazone","troglitazone","C057693","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2001,"11347086","[Lipodystrophia].","11347086",57]
["troglitazone","troglitazone","C057693","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"16220075","Troglitazone inhibits long-term glycation and oxidation of low-density lipoprotein.","16220075",57]
["troglitazone","troglitazone","C057693","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9703316","Troglitazone upregulates LDL receptor activity in HepG2 cells.","9703316",57]
["Troleandomycin","Troleandomycin","D014217","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1990,"2395109","Inhibition of rat liver estrogen 2/4-hydroxylase activity by troleandomycin: comparison with erythromycin and roxithromycin.","2395109",57]
["Tyramine","Tyramine","D014439","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1637798","Autoradiographic analysis of the distribution of 125I-tyramine-cellobiose-LDL in atherosclerotic lesions of the WHHL rabbit.","1637798",57]
["tyrphostin AG 1478","tyrphostin AG 1478","C101044","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"29038049","Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease.","29038049",57]
["ubiquinol-10","ubiquinol-10","C026663","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1637852","Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation.","1637852",57]
["Ubiquinone","Ubiquinone","D014451","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1991,"1991113","Tryptophan fluorescence in electron-transfer flavoprotein:ubiquinone oxidoreductase: fluorescence quenching by a brominated pseudosubstrate.","1991113",57]
["Ubiquinone","Ubiquinone","D014451","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2009,"19592219","Induction of non-alcoholic fatty liver disease and insulin resistance by feeding a high-fat diet in rats: does coenzyme Q monomethyl ether have a modulatory effect?","19592219",57]
["Ubiquinone","Ubiquinone","D014451","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17365991","High plasma levels of CD40 are associated with low coenzyme Q and vitamin E content of low-density lipoprotein in healthy men.","17365991",57]
["Ubiquinone","Ubiquinone","D014451","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2015,"26284974","Idebenone protects against oxidized low density lipoprotein induced mitochondrial dysfunction in vascular endothelial cells via GSK3β/β-catenin signalling pathways.","26284974",57]
["Ubiquinone","Ubiquinone","D014451","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27495100","High plasma coenzyme Q10 concentration is correlated with good left ventricular performance after primary angioplasty in patients with acute myocardial infarction.","27495100",57]
["Ubiquinone","Ubiquinone","D014451","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9098093","Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations.","9098093",57]
["Ubiquinone","Ubiquinone","D014451","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"25450583","Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.","25450583",57]
["Ultrafine","Ultrafine","C043595","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23502512","Combustion derived ultrafine particles induce cytochrome P-450 expression in specific lung compartments in the developing neonatal and adult rat.","23502512",57]
["Urea","Urea","D014508","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1959,"13808129","[Action of N-(4-methylbenzenesulfonyl)-N'-butylurea on experimental hepatic steatosis].","13808129",57]
["Urea","Urea","D014508","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2005,"15866482","Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI.","15866482",57]
["Urethane","Urethane","D014520","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9344892","Metabolism of ethyl carbamate by pulmonary cytochrome P450 and carboxylesterase isozymes: involvement of CYP2E1 and hydrolase A.","9344892",57]
["Uric Acid","Uric Acid","D014527","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20458845","Elevated serum uric acid is an independent risk factor for nonalcoholic fatty liver disease in Japanese undergoing a health checkup.","20458845",57]
["Uric Acid","Uric Acid","D014527","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23036645","Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.","23036645",57]
["Uric Acid","Uric Acid","D014527","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1971,"5548321","[Alterations of lipid metabolism in primary gout and hyperuircemia].","5548321",57]
["Uric Acid","Uric Acid","D014527","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21789541","Altered serum selenium and uric acid levels and dyslipidemia in hemodialysis patients could be associated with enhanced cardiovascular risk.","21789541",57]
["Uric Acid","Uric Acid","D014527","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1988,"2850600","[Effects of low density lipoproteins on uric acid crystals].","2850600",57]
["Uric Acid","Uric Acid","D014527","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22998508","Renal function-dependent association of serum uric acid with metabolic syndrome and hepatic fat content in a middle-aged and elderly Chinese population.","22998508",57]
["Uric Acid","Uric Acid","D014527","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25845417","The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort.","25845417",57]
["Uric Acid","Uric Acid","D014527","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27382573","Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients.","27382573",57]
["Uric Acid","Uric Acid","D014527","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28790228","Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.","28790228",57]
["Ursodeoxycholic Acid","Ursodeoxycholic Acid","D014580","7_KE",54,7,"CD36","Up Regulation","Fatty Acid Transport Proteins","D050612","Fatty Acid Transport Proteins",0,1,2012,"22531947","Specific bile acids inhibit hepatic fatty acid uptake in mice.","22531947",57]
["Ursodeoxycholic Acid","Ursodeoxycholic Acid","D014580","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2007,"17376209","Psoriasis treated with ursodeoxycholic acid: three case reports.","17376209",57]
["Ursodeoxycholic Acid","Ursodeoxycholic Acid","D014580","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"22629789","[UDCA in the treatment of nonalcoholic fatty liver disease].","22629789",57]
["Ursodeoxycholic Acid","Ursodeoxycholic Acid","D014580","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"2828498","Modulation of low density lipoprotein receptor activity by bile acids: differential effects of chenodeoxycholic and ursodeoxycholic acids in the hamster.","2828498",57]
["Ursodeoxycholic Acid","Ursodeoxycholic Acid","D014580","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"22629789","[UDCA in the treatment of nonalcoholic fatty liver disease].","22629789",57]
["Ursodeoxycholic Acid","Ursodeoxycholic Acid","D014580","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26190501","Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.","26190501",57]
["ursolic acid","ursolic acid","C005466","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2014,"24489777","Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.","24489777",57]
["Vaccinium myrtillus extract","Vaccinium myrtillus extract","C073305","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1997,"9182074","Antioxidant action of Vaccinium myrtillus extract on human low density lipoproteins in vitro: initial observations.","9182074",57]
["Valproic Acid","Valproic Acid","D014635","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1992,"1519593","Re:Incidental microvesicular steatosis due to valproic acid anticonvulsant therapy.","1519593",57]
["Valproic Acid","Valproic Acid","D014635","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2014,"24489787","Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices.","24489787",57]
["Valproic Acid","Valproic Acid","D014635","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23182413","The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep?","23182413",57]
["vanadyl sulfate","vanadyl sulfate","C034028","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2112099","Tetravalent vanadium mediated oxidation of low density lipoprotein.","2112099",57]
["Verapamil","Verapamil","D014700","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1985,"3966907","Verapamil enhances receptor-mediated endocytosis of low density lipoproteins by aortic cells in culture.","3966907",57]
["Veratridine","Veratridine","D014701","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2009,"19097948","Investigating the in vitro metabolism of veratridine: characterization of metabolites and involved cytochrome P450 isoforms.","19097948",57]
["vinclozolin","vinclozolin","C025643","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15651921","Cytotoxicity of the dicarboximide fungicides, vinclozolin and iprodione, in rat hepatoma-derived Fa32 cells.","15651921",57]
["vinylidene chloride","vinylidene chloride","C029297","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1984,"6610421","Selective induction of renal microsomal cytochrome P-450-linked monooxygenases by 1,1-dichloroethylene in mice.","6610421",57]
["vinylidene chloride","vinylidene chloride","C029297","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1997,"9458185","Changes in cytochrome P450 enzymes by 1,1-dichloroethylene in rat liver and kidney.","9458185",57]
["Vitamin A","Vitamin A","D014801","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14110964","[CLINICAL ASPECTS OF FATTY LIVER].","14110964",57]
["Vitamin A","Vitamin A","D014801","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2008,"18264740","Non-alcoholic fatty liver disease and its relationship with the nutritional status of vitamin A in individuals with class III obesity.","18264740",57]
["Vitamin A","Vitamin A","D014801","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,1981,"7197710","Hepatic vitamin A depletion after chronic ethanol consumption in baboons and rats.","7197710",57]
["Vitamin A","Vitamin A","D014801","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1978,"219208","[Study of retinol and its protein-binder in chronic renal insufficiency: the effect of therapeutic measures].","219208",57]
["Vitamin A","Vitamin A","D014801","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1995,"9101230","Contribution of vitamin A to the oxidation resistance of human low density lipoproteins.","9101230",57]
["Vitamin A","Vitamin A","D014801","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,"24975216","Retinol status and expression of retinol-related proteins in methionine-choline deficient rats.","24975216",57]
["Vitamin A","Vitamin A","D014801","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2008,"18364238","Vitamin A regulates obesity in WNIN/Ob obese rat; independent of stearoyl-CoA desaturase-1.","18364238",57]
["Vitamin B 12","Vitamin B 12","D014805","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1954,"13198593","[Vitamin B12 activity in dietary hepatic steatosis in albino rat].","13198593",57]
["Vitamin B 12","Vitamin B 12","D014805","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1966,"6013869","[Experiences with Vitamin B-12 therapy of chronic liver diseases in a resort practice].","6013869",57]
["Vitamin B 12","Vitamin B 12","D014805","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1996,"8710919","Megalin-mediated endocytosis of transcobalamin-vitamin-B12 complexes suggests a role of the receptor in vitamin-B12 homeostasis.","8710919",57]
["Vitamin D","Vitamin D","D014807","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2015,"26186300","Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment.","26186300",57]
["Vitamin D","Vitamin D","D014807","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19667238","1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus.","19667238",57]
["Vitamin D","Vitamin D","D014807","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24968737","Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial.","24968737",57]
["Vitamin D","Vitamin D","D014807","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27044765","The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease.","27044765",57]
["Vitamin D","Vitamin D","D014807","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28211513","NAFLD: Vitamin D-induced autophagy prevents steatosis.","28211513",57]
["Vitamin D","Vitamin D","D014807","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"23349943","Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice.","23349943",57]
["Vitamin E","Vitamin E","D014810","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2011,"21228269","Polymorphisms in the CD36/FAT gene are associated with plasma vitamin E concentrations in humans.","21228269",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2000,"10839868","Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.","10839868",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2005,"16424622","Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease.","16424622",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19571473","Children's toxicology from bench to bed--Liver Injury (2): Mechanism of antioxidant therapy for nonalcoholic fatty liver disease.","19571473",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"22149573","Medical therapy for nonalcoholic fatty liver disease in children and adolescents.","22149573",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27468193","Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells.","27468193",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, IDL","D053419","Lipoproteins, IDL",1,1,2004,"15753174","The decrease in gamma-tocopherol in plasma and lipoprotein fractions levels off within two days of vitamin E supplementation.","15753174",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10072120","Vitamin E (alpha-tocopherol) does not inhibit platelet stimulation by oxidized low density lipoprotein in vitro.","10072120",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10520814","Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis.","10520814",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10751558","Modulation by alpha- and gamma-tocopherol and oxidized low-density lipoprotein of apoptotic signaling in human coronary smooth muscle cells.","10751558",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10975585","Effects of alpha-tocopherol on ox-LDL-mediated degradation of IkappaB and apoptosis in cultured human coronary artery endothelial cells.","10975585",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"11270503","Alpha-tocopherol protects against monocyte Mac-1 (CD11b/CD18) expression and Mac-1-dependent adhesion to endothelial cells induced by oxidized low-density lipoprotein.","11270503",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11498450","Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis.","11498450",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11912561","Sex and hormonal status influence the effects of psyllium on lipoprotein remodeling and composition.","11912561",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1336435","Alpha-tocopherol, lipids and lipoproteins in knee-joint synovial fluid and serum from patients with inflammatory joint disease.","1336435",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1431596","Discrimination between forms of vitamin E by humans with and without genetic abnormalities of lipoprotein metabolism.","1431596",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1637177","Lipid peroxidation and its inhibition in low density lipoproteins: quenching of cis-parinaric acid fluorescence.","1637177",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"27966778","Anti-Atherosclerotic Effects of Vitamins D and E in Suppression of Atherogenesis.","27966778",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"19001773","Effects of genistein on oxidative injury in endothelial cells.","19001773",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2282108","Effect of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking.","2282108",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3598395","Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes.","3598395",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1974,"4376543","[Relation between beta-lipoprotein content in serum and plasma vitamin E content. A contribution to the question of the estimation of the vitamin E status in man].","4376543",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7495231","Coantioxidants make alpha-tocopherol an efficient antioxidant for low-density lipoprotein.","7495231",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7749825","The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study.","7749825",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7800981","[Vitamin E and atherosclerosis].","7800981",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7800984","[Vitamin E, antioxidants and atherosclerosis].","7800984",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7832785","Human plasma phospholipid transfer protein accelerates exchange/transfer of alpha-tocopherol between lipoproteins and cells.","7832785",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7842136","Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol.","7842136",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7857373","Effects of supplementing with vitamin E on the uptake of low density lipoprotein and the stimulation of cholesteryl ester formation in macrophages.","7857373",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7864980","Effects of combined supplementation with antioxidants on low-density lipoprotein oxidation.","7864980",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7867194","Protection from oxidized LDL-induced leukocyte adhesion to microvascular and macrovascular endothelium in vivo by vitamin C but not by vitamin E.","7867194",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7871818","Peroxidation of low density lipoproteins and endothelial phospholipids: effect of vitamin E and fatty acid composition.","7871818",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7872651","Oxidized low-density lipoproteins delay endothelial wound healing: lack of effect of vitamin E.","7872651",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7883046","Alpha-tocopherol mediated peroxidation in the copper (II) and met myoglobin induced oxidation of human low density lipoprotein: the influence of lipid hydroperoxides.","7883046",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7883949","Effect of alpha-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis.","7883949",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7889898","Effects of fish oil and vitamin E supplementation on copper-catalysed oxidation of human low density lipoprotein in vitro.","7889898",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7890704","Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein.","7890704",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7896173","Copper-induced lipid peroxidation in liposomes, micelles, and LDL: which is the role of vitamin E?","7896173",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1994,"7945331","In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol.","7945331",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8001520","Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: a randomized double-blind placebo-controlled clinical trial.","8001520",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8007611","[Acute pancreatitis and biological antioxidants].","8007611",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8015479","Quantitative low-density lipoprotein oxidation by gamma radiolysis.","8015479",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8019642","Differing effects of probucol and vitamin E on the oxidation of lipoproteins, ceroid accumulation and protein uptake by macrophages.","8019642",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8031313","The influence of magnesium-pyridoxal-5'-phosphate-glutamate in comparison with probucol, alpha-tocopherol and trolox on copper-induced oxidation of human low density lipoprotein in vitro.","8031313",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8036736","Oxidized low-density lipoproteins and endothelium: oral vitamin E supplementation prevents oxidized low-density lipoprotein-mediated vascular injury.","8036736",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8049202","Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.","8049202",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8077571","Effects of alcohol consumption on antioxidant content and susceptibility of low-density lipoprotein to oxidative modification.","8077571",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8148354","Effects of linoleate-enriched and oleate-enriched diets in combination with alpha-tocopherol on the susceptibility of LDL and LDL subfractions to oxidative modification in humans.","8148354",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1994,"8206992","Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation.","8206992",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8241098","Vitamin E, LDL, and endothelium. Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro.","8241098",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8241711","Ubiquinone and alpha-tocopherol in plasma; means of translocation or depot.","8241711",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8252691","Effect of combined supplementation with alpha-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation.","8252691",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8263411","Interrelationships of alpha-tocopherol with plasma lipoproteins in African green monkeys: effects of dietary fats.","8263411",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8284976","Antioxidants and risk of myocardial infarction. EURAMIC Study Group.","8284976",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C33475,B33475)","v":"Vitamin E"},"Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J33475,K33475)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1993,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q33475,Q33475)","v":"8284977"},"The role of lipid peroxidation, antioxidants and pro-oxidants in atherosclerosis.","8284977",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8299431","Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients.","8299431",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8302680","The antioxidant vitamins: impact on atherosclerosis.","8302680",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"8302851","Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content.","8302851",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8391994","The oxidation of alpha-tocopherol in human low-density lipoprotein by the simultaneous generation of superoxide and nitric oxide.","8391994",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8419943","Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein.","8419943",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8429255","Impaired discrimination between stereoisomers of alpha-tocopherol in patients with familial isolated vitamin E deficiency.","8429255",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8443232","Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins.","8443232",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8466894","Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene.","8466894",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8483283","[Atherosclerosis, with special reference to vitamin E].","8483283",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8486164","d-alpha-Tocopherol inhibits low density lipoprotein induced proliferation and protein kinase C activity in vascular smooth muscle cells.","8486164",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8517860","The role of alpha-tocopherol as a peroxyl radical scavenger in human low density lipoprotein.","8517860",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1995,"8529921","Comparison of the effects of dietary vitamin E on in vivo and in vitro parameters of lipid peroxidation in the rabbit.","8529921",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8546752","Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents.","8546752",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8561059","Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy.","8561059",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8562571","Effect of magnesium deficiency on triacylglycerol-rich lipoprotein and tissue susceptibility to peroxidation in relation to vitamin E content.","8562571",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8582644","Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation.","8582644",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8598108","Rapid quantification of alpha-tocopherol in plasma and low- and high-density lipoproteins.","8598108",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8598422","Effect of beta-carotene supplementation on the concentrations and distribution of carotenoids, vitamin E, vitamin A, and cholesterol in plasma lipoprotein and non-lipoprotein fractions in healthy older women.","8598422",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8602596","Inverse relation between the concentration of low-density-lipoprotein vitamin E and severity of coronary artery disease.","8602596",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8605710","Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration.","8605710",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8615360","RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.","8615360",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8626654","Alpha-tocopherol as a reductant for Cu(II) in human lipoproteins. Triggering role in the initiation of lipoprotein oxidation.","8626654",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8640336","Prevention by alpha-tocopherol and rutin of glutathione and ATP depletion induced by oxidized LDL in cultured endothelial cells.","8640336",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8698868","The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium.","8698868",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8729097","Factors affecting resistance of low density lipoproteins to oxidation.","8729097",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8732785","A rapid and simple screening test for potential inhibitors of tocopherol-mediated peroxidation of LDL lipids.","8732785",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8743055","A rapid method for separation of plasma low and high density lipoproteins for tocopherol and carotenoid analyses.","8743055",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8744745","Blood-lipid and lactation-stage factors affecting serum vitamin E concentrations and vitamin E cholesterol ratios in dairy cattle.","8744745",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8755649","Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation.","8755649",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8770313","Lipoproteins containing apolipoprotein B isolated from patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia: identification and characterization.","8770313",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8800496","Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men.","8800496",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8808494","The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy.","8808494",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8827516","Antioxidant and prooxidant activity of alpha-tocopherol in human plasma and low density lipoprotein.","8827516",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1996,"8845913","Inhibition of oxidation of low density lipoprotein by vitamin E and related compounds.","8845913",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8870982","Radical-initiated lipid peroxidation in low density lipoproteins: insights obtained from kinetic modeling.","8870982",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1996,"8873932","What dose of vitamin E is required to reduce susceptibility of LDL to oxidation?","8873932",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8878940","Contribution of alpha-tocopherol in HDL3 to inhibition of LDL oxidation by human macrophages.","8878940",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8895059","Lack of correlation between the alpha-tocopherol content of plasma and LDL, but high correlations for gamma-tocopherol and carotenoids.","8895059",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8895064","Effect of alpha-tocopherol on LDL oxidation and glycation: in vitro and in vivo studies.","8895064",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8896905","Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects.","8896905",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8905298","Influence of native and modified lipoproteins on migration of mouse peritoneal macrophages and the effect of the antioxidants vitamin E and Probucol.","8905298",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8909155","Vitamins C and E and LDL oxidation.","8909155",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8955104","3-Hydroxyanthranilic acid is an efficient, cell-derived co-antioxidant for alpha-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation.","8955104",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"8958130","Requirement for, promotion, or inhibition by alpha-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation.","8958130",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8963727","Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation.","8963727",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8983670","Beyond cholesterol reduction in coronary heart disease: is vitamin E the answer?","8983670",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"9006806","The serum cholesterol ester fatty acid composition but not the serum concentration of alpha tocopherol predicts the development of myocardial infarction in 50-year-old men: 19 years follow-up.","9006806",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"9017516","Oxidation of LDL by recombinant human 15-lipoxygenase: evidence for alpha-tocopherol-dependent oxidation of esterified core and surface lipids.","9017516",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9374483","Oxidation of free fatty acids in low density lipoprotein by 15-lipoxygenase stimulates nonenzymic, alpha-tocopherol-mediated peroxidation of cholesteryl esters.","9374483",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9733025","Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners.","9733025",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9736308","Dynamics of vitamin E action against LDL oxidation.","9736308",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9063873","Role of alpha-tocopheroxyl radical in the initiation of lipid peroxidation in human low-density lipoprotein exposed to horse radish peroxidase.","9063873",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9089561","The effect of hormone replacement therapy on vitamin E status in postmenopausal women.","9089561",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9090072","Binding and uptake of 125iodine-labelled, oxidized low density lipoprotein by macrophages: comparison of the effects of alpha-tocopherol, probucol, pyridoxal-5'-phosphate and magnesium-pyridoxal-5'-phosphate-glutamate.","9090072",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9096373","gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications.","9096373",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9102160","Vitamin E inhibits low-density lipoprotein-induced adhesion of monocytes to human aortic endothelial cells in vitro.","9102160",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9223282","Alpha-tocopheryl hydroquinone is an efficient multifunctional inhibitor of radical-initiated oxidation of low density lipoprotein lipids.","9223282",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"9248832","Oxidation of low density lipoproteins leads to disturbance of their binding with alpha-tocopherol.","9248832",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9261277","Increased oxidation of LDL in patients with coronary artery disease is independent from dietary vitamins E and C.","9261277",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9261278","Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus.","9261278",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9266510","Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis?","9266510",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9267325","Suitability of chemical in vitro models to investigate LDL oxidation: study with different initiating conditions in native and alpha-tocopherol-supplemented LDL.","9267325",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9288073","Antioxidants and ischaemic heart disease.","9288073",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C33539,B33539)","v":"Vitamin E"},"Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J33539,K33539)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1997,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q33539,Q33539)","v":"9296448"},"The role of copper reduction by alpha-tocopherol in low-density lipoprotein oxidation.","9296448",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1997,"9298686","Vitamin E supplementation in elderly lowers the oxidation rate of linoleic acid in LDL.","9298686",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1997,"9323031","Alpha-tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein.","9323031",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9347289","Supplementation with wine phenolic compounds increases the antioxidant capacity of plasma and vitamin E of low-density lipoprotein without changing the lipoprotein Cu(2+)-oxidizability: possible explanation by phenolic location.","9347289",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9349932","Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals.","9349932",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9351400","Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation.","9351400",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"9420181","Low fat diet decreases alpha-tocopherol levels, and stimulates LDL oxidation and eicosanoid biosynthesis in man.","9420181",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9427704","Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E.","9427704",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9428715","Physical partitioning is the main mechanism of alpha-tocopherol and cholesterol transfer between lipoproteins and P388D1 macrophage-like cells.","9428715",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9458281","RRR-alpha-tocopherol can be substituted for by Trolox in determination of kinetic parameters of LDL oxidizability by copper.","9458281",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9461231","Low-density lipoprotein oxidation and vitamins E and C in sustained and white-coat hypertension.","9461231",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9469591","Alpha-tocopherol supplementation of macrophages does not influence their ability to oxidize LDL.","9469591",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9502329","The effects of alpha-tocopherol on critical cells in atherogenesis.","9502329",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9507996","Radical-induced lipoprotein and plasma lipid oxidation in normal and apolipoprotein E gene knockout (apoE-/-) mice: apoE-/- mouse as a model for testing the role of tocopherol-mediated peroxidation in atherogenesis.","9507996",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9512961","Effect of a single oral dose of antioxidant mixture (vitamin E, carotenoids) on the formation of cholesterol oxidation products after ex vivo LDL oxidation in humans.","9512961",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9514418","Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza.","9514418",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9523027","Action of vitamin E as antioxidant against oxidative modification of low density lipoprotein.","9523027",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9523028","Effect of supplementation with vitamin E on LDL oxidizability and prevention of atherosclerosis.","9523028",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9527400","Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome.","9527400",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9550461","Oxidative changes associated with beta-carotene and alpha-tocopherol enrichment of human low-density lipoproteins.","9550461",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9576851","High-density lipoprotein (HDL3)-associated alpha-tocopherol is taken up by HepG2 cells via the selective uptake pathway and resecreted with endogenously synthesized apo-lipoprotein B-rich lipoprotein particles.","9576851",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9586809","Erythrocyte ascorbate recycling: antioxidant effects in blood.","9586809",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9591910","Effects of increasing doses of alpha-tocopherol in providing protection of low-density lipoprotein from oxidation.","9591910",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9610766","Impact of LDL carotenoid and alpha-tocopherol content on LDL oxidation by endothelial cells in culture.","9610766",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9622286","Oxidation resistance of LDL is correlated with vitamin E status in beta-thalassemia intermedia.","9622286",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9649599","alpha-Tocopherol concentrations in plasma but not in lipoproteins fluctuate during the menstrual cycle in healthy premenopausal women.","9649599",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9672881","Distribution of tocopherol and apolipoprotein A-I immunoreactivity in rat liver chromatin.","9672881",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9690909","Monocyte superoxide production is inversely related to normal content of alpha-tocopherol in low-density lipoprotein.","9690909",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9701189","Antioxidant vitamin supplementation and lipid peroxidation in smokers.","9701189",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9721629","Very slow autoxidation of low-density lipoprotein spares alpha-tocopherol.","9721629",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9763541","Vitamin C protects human arterial smooth muscle cells against atherogenic lipoproteins: effects of antioxidant vitamins C and E on oxidized LDL-induced adaptive increases in cystine transport and glutathione.","9763541",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9781926","A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells.","9781926",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9808219","A randomized, single-blind, placebo-controlled trial of the effects of 200 mg alpha-tocopherol on the oxidation resistance of atherogenic lipoproteins.","9808219",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9832080","Comparison of RRR-alpha- and all-rac-alpha-tocopherol uptake by permanent rat skeletal muscle myoblasts (L6 cells): effects of exogenous lipoprotein lipase.","9832080",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9853697","Effects of postprandial hyperlipemia on the vitamin E content of lipoproteins. GERBAP section Lipoprotéines. Groupe d'Evaluation et de Recherche de l'Assistance Publique des Hôpitaux de Paris.","9853697",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9862276","Improvement in the endothelium-dependent relaxation in hypercholesterolemic rabbits treated with vitamin E.","9862276",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9863536","Dietary L-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms.","9863536",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"9916215","Assessment of prooxidant activity of vitamin E in human low-density lipoprotein and plasma.","9916215",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9919489","alpha-tocopherol protects the peroxidative modification of LDL to be recognized by LDL receptors.","9919489",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"9919581","Interaction of carotenoids and tocopherols with peroxynitrite.","9919581",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9930402","Vitamin E reduces cholesterol esterification and uptake of acetylated low density lipoprotein in macrophages.","9930402",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9932522","The molecular action of alpha-tocopherol in lipoprotein lipid peroxidation. Pro- and antioxidant activity of vitamin E in complex heterogeneous lipid emulsions.","9932522",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9932527","Role of coenzyme Q and superoxide in vitamin E cycling.","9932527",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9951745","In vivo metabolism of alpha-tocopherol in lipoproteins and liver: studies on rabbits in response to acute cholesterol loading.","9951745",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2000,"10832094","Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells.","10832094",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2000,"11063441","Effects of long-term supplementation with moderate pharmacologic doses of vitamin E are saturable and reversible in patients with type 1 diabetes.","11063441",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2004,"15753129","Vitamin E trafficking.","15753129",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2004,"15753174","The decrease in gamma-tocopherol in plasma and lipoprotein fractions levels off within two days of vitamin E supplementation.","15753174",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1999,"10380122","Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol.","10380122",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2000,"10600271","Distribution of lipid-soluble antioxidants in lipoproteins from healthy subjects. II. Effects of in vivo supplementation with alpha-tocopherol.","10600271",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2000,"11110867","Secretion of alpha-tocopherol in VLDL is decreased by dietary protein insufficiency in young growing rats.","11110867",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2000,"11121723","Dependence of plasma alpha-tocopherol flux on very low-density triglyceride clearance in humans.","11121723",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2000,"11271860","Vitamin E and factors affecting atherosclerosis in rabbits fed a cholesterol-rich diet.","11271860",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"11979394","Impaired vitamin E status in patients with parenchymal liver cirrhosis: relationships with lipoprotein compositional alterations, nutritional factors, and oxidative susceptibility of plasma.","11979394",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2003,"12529493","Lipoprotein oxidation and plasma vitamin E in nondiabetic normotensive obese patients.","12529493",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1317655","Growth inhibition of human hepatoma cells (HepG2) by polyunsaturated fatty acids. Protection by albumin and vitamin E.","1317655",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1431596","Discrimination between forms of vitamin E by humans with and without genetic abnormalities of lipoprotein metabolism.","1431596",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1483416","Vitamin A metabolism in plasma of normal and anorectic women.","1483416",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1487963","Studies on the transfer of tocopherol between lipoproteins.","1487963",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1992,"1526016","Simple method for quantifying alpha-tocopherol in low-density+very-low-density lipoproteins and in high-density lipoproteins.","1526016",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2005,"16187540","[Effect of vitamin E supplementation on the vitamin content of lipoprotein in young men and women].","16187540",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1975,"162930","Comparison of exchange of alpha-tocopherol and free cholesterol between rat plasma lipoproteins and erythrocytes.","162930",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1991,"1762518","Tocopherol contents of lipoproteins from frozen plasma separated by affinity chromatography.","1762518",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1991,"1778110","The transport of vitamin E in plasma and its correlation to plasma lipoproteins in non-insulin-dependent diabetes mellitus.","1778110",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C33603,B33603)","v":"Vitamin E"},"Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J33603,K33603)","v":"Lipoproteins, VLDL"},"D008079","Lipoproteins, VLDL",1,1,1976,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q33603,Q33603)","v":"181502"},"The transport of alpha-tocopherol and beta-carotene in human blood.","181502",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1977,"192264","Effect of protein deficiency on absorption, transport and distribution of alpha-tocopherol in the rat.","192264",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1978,"202160","Effect of vitamin E on serum cholesterol and triglycerides in hyperlipidemic patients treated with diet and clofibrate.","202160",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2010,"20702976","Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion.","20702976",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1985,"4019071","Effect of vitamin E on cholesterol plasma lipoprotein distribution and metabolism in rabbit.","4019071",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1979,"228547","The effect of tocopherol on high-density lipoprotein cholesterol. A clinical observation.","228547",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1979,"233011","Effect of dietary supplementation of vitamin E on serum lipids and lipoproteins in rabbits fed a cholesterolemic diet.","233011",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1990,"2351872","RRR- and SRR-alpha-tocopherols are secreted without discrimination in human chylomicrons, but RRR-alpha-tocopherol is preferentially secreted in very low density lipoproteins.","2351872",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1990,"2351873","Nascent VLDL from liver perfusions of cynomolgus monkeys are preferentially enriched in RRR- compared with SRR-alpha-tocopherol: studies using deuterated tocopherols.","2351873",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2585146","Tocopherol distribution in serum lipoproteins with respect to red blood cell tocopherol levels in children.","2585146",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2016,"26206460","The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response.","26206460",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2629597","Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology.","2629597",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2629610","The role of the low density lipoprotein receptor for alpha-tocopherol delivery to tissues.","2629610",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2629612","Alpha-tocopherol as compared with gamma-tocopherol is preferentially secreted in human lipoproteins.","2629612",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1989,"2755302","Alpha- and gamma-tocopherol levels in lipoproteins fractionated by affinity chromatography.","2755302",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1988,"3235918","Alpha-tocopherol is secreted from rat liver in very low density lipoproteins.","3235918",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1988,"3352469","Neutral lipid transfer protein does not regulate alpha-tocopherol transfer between human plasma lipoproteins.","3352469",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1988,"3390957","Distribution of tocopherol among human plasma lipoproteins.","3390957",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1986,"3457548","Effects of dietary selenium and vitamin E on plasma lipoprotein cholesterol levels in male rats.","3457548",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1987,"3651482","Serum half-life, distribution, hepatic uptake and biliary excretion of alpha-tocopherol in rats.","3651482",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1972,"4337563","A comparison of the intestinal absorption, lymph and plasma transport, and tissue uptake of  -and  -tocopherols in the rat.","4337563",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1972,"4348721","The dynamics of vitamin E transport in the human erythrocyte.","4348721",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1974,"4374942","Involvement of binding lipoproteins in the absorption and transport of alpha-tocopherol in the rat.","4374942",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1984,"6496256","Transient lipoprotein deficiency at birth: a cause of low levels of vitamin E in the newborn.","6496256",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1983,"6574998","Lack of effect of ingestion of vitamin E on lipoprotein-cholesterol fractions in healthy adults.","6574998",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"6947861","[Vitamin E megadoses and their effect on HDL cholesterol levels in patients with atherosclerotic complications (author's transl)].","6947861",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"6959567","The effect of vitamin E on lipoprotein cholesterol distribution.","6959567",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"7072621","Distribution of alpha-tocopherol in human plasma lipoproteins.","7072621",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"7102581","Lack of effect of tocopherol on plasma lipids and lipoproteins in man.","7102581",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1981,"7242274","alpha-Tocopherol and serum lipoproteins.","7242274",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"7441363","Effects of the source of dietary protein on serum lower density lipoprotein (VLDL + LDL) and tocopherol levels in female rats.","7441363",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1980,"7443093","Levels of minerals, lipoproteins and lipids in plasma, liver and tibia from female rats fed on a zinc-supplemented rapeseed protein diet.","7443093",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1995,"7562097","Distributions of carotenoids and alpha-tocopherol among lipoproteins do not change when human plasma is incubated in vitro.","7562097",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1995,"7832785","Human plasma phospholipid transfer protein accelerates exchange/transfer of alpha-tocopherol between lipoproteins and cells.","7832785",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1994,"7848372","Dietary vitamin E increases the resistance to lipoprotein oxidation and attenuates endothelial dysfunction in the cholesterol-fed rabbit.","7848372",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1994,"8001520","Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: a randomized double-blind placebo-controlled clinical trial.","8001520",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1994,"8005519","Determinants of plasma vitamin E concentrations.","8005519",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1993,"8263411","Interrelationships of alpha-tocopherol with plasma lipoproteins in African green monkeys: effects of dietary fats.","8263411",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1993,"8429255","Impaired discrimination between stereoisomers of alpha-tocopherol in patients with familial isolated vitamin E deficiency.","8429255",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1995,"8598422","Effect of beta-carotene supplementation on the concentrations and distribution of carotenoids, vitamin E, vitamin A, and cholesterol in plasma lipoprotein and non-lipoprotein fractions in healthy older women.","8598422",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1996,"8626654","Alpha-tocopherol as a reductant for Cu(II) in human lipoproteins. Triggering role in the initiation of lipoprotein oxidation.","8626654",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1996,"8744745","Blood-lipid and lactation-stage factors affecting serum vitamin E concentrations and vitamin E cholesterol ratios in dairy cattle.","8744745",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1996,"8800496","Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men.","8800496",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1997,"9199513","Affinity for alpha-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs.","9199513",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1997,"9356544","Effect of cholesterol-rich diets with and without added vitamins E and C on the severity of atherosclerosis in rabbits.","9356544",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9427704","Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E.","9427704",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9507996","Radical-induced lipoprotein and plasma lipid oxidation in normal and apolipoprotein E gene knockout (apoE-/-) mice: apoE-/- mouse as a model for testing the role of tocopherol-mediated peroxidation in atherogenesis.","9507996",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9649599","alpha-Tocopherol concentrations in plasma but not in lipoproteins fluctuate during the menstrual cycle in healthy premenopausal women.","9649599",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9672881","Distribution of tocopherol and apolipoprotein A-I immunoreactivity in rat liver chromatin.","9672881",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,2,1998,"9733025","Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners.","9733025",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9808219","A randomized, single-blind, placebo-controlled trial of the effects of 200 mg alpha-tocopherol on the oxidation resistance of atherogenic lipoproteins.","9808219",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9832080","Comparison of RRR-alpha- and all-rac-alpha-tocopherol uptake by permanent rat skeletal muscle myoblasts (L6 cells): effects of exogenous lipoprotein lipase.","9832080",57]
["Vitamin E","Vitamin E","D014810","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1998,"9888653","Fat loading experiments with the vitamins A and E suggest that in postprandial lipemia transfer/diffusion of chylomicron lipids to VLDL contributes to beta-VLDL formation.","9888653",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2012,"22149573","Medical therapy for nonalcoholic fatty liver disease in children and adolescents.","22149573",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22154224","Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results.","22154224",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2012,"22197855","Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.","22197855",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"20890896","On the mechanism of action of vitamin E for nonalcoholic steatohepatitis.","20890896",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2010,"21374988","[Influence of genipin and vitamin E on UCP2 and other correlation factors in non-alcoholic fatty liver disease].","21374988",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21436212","Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.","21436212",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21476908","Does vitamin E cure nonalcoholic steatohepatitis?","21476908",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21521847","Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.","21521847",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21750513","Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way?","21750513",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2011,"21947647","Vitamin E for nonalcoholic fatty liver disease.","21947647",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22532269","Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.","22532269",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C33667,B33667)","v":"Vitamin E"},"Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J33667,K33667)","v":"Non-alcoholic Fatty Liver Disease"},"D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q33667,Q33667)","v":"22673924"},"Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver.","22673924",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22707355","Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.","22707355",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"23028489","Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH).","23028489",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"23075940","Vitamin E and nonalcoholic fatty liver disease.","23075940",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23329465","Nonalcoholic fatty liver disease: current issues and novel treatment approaches.","23329465",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23718573","Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.","23718573",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2013,"23933938","Long-term (&gt;=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis.","23933938",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28611274","Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.","28611274",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24081374","Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose.","24081374",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24759732","Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.","24759732",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"24849310","Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.","24849310",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"24975580","Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E: therapeutic implications for nonalcoholic steatohepatitis.","24975580",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24976277","Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis.","24976277",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2014,"24976430","Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.","24976430",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25209009","Reply: To PMID 24849310.","25209009",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25209117","GLI2 as a marker of hedgehog-responsive cells.","25209117",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25429853","NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.","25429853",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25617046","Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease.","25617046",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25933501","Vitamin E therapy for NAFLD/NASH.","25933501",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"25933502","Vitamin E therapy on aminotransferase levels in NAFLD/NASH patients.","25933502",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26059365","Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.","26059365",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26206460","The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response.","26206460",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26206676","Reply.","26206676",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26367736","Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.","26367736",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26592818","Effect of anti-oxidant agents in patients with hepatocellular diseases.","26592818",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26592819","Reply to the Letter \"Effect of anti-oxidant agents in patients with hepatocellular diseases\".","26592819",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"26600128","Vitamin E Attenuates the Progression of Non-Alcoholic Fatty Liver Disease Caused by Partial Hepatectomy in Mice.","26600128",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26603489","Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E.","26603489",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26770927","Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.","26770927",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2015,"26817117","[COMPARISON OF DIFFERENT TREATMENT REGIMENS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE].","26817117",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"27184636","An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.","27184636",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"28282876","Hepatic Transcriptome Profiles of Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E.","28282876",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28494529","NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.","28494529",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28511023","Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.","28511023",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28825992","Effects of delta-tocotrienol on obesity-related adipocyte hypertrophy, inflammation and hepatic steatosis in high-fat-fed mice.","28825992",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2017,"29028831","Short-term vitamin E treatment impairs reactive oxygen species signaling required for adipose tissue expansion, resulting in fatty liver and insulin resistance in obese mice.","29028831",57]
["Vitamin E","Vitamin E","D014810","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"29057829","Association of Vitamin E Levels with Metabolic Syndrome, and MRI-Derived Body Fat Volumes and Liver Fat Content.","29057829",57]
["Vitamin E","Vitamin E","D014810","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"27055589","γ-Tocotrienol upregulates aryl hydrocarbon receptor expression and enhances the anticancer effect of baicalein.","27055589",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2007,"17368686","The effect of essential oils of dietary wormwood (Artemisia princeps), with and without added vitamin E, on oxidative stress and some genes involved in cholesterol metabolism.","17368686",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10224231","Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells.","10224231",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1999,"10614803","Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia.","10614803",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2000,"10832094","Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells.","10832094",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,2000,"11032045","Influence of a single treatment with vitamin E or K (hormonal imprinting) of neonatal rats on the sexual behavior of adults.","11032045",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2001,"11602498","Lipid peroxidation and platelet activation in murine atherosclerosis.","11602498",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2003,"12566360","Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions.","12566360",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2007,"16781857","Effects of vitamin E on oxidative stress and atherosclerosis in an obese hyperlipidemic mouse model.","16781857",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20166147","Vitamin E transport, membrane incorporation and cell metabolism: Is alpha-tocopherol in lipid rafts an oar in the lifeboat?","20166147",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2010,"20702976","Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion.","20702976",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1990,"2165554","Serum concentrations and cellular uptake of vitamin E.","2165554",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2014,"24529144","Long-term vitamin E supplementation reduces atherosclerosis and mortality in Ldlr-/- mice, but not when fed Western style diet.","24529144",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1989,"2629610","The role of the low density lipoprotein receptor for alpha-tocopherol delivery to tissues.","2629610",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1985,"4067658","In vitro uptake of [3H]alpha-tocopherol from low density lipoprotein by cultured human fibroblasts.","4067658",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1980,"6255955","Specific receptor sites for alpha-tocopherol in purified isolated adrenocortical cell membrane.","6255955",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1981,"6270112","Membrane transfer of alpha-tocopherol. Influence of soluble alpha-tocopherol-binding factors from the liver, lung, heart, and brain of the rat.","6270112",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1982,"6293366","Demonstration of specific binding sites for 3H-RRR-alpha-tocopherol on human erythrocytes.","6293366",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1984,"6486081","Vitamin E is delivered to cells via the high affinity receptor for low-density lipoprotein.","6486081",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1995,"8801867","Effect of vitamin E on atherogenesis in LDL receptor-deficient rabbits.","8801867",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1997,"9090072","Binding and uptake of 125iodine-labelled, oxidized low density lipoprotein by macrophages: comparison of the effects of alpha-tocopherol, probucol, pyridoxal-5'-phosphate and magnesium-pyridoxal-5'-phosphate-glutamate.","9090072",57]
["Vitamin E","Vitamin E","D014810","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,1998,"9919489","alpha-tocopherol protects the peroxidative modification of LDL to be recognized by LDL receptors.","9919489",57]
["Vitamin E","Vitamin E","D014810","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2011,"20648548","Selective regulation of UGT1A1 and SREBP-1c mRNA expression by docosahexaenoic, eicosapentaenoic, and arachidonic acids.","20648548",57]
["Vitamin E","Vitamin E","D014810","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2008,"18181169","Cooperation of docosahexaenoic acid and vitamin E in the regulation of UDP-glucuronosyltransferase mRNA expression.","18181169",57]
["Vitamin E","Vitamin E","D014810","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2010,"20438496","Effects of dietary corn oil and vitamin E supplementation on fatty acid profiles and expression of acetyl CoA carboxylase and stearoyl-CoA desaturase gene in Hu sheep.","20438496",57]
["Vitamin E","Vitamin E","D014810","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,1977,"22349","Effects of dietary vitamin B-2 and vitamin E on the delta9-desaturase and catalase activities in the rat liver microsomes.","22349",57]
["Vitamin E","Vitamin E","D014810","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2013,"23727646","γ-Tocotrienol attenuates triglyceride through effect on lipogenic gene expressions in mouse hepatocellular carcinoma Hepa 1-6.","23727646",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C33731,B33731)","v":"Vitamin K"},"Vitamin K","D014812","11_KE",80,11,"CYP1A1","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J33731,K33731)","v":"Cytochrome P-450 CYP1A1"},"D019363","Cytochrome P-450 CYP1A1",1,1,1999,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q33731,Q33731)","v":"10462515"},"Inhibitory effects of vitamin A and vitamin K on rat cytochrome P4501A1-dependent monooxygenase activity.","10462515",57]
["Vitamin K","Vitamin K","D014812","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1999,"10901669","Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in male and female WAG/Rij-rats.","10901669",57]
["Vitamin K","Vitamin K","D014812","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1992,"1462349","Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in female germfree WAG/Rij-rats.","1462349",57]
["Vitamin K","Vitamin K","D014812","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1955,"13334338","[Functional hypocorticalism during steatorrhea with a major liver steatosis].","13334338",57]
["Vitamin K","Vitamin K","D014812","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1958,"13508413","[Therapy of fatty liver and fatty cirrhosis by thloctic acid; comparative examinations by liver biopsy].","13508413",57]
["Vitamin K","Vitamin K","D014812","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1964,"14110964","[CLINICAL ASPECTS OF FATTY LIVER].","14110964",57]
["Vitamin K","Vitamin K","D014812","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1965,"14301352","LIVER LIPIDS IN A CASE OF HYPERVITAMINOSIS A.","14301352",57]
["Vitamin K","Vitamin K","D014812","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1971,"5094269","Vitamin K in Reye's syndrome.","5094269",57]
["Vitamin K","Vitamin K","D014812","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1968,"5755803","[On the problem of a selective thermosensitization of carcinoma cells in vivo with vitamin K3-sodium bisulfite, methylene blue and other thermosensitizators. 1. On the toxicology of vitamin K3-sodium bisulfite in combination with methylene blue on rats and dogs].","5755803",57]
["Vitamin K","Vitamin K","D014812","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11960685","Differential lipoprotein transport pathways of K-vitamins in healthy subjects.","11960685",57]
["Vitamin K","Vitamin K","D014812","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1988,"3051390","Vitamin K-dependent proteins bind to very low-density lipoproteins.","3051390",57]
["Vitamin K","Vitamin K","D014812","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,4,1995,"8615869","Response of [Ah] battery genes to compounds that protect against menadione toxicity.","8615869",57]
["Vitamin K 1","Vitamin K 1","D010837","7_KE",54,7,"CD36","Up Regulation","CD36 Antigens","D018955","CD36 Antigens",1,1,2014,"25228690","Intestinal scavenger receptors are involved in vitamin K1 absorption.","25228690",57]
["Vitamin K 1","Vitamin K 1","D010837","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"21199642","Letter: Localized cutaneous reaction to intramuscular vitamin K in a patient with acute fatty liver of pregnancy.","21199642",57]
["Vitamin K 1","Vitamin K 1","D010837","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11874234","The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: role of heparan sulfate proteoglycans and apolipoprotein E.","11874234",57]
["Vitamin K 1","Vitamin K 1","D010837","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2002,"11874234","The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: role of heparan sulfate proteoglycans and apolipoprotein E.","11874234",57]
["Vitamin K 1","Vitamin K 1","D010837","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,2,2000,"11032045","Influence of a single treatment with vitamin E or K (hormonal imprinting) of neonatal rats on the sexual behavior of adults.","11032045",57]
["Vitamin K 1","Vitamin K 1","D010837","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2005,"15647823","Expression of LRP1 by human osteoblasts: a mechanism for the delivery of lipoproteins and vitamin K1 to bone.","15647823",57]
["Vitamin K 2","Vitamin K 2","D024482","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11960685","Differential lipoprotein transport pathways of K-vitamins in healthy subjects.","11960685",57]
["Vitamin K 3","Vitamin K 3","D024483","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2001,"11710520","Induction of cytochrome P450 1A1 gene expression by a vitamin K3 analog in mouse hepatoma Hepa-1c1c7 cells.","11710520",57]
["Vitamin K 3","Vitamin K 3","D024483","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15232626","Dose- and time-dependent effects of menadione on enzymes of xenobiotic metabolism in rat liver.","15232626",57]
["Vitamin K 3","Vitamin K 3","D024483","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2005,"15603920","Rat hepatic CYP1A1 and CYP1A2 induction by menadione.","15603920",57]
["Vitamin K 3","Vitamin K 3","D024483","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"27167070","Menadione Suppresses Benzo(α)pyrene-Induced Activation of Cytochromes P450 1A: Insights into a Possible Molecular Mechanism.","27167070",57]
["Vitamin K 3","Vitamin K 3","D024483","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2001,"11710520","Induction of cytochrome P450 1A1 gene expression by a vitamin K3 analog in mouse hepatoma Hepa-1c1c7 cells.","11710520",57]
["Vitamin K 3","Vitamin K 3","D024483","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2005,"15603920","Rat hepatic CYP1A1 and CYP1A2 induction by menadione.","15603920",57]
["Vitamin K 3","Vitamin K 3","D024483","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2016,"27167070","Menadione Suppresses Benzo(α)pyrene-Induced Activation of Cytochromes P450 1A: Insights into a Possible Molecular Mechanism.","27167070",57]
["vitexin","vitexin","C032731","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28288411","Vitexin alleviates ox-LDL-mediated endothelial injury by inducing autophagy via AMPK signaling activation.","28288411",57]
["voglibose","voglibose","C102817","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26011816","Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study.","26011816",57]
["Voriconazole","Voriconazole","D065819","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2007,"17606679","Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis.","17606679",57]
["vorinostat","vorinostat","C111237","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22223166","Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.","22223166",57]
["vorinostat","vorinostat","C111237","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"24058584","Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor.","24058584",57]
["vorinostat","vorinostat","C111237","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"28108250","Synthesis of Vorinostat and cholesterol conjugate to enhance the cancer cell uptake selectivity.","28108250",57]
["W 7","W 7","C017967","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,2004,"15158760","Calmodulin antagonist W-7 inhibits de novo synthesis of cholesterol and suppresses secretion of de novo synthesized and preformed lipids from cultured hepatocytes.","15158760",57]
["Warfarin","Warfarin","D014859","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2017,"27740732","Identification of novel variants associated with warfarin stable dosage by use of a two-stage extreme phenotype strategy.","27740732",57]
["Warfarin","Warfarin","D014859","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1962,"13997187","Effect of oral administration of anticoagulants on serum cholesterol and beta-lipoprotein levels.","13997187",57]
["Warfarin","Warfarin","D014859","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"19004034","Risk factors for developing osteonecrosis after prophylaxis in steroid-treated rabbits.","19004034",57]
["Warfarin","Warfarin","D014859","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7780050","Plasma lipoproteins as targeting carriers to tumour tissues after administration of a lipophilic agent to mice.","7780050",57]
["warfarin hexadecyl ether","warfarin hexadecyl ether","C094088","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7780050","Plasma lipoproteins as targeting carriers to tumour tissues after administration of a lipophilic agent to mice.","7780050",57]
["Waste Water","Waste Water","D062065","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24816276","Diversity of the molecular responses to separate wastewater effluents in freshwater mussels.","24816276",57]
["Waste Water","Waste Water","D062065","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25226834","Biochemical response of crayfish Astacus leptodactylus exposed to textile wastewater treated by indigenous white rot fungus Coriolus versicolor.","25226834",57]
["Waste Water","Waste Water","D062065","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"25260601","Biological plausibility as a tool to associate analytical data for micropollutants and effect potentials in wastewater, surface water, and sediments with effects in fishes.","25260601",57]
["Waste Water","Waste Water","D062065","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2015,"26356994","In situ evaluation of wastewater discharges and the bioavailability of contaminants to marine biota.","26356994",57]
["Waste Water","Waste Water","D062065","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26829069","Toxicological and chemical investigation of untreated municipal wastewater: Fraction- and species-specific toxicity.","26829069",57]
["Waste Water","Waste Water","D062065","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26919805","Endocrine disrupting effects of domestic wastewater on reproduction, sexual behavior, and gene expression in the brackish medaka Oryzias melastigma.","26919805",57]
["Waste Water","Waste Water","D062065","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23911337","Estrogen-, androgen- and aryl hydrocarbon receptor mediated activities in passive and composite samples from municipal waste and surface waters.","23911337",57]
["Waste Water","Waste Water","D062065","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2014,"24680543","Monitoring of xenobiotic ligands for human estrogen receptor and aryl hydrocarbon receptor in industrial wastewater effluents.","24680543",57]
["Waste Water","Waste Water","D062065","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"27884472","Impact of untreated wastewater on a major European river evaluated with a combination of in vitro bioassays and chemical analysis.","27884472",57]
["Water","Water","D014867","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2006,"16833156","A biomarker approach to measure biological effects of contaminant exposure in largemouth bass from Lake Conestee, South Carolina, U.S.A.","16833156",57]
["Water","Water","D014867","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2010,"19760798","Tertiary butyl alcohol in drinking water induces phase I and II liver enzymes with consequent effects on thyroid hormone homeostasis in the B6C3F1 female mouse.","19760798",57]
["Water","Water","D014867","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2014,"24929352","Effects of water accommodated fractions of crude oils and diesel on a suite of biomarkers in Atlantic cod (Gadus morhua).","24929352",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1956,"13415403","[Effects of sulfate-alkaline-terreous water in experimental hepatic steatosis caused by carbon tetrachloride].","13415403",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1963,"14050800","GROWTH OF INBRED YELLOW (AYA) AND NON-YELLOW (AA) MICE IN PARABIOSIS.","14050800",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1963,"14095272","[THE SIGNIFICANCE OF THE RELATION BETWEEN THE QUANTITY AND SPECIFIC WEIGHT OF URINE EXCRETED AFTER THE WOLLHEIM WATER TOLERANCE TEST IN LIVER DISEASES].","14095272",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1950,"14817532","[Thyroidectomy and modifications of the glycogen content of liver, muscle and kidney in guinea pigs and white rats in carbon tetrachloride liver steatosis; variations of the relations between glycogen, water, total fats and residual protein].","14817532",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2007,"17896369","Multiecho reconstruction for simultaneous water-fat decomposition and T2* estimation.","17896369",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2012,"22505328","Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice.","22505328",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"26590825","The effect of water suppression on the hepatic lipid quantification, as assessed by the LCModel, in a preclinical and clinical scenario.","26590825",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1976,"935027","An association of hardness of water with incidence of fatty liver syndrome in laying hens.","935027",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2016,"27756550","Hydroethanolic extract of Baccharis trimera ameliorates alcoholic fatty liver disease in mice.","27756550",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10229669","When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid.","10229669",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15190934","Application of water-soluble radical initiator, 2,2'-azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride, to a study of oxidative stress.","15190934",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2006,"16636271","Apolipoprotein B is conformationally flexible but anchored at a triolein/water interface: a possible model for lipoprotein surfaces.","16636271",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"18066135","Pressurized water versus ethanol as a Silybum marianum extraction solvent for inhibition of low-density lipoprotein oxidation mediated by copper and J774 macrophage cells.","18066135",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19937200","Water filtration rate and infiltration/accumulation of low density lipoproteins in 3 different modes of endothelial/smooth muscle cell co-cultures.","19937200",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C33795,B33795)","v":"Water"},"Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J33795,K33795)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,2010,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q33795,Q33795)","v":"20645752"},"The polyphenolics in the aqueous extract of Psidium guajava kinetically reveal an inhibition model on LDL glycation.","20645752",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22198178","A theory for water and macromolecular transport in the pulmonary artery wall with a detailed comparison to the aorta.","22198178",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22607937","Hydrogen-rich water prevents lipid deposition in the descending aorta in a rat periodontitis model.","22607937",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24583416","Effect of shear stress on water and LDL transport through cultured endothelial cell monolayers.","24583416",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"26589608","Aqueous extracts of Tribulus terrestris protects against oxidized low-density lipoprotein-induced endothelial dysfunction.","26589608",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1972,"4113061","A dielectric investigation of the water of hydration of low-density lipoproteins in familial hyperbetalipoproteinaemia.","4113061",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1993,"8391151","Oxidation of low-density lipoproteins by OH. and OH./O2-. free radicals produced by gamma radiolysis.","8391151",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9606403","[Evaluation of relative biological effectiveness of tritium oxide based on biochemical indices of blood in rats].","9606403",57]
["Water","Water","D014867","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2012,"22505328","Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice.","22505328",57]
["Water","Water","D014867","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2008,"18988099","Assessing the ecological risk of soil irrigated with wastewater using in vitro cell bioassays.","18988099",57]
["Water","Water","D014867","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"27348418","Water-Soluble Components of Sesame Oil Reduce Inflammation and Atherosclerosis.","27348418",57]
["Water","Water","D014867","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2010,"20510534","Association of polymorphisms in candidate genes with colour, water-holding capacity, and composition traits in bovine M. longissimus and M. semimembranosus.","20510534",57]
["WAY-169916","WAY-169916","C499198","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2010,"19903824","Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity.","19903824",57]
["WAY-169916","WAY-169916","C499198","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2010,"20423157","Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties.","20423157",57]
["WAY-362450","WAY-362450","C540004","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2009,"19501927","Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.","19501927",57]
["WAY-362450","WAY-362450","C540004","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"24269813","Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.","24269813",57]
["WAY-362450","WAY-362450","C540004","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2014,"24875360","Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction.","24875360",57]
["WAY-362450","WAY-362450","C540004","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2014,"24875360","Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction.","24875360",57]
["WAY-362450","WAY-362450","C540004","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2009,"19136377","A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.","19136377",57]
["WAY-362450","WAY-362450","C540004","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2009,"19159286","Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).","19159286",57]
["WB 4291","WB 4291","C066486","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2245164","Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex.","2245164",57]
["We 201","We 201","C006065","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10543409","Lysophosphatidylcholine molecular species in low density lipoprotein and high density lipoprotein in alloxan-induced diabetic rats: effect of probucol.","10543409",57]
["We 201","We 201","C006065","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,2000,"10805055","Probucol reduces lysophosphatidylcholines in low-density lipoprotein.","10805055",57]
["We 201","We 201","C006065","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"12647268","Atherogenic role of lysophosphatidylcholine in low-density lipoprotein modified by phospholipase A2 and in diabetic patients: protection by nitric oxide donor.","12647268",57]
["We 201","We 201","C006065","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"17350631","Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.","17350631",57]
["We 201","We 201","C006065","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1996,"8663300","Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2.","8663300",57]
["WEB 2086","WEB 2086","C052518","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17543178","Opposite effects of WEB2086 on angiogenesis in atheromas and ischemic hindlimb of apoE gene deficient mice.","17543178",57]
["WEB 2086","WEB 2086","C052518","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1991,"1804564","Long time incubation of monocytic U 937 cells with LDL increases specific paf-acether binding and the cellular acetylhydrolase activity.","1804564",57]
["WEB 2086","WEB 2086","C052518","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1997,"9561175","Monocyte binding to endothelial cells induced by oxidized phospholipids present in minimally oxidized low density lipoprotein is inhibited by a platelet activating factor receptor antagonist.","9561175",57]
["wedelolactone","wedelolactone","C051122","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2015,"26168156","Wedelolactone Regulates Lipid Metabolism and Improves Hepatic Steatosis Partly by AMPK Activation and Up-Regulation of Expression of PPARα/LPL and LDLR.","26168156",57]
["wedelolactone","wedelolactone","C051122","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2015,"26168156","Wedelolactone Regulates Lipid Metabolism and Improves Hepatic Steatosis Partly by AMPK Activation and Up-Regulation of Expression of PPARα/LPL and LDLR.","26168156",57]
["WHI P131","WHI P131","C116180","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"11744615","CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation.","11744615",57]
["Win 55212-2","Win 55212-2","C070417","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20305287","The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages.","20305287",57]
["Win 55212-2","Win 55212-2","C070417","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20868672","WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice.","20868672",57]
["withaferin A","withaferin A","C009684","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2016,"27479085","Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice.","27479085",57]
["wogonin","wogonin","C085514","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21190831","Wogonin promotes cholesterol efflux by increasing protein phosphatase 2B-dependent dephosphorylation at ATP-binding cassette transporter-A1 in macrophages.","21190831",57]
["wogonin","wogonin","C085514","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28486193","Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro.","28486193",57]
["wogonin","wogonin","C085514","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2000,"11045600","Effects of baicalein and wogonin on drug-metabolizing enzymes in C57BL/6J mice.","11045600",57]
["wortmannin","wortmannin","C009687","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1995,"8654730","Wortmannin influences insulin regulation of gene 33 expression in rat hepatoma cells.","8654730",57]
["Wu-Hu-Tang","Wu-Hu-Tang","C105819","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2002,"12184732","Effects of Wu-chu-yu-tang and its component herbs on drug-metabolizing enzymes.","12184732",57]
["Xanthinol Niacinate","Xanthinol Niacinate","D014971","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1976,"177335","[Lipids in pregnant patients with severe course of gestosis treated with xanthinol nicotinate and bufenin hydrochloride].","177335",57]
["Xanthinol Niacinate","Xanthinol Niacinate","D014971","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1977,"196168","[Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].","196168",57]
["Xanthinol Niacinate","Xanthinol Niacinate","D014971","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1982,"6953613","[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].","6953613",57]
["Xanthinol Niacinate","Xanthinol Niacinate","D014971","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1976,"185036","[Xantinol-nicotinate in primary type-V hyperlipoproteinaemia (author's transl)].","185036",57]
["Xanthinol Niacinate","Xanthinol Niacinate","D014971","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1977,"196168","[Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].","196168",57]
["Xanthinol Niacinate","Xanthinol Niacinate","D014971","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1988,"3279969","Decrease in LDL and increase in HDL concentrations in type II hyperlipoproteinaemic patients on low-dose combination therapy of cholestyramine and Complamin.","3279969",57]
["Xanthinol Niacinate","Xanthinol Niacinate","D014971","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1982,"6953613","[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].","6953613",57]
["xanthohumol","xanthohumol","C104536","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2000,"10752639","In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus.","10752639",57]
["xanthohumol","xanthohumol","C104536","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"17981005","Antigenotoxic effect of Xanthohumol in rat liver slices.","17981005",57]
["xanthohumol","xanthohumol","C104536","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2013,"23503627","Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis.","23503627",57]
["xanthohumol","xanthohumol","C104536","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20087858","Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis.","20087858",57]
["xanthohumol","xanthohumol","C104536","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2012,"22295144","Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis.","22295144",57]
["xanthohumol","xanthohumol","C104536","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2013,"23650230","Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice.","23650230",57]
["xanthohumol","xanthohumol","C104536","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2015,"26140926","Xanthohumol Improves Diet-induced Obesity and Fatty Liver by Suppressing Sterol Regulatory Element-binding Protein (SREBP) Activation.","26140926",57]
["xanthohumol","xanthohumol","C104536","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2003,"14565769","Inhibition of peroxynitrite-mediated LDL oxidation by prenylated flavonoids: the alpha,beta-unsaturated keto functionality of 2'-hydroxychalcones as a novel antioxidant pharmacophore.","14565769",57]
["xanthohumol","xanthohumol","C104536","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2017,"28812343","Xanthohumol Suppresses Mylip/Idol Gene Expression and Modulates LDLR Abundance and Activity in HepG2 Cells.","28812343",57]
["xanthone","xanthone","C009689","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2012,"22640928","Benzophenones and xanthones from Garcinia cantleyana var. cantleyana and their inhibitory activities on human low-density lipoprotein oxidation and platelet aggregation.","22640928",57]
["Xanthopterin","Xanthopterin","D014976","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1993,"8490058","A comparative study of urinary xanthopterin and neopterin in liver diseases.","8490058",57]
["xanthurenic acid","xanthurenic acid","C028330","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2001,"11767212","Xanthurenic acid inhibits metal ion-induced lipid peroxidation and protects NADP-isocitrate dehydrogenase from oxidative inactivation.","11767212",57]
["xiaoxianggou","xiaoxianggou","C000613729","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2016,"27470353","Xiaoxianggou attenuates atherosclerotic plaque formation in endogenous high Ang II ApoE(-/-) mice via the inhibition of miR-203 on the expression of Ets-2 in endothelial cells.","27470353",57]
["ximenynic acid","ximenynic acid","C053760","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,1997,"9307938","Dietary sandalwood seed oil modifies fatty acid composition of mouse adipose tissue, brain, and liver.","9307938",57]
["xiongshao","xiongshao","C528128","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21565141","[Effects of Chinese herbal drug-containing serum on oxidative damage and apoptosis of umbilical vein endothelial cells induced by oxidized low-density lipoprotein].","21565141",57]
["Xue-Fu-Zhu-Yu decoction","Xue-Fu-Zhu-Yu decoction","C513826","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"28743670","Xuefu Zhuyu decoction ameliorates obesity, hepatic steatosis, neuroinflammation, amyloid deposition and cognition impairment in metabolically stressed APPswe/PS1dE9 mice.","28743670",57]
["xuezhikang","xuezhikang","C496822","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2007,"17201732","Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.","17201732",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C33859,B33859)","v":"xuezhikang"},"xuezhikang","C496822","13_AO",455,13,"Accumulation, Liver lipid",null,{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J33859,K33859)","v":"Fatty Liver"},"D005234","Fatty Liver",2,2,2009,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q33859,Q33859)","v":"19723204"},"Dietary intervention with AHP, a functional formula diet, improves both serum and hepatic lipids profile in dyslipidemia mice.","19723204",57]
["xuezhikang","xuezhikang","C496822","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20473736","Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia.","20473736",57]
["xuezhikang","xuezhikang","C496822","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"21425565","[Effect of xuezhlkang capsule in intervening different Chinese medical syndrome patterns of non-alcoholic fatty liver disease complicated with carotid atherosclerosis].","21425565",57]
["xuezhikang","xuezhikang","C496822","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2011,"21697731","Xuezhikang, extract of red yeast rice, inhibited tissue factor and hypercoagulable state through suppressing nicotinamide adenine dinucleotide phosphate oxidase and extracellular signal-regulated kinase activation.","21697731",57]
["xuezhikang","xuezhikang","C496822","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"21425565","[Effect of xuezhlkang capsule in intervening different Chinese medical syndrome patterns of non-alcoholic fatty liver disease complicated with carotid atherosclerosis].","21425565",57]
["xuezhikang","xuezhikang","C496822","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2016,"24993334","Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.","24993334",57]
["xylenol orange","xylenol orange","C016833","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1999,"10499781","Spectrophotometric measurement of hydroperoxides at increased sensitivity by oxidation of Fe2+ in the presence of xylenol orange.","10499781",57]
["xylenol orange","xylenol orange","C016833","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1519766","Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein.","1519766",57]
["Xylitol","Xylitol","D014993","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1975,"1172593","[Nucleic acid metabolism in the liver in cells in liver diseases 2. Observation on fatty liver in choline-deficient rat, with special reference to modification of the disease process with xylitol].","1172593",57]
["Xylitol","Xylitol","D014993","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1977,"411069","Fatty liver in rats following parenteral hyperalimentation with glucose or glucose substitutes.","411069",57]
["Xylitol","Xylitol","D014993","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1992,"1494207","Effect of excess xylitol on nitrogen and glucose metabolism in parenterally fed rats.","1494207",57]
["Xylitol","Xylitol","D014993","5_KE",216,5,"PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Decreased","Phosphoenolpyruvate Carboxykinase (GTP)","D010729","Phosphoenolpyruvate Carboxykinase (GTP)",1,1,1973,"4349871","Influence of glucagon on the metabolism of xylitol and dihydroxyacetone in the isolated perfused rat liver.","4349871",57]
["xyloketal A","xyloketal A","C438053","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20481602","Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen.","20481602",57]
["xyloketal B","xyloketal B","C515343","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19481065","A novel marine compound xyloketal B protects against oxidized LDL-induced cell injury in vitro.","19481065",57]
["xyloketal B","xyloketal B","C515343","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2010,"20481602","Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen.","20481602",57]
["xyloketal B","xyloketal B","C515343","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28587208","Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models.","28587208",57]
["Xylose","Xylose","D014994","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,1977,"908147","The conversion of D-xylose into D-threitol in patients without liver disease and in patients with portal liver cirrhosis.","908147",57]
["xylosides","xylosides","C010807","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2002,"11788461","Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs.","11788461",57]
["Y 27632","Y 27632","C108830","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,2015,"25307969","Rho-kinase inhibitor targeting the liver prevents ischemia/reperfusion injury in the steatotic liver without major systemic adversity in rats.","25307969",57]
["Y 27632","Y 27632","C108830","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2005,"15643129","Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats.","15643129",57]
["Y 39041","Y 39041","C406663","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2009,"19938191","Immunotherapy for nonalcoholic steatohepatitis using the multiple cytokine production modulator Y-40138.","19938191",57]
["YH 439","YH 439","C098009","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1996,"8937429","Suppression of rat hepatic cytochrome P450 2E1 expression by isopropyl 2-(1,3-dithioetane-2-ylidene)-2-[N-(4-methyl-thiazol-2-yl)carbamoyl] acetate (YH439), an experimental hepatoprotectant: protective role against hepatic injury.","8937429",57]
["YH 439","YH 439","C098009","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,1996,"8649358","Transcriptional induction of the cytochrome P4501A1 gene by a thiazolium compound, YH439.","8649358",57]
["YHK herbal compound","YHK herbal compound","C516652","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2007,"17394061","Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP).","17394061",57]
["yiki-huoxue","yiki-huoxue","C033946","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2007,"17343008","[Yiqi Huoxue Recipe combined with polyene phosphatidycholine capsule in treating 50 patients with non-alcoholic fatty hepatitis].","17343008",57]
["yin-chen-hao-tang","yin-chen-hao-tang","C542425","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20428786","Alleviation of hepatic oxidative stress by Chinese herbal medicine Yin-Chen-Hao-Tang in obese mice with steatosis.","20428786",57]
["yin-chen-hao-tang","yin-chen-hao-tang","C542425","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2017,"28275293","Therapeutic mechanism of Yīn-Chén-Hāo decoction in hepatic diseases.","28275293",57]
["Yiqi Sanju formula","Yiqi Sanju formula","C528001","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2008,"18664346","[Effects of Yiqi Sanju Formula on non-alcoholic fatty liver disease: a randomized controlled trial].","18664346",57]
["YM17E","YM17E","C080390","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,2,1998,"9568741","Relationship between bioavailability and hypocholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rats.","9568741",57]
["YM17E","YM17E","C080390","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1997,"9450115","The effect of ACAT inhibition on VLDL secretion in rats fed a diet rich in fish-oil.","9450115",57]
["yuehchukene","yuehchukene","C047409","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9865536","Induction of estradiol-2-hydroxylase and ethoxyresorufin-O-deethylase by 3-substituted indole compounds.","9865536",57]
["yuehchukene","yuehchukene","C047409","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,1998,"9865536","Induction of estradiol-2-hydroxylase and ethoxyresorufin-O-deethylase by 3-substituted indole compounds.","9865536",57]
["zanoterone","zanoterone","C060492","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,2,1996,"9029268","Induction of liver cytochrome P-450 (CYP) 3A in male and female rats by a steroidal androgen receptor antagonist, zanoterone.","9029268",57]
["zearalenol","zearalenol","C029659","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"17656051","Effects of Fusarium mycotoxins on steroid production by porcine granulosa cells.","17656051",57]
["zearalenol","zearalenol","C029659","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18579320","alpha-Zearalanol attenuates oxLDL-induced ET-1 gene expression, ET-1 secretion and redox-sensitive intracellular signaling activation in human umbilical vein endothelial cells.","18579320",57]
["Zearalenone","Zearalenone","D015025","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2004,"15157572","Effects of zearalenone on mRNA expression and activity of cytochrome P450 1A1 and 1B1 in MCF-7 cells.","15157572",57]
["Zearalenone","Zearalenone","D015025","12_KE",462,12,"SCD-1","Increased","Fatty Acid Desaturases","D044943","Fatty Acid Desaturases",2,2,2006,"16751498","The PKS4 gene of Fusarium graminearum is essential for zearalenone production.","16751498",57]
["Zearalenone","Zearalenone","D015025","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,3,2011,"21787672","Zearalenone activates pregnane X receptor, constitutive androstane receptor and aryl hydrocarbon receptor and corresponding phase I target genes mRNA in primary cultures of human hepatocytes.","21787672",57]
["zeaxanthin dipalmitate","zeaxanthin dipalmitate","C109854","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2014,"24740309","Zeaxanthin dipalmitate therapeutically improves hepatic functions in an alcoholic fatty liver disease model through modulating MAPK pathway.","24740309",57]
["zeaxanthin dipalmitate","zeaxanthin dipalmitate","C109854","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28816082","Zeaxanthin dipalmitate alleviates hepatic injury induced by superimposed chronic hepatitis B and non-alcoholic steatohepatitis in non-obese mice.","28816082",57]
["zederone","zederone","C586942","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2013,"23850985","Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system.","23850985",57]
["Zeranol","Zeranol","D015029","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2008,"17656051","Effects of Fusarium mycotoxins on steroid production by porcine granulosa cells.","17656051",57]
["Zeranol","Zeranol","D015029","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15758251","Phytoestrogen alpha-zearalanol antagonizes oxidized LDL-induced inhibition of nitric oxide production and stimulation of endothelin-1 release in human umbilical vein endothelial cells.","15758251",57]
["Zeranol","Zeranol","D015029","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2008,"18579320","alpha-Zearalanol attenuates oxLDL-induced ET-1 gene expression, ET-1 secretion and redox-sensitive intracellular signaling activation in human umbilical vein endothelial cells.","18579320",57]
["zerumbone","zerumbone","C403304","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2007,"17420607","Zerumbone suppresses phorbol ester-induced expression of multiple scavenger receptor genes in THP-1 human monocytic cells.","17420607",57]
["zhenqing","zhenqing","C550196","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2014,"25137852","[Effect of zhenqing recipe on non-alcoholic fatty liver in type 2 diabetes rats and the expression of SIK1].","25137852",57]
["Zinc Oxide","Zinc Oxide","D015034","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26878645","Tissue distribution of zinc and subtle oxidative stress effects after dietary administration of ZnO nanoparticles to rainbow trout.","26878645",57]
["Zinc Oxide","Zinc Oxide","D015034","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,3,1998,"9690608","Dietary zinc oxide in weaned pigs--effects on performance, tissue concentrations, morphology, neutrophil functions and faecal microflora.","9690608",57]
["Zinc Oxide","Zinc Oxide","D015034","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2014,"24746987","Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.","24746987",57]
["Zinc Oxide","Zinc Oxide","D015034","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2017,"28285566","Involvement of the cytokine-IDO1-AhR loop in zinc oxide nanoparticle-induced acute pulmonary inflammation.","28285566",57]
["zinc phthalocyanine sulfonate","zinc phthalocyanine sulfonate","C064328","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7781124","[Apoptosis of mouse MS-2 fibrosarcoma cells induced by photodynamic therapy with LDL-administered zinc-phthalocyanine].","7781124",57]
["zinc protoporphyrin","zinc protoporphyrin","C017803","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2010,"20979658","Heme oxygenase-1 prevents non-alcoholic steatohepatitis through suppressing hepatocyte apoptosis in mice.","20979658",57]
["zinc protoporphyrin","zinc protoporphyrin","C017803","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2012,"22036622","Protective effect of heme oxygenase-1 induction against hepatic injury in alcoholic steatotic liver exposed to cold ischemia/reperfusion.","22036622",57]
["Zinc Sulfate","Zinc Sulfate","D019287","12_KE",462,12,"SCD-1","Increased","Stearoyl-CoA Desaturase","D013230","Stearoyl-CoA Desaturase",1,1,2017,"29057818","Chronic High Dose Zinc Supplementation Induces Visceral Adipose Tissue Hypertrophy without Altering Body Weight in Mice.","29057818",57]
["zinc(II)-tetradibenzobarrelenooctabutoxyphthalocyanine","zinc(II)-tetradibenzobarrelenooctabutoxyphthalocyanine","C092992","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"7716192","Unusually high affinity of Zn(II)-tetradibenzobarrelenooctabutoxy-phthalocyanine for low-density lipoproteins in a tumor-bearing mouse.","7716192",57]
["ZINC32101539","ZINC32101539","C000612733","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26994845","Identification of leads for antiproliferative activity on MDA-MB-435 human breast cancer cells through pharmacophore and CYP1A1-mediated metabolism.","26994845",57]
["ZINC33468944","ZINC33468944","C000612732","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2016,"26994845","Identification of leads for antiproliferative activity on MDA-MB-435 human breast cancer cells through pharmacophore and CYP1A1-mediated metabolism.","26994845",57]
["Zineb","Zineb","D015038","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2016,"27016407","Mancozeb, a fungicide routinely used in agriculture, worsens nonalcoholic fatty liver disease in the human HepG2 cell model.","27016407",57]
["zingerone","zingerone","C013738","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2017,"28442378","Antihyperlipidemic and antiapoptotic potential of zingerone on alcohol induced hepatotoxicity in experimental rats.","28442378",57]
["zingerone","zingerone","C013738","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2016,"26915720","Hepatoprotective potential of zingerone against nonalcoholic fatty liver disease in rats fed with fructose-enriched diet.","26915720",57]
["ZK 112993","ZK 112993","C064879","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7962545","Antioxidant: a new role for RU-486 and related compounds.","7962545",57]
["Zn(II)-phthalocyanine","Zn(II)-phthalocyanine","C052159","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1990,"2328207","Liposome- or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency.","2328207",57]
["Zn(II)-phthalocyanine","Zn(II)-phthalocyanine","C052159","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1987,"3559547","Spectroscopic studies on Zn(II)-phthalocyanine in homogeneous and microheterogeneous systems.","3559547",57]
["Zn(II)-phthalocyanine","Zn(II)-phthalocyanine","C052159","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1994,"7799138","In vitro interaction of zinc(II)-phthalocyanine-containing liposomes and plasma lipoproteins.","7799138",57]
[{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & C33923,B33923)","v":"Zn(II)-phthalocyanine"},"Zn(II)-phthalocyanine","C052159","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation",{"$f":"HYPERLINK(\"https://meshb.nlm.nih.gov/record/ui?ui=\" & J33923,K33923)","v":"Lipoproteins, LDL"},"D008077","Lipoproteins, LDL",1,1,1994,{"$f":"HYPERLINK(\"https://www.ncbi.nlm.nih.gov/pubmed/\" & Q33923,Q33923)","v":"8040754"},"Interaction between zinc(II)-phthalocyanine-containing liposomes and human low density lipoprotein.","8040754",57]
["Zn(II)-phthalocyanine","Zn(II)-phthalocyanine","C052159","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1995,"8581821","The effect of different liposomal formulations on the interaction of Zn(II)-phthalocyanine with isolated low and high density lipoproteins.","8581821",57]
["Zn(II)-phthalocyanine","Zn(II)-phthalocyanine","C052159","2_KE",450,2,"VLDL secretion","Suppression","Lipoproteins, VLDL","D008079","Lipoproteins, VLDL",1,1,1994,"7799138","In vitro interaction of zinc(II)-phthalocyanine-containing liposomes and plasma lipoproteins.","7799138",57]
["Zolazepam","Zolazepam","D015041","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"9448743","Induction of hepatic cytochrome P450 2B and P450 3A isozymes in rats by zolazepam, a constituent of Telazol.","9448743",57]
["zoledronic acid","zoledronic acid","C088658","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver","D005234","Fatty Liver",2,2,2011,"20407889","Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.","20407889",57]
["zoledronic acid","zoledronic acid","C088658","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2011,"20407889","Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.","20407889",57]
["zoledronic acid","zoledronic acid","C088658","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,1,2017,"28843826","Zoledronic acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis.","28843826",57]
["zoledronic acid","zoledronic acid","C088658","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2011,"21903868","A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.","21903868",57]
["zoledronic acid","zoledronic acid","C088658","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2013,"24225494","Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-κB pathway.","24225494",57]
["zolpidem","zolpidem","C049109","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,2,2009,"19686824","Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes.","19686824",57]
["zopolrestat","zopolrestat","C067172","13_AO",455,13,"Accumulation, Liver lipid",null,"Fatty Liver, Alcoholic","D005235","Fatty Liver, Alcoholic",1,1,2017,"28447762","Inhibition of aldose reductase ameliorates ethanol‑induced steatosis in HepG2 cells.","28447762",57]
["zopolrestat","zopolrestat","C067172","13_AO",455,13,"Accumulation, Liver lipid",null,"Non-alcoholic Fatty Liver Disease","D065626","Non-alcoholic Fatty Liver Disease",1,2,2015,"25333350","Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor α.","25333350",57]
["Zoxazolamine","Zoxazolamine","D015049","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,1998,"10323328","Zoxazolamine-induced paralysis in two rat substrains: differences in hepatic drug metabolism.","10323328",57]
["Zyflamend","Zyflamend","C519312","11_KE",80,11,"CYP1A1","Up Regulation","Cytochrome P-450 CYP1A1","D019363","Cytochrome P-450 CYP1A1",1,1,2012,"22374940","Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis.","22374940",57]
["Zyflamend","Zyflamend","C519312","1_MIE",18,1,"AHR","Activation","Receptors, Aryl Hydrocarbon","D018336","Receptors, Aryl Hydrocarbon",1,1,2012,"22374940","Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis.","22374940",57]
["Zymosan","Zymosan","D015054","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2000,"10695924","Lipoproteins modify the macrophage uptake of triacylglycerol emulsion and of zymosan particles by similar mechanisms.","10695924",57]
["Zymosan","Zymosan","D015054","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1992,"1391222","[Lipid biosynthesis and metabolism of native and acetylated low density lipoproteins in macrophages stimulated by zymosan in vivo and in vitro].","1391222",57]
["Zymosan","Zymosan","D015054","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2004,"15030176","The protective effects of HDL and its constituents against neutrophil respiratory burst activation by hypochlorite-oxidized LDL.","15030176",57]
["Zymosan","Zymosan","D015054","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,2009,"19073604","Scavenger receptor collectin placenta 1 (CL-P1) predominantly mediates zymosan phagocytosis by human vascular endothelial cells.","19073604",57]
["Zymosan","Zymosan","D015054","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Lipoproteins, LDL","D008077","Lipoproteins, LDL",1,1,1998,"9799806","LDL oxidation by activated monocytes: characterization of the oxidized LDL and requirement for transition metal ions.","9799806",57]
["Zymosan","Zymosan","D015054","9_KE",466,9,"LDLR (low density lipoprotein receptor)","Up Regulation","Receptors, LDL","D011973","Receptors, LDL",1,1,2002,"12355497","Lectin-like oxidized low-density lipoprotein receptor 1 mediates leukocyte infiltration and articular cartilage destruction in rat zymosan-induced arthritis.","12355497",57]
[null,"Glucose","D005947","12_KE",462,12,"SCD-1","Increased",null,"D013230","Stearoyl-CoA Desaturase",1,2,1998,"9867800","Glucose induces expression of stearoyl-CoA desaturase in 3T3-L1 adipocytes.","9867800",57]